0001558370-22-017528.txt : 20221114 0001558370-22-017528.hdr.sgml : 20221114 20221114060523 ACCESSION NUMBER: 0001558370-22-017528 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 121 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: P3 Health Partners Inc. CENTRAL INDEX KEY: 0001832511 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 852992794 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40033 FILM NUMBER: 221379523 BUSINESS ADDRESS: STREET 1: 2045 W GRAND AVE STE B STREET 2: PMB # 82152 CITY: CHICAGO STATE: IL ZIP: 60612-1577 BUSINESS PHONE: 312-822-8897 MAIL ADDRESS: STREET 1: 2045 W GRAND AVE STE B STREET 2: PMB # 82152 CITY: CHICAGO STATE: IL ZIP: 60612-1577 FORMER COMPANY: FORMER CONFORMED NAME: Foresight Acquisition Corp. DATE OF NAME CHANGE: 20201116 10-Q 1 piii-20220930x10q.htm 10-Q
41578890415788904157889041578890430000004300000016130034161300340001832511--12-312022Q3falsehttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent2015307961965535231218797183308520P21M1.00http://www.p3hp.org/20220930#MarkToMarketAdjustmentOfForesightStockWarrants84000000840000008400000084000000P3MP9M01965535232015307968000000600000019258331302083P2YP1YP1YP5Y3100000P10YP30D0001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2022-09-300001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2022-09-300001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2021-12-310001832511piii:ClassPreferredUnitsMember2021-09-300001832511piii:ClassDPreferredUnitsMember2021-09-300001832511piii:ClassPreferredUnitsMember2021-06-300001832511piii:ClassDPreferredUnitsMember2021-06-300001832511piii:ClassPreferredUnitsMember2021-03-310001832511piii:ClassDPreferredUnitsMember2021-03-310001832511piii:ClassPreferredUnitsMember2020-12-310001832511piii:ClassDPreferredUnitsMember2020-12-310001832511piii:ClassCPreferredUnitsMember2020-06-072020-06-070001832511us-gaap:CommonClassAMemberpiii:PrivatePlacementPursuantToSubscriptionAgreementsMember2022-01-012022-09-300001832511piii:ClassBForesightFounderSharesMemberus-gaap:PrivatePlacementMember2022-01-012022-09-300001832511us-gaap:CommonClassAMember2021-12-032021-12-030001832511us-gaap:RetainedEarningsMember2022-09-300001832511us-gaap:AdditionalPaidInCapitalMember2022-09-300001832511us-gaap:RetainedEarningsMember2022-06-300001832511us-gaap:AdditionalPaidInCapitalMember2022-06-3000018325112022-06-300001832511us-gaap:RetainedEarningsMember2022-03-310001832511us-gaap:AdditionalPaidInCapitalMember2022-03-3100018325112022-03-310001832511us-gaap:RetainedEarningsMember2021-12-310001832511us-gaap:AdditionalPaidInCapitalMember2021-12-310001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-09-300001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-09-300001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-06-300001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-06-300001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-03-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-03-310001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2021-12-310001832511piii:ClassCPreferredUnitsMember2020-06-070001832511us-gaap:RestrictedStockMemberpiii:CommonClassVMember2022-01-012022-09-300001832511us-gaap:RestrictedStockMemberpiii:CommonClassVMember2021-01-012021-12-310001832511piii:TimeBasedProfitsInterestAwardsMember2022-09-300001832511piii:TimeBasedProfitsInterestAwardsMember2021-12-310001832511srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001832511srt:MinimumMemberpiii:TimeBasedProfitsInterestAwardsMember2022-01-012022-09-300001832511srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300001832511srt:MaximumMemberpiii:TimeBasedProfitsInterestAwardsMember2022-01-012022-09-300001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2022-01-012022-09-300001832511piii:P3LlcMember2022-01-012022-09-300001832511piii:HealthCareClinicalFeesInsuranceRevenueMember2022-01-012022-09-300001832511us-gaap:HealthCarePatientServiceMember2022-07-012022-09-300001832511piii:CapitatedRevenueMember2022-07-012022-09-300001832511us-gaap:HealthCarePatientServiceMember2022-01-012022-09-300001832511us-gaap:HealthCarePatientServiceMembersrt:ScenarioPreviouslyReportedMember2021-07-012021-09-300001832511us-gaap:HealthCarePatientServiceMemberpiii:RevenueAdjustmentMember2021-07-012021-09-300001832511piii:CapitatedRevenueMembersrt:ScenarioPreviouslyReportedMember2021-07-012021-09-300001832511piii:CapitatedRevenueMemberpiii:RevenueAdjustmentMember2021-07-012021-09-300001832511us-gaap:HealthCarePatientServiceMember2021-07-012021-09-300001832511piii:CapitatedRevenueMember2021-07-012021-09-300001832511us-gaap:HealthCarePatientServiceMembersrt:ScenarioPreviouslyReportedMember2021-01-012021-09-300001832511us-gaap:HealthCarePatientServiceMemberpiii:RevenueAdjustmentMember2021-01-012021-09-300001832511piii:CapitatedRevenueMembersrt:ScenarioPreviouslyReportedMember2021-01-012021-09-300001832511piii:CapitatedRevenueMemberpiii:RevenueAdjustmentMember2021-01-012021-09-300001832511us-gaap:HealthCarePatientServiceMember2021-01-012021-09-300001832511piii:CapitatedRevenueMember2021-01-012021-09-300001832511piii:LtdELoanMember2022-01-012022-09-300001832511us-gaap:NoncontrollingInterestMember2022-09-300001832511us-gaap:NoncontrollingInterestMember2022-06-300001832511us-gaap:NoncontrollingInterestMember2022-03-310001832511us-gaap:NoncontrollingInterestMember2021-12-310001832511us-gaap:VehiclesMember2022-09-300001832511us-gaap:SoftwareDevelopmentMember2022-09-300001832511us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2022-09-300001832511us-gaap:LeaseholdImprovementsMember2022-09-300001832511us-gaap:FurnitureAndFixturesMember2022-09-300001832511us-gaap:ComputerEquipmentMember2022-09-300001832511piii:MedicalEquipmentMember2022-09-300001832511us-gaap:SoftwareDevelopmentMember2021-12-310001832511us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2021-12-310001832511us-gaap:LeaseholdImprovementsMember2021-12-310001832511us-gaap:FurnitureAndFixturesMember2021-12-310001832511us-gaap:ComputerEquipmentMember2021-12-310001832511piii:MedicalEquipmentMember2021-12-310001832511us-gaap:RetainedEarningsMember2021-07-012021-09-300001832511us-gaap:RetainedEarningsMember2021-04-012021-06-300001832511srt:ScenarioPreviouslyReportedMember2021-04-012021-06-300001832511piii:RevenueAdjustmentMember2021-04-012021-06-300001832511piii:PreferredReturnsRestatementAdjustmentMember2021-04-012021-06-300001832511us-gaap:RetainedEarningsMember2021-01-012021-03-310001832511srt:ScenarioPreviouslyReportedMember2021-01-012021-03-310001832511piii:PreferredReturnsRestatementAdjustmentMember2021-01-012021-03-310001832511piii:LtdCLoanMember2020-11-192020-11-190001832511us-gaap:CommonClassAMember2021-09-300001832511piii:ClassDPreferredUnitsMember2021-09-300001832511piii:ClassCPreferredUnitsMember2021-09-300001832511piii:ClassBPreferredUnitsMember2021-09-300001832511us-gaap:CommonClassAMember2020-12-310001832511piii:ClassDPreferredUnitsMember2020-12-310001832511piii:ClassCPreferredUnitsMember2020-12-310001832511piii:ClassBPreferredUnitsMember2020-12-310001832511piii:ClassAndClassDPreferredUnitsMember2022-01-012022-09-300001832511piii:ClassPreferredUnitsMember2021-07-012021-09-300001832511piii:ClassPreferredUnitsMember2021-04-012021-06-300001832511piii:ClassPreferredUnitsMember2021-01-012021-09-300001832511piii:ClassPreferredUnitsMember2021-01-012021-03-310001832511piii:ClassPreferredUnitsMember2019-01-012019-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2021-01-012021-12-310001832511piii:ClassCPreferredUnitsMember2021-07-012021-09-300001832511piii:ClassCPreferredUnitsMember2021-04-012021-06-300001832511piii:ClassB1PreferredUnitsMember2021-04-012021-06-3000018325112021-04-012021-06-300001832511piii:ClassCPreferredUnitsMember2021-01-012021-03-3100018325112021-01-012021-03-310001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-300001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-07-012021-09-300001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-09-300001832511us-gaap:RetainedEarningsMember2022-07-012022-09-300001832511us-gaap:RetainedEarningsMember2022-04-012022-06-300001832511us-gaap:RetainedEarningsMember2022-01-012022-03-310001832511piii:NetworkAdjustmentsMember2021-07-012021-09-300001832511piii:NetworkAdjustmentsMember2021-01-012021-09-300001832511piii:P3HealthGroupLlcMember2022-09-300001832511piii:NetworkMemberus-gaap:PrimeRateMember2022-09-300001832511piii:P3NvMemberpiii:KahanWakefieldAbdouPllcMember2022-01-012022-09-300001832511piii:P3NvMemberpiii:KahanWakefieldAbdouPllcMember2021-01-012021-12-3100018325112020-03-012022-09-300001832511us-gaap:RetainedEarningsMember2021-09-300001832511srt:ScenarioPreviouslyReportedMember2021-09-300001832511piii:RedemptionOfProfitsInterestMember2021-09-300001832511piii:PreferredReturnsRestatementAdjustmentMember2021-09-300001832511piii:ClassUnitsAdjustmentMember2021-09-300001832511piii:ClassCPreferredUnitsMember2021-09-300001832511piii:ClassB1PreferredUnitsMember2021-09-300001832511us-gaap:RetainedEarningsMember2021-06-300001832511srt:ScenarioPreviouslyReportedMember2021-06-300001832511piii:RedemptionOfProfitsInterestMember2021-06-300001832511piii:PreferredReturnsRestatementAdjustmentMember2021-06-300001832511piii:ClassUnitsAdjustmentMember2021-06-300001832511piii:ClassCPreferredUnitsMember2021-06-300001832511piii:ClassB1PreferredUnitsMember2021-06-3000018325112021-06-300001832511us-gaap:RetainedEarningsMember2021-03-310001832511srt:ScenarioPreviouslyReportedMember2021-03-310001832511piii:RevenueAdjustmentMember2021-03-310001832511piii:RedemptionOfProfitsInterestMember2021-03-310001832511piii:PreferredReturnsRestatementAdjustmentMember2021-03-310001832511piii:ClassUnitsAdjustmentMember2021-03-310001832511piii:ClassCPreferredUnitsMember2021-03-310001832511piii:ClassB1PreferredUnitsMember2021-03-3100018325112021-03-310001832511us-gaap:RetainedEarningsMember2020-12-310001832511srt:ScenarioPreviouslyReportedMember2020-12-310001832511piii:RevenueAdjustmentMember2020-12-310001832511piii:RedemptionOfProfitsInterestMember2020-12-310001832511piii:PreferredReturnsRestatementAdjustmentMember2020-12-310001832511piii:ClassUnitsAdjustmentMember2020-12-310001832511piii:ClassCPreferredUnitsMember2020-12-310001832511piii:ClassB1PreferredUnitsMember2020-12-310001832511srt:MinimumMemberpiii:EquipmentOnLeaseMember2022-09-300001832511srt:MaximumMemberpiii:EquipmentOnLeaseMember2022-09-300001832511srt:MinimumMemberus-gaap:RealEstateMember2022-09-300001832511srt:MaximumMemberus-gaap:RealEstateMember2022-09-300001832511stpr:NVus-gaap:RealEstateMember2022-06-090001832511piii:PreferredReturnsRestatementAdjustmentMember2021-07-012021-09-300001832511piii:PreferredReturnsRestatementAdjustmentMember2021-01-012021-09-300001832511us-gaap:TransmissionServiceAgreementMember2022-09-300001832511us-gaap:TrademarksMember2022-09-300001832511us-gaap:OtherIntangibleAssetsMember2022-09-300001832511us-gaap:CustomerRelationshipsMember2022-09-300001832511piii:ProviderContractsMember2022-09-300001832511us-gaap:TransmissionServiceAgreementMember2021-12-310001832511us-gaap:TrademarksMember2021-12-310001832511us-gaap:OtherIntangibleAssetsMember2021-12-310001832511us-gaap:CustomerRelationshipsMember2021-12-310001832511piii:ProviderContractsMember2021-12-310001832511us-gaap:CommonClassAMember2022-07-012022-09-300001832511us-gaap:CommonClassAMember2021-07-012021-09-300001832511us-gaap:CommonClassAMember2021-01-012021-09-300001832511piii:ClassDWarrantsMember2020-01-012020-12-310001832511piii:TimeBasedProfitsInterestAwardsMember2022-01-012022-09-300001832511piii:P3LlcMember2022-09-300001832511us-gaap:LineOfCreditMember2021-12-310001832511srt:MinimumMemberus-gaap:LineOfCreditMember2021-01-012021-12-310001832511srt:MaximumMemberus-gaap:LineOfCreditMember2021-01-012021-12-310001832511piii:LtdELoanMember2020-06-070001832511piii:LtdDLoanMember2020-11-190001832511piii:LtdELoanMember2021-12-310001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthCareSharedRiskRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthCareSharedRiskRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthCareSharedRiskRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthCareSharedRiskRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001832511piii:P3LlcMemberus-gaap:RestrictedStockMember2022-09-300001832511piii:P3LlcMemberus-gaap:NoncontrollingInterestMember2022-09-300001832511piii:P3LlcMemberus-gaap:CommonClassAMember2022-09-300001832511piii:P3LlcMember2022-09-300001832511piii:P3LlcMemberus-gaap:RestrictedStockMember2021-12-310001832511piii:P3LlcMemberus-gaap:NoncontrollingInterestMember2021-12-310001832511piii:P3LlcMemberus-gaap:CommonClassAMember2021-12-310001832511piii:P3LlcMember2021-12-310001832511us-gaap:CommonClassAMember2021-12-030001832511piii:CommonClassVMember2022-09-300001832511piii:CommonClassVMember2021-12-310001832511piii:ClassDWarrantsMember2022-09-300001832511piii:ClassDWarrantsMember2020-12-310001832511us-gaap:CommonClassAMember2022-09-300001832511us-gaap:CommonClassAMember2021-12-310001832511piii:ClassDWarrantsMember2021-12-310001832511piii:ClassDWarrantsMember2020-11-1900018325112020-12-3100018325112021-09-300001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:TransmissionServiceAgreementMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:TrademarksMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:OtherIntangibleAssetsMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:ContractualRightsMember2021-12-310001832511piii:P3LlcMemberus-gaap:TransmissionServiceAgreementMember2021-12-030001832511piii:P3LlcMemberus-gaap:TrademarksMember2021-12-030001832511piii:P3LlcMemberus-gaap:CustomerRelationshipsMember2021-12-030001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2021-12-020001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2022-12-310001832511piii:OmniIpaMedicalGroupInc.Member2021-12-310001832511piii:MedcoreHpMember2021-12-270001832511piii:P3HealthGroupLlcMember2021-12-030001832511piii:P3LlcMember2021-01-010001832511us-gaap:RestrictedStockMember2022-01-012022-09-300001832511us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001832511piii:PublicWarrantsMember2022-01-012022-09-300001832511piii:PrivateWarrantsMember2022-01-012022-09-300001832511us-gaap:TransmissionServiceAgreementMember2022-01-012022-09-300001832511us-gaap:TrademarksMember2022-01-012022-09-300001832511us-gaap:CustomerRelationshipsMember2022-01-012022-09-300001832511piii:ProviderContractsMember2022-01-012022-09-300001832511us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001832511us-gaap:PerformanceSharesMember2022-01-012022-09-300001832511us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001832511piii:P3LlcMember2021-01-012021-01-010001832511us-gaap:CommonClassAMember2021-01-012021-12-310001832511piii:ClassDWarrantsMember2021-01-012021-12-310001832511us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001832511us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001832511us-gaap:FairValueMeasurementsRecurringMember2022-09-300001832511us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001832511us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001832511us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2022-09-300001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2021-12-310001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2021-12-0300018325112022-04-012022-06-3000018325112022-01-012022-03-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-07-012022-09-300001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-04-012022-06-300001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-01-012022-03-310001832511srt:ScenarioPreviouslyReportedMemberpiii:ClassAndClassDPreferredUnitsMember2021-01-012021-09-300001832511piii:PreferredReturnsRestatementAdjustmentMemberpiii:ClassAndClassDPreferredUnitsMember2021-01-012021-09-300001832511piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2022-01-012022-09-300001832511piii:LtdDLoanMember2022-01-012022-09-300001832511piii:HealthCareSharedRiskRevenueMember2022-01-012022-09-300001832511piii:ClassCPreferredUnitsMember2019-12-310001832511srt:MinimumMemberus-gaap:RealEstateMember2022-01-012022-09-300001832511srt:MaximumMemberus-gaap:RealEstateMember2022-01-012022-09-3000018325112021-01-012021-12-310001832511srt:ScenarioPreviouslyReportedMember2021-07-012021-09-300001832511piii:RevenueAdjustmentMember2021-07-012021-09-300001832511srt:ScenarioPreviouslyReportedMember2021-01-012021-09-300001832511piii:RevenueAdjustmentMember2021-01-012021-09-3000018325112021-07-012021-09-300001832511piii:AtrioMember2022-07-012022-09-300001832511piii:AtrioMember2022-01-012022-09-300001832511srt:ScenarioPreviouslyReportedMemberpiii:ClassPreferredUnitsMember2021-07-012021-09-300001832511piii:PreferredReturnsRestatementAdjustmentMemberpiii:ClassPreferredUnitsMember2021-07-012021-09-300001832511srt:ScenarioPreviouslyReportedMemberpiii:ClassPreferredUnitsMember2021-04-012021-06-300001832511piii:PreferredReturnsRestatementAdjustmentMemberpiii:ClassPreferredUnitsMember2021-04-012021-06-300001832511srt:ScenarioPreviouslyReportedMemberpiii:ClassPreferredUnitsMember2021-01-012021-09-300001832511piii:PreferredReturnsRestatementAdjustmentMemberpiii:ClassPreferredUnitsMember2021-01-012021-09-300001832511srt:ScenarioPreviouslyReportedMemberpiii:ClassPreferredUnitsMember2021-01-012021-03-310001832511piii:PreferredReturnsRestatementAdjustmentMemberpiii:ClassPreferredUnitsMember2021-01-012021-03-310001832511stpr:NVus-gaap:RealEstateMember2022-01-012022-09-300001832511piii:RenegotiationOfAgreementOfHealthPlanDueToDiscrepancyMember2021-10-012021-12-310001832511piii:HealthPlanVMember2022-09-300001832511piii:HealthPlanUMember2022-09-300001832511piii:HealthPlanOMember2022-09-300001832511piii:HealthPlanMember2022-09-300001832511piii:HealthPlanIMember2022-09-300001832511piii:HealthPlanGMember2022-09-300001832511piii:HealthPlanFMember2022-09-300001832511piii:HealthPlanBMember2022-09-300001832511piii:HealthPlanVMember2021-12-310001832511piii:HealthPlanUMember2021-12-310001832511piii:HealthPlanOMember2021-12-310001832511piii:HealthPlanIMember2021-12-310001832511piii:HealthPlanGMember2021-12-310001832511piii:HealthPlanFMember2021-12-310001832511piii:HealthPlanDMember2021-12-310001832511piii:HealthPlanBMember2021-12-310001832511piii:HealthPlanWMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanTMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanSMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanQMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanPMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanOMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanNMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanMMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanJMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanIMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanHMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanGMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanFMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanEMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanDMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanCMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanBMemberpiii:CapitatedRevenueMember2022-09-300001832511piii:CapitatedRevenueMember2022-09-300001832511piii:HealthPlanUMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanTMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanRMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanQMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanPMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanOMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanNMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanMMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanLMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanKMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanJMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanIMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanHMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanGMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanFMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanEMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanDMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanCMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanBMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:CapitatedRevenueMember2021-12-310001832511srt:MinimumMember2022-09-300001832511srt:MaximumMember2022-09-300001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2021-12-032021-12-030001832511piii:LtdCLoanMember2020-11-190001832511piii:LtdDLoanMember2025-01-012025-12-310001832511piii:LtdDLoanMember2024-01-012024-12-310001832511piii:LtdDLoanMember2023-01-012023-12-310001832511piii:LtdDLoanMember2022-01-012022-12-310001832511piii:LtdDLoanMember2021-01-012021-12-310001832511piii:LtdDLoanMember2022-09-300001832511piii:LtdDLoanMember2021-12-310001832511piii:LtdCLoanMember2022-09-300001832511piii:LtdCLoanMember2021-12-310001832511piii:LtdDLoanMember2020-11-192020-11-190001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-09-300001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001832511piii:ClassDWarrantsMember2020-11-192020-11-1900018325112022-09-3000018325112021-12-310001832511piii:CommonClassVMember2022-01-012022-09-300001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-020001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2021-12-310001832511piii:P3LlcMember2021-12-030001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-07-012022-09-300001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2021-12-272021-12-310001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-022021-12-0200018325112021-01-012021-09-300001832511piii:P3LlcMember2021-12-032021-12-030001832511piii:LtdELoanMemberpiii:ClassCPreferredUnitsMember2020-06-072020-06-070001832511piii:CapitatedRevenueMember2022-01-012022-09-300001832511us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-3000018325112022-07-012022-09-300001832511us-gaap:CommonClassAMember2022-01-012022-09-300001832511piii:WarrantsExercisableForOneShareOfCommonStockMember2022-01-012022-09-300001832511us-gaap:CommonClassAMember2022-11-080001832511piii:CommonClassVMember2022-11-0800018325112022-01-012022-09-30piii:Optionpiii:shareholderpiii:statepiii:paymentpiii:segmentpiii:Yxbrli:sharesiso4217:USDpiii:itemiso4217:USDxbrli:sharespiii:Dpiii:Votexbrli:purepiii:planpiii:agreement

z

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number: 001-40033

P3 Health Partners Inc.

(Exact name of registrant as specified in its charter)

Delaware

85-2992794

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2370 Corporate Circle Suite 300 Henderson, Nevada

89074

(Address of principal executive offices)

(Zip code)

(702) 910–3950

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Name of each exchange

Title of each class

    

Trading Symbol(s)

    

on which registered

Class A Common Stock, Par Value $0.0001 per share Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50

PIII

PIIIW

The Nasdaq Stock Market LLC

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer 

Accelerated filer 

Non-accelerated filer 

Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of outstanding shares of the Registrant’s Class A Common Stock, par value $0.0001 as of November 8, 2022 was 41,578,890. The number of outstanding shares of the Registrant’s Class V Common Stock, par value $0.0001 as of November 8, 2022 was 202,024,923.

TABLE OF CONTENTS

    

Page

Cautionary Statement Regarding Forward-Looking Statements

3

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

5

Condensed Consolidated Balance Sheets (Unaudited)

5

Condensed Consolidated Statements of Operations (Unaudited)

6

Condensed Consolidated Statements of Stockholders’/Members’ Equity (Deficit) and Mezzanine Equity (Unaudited)

7

Condensed Consolidated Statements of Cash Flows (Unaudited)

8

Notes to Condensed Consolidated Financial Statements (Unaudited)

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

44

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

58

Item 4.

Controls and Procedures

59

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

60

Item 1A.

Risk Factors

62

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

62

Item 3.

Defaults Upon Senior Securities

62

Item 4.

Mine Safety Disclosures

62

Item 5.

Other Information

62

Item 6.

Exhibits

63

SIGNATURES

65

2

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical information, this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (this “Form 10-Q”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective product and services, regulatory approvals of our products and services, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and services and prospects, plans and objectives of management, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “would” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Form 10-Q entitled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Form 10-Q. These forward-looking statements are subject to numerous risks, including, without limitation, the following:

our ability to preserve an adequate level of liquidity for a period extending twelve months, which has raised substantial doubt about our ability to continue as a going concern, and as a result of which, we may need to look to add additional capital or may delay or scale back growth as needed to generate liquidity and positive cash flow as soon as possible;
our ability to recognize the anticipated benefits of the Business Combinations (as defined below), which may be affected by, among other things, competition and our ability to grow and manage growth profitably following the Business Combinations;
changes in applicable laws or regulations;
the possibility that we may be adversely affected by other economic, business, and/or competitive factors, including economic instability and inflationary conditions;
the possibility that we may never achieve or maintain profitability;
the difficulty in evaluating our future prospects, as well as risks and challenges, due to the new and rapidly evolving business and market and our limited operating history;
the possibility that we may need to raise additional capital to fund our existing operations, develop and commercialize new services or expand our operations;
possible difficulty managing growth and expanding operations;
the continuing impact of the COVID-19 pandemic on operations, which may materially and adversely affect our business and financial results;
our ability to retain qualified personnel;
our ability to successfully execute on growth strategies, including identifying and developing successful new geographies, physician partners, payors and patients, and accurately estimating the size, revenue or medical expense amounts of target geographies;
delays and uncertainties in the timing and process of reimbursements by third-party payors and individuals, including any changes or reductions in Medicare reimbursement rates or rules;

3

the termination or non-renewal of the Medicare Advantage contracts held by the health plans with which we contract, or the termination or non-renewal of our contracts with those plans;
reductions in the quality ratings of the health plans we serve;
the effectiveness and efficiency of our marketing efforts, and our ability to develop brand awareness cost-effectively;
spending changes in the healthcare industry;
we, our affiliated professional entities and other physician partners may become subject to medical liability claims;
a failure in our information technology systems;
security breaches, loss of data or other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information, expose us to liability and our reputation may be harmed and we could lose revenue, clients and members;
any future litigation against us could be costly and time-consuming to defend;
failure to adhere to all of the complex government laws and regulations that apply to our business could result in fines or penalties, being required to make changes to our operations or experiencing adverse publicity;
failure to establish and maintain effective internal control over financial reporting and remediate identified material weaknesses;
failure to comply with the continued listing standards of Nasdaq;
the possibility that our arrangements with affiliated professional entities and other physician partners is found to constitute improper rendering of medical services or fee splitting under applicable state laws;
the possibility that we face inspections, reviews, audits and investigations under federal and state government programs and contracts;
the impact on us of recent healthcare legislation and other changes in the healthcare industry and in healthcare spending is currently unknown;
the transition from volume to value-based reimbursement models may have a material adverse effect on our operations;
the risks and uncertainties identified in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Form 10-Q; and
the risks and uncertainties described under Part II, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”).

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

You should read this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

4

PART I            FINANCIAL INFORMATION

Item 1.Financial Statements

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

    

As of September 30, 2022

    

As of December 31, 2021

ASSETS

CURRENT ASSETS:

Cash

$

34,357,237

$

140,477,586

Restricted Cash

 

1,003,307

 

356,286

Health Plan Receivables, Net

 

81,497,703

 

50,251,004

Clinic Fees and Insurance Receivables, Net

 

1,049,253

 

1,090,104

Other Receivables

 

2,736,184

 

726,903

Prepaid Expenses and Other Current Assets

 

3,523,867

 

6,959,067

TOTAL CURRENT ASSETS

 

124,167,551

 

199,860,950

LONG-TERM ASSETS:

Property and Equipment

 

11,509,656

 

8,230,250

Less: Accumulated Depreciation

 

(1,994,380)

 

(182,321)

Property and Equipment, Net

 

9,515,276

 

8,047,929

Goodwill

 

463,496,191

 

1,309,750,216

Intangible Assets, Net

 

772,411,083

 

835,838,605

Notes Receivable, Net

 

3,563,462

 

3,590,715

Right of Use Asset

 

9,977,886

 

7,020,045

TOTAL LONG-TERM ASSETS

 

1,258,963,898

 

2,164,247,510

TOTAL ASSETS (1)

$

1,383,131,449

$

2,364,108,460

LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts Payable and Accrued Expenses

$

24,072,391

$

17,730,683

Accrued Payroll

 

7,358,102

 

6,304,362

Health Plans Settlements Payable

 

20,626,836

 

22,548,694

Claims Payable

 

134,705,426

 

101,958,324

Premium Deficiency Reserve

 

27,719,928

 

37,835,642

Accrued Interest

 

12,655,918

 

8,771,065

Current Portion of Long-Term Debt

 

 

46,101

Short-Term Debt

 

 

3,578,561

TOTAL CURRENT LIABILITIES

 

227,138,601

 

198,773,432

LONG-TERM LIABILITIES:

Right of Use Liability

 

11,156,949

 

6,296,883

Warrant Liabilities

 

7,996,432

 

11,382,826

Contingent Consideration

 

4,684,503

 

3,486,593

Long-Term Debt

 

80,000,000

 

80,000,000

TOTAL LONG-TERM LIABILITIES

 

103,837,884

 

101,166,302

TOTAL LIABILITIES (1)

 

330,976,485

 

299,939,734

COMMITMENTS AND CONTINGENCIES (NOTE 23)

MEZZANINE EQUITY

Redeemable Non-Controlling Interest

 

974,078,949

 

1,790,617,285

STOCKHOLDERS’ EQUITY:

Class A Common Stock, $.0001 par value; 800,000,000 shares authorized; 41,578,890 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 

4,158

 

4,158

Class V Common Stock, $.0001 par value; 205,000,000 shares authorized; 201,530,796 shares and 196,553,523 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 

20,153

 

19,655

Additional Paid in Capital

 

293,570,464

 

312,945,752

Accumulated Deficit

 

(215,518,760)

 

(39,418,124)

TOTAL STOCKHOLDERS’ EQUITY

 

78,076,015

 

273,551,441

TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS’ EQUITY

$

1,383,131,449

$

2,364,108,460

(1)

The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 25 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the P3 LLC’s VIEs totaling $6.8 million and $8.1 million as of September 30, 2022 and December 31, 2021, respectively, and total liabilities of the P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $9.9 million and $6.1 million as of September 30, 2022 and December 31, 2021, respectively. These VIE assets and liabilities do not include $6.0 million of investment in affiliates as of September 30, 2022 and December 31, 2021, and $27.0 million and $24.1 million of amounts due to affiliates as of September 30, 2022 and December 31, 2021, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 25 “Variable Interest Entities.”

See accompanying notes to condensed consolidated financial statements.

5

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Successor

Predecessor

Successor

Predecessor

 

Three Months Ended

 

Three Months Ended

 

Nine Months Ended

 

Nine Months Ended

    

September 30, 2022

    

    

September 30, 2021

    

September 30, 2022

    

    

September 30, 2021

 

(As Restated)

 

(As Restated)

OPERATING REVENUE:

 

  

 

  

 

  

 

  

Capitated Revenue

$

243,988,004

$

153,072,995

$

780,775,285

$

443,598,050

Other Patient Service Revenue

 

4,272,069

 

3,112,960

 

10,483,093

 

8,472,288

TOTAL OPERATING REVENUE

 

248,260,073

 

156,185,955

 

791,258,378

 

452,070,338

OPERATING EXPENSES:

 

  

 

  

 

  

 

  

Medical Expenses

 

254,776,548

 

161,328,123

 

788,045,718

 

458,333,145

Premium Deficiency Reserve

 

(7,301,630)

 

1,600,000

 

(10,115,714)

 

4,600,000

Corporate, General and Administrative Expenses

 

37,862,737

 

20,433,538

 

117,560,549

 

53,883,267

Sales and Marketing Expenses

 

1,119,552

 

491,418

 

3,392,178

 

1,118,160

Goodwill Impairment

851,455,754

Depreciation and Amortization

 

21,814,803

 

456,418

 

65,286,715

 

1,218,797

TOTAL OPERATING EXPENSES

 

308,272,010

 

184,309,497

 

1,815,625,200

 

519,153,369

OPERATING LOSS

 

(60,011,937)

 

(28,123,542)

 

(1,024,366,822)

 

(67,083,031)

OTHER INCOME (EXPENSES):

 

  

 

  

 

  

 

  

Interest Expense, net

 

(2,749,681)

 

(2,529,133)

 

(8,244,806)

 

(7,023,187)

Mark-to-Market of Stock Warrants

 

(2,567,423)

 

(1,401,686)

 

3,386,394

 

(12,063,265)

TOTAL OTHER INCOME (EXPENSE)

 

(5,317,104)

 

(3,930,819)

 

(4,858,412)

 

(19,086,452)

LOSS BEFORE INCOME TAXES

 

(65,329,041)

 

(32,054,361)

 

(1,029,225,234)

 

(86,169,483)

PROVISION FOR INCOME TAXES

 

 

 

 

NET LOSS

 

(65,329,041)

 

(32,054,361)

(1,029,225,234)

(86,169,483)

LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS

 

(54,155,858)

 

 

(853,124,598)

 

NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS

$

(11,173,183)

$

(32,054,361)

$

(176,100,636)

$

(86,169,483)

NET LOSS PER SHARE (BASIC)

$

(0.27)

N/A1

$

(4.24)

N/A1

NET LOSS PER SHARE (DILUTED)

$

(0.27)

 

N/A1

$

(4.27)

 

N/A1

See accompanying notes to condensed consolidated financial statements.

1 The Company analyzed the calculation of net loss per member unit for predecessor periods prior to the Business Combinations and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, net loss per member unit information has not been presented for predecessor periods prior to the Business Combinations on December 3, 2021.

6

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’/MEMBERS’ EQUITY (DEFICIT) AND MEZZANINE EQUITY

(UNAUDITED)

    

    Class A

Class D

Class B-1

    

Class C

    

Redemption of 

    

    

 

Units

    

Amount

    

Units

    

Amount

  

  

Units

    

Amounts

 

Units

    

Amount

Profit Interest

Accumulated Deficit

Total Member's Deficit

MEMBERS' DEFICIT, DECEMBER 31, 2020 As Restated

 

43,000,000

$

43,656,270

16,130,034

$

47,041,554

6,000,000

$

380,000

 

1,302,083

$

67,474

$

(180,000)

$

(130,485,179)

$

(130,217,705)

Class C Unit Based Compensation

 

 

 

 

 

333,750

 

460,515

 

 

 

460,515

Net Loss

 

 

 

 

 

 

 

 

(24,650,712)

 

(24,650,712)

MEMBERS’ DEFICIT, MARCH 31, 2021 As Restated

 

43,000,000

$

43,656,270

16,130,034

$

47,041,554

6,000,000

$

380,000

 

1,635,833

$

527,989

$

(180,000)

$

(155,135,891)

$

(154,407,902)

Class B-1 and Class C Unit Based Compensation

 

 

 

2,000,000

 

380,000

 

140,000

 

183,792

 

 

 

563,792

Net Loss

 

 

 

 

 

 

 

 

(29,464,410)

 

(29,464,410)

MEMBERS’ DEFICIT, June 30, 2021 As Restated

 

43,000,000

$

43,656,270

16,130,034

47,041,554

8,000,000

$

760,000

 

1,775,833

$

711,781

$

(180,000)

$

(184,600,301)

$

(183,308,520)

Class B-1 and Class C Unit Based Compensation

 

 

 

 

 

150,000

 

355,088

 

 

 

355,088

Net Loss

 

 

 

 

 

 

 

 

(32,054,361)

 

(32,054,361)

MEMBERS’ DEFICIT, September 30, 2021 As Restated

 

43,000,000

$

43,656,270

16,130,034

47,041,554

8,000,000

$

760,000

 

1,925,833

$

1,066,869

$

(180,000)

$

(216,654,662)

$

(215,007,793)

Successor

Redeemable

Noncontrolling

Class A Common Stock

Class V Common Stock

Additional 

Accumulated 

Total 

    

Interests

    

    

Shares

    

Amount

    

Shares

    

Amount

    

Paid in Capital

    

Deficit

    

Stockholders' Equity

STOCKHOLDERS' EQUITY (DEFICIT), December 31, 2021

$

1,790,617,285

 

41,578,890

$

4,158

 

196,553,523

$

19,655

$

312,945,752

$

(39,418,124)

$

273,551,441

Vesting of stock compensation awards

 

 

 

 

549,822

 

55

 

 

 

55

Stock compensation

 

11,711,427

 

 

 

 

 

 

 

Net Loss

 

(50,212,750)

 

 

 

 

 

 

(10,577,504)

 

(10,577,504)

STOCKHOLDERS' EQUITY (DEFICIT), March 31, 2022

$

1,752,115,962

 

41,578,890

$

4,158

 

197,103,345

$

19,710

$

312,945,752

$

(49,995,628)

$

262,973,992

Vesting of stock compensation awards

 

 

 

 

4,319,964

 

432

 

 

 

432

Stock compensation

 

3,715,553

 

 

 

 

 

 

 

Net Loss

 

(748,755,990)

 

 

 

 

 

 

(154,349,949)

 

(154,349,949)

STOCKHOLDERS' EQUITY (DEFICIT), June 30, 2022

$

1,007,075,525

 

41,578,890

$

4,158

 

201,423,309

$

20,142

$

312,945,752

$

(204,345,577)

$

108,624,475

Vesting of stock compensation awards

107,487

11

11

Stock compensation

1,783,994

Adjustments to Redeemable Non-Controlling Interest

19,375,288

(19,375,288)

(19,375,288)

Net Loss

(54,155,858)

(11,173,183)

(11,173,183)

STOCKHOLDERS' EQUITY (DEFICIT), September 30, 2022

$

974,078,949

41,578,890

$

4,158

201,530,796

$

20,153

$

293,570,464

$

(215,518,760)

$

78,076,015

See accompanying notes to condensed consolidated financial statements.

7

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

    

Successor

  

  

Predecessor

 

Nine Months Ended

 

Nine Months Ended

September 30, 2022

September 30, 2021

 

(As Restated)

Cash Flows from Operating Activities

 

  

 

  

Net Loss

$

(1,029,225,234)

$

(86,169,483)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

  

 

  

Depreciation and Amortization

 

65,286,715

 

1,218,796

Stock-Based Compensation

 

17,210,974

 

1,379,400

Goodwill Impairment

851,455,754

Amortization of Debt Origination Fees

 

 

525,783

Amortization of Discount from Issuance of Debt

 

 

931,958

Mark-to-Market Adjustment of Stock Warrants

 

(3,386,394)

 

12,063,265

Premium Deficiency Reserve

 

(10,115,714)

 

4,600,000

Non-cash Interest Expense

290,910

Changes in Assets and Liabilities:

 

 

  

Accounts Receivable

 

(1,623,188)

 

54,602

Health Plan Receivables / Premiums

 

(31,246,699)

 

(884,523)

Other Current Assets

 

3,462,453

 

2,667,427

Net Change in ROU Assets and Liabilities

3,500,981

379,235

Accounts Payable

 

4,560,474

 

3,606,729

Accrued Payroll

 

1,053,740

 

(1,842,877)

Accrued Interest

 

3,884,853

 

3,952,044

Health Plan Payables / Premiums

 

(1,921,858)

 

(483,657)

Claims Payable

 

32,747,102

 

18,173,851

Net Cash used in Operating Activities

 

(94,065,131)

 

(39,827,450)

Cash Flows from Investing activities

 

  

 

  

Purchase of Property, Plant and Equipment

 

(2,283,404)

 

(2,990,130)

Acquisitions

 

(5,500,131)

 

(5,014,500)

Increase in Notes Receivable, Net

 

 

120,463

Net Cash used in Investing Activities

 

(7,783,535)

 

(7,884,167)

Cash Flows from Financing activities

 

  

 

  

Issuance of Long-Term Debt

 

 

12,750,000

Repayment of Short-Term and Long-Term Debt

 

(3,624,662)

 

(67,216)

Loan Origination and Closing Fees

 

 

(191,250)

Net Cash (used in) provided by Financing Activities

 

(3,624,662)

 

12,491,534

Net Change in Cash and Restricted Cash

 

(105,473,328)

 

(35,220,083)

Cash and Restricted Cash, Beginning of Period

 

140,833,872

 

39,902,947

Cash and Restricted Cash, End of Period

$

35,360,544

$

4,682,864

See accompanying notes to condensed consolidated financial statements.

8

P3 HEALTH PARTNERS INC and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1: Organization and Basis of Presentation

Description of Business and Business Combination

P3 Health Partners Inc. (the “Company” or “P3”) is a patient-centered and physician-led population health management company and the successor to P3 Health Group Holdings, LLC

P3 Health Group Holdings, LLC and Subsidiaries was founded on April 12, 2017 and began commercial operations on April 20, 2017 to provide population health management services on an at-risk basis to insurance plans offering medical coverage to Medicare beneficiaries under Medicare Advantage programs. Medicare Advantage programs are insurance products created solely for Medicare beneficiaries. Insurance plans contract directly with the Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare beneficiaries benefits that replace traditional Medicare Fee for Service (“FFS”) coverage.

On December 3, 2021, (the “Closing Date”), the Company consummated the transactions pursuant to which, among other things, P3 Health Group Holdings, LLC merged with and into FAC Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Foresight Acquisition Corp. (“Foresight” or “Merger Sub”) (the “P3 Merger”), with Merger Sub as the surviving company, which was renamed P3 Health Group, LLC (“P3 LLC”), and FAC-A Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight, FAC-B Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight (together with FAC-A Merger Sub Corp., the “Merger Corps”) merged with and into CPF P3 Blocker-A, LLC, a Delaware limited liability company, CPF P3 Blocker-B, LLC a Delaware limited liability company (together with CPF P3 Blocker-A, LLC, the “Blockers”), with the Blockers as the surviving entities and wholly-owned subsidiaries of Foresight (collectively, the “Business Combinations”). Upon completion of the Business Combinations (the “Closing”), the Company and P3 LLC were organized in an “Up-C” structure in which all of the P3 LLC operating subsidiaries are held directly or indirectly by P3 LLC, and the Company directly owned approximately 17.1% of P3 LLC and became the sole manager of P3 LLC. Following Closing, substantially all of the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interest in P3 LLC (“P3 LLC Units”). In connection with the closing of the transactions, the Company changed its name from Foresight Acquisition Corp. to P3 Health Partners Inc.

The Company’s contracts with health plans are based on an at-risk shared savings model. Under this model, the Company is financially responsible for the cost of all contractually covered services provided to members assigned to the Company by health plans in exchange for a fixed monthly “capitation” payment, which is generally a percentage of the payment health plans receive from CMS. Under this arrangement, Medicare beneficiaries generally receive all their healthcare coverage through the Company’s network of employed and affiliated physicians and specialists (except for emergency situations).

The services provided to health plans’ members vary by contract. These may include utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of Company providers, processing and payment of claims and the establishment of a provider network for certain health plans. At September 30, 2022 and December 31, 2021, the Company had agreements with twenty and seventeen health plans, respectively.

The Company has Management Services Agreements (“MSAs”) and deficit funding agreements with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, P3 Health Partners Professional Services P.C., P3 Medical Group, P.C. and P3 Health Partners California, P.C. (collectively, the “Network”). As more fully described in Note 25 “Variable Interest Entities,” the entities in the Network are variable interest entities and the Company is the primary beneficiary of the Network. The MSAs provide that the Company or its subsidiaries will furnish administrative personnel, office supplies and equipment, general business services, contract negotiation and billing and collection services to the Network. Fees for these services are the excess of the Network’s revenue over expenses. Per the deficit funding agreements, the Company or its subsidiaries are obligated to lend amounts to the Network to the extent expenses exceed revenues. The loan will bear interest at prime plus 2%.

9

In addition to the Company’s contracts with health plans, through its relationship with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, the Company provides primary healthcare services through its employed physician clinic locations. These primary care clinics are reimbursed for services provided under FFS contracts with various payers and through capitated – per member, per month (“PMPM”) arrangements.

Basis of Presentation

These unaudited interim condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of the U.S. Securities and Exchange Commission (“SEC”) Regulation S-X. The condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). Certain information and footnote disclosures, normally included in financial statements prepared in accordance with U.S. GAAP, have been condensed or omitted pursuant to SEC rules and regulations dealing with interim financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. For further information, refer to the consolidated financial statements and notes thereto included in our 2021 Form 10-K. There have been no significant changes to our accounting policies and estimates during the nine months ended September 30, 2022 from those previously disclosed in the 2021 Form 10-K.

As a result of the Business Combinations, for accounting purposes, Foresight is the acquirer and P3 Health Group Holdings, LLC is the accounting acquiree and predecessor. The financial statement presentation includes the financial statements of P3 Health Group Holdings, LLC as “Predecessor” for the periods prior to the Closing Date (the “Predecessor Period(s)”) and of the Company as “Successor” for the periods after the Closing Date (the “Successor Period(s)”), including the consolidation of P3 Health Group Holdings, LLC.

As a result of the application of the acquisition method of accounting as of the Closing Date of the Business Combinations, the accompanying unaudited condensed consolidated financial statements include a black line division that indicates that the Predecessor and Successor reporting entities shown are presented on a different basis and are, therefore, not comparable.

The Company qualifies as an Emerging Growth Company (“EGC”) and as such, has elected the extended transition period for complying with certain new or revised accounting pronouncements. During the extended transition period, the Company is not subject to certain new or revised accounting standards applicable to public companies. The accounting pronouncements pending adoption as described in Note 6 “Recent Accounting Pronouncements Not Yet Adopted” reflect effective dates for the Company as an EGC with the extended transition period.

Restatement of Prior Year Amounts

As discussed in the Company's 2021 consolidated financial statements included in the 2021 Form 10-K, the Company restated the previously issued unaudited condensed consolidated financial statements for each interim period within the fiscal years ended December 31, 2021 and December 31, 2020.

10

Note 2: Restatement of Previously Issued Financial Statements

The Company has restated the condensed consolidated financial statements for the three and nine months ended September 30, 2021.

Network

Since 2017, P3 Health Group Holdings and P3 Health Partners, LLC (collectively with P3 Health Partners, Inc., “P3”) have entered into a collective of arrangements with the Network whereby P3 consolidates the Network under the Variable Interest Entity model in accordance with ASC Topic 810, Consolidation (“ASC 810”). Historically, all of the net losses incurred by the Network were allocated to loss attributable to non-controlling interests. Based on an analysis of the deficit funding agreement between P3 and the Network, P3 is obligated to fund losses incurred by the Network. Because P3 is contractually obligated to fund the losses, losses incurred by the Network should not be allocated to non-controlling interests.

Based on management’s evaluation, it was concluded that the Company’s accounting for non-controlling interests related to the Network is not attributed in the manner contemplated by ASC 810. As a result, the Company has reclassified the loss attributable to non-controlling interest related to the Network to loss attributable to controlling interests on the Consolidated Balance Sheets, Consolidated Statements of Operations, and the Consolidated Statements of Changes in Stockholders’/Members’ Equity for the periods described above.

The Company's accounting for the loss in controlling interests instead of non-controlling interests has no impact on the Company's current or previously reported cash position, revenue, operating expenses or total operating, investing or financing cash flows.

Preferred Returns

P3's capital structure consists of Class A Units, which represent commitments from the Company’s private equity sponsors, and Class D Units, which represents an additional investment from a private equity sponsor. Both the Class A and Class D Units have voting rights and, accrue a preferred return in the amount of 8.0% per annum.

Historically, all of the accrued returns were recognized as interest expense on P3’s Statements of Operations and as equity on P3’s Balance Sheets. Based on the analysis of the Class A and Class D Units, the preferred returns should not be accrued until they are legally declared. As a result, the Company’s historical recording of preferred returns in equity and interest expense has been removed as no recognition is necessary until legally declared.

Class A Units

Historically, the Class A Preferred Units issued by P3 were accounted for as permanent equity. Since the Class A Preferred Units are redeemable upon the occurrence of a Sale of the Company via the liquidation and distribution preferences that returns invested capital and the preferred return, management evaluated whether the occurrence of such an event is outside of the Company’s control. As the Class A preferred unit holders hold a majority vote, the redemption of Class A Preferred Units upon a Sale of the Company, irrespective of probability, is outside of the Company’s control.

Based on management’s evaluation, the Class A Preferred Units should be reclassified from permanent to mezzanine equity. Additionally, the Company entered into the Second Amended and Restated Limited Liability Company Agreement in 2019, which provided the holders of Class A units an 8% per annum preferred return.  The Company determined that the amendment should be accounted for as a modification. Therefore, the Company recorded the incremental increase in fair value as an adjustment to the carrying value of Class A units with an offset to additional paid in capital equivalent and accumulated deficit.

11

Capitated Revenues

Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient (via a Risk Adjustment Factor, “RAF”). The Company’s policy is to recognize the variable RAF component of capitation revenues, to the extent that it is probable a significant reversal will not occur. At the December 31, 2020 balance sheet date the Company determined its estimates of the RAF components of certain capitation revenues were constrained and therefore not estimable, as it was not probable a significant reversal would not occur. The Company subsequently collected the RAF components of capitation payments prior to the issuance of the 2020 financial statements, effectively relieving the constraints which previously existed at the December 31, 2020 balance sheet date. As a result, capitation revenues for 2020 were restated based on the results of management’s analysis of the RAF component of cash receipts collected prior to the issuance 2020 financial statements which were previously determined to not be estimable. The revenue now recognized in 2020 was previously recognized in June of 2021. The total amount of the RAF adjustment was $6,532,954.

There were two other errors related to capitated revenue, other patient service revenue, and medical expenses which were corrected in the restatement. Firstly, the Company has reclassified capitated revenue streams attributable to the Network. These capitated revenues were previously classified as “other patient service revenue” and have been reclassified into “capitated revenue”. Secondly, the Company has eliminated intercompany revenue and expense related to transactions between Bacchus and P3-NV that should have been eliminated in consolidation. Prior to the restatement noted above regarding capitated revenue, this adjustment was a decrease to other patient service revenue and a decrease to medical expenses.

Disclosure Correction

The disclosure of the condensed financial statements of the Company’s consolidated VIE have been corrected for accrued interest and interest expense relating to the advances made to the VIE for the three and nine month periods ended September 30, 2021 (see Note 25). There is no impact to the condensed consolidated financial statements of the Company for this correction to the disclosures.

12

The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:

    

As Previously

    

Network

    

Preferred Returns

    

Class A Units

    

Revenue

    

    

Reported

    

Adjustments

    

Adjustments

    

Adjustments

    

Adjustment

    

As Restated

Condensed Consolidated Statement of Operations for the Nine Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

447,137,121

$

$

$

$

(3,539,071)

$

443,598,050

Other Patient Service Revenue

 

12,366,111

 

 

 

 

(3,893,823)

 

8,472,288

Total Operating Revenue

 

459,503,232

 

 

 

 

(7,432,894)

 

452,070,338

Medical Expenses

 

459,233,085

 

 

 

 

(899,940)

 

458,333,145

Total Operating Expenses

 

520,053,309

 

 

 

 

(899,940)

 

519,153,369

Operating Loss

 

(60,550,077)

 

 

 

 

(6,532,954)

 

(67,083,031)

Interest Expense, net

 

(13,130,628)

 

 

6,107,441

 

 

 

(7,023,187)

Total Other Expenses

 

(25,193,893)

 

 

6,107,441

 

 

 

(19,086,452)

Net Loss Attributable to Non-Controlling Interests

 

(8,043,678)

 

8,043,678

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(77,700,292)

 

(8,043,678)

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

152,276,992

$

$

$

$

796,003

$

153,072,995

Other Patient Service Revenue

 

4,243,263

 

 

 

 

(1,130,303)

 

3,112,960

Total Operating Revenue

 

156,520,255

 

 

 

 

(334,300)

 

156,185,955

Medical Expenses

 

161,662,423

 

 

 

 

(334,300)

 

161,328,123

Total Operating Expenses

 

184,643,797

 

 

 

 

(334,300)

 

184,309,497

Interest Expense, net

 

(4,643,254)

 

 

2,114,121

 

 

 

(2,529,133)

Total Other Expenses

 

(6,044,940)

 

 

2,114,121

 

 

 

(3,930,819)

Net Loss Attributable to Non-Controlling Interests

 

(2,801,965)

 

2,801,965

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(31,366,517)

 

(2,801,965)

 

2,114,121

 

 

 

(32,054,361)

Condensed Consolidated Statement of Changes in Members' Deficit for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

2,779,619

$

$

(2,779,619)

$

$

$

Net Loss

 

(85,743,970)

 

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

962,163

$

$

(962,163)

$

$

$

Net Loss

 

(34,168,482)

 

 

2,114,121

 

 

 

(32,054,361)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Net Loss

$

(85,743,970)

$

$

6,107,441

$

$

(6,532,954)

$

(86,169,483)

Health Plan Settlements Receivable/Premiums Receivable

 

(7,417,477)

 

 

 

 

6,532,954

 

(884,523)

Class A and Class D Preferred Returns

 

6,107,441

 

 

(6,107,441)

 

 

 

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended June 30, 2021

Preferred Return at 8% for Class A Units

$

926,852

$

$

(926,852)

$

$

$

Net Loss

(24,967,931)

2,036,476

(6,532,955)

(29,464,410)

Balance as of June 30, 2021

(146,395,455)

6,743,106

(43,656,170)

(183,308,519)

Condensed Consolidated Statements of Changes in Members' Deficit for the 3 Months Ended March 31, 2021

Preferred Return at 8% for Class A Units

$

890,612

$

$

(890,612)

$

$

$

Net Loss

(26,607,560)

1,956,848

(24,650,712)

Balance as of March 31, 2021

(122,918,168)

5,633,581

(43,656,269)

6,532,954

(154,407,902)

Consolidated Statements of Changes in Members' Deficit for the Year Ended December 31, 2020

 

  

 

  

 

  

 

  

 

  

 

  

Balance as of December 31, 2020

$

(97,661,735)

$

$

4,567,346

$

(43,656,270)

$

6,532,954

$

(130,217,705)

*Rounding may cause variances

Note 3: Going Concern and Liquidity

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced losses since its inception and had losses of $ 65,329,041 for the three-months ended September 30, 2022 and $1,029,225,234 for the nine-months ended September 30, 2022. Such losses were primarily the result of costs

13

incurred in adding new members, building relationships with physician partners and payors, and developing new services. The Company anticipates operating losses and negative cash flows to continue for the foreseeable future as it continues to grow membership.

As of September 30, 2022, and December 31, 2021, the Company had $34,357,237 and $140,477,586, respectively, in unrestricted cash and cash equivalents available to fund future operations. The Company’s capital requirements will depend on many factors, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital. The Company will need to use available capital resources and/or raise additional capital earlier than currently anticipated. When the Company pursues additional debt and/or equity financing, there can be no assurance that such financing will be available on terms commercially acceptable to the Company. If the Company is unable to obtain additional funding when needed, it will need to curtail planned activities in order to reduce costs, which will likely have an unfavorable effect on the Company’s ability to execute on its business plan, and have an adverse effect on its business, results of operations and future prospects. As a result of these matters, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Note 4: Significant Accounting Policies

Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities,” the Company is the primary beneficiary of the following physician practices (“Network”):

Kahan, Wakefield, Abdou, PLLC (“KWA”)
Bacchus, Wakefield, Kahan, PC (“BACC”)
P3 Health Partners Professional Services PC
P3 Medical Group, P.C.
P3 Health Partners California, P.C.

All intercompany accounts and transactions have been eliminated in consolidation.

Variable Interest Entities

Management analyzes whether the Company has any financial interests in Variable Interest Entities (“VIE” or “VIEs”). This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.

Segment Reporting

The Company presents its financial statements by segment in accordance with ASC Topic No. 280, Segment Reporting (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined that the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment, which reflects how the CODM manages the Company.

14

Management’s Use of Estimates

Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.

The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.

Earnings (Loss) per Share and Member Unit

Basic and diluted net loss per share attributable to common stockholders in the Successor Periods is presented in conformity with the two-class method required for participating securities. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.

The Company analyzed the calculation of net loss per member unit for the Predecessor Periods and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Periods.

Cash and Restricted Cash

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At September 30, 2022 and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.

At September 30, 2022 and December 31, 2021, the Company had unrestricted cash of $34,357,237 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.

Successor

    

September 30, 2022

    

December 31, 2021

Unrestricted

$

34,357,237

$

140,477,586

Restricted

 

1,003,307

 

356,286

Total Cash Balances

$

35,360,544

$

140,833,872

Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.

15

The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at September 30, 2021, that sum to the total of these items reported in the condensed consolidated statements of cash flows.

Predecessor

    

September 30, 2021

Unrestricted

$

4,336,565

Restricted

 

346,299

Total Cash Balances

$

4,682,864

Revenue Recognition and Revenue Sources

The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:

Successor

Predecessor

 

 

 

Three Months Ended

Three Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Capitated Revenue

$

243,988,004

 

98.3

%  

$

153,072,995

 

98.0

%

Other Patient Service Revenue:

 

  

 

  

 

  

 

  

Clinical Fees & Insurance Revenue

 

1,956,604

 

0.8

%  

 

1,278,339

 

0.8

%

Shared Risk Revenue

 

 

0.0

%  

 

139,331

 

0.1

%

Care Coordination / Management Fees

 

1,729,800

 

0.7

%  

 

1,146,355

 

0.7

%

Incentive Fees

 

585,665

 

0.2

%  

 

548,935

 

0.4

%

Total Other Patient Service Revenue

 

4,272,069

 

1.7

%  

 

3,112,960

 

2.0

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

  

  

Nine Months Ended

Nine Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

(As Restated)

    

% of Total

Capitated Revenue

$

780,775,285

 

98.7

%  

$

443,598,050

 

98.1

%

Other Patient Service Revenue:

 

  

 

  

 

Clinical Fees & Insurance Revenue

 

4,103,481

 

0.5

%  

 

3,386,966

 

0.7

%

Shared Risk Revenue

 

55,154

 

0.0

%  

 

341,342

 

0.1

%

Care Coordination / Management Fees

 

4,412,973

 

0.6

%  

 

2,994,755

 

0.7

%

Incentive Fees

 

1,911,485

 

0.2

%  

 

1,749,225

 

0.4

%

Total Other Patient Service Revenue

 

10,483,093

 

1.3

%  

 

8,472,288

 

1.9

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

16

The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:

Successor

Predecessor

 

 

  

  

Three Months Ended

Three Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Health Plan C

$

48,538,454

 

19.5

%  

$

29,563,741

 

18.9

%

Health Plan B

 

46,082,052

 

18.5

%  

 

38,227,530

 

24.5

%

Health Plan A

 

35,936,246

 

14.5

%  

 

36,417,184

 

23.3

%

Health Plan D

 

31,563,532

 

12.8

%  

 

18,913,641

 

12.1

%

All Other

 

86,139,789

 

34.7

%  

 

33,063,859

 

21.2

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

 

Nine Months Ended

Nine Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

  

    

(As Restated)

    

% of Total

Health Plan C

$

158,252,527

 

20.0

%  

$

84,489,621

 

18.7

%

Health Plan B

 

139,920,223

 

17.7

%  

 

105,261,569

 

23.3

%

Health Plan A

 

124,681,687

 

15.8

%  

 

114,230,860

 

25.3

%

Health Plan D

 

104,439,689

 

13.2

%  

 

56,606,725

 

12.5

%

All Other

 

263,964,252

 

33.3

%  

 

91,481,563

 

20.2

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.

Capitated Revenue

The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on the health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.

17

The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.

Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first three quarters in 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).

At September 30, 2022 and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across five states) and 17 health plans (across four states), respectively.

Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within twenty-one months following each year-end.

18

At September 30, 2022, and December 31,2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:

    

Health Plan Receivables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

524,540

$

4,695,712

Health Plan B

 

24,387,307

 

15,473,828

Health Plan C

 

28,798,095

 

1,380,752

Health Plan D

 

15,136,034

 

6,651,586

Health Plan E

 

184,332

 

2,439,046

Health Plan F

 

1,467,834

 

2,925,751

Health Plan G

 

35,179

 

239,375

Health Plan H

 

3,570,820

 

2,185,619

Health Plan I

 

1,586,752

 

1,134,750

Health Plan J

 

(102,380)

 

149,915

Health Plan K

 

 

2,705,147

Health Plan L

 

 

899,560

Health Plan M

 

1,388,190

 

1,747,116

Health Plan N

 

598,056

 

974,092

Health Plan O

 

2,279,489

 

666,291

Health Plan P

 

511,469

 

106,162

Health Plan Q

 

476,057

 

61,990

Health Plan R

 

 

3,578,682

Health Plan S

 

600,639

 

Health Plan T

 

57,607

 

2,175,324

Health Plan U

 

 

60,306

Health Plan W

 

(2,317)

 

Total Health Plan Receivables

$

81,497,703

$

50,251,004

    

Health Plan Settlement Payables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

2,579,575

$

Health Plan B

 

11,700,274

 

11,700,274

Health Plan D

 

 

3,882,250

Health Plan F

 

5,103,534

 

6,085,425

Health Plan G

 

900,314

 

776,164

Health Plan I

 

(10,915)

 

(215,626)

Health Plan O

 

39,365

 

(39,151)

Health Plan U

 

226,209

 

226,209

Health Plan V

 

88,480

 

133,149

Total Health Plan Settlement Payables

$

20,626,836

$

22,548,694

At September 30, 2022, and December 31, 2021, management has deemed the Company’s settlement receivables to be fully collectible from those health plans where the Company is not delegated for claims processing. Accordingly, a constraint on the variable consideration associated with settlement receivables is not necessary.

19

Other Patient Service Revenue – Clinical Fees and Insurance Revenue

Clinic fees and insurance revenues relate to net patient fees received from various payers and direct patients (“self-payers”) under contracts in which the Company’s sole performance obligation is to provide healthcare services through the operation of medical clinics. The Company recognizes clinic fees and insurance revenue in the period in which services are provided, on the date of service, under FFS payment arrangements, revenue is recognized on the date of service. The Company’s performance obligations are typically satisfied in the same day services are provided. All the Company’s contracts with its customers under these arrangements include a single performance obligation.

The Company’s contractual relationships with patients, in most cases, also involve third-party payers (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through state-sponsored health insurance exchanges). Transaction prices for services provided are dependent upon specific rules in place with third party payers – specifically, Medicare/Medicaid and pre-negotiated rates with managed care health plans and commercial insurance companies. Contractual arrangements with third parties typically include payments at amounts which are less than standard charges. These charges generally have predetermined rates for diagnostic service codes or discounted FFS rates. Management perpetually reviews the Company’s contractual estimation processes to consider and incorporate updates to laws, regulations and frequent changes in the managed care system. Contractual terms are negotiated and updated accordingly upon renewal.

The Company’s revenue is based upon the estimated amounts management expects to receive from patients and third-party payers. Estimates of explicit price concessions under managed care and commercial insurance plans are tied to payment terms specified in related contractual agreements. Retroactively calculated explicit price concessions tied to reimbursement agreements with third-party payers are recognized on an estimated basis in the period related services are rendered and adjusted in future periods as final payments are received. Revenue related to uninsured patients, uninsured co-payments, and deductibles (for patients with healthcare coverage) may also be discounted. The Company records implicit price concessions (based on historical collection experience) related to uninsured accounts to recognize self-pay revenues at their most likely amounts to be collected.

The Company deems FFS revenue to be variable consideration and that its estimates of associated transaction prices will not result in a significant revenue reversal in the future.

Based on satisfaction of single performance obligations occurring on the dates of service, revenue is recognized as of the date services are provided. The Company, therefore, applies a portfolio approach to recognizing revenue from its FFS contracts.

Management has elected two of the available practical expedients provided for by ASC 606. First, the Company did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

Other Patient Service Revenue – Shared Risk Revenue

P3 LLC (via one of its wholly owned subsidiaries – P3 Health Partners ACO, LLC “AzCC”) receives 30% of the shared risk savings from parties with whom it contracts under four separate arrangements. These arrangements are driven solely by medical cost containment year-over-year (“YoY”) expense reductions. This key performance indicator (“KPI”) is measured by the aggregate change in per member per year (“PMPY”) medical costs. If the sequential YoY PMPY aggregate change yields a reduction, the Company receives 30% of the associated total cost savings for that year. Conversely, if the sequential YoY PMPY aggregate change yields an increase in medical costs, no monies are due the Company that year. This KPI is compiled and reviewed on a calendar year basis. The Company recognizes shared risk revenue only upon the receipt of cash. Therefore, the likelihood of any significant revenue reversal in the future is non-existent.

Other Patient Service Revenue – Care Coordination Fees and Management Fees

The Company’s delegated health plans may also pay a Care Coordination Fee (“CCF”) or Management Fee to the Company. CCFs and Management Fees are intended to fund the costs of delegated services provided to certain health plans. CCFs are specifically identified and separated in each monthly capitation payment the Company receives from these parties. None of the Company’s other health plans bifurcate CCFs nor are any of them contractually required to do so.

20

The Company uses a portfolio approach to account for CCFs and Management Fees. Based on similarities of the terms of the care coordination and administrative services, management believes that revenue recognized by utilizing the portfolio approach approximates that which it would have realized if an individual contract approach were applied.

Patient Fees Receivable

Substantially, all client fees and insurance receivables are due under FFS contracts with third party payors, such as commercial insurance companies (“Commercial”), government-sponsored healthcare programs (“Medicare/Medicaid”) or directly from patients (“Self-Pay”). Management continuously monitors activities from payors (including patients) and records an estimated price concession based on specific contracts and actual historical collection patterns. Patient fees receivable, where a third-party payor is responsible for the amount due, are carried at amounts determined by the original charges for services provided less implicit and explicit price concessions. Price concessions represent amounts made for contractual adjustments (discounts). Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and are recorded net of contractual allowances.

Patient fees receivable are recorded at the invoiced amount, net of any expected contractual adjustments and implicit price concessions, and do not bear interest. The Company has agreements with third-party payors that provide for payments at amounts different from the established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Contractual adjustments arising under reimbursement arrangements with third- party payors are accrued on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined. Implicit price concessions are taken based on historical collection experience and reflect the estimated amounts the Company expects to collect.

Goodwill

In accordance with ASC 350, Intangibles - Goodwill and Other, management tests goodwill for impairment at the reporting unit level. The Company has one reporting unit for goodwill impairment testing purposes. Goodwill is tested for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate the carrying value of goodwill may not be recoverable (a “triggering event”). On the occurrence of a triggering event, an entity has the option to first assess qualitative factors to determine whether a quantitative impairment test is necessary. If it is more likely than not that goodwill is impaired, the fair value of the reporting unit (the Company) is compared with its carrying value. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value, provided, the loss recognized cannot exceed the total amount of goodwill. No goodwill impairment charges were recorded in the first quarter or third quarter of 2022, respectively. Based on management’s analysis, a goodwill impairment charge of $851.5 million was recorded in the second quarter of 2022. See Note 11 “Goodwill.”

Intangible Assets

Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. In determining the estimated useful lives of definite-lived intangibles, the Company considers the nature, competitive position, life cycle position and historical and expected future operating cash flows of each acquired asset, as well as its commitment to support these assets through continued investment and legal infringement protection.

The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. Such events and circumstances include the occurrence of an adverse change in the market involving the business employing the assets or a situation in which it is more likely than not that the Company will dispose of such assets. If the comparison indicates that there is impairment, the impairment loss to be recognized as a non-cash charge to earnings is measured by the amount by which the carrying amount of the asset exceeds its fair value. The impaired asset is written down to its fair value or, if fair value is not readily determinable, to an estimated fair value based on discounted expected future cash flows.

21

Fair Value Measurements

The Company accounts for fair value measurements in accordance with ASC 820, Fair Value Measurements (“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 8 “Fair Value Measurements and Hierarchy” for further discussion):

Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Note 5: Recent Accounting Pronouncements Adopted

ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. It is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted the ASU in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures

Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”)

ASU 2021-04 requires issuers to account for modifications or exchanges of freestanding equity-classified written call options (e.g., warrants) that remain equity classified after the modification or exchange based on the economic substance of the modification or exchange. The Company adopted ASU 2014-04 in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.

ASU 2021-10, Government Assistance (Topic 8352), Disclosures by Business Entities about Government Assistance (“ASU 2021-10”)

In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10. ASU 2021-10 requires annual disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model including (i) information about the nature of the transactions and the related accounting policy used to account for the transaction; (ii) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (iii) significant terms and conditions of the transactions, including commitments and contingencies. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company adopted the ASU prospectively on January 1, 2022. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.

22

Note 6: Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016 13”). ASU 2016 13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for the Company beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 eliminates two of the three models in ASC 470-20 that require issuers to separately account for embedded conversion features and eliminates some of the requirements for equity classification in ASC 815-40-25 for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and generally requires them to include the effect of potential share settlement for instruments that may be settled in cash or shares. It is effective for annual periods beginning after December 15, 2023, and interim periods therein. Early adoption is permitted in fiscal years beginning after December 15, 2020, but the Company must adopt the guidance as of the beginning of a fiscal year. The Company is evaluating the effect ASU 2020-06 will have on its financial statements and related disclosures.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires that an entity (acquirer) recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts as if it had originated the contracts. The amendments in this update are effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. Adoption is not currently expected to have a material impact on the Company’s financial statements and related disclosures.

Note 7: Business Combinations

Foresight Business Combinations

On December 3, 2021, the Company entered into the Business Combinations described in Note 1 “Organization and Basis of Presentation.” The Business Combinations represent a forward merger and is accounted for using the acquisition method of accounting under which P3 Health Group Holdings, LLC is treated as the acquired company for financial reporting purposes. This determination is based primarily on the following facts:

(i)The Company is the sole managing member of P3 LLC subsequent to the consummation of the Business Combinations, and the managing member conducts, directs and exercises full control over all activities of P3 LLC. The non-managing members of P3 LLC do not have substantive kick-out or participating rights; and
(ii)No one predecessor stakeholder of P3 had a controlling interest in P3 before or has a controlling interest in the combined company after the Business Combination. The Business Combination is not a transaction between entities under common control.

23

These factors support the conclusion that the Company acquired a controlling interest in P3 LLC and is the accounting acquirer. For accounting purposes, the accounting acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated based on the variable interest or voting interest model pursuant to ASC 810. If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. The Company is the primary beneficiary of P3 LLC, which is a variable interest entity, since it has the power to direct the activities of P3 LLC that most significantly impact P3 LLC’s economic performance through its role as the sole managing member. Therefore, the Company is the accounting acquirer of P3 LLC and the Business Combinations should be accounted for using the acquisition method.

Under the acquisition method of accounting, Foresight’s assets and liabilities are recorded at carrying value and the assets and liabilities associated with P3 LLC are recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The acquisition method of accounting is based on ASC Topic 805, Business Combinations (“ASC 805”) and uses the fair value concepts defined in ASC 820. In general, ASC 805 requires, among other things, that assets acquired, and liabilities assumed be recognized at their fair values as of the acquisition date by the accounting acquirer, which was determined to be Foresight.

ASC 820 defines fair value, establishes a framework for measuring fair value, and sets forth a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to develop the fair value measurements. Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for a non-financial asset assume the highest and best use by these market participants. Many of these fair value measurements can be highly subjective, and it is possible that other professionals applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

As a result of the Business Combinations, P3 LLC, which represents substantially all of the economic activity of the Company, is a subsidiary of the Company. Since the Company is the sole managing member of P3 LLC following the Business Combinations, the P3 LLC Units held by certain of the former owners of P3 Health Group Holdings, LLC (the “P3 Equity Holders”) are classified as Redeemable Noncontrolling Interests in the Company’s financial statements for financial reporting purposes. An allocation of net income or loss representing the percentage of ownership of P3 LLC not controlled by the Company, will be attributed to the Redeemable Noncontrolling Interests in the Company’s statement of operations.

Upon the completion of the Business Combinations, the Company entered into a Tax Receivable Agreement (“TRA”) with certain of the P3 Equity holders and P3 LLC. The TRA provides for the payment to the P3 Equity holders of 85% of the income tax benefits, if any, that are actually realized. At the completion of the Business Combinations, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such tax benefits after concluding it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets. See Note 16 “Income Taxes” for further information.

The following summarizes the purchase price consideration:

    

Successor

December 31,

Foresight

2021

Equity

$

80,300,733

Fair Value of Non-controlling Interest

 

1,807,427,576

Stock Compensation Pre-combination Services

26,313,476

Cash Consideration

 

18,405,083

Payment of P3 Health Group Holdings, LLC’s Transaction Costs

 

19,151,752

Total Purchase Consideration

$

1,951,598,620

The Company recorded the allocation of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the Closing Date. The allocation reflects the fair value of assets and liabilities

24

associated with the Company’s other acquisitions in 2021 which occurred in the Predecessor period described below with the exception of Medcore Health Plan, Inc. (“Medcore HP”) and Omni IPA Medical Group, Inc. (“Omni”), which occurred in the Successor Period.

The aggregate purchase price consideration for the P3 LLC acquisition has been allocated as follows:

Purchase Price Allocation

    

Amounts

Assets Acquired:

Cash

$

5,300,842

Restricted Cash

 

54,095

Health Plan Settlement Receivables

 

47,733,033

Clinic Fees and Insurance Receivables, Net

 

426,064

Other Receivables

 

1,880,939

Prepaid Expenses and Other Current Assets

 

938,413

Property and Equipment, Net

 

7,875,234

Intangible Assets, Net:

 

  

Customer Relationships

 

684,000,000

Provider Network

 

3,700,000

Trademarks

 

147,700,000

Goodwill

 

1,278,452,778

Notes Receivable, Net

 

3,734,012

Right of Use Assets

 

6,870,279

Total Assets Acquired

$

2,188,665,689

Liabilities Assumed:

 

  

Accounts Payable and Accrued Expenses

$

25,819,091

Accrued Payroll

 

2,868,664

Health Plans Settlements Payable

 

25,007,542

Claims Payable

 

76,031,460

Premium Deficiency Reserve

 

11,559,067

Accrued Interest

 

9,268,846

Current Portion of Long-Term Debt

 

301,443

Lease Liability

 

6,210,956

Long-Term Debt, Net of Current Portion

 

80,000,000

Total Liabilities Assumed

$

237,067,069

Net Assets Acquired

$

1,951,598,620

Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $3.8 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes. See Note 16 “Income Taxes.” The useful life of acquired definite lived intangible assets is 10 years.

Other Acquisitions

On December 27, and December 31, 2021, respectively, the Company acquired 100% of the outstanding equity of Medcore HP and the net assets of Omni (collectively the “Medcore Acquisition”). Medcore HP is a health plan licensed under the California Knox-Keen Health Care Service Plan Act of 1975, and Omni is an independent practice association located in California. Omni serves as Medcore HP’s contracted and fully delegated physician network providing medical services to Medcore HP’s patients and members. Because of the extensive inter-reliance of these two businesses, the Company accounted for the purchases as a single, combined business. The total purchase price of $40,013,321 includes $3,486,593 to be paid to the sellers upon resolution of the assumed claims payable, or the cost of services that have been incurred, but not yet reported (“IBNR”), and risk adjustment factor. Due to the volatility of these items, the outcome cannot be currently estimated. Release of this payment, currently expected in the first quarter of 2023, is not subject to resolution of a substantive future contingent event and has therefore been included in the total consideration to be transferred. The cash payment, net of cash acquired and the $3,486,593 retained, was $15,677,205.

25

Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $8.1 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes.

The aggregate purchase price consideration of the other acquisitions in 2021 has been allocated as follows:

    

Successor Period

  

  

Predecessor Period

Assets Acquired:

Cash

$

20,547,337

$

3,000

Restricted Cash

 

302,187

 

Health Plan Settlement Receivables

 

5,754,006

 

Clinic Fees and Insurance Receivables, Net

 

141,186

 

Other Receivables

 

726,378

 

Prepaid Expenses and Other Current Assets

 

1,189,575

 

Property and Equipment, Net

 

113,436

 

5,896

Intangible Assets, Net:

 

 

Customer Relationships

 

 

2,045,604

Pay or Contracts

 

4,700,271

 

  

Provider Network

 

1,100,000

 

Trademarks

 

900,000

 

Medical Licenses

 

700,000

 

Goodwill

 

31,297,438

 

2,934,500

Total Assets Acquired

$

67,471,814

$

4,989,000

Liabilities Assumed:

 

  

 

  

Accounts Payable and Accrued Expenses

$

150,196

$

Accrued Payroll

 

277,074

 

Health Plans Settlements Payable

 

133,149

 

Claims Payable

 

26,898,074

 

Total Liabilities Assumed

 

27,458,493

 

Net Assets Acquired

$

40,013,321

$

4,989,000

The Company also purchased three other medical practices during the Predecessor Period of 2021 for a total net cash purchase price of $4,989,000. As referenced above, the assets acquired and liabilities assumed in these acquisitions was included in the purchase consideration and allocation for the Business Combinations.

In the third quarter of 2022, the Company acquired two medical practices in separate transactions. The total cash purchase price was $5,500,131, net of cash acquired, and was allocated primarily to goodwill. The acquisitions were determined to be immaterial for disclosure.

26

Pro Forma Financial Information (Unaudited)

The following unaudited pro forma financial information presents combined results of operations for the periods presented as if the acquisition of P3 Health Group Holdings, LLC and the Medcore Acquisition had occurred on January 1, 2021. The unaudited pro forma results may not necessarily reflect actual results of operations that would have been achieved, nor are they necessarily indicative of future results of operations. The unaudited pro forma results reflect the step-up amortization adjustments for the fair value of intangible assets acquired, transaction expenses, accelerated vesting of equity compensation and income attributable to non-controlling interest holders.

Nine Months Ended

September 30,

2021

    

(Unaudited)

Total Operating Revenue

$

567,305,732

Net Profit

(179,492,450)

Net Loss Attributable to Non-controlling Interest

(148,260,764)

Net Loss Attributable to Controlling Interest

$

(31,231,686)

The unaudited pro forma financial information has been presented for illustrative purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition taken place on the date indicated, or the future consolidated results of operations of the Company. The pro forma financial information presented above has been derived from the historical condensed consolidated financial statements of the Company, the Company's Predecessor Periods and the Company's Successor Period.

The unaudited pro forma results include certain pro forma adjustments to revenue and net loss that were directly attributable to the P3 Health Group Holdings, LLC acquisition, assuming the acquisition had occurred on January 1, 2021, including the following:

1)Transaction costs of approximately $39.4 million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.
2)The acceleration of certain stock-based awards of $2.4 million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.

Note 8: Fair Value Measurements and Hierarchy

See Note 4 “Significant Accounting Policies” for a summary of the Company’s policies relating to fair value measurements.

The following table presents the carrying amounts of the Company’s financial instruments as of September 30, 2022 and December 31, 2021, respectively:

    

Successor

    

September 30, 2022

    

December 31, 2021

Financial assets:

 

  

 

  

Cash

$

34,357,237

$

140,477,586

Restricted cash

 

1,003,307

 

356,286

Clinics fees and insurance receivables, net

 

1,049,253

 

1,090,104

Other receivables

 

2,736,184

 

726,903

Financial liabilities:

 

  

 

  

Accounts payable and accrued expenses

 

24,072,391

 

17,730,683

Warrants liabilities

 

7,996,432

 

11,382,826

The book value of cash, clinic fees and insurance receivables, net, other receivables, and accounts payable and accrued expenses approximate fair value because of the short maturity and high liquidity of these instruments. Liabilities for private placement warrants are measured at fair value using Level 3 inputs.

27

The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021:

    

Level 1

    

Level 2

    

Level 3

    

Total

Warrant liability as of September 30, 2022

$

7,774,549

$

$

221,883

$

7,996,432

Warrant liability as of December 31, 2021

 

10,880,550

 

 

502,276

 

11,382,826

The key Level 3 inputs into the option pricing model as of September 30, 2022 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

4.16

%

Exercise Price

$

11.50

Expected Term

 

4.2

Years

The key Level 3 inputs into the option pricing model as of December 31, 2021 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

1.26

%

Exercise Price

$

11.50

Expected Term

 

4.9

Years

Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock, and an increase in the remaining term of the warrants would each result in a directionally similar change in the estimated fair value of the Company’s warrant liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability. The Company has not, and does not plan to, declare dividends on its common stock and, as such, there is no change in the estimated fair value of the warrant liabilities due to the dividend assumption.

The following tables set forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated:

Successor

Predecessor

    

Nine Months Ended September

  

  

Nine Months Ended September

30, 2022

30, 2021

Beginning Balance of Private Warrant Liability

$

502,276

$

6,316,605

Mark-to-Market Adjustment for Stock Warrants

 

(280,393)

 

12,063,265

Ending Balance of Private Warrant Liability

$

221,883

$

18,379,870

Note 9: Patient Fees Receivable

Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and consisted of the following categories for each of the periods ending September 30, 2022 and December 31, 2021 presented below:

Successor

    

September 30, 2022

    

December 31, 2021

Total Receivables: Gross

$

5,383,421

$

2,641,182

Less: Contractual Allowances

 

(4,745,367)

 

(1,968,750)

Receivables Net of Contractual Allowances

$

638,054

$

672,432

28

Note 10: Property and Equipment

The Company’s property and equipment balances as of September 30, 2022 and December 31, 2021 consisted of the following:

Successor

    

September 30, 2022

    

December 31, 2021

Leasehold Improvements

$

1,809,927

$

1,537,091

Furniture & Fixtures

 

1,450,626

 

1,108,184

Computer Equipment & Software

 

2,852,746

 

2,700,617

Medical Equipment

 

1,066,959

 

414,100

Software (Development in Process)

 

3,918,615

 

2,433,470

Vehicles

373,995

Other

 

36,788

 

36,788

 

11,509,656

 

8,230,250

Less: Accumulated Depreciation

 

(1,994,380)

 

(182,321)

Property and Equipment, Net

$

9,515,276

$

8,047,929

Note 11: Goodwill

A summary of changes in the Company’s goodwill during the nine months ended September 30, 2022 is as follows:

    

September 30, 2022

Balance at December 31, 2021

$

1,309,750,216

Acquisition

5,201,729

Impairment charge

 

(851,455,754)

Balance at September 30, 2022

$

463,496,191

Goodwill, which represents the excess of cost over the fair value of net assets acquired, was $463,496,191 and $1,309,750,216 as of September 30, 2022, and December 31, 2021. The Company acquired two medical practices during the nine months ended September 30, 2022. In the second quarter of 2022, the overall market had significantly deteriorated and there was a sustained decrease in the Company’s share price. As a result, and as required by ASC 350, the Company performed an interim goodwill impairment test as of June 30, 2022.

The Company first assessed qualitative factors to determine if it was more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Management noted that the steady decline in share price from April 1, 2022, through June 30, 2022, covers a period of three months. The stock was 63% lower than its opening price on December 2, 2021, and has not surpassed that price since December 15, 2021. Additionally, the Company’s share price continued to decline in May 2022, which did not follow the overall rebound pattern in the healthcare industry. Thus, management determined that it was not just market factors affecting the price and that the share price performance covered a sustained period of time. In addition, the Company incurred higher than expected medical expenses due to the COVID-19 pandemic, which resulted in a decrease in adjusted EBITDA. Management concluded that, given the macroeconomic and financial market conditions, industry-specific considerations, the Company’s performance, and the sustained decrease in share price, it was more likely than not that the fair value of P3 was less than its carrying amount at June 30, 2022. As a result, management performed an interim test of impairment using quantitative methods.

When performing quantitative testing, the Company first estimated the fair values of its reporting units using a weighted combination of discounted cash flows and a market-based method. Taking into consideration the updated business outlook and current difficult market conditions, management updated the assumption for future cash flow estimation. In particular, management increased expected medical expense in the cash flow projection for the goodwill impairment test, which lowered the forecast for adjusted EBITDA. Under the market approach, management estimated a fair value based on comparable companies' market multiples of revenues and EBITDA. Finally, management compared the weighted estimated fair value to the carrying amount. Based on management’s quantitative analysis, an $851.5 million goodwill impairment charge was recorded for the three-month period ended June 30, 2022. No goodwill impairment was recorded for the three-month period ended September 30, 2022 as there were no indicators of impairment during this period.

29

Because the Company’s goodwill impairment analysis is sensitive to market capitalization, projected revenues, and adjusted EBITDA, the Company will continue to monitor key assumptions and other factors utilized in the interim goodwill impairment analysis.

Note 12: Intangible Assets

The follow tables provide changes in other intangible assets for the nine months ended September 30, 2022.

    

Customer

    

    

Provider

Medical

    

Relationships

    

Trademarks

    

Payor Contracts

    

Network

    

Licenses

    

Total

Balance at December 31, 2021

$

678,300,000

$

147,369,167

$

4,700,271

$

4,769,167

$

700,000

$

835,838,605

Amortization

 

(51,300,000)

 

(11,415,000)

 

(352,522)

 

(360,000)

 

 

(63,427,522)

Balance at September 30, 2022

$

627,000,000

$

135,954,167

$

4,347,749

$

4,409,167

$

700,000

$

772,411,083

Amortization of intangible assets is anticipated to be approximately $84 million in each of the years 2022 through 2026. The weighted average remaining useful life of definite lived intangible assets is 9.2 years.

Note 13: Notes Receivable, Net

The Company entered into five Promissory Notes (the “Notes”) with three family medical practices (the “Practices”) to fund their working capital needs. The Company simultaneously entered into separate Provider Agreements with each Practice related to four of these five Notes. Each Provider Agreement establishes a preferred, predetermined reimbursement rate for services rendered to the Company’s members and requires that Practice to furnish healthcare services to the Company’s members. The Provider Agreements mature in concert with each practice’s loan. In accordance with each of these four Notes, so long as the corresponding Provider Agreement is in effect on the maturity date of each Note and has not been terminated by the borrower for any reason, the Company will forgive the entire principal, plus accrued interest due on the date of maturity. Likewise, if the Company terminates the Provider Agreement prior to maturity without cause, all principal plus accrued interest due from the borrower will be forgiven. Upon early termination of the Provider Agreement by borrower, all principal and accrued interest will become immediately payable and due the Company. Related to potential forgiveness, the Company records a valuation allowance on a straight-line basis following the early termination date through the date of maturity, due to the probable likelihood of forgiveness of the Notes at maturity, with a full valuation allowance set at the time of maturity.

At September 30, 2022 and December 31, 2021, the Company has recorded notes receivable of $4,526,522 (including $963,060 current portion) and $3,590,715 including accrued interest receivable of $1,040,729 and $885,243, and net of valuation allowances of $709,547 and $526,808, respectively. The Notes carry maturity dates ranging from December 31, 2021 through December 31, 2028 with interest rates ranging from 5.0% to 10.0%. The short-term components of these Notes as of September 30, 2022 and December 31, 2021, is included in Other Receivables in the Company’s condensed consolidated balance sheets.

30

Note 14: Claims Payable

Claims payable includes claims reported as of the balance sheet date, including estimates for IBNR, due to third parties for health care services provided to members. IBNR was $134,705,426 and $101,958,324 at September 30, 2022 and December 31, 2021, respectively. Activity in the liability for claims payable and healthcare expenses for the nine months ended September 30, 2022 was as follows:

    

Successor

Nine Months Ended

    

September 30, 2022

Claims Unpaid, Beginning of Period

$

101,958,324

Incurred, Related to:

 

  

Current Period

 

700,236,928

Prior Period(s)

 

5,024,653

Total Incurred

 

705,261,581

Paid, Related to:

 

  

Current Period

 

570,830,033

Prior Period(s)

 

101,684,446

Total Paid

 

672,514,479

Claims Unpaid, End of Period

$

134,705,426

Estimates for incurred claims are based on historical enrollment and cost trends while also taking into consideration operational changes. Future and actual results typically differ from estimates. Differences could result from an overall change in medical expenses per member, changes in member mix or simply due to the addition of new members.

Note 15: Long-Term Debt

On November 19, 2020, the Company entered a Term Loan and Security Agreement (the “Facility” or “Term Loan”) with a commercial lender (“LTD-D”). The Facility was amended on December 21, 2021. The Facility provided funding up to $100,000,000, of which $65,000,000 has been drawn as of September 30, 2022. Access to additional borrowings above $65,000,000 under the Facility ended upon termination of the commitment period on February 28, 2022. Of the $65,000,000 drawn, $61,058,281 was received (net of $3,941,719 in financing costs). Upon closing of the Business Combinations on December 3, 2021, the unamortized financing costs were written off and the debt was recorded at fair value. The Facility may be used to pay certain indebtedness of the Company and for general working capital needs. Accrued interest was $4,320,493 and $2,259,588 at September 30, 2022 and December 31, 2021, respectively. The Facility includes certain restrictive covenants, including restrictions on the payment of cash dividends. Repayment of principal of all amounts drawn are due at maturity.

The Company was required to meet a borrowing base milestone by demonstrating to the lenders that revenue for any three consecutive month period (ending after the Facility’s closing date, but on or prior to December 31, 2021) was greater than or equal to $125.0 million. Additionally, the Company must remain in compliance with financial covenants including minimum liquidity of $5.0 million and annual minimum revenue levels. Beginning in 2021, and on an annual basis thereafter, the Company must post minimum annual revenue equal to or greater than $395.0 million; increasing to $460.0 million in 2022; $525.0 million in 2023; $585.0 million in 2024 and $650.0 million in 2025 and thereafter. Also, the Company is subject to certain restrictions that include indebtedness and liens. As of December 31, 2021, the Company was not in compliance with its Term Loan covenants related to issuance of the 2021 financial statements with an audit opinion free of a “going concern” qualification or timely filing of the 2021 financial statements. The Term Loan lenders granted (i) a waiver of the covenant under the Facility related to the existence of a “going concern” qualification in the audit opinion for our audited financial statements for the fiscal year ended December 31, 2021 and (ii) a consent to extend the deadline to provide audited financial statements for the year ended December 31, 2021 to October 21, 2022. The Company issued the 2021 financial statements on October 21, 2022. The Company was in compliance with all other covenants under the Facility as of September 30,2022. However, there can be no assurance that the Company will be able to maintain compliance with these covenants in the future or that the lenders under the Facility or the lenders of any future indebtedness the Company may incur will grant us any such waiver or forbearance in the future.

31

The Facility’s expected maturity date is December 31, 2025. This maturity date may be accelerated as a remedy under the certain default provisions in the agreement or in the event a mandatory prepayment trigger occurs. Interest is payable at 12.0% per annum on a quarterly cycle (in arrears) beginning March 31, 2021. Management may elect to pay the full 12.0% per annum in cash or 8.0% per annum interest in cash with the remaining 4.0% per annum being added to principal as “paid in kind” (“PIK”) for a period of three years (or twelve payments). The PIK is subject to acceleration in the event certain occurrences in the Facility’s agreement are triggered. The Facility’s Lenders also received ten-year warrants to purchase 858,351 shares of Series D Preferred Units at $4.68 per share. These warrants have been recorded as a liability in the Company’s consolidated balance sheets at fair market value and are marked to market on a quarterly basis until exercised. A discount was recorded on the debt issued for the same amount and written off upon closing of the Business Combinations.

The Security Agreement provides the Lenders collateral in 100% of the Company’s pledged stock, its subsidiaries (including tangible and intangible personal property) and bank accounts.

On June 7, 2020, the Company repurchased 200,000 Class C (Time-based) Units, at $0.90 per Unit from a former Executive through issuance of a long-term note (“LTD-E”). This repurchase was recognized in the Company’s consolidated balance sheets as a reduction to Members’ Deficit in the amount of $180,000 and a corresponding increase in long-term debt. LTD-E bore interest of 3.25% and fixed monthly payments of $7,757 through date of maturity. On June 7, 2022, the Company repaid all amounts outstanding under the long-term note.

In 2019, the Company executed a share repurchase agreement with one of its investors (“LTD-C”) which was subsequently amended on November 19, 2020. The agreement, as amended stipulated $15.0 million originally contributed by the investor would be repaid by the earlier of June 30, 2026 or a change in control transaction. As part of this repurchase agreement, the investor exchanged its owned units back for a $15.0 million note receivable from the Company – thus, no longer holding its former equity position. The note carries interest of 11.0% per year. The principal balance, accrued interest and an exit fee of $600,000 is due at maturity. Accrued interest was $8,335,425 and $6,511,477 at September 30, 2022 and December 31, 2021, respectively. The total principal balance is included in Long-Term Debt on the Company’s consolidated balance sheets at September 30, 2022 and December 31, 2021.

The following tables roll forward the long-term debt balances, including current portion, presented in the Company’s condensed consolidated balance sheets:

Successor

    

LTD-A

    

LTD-C

    

LTD-D

    

LTD-E

    

Total

Balance at December 31, 2021

$

$

15,000,000

$

65,000,000

$

46,101

$

80,046,101

Issued in 2022

 

 

 

 

 

Principal Payments in 2022

 

 

 

 

(46,101)

 

(46,101)

Balance at September 30, 2022

$

$

15,000,000

$

65,000,000

$

$

80,000,000

As of September 30, 2022, for the periods presented below, the Company’s minimum payments due under debt obligations were as follows:

    

    

Interest

    

Total Cash

    

Principal

    

PIK

    

Cash Interest

    

Payments*

October 1, 2022 to December 31, 2022

$

$

1,342,321

$

1,401,192

$

1,401,192

2023

 

 

5,624,513

 

5,675,461

 

5,675,461

2024

 

 

6,061,814

 

5,882,309

 

5,882,309

2025

 

65,000,000

 

6,274,526

 

19,518,225

 

84,518,225

2026

 

15,000,000

 

1,851,284

 

20,054,451

 

35,054,451

Total

$

80,000,000

$

21,154,458

$

52,531,638

$

132,531,638

*    Total Payments Cash and Non-Cash (PIK)

32

Long-term debt was comprised of the following at September 30, 2022 and December 31, 2021:

    

Successor

    

September 30, 2022

    

December 31, 2021

Total Principal

$

80,000,000

$

80,046,101

Less: Current Portion of Long-Term Debt

 

 

(46,101)

Long Term Debt

$

80,000,000

$

80,000,000

Short-Term Debt

In 2021, the Company entered into short term financing agreements totaling $3,683,100 for the funding of certain insurance policies. The terms of the agreements ranged from nine to ten months and the weighted average annual interest rate was 2.6%. There are no remaining scheduled principal payments as of September 30, 2022 as the debt was paid off during the third quarter of 2022.

Note 16: Income Taxes

As a result of the Business Combinations, substantially all the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interests in P3 LLC. P3 LLC is treated as a partnership for U.S. federal and most applicable state and local income tax jurisdictions. As a partnership, P3 LLC is generally not subject to U.S. federal, state, and local income taxes. Any taxable income or loss generated by P3 LLC is passed through to and included within the taxable income or loss of its members in accordance with the terms of the P3 LLC A&R LLC Agreement. Prior to the Business Combinations, the income and losses of P3 LLC was passed through to its members and nontaxable to P3 LLC.

The Company is taxed as a corporation and pays corporate federal, state, and local taxes on income allocated to it from P3 LLC based on the Company’s economic interest held in P3 LLC. While the Company consolidates P3 LLC for financial purposes, the Company will not be taxed on the earnings attributed to the non-controlling interests. As a result, the income tax burden on the earnings taxed on the non-controlling interests is not reported by the Company in its financial statements.

To calculate the interim tax provision, at the end of each interim period, the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgements including, but not limited to, the expected operating income for the year, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes.

During the quarter ended June 30, 2022, the Company impaired goodwill related to the intangible asset recorded at P3 LLC in the amount of $851.5 million. The impairment reduced the book basis of the Company's investment in P3 LLC such that the recognition of a deferred tax asset on the outside book and tax basis investment difference resulted. The deferred tax asset related to the investment on P3 LLC has been simultaneously reduced fully by an increase to the recorded valuation allowance due to both cumulative losses in recent years of the Company, and the capital character for income tax purposes of the outside basis difference such that the Company would need sufficient capital character gains for income tax purposes to realize the tax over book outside basis difference. Prior to the impairment, the outside basis difference was an unrecognized deferred tax liability due to the amount of book goodwill more than tax goodwill for which a recognition exception applied. The amount of the deferred tax asset and offsetting valuation allowance related to the outside basis difference for the investment in P3 LLC as of September 30, 2022 is an estimated $7.2 million.

No income tax expenses were incurred for the nine months ended September 30, 2022 and 2021. The Company continues to be in a net operating loss and deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to zero. The Company’s effective tax rate for the nine-months ended September 30, 2022 and 2021 was 0.00%. There was no uncertain tax provision nor contingencies as of September 30, 2022 and December 31, 2021.

33

Tax Receivable Agreement

Pursuant to our election under Section 754 of the Internal Revenue Code (the “Code”), the Company expects to obtain an increase in our share of the tax basis in the net assets of P3 LLC when its units are redeemed or exchanged. The Company intends to treat any redemptions and exchanges of P3 LLC Units as direct purchases of the units for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent the tax basis is allocated to those capital assets.

The Company entered into a TRA with selling equity holders of P3 LLC that require the Company to pay 85% of the tax savings that are realized as a result of (i) the Company’s direct and indirect allocable share of existing tax basis acquired in the Business Combinations, (ii) increases in the tax basis in P3 LLC’s assets as a result of the sale and exchange of the P3 LLC Units for the Company’s Class A Common Stock and cash, and (iii) the Company’s utilization of certain tax attributes and of certain other tax benefits, including those attributable to payments under the TRA. The Company will retain the benefit of the remaining 15% of these cash savings.

The timing and amount of aggregate payments due under the TRA may vary based on a number of factors, including the timing and amount of taxable income generated by the Company each year, as well as the tax rate then applicable, among other factors. Actual tax benefits realized by the Company may differ from tax benefits calculated under the TRA as a result of the use of certain assumptions in the TRA, including the use of an assumed weighted-average state and local income tax rate to calculate tax benefits.

The payment obligation under the TRA is an obligation of the Company and not of P3 LLC. The payments that the Company will be required to make will generally reduce the amount of the overall cash flow that might have otherwise been available, but the Company expects the cash tax savings it will realize from the utilization of the related tax benefits will exceed the amount of any required payments.

As a result of the Business Combinations, the potential future tax benefits are estimated to be $5.4 million, of which $4.6 million is estimated to be the associated TRA liability.

As of September 30, 2022 and December 31, 2021, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such deferred tax assets because it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets.

As non-controlling interest holders exercise their right to exchange their units in P3 LLC, a TRA liability may be recorded based on 85% of the estimated future tax benefits that the Company may realize as a result of increases in the tax basis of P3 LLC. The amount of the increase in the tax basis, the related estimated tax benefits, and the related TRA liability to be recorded will depend on the price of the Company’s Class A Common Stock at the time of the relevant redemption or exchange.

Note 17: Capitalization and Management Incentive Units

Successor Period

Class A Common Stock

The Company is authorized to issue 800,000,000 shares of Class A Common Stock with a par value of $0.0001 per share, of which 41,578,890 shares were issued and outstanding on September 30, 2022 and December 31, 2021. As discussed in the Note 7 “Business Combinations,” upon closing of the Foresight Business Combinations:

8,732,517 shares of Class A Common Stock  were issued as part of the purchase consideration;
3,737,316 shares of Class A Common Stock  (after redemptions) were no longer subject to redemption;

34

8,738,750 shares of Class A Common Stock were issued in a private placement to the Founder Holders; and
20,370,307 shares of Class A Common Stock were issued in a private placement pursuant to subscription agreements entered into effective as of March 25, 2021 (the “PIPE Investment”).

Class V Common Stock

The Company is authorized to issue 205,000,000 shares of Class V Common Stock with a par value of $0.0001 per share. These shares have no economic value but entitle the holder to one vote per share. The holders of Common Units of P3 LLC subscribed for shares of Class V Common Stock on a one-for-one basis and may exchange their Common Units and Class V Common Stock together for Class A Common Stock on a one-for-one basis. All Class V Common Stock issued as of the Business Combinations date is subject to a 180 day lockup period. As of September 30, 2022 and December 31, 2021, there were 201,530,796 and 196,553,523 shares of Class V Common Stock issued and outstanding, respectively, and an additional 494,127 and 5,471,400 Class V shares which are restricted and subject to time-based vesting requirements related to the underlying incentive units on September 30, 2022 and December 31, 2021, respectively, as further discussed in Note 18.

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share, of which zero shares were outstanding as of September 30, 2022 and December 31, 2021.

P3 Health Group, LLC Common Units

In connection with the Business Combinations, all outstanding Class A Units, Class B Units, Class C Units and Class D Units of P3 Health Group Holdings, LLC were converted into the right to receive the merger consideration, which consisted of cash and newly-issued Common Units of P3 LLC. The Common Units were issued in amounts determined in accordance with the Merger Agreement and the then-existing limited liability company agreement of P3 Health Group Holdings, LLC. Each holder of Common Units was issued shares of Class V Common Stock on a one-for-one basis. At September 30, 2022 and December 31, 2021, there were 243,603,813 Common Units outstanding at P3 LLC of which the Company held 41,578,890 Common Units and non-controlling interests held the remaining 202,024,923 Common Units outstanding, 494,127 and 5,471,400 of which are restricted as discussed above, respectively.

Predecessor Period

Prior to the Business Combinations, P3 Health Group Holdings, LLC’s capital structure consists of Class A Units, which represented commitments from the Company’s private equity sponsors; Class B Units, which represented founders common equity; Class C Units, which represented Management Incentive Units; and Class D Units, which represented an additional investment from a private equity sponsor. Class A and D Units are presented outside of permanent equity in accordance with ASC 480 due to the existence of a redemption provision that is not solely within the control of the P3 Health Group Holdings, LLC.

At December 31, 2020 and September 30, 2021, there were 43,000,000 Class A Units authorized and outstanding; 6,000,000 and 8,000,000 Class B Units authorized and outstanding, respectively; 1,302,083 and 1,925,833 Class C Units authorized and outstanding, respectively; 16,130,034 Class D Units authorized and outstanding. In connection with the Business Combinations, all outstanding Class A, B, C and D Units were converted into the right to receive the merger consideration described above.

35

Note 18: Share-Based Compensation

Successor Company

Successor Awards

In connection with the Business Combinations, Foresight’s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), in order to facilitate the grant of cash and equity incentives to employees, consultants, and directors of the Company and certain affiliates. The 2021 Plan became effective on December 3, 2021. The following table sets forth a summary of Class V share-based compensation activity of the Successor Company:

Weighted

Weighted

    

Average

Average

Grant-Date

Time Based

Grant-Date

Performance

    

Fair Value

    

Units

    

Fair Value

    

Based Units

Outstanding and non-vested at December 31, 2021

$

9.20

 

5,471,400

$

 

Granted during period

 

 

 

 

Vested

 

9.20

 

4,977,273

 

 

Cancelled/forfeited

 

 

 

 

Outstanding and non-vested at September 30, 2022

$

9.20

 

494,127

$

 

Profit interest awards were issued as part of the Business Combination. Time-based units vest ratably over periods of between one month and two years, so long as the optionee stays employed. The time-based units have a weighted average remaining time to vest of 0.12 years at September 30, 2022.

Stock-Based Compensation Expense

The Company recorded $1,783,994 and $17,210,974 of stock-based compensation cost for the three and nine months ended September 30, 2022, respectively, which is classified in Corporate, General and Administrative Expenses. As of September 30, 2022, there was $7,233,627 of unrecognized equity-based compensation cost. The Company did not recognize any tax benefits related to stock-based compensation for the nine months ended September 30, 2022. The Company accounts for forfeitures of awards as they occur.

Stock Options

The following table summarizes stock option activities for the nine months ended September 30, 2022:

Weighted 

Average 

Number of 

Weighted 

Remaining 

Options 

Average 

Contractual 

    

Outstanding

    

Exercise Price

    

Life (Years)

Outstanding and non-vested at December 31, 2021

$

Granted

2,034,279

6.43

3.10

Vested

91,667

5.02

Cancelled/forfeited

Outstanding and non-vested at September 30, 2022

 

1,942,612

 

$

6.50

 

2.52

The majority of the stock options issued during the period follow a time-based vesting schedule. Most stock options vest ratably over a period between two and five years, so long as the optionee continues to provide services to the Company. Stock options are exercisable into shares of Class V Common Stock. In addition to the time-based units, the Company granted 100,000 performance-based option units to an employee during the period with a strike price of $5.02. The vesting criteria for these units has not yet been achieved, therefore no expense has been recorded in relation to these units.

36

Note 19: Earnings (Loss) per Share

Loss per Share – Successor Period

Basic earnings per share is calculated as net income divided by the average number of shares of common stock outstanding. Diluted earnings per share assumes, when dilutive, the issuance of the net incremental shares from restricted shares. The following is a reconciliation of the denominators of the basic and diluted per share computations for net income:

    

Successor

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

2022

    

2022

Numerator - Basic:

Net loss

$

(65,329,041)

 

$

(1,029,225,234)

Less: Net loss attributable to Non-controlling interest

 

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Basic

 

(11,173,183)

(176,100,636)

Numerator - Diluted:

Net loss attributable to Class A Common Stockholders - Basic

$

(11,173,183)

$

(176,100,636)

Add: Net loss and tax effect attributable to Non-controlling interest

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Diluted

(65,329,041)

(1,029,225,234)

Denominator - Basic:

Weighted average Class A common shares outstanding - Basic

 

41,578,890

41,578,890

Loss per share attributable to Class A common shareholders - Basic

 

$

(0.27)

$

(4.24)

Denominator - Diluted:

Weighted average Class A common shares outstanding - Basic

41,578,890

41,578,890

Weighted average effect of dilutive Class V shares

201,457,191

199,684,102

Weighted average Class A common shares outstanding - Diluted

243,036,081

241,262,992

Loss per share attributable to Class A common shareholders - Diluted

$

(0.27)

$

(4.27)

The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive. The liability-classified Public and Private Warrants are out of the money and thus have no impact on diluted EPS:

    

Successor

As of September 30, 2022

Public Warrants

 

10,591,605

Private Warrants

 

227,500

Restricted Shares

 

494,127

Options

 

2,134,279

 

13,447,511

Note 20: Premium Deficiency Reserve

The Company assesses the profitability of our at-risk share savings arrangements to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a PDR is recognized. Management concluded a PDR of $27,719,928 and $37,835,642 existed at September 30, 2022 and December 31, 2021, respectively, which represented its estimate of probable contract losses expected to be generated by the Company’s contracts with its health plan partners.

37

Note 21: Leases

The Company leases real estate in the form of corporate office space and operating facilities. The Company additionally leases certain machinery in the form of office equipment. Generally, the term for real estate leases ranges from one to eight years at inception of the contract. Generally, the term for equipment leases is one to three years at inception of the contract. Some real estate leases include one to two options to renew that can extend the original term by five to ten years.

The Company entered one new operating lease in the nine months ended September 30, 2022. On June 9, 2022, the company entered into the first amendment to the lease agreement for its lease in Henderson, NV. This lease amendment will expand the premises to include three other suites in the same building and extend the term of the lease 94 months commencing on October 1, 2022, after the original lease matured on September 30, 2022. As a result of the lease modification related to the existing premises, ROU Assets and Liabilities increased $3.1 million.

Additionally, during the three months ended September 30, 2022, the Company acquired four new leases as a part of the medical practice acquisitions, as described in Note 7 “Business Combinations.” The acquisitions and related addition to ROU Assets and Liabilities were determined to be immaterial for disclosure.

Operating lease costs are included within operating expenses in the condensed consolidated statements of operations. The Company does not have any finance leases, short-term lease costs, nor any sublease income.

Successor

    

Predecessor

Three Months Ended

Three Months Ended

    

September 30, 2022

    

September 30, 2021

Lease costs

    

$

901,079

    

$

688,104

Successor

    

Predecessor

Nine Months Ended

Nine Months Ended

September 30, 2022

    

September 30, 2021

Lease costs

$

2,374,789

$

1,740,067

Lease terms and discount rates consisted of the following at each of the periods presented below:

Successor

    

Predecessor

 

Nine Months Ended

Nine Months Ended

 

    

September 30, 2022

    

September 30, 2021

Weighted average remaining lease term (years)

 

6.42

 

5.09

Weighted average discount rate

 

11.7

%  

11.2

%

The table below reconciles the undiscounted future minimum lease payments under noncancelable operating leases with terms of more than one year to the total operating and finance lease liabilities recognized on the condensed consolidated balance sheets as of the dates presented.

    

September 30, 2022

October 1, 2022 to December 31, 2022

$

712,565

2023

 

1,347,234

2024

 

2,958,684

2025

 

2,602,888

2026

 

1,950,448

Thereafter

 

4,619,793

Total Payments

 

14,191,612

Less: Interest

 

(2,821,505)

Present Value of Lease Liabilities

$

11,370,107

The current portions of ROU liabilities of $213,158 and $2,087,235 are included in Accounts Payable and Accrued Expenses in the Company’s condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively.

38

Note 22: Redeemable Non-Controlling Interests

Non-controlling interests represents the portion of P3 LLC that the Company controls and consolidates but does not own (i.e., the P3 LLC Common Units held directly by the shareholders other than the Company). The non-controlling interests represent an approximately 83% ownership in P3 LLC as of September 30, 2022.

Generally, P3 LLC Common Units participate in net income or loss allocations and distributions and entitle their holder to the right, subject to the terms set forth in the limited liability agreement, to require P3 to redeem all or a portion of the Common Units held by such participant, together with a corresponding number of shares of Class V Common Stock, in exchange for Class A Common Stock or at the Company’s option, and subject to certain limitations, in cash. As the noncontrolling interest holders have approximately an 83% voting interest in P3 LLC through their Class V Common Stock and can appoint most of the initial members to the Board of Directors, the ability to elect cash settlement upon redemption is outside of the control of the Company.

The P3 LLC Common Units held by outside shareholders have been classified as redeemable noncontrolling interest in the Company. The cash redemption feature is considered outside of the control of the Company for the reason described above. Therefore, in accordance with ASC Topic 480, Distinguishing Liabilities from Equity, the P3 LLC Units are classified as temporary equity in the Company’s condensed consolidated balance sheets.

The redeemable noncontrolling interest was initially measured at its fair value on December 3, 2021. Net income or loss is attributed to the redeemable noncontrolling interest during each reporting period based on its ownership percentage, as appropriate. Subsequent to that, the redeemable noncontrolling interest is measured at its fair value (i.e., based on the Class A stock price) at the end of each reporting period, with the remeasurement amount being no less than the initial value, as adjusted for the redeemable noncontrolling interest’s share of net income or loss. The offset of any fair value adjustment is recorded to equity, with no impact to net income or loss. As of September 30, 2022, the fair value of redeemable non-controlling interest was higher than the carrying value and thus, a remeasurement adjustment of $19,375,288 was recorded to redeemable non-controlling interests with an offset to additional paid in capital. As of December 31, 2021, the fair value of redeemable non-controlling interest was lower than the initial value and there was no remeasurement adjustment recorded.

In addition, pursuant to the Agreement and Plan of Merger, all non-controlling interest holders are subject to certain lock-up period and as a result, there was no exchange or redemption activity as of September 30, 2022 and December 31, 2021.

Note 23: Commitments and Contingencies

Commitments

The Company has non-cancelable contractual agreements primarily related to leases. For additional discussion on leases, see Note 21 “Leases.”.

Contingencies

The Company is a party to various claims, legal and regulatory proceedings, lawsuits and administrative actions arising in the ordinary course of business and associated with the Business Combinations. The Company carries general and professional liability insurance coverage to mitigate the Company’s risk of potential loss in such cases. An accrual is established when a specific contingency is probable and estimable. The Company also faces contingencies that are reasonably possible to occur that cannot currently be estimated. The Company believes that disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, net loss or cash flows. It is the Company’s policy to expense costs associated with loss contingencies, including any related legal fees, as they are incurred.

In 2021, a discrepancy was identified in the service agreement with one of the Company’s health plans resulting in a renegotiation of the agreement. As of the date of issuance of this Form 10-Q, the renegotiation was in process. The Company has determined it is reasonably possible that resolution of this discrepancy will result in a payment to the health plan of approximately $10.6 million. This contingent liability was reflected in the Company’s financial statements presented in the 2021 Form 10-K. In the fourth quarter of 2021 during the Predecessor Period, the Company recorded a $3.6 million reduction in operating revenue and a $7.0 million charge to operating expense to account for amounts not previously recorded.

39

Uncertainties

The healthcare industry is subject to numerous laws and regulations of Federal, state, and local governments. These laws and regulations include, but are not limited to, matters of licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare / Medicaid Fraud, Waste and Abuse Prevention. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of Fraud, Waste and Abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties as well as significant repayment for patient services billed.

Management believes the Company is compliant with Fraud, Waste and Abuse regulations as well as other applicable government laws. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as other regulatory actions which might be unknown at this time.

Healthcare reform legislation at both the Federal and state levels continues to evolve. Changes continue to impact existing and future laws and rules. Such changes may impact the manner in which the Company conducts business, restrict the Company’s revenue growth in certain eligibility categories, slow down revenue growth rates for certain eligibility categories, increase certain medical, administrative and capital costs, and expose the Company to increased risk of loss or further liabilities. As a result, the Company’s consolidated financial position could be impacted by such changes.

COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated COVID 19 a global pandemic. The rapid spread of COVID 19 around the world and throughout the U.S. has altered the behavior of businesses and people, with significant negative effects on Federal, state, and local economies, the duration of which continues to remain unknown. Various mandates were implemented by Federal, state, and local governments in response to the pandemic, which caused many people to remain at home along with forced closure of or limitations on certain businesses. This included suspension of elective procedures by healthcare facilities. While restrictions have been eased across the U.S. and most states have lifted moratoriums on non-emergency procedures, some restrictions remain in place. COVID 19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of the Company’s patients.

The COVID 19 pandemic did not have a material impact on the Company’s revenues for the nine-month period ended September 30, 2022 and the year ended December 31, 2021. Nearly 99% of the Company’s total revenues are recurring, consisting of fixed monthly PMPM capitation payments received from Medicare Advantage health plans. Based on claims paid to date, direct costs associated with COVID-19 claims was approximately $93.3 million for the period March 1, 2020 through September 30, 2022. Management instituted multiple safety measures for the Company’s employees including a work-from-home policy and access to free vaccinations and personal protective equipment.

The full extent to which COVID 19 will directly or indirectly impact the Company, its future results of operations and financial condition will depend on factors which are highly uncertain and cannot be accurately predicted. This includes new and emerging information from the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on the Company’s markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, government imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these and other uncertainties, management cannot estimate the length or severity of the impact of the pandemic on the Company’s business. Furthermore, because of the Company’s business model, the full impact of COVID 19 may not be fully reflected in the Company’s results of operations and overall financial condition until future periods. However, management continues to closely evaluate and monitor the nature and extent of these potential impacts to the Company’s business, results of operations and liquidity.

Note 24: Related Parties

Intercompany Transactions

P3 has entered into agreements (“Services Agreements”) with the Network, under which P3 provides the Network with certain management, administrative, and other non-medical support services.

40

The Company and its subsidiaries have “Deficit Funding Agreements” with the Network, whereby the Company or its subsidiaries provide loans (“Advances”) from time to time principally for the purpose of working capital support.  Net Advances made to the Network and accrued interest expense in the three-month period ended September 30, 2022 were as follows:

    

Successor

September 30, 2022

Balance at December 31, 2021

$

27,907,247

Advanced During Period

 

1,742,914

Interest Accrued During period

 

463,905

Balance at September 30, 2022

$

30,114,066

Advances, in most cases, have been constructively made by P3 Health Group Holdings, LLC on P3 NV’s behalf, and were therefore deemed Advances made by P3 NV. P3 NV’s Advances to BACC include all years prior, for which balances have, historically, not been settled periodically between the Parties and, thus have carried forward one year to the next. However, all transactions related to these Services and Deficit Funding Agreements (including accrued interest) have been eliminated in consolidation.

There were no advances transacted between P3 NV and KWA during the periods ended September 30, 2022 or December 31, 2021.

Atrio Health Plans

Successor

    

Three Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

35,365,746

Management Fees

 

570,500

Claims Paid

 

39,861,830

    

Successor

Nine Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

127,505,484

Management Fees

 

1,716,134

Claims Paid

 

137,367,493

Atrio Health Plans was established in 2004 and has since grown to serve Medicare beneficiaries in numerous counties throughout Oregon. Atrio works closely with local providers to improve healthcare outcomes of the population(s) served. In 2019, Chicago Pacific Founders (“CPF”) made an equity investment in Atrio. CPF is also a principal holder of shares of Class V Common Stock and Common Units of P3 LLC. Beginning in 2020, the Company has a Full-Risk capitation agreement in place with Atrio whereby the Company is delegated to perform services on behalf of Atrio’s members assigned to the Company. These delegated services include but are not limited to provider network credentialing, patient authorizations and medical management (care management, quality management and utilization management).

Note 25: Variable Interest Entities

The Company prepares its consolidated financial statements in accordance with ASC 810, Consolidation, which provides for the consolidation of VIEs of which an entity is the primary beneficiary.

In connection with the Business Combinations further described in Note 1 and Note 7, the Company became the sole managing member of P3 LLC. The rights of the non-managing members of P3 LLC are limited and protective in nature and do not give substantive participation rights over the sole managing member. As a result, P3 LLC is considered a VIE. As the sole managing member, the Company has the right to direct the most significant activities of P3 LLC and the obligation to absorb losses and receive benefits and accordingly is considered the primary beneficiary.

41

Additionally, P3 LLC is the primary beneficiary of the Network.

P3, LLC entered Stock Transfer Restriction Agreements with the Practice Shareholders of the Network. The Stock Transfer Restriction Agreements, by way of a call option, unequivocally permit P3 LLC to appoint Successor Physicians if a Practice Shareholder vacates their ownership position.

Pursuant to ASC 810, Consolidation, both the “power of control” and “economics” criteria were reviewed for VIE consideration. P3 LLC’s ability to appoint Successor Physicians the Network demonstrates “power of control”. Also, there are Deficit Funding Agreements in place between P3 LLC and the Network. The Deficit Funding Agreement between P3 LLC and the members of the Network states that P3 LLC will advance funds, as needed, to support working capital needs to the extent operating expenses exceed gross revenue. These funding arrangements further illustrate and fulfill the economic criteria for VIE consolidation.

Practice Shareholders, who are employees of the Company, retain equity ownership in the Network, which represents nominal noncontrolling interests. The noncontrolling interests do not participate in the profit or loss of the Network, however.

P3 LLC, directly or indirectly via its wholly-owned subsidiaries, may not use or access any net assets of these VIEs to settle its obligations or the obligations of its wholly-owned subsidiaries.

The following tables provide a summary of the VIE’s assets, liabilities and operating performance.

Successor

ASSETS

    

September 30, 2022

    

December 31, 2021

Cash

$

5,413,965

$

7,570,247

Client Fees and Insurance Receivable, net

 

16,653

 

60,815

Prepaid Expenses and Other Current Assets

 

1,353,408

 

406,372

Property, Plant and Equipment, net

 

44,494

 

36,416

Investment in Other P3 Entities

 

6,000,000

 

6,000,000

TOTAL ASSETS

 

12,828,520

 

14,073,850

LIABILITIES AND MEMBERS’ DEFICIT

 

  

 

  

Accounts Payable and Accrued Expenses

 

7,653,560

 

4,804,704

Accrued Payroll

 

2,233,567

 

1,303,615

Due to Consolidated Entities of P3

 

27,001,570

 

24,110,831

TOTAL LIABILITIES

 

36,888,697

 

30,219,150

MEMBERS’ DEFICIT

 

(24,060,177)

 

(16,145,300)

TOTAL LIABILITIES AND MEMBERS’ DEFICIT

$

12,828,520

$

14,073,850

Successor

Predecessor

    

Three Months Ended

    

Three Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

13,594,142

$

1,905,404

Expenses

 

15,731,721

 

4,707,369

Net Loss

$

(2,137,579)

$

(2,801,965)

Successor

Predecessor

    

Nine Months Ended

    

Nine Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

39,462,716

$

5,815,261

Expenses

 

46,708,335

 

13,858,939

Net Loss

$

(7,245,619)

$

(8,043,678)

42

Note 26: Warrants

As of December 31, 2020, there were 858,351 Class D warrants outstanding for the predecessor entity. In conjunction with the Term Loan issued November 19, 2020, the predecessor entity issued 858,351 10-year warrants to purchase shares of Series D Preferred Units at $4.68 per share. The warrants were recorded as a liability on the consolidated balance sheet with a balance of $6,316,605 as of December 31, 2020. During the year ended December 31, 2020, no change in the fair value of the warrant liability was recognized in the consolidated statements of operations. During 2021, 858,351 warrants were exercised on a cashless basis, with an exercise price of $4.68 per share as part of the Business Combination. There are no Class D Warrants outstanding as of September 30, 2022 and December 31, 2021.

As of September 30, 2022 and December 31, 2021, there were an aggregate of 10,819,105 warrants outstanding, which include the Public Warrants and Private Placement Warrants. Each warrant entitles the holder to purchase one share of Class A Common Stock at a price of $11.50 per share. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire five years after the completion of a Business Combinations. The Company has the right to redeem the Public Warrants when the price per Class A ordinary share equals or exceeds $18.00 for 20 days within a 30-day trading period. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants are subject to certain transfer restrictions, are not redeemable by the Company if they are held by Sponsors, and are exercisable on a cashless basis.

The Public Warrants and Private Placement Warrants are recorded as a liability on the consolidated balance sheets with a balance of $7,996,432 and $11,382,826 as of September 30, 2022 and December 31, 2021, respectively. A loss of $2,567,423 and a gain of $3,386,394 were recognized in the three months and nine months ended September 30, 2022, respectively, and a loss of $1,401,686 and $12,063,265 was recognized in the three months and nine months ended September 30, 2021, respectively from the change in fair value of the warrant liability in the consolidated statements of operations. During the nine months ended September 30, 2022 and the year ended December 31, 2021, zero Public Warrants and Private Placement Warrants were exercised.

43

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis is intended to provide the reader with an understanding of our business, including an overview of our results of operations and liquidity and should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this Form 10-Q, as well as our audited financial statements and related notes included in our 2021 Form 10-K and in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2021 Form 10-K. This discussion contains forward-looking statements and involves numerous risks and uncertainties. Our actual results may differ materially from those anticipated in any forward-looking statements as a result of many factors, including those set forth under “Cautionary Statement Regarding Forward-Looking Statements,” in Part II, Item 1A. “Risk Factors” and elsewhere in this Form 10-Q.

Overview

P3 is a patient-centered and physician-led population health management company. We strive to offer superior care to all those in need. We believe that the misaligned incentives in the fee-for-service (“FFS”) healthcare payment model and the fragmentation between physicians and care teams has led to sub-optimal clinical outcomes, limited access, high spending and unnecessary variability in the quality of care. We believe that a platform such as ours, which helps to realign incentives and focuses on treating the full patient, is uniquely positioned to address these healthcare challenges.

We have leveraged the expertise of our management team’s more than 20 years of experience in population health management, to build our “P3 Care Model.” The key attributes that differentiate P3 include: 1) patient-focused model, 2) physician-led model, and 3) our broad delegated model. Our model operates by entering into arrangements with payors providing for monthly payments to manage the total healthcare needs of members attributed to our primary care physicians. In tandem, we enter into arrangements directly with existing physician groups or independent physicians in the community to join our value-based care network. In our model, physicians are able to retain their independence and entrepreneurial spirit, while gaining access to the tools, teams and technologies that are key to success in a value-based care model, all while sharing in the savings from successfully improving the quality of patient care and reducing costs.

We operate in the $830 billion Medicare market, which covers approximately 63 million eligible lives. Our core focus is the Medicare Advantage market, which makes up approximately 42% of the overall Medicare market, or nearly 26 million Medicare eligible lives. Medicare beneficiaries may enroll in a Medicare Advantage plan, under which payors contract with the Centers for Medicare & Medicaid Services (“CMS”) to provide a defined range of healthcare services that are comparable to Medicare FFS (which is also referred to as “traditional Medicare”).

We predominantly enter into capitated contracts with the nation’s largest health plans to provide holistic, comprehensive healthcare to Medicare Advantage members. Under the typical capitation arrangement, we are entitled to per member per month fees from payors to provide a defined range of healthcare services for Medicare Advantage health plan members attributed to our primary care physicians (“PCPs”). These per member per month (“PMPM”) fees comprise our capitated revenue and are determined as a percent of the premium (“POP”) payors receive from CMS for these members. Our contracted recurring revenue model offers us highly predictable revenue, and rewards us for providing high-quality care rather than driving a high volume of services. In this capitated arrangement, our goals are well-aligned with payors and patients alike—the more we improve health outcomes, the more profitable we will be over time.

Under this capitated contract structure, we are generally responsible for all members’ medical costs across the care continuum, including, but not limited to emergency room and hospital visits, post-acute care admissions, prescriptions drugs, specialist physician spend and primary care spend. Keeping members healthy is our primary objective. When they need medical care, delivery of the right care in the right setting can greatly impact outcomes.

When our members need care outside of our network of PCPs, we utilize a number of tools including network management, utilization management and claims processing to ensure that the appropriate quality care is provided.

44

Our company was formed in 2017, and our first at-risk contract became effective on January 1, 2018. We have demonstrated an ability to rapidly scale, primarily entering markets with our affiliate physician model, and expanding to a PCP network of approximately 2,800 physicians, in 15 markets (counties) across 5 states in five full years of operations as of September 30, 2022. Our platform has enabled us to grow our annual revenue by 94% from December 31, 2018 to December 31, 2021. As of September 30, 2022, our PCP network served approximately 101,000 at-risk Medicare Advantage members. We believe we have significant growth opportunities available to us across existing and new markets, with less than 1% of the 491,060 PCPs in the U.S. currently included in our physician network.

Impact of COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 a global pandemic. The rapid spread of COVID-19 around the world and throughout the U.S. has altered the behavior of businesses and people, with significant negative effects on Federal, state, and local economies, the duration of which continues to remain unknown. Various mandates were implemented by Federal, state, and local governments in response to the pandemic, which caused many people to remain at home, along with forced closure of or limitations on certain businesses. This included suspension of elective procedures by healthcare facilities. While restrictions have been eased across the U.S. and most states have lifted moratoriums on non-emergency procedures, some restrictions remain in place.

COVID-19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of P3’s patients. To ensure a coordinated response to the pandemic, we created a COVID-19 Task Force that is supported by team members from across the organization. Our company owned clinics remained open to those members with urgent needs, and we successfully pivoted to a telemedicine offering for routine care in order to protect and better serve our patients, providers, care teams and community. We continued to support our affiliate physician network with the tools, team and technology to provide care to the members we serve. Management instituted multiple safety measures for P3 employees including a work-from-home policy and access to free vaccinations and personal protective equipment. Deeply committed to our employees, we made a conscious decision not to furlough any of our employees, even if their function was disrupted by COVID-19. Due to our recurring contracted revenue model, the COVID-19 pandemic did not have a material impact on P3’s revenues during 2020, 2021 and the nine-month period ended September 30, 2022. Nearly 99% the Company’s total revenues are recurring, consisting of fixed monthly PMPM capitation payments received from Medicare Advantage health plans. P3 estimates that it incurred approximately $93.3 million of direct costs related to COVID-19 claims during the period from March 1, 2020 through September 30, 2022. We expect to incur additional COVID-19 related costs given the volume of positive cases and “breakthrough” cases (positive cases in vaccinated patients) present in our markets.

Because of the nature of capitation arrangements, the full impact of the COVID-19 pandemic may not be fully reflected in our results of operations and overall financial condition until future periods. The full extent to which COVID-19 will directly or indirectly impact our future results of operations and financial condition will depend on multiple factors. This includes new and emerging information from the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on our markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these factors, management may not be able to fully estimate the length or severity of the impact of the pandemic on our business. However, management continues to closely evaluate and monitor the nature and extent of these potential impacts to P3’s business, results of operations and liquidity.

Business Combinations

On December 3, 2021, the Company consummated the transactions pursuant to which, among other things, P3 Health Group Holdings, LLC merged with and into FAC Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Foresight Acquisition Corp. (“Foresight” or “Merger Sub”), with Merger Sub as the surviving company, which was renamed P3 Health Group, LLC (“P3 LLC”), and Foresight, FAC-A Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight, FAC-B Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight (together with FAC-A Merger Sub Corp., the “Merger Corps”) merged with and into CPF P3 Blocker-A, LLC, a Delaware limited liability company, CPF P3 Blocker-B, LLC a Delaware limited liability company (together with CPF P3 Blocker-A, LLC, the “Blockers”), with the Blockers as the surviving entities and wholly-owned subsidiaries of Foresight (collectively, the “Business Combinations”).

As a result of the Business Combinations (see Note 7 “Business Combinations” to the accompanying condensed consolidated financial statements), the Company was deemed to be the acquirer for accounting purposes, and P3 Health Group Holdings, LLC, which

45

is the business conducted prior to the closing of the Business Combinations, was deemed to be the acquiree and accounting predecessor (the “Predecessor”). The financial statement presentation includes the financial statements of P3 Health Group Holdings, LLC as “Predecessor” for the periods prior to the Closing Date (the “Predecessor Period(s)”) and of the Company as “Successor” for the periods after the Closing Date (the “Successor Period(s)”), including the consolidation of P3 Health Group Holdings, LLC. The Business Combinations were accounted for as a business combination using the acquisition method of accounting, and the Successor’s financial statements reflect a new basis of accounting that is based on the fair value of net assets acquired. As a result of the application of the acquisition method of accounting as of the effective time of the Business Combinations, the financial statements for the Predecessor Period and for the Successor Period are presented on different bases. The historical financial information of the Company (the acquirer) has not been reflected in the Predecessor Period financial statements.

Key Factors Affecting our Performance

Growing Medicare Advantage Membership on Our Platform

Membership and revenue are tied to the number of members attributed to our physician network by our payors. We believe we have multiple avenues to serve additional members, including through:

Growth in membership under our existing contracts and existing markets:

o

Patients who are attributed to our physician network who (a) age into Medicare and elect to enroll in Medicare Advantage or (b) elect to convert from Medicare FFS to Medicare Advantage.

Adding new contracts (either payor contracts or physician contracts) in existing markets.
Adding new contracts (either payor contracts or physician contracts) in adjacent and new markets.

At September 30, 2022 the number of Medicare Advantage at-risk members on our platform was approximately 101,000 compared to approximately 60,600 members at September 30, 2021, representing a growth rate of 67% over this period. The table below illustrates membership growth from 2019 to 2022:

    

December 31, 

    

December 31, 

    

December 31, 

    

September 30, 

    

    

 

2019

2020

2021

2022

CAGR

 

At-risk Medicare Advantage Members

 

19,700

50,600

 

67,000

 

101,000

 

81

%

Year-over-year % change

 

89

%  

157

%  

32

%  

67

%  

Growing Existing Contract Membership

According to CMS, the Medicare market covers approximately 63 million eligible lives as of 2021. Over the last decade, Medicare Advantage penetration of the Medicare beneficiary population has increased from 26% to 42% of the overall Medicare beneficiary market and makes up nearly 26 million Medicare eligible lives today. Recent data suggests that the number of Medicare-eligible patients will continue to increase as the US population ages and becomes eligible for the program. Additionally, recent data from the Kaiser Family Foundation suggests the Medicare Advantage penetration rates will continue to increase in the upcoming years. As these new patients age-in to Medicare and enroll in Medicare Advantage through our payors, they become attributed to our network of physicians with little incremental cost to us.

In addition to age-ins, Medicare eligible patients can change their enrollment selections during select periods throughout the year. Our sales and marketing teams actively work with local community partners to connect with Medicare eligible patients and make them aware of their healthcare choices and the services that P3 offers with our value-based care model, including greater access to their physicians and customized care plans catered to their needs. The ultimate effect of our marketing efforts is increased awareness of P3 and additional patients choosing us as their primary care provider. We believe that our marketing efforts also help to grow our payor partners’ membership base as we grow our own patient base and help educate patients about their choices on Medicare, further aligning our model with that of healthcare payors.

46

Growing Membership in Adjacent and New Markets

Our affiliate model allows us to quickly and efficiently enter into new and adjacent markets in two ways: 1) partnering with payors and 2) partnering with providers. Because our model honors the existing patient-provider relationship, we are able to deploy our care model around existing physicians in a given a market. By utilizing the local healthcare infrastructure, we can quickly build a network of PCPs to serve the healthcare needs of contracted members.

Our business development and managed care teams maintain an active pipeline of new partnership opportunities for both providers and payors. These potential opportunities are developed through significant inbound interest and the deep relationships our team has developed with their more than 20 years of experience in the value-based care space and our proactive assessment of expansion markets. When choosing a market to enter, we make our decision on a county-by-county basis across the United States. We look at various factors including: (i) population size, (ii) payor participants and concentration, (iii) health system participants and concentration, and (iv) competitive landscape.

When entering a new market, we supplement the existing physician network with local market leadership teams and support infrastructure to drive the improvement in medical cost and quality. When entering an adjacent market, we’re able to leverage the investments we previously made to have a faster impact on our expanded footprint. We have historically demonstrated success in effectively growing into new and adjacent markets. As of September 30, 2022, we operate in 15 markets, markets being counties, across five states. P3 is actively pursuing opportunities to expand operations to additional states in the Southwest and Midwest.

Growing Membership in Existing Markets

Once established in a market, we have an opportunity to efficiently expand both our provider and payor contracts. Given the benefits PCPs experience from joining our P3 Care Model, which offers providers the teams, tools and technologies to better support their patient base, we often experience growth in our affiliate network after entering a market. Because of the benefits, we have also historically experienced high retention with our affiliate providers. From 2018 through September 30, 2022, P3 experienced an average of  98% physician retention rate in our affiliate provider network. By expanding our affiliate provider network and adding new physicians to the P3 network, we can quickly increase the number of contracted at-risk members under our existing health plan arrangements.

Additionally, by expanding the number of contracted payors, we can leverage our existing infrastructure to quickly increase our share of patients within our physician network. We have a proven ability to manage medical costs and improve clinical outcomes of our lives under management on behalf of our payor partners. This is evidenced by the receipt of inbound partnership requests from payors to improve growth, quality and profitability in their markets.

Growing Capitated Revenue Per Member

Medicare pays capitation using a risk adjusted model, which compensates payors based on the health status, or acuity, of each individual member. Payors with higher acuity members receive a higher payment and those with lower acuity members receive a lower payment. Moreover, some of our capitated revenues also include adjustments for performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. Given the prevalence of fee-for-service arrangements, our patients often have historically not participated in a value-based care model, and therefore their health conditions are poorly documented. Through the P3 Care Model, we determine and assess the health needs of our patients and create an individualized care plan consistent with those needs. We capture and document health conditions as a part of this process. We expect that our PMPM revenue will continue to improve the longer members participate in our care model as we better understand and assess their health status (acuity) and coordinate their medical care.

Effectively Managing Member Medical Expense

Our medical claims expense is our largest expense category (except for goodwill impairment), representing 83% of our total operating expenses (excluding goodwill impairment) for the three months and nine months ended September 30, 2022, respectively. We manage our medical costs by improving our members access to healthcare. Our care model focuses on maintaining health and leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as emergency department visits and acute hospital inpatient admissions. The power of our model is reflected in the relative performance of our network when compared to local

47

FFS benchmarks. For example, in 2019 our Arizona members’ emergency department (“ED”) utilization was 36% lower than the local FFS benchmark and inpatient hospital admission rate was 35% lower than the local FFS benchmark.

Achieving Operating Efficiencies

As a result of our affiliate model and ability to leverage our existing local and national infrastructure, we generate operating efficiencies at both the market and enterprise level. Our local corporate, general and administrative expense, which includes our local leadership, care management teams and other operating costs to support our markets, are expected to decrease over time as a percentage of revenue as we add members to our existing contracts, grow membership with new payor and physician contracts, and our revenue subsequently increases. Our corporate general and administrative expenses at the enterprise level include resources and technology to support payor contracting, quality, data management, delegated services, finance and legal functions. While we expect our absolute investment in our enterprise resources to increase over time, we expect it will decrease as a percentage of revenue when we are able to leverage our infrastructure across a broader group of at-risk members. We expect our corporate, general and administrative expenses to increase in absolute dollars in the future as we continue to invest to support growth of our business, as well as due to the costs required to operate as a public company, including insurance coverage, investments in internal audit, investor relations and financial reporting functions, fees paid to the exchange on which we list our securities, and increased legal and audit fees.

Impact of Seasonality

Our operational and financial results will experience some variability depending upon the time of year in which they are measured. This variability is most notable in the following areas:

At-Risk Member Growth. While new members are attributed to our platform throughout the year, we experience the largest portion of our at-risk member growth during the first quarter. Contracts with new payors typically begin on January 1, at which time new members become attributed to our network of physicians. Additionally, new members are attributed to our network on January 1, when plan enrollment selections made during the prior Annual Enrollment Period from October 15th through December 7th of the prior year take effect.

Revenue Per Member. Our revenue is based on percentage of premium we have negotiated with our payors as well as our ability to accurately and appropriately document the acuity of a member’s health status. We experience some seasonality with respect to our per member revenue as it will generally decline over the course of the year. In January of each year, CMS revises the risk adjustment factor for each patient based upon health conditions documented in the prior year, leading to an overall increase in per-patient revenue. As the year progresses, our per-patient revenue declines as new patients join us typically with less complete or accurate documentation (and therefore lower risk-adjustment scores) and patients with more severe acuity profiles (and, therefore, higher per member revenue rates) expire.

Medical Costs. Medical expense is driven by utilization of healthcare services by our attributed membership. Medical expense will vary seasonally depending on a number of factors, including the weather and the number of business days. Certain illnesses, such as the influenza virus, are far more prevalent during colder months of the year, which will result in an increase in medical expenses during these time periods. We would therefore expect to see higher levels of per-member medical expense in the first and fourth quarters. Business days can also create year-over-year comparability issues if one year has a different number of business days compared to another.

Non-GAAP Financial Measures and Key Performance Metrics

We use certain non-GAAP financial measures to supplement our condensed consolidated financial statements, which are presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). These non-GAAP financial measures include Adjusted EBITDA. A non-GAAP financial measure is a numerical measure that departs from GAAP because it includes or excludes amounts that are required under GAAP. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as used by P3 may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP financial measures provides additional information to investors regarding our  results of operations that our management believes is useful for trending, analyzing and benchmarking the performance of our business. See “Supplemental Unaudited Presentation of Consolidated Adjusted EBITDA,” below, for a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure.

48

In addition to our GAAP and non-GAAP financial information, we monitor the following operating metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following key metrics are useful in evaluating our business:

    

December 31, 

    

December 31, 

    

December 31, 

    

September 30, 

2019

2020

2021

2022

At-risk members

 

19,700

 

50,600

 

67,000

 

101,000

Affiliate PCPs

 

1,000

 

1,500

 

2,100

 

2,800

At-Risk Membership

At-risk membership represents the approximate number of Medicare Advantage members for whom we receive a fixed per member per month fee under capitation arrangements as of the end of a particular period.

Contracted Primary Care Physicians

Contracted primary care physicians represent the approximate number of primary care physicians included in our affiliate network, with whom members may be attributed under our capitation arrangements, as of the end of a particular period.

The key metric we utilize to measure our profitability and performance is Adjusted EBITDA.

Key Components of Results of Operations

Revenue

Capitated revenue

We contract with health plans using an at-risk model. Under the at-risk model, we are responsible for the cost of all covered health care services provided to members assigned by the health plans to the Company in exchange for a fixed payment, which generally is a POP based on health plans’ premiums received from CMS. Through this capitation arrangement, we stand ready to provide assigned Medicare Advantage members all their medical care via our directly employed and affiliated physician/specialist network.

The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. As premiums are adjusted via this risk adjustment model (via a Risk Adjustment Factor, “RAF”), our PMPM payments will change commensurately with how our contracted Medicare Advantage plans’ premiums change with CMS.

Management determined the transaction price for these contracts is variable as it primarily includes PMPM fees, which can fluctuate throughout the course of the year based on the acuity of each individual enrollee. The Company generally estimates the transaction price using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management can reasonably estimate the ultimate PMPM payment of those contracts. We recognize revenue in the month in which attributed members are entitled to receive healthcare benefits during the contract term.

As previously noted, it is the Company’s policy to recognize the variable RAF component of capitation revenues, to the extent it is probable that a significant reversal will not occur. Generally, the Company’s estimate of the variable RAF component of capitation at the December 31 balance sheet is constrained, as it is not probable that a significant reversal would not occur. Due to the timing of

49

filing the 2021 annual financial statements in October 2022, the Company subsequently collected the RAF component of capitation payments prior to the issuance of the 2021 financial statements, effectively relieving the constraints which normally exist at our December 31, 2021 balance sheet date.  As a result, capitation revenues of $12.3 million which would have been recognized in 2022 were instead recognized in the 2021 annual report.

Other patient service revenue. Other patient service revenue is comprised primarily of encounter-related fees to treat patients outside of P3’s at-risk arrangements at company owned clinics. Other patient service revenue also includes ancillary fees earned under contracts with certain payors for the provision of certain care coordination and other care management services. These services are provided to patients covered by these payors regardless of whether those patients receive their care from our directly employed or affiliated medical groups.

Operating expenses

Medical expenses. Medical expenses primarily include costs of all covered services provided to members by non-P3 employed providers. This also includes an estimate of IBNR. IBNR is recorded as Claims Payable in the accompanying condensed consolidated balance sheets. Estimates for incurred claims are based on historical enrollment and cost trends while also taking into consideration operational changes. Future and actual results typically differ from estimates. Differences could result from an overall change in medical expenses per member, changes in member mix or simply due to the addition of new members. IBNR estimates are made on an accrual basis and adjusted in future periods as required. To the extent we revise our estimates of incurred but not reported claims for prior periods up or down, there would be a correspondingly favorable or unfavorable effect on our current period results that may or may not reflect changes in long term trends in our performance.

Corporate, general and administrative expenses. Corporate, general and administrative expenses include employee-related expenses, including salaries and related costs and stock-based compensation for our executive, technology infrastructure, operations, clinical and quality support, finance, legal, and human resources departments. In addition, general and administrative expenses include all corporate technology and occupancy costs.

Sales and marketing expenses. Sales and marketing expenses consist of costs related to patient and provider marketing and community outreach. These expenses capture all costs for both our local and enterprise sales and marketing efforts.

Depreciation and amortization expense. Depreciation expense is associated with our property and equipment. Depreciation includes expenses associated with leasehold improvements, computer equipment and software, furniture and fixtures and internally developed software. Amortization expense is associated with definite lived intangible assets, including trademarks and tradenames, customer contracts, provider network agreements and payor contracts.

Premium deficiency reserve (“PDR”). Premium deficiency reserves are recognized when there is a future probable loss on unearned capitated premiums after deducting estimated and expected claim costs and claim adjustment expenses and maintenance expenses. PDR represents the advance recognition of a probable future loss in the current period’s financial statements. If a PDR exists, the amount is recognized by recording an additional liability for the probable future deficiency on the current period’s condensed consolidated balance sheet with a corresponding non-cash charge to the condensed consolidated statement of operations.

Results of Operations

The Business Combination resulted in the presentation of the Company’s financial statements on different basis for the periods July 1, 2022 through September 30, 2022 and January 1, 2022 through September 30, 2022; and the period July 1, 2021 through September 30, 2021 and January 1, 2021 through September 30, 2021. The Company has not provided pro forma statements of operations and cash flows for the three and nine-month periods ended September 30, 2021.

The historical financial information of Foresight (a special purpose acquisition company or “SPAC”) prior to the Business Combinations has not been included in the Predecessor financial statements as this information has been determined not to be useful to a user of the financial statements. SPACs deposit the proceeds from their initial public offerings into segregated trust accounts until a business combination occurs, at which point they are utilized to fund the business combination. The operations of a SPAC until the closing of a business combination, other than income from the trust account investments and transaction expenses, are nominal. Accordingly, the only activity reported in the Predecessor period was the operations of P3 LLC. Foresight’s historical financial

50

information is excluded from the Predecessor financial information. Thus, the financial results of the Successor and Predecessor entities are expected to be largely consistent with the exception of certain financial statement line items impacted by the Business Combinations. Therefore, management believes that a discussion of the financial results of the Successor Period of 2022 compared with the Predecessor Period of 2021 is reasonable.

The following table sets forth our condensed consolidated statements of operations data for the periods indicated (dollars in thousands):

Successor

  

  

Predecessor

    

Successor

  

  

Predecessor

 

Three Months Ended

Three Months Ended

Nine Months Ended

Nine Months Ended

 

September 30, 2022

% of

September 30, 2021

% of

September 30, 2022

% of

September 30, 2021

% of 

    

(Unaudited)

    

Revenue

(Unaudited, As Restated)

    

Revenue

    

(Unaudited)

    

Revenue

(Unaudited, As Restated)

    

Revenue

 

 

OPERATING REVENUE:

    

  

    

  

  

  

  

    

  

    

  

    

  

  

  

  

    

  

Capitated Revenue

$

243,988

 

98

%  

$

153,073

 

98

%  

$

780,775

 

99

%  

$

443,598

 

98

%  

Other Patient Service Revenue

 

4,272

 

2

%  

 

3,113

 

2

%  

 

10,483

 

1

%  

 

8,472

 

2

%  

TOTAL OPERATING REVENUE

 

248,260

 

100

%  

 

156,186

 

100

%  

 

791,258

 

100

%  

 

452,070

 

100

%  

OPERATING EXPENSES:

 

  

 

 

 

 

 

 

  

 

Medical Expenses

 

254,776

 

103

%  

 

161,328

 

104

%  

 

788,046

 

99

%  

 

458,333

 

102

%  

Premium Deficiency Reserve

 

(7,302)

 

-3

%  

 

1,600

 

1

%  

 

(10,116)

 

-1

%  

 

4,600

 

1

%  

Corporate, General and Administrative Expenses

 

37,864

 

15

%  

 

20,434

 

13

%  

 

117,560

 

15

%  

 

53,883

 

12

%  

Sales and Marketing Expenses

 

1,119

 

0

%  

 

491

 

0

%  

 

3,392

 

0

%  

 

1,118

 

0

%  

Goodwill impairment

0

%

0

%

851,456

108

%

0

%

Depreciation and Amortization

 

21,815

 

9

%  

 

456

 

0

%  

 

65,287

 

8

%  

 

1,219

 

0

%  

TOTAL OPERATING EXPENSES

 

308,272

 

124

%  

 

184,309

 

118

%  

 

1,815,625

 

229

%  

 

519,153

 

115

%  

OPERATING LOSS

 

(60,012)

 

-24

%  

 

(28,123)

 

-18

%  

 

(1,024,367)

 

-129

%  

 

(67,083)

 

-15

%  

OTHER INCOME (EXPENSE):

Interest Expense, net

 

(2,750)

 

-1

%  

 

(2,529)

 

-2

%  

 

(8,244)

 

-1

%  

 

(7,023)

 

-1

%  

Mark-to-Market of Stock Warrants

 

(2,567)

 

-1

%  

 

(1,402)

 

-1

%  

 

3,386

 

0

%  

 

(12,063)

 

-3

%  

TOTAL OTHER INCOME (EXPENSE)

 

(5,317)

 

-2

%  

 

(3,931)

 

-3

%  

 

(4,858)

 

-1

%  

 

(19,086)

 

-4

%  

LOSS BEFORE INCOME TAXES

 

(65,329)

 

-26

%  

 

(32,054)

 

-21

%  

 

(1,029,225)

 

-130

%  

 

(86,169)

 

-19

%  

PROVISION FOR INCOME TAXES

 

 

0

%  

 

 

0

%  

 

 

0

%  

 

 

0

%  

NET LOSS

 

(65,329)

 

-26

%  

 

(32,054)

 

-21

%  

(1,029,225)

 

-130

%  

(86,169)

 

-19

%  

LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS

(54,156)

-22

%  

0

%  

(853,124)

-108

%  

0

%  

NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS

$

(11,173)

-4

%  

$

(32,054)

-21

%  

$

(176,101)

-22

%  

$

(86,169)

-19

%  

NET LOSS PER SHARE (BASIC)

$

(0.27)

 

$

 

$

(4.24)

 

$

 

NET LOSS PER SHARE (DILUTED)

$

(0.27)

 

$

 

$

(4.27)

 

$

 

Revenue

Capitated revenue was $244.0 million for the three months ended September 30, 2022, a 59% increase compared to capitated revenue of $153.1 million for the three months ended September 30, 2021. Capitated revenue was $780.8 million for the nine months ended September 30, 2022, an 76% increase compared to capitated revenue of $443.6 million for the nine months ended September 30, 2021. These increases were driven primarily by a 67% increase in the total number of at-risk members from 60,600 at September 30, 2021 to 101,000 at September 30, 2022, as we increased the number of health plan contracts from fourteen to twenty and a 5% increase

51

in capitation revenue rates, due to increased premiums from patients with a higher average level of acuity. Capitated revenue was approximately 98% and 99% of total revenue for the three and nine months ended September 30, 2022, respectively.

Other patient service revenue was $4.3 million for the three months ended September 30, 2022, a 37% increase compared to other patient service revenue of $3.1 million for the three months ended September 30, 2021. Other patient service revenue was $10.5 million for the nine months ended September 30, 2022, a 24% increase compared to other patient service revenue of $8.5 million for the nine months ended September 30, 2021. These increases were primarily driven by increased fees associated with care coordination services and additional fees earned at owned clinics. Other patient service revenue was approximately 2% and 1% of total revenue for the three and nine months ended September 30, 2022, respectively.

Operating expenses

Medical Expenses

Medical expenses were $254.8 million for the three months ended September 30, 2022, a 58% increase compared to medical expenses of $161.3 million for the three months ended September 30, 2021. Medical expenses were $788.0 million for the nine months ended September 30, 2022, a 72% increase compared to medical expenses of $458.3 million for the nine months ended September 30, 2021. These increases were primarily driven by a 56% increase in the total number of at-risk members year-over-year (“YoY”).

Corporate, General and Administrative Expenses

Corporate, general, and administrative expenses were $37.9 million for the three months ended September 30, 2022, an 85% increase compared to corporate, general and administrative expenses of $20.4 million for the three months ended September 30, 2021. The increase was primarily due to a $1.4 million increase in stock-based compensation expense, a $6.2 million increase in professional fees supporting our operations as a public company, a $1.1 million increase in insurance expense, $1.4 million transaction bonus , and a $6.6 million increase in salary related expenses as the average full time employee count increased from 307 for the three months ended September 30, 2021 to 527 for the three months ended September 30, 2022.

Corporate, general and administrative expenses were $117.6 million for the nine months ended September 30, 2022, a 118% increase compared to corporate, general and administrative expenses of $53.9 million for the nine months ended September 30, 2021. The increase was primarily due to a $15.8 million increase in stock-based compensation expense, a $16.6 million increase in professional fees supporting our operations as a public company, $7.3 million transaction bonus , $1.1 million increase in computer software expense, and a $21.6 million increase in salary related expenses as the average full time employee count increased from 307 for the nine months ended September 30, 2021 to 527 for the nine months ended September 30, 2022.

Sales and Marketing Expenses

Sales and marketing expenses were $1.1 million for the three months ended September 30, 2022, a 128% increase compared to sales and marketing expenses of $0.5 million for the three months ended September 30, 2021. Sales and marketing expenses were $3.4 million for the nine months ended September 30, 2022, a 203% increase compared to sales and marketing expenses of $1.1 million for the nine months ended September 30, 2021.  These increases were driven by increases in community outreach spend and higher spending related to patient and provider marketing initiatives.

Depreciation and Amortization Expense

Depreciation and amortization expenses were $21.8 million for the three months ended September 30, 2022, compared to amortization expenses of $0.5 million for the three months ended September 30, 2021. Depreciation and amortization expenses were $65.3 million for the nine months ended September 30, 2022, compared to $1.2 million for the nine months ended September 30, 2021. These increases were associated with definite lived intangible assets acquired in the Business Combinations in the fourth quarter of 2021, including trademarks and tradenames, customer contracts, provider network agreements and payor contracts.

52

Premium Deficiency Reserve (PDR)

Reductions to the PDR of $7.3 million and $10.1 million were recorded for the three and nine month periods ended September 30, 2022, respectively. A PDR of $1.6 million and $4.6 million were recorded in the three and nine month periods ended September 30, 2021, respectively.

Goodwill Impairment

The Company recorded an $851.5 goodwill impairment charge in the three month period ended June 30, 2022 due to the macroeconomic and financial market conditions, industry-specific considerations, the Company’s performance, and its sustained decrease in share price. See Note 11 “Goodwill.”

Other (Income)/Expense

Interest expense, net was $2.8 million for the three months ended September 30, 2022, an 8.7% increase compared to interest expense of $2.5 million for the three months ended September 30, 2021. Interest expense, net was $8.2 million for the nine months ended September 30, 2022, a 17% increase compared to interest expense of $7.0 million for the nine months ended September 30, 2021. These increases were primarily due to interest associated with the Company’s Term Loan Facility (defined below).

A loss of $2.6 million and $1.4 million were recorded for the three months ended September 30, 2022 and the three months ended September 30, 2021, respectively, for the change in the fair value of warrant liabilities associated with our public, private placement and forward purchase warrants. A gain of $3.4 million and loss of $12.1 million were recorded for the nine months ended September 30, 2022 and the nine months ended September 30, 2021, respectively.

Provision for Income Taxes

The provision for income taxes was zero in each of the three and nine-month periods ended September 30, 2022 and September 30, 2021. As a result of the Business Combinations, substantially all of the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interest in P3 LLC. P3 LLC is treated as a partnership for U.S. federal and most applicable state and local income tax jurisdictions. As a partnership, P3 LLC is generally not subject to U.S. federal, state and local income taxes. Any taxable income or loss generated by P3 LLC is passed through to and included within the taxable income or loss of its members. Prior to the Business Combinations, the income and losses of P3 LLC was passed through to its members and nontaxable to P3 LLC.

Net Loss

Net loss was $65.3 million for the three-months ended September 30, 2022, or a 103% increase compared to a net loss of $32.1 million for the three-months period ended September 30, 2021. The $33.3 million increase primarily reflects a $93.4 million increase in medical expenses, net, a $17.4 million increase in corporate, general and administrative expenses, and a $21.4 million increase in depreciation and amortization expenses, partially offset by the $92.0 million increase in total operating revenue, a $8.9 million decrease in PDR expense, and a $1.2 million increase on the mark-to-market of stock warrants loss in the third quarter of 2022 compared with 2021. Net loss was $1,029.2 million for the nine-month periods ended September 30, 2022, or a 1,194% increase compared to a net loss of $86.2 million in the nine-months ended September 30, 2021. The $943.1 million increase primarily reflects a $329.7 million increase in medical expenses, net, a $851.5 million goodwill impairment charge in 2022, a $63.7 million increase in corporate, general and administrative expenses, and a $64.1 million increase in depreciation and amortization expenses, partially offset by a $339.2 million increase in total operating revenue, a $14.7 million decrease in PDR expense, and a $3.4 million gain on the mark-market of stock warrants in 2022 compared with a $12.1 million loss in 2021.

Supplemental Unaudited Presentation of Consolidated Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure. We present Adjusted EBITDA because we believe it helps investors understand underlying trends in our business and facilitates an understanding of our operating performance from period to period because it facilitates a comparison of our recurring core business operating results. Adjusted EBITDA is intended as a supplemental measure of our performance that is neither required by, nor presented in accordance with, GAAP. Our presentation of these measures should not be

53

construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies may not calculate Adjusted EBITDA in the same fashion. The definition of Adjusted EBITDA may not be the same as the definitions used in any of our debt agreements.

By definition, EBITDA consists of net income (loss) before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA, further adjusted to add back the effect of certain expenses, such as mark-to-market warrant expense, PDR, stock-based compensation expense and transaction expenses.

Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with GAAP. It is unaudited and should not be considered an alternative to, or more meaningful than, net income (loss) as an indicator of our operating performance. Uses of cash flows that are not reflected in Adjusted EBITDA include capital expenditures, interest payments, debt principal repayments, and other expenses defined above, which can be significant. As a result, Adjusted EBITDA should not be considered as a measure of our liquidity.

Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA on a supplemental basis. You should review the reconciliation of net loss to Adjusted EBITDA set forth above and not rely on any single financial measure to evaluate our business.

The following table sets forth a reconciliation of net loss to Adjusted EBITDA using data derived from our unaudited consolidated financial statements for the periods indicated (dollars in thousands):

Successor

Predecessor

Successor

Predecessor

    

Three Months Ended

    

Three Months Ended

    

Nine Months Ended

    

Nine Months Ended

September 30, 2022

September 30, 2021

September 30, 2022

September 30, 2021

(Unaudited)

(Unaudited, As Restated)

(Unaudited)

(Unaudited, As Restated)

Net loss

$

(65,329)

$

(32,054)

$

(1,029,225)

$

(86,169)

Adjustments to net loss

 

 

 

 

Interest expense, net

 

2,751

 

2,529

 

8,245

 

7,023

Depreciation and amortization expense

 

21,815

 

456

 

65,287

 

1,219

Goodwill impairment

851,456

Mark-to-market warrants

 

2,567

 

1,402

 

(3,386)

 

12,063

Premium deficiency reserve

 

(7,302)

 

1,600

 

(10,116)

 

4,600

Transaction expense, Business Combinations

 

112

 

 

2,248

 

Transaction related litigation expense

 

300

 

 

1,371

 

Transaction bonuses

 

1,432

 

 

7,337

 

Stock-based compensation expense

 

1,784

 

355

 

17,211

 

1,379

Restatement related costs

1,563

1,563

Other

 

 

 

109

 

Total adjustments to net loss

 

25,022

 

6,342

 

941,325

 

26,284

Adjusted EBITDA loss

$

(40,307)

$

(25,712)

$

(87,900)

$

(59,885)

Liquidity and Capital Resources

General

To date, we have financed our operations principally through the Business Combination, private placements of our equity securities, payments from our payors and borrowings under the Term Loan Facility (defined below). We generate cash primarily from our contracts with payors. As of September 30, 2022, we had cash and restricted cash of $35.4 million.

We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the strong growth we have experienced over the last four years and the investments we intend to make in expanding our business,

54

which will require up-front expenses. Our future capital requirements will depend on many factors, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital. We may need to raise additional capital through a combination of debt financing, other non-dilutive financing and/or equity financing and to the extent we are unsuccessful at doing so, we may need to adjust the Company’s growth trajectory to accommodate its capital needs and look for additional ways to generate cost efficiencies.

Our primary uses of cash include payments for medical expenses, administrative expenses, cost associated with our care model, debt service and capital expenditures. Final reconciliation and receipts of amounts due from payors are typically settled in arrears.

Following the completion of the Business Combinations (the “Closing”) on December 3, 2021, substantially all of P3’s assets and operations are held and conducted by P3 LLC, the surviving company post-combination. The ability of P3 Health Partners Inc. to pay taxes, make payments under the Tax Receivable Agreement (defined below) and to pay dividends will depend on the financial results and cash flows of P3 LLC and the distributions received from P3 LLC. Deterioration in the financial condition, earnings or cash flow of P3 LLC for any reason could limit or impair P3 LLC’s ability to pay such distributions. Additionally, to the extent that P3 needs funds and P3 LLC is restricted from making such distributions under applicable law or regulation or under the terms of any financing arrangements, or P3 LLC is otherwise unable to provide such funds, it could materially adversely affect the liquidity and financial condition of P3. It is anticipated that the distributions P3 will receive from P3 LLC may, in certain periods, exceed the actual tax liabilities and obligations to make payments under the Tax Receivable Agreement.

Tax Receivable Agreement

Pursuant to our election under Section 754 of the Internal Revenue Code (the “Code”), we expect to obtain an increase in our share of the tax basis in the net assets of P3 LLC when its units are redeemed or exchanged. We intend to treat any redemptions and exchanges of P3 LLC Units as direct purchases of the units for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that we would otherwise pay in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent the tax basis is allocated to those capital assets.

In connection with the Business Combinations, we entered into a Tax Receivable Agreement (“TRA”) with certain of the P3 Equityholders and P3 LLC that provides for the payment by us of 85% of the amount of any tax benefits that we actually realize, or in some cases are deemed to realize, as a result of (i) increases in our share of the tax basis in the net assets of P3 LLC resulting from any redemptions or exchanges of P3 LLC, (ii) tax basis increases attributable to payments made under the TRA, and (iii) deductions attributable to imputed interest pursuant to the TRA (the “TRA Payments”). We expect to benefit from the remaining 15% of any tax benefits that we may actually realize. The estimation of a liability under the TRA is, by its nature, imprecise and subject to significant assumptions regarding a number of factors, including (but not limited to) the amount and timing of taxable income generated by the Company each year as well as the tax rate then applicable. As a result of the Business Combinations, the potential future tax benefits are estimated to be $5.4 million, of which $4.6 million is estimated to be the associated TRA liability.

As noted above, we have no recorded tax benefits associated with the increase in tax basis as a result of the Business Combinations. As a result, we determined that payments to TRA holders are not probable and no TRA liability has been recorded as of September 30, 2022 and December 31, 2021.

As non-controlling interest holders exercise their right to exchange their units in P3 LLC(“P3 LLC Units”), a TRA liability may be recorded based on 85% of the estimated future tax benefits that the Company may realize as a result of increases in the tax basis of P3 LLC. The amount of the increase in the tax basis, the related estimated tax benefits, and the related TRA liability to be recorded will depend on the price of our Class A Common Stock at the time of the relevant redemption or exchange.

Liquidity

As of the date of this report, we believe that our cash, cash equivalents and restricted cash are not sufficient to fund our operating and capital needs for at least the next 12 months from the issuance of this Form 10-Q. This evaluation of our cash resources available over the next twelve months does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or the many factors that determine the company’s capital requirements, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital.  Management continues to explore raising additional capital through a combination of debt financing and equity issuances. If we raise funds by issuing debt securities or preferred stock, or

55

by incurring loans, these forms of financing would have rights, preferences, and privileges senior to those of holders of our Common Stock. If we raise capital through the issuance of additional equity, such sales and issuance would dilute the ownership interests of the existing holders of the Company’s Common Stock. The availability and the terms under which we may be able to raise additional capital could be disadvantageous, and the terms of debt financing or other non-dilutive financing may involve restrictive covenants and dilutive financing instruments, which could place significant restrictions on our operations. Macroeconomic conditions and credit markets could also impact the availability and cost of potential future debt financing. There can be no assurances that any additional debt, other non-dilutive and/or equity financing would be available to us on favorable terms, or potentially at all. We expect to continue to incur net losses, comprehensive losses, and negative cash flows from operating activities in accordance with our operating plan.

As of the date of this report, we believe that our existing cash resources are not sufficient to support planned operations. The matters discussed above raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Cash Flows

The following discussion of our cash flows is based on the consolidated statements of cash flows. The following table sets forth summarized cash flows for the periods indicated:

    

Successor

    

Predecessor

Nine Months Ended

Nine Months Ended

September 30, 2022

September 30, 2021

(Unaudited)

(Unaudited,

As Restated)

Net cash used in operating activities

$

(94,065,131)

$

(39,827,450)

Net cash used in investing activities

 

(7,783,535)

 

(7,884,167)

Net cash (used in) provided by financing activities

 

(3,624,662)

 

12,491,534

Net change in cash

 

(105,473,328)

 

(35,220,083)

Cash at beginning of period

 

140,833,872

 

39,902,947

Cash at end of period

$

35,360,544

$

4,682,864

Net cash used in operating activities for the nine months ended September  30, 2022, was $94.1 million, an increase of $54.3 million compared to net cash used in operating activities of $39.8 million for the nine months ended September 30, 2021. Significant changes impacting net cash used in operating activities for the nine months ended September  30, 2022 as compared to the nine months ended September 30, 2021 were as follows:

a $943.1 million increase in our net loss from $86.2 million for the nine months ended September 30, 2021 to $1,029.2 million for the nine months ended September 30, 2022, driven in part by a $851.5 million goodwill impairment charge and a $51.7 million increase in certain non-cash expenses including depreciation, amortization, stock-based compensation, mark-to-market adjustments for warrants and premium deficiency reserves and the performance in our capitated contracts and increased at-risk Medicare Advantage members, as described above;
a decrease in our net health plan receivables for the nine months ended September 30, 2022 of $31.2 million compared to a decrease in our net health plan receivables for the nine months ended September 30, 2021 of $0.9 million.
a decrease in our net health plan payables for the nine months ended September 30, 2022 of $1.9 million compared to a decrease in our net health plan payables for the nine months ended September 30, 2021 of $0.5 million; and
offset by an increase in our claims payable for the nine months September 30, 2022 of $32.7 million compared to an increase in our claims payable for the nine months ended September 30, 2021 of $18.2 million;

56

Net cash used in investing activities for the nine months ended September 30, 2022 was $7.8 million compared to $7.9 million for the nine months ended September 30, 2021. The decrease in net cash used in investing activities was primarily driven by a decrease in purchases of property, plant and equipment, which is partially offset by increase in cash from acquisitions.

Net cash used in financing activities for the nine months ended September 30, 2022, was $3.6 million, a $16.1 million decrease, compared to net cash provided by financing of $12.5 million for the nine months ended September 30, 2021. This decrease reflects net proceeds of $12.8 million from the issuance of long-term debt during the nine months ended September 30, 2021 and repayment of short-term and long-term debt totaling $3.6 million during the nine months ended September 30, 2022.

Contractual Obligations and Commitments

Our principal commitments consist of repayments of unpaid claims, long-term debt on term loans, unsecured debt and leases obligation for our facilities.

The following table summarizes our contractual obligations as of September 30, 2022 (in thousands):

Payments due by Period

Less than

More than

    

Total

    

1 year

    

1-3 years

    

3-5 years

    

5 years

Unpaid Claims

$

134,705,426

$

134,705,426

$

$

$

Short-term debt

 

 

 

 

 

Term loan

 

65,000,000

 

 

 

65,000,000

 

Unsecured debt

 

15,000,000

 

 

 

15,000,000

 

Lease obligation

 

11,370,108

 

570,897

 

3,449,837

 

3,648,065

 

3,701,309

Other

 

 

 

 

 

Total

$

226,075,534

$

135,276,323

$

3,449,837

$

83,648,065

$

3,701,309

Unpaid claims

As of September 30, 2022, we estimated a balance of unpaid claims due to third parties for health care services provided to members, including estimates for incurred but not reported claims, of $134.7 million. Estimates for incurred claims are based on historical enrollment and cost trends while also taking into consideration operational changes. Future and actual results typically differ from estimates. Differences could result from an overall change in medical expenses per members, changes in member mix or simply due to addition of new members.

Term Loan

On November 19, 2020, the Company entered a Term Loan and Security Agreement with CRG Servicing, LLC (the “Term Loan Agreement”) providing for funding of up to $100 million (the “Term Loan Facility”). The maturity date of the Term Loan Facility is December 31, 2025. As of September 30, 2022, we had $65.0 million of borrowings outstanding under the Term Loan Facility, and the remaining availability under the Term Loan Facility ended upon termination of the commitment period on February 28, 2022. Interest is payable at 12.0 % per annum on a quarterly cycle (in arrears) beginning March 31, 2021. Commencing in March of 2021, we elected to pay 8.0% with the remaining 4.0% being added to principal as “paid in kind” (“PIK”) for a period of three years (or twelve payments), in lieu of the full 12.0% in cash.

Under the terms of the Term Loan Agreement, we must remain in compliance with financial covenants such as minimum liquidity of $5.0 million and annual minimum revenue levels. In addition, the Term Loan Facility restricts our ability and the ability of our subsidiaries to, among other things, incur indebtedness and liens. Beginning in 2021, and on an annual basis thereafter, the Company must post a minimum amount of annual revenue equal to or greater than $395.0 million; increasing to $460.0 million in 2022; $525.0 million in 2023; $585.0 million in 2024 and $650.0 million in 2025 and thereafter. The maturity date may be accelerated as a remedy under the certain default provisions in the agreement, or in the event a mandatory prepayment event occurs. The Company was in compliance with all covenants at September 30, 2022, except for the condition disclosed in Note 15 “Long-term Debt”, where the Company was not in compliance with a covenant related to the issuance of the 2021 financial statements with an audit opinion free of a “going concern” qualification or timely filing of the 2021 financial statements. The Term Loan lenders granted (i) a waiver of the covenant under the Facility related to the existence of a “going concern” qualification in the audit opinion for our audited financial

57

statements for the fiscal year ended December 31, 2021 and (ii) a consent to extend the deadline to provide audited financial statements for the year ended December 31, 2021 to October 21, 2022.

Unsecured Debt

As of September 30, 2022, we have a $15.0 million unsecured note with a former equity investor. The note carries interest of 11.0% per year. The principal balance plus accrued interest is due at maturity, which is the earlier of June 30, 2026 or a change in control transaction. The transaction pertaining to P3’s merger with Foresight did not constitute a change in control. As of September 30, 2022, accrued interest totaled $8.3 million on this note.

For additional discussion of our unpaid claims, term loan, unsecured debt and lease obligation, see Note 3 “Going Concern and Liquidity,” Note 14 “Claims Payable,” Note 15 “Long-term Debt,” and Note 21 “Leases” in our condensed consolidated financial statements as of and for the period ended September 30, 2022, included elsewhere in this Quarterly Report on Form 10-Q.

JOBS Act

We qualify as an “Emerging Growth Company” pursuant to the provisions of the JOBS Act. For as long as we are an “Emerging Growth Company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation and shareholder advisory votes on golden parachute compensation.

In addition, under the JOBS Act, Emerging Growth Companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards under the JOBS Act until we are no longer an Emerging Growth Company. Our election to use the phase-in periods permitted by this election may make it difficult to compare our financial statements to those of non-Emerging Growth Companies and other Emerging Growth Companies that have opted out of the longer phase-in periods permitted under the JOBS Act and who will comply with new or revised financial accounting standards. If we were to subsequently elect instead to comply with public company effective dates, such election would be irrevocable pursuant to the JOBS Act.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Preparation of the financial statements requires management to make judgments, estimates and assumptions that impact the reported amount of revenue and expenses, assets and liabilities and the disclosure of contingent assets and liabilities. We consider an accounting judgment, estimate or assumption to be critical when (1) the estimate or assumption is complex in nature or requires a high degree of judgment and (2) the use of different judgments, estimates and assumptions could have a material impact on our consolidated financial statements.

Accounting policies, including those requiring the application of significant judgement by management, are described in Note 4 “Significant Accounting Policies” to our condensed consolidated financial statements included elsewhere in this Form 10-Q and in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 Form 10-K. There were no material changes to these policies and estimates as compared to those described in our 2021 Form 10-K.

Recent Accounting Pronouncements

See Note 5 “Recent Accounting Pronouncements Adopted” to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting standards issued and the anticipated effects on our consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not

58

hold financial instruments for trading purposes. As of September 30, 2022, there have been no material changes to our market risk assessment previously disclosed in our 2021 Form 10-K.

Item 4. Controls and Procedures

Limitations on effectiveness of controls and procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the Company’s reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the principal executive officer and the principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of September 30, 2022, under the supervision and with the participation of Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), management carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Form 10-Q due to material weaknesses in internal control over financial reporting identified in our 2021 Form 10-K for the year ended December 31, 2021, as further described below.

Material Weaknesses

In connection with the audit of our financial statements for the year ended December 31, 2021, and as previously reported, the restatement of the Company’s financial statements for the years ended December 31, 2020 and 2019 as more fully described in Note 2 “Restatement of Previously Issued Financial Statements” to our consolidated financial statements in our 2021 Form 10-K, we concluded that there were material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Management has determined that the Company had the following material weaknesses in its internal control over financial reporting:

Control Environment, Risk Assessment and Monitoring

We did not maintain appropriately designed entity-level controls impacting the control environment, risk assessment procedures, and effective monitoring activities to prevent or detect material misstatements to the consolidated financial statements.  These material weaknesses are specifically attributed to the following:

We did not have adequate policies and procedure or sufficient qualified resources with sufficient technical knowledge to maintain effective controls over the accounting related to significant accounts and related financial statement disclosures.
We did not design and implement a sufficient risk assessment process to identify and assess risks impacting control over financial reporting.
We had ineffective evaluation and determination as to whether the components of internal control were present and functioning.

Control Activities and Information and Communication

59

As a consequence of these entity-level material weaknesses, we did not design, implement, and maintain effective control activities within certain business processes and the information technology environment to mitigate the risk of material misstatement in financial reporting. Specifically:

We did not maintain effective controls over our information systems to ensure that relevant and reliable information was communicated on a timely basis across the organization to support the financial reporting process.  Particularly:
oWe did not design and implement effective information technology general controls in the areas of user access related to certain information technology systems that support our financial reporting process.
oWe did not maintain sufficient segregation of duties over the performance of control activities for financial close and reporting, including over the review of account reconciliations and journal entries.
We did not design and maintain effective management review controls at a sufficient level of precision over the accounting for transactions related to the risk adjustment factor receivable and related revenue, capitated revenue classification, premium deficiency reserves, business combinations, goodwill and intangibles, income taxes, warrant valuation, and equity awards.  This material weakness resulted in certain material corrections to the financial statements.
We did not design and maintain effective controls at a sufficient level of precision over the estimation of claims expense and payable including controls over the review of historical claims data, including the completeness and accuracy of data used to determine the financial statement amounts.
We did not design and maintain effective controls over accounting for complex transactions, including the inaccurate attribution of net income or loss to the controlling and non-controlling interest pursuant to ASC 810 for subsidiaries that are variable interest entities, the improper classification of the Class A Units as permanent equity instead of temporary equity, and the improper accounting of preferred returns in equity and interest expense, as no recognition is necessary until legally declared. This material weakness resulted in the restatement discussed in Note 2 to the financial statements included herein.

Remediation Activities

We have taken and are taking steps to remediate these material weaknesses through (i) hiring qualified accounting, financial reporting, IT, and other key management personnel with public company experience, (ii) engaging an external advisor to assist with documenting internal controls, including enhancing controls to ensure proper communication of critical information, review and approvals; evaluating effectiveness of internal controls and assist with the remediation of deficiencies and training of personnel, as necessary, and establishment of a formal internal audit function and (iii) enhancing policies, procedures, and documentation for significant areas of accounting, including each area where a material weakness was identified. We are still in the process of implementing these steps and cannot assure investors that these measures will significantly improve or remediate the material weaknesses described above.

Changes in internal control over financial reporting

Other than the actions to remediate the material weaknesses in our internal control over financial reporting as described above, which was ongoing as of the date of issuance of this Form 10-Q, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II    OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are involved in litigation and proceedings in the ordinary course of our business. Other than the legal proceedings disclosed in Part I, Item 3., “Legal Proceedings” of our 2021 Form 10-K, we are not involved in any legal proceeding that we believe would have a material effect on our business or financial condition. There have been no material changes or developments in our legal proceedings during the nine months ended September 30, 2022, from those previously disclosed in Part I, Item 3., “Legal Proceedings” of our 2021 Form 10-K , other than as described below.

60

Class D Dispute

On June 11, 2021, Hudson Vegas Investment SPV, LLC (“Hudson”), a holder of P3’s Class D Units, filed an action in the Delaware Court of Chancery captioned Hudson Vegas Investments SPV, LLC v. Chicago Pacific Founders Fund, L.P., et al., C.A. No. 2021-0518-JTL (the “Hudson Action”), in which it challenged the Business Combinations. Specifically, Hudson purports to assert claims against P3, certain managers that were on the P3 Board of Managers, certain of its officers, and Chicago Pacific Founders Fund, L.P. (“CPF”) for breach of P3’s then-existing LLC agreement (against P3 and CPF), breach of fiduciary duty (against certain of P3’s officers) and breach of contract claims related to the then-existing LLC Agreement (against the P3 Board of Managers) in connection with the process leading up to, and approval of, the Business Combinations. In the Hudson Action, Hudson sought to enjoin the consummation of the Business Combinations and seeks a declaration that the Business Combinations violate its rights under the P3 then-existing LLC agreement, a declaration that certain managers on the P3 Board of Managers and certain of P3’s officers breached their fiduciary duties, and money damages including attorneys’ fees.

On June 13, 2021, P3 filed an action in the Delaware Court of Chancery captioned P3 Health Group Holdings, L.L.C. v. Hudson Vegas Investment SPV, LLC, C.A. No. 2021-0519-JTL (the “P3 Action”). In the P3 Action, P3 seeks: (i) a declaration that the Business Combinations do not violate Section 3.10 of P3’s Existing LLC Agreement; and (ii) reformation of a provision of P3’s Existing LLC Agreement. The P3 Action was consolidated with the Hudson Action. The combined cases are captioned In re P3 Health Group Holdings, L.L.C, C.A. No. 2021-0518-JTL.

On June 22, 2021, Hudson filed a motion for expedited proceedings in the Hudson Action in which it sought expedited discovery and a hearing on its motion for preliminary injunction to enjoin the consummation of the Business Combinations. The defendants in the Hudson Action determined not to oppose Hudson’s motion for expedited proceedings and engaged in expedited discovery in advance of a preliminary injunction hearing that took place September 9, 2021.

On September 14, 2021, the Court of Chancery issued an oral ruling denying Hudson’s motion for preliminary injunction due to the lack of probability of success on the merits or, with respect to the Section 5.10 of the then-existing P3 LLC agreement (the “Purchase Option”) only, lack of a showing of irreparable harm based on the condition that the escrow described below be created. In its ruling, the Court held that Hudson had not demonstrated a reasonable probability of success on its claims, except for its claim under the Purchase Option, which - if applicable - would allow Hudson to exercise an option to purchase additional equity interests in P3 in connection with the pending transaction with Foresight. With respect to the Purchase Option claim, the Court declined to address the merits and instead denied Hudson’s motion finding that Hudson failed to demonstrate irreparable harm. This ruling was made subject to the condition that Defendants memorialize their commitment to escrow, pending final resolution of this action, the consideration Hudson would be entitled to receive if it is determined that the Purchase Option can be validly exercised, in a stipulation filed with the Court. On September 17, 2021, Defendants filed a stipulation and proposed order regarding escrow which confirmed their commitment to do so and to cause the Payment Spreadsheet (as that terms is defined in Section 2.01(f) of the Merger Agreement) to provide that such consideration will be directed to such escrow. The Court granted and entered the stipulation and proposed order on September 17, 2021.

The former members of P3 (other than Hudson) have agreed to indemnify the Company and P3 LLC following the Closing, for any damages, including reasonable attorney’s fees, arising out of matters relating to the dispute with Hudson.

On December 27, 2021, Hudson filed a Motion for Leave to Amend the Verified Complaint. The proposed Amended Complaint contains certain of Hudson’s original claims and also adds additional claims, including bad faith breach of contract claims against certain of the former P3 Managers, an additional contractual claim against P3, and a tortious interference with contract claim against Foresight Acquisition Corp., Foresight Acquisition Corp. II, P3 Partners Inc., Sameer Mathur, and Greg Wasson. Defendants informed Hudson that they did not oppose the Motion for Leave to Amend the Verified Complaint, and on February 4, 2022, Hudson filed its Verified Amended Complaint.

On March 9, 2022, all Defendants moved to dismiss the Verified Amended Complaint. The Briefing on Defendants’ Motion to Dismiss was completed on May 17, 2022.

On March 25, 2022, Hudson served its Second Request for the Production of Documents directed to Defendants, and on April 14, 2022, Defendants filed a Motion to Stay Discovery and for Protective Order Pending Resolution of Motions to Dismiss (the “Motion to Stay”). Defendants served formal responses and objections to the Second Request for the Production of Documents on April 25, 2022.

61

Hudson opposed the Motion to Stay on May 12, 2022. On July 13, 2022, the Court heard argument on both the Motions to Dismiss and the Motion to Stay and took the matters under advisement.

On September 12, 2022, the Court issued an opinion which concluded that the Court could exercise personal jurisdiction over Ms. Puathasnanon, an officer defendant in the action. The Court has not addressed any of the other arguments in the Motions to Dismiss, including Ms. Puathasnanon’s other defenses. On October 14, 2022, the Court issued an opinion which concluded that the Court could exercise personal jurisdiction over Mr. Wasson. The Court has not addressed any of the other arguments in the Motions to Dismiss, including Mr. Wasson’s other defenses.

On October 31, 2022, the Court issued an opinion granting in part and denying in part the Company’s Motion to Dismiss. The Court denied Defendants’ motion with respect to Hudson’s claims that the Company breached the LLC Agreement by: (i) allegedly failing to obtain Hudson’s consent before allocating seats on the board of directors for the new company to certain representatives from Chicago Pacific; (ii) combining the Company with a CPF affiliate, MyCare; (iii) allegedly not making a full first-priority distribution to Hudson; (iv) using blocker transactions as part of the merger; and (v) allegedly failing to provide Hudson managers with certain information during the transaction and allegedly not permitting them to participate in the planning of the transaction.  The Court granted all other breach of contract claims against the Company.

On November 1, 2022, the Court issued an opinion granting in part and denying in part a motion to dismiss filed by Mr. Leisure, Mr. Kazarian, Mr. Abdou, Mr. Bacchus, Mr. Garrett, Mr. Price, Ms. Glisson, and Mr. Leavitt (the “Manager Defendants”) with respect to Hudson’s claim for bad faith breach of contract under a variety of theories.  The Court’s opinion granted in part and denied in part the Manager Defendants’ motion, permitting certain of Hudson’s bad faith breach of contract claims to proceed against the Manager Defendants, but dismissing others.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those previously disclosed in Part I, Item 1A., “Risk Factors” of our 2021 Form 10-K. You should carefully consider the risk factors discussed in our 2021 Form 10-K, which could materially affect our business, financial condition or future results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

On November 11, 2022, certain subsidiaries of the Company and Eric Atkins entered into a Confidential Separation Agreement and Release (the “Separation Agreement”) in connection with Mr. Atkin’s resignation as Chief Financial Officer of the Company. Pursuant to the Separation Agreement, 81,264 unvested P3 LLC Units and Class V common stock of the Company held by Mr. Atkins will vest on January 20, 2023 (rather than be forfeited for no consideration) in exchange for Mr. Atkins’s execution and non-revocation of a general release of claims and his continued compliance with non-competition, non-solicitation, non-disparagement and confidentiality covenants.

The foregoing description of the Separation Agreement is only a summary and is qualified in its entirety by the full text of the Separation Agreement, a copy of which is attached to this Form 10-Q as Exhibit 10.1.

62

Item 6. Exhibits

Exhibit
Number

    

Description

    

Form

File No.

Exhibit

Filing
Date

Filed/Furnished

Herewith

2.1

Agreement and Plan of Merger, dated as of May 25, 2021, by and between Foresight, P3 Health Group Holdings, LLC, FAC Merger Sub LLC.

8-K

001-40033

2.1

6/1/2021

2.2

Transaction and Combination Agreement, dated as of May 25, 2021, by and among Foresight, the Merger Corps, the Blockers, Splitter and the Blocker Sellers.

8-K

001-40033

2.2

6/1/2021

2.3

First Amendment to Merger Agreement, dated as of November 21, 2021, by and among Foresight, Merger Sub and P3.

8-K

001-40033

2.1

11/22/2021

2.4

Second Amendment, dated as of December 3, 2021, to the Agreement and Plan of Merger, dated as of May 25, 2021, by and among Foresight Acquisition Corp. (“Foresight”), FAC merger Sub LLC and P3 Health Group Holdings, LLC.

8-K

001-40033

2.4

12/3/2021

2.5

The First Amendment to the Transaction and Combination Agreement between Foresight, the Merger Corps, the Blockers, Splitter and the Blocker Sellers.

8-K

001-40033

2.5

12/3/2021

3.1

Amended and Restated Certificate of Incorporation of the Company.

8-K

001-40033

3.1

12/3/2021

3.2

Bylaws of the Company.

8-K

001-40033

3.2

12/3/2021

10.1

Separation Agreement, by and between P3 Health Partners Inc. and Eric Atkins.

*

31.1

Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*

31.2

Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302

*

63

of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*

101.SCH

Inline XBRL Taxonomy Extension Scheme Document

*

101.CAL

Inline XBEL Taxonomy Extension Calculation Linkbase Document

*

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

*

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

*

104

Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)

*

*

Filed herewith.

**

Furnished herewith.

64

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 14, 2022

P3 Health Partners Inc.

By:

/s/ Erin Darakjian

Erin Darakjian

Interim Chief Financial Officer

(Principal Financial Officer and Principal
Accounting Officer)

65

EX-10.1 2 piii-20220930xex10d1.htm EX-10.1

Exhibit 10.1

CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE

This Confidential Separation Agreement and Release (the “Agreement”) is entered into by and between Eric Atkins (“Employee”), P3 Health Partners Inc. (the “Company”), P3 Health Group Management, LLC (“Employer”), and P3 Health Group, LLC (“P3 LLC”) (each individually referred to as a “Party” and collectively as “Parties”). Employee resigned his employment with Employer, effective as of November 1, 2022 (“Separation Date”). The Parties wish to resolve any issues that may exist surrounding Employee’s employment and separation from employment with Employer. By offering and entering into this Agreement, none of the Parties admit to any liability or wrongdoing with respect to each other and/or any third party.

Therefore, for good and sufficient consideration, the Parties agree as follows.

1.Effective Date. The Effective Date of this Agreement shall be upon Employer’s receipt of this Agreement, dated and signed by Employee. Employee shall have 10 days following receipt of this Agreement to review this Agreement.

2.Consideration.  Employee is a party to that certain Incentive Unit Grant Agreement, dated March 1, 2021 (the “Grant Agreement”), pursuant to which Employee was granted 215,000 Class C-1 Units of P3 Health Group Holdings, LLC (the “Incentive Units”), subject to the terms of the Grant Agreement.  The Incentive Units previously were converted into 406,320 P3 LLC units and 406,320 corresponding shares of Class V common stock of P3 Health Partners Inc. (together, the “P3 Units/Shares”).  As of the Separation Date, (i) Employee had vested in 284,424 of such P3 Units/Shares, and (ii) of the remaining P3 Units/Shares, 81,264 were scheduled to vest on January 20, 2023 and 40,632 were scheduled to vest on January 20, 2024, subject to Employee’s continued employment through the applicable vesting date.  Pursuant to the Grant Agreement, no vesting would occur upon or following a termination of employment, unless Employer terminated Employee’s employment for reasons other than Cause (as defined in the Grant Agreement).

In consideration for the promises made by Employee, and contingent on Employee’s fulfillment of the conditions of this Agreement, Employer, P3 LLC and the Company agree to waive the employment condition for 81,264 P3 Units/Shares, such that such P3 Units/Shares will become vested on January 20, 2023, even though Employee’s employment had terminated as of the Separation Date and prior to the January 20, 2023 vesting date. The Parties each agree that for purposes of this Agreement, the vesting provisions in the Grant Agreement are deemed to be amended to allow for waiver of the employment condition as described in this Section 2, and this waiver of the employment condition and vesting of the 81,264 P3 Units/Shares will be the “Consideration” for purposes of this Agreement.

The Parties each agree to execute and deliver any and all further agreements, documents or instruments necessary to effectuate this Agreement and the transactions referred to herein or contemplated hereby or reasonably requested by the other Party to perfect or evidence its rights hereunder (including an amendment to the Grant Agreement, if the Company, P3 LLC or Employer determines that such amendment is reasonably necessary).

1 of 8


Employee understands and agrees that none of the Company, Employer or P3 LLC is providing tax or legal advice, or making representations regarding tax obligations or consequences, if any, related to this Agreement. Employee further agrees that Employee is solely responsible for and will fully assume all tax obligations or consequences that may arise in connection with the Consideration. Employee further agrees to fully indemnify and hold Employer and the Releasees (as defined below) harmless from any claims, demands, deficiencies, levies, assessments, executions, judgments, or recoveries made by any governmental entity against any of the Releasees or for any failure by Employee to pay taxes or by the Company, Employer or P3 LLC to make any withholdings or take any tax actions on the Consideration. Employee further agrees that note of the Company, Employer or P3 LLC shall have any obligation to oppose or defend any claims or actions filed by any entity or person arising from amounts claimed due on account of the Consideration or otherwise relating to any payment or benefit under this Agreement.

Employee acknowledges that the Consideration exceeds any obligation of the Company, the Employer or P3 LLC and that but for this Agreement, Employee would not be entitled to any such consideration. Employee acknowledges that Employee has previously / separately been paid all wages due, including all or any regular compensation, overtime compensation, bonuses, commissions, and all amounts owed for accrued but unused vacation/paid time off pay; that none of the Company, the Employer or P3 LLC owe Employee any payments for business expenses related to Employee’s employment; and that Employee is not presently aware of any injury for which Employee may be entitled to file a claim for workers’ compensation benefits.

3.COBRA Benefits.  Employee’s current health benefits coverage will end on November 30, 2022, as a result of Employee’s separation from Employer. Beginning December 1, 2022, Employee will be eligible for and may elect to continue coverage under COBRA at Employee’s own expense.

4.General Release of Claims. In exchange for the Consideration to be provided by the Company, Employer and P3 LLC, and the promises in this Agreement, Employee, for Employee and Employee’s heirs, legal representatives, successors and assigns, knowingly and voluntarily releases and forever discharges the Company, Employer, P3 LLC, their parents, subsidiaries and affiliated entities, and each of their current and former shareholders, members, managers, officers, directors, trustees, beneficiaries, settlors, representatives, employees, volunteers, advisors, agents, attorneys, insurers, successors, predecessors, and assigns (collectively the “Releasees”) from any and all claims, rights, demands, actions, causes of action, judgments, rights, fees, damages, debts, liabilities, expenses and obligations of any kind or nature, whether known or unknown, that Employee has or ever had against them, as permitted by law. This release includes, without limitation, any and all claims for compensation and all claims arising from contract (express or implied), tort, public policy, and equity, and any and all claims of wrongful discharge, retaliation, harassment and/or employment discrimination arising under local, state, and/or federal law and statutes including, without limitation, Title VII of the Civil Rights Act of 1964, as amended, the Americans with Disabilities Act, the Family Medical Leave Act, the Fair Labor Standards Act, the federal Occupational Safety and Health Act (“OSHA”), any claims arising under Colorado law, including but not limited to the Colorado Anti-Discrimination Act, the Lawful Off-Duty Activities Statute, the Personnel Files Employee Inspection Right Statute, the Colorado Labor Peace Act, the Colorado Labor Relations Act, and the Colorado Equal Pay Act, as well as any claims arising under Nevada law, including but not limited to the Nevada Fair Employment Practices Act, and all local laws that may be legally waived; claims for unpaid salary, wages (but not including failure to pay applicable minimum wage, where release of such claims is prohibited by law), commissions, bonuses, incentive compensation, equity plan compensation, unused accrued vacation leave or other compensation under any federal, state or local wage and hour laws or wage claim statutes including

2 of 8


without limitation, the Fair Labor Standards Act, and Nevada and Colorado wage and hour laws (to the extent permitted by law); claims regarding the Employee Retirement Income Security Act or the federal Worker Adjustment and Retraining Notification (WARN) Act and any WARN act under applicable state law; and claims including, without limitation, wrongful discharge, defamation, tortious interference with business expectancy or emotional distress; or claims alleging a breach of express or implied employment contract or any other contract related to Employee’s employment. Employee acknowledges and agrees that included in the general release of claims are any and all claims that have been or may be asserted by Employee or by any other person or entity on Employee’s behalf in any class or collective action relating to Employee’s employment and/or termination of employment with Employer.

However, this release shall not apply to: (a) claims, charges, complaints, causes of action or demands of whatever kind or nature that arise after the date on which Employee executes this Agreement; (b) to any claims for indemnification and/or advancement of expenses arising under any indemnification agreement between Employee and any Releasee or under the bylaws, certificate of incorporation or other similar governing document of any Releasee; (c) any claim for workers’ compensation insurance benefits; (d) any unemployment benefits to which Employee may be entitled; or (e) any other claim that cannot be waived as a matter of law.

Employee acknowledges and agrees that included in the general release of claims are any and all claims that have been or may be asserted by Employee or by any other person or entity on Employee’s behalf in any class or collective action relating to Employee’s employment and/or termination of employment with Employer. Employee understands that this Agreement does not limit Employee’s ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Securities and Exchange Commission, the National Labor Relations Board, or any other federal, state or local governmental agency or commission (each, a “Government Agency”).  Employee further understands that this Agreement does not limit Employee’s ability to communicate with, or otherwise participate in any investigation or proceeding that may be conducted by, a Government Agency.  However, Employee agrees that Employee is waiving the right to monetary damages or other equitable or monetary relief arising out of or resulting from any such charge, complaint, investigation or proceeding.

Pursuant to 18 U.S.C. Section 1833(b), (1) Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (2) Employee acknowledges that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.

Nothing herein is intended to limit Employee’s right to testify in an administrative, legislative, or judicial proceeding concerning any alleged criminal conduct or alleged harassment by Employer, Employer’s agents, or Employer’s employees, when Employee is required or requested to attend the proceeding pursuant to a court order, subpoena, or written request from an administrative agency or the legislature.

5.Waiver of Unknown Claims.  Employee agrees that this Agreement is a full and final general release of all claims, including, but not limited to, unknown, unanticipated, and undisclosed

3 of 8


losses, wrongs, injuries, claims and damages that arise wholly or in part from any act or omission occurring before this Agreement becomes effective.

6.Agreement Not to Sue. Employee affirms that Employee has not filed, caused to be filed, and presently is not a party to any claim, charge, complaint, causes of action, or action against Employer or any of the Releasees except for a claim for unemployment insurance benefits and/or workers’ compensation insurance benefits. Other than a claim for unemployment insurance benefits or workers’ compensation insurance benefits, Employee agrees not to file or maintain any other charge, claim or action against Employer or any of the Releasees arising out of the matters covered by this Agreement, and agrees not to participate in or encourage the pursuit of any claims against Employer, the Company, or P3 LLC, their employees or agents, unless compelled to testify pursuant to an order of a court of competent jurisdiction or subpoena or unless testifying pursuant to a written request from an administrative agency or the legislature. This Section 6 does not limit Employee from filing a claim with a governmental agency regarding the enforceability of this Agreement or from filing a claim that may not be waived as a matter of law. With the exception of payments for any claims made for workers’ compensation benefits, any unemployment benefits, and any claims that may not be released as a matter of law, Employee agrees not to accept any payments arising out of any such claim.

7.Confidential Information. Employee acknowledges and agrees that as otherwise expressly permitted in this Agreement, nothing contained in this Agreement shall affect Employee’s continuing obligations to keep all confidential information belonging to Employer or any of its affiliates confidential and not to disclose or use such information, directly or indirectly, for any purpose.

8.Forfeiture of Incentive Units. Consistent with the terms set forth in the Grant Agreement, a copy of which is attached herein as Exhibit A, the Parties each also acknowledge and agree that the remaining unvested 40,632 P3 Units/Shares were forfeited for no consideration as of the Separation Date, and Employee shall have no further right, title or interest therein. Except as provided in this Agreement (including Section 2 above), all vested P3 Units/Shares held by Employee remain otherwise subject to the Grant Agreement.

9.Non-Competition. Pursuant to Section 5(b) of the Grant Agreement, for a period of twelve (12) months after the Separation Date, Employee agrees that Employee will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation), or render services to any Competitive Opportunity in any county in the United States where the Company Group (as defined in the Grant Agreement) is operating or has a pending letter of intent or other similar agreement to commence operations. A “Competitive Opportunity” is as defined in Section 5(b) of the Grant Agreement.

10.Non-Solicitation. For a period of twelve (12) months after the Separation Date, Employee agrees not to  directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity: (i) solicit, aid or induce any individual or entity that is, or was during the twenty-four (24) month period immediately prior to the end of Employee’s employment with the Company Group (as defined in the Grant Agreement), a customer, strategic partner, health insurance provider, patient or referral source of the Company Group to purchase goods or services then sold by the Company Group from another person, firm, corporation or other entity or assist or aid any other persons or entity in identifying or soliciting any such customer; (ii) solicit, aid or induce any employee, representative or agent of any member of the Company Group to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity

4 of 8


unaffiliated with the Company Group or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent; (iii) interfere, or aid or induce any other person or entity in interfering with the relationship between the Company Group and any of its payors, joint venturers, licensors or contractors with whom the Company Group has a contract relating to its at-risk Medicare Advantage business; or (iv) attempt to do any of the foregoing either for Employee’s own purposes or for any third party, including without limitation, by engaging in any of the foregoing with customers, strategic partners, health insurance providers and/or referral sources that have referred to the Company Group within the twenty-four (24) month period prior to the termination of Employee’s affiliation with the Company Group, or who have otherwise been a part of an active business development effort such as hosting them for a site visit, conference, dinner or any related activity.

11.Non-Disparagement.  Employee agrees that at no time in the future will Employee in any way disparage Employer or any of the Releasees, verbally or in a writing, including in any electronic media, or make any statements to the press or to third parties that may be derogatory or detrimental to Employer’s or the Releasees’ good name and reputation.  Employee represents that during the period from the Separation Date until the Effective Date, Employee has not in any way disparaged Employer or any of the Releasees, verbally or in a writing, including in any electronic media, or made any statements to the press or to third parties that may be derogatory or detrimental to Employer’s or the Releasees’ good name and reputation.

12.Permitted Disclosures. Nothing in this Agreement or any other agreement prohibits Employee from reporting violations of law or regulation to an appropriate governmental agency or entity or making other disclosures that are protected under applicable law. Employee does not need the prior authorization of Employer to make any such reports or disclosures, and Employee is not required to notify Employer that Employee has made such reports or disclosures.

13.Return of Employer Property. Employee represents and agrees that Employee has returned to Employer all equipment (including but not limited to a laptop computer and/or mobile phone), keys and keycards, business records, confidential information, and/or other Employer property that has been or is in Employee’s care, custody, possession or control.

14.Attorneys’ Fees. In the event of any dispute or litigation arising out of this Agreement, the prevailing Party shall be entitled to reimbursement from the other Party for the prevailing Party’s reasonable attorneys’ fees and costs and expenses incurred with respect to such dispute or litigation. Each Party shall otherwise bear its own attorneys’ fees and costs fees related to the subject matter of or arising out of this Agreement.

15.Severability. If any term or provision of this Agreement is determined by a court of competent jurisdiction to be unenforceable or contrary to any applicable law or policy, such term or provision shall be effective to the maximum extent permitted by law, and the same shall not affect any other term or provision of this Agreement which shall otherwise remain in full force and effect.

16.Choice of Law & Venue.  To the extent not governed by federal law or otherwise prohibited by state law, Employee agrees that this Agreement is governed by the laws of Colorado, without regard to its principles on conflicts of law.  To the extent that a federal court or agency does not have jurisdiction over any action involving the validity, interpretation, or enforcement of this Agreement, or any of its terms, provisions or obligations, Employee agrees that jurisdiction and venue

5 of 8


shall exist exclusively in a court or government agency located within the County of Denver, Colorado, unless specifically prohibited by applicable state law.  To the extent the Parties have entered into a valid agreement to arbitrate their claims, such agreement governs.

17.Assignment. Employee represents and warrants that Employee has not assigned or transferred to any person or entity any of Employee’s rights that are or could be covered by this Agreement, including but not limited to any covenant not to sue and the waivers and releases contained in this Agreement.

18.Future Cooperation.  Employee agrees that during and after the term of this Agreement Employee will be available, upon reasonable notice and under reasonable conditions, to assist Employer in any capacity with respect to matters of which Employee was involved or had knowledge while employed by Employer.  Without limitation, such assistance may include providing information or documents, cooperating with investigations, negotiations, lawsuits, or administrative proceedings involving Employer, preparing for and giving testimony, including written declarations or statements, and other similar activities.  Employee understands that Employer will reimburse Employee for all reasonable, documented out-of-pocket expenses incurred as a result of Employee’s obligations under this Section 18, in accordance with Employer’s then applicable expense guidelines.

19.Entire Agreement. This Agreement, along with the Grant Agreement, constitutes the entire agreement between Employee and Employer regarding Employee’s employment and separation from employment with Employer, and supersedes any previous agreements or understandings between the Parties, with the exception of any agreement concerning confidentiality of the Company’s, P3 LLC, or the Employer’s trade secrets and/or confidential information (including but not limited to the Non-Solicitation and Confidentiality Addendum by and between Employee and P3 Health Group Holdings, LLC (a/k/a P3 Health Partners), dated January 13, 2021, that certain Confidentiality Agreement by and between Employee and P3 Health Group Holdings, LLC (a/k/a P3 Health Partners), dated 20, 2021, and that certain IT Confidentiality and Acceptable Use Agreement by and between Employee and P3 Health Group Holdings, LLC (a/k/a P3 Health Partners)), dated January 20, 2021, any agreement to arbitrate employment disputes, any non-solicitation or non-compete agreement, and any agreement concerning the ownership of intellectual property that provides Employer with greater rights than this Agreement.

20.Knowing and Voluntary. Employee represents that Employee has read and fully understands this Agreement, the review period provided to Employee is reasonable, Employee is not executing this Agreement in reliance on any promises or representations other than those contained in the Agreement, and that Employee is executing this Agreement voluntarily. Employee acknowledges that Employer has informed Employee that Employee has a right to and should consult with an attorney before executing this Agreement.

I, THE UNDERSIGNED, HAVE BEEN ADVISED IN WRITING THAT I HAVE HAD 10 DAYS TO CONSIDER THIS AGREEMENT AND RELEASE AND TO CONSULT WITH AN ATTORNEY CONCERNING ITS TERMS AND EFFECT PRIOR TO EXECUTING THIS AGREEMENT AND RELEASE.

I, THE UNDERSIGNED, HAVE READ THIS AGREEMENT AND RELEASE, UNDERSTAND ITS TERMS, AND UNDERSTAND THAT I ENTER THIS AGREEMENT AND RELEASE INTENDING TO AND DO WAIVE, SETTLE AND RELEASE ALL CLAIMS I HAVE OR MIGHT HAVE AGAINST THE EMPLOYER AND THE RELEASED PARTIES TO THE FULL EXTENT

6 of 8


PERMITTED BY LAW. I SIGN THIS AGREEMENT AND RELEASE VOLUNTARILY AND KNOWINGLY.

Date: November 11, 2022

Eric Atkins

/s/ Eric Atkins

Date: November 11, 2022

P3 Health Partners Inc.

by /s/ Dr. Sherif Abdou, its authorized agent

Date: November 11, 2022

P3 Health Group, LLC

by /s/ Dr. Sherif Abdou, its authorized agent

Date: November 11, 2022

P3 Health Group Management, LLC

by /s/ Dr. Sherif Abdou, its authorized agent

7 of 8


Exhibit A

Incentive Unit Grant Agreement

(Attached)


INCENTIVE UNIT GRANT AGREEMENT

THIS INCENTIVE UNIT GRANT AGREEMENT (this “Agreement”) is effective as of March l, 2021, by and among P3 Health Group Holdings, LLC, a Delaware limited liability company (the “Company”), P3 Health Group Management, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Employer”), and Eric Atkins, individually (“Employee”). Capitalized terms used herein shall have the meanings ascribed to such terms in Section 7 of this Agreement, or if not defined herein, the meanings ascribed to such terms in the LLC Agreement (as defined in Section 7 below).

WHEREAS, the Company’s Board has adopted a Management Incentive Plan (the “Plan”) designed to provide incentives to such present and future employees, managers, consultants or advisers of the Company or its Subsidiaries, as may be selected in the sole discretion of the Company’s Board (“Participants”) through, among other things, the issuance of the Company’s Management Incentive Units to certain Participants;

WHEREAS, Employee is an employee of Employer;

WHEREAS, the Plan is intended to qualify under Securities and Exchange Commission Rule 701;

WHEREAS, pursuant to the Plan, the Company, on behalf of itself and Employer, desires to issue to Employee, on the terms and subject to the conditions contained herein 215,000 Class C-l Units of the Company, which Class C-l Units are designated as Management Incentive Units in accordance with Section 3.8 of the LLC Agreement (theManagement Incentive Units”).

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows:

1.

Issuance of Management Incentive Units.

(a)Issuance Incentive. Upon the complete execution of this Agreement, the Company will issue the Management Incentive Units to Employee. The Management Incentive Units shall vest in accordance with Section 2 below. The Company will amend and update the Company’s schedule of ownership as attached to the LLC Agreement to reflect the issuance of the Management Incentive Units, and Employee by his/her execution of this Agreement agrees to be bound by the terms and conditions of the LLC Agreement. If Employee is a married individual who resides in a community property state, Employee will deliver to the Company an executed consent and agreement by Employee’s spouse in a form satisfactory to the Company. The initial Participation Threshold applicable to each Management Incentive Unit shall be $2.89 per unit, which shall be subject to adjustment in accordance with Section 3.8(c) of the LLC Agreement (which includes, without limitation, an increase in the Participation Threshold as a result of Members making additional Capital Contributions to the Company).

(b)83(b) Election. Within 30 days after the issuance by the Company of such Management Incentive Units, Employee will make an effective election with the Internal Revenue Service under Section 83(b) of the Internal Revenue Code of 1986, as amended, and the regulations


promulgated thereunder in the form of Exhibit A attached hereto. Employee acknowledges that he or she is responsible for making the proper election with the Internal Revenue Service and is not relying on the Company or Employer to make such an election.

(c)Representations and Warranties. In connection with the receipt of Management Incentive Units, Employee represents and warrants to the Company that:

(i)The Management Incentive Units to be acquired by Employee pursuant to this Agreement will be acquired for Employee’s own account and not with a view to, or intention of, distribution thereof in violation of the Securities Act, or any applicable state securities laws;

(ii)Employee is an “accredited investor” within the meaning of Rule 501 of Regulation D of the Securities and Exchange Commission, is sophisticated in financial matters and is able to evaluate the risks and benefits of the receipt of the Management Incentive Units;

(iii)Employee is able to bear the economic risk of his/her investment in receipt of the Management Incentive Units for an indefinite period of time because the Management Incentive Units have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration is available;

(iv)Employee has had an opportunity to ask questions and receive answers concerning the terms and conditions of the Management Incentive Units;

(v)this Agreement constitutes the legal, valid and binding obligation of Employee, enforceable in accordance with its terms;

(vi)other than as previously disclosed to the Company, Employee is neither party to, nor bound by, any employment agreement, consulting agreement, noncompetition agreement, nonsolicitation agreement or confidentiality agreement or any other agreement which could impair or interfere with Employee’s obligations hereunder or otherwise to the Company or Employer, or their respective Subsidiaries;

(vii)Employee acknowledges and agrees that there may be additional issuances of equity securities of the Company after the date hereof and the equity interests of Employee may be diluted in connection with any such issuance;

(viii)Employee has had the opportunity to consult Employee’s own tax counsel and financial advisor as to the U.S. federal, state, local and foreign tax consequences of the transactions contemplated by this Agreement, and the Company and Employer have not made any representations regarding such tax consequences or benefits upon which Employee has relied;

(ix)Employee acknowledges that the Management Incentive Units are illiquid and may be illiquid indefinitely; and

2


(x)Employee is a resident of the State set forth in Employee’s address for notices in Section 8 hereof.

2.

Vesting of the Management Incentive Units.

(a)The Management Incentive Units shall become vested, except as otherwise provided in this Section 2, and further provided that Employee has been providing continuous service as an employee of the Company from the date hereof through the applicable time, as follows:

215,000 C-1 Units of the Management Incentive Units (the “Time Units”) granted to Employee will vest so that 20% of such Time Units shall be released and vest on the one year anniversary of the Vesting Start Date, and an additional 20% of the total number of Time Units shall be released and vest on each subsequent anniversary of the Vesting Start Date, until all of the Time Units have been released on the five year anniversary of the Vesting Start Date. Employee’s Vesting Start Date shall be January 20, 2021. In the event employee is terminated, other than for Cause, the employee shall be deemed vested in 1/12th of the shares which would vest on the next vesting anniversary date for each month of employment since the last vesting anniversary date.

(b)Subject to Section 4 below and the terms of the LLC Agreement, if Employee’s employment with Employer is terminated for any reason, Employee shall only be entitled to those Management Incentive Units which have vested as of the date of such termination.

(c)Notwithstanding anything else contained herein, in the event that Employee is terminated for Cause, as determined by the Board in good faith, or violates his/her obligations under Sections 5 or 6 below, all Management Incentive Units, whether vested or unvested, shall, notwithstanding the enforcement or lack thereof of any of Employee’s obligations under Sections 5 or 6 hereof, be forfeited, and Employee will be deemed not to own any Management Incentive Units. For the purposes of this paragraph Cause shall mean (i) Employee’s material breach of this Agreement or any other agreement with the Company; (ii) Executive’s conviction of any felony or any act including moral turpitude, or Executive’s commission of any act of fraud or embezzlement against the Company; (iii) conduct by Executive that brings the Company into public disgrace or disrepute or otherwise publicly injures the integrity, character or reputation of the Company in any material respect as determined by the Board in its reasonable discretion; (iv) Executive’s unauthorized dissemination of information, observations or data concerning the business plans, financial data, referral sources, customers, suppliers, trade secrets, acquisition strategies or other confidential information of the Company; or (v) Executive’s breach of the provisions of Sections 5 or 6 of this Agreement or of any restrictive covenants in any other agreement between Employee and the Company.

(d)Upon the occurrence of a Sale of the Company (or any of its Subsidiaries) or equity Transfer and for the benefit of the prospective buyer and its Affiliates, Employee may be required, and Employee hereby agrees, to execute customary noncompetition agreements, nonsolicitation agreements and confidentiality agreements; provided, that (i) the stated terms and conditions of such noncompetition agreements and nonsolicitation agreements shall be on terms that are not more restrictive than as set forth in any existing agreement between Employee, on the one hand,

3


and the Company or its Subsidiaries, on the other hand, and (ii) such agreements shall survive the occurrence of a Sale of the Company (or any of its Subsidiaries) or equity Transfer for a term not to exceed (x) if terminated prior to the occurrence of a Sale of the Company (or any of its Subsidiaries) or equity Transfer, the remaining term of such covenants under an existing agreement and (y) otherwise, one year.

(e)Upon the occurrence of a Sale of the Company 50% of the Time Units which have not yet become vested shall become vested as of the consummation of such Sale of the Company, if, as of the date of such Sale of the Company, Employee is still employed by Employer as of such date.

(f)All Management Incentive Units which have become vested hereunder, if any, are collectively referred to herein as the “Vested Management Incentive Units.”

3.Restrictions on Transfer. The holders of Management Incentive Units shall not Transfer any interest in any Management Incentive Units, except pursuant to the provisions of the LLC Agreement.

4.Purchase Option on Employee Units. The provisions of this Section 4 and the LLC Agreement shall apply to all of Employee’s Units in the Company, including the Management Incentive Units, vested and unvested, granted pursuant to this Agreement (collectively, the “Employee Units”).

(a)In the event that Employee’s employment with Employer is terminated, the Company may, within its sole discretion, elect in writing by delivering notice to Employee pursuant to Section 8 hereof, require Employee to sell to the Company and/or its designee the Employee Units set forth in the notice (the “Purchased Units”), which may or may not be all of the Employee Units held by Employee.

(b)The purchase price for the Purchased Units under this Agreement, shall be the Fair Market Value (as defined below) of such Purchased Units as of the date of termination of employment. For the purpose of this Section 4, “Fair Market Value” means, with respect to the Purchased Units, the fair value as of the date of termination determined by the Board in good faith, according to a reasonable and customary methodology approved by the Board, which shall be the final determination of Fair Market Value. For the avoidance of doubt, the Fair Market Value of the Purchased Units will incorporate appropriate discounts for size, control and the fact the Purchased Units are not available on publicly traded markets. The Fair Market Value will also take into account comparable transactions in terms of size and industry (both public and private).

(c)If the purchase option described in Section 4(a) hereof has been exercised, the closing (the “Closing”) of the purchase of any Purchased Units shall occur following the final determination of Fair Market Value as provided in Section 4(b). The Company (or any designee of the Company) shall have the option of making payment of the purchase price in any combination of cash at Closing and/or delivery of a promissory note bearing interest at an annual rate equal to the Base Rate on the date of such purchase and payable in forty-eight (48) equal consecutive monthly installments of principal and interest, subject to payment restrictions required by any lender, with the first monthly payment being due on the first day of the calendar month following

4


the calendar month in which the Closing occurs, provided that, in any case, the balance of the purchase price shall be due on or prior to the Sale of the Company. In the event the Company (or its designee) elects to deliver a promissory note at Closing in satisfaction of all or a portion of the purchase price, the Company (or its designee) shall have the option to prepay all or any part of the outstanding principal of any such promissory note at any time without penalty or premium.

(d)At the time of the Closing of any repurchase of the Purchased Units hereunder by the Company, the Employee shall deliver to the Company any assignments or other documents as may be necessary to transfer title to the Purchased Units to the Company, which shall include representations by the Employee that he owns all right, title and interest to the Purchased Units free and clear of any and all liens and encumbrances.

(e)In the event of any conflict or inconsistency between the terms of this Section 4 on the one hand and the terms of the LLC Agreement on the other hand, the terms of this Section 4 shall prevail and be given priority, provided, however, that the terms of this Section 4 and the terms of the LLC Agreement are to be taken as mutually explanatory of one another and in the case of ambiguities or discrepancies between such terms, the same shall be explained and interpreted, if possible, in a manner which gives effect to such terms and avoids or minimizes conflicts.

5.

Restrictive Covenants.

(a)Confidentiality. During the course of Employee’s affiliation with the Company Group, Employee will learn confidential information on behalf of the Company Group. Employee acknowledges that the Company Group derives considerable economic value from such confidential information being kept secret, and the Company Group has expended significant time, effort and funds to ensure that the confidential information is kept secret. Employee agrees that Employee shall not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any person, other than in the course of Employee’s assigned duties and for the benefit of the Company Group, either during the period of Employee’s affiliation with the Company Group or at any time thereafter, any confidential business or technical information, trade secrets, or other nonpublic, proprietary or confidential information, knowledge or data relating to the Company Group, any of its subsidiaries, affiliated companies or businesses, or received from third parties subject to a duty on the Company Group’s part to maintain the confidentiality of such information and to use it only for certain limited purposes, in each case which shall have been obtained by Employee during Employee’s affiliation with the Company Group. The foregoing shall not apply to information that (i) was known to the public prior to its disclosure to Employee; (ii) becomes generally known to the public subsequent to disclosure to Employee through no wrongful act of Employee or any representative of Employee; or (iii) Employee is required to disclose by applicable law, regulation or legal process (provided that Employee provides the Company Group with prior notice of the contemplated disclosure and cooperates with the Company Group at the Company Group’s expense in seeking any protective order or other appropriate protection of such information).

(b)Noncompetition. Employee acknowledges that during the course of Employee’s affiliation with the Company Group (i) Employee performs services of a unique nature for the Company Group that are irreplaceable, and that Employee’s performance of such services to a

5


competing business will result in irreparable harm to the Company Group, (ii) Employee has had and will continue to have access to trade secrets and other confidential information of the Company Group, which, if disclosed, would unfairly and inappropriately assist in competition against the Company Group, (iii) in the course of Employee’s employment or affiliation by a competitor, Employee would inevitably use or disclose such trade secrets and confidential information, (iv) the Company Group has substantial relationships with their customers, strategic partners, the health insurance providers with whom they enter into agreements, patients and patient referral Graphicsources (including, but not limited to any health care professional, consultant and any similar type referral sources, collectively, the “Referral Sources”) and Employee has had and will continue to have access to these customers and Referral Sources, (v) Employee will receive specialized training from the Company Group, and (vi) Employee is acquiring an equity interest in the Company in connection with his/her entering into this Agreement. Accordingly, during Employee’s employment with the Company Group and for a period of twelve (12) months thereafter, Employee agrees that Employee will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any Competitive Opportunity in any county in the United States that the Company Group where the Company is operating, or has a pending letter of intent or other similar agreement to commence operations. A “Competitive Opportunity” means any business in which the primary purpose is to engage in primary care medicine or the creation and maintenance of an integrated healthcare network of providers which receives or is intended to receive a substantial portion (i.e., in excess of 25%) of its revenue through at-risk Medicare Advantage reimbursements or percentage of premium payments.

(c)Nonsolicitation. During Employee’s employment with the Company Group and for a period of twelve (12) months thereafter, Employee agrees that Employee shall not, except in the furtherance of Employee’s duties to the Company Group, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (i) solicit, aid or induce any individual or entity that is, or was during the twenty-four (24) month period immediately prior to the termination of Employee’s employment with the Company Group for any reason, a customer, strategic partner, health insurance provider, patient or Referral Source of the Company Group to purchase goods or services then sold by the Company Group from another person, firm, corporation or other entity or assist or aid any other persons or entity in identifying or soliciting any such customer, strategic partner, health insurance provider, patient or Referral Source; (ii) solicit, aid or induce any employee, representative or agent of the Company Group to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company Group or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent; (iii) interfere, or aid or induce any other person or entity in interfering with the relationship between the Company Group and any of its payors, joint venturers, licensors or contractors with whom the Company Group has a contract relating to its at-risk Medicare Advantage business; or (iv) attempt to do any of the foregoing either for Employee’s own purposes or for any third party, including without limitation, by engaging in any of the foregoing with customers, strategic partners, health insurance providers and/or Referral Sources that have referred to the Company Group within the twenty-four (24) month period prior to the termination of Employee’s affiliation with the Company Group, or who have otherwise been a part of an active

6


business development effort such as hosting them for a site visit, conference, dinner or any related activity.

(d)Reasonableness of Covenants. Employee hereby acknowledges and agrees that the restrictive covenants set forth in this Section 5 (the “Restrictive Covenants”) are appropriate for the consideration provided, are an integral part of this Agreement and but for the Restrictive Covenants, Employer and the Company would not enter into this Agreement and issue the Management Incentive Units to Employee. Employee further agrees that: (i) the Restrictive Covenants impose no undue hardship on Employee and do not preclude Employee from earning a livelihood, nor do they unreasonably impose limitations on Employee’s ability to earn a living; and (ii) the terms of the Restrictive Covenants are reasonable and narrowly tailored to protect the Company Group’s protectable interests in its confidential information and other protectable business relationships, and do not impose any restraint that is greater than is required for the protection of the interests of the Company Group. Employee has carefully read this Agreement and consulted with legal counsel of Employee’s choosing regarding its contents, and has given careful consideration to the restraints imposed upon Employee by this Agreement.

(e)Enforcement. Employee agrees and acknowledges that:

(i)If, at the time of enforcement of this Section 5, a court of competent jurisdiction determines that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that they shall substitute the maximum duration or scope that is reasonable under such circumstances for the stated duration or scope, and that they shall revise the restrictions contained herein to cover the maximum duration or scope permitted by law.

(ii)Because Employee has access to confidential information and customer and other relationships, the parties hereto agree that money damages would be an inadequate remedy for any breach of this Agreement, including this Section 5. Therefore, Employee agrees that in the event of a breach or threatened breach of this Agreement, including this Section 5, the Company and Employer, their respective Subsidiaries and/or their respective successors shall be entitled to specific performance and/or injunctive or other relief without posting a bond or other security.

(f)Survival of Provisions. The obligations contained in Sections 5 and 6 hereof shall survive the termination of Employee’s employment or affiliation with the Company Group and shall be fully enforceable thereafter.

6.Cooperation. Upon the receipt of reasonable notice from the Company (including outside counsel of the Company), Employee agrees that while an employee or affiliated with the Company Group in any capacity and thereafter, Employee will respond and provide information with regard to matters in which Employee has knowledge as a result of his/her involvement with the Company Group, and will provide reasonable assistance to the Company Group in defense of any claims that may be made against the Company Group, and will assist the Company Group in the prosecution of any claims that may be made by the Company Group, to the extent that such claims may relate to the period of Employee’s affiliation with the Company Group (collectively, “Claims”).

7


Employee agrees to promptly inform the Company if Employee becomes aware of any lawsuits involving Claims that may be filed or threatened against the Company or its Affiliates.

7.

Definitions.

(a)Base Rate” means, as of any date, a variable rate per annum equal to the rate of interest most recently published by The Wall Street Journal as the “prime rate” at large U.S. money center banks.

(b)Board” means the Company’s Board of Managers.

(c)Company Groupmeans the Company, Employer and any of their respective Affiliates and Subsidiaries.

(d)LLC Agreement” means the Limited Liability Company Agreement of the Company, effective as of April 20, 2017, as amended or modified from time to time in accordance with its terms.

(e)Person” means an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, investment fund, any other business entity and a governmental entity or any department, agency or political subdivision thereof.

(f)Sale of the Company” means either (i) the sale, lease, license, transfer, conveyance or other disposition, in one transaction or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole or (ii) a transaction or a series of related transactions (including by way of merger, consolidation, recapitalization, reorganization or sale of securities by the holders of securities of the Company) the result of which is that (A) the holders of the Company’s outstanding voting securities or their Affiliates immediately prior to such transaction or series of related transactions are (after giving effect to such transaction or series of related transactions) no longer, in the aggregate, the “beneficial owners” (as such term is defined in Rule 13d-3 and Rule 13d-5 promulgated under the Securities Exchange Act), directly or indirectly through one or more intermediaries, of more than 50% of the voting power of the outstanding voting securities of the Company, and (B) the CPF Members are no longer entitled to appoint at least three managers to the Board. Notwithstanding the foregoing, (a) no such transaction or series of related transactions (including by way of merger, consolidation, recapitalization, reorganization, sale of units or otherwise) in connection with a Public Offering of the Company shall be deemed a Sale of the Company and (b) a Sale of the Company shall not include any such transaction or series of related transactions effected by the issuance of voting securities by the Company, unless in connection with such issuance the Company either (x) redeems securities of the Company outstanding immediately prior to such issuance having a redemption price equal to more than 50% of the Company Total Equity Value immediately prior to such issuance or (y) makes a distribution upon the securities of the Company outstanding immediately prior to such issuance in an amount equal to more than 50% of the Company Total Equity Value immediately prior to such issuance payable otherwise than in cash out of earnings or earned surplus and other than a dividend payable solely in equity securities of the Company. Notwithstanding this definition of “Sale of the Company”, holders of a majority of the Class A

8


Units and holders of a majority of the Class D Units, voting separately, may waive the classification of a certain transfer, acquisition, merger or other transaction as a “Sale of the Company”.

(g)Securities Act” means the Securities Act of 1933, as amended from time to time.

(h)Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, association, or business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof or (ii) if a limited liability company, partnership, association, or other business entity (other than a corporation), a majority of partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person Graphicor one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, and without limitation, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association, or other business entity (other than a corporation) if such Person or Persons shall be allocated a majority of limited liability company, partnership, association, or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association, or other business entity. For purposes hereof, references to a “Subsidiary” of any Person shall be given effect only at such times that such Person has one or more Subsidiaries, and, unless otherwise indicated, the term “Subsidiary” refers to a Subsidiary of the Company.

(i)Transfer” means to sell, transfer, assign, pledge or otherwise dispose (whether with or without consideration and whether voluntarily or involuntarily or by operation of law).

8.Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when (a) delivered personally to the recipient, (b) sent to the recipient by reputable express courier service (charges prepaid), (c) mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, or (d) telecopied to the recipient (with hard copy sent to the recipient by reputable overnight courier service (charges prepaid) that same day) if telecopied before 5:00 p.m. Chicago, Illinois time on a business day, and otherwise on the next business day. Such notices, demands and other communications shall be sent to the parties at the addresses indicated below, or at such address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party:

If to the Company:

P3 Health Group Holdings, LLC

c/o Chicago Pacific Founders

980 N. Michigan Avenue, Suite 1998

Chicago, Illinois 60611

Attention: Greg Kazarian

If to Employee:

To the address set forth beneath Employee’s name on the

signature page hereto

9


9.

General Provisions.

(a)Transfers in Violation of Agreement. Any Transfer or attempted Transfer of any Management Incentive Units in violation of any provision of this Agreement or the LLC Agreement shall be void, and the Company shall not record such Transfer on its books or treat any purported transferee of such Management Incentive Units as the owner of such equity for any purpose.

(b)Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

(c)Complete Agreement. This Agreement, the LLC Agreement and those documents expressly referred to herein embody the complete agreement and understanding among the parties hereto and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. Except as otherwise expressly provided herein in Section 4(e), in the event of any inconsistency between the terms of this Agreement and the LLC Agreement, the terms of the LLC Agreement shall control.

(d)No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.

(e)Counterparts. This Agreement may be executed in separate counterparts each of which shall be an original and all of which taken together shall constitute one and the same agreement.

(f)Successors and Assigns. Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Company Group, Employee and their respective successors and assigns (including subsequent holders of Units).

(g)Choice of Law. The laws of the State of Delaware will govern all questions concerning the relative rights of Employee, and the Company Group and its security holders and all other questions concerning the construction, validity and interpretation of this Agreement, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

(h)Mutual Waiver of Jury Trial. Each party to this agreement hereby waives all rights to trial by jury in any action, suit, or proceeding brought to resolve any dispute between or among any of the parties hereto, whether arising in contract, tort, or otherwise, arising out of, connected with, related or incidental to this Agreement and/or the transactions contemplated hereby.

10


(i)Electronic Delivery. This Agreement, the agreements referred to herein, and each other agreement or instrument entered into in connection herewith or therewith or contemplated hereby or thereby, and any amendments hereto or thereto, to the extent signed and delivered by means of a photographic, photostatic, facsimile, portable document format (.pdf), or similar reproduction of such signed writing using a facsimile machine or electronic mail shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

(j)Remedies. Each of the parties to this Agreement will be entitled to enforce its rights under this Agreement specifically, to recover damages and costs (including attorney’s fees) caused by any breach of any provision of this Agreement.

(k)Code Section 409A.

(i)The intent of the parties is that payments and benefits under this Agreement comply with or otherwise be exempt from Internal Revenue Code Section 409A and the regulations and guidance promulgated thereunder (collectively, “Code Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be either exempt from or in compliance therewith. In no event whatsoever shall the Company or Employer be liable for any additional tax, interest or penalty that may be imposed on Employee by Code Section 409A or damages for failing to comply with Code Section 409A.

(ii)Notwithstanding any other provision to the contrary, in no event shall any payment under this Agreement that constitutes “deferred compensation” for purposes of Code Section 409A be subject to offset by any other amount unless otherwise permitted by Code Section 409A.

(l)Incentive Unit Grant Agreement. This Agreement constitutes an Incentive Unit Grant Agreement for purposes of the LLC Agreement.

* * * * *

11


IN WITNESS WHEREOF, the parties hereto have executed this Incentive Unit Grant Agreement as of the date first above written.

P3 HEALTH GROUP HOLDINGS, LLC

By:

/s/ Mary Tolan

Name:

Mary Tolan

Its:

Chairman

P3 HEALTH GROUP MANAGEMENT, LLC

By:

/s/ Sherif Abdou

Name:

Sherif Abdou

Its:

Chief Executive Officer

/s/ Eric Atkins

Name:

Eric Atkins

Address:

1624 Market Street, Suite 202

Denver, CO 80202

[Signature Page - Incentive Unit Grant Agreement]


EXHIBIT A

ELECTION TO INCLUDE MEMBERSHIP INTERESTS IN GROSS INCOME PURSUANT TO SECTION 83(b) OF THE INTERNAL REVENUE CODE

Effective as of                   , 2021, the undersigned received limited liability company membership interests (the “Membership Interests”) in P3 Health Group Holdings, LLC, a Delaware limited liability company (the “Company”). Pursuant to the Limited Liability Company Agreement of the Company, the undersigned is entitled to an interest in Company capital equal to the amount paid therefor and an interest in Company profits.

Pursuant to Internal Revenue Code Section 83(b) and Treasury Regulation Section 1.83-2 promulgated thereunder, the undersigned hereby makes an election, with respect to the Membership Interests, to report as taxable income for the calendar year 2021 the excess (if any) of the value of the Membership Interests on                   , 2021, determined without regard to lapse restrictions and in Graphicaccordance with the principles of Rev. Proc. 93-27, over the purchase price thereof.

The following information is supplied in accordance with Treasury Regulation Section 1.83-2(e):

1.

The name, address and social security number of the undersigned:

Name:

Eric Atkins

Address:

Soc. Sec. No.:

-

-

2.

A description of the property with respect to which the election is being made: 215,000 Class C-1 Units of the Company representing a membership interest in the Company entitling the undersigned to an interest in the Company’s profits.

3.

The date on which the Membership Interests were transferred:               , 2021. The taxable year for which such election is made: 2021.

4.

The restrictions to which the property is subject: If the undersigned ceases to be employed by the Company or any of its affiliates, the unvested units will be subject to forfeiture.

5.

The fair market value on March 1, 2021 of the property with respect to which the election is being made, determined without regard to any lapse restrictions and in accordance with Revenue Procedure 93-27: $0.

6.

The amount paid or to be paid for such property: $0.

A copy of this election is being furnished to the Company pursuant to Treasury Regulation Section 1.83-2(e)(7). A copy of this election will be submitted with the federal income tax return of the undersigned pursuant to Treasury Regulation Section 1.83-2(c).

Dated:

, 2021

Name:


EX-31.1 3 piii-20220930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION

I, Sherif W. Abdou, M.D., certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 of P3 Health Partners Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2022

    

/s/ Sherif W. Abdou, M.D.

Sherif W. Abdou, M.D.

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 4 piii-20220930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION

I, Erin Darakjian, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 of P3 Health Partners Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2022

    

/s/ Erin Darakjian

Erin Darakjian

Interim Chief Financial Officer

(Principal Financial Officer)


EX-32.1 5 piii-20220930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of P3 Health Partners Inc. (the “Company”) for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sherif W. Abdou, M.D., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: November 14, 2022

    

/s/ Sherif W. Abdou, M.D.

Sherif W. Abdou, M.D.

Chief Executive Officer

(Principal Executive Officer)


EX-32.2 6 piii-20220930xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of P3 Health Partners Inc. (the “Company”) for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Erin Darakjian, Interim Chief Financial Officer, do hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: November 14, 2022

    

/s/ Erin Darakjian

Erin Darakjian

Interim Chief Financial Officer

(Principal Financial Officer)


GRAPHIC 7 piii-20220930xex10d1003.jpg GRAPHIC begin 644 piii-20220930xex10d1003.jpg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end GRAPHIC 8 piii-20220930xex10d1002.jpg GRAPHIC begin 644 piii-20220930xex10d1002.jpg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end GRAPHIC 9 piii-20220930xex10d1001.jpg GRAPHIC begin 644 piii-20220930xex10d1001.jpg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end EX-101.SCH 10 piii-20220930.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Business Combinations - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Claims Payable (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Long-Term Debt - Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - Earnings (Loss) per Share - Computation (Details) link:presentationLink link:calculationLink link:definitionLink 42004 - Disclosure - Leases - Future Minimum Lease Payments (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 42104 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Restatement of Previously Issued Financial Statements link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Going Concern and Liquidity link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Recent Accounting Pronouncements Adopted link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Recent Accounting Pronouncements Not Yet Adopted link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Fair Value Measurements and Hierarchy link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Patient Fees Receivable link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Notes Receivable, Net link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Claims Payable link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Capitalization and Management Incentive Units link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Earnings (Loss) per Share link:presentationLink link:calculationLink link:definitionLink 12001 - Disclosure - Premium Deficiency Reserve link:presentationLink link:calculationLink link:definitionLink 12101 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 12201 - Disclosure - Redeemable Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 12301 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 12401 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 12501 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 12601 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 20402 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Fair Value Measurements and Hierarchy (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Patient Fees Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Claims Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31803 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31903 - Disclosure - Earnings (Loss) per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 32103 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 32403 - Disclosure - Related Parties (Tables) link:presentationLink link:calculationLink link:definitionLink 32503 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Restatement of Previously Issued Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Going Concern and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Significant Accounting Policies - Concentration of revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Significant Accounting Policies - Capitated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - Significant Accounting Policies - Health Plan Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 40406 - Disclosure - Significant Accounting Policies - Health Plan Settlement Payables (Details) link:presentationLink link:calculationLink link:definitionLink 40407 - Disclosure - Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40408 - Disclosure - Significant Accounting Policies - Shared Risk Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40409 - Disclosure - Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Business Combinations - Foresight (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Business Combinations - Other (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Business Combinations - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Fair Value Measurements and Hierarchy - Option Pricing (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Patient Fees Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Intangible Assets - Changes (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Notes Receivable, Net (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Claims Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Long-Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Long-Term Debt - Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - Long-Term Debt - Current and Long Term (Details) link:presentationLink link:calculationLink link:definitionLink 41505 - Disclosure - Long-Term Debt - Short-Term (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Capitalization and Management Incentive Units (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Share-Based Compensation - Class V Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41802 - Disclosure - Share-Based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41803 - Disclosure - Share-Based Compensation - Stock options activities (Details) link:presentationLink link:calculationLink link:definitionLink 41902 - Disclosure - Earnings (Loss) per Share - Anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 42001 - Disclosure - Premium Deficiency Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 42101 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 42102 - Disclosure - Leases - Operating Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 42103 - Disclosure - Leases - Lease Terms And Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 42105 - Disclosure - Leases - Current Portions Of ROU Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 42201 - Disclosure - Redeemable Non-Controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 42301 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 42401 - Disclosure - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 42501 - Disclosure - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 42601 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 piii-20220930_cal.xml EX-101.CAL EX-101.DEF 12 piii-20220930_def.xml EX-101.DEF EX-101.LAB 13 piii-20220930_lab.xml EX-101.LAB EX-101.PRE 14 piii-20220930_pre.xml EX-101.PRE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 08, 2022
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Entity File Number 001-40033  
Entity Registrant Name P3 Health Partners Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-2992794  
Entity Address State Or Province NV  
Entity Address, Address Line One 2370 Corporate Circle Suite 300  
Entity Address, City or Town Henderson  
Entity Address, Postal Zip Code 89074  
City Area Code 702  
Local Phone Number 910–3950  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Central Index Key 0001832511  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Common Class A    
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share  
Trading Symbol PIII  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   41,578,890
Warrants    
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50  
Trading Symbol PIIIW  
Security Exchange Name NASDAQ  
Common Class V    
Entity Common Stock, Shares Outstanding   202,024,923
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash $ 34,357,237 $ 140,477,586
Restricted Cash 1,003,307 356,286
Health Plan Receivables, Net 81,497,703 50,251,004
Clinic Fees and Insurance Receivables, Net 1,049,253 1,090,104
Other Receivables 2,736,184 726,903
Prepaid Expenses and Other Current Assets 3,523,867 6,959,067
TOTAL CURRENT ASSETS 124,167,551 199,860,950
LONG-TERM ASSETS:    
Property and Equipment 11,509,656 8,230,250
Less: Accumulated Depreciation (1,994,380) (182,321)
Property and Equipment, Net 9,515,276 8,047,929
Goodwill 463,496,191 1,309,750,216
Intangible Assets, Net 772,411,083 835,838,605
Notes Receivable, Net 3,563,462 3,590,715
Right of Use Asset 9,977,886 7,020,045
TOTAL LONG-TERM ASSETS 1,258,963,898 2,164,247,510
TOTAL ASSETS (1) [1] 1,383,131,449 2,364,108,460
CURRENT LIABILITIES:    
Accounts Payable and Accrued Expenses 24,072,391 17,730,683
Accrued Payroll 7,358,102 6,304,362
Health Plans Settlements Payable 20,626,836 22,548,694
Claims Payable 134,705,426 101,958,324
Premium Deficiency Reserve 27,719,928 37,835,642
Accrued Interest 12,655,918 8,771,065
Current Portion of Long-Term Debt   46,101
Short-Term Debt 0 3,578,561
TOTAL CURRENT LIABILITIES 227,138,601 198,773,432
LONG-TERM LIABILITIES:    
Right of Use Liability 11,156,949 6,296,883
Warrant Liabilities 7,996,432 11,382,826
Contingent Consideration 4,684,503 3,486,593
Long-Term Debt 80,000,000 80,000,000
TOTAL LONG-TERM LIABILITIES 103,837,884 101,166,302
TOTAL LIABILITIES (1) [1] 330,976,485 299,939,734
COMMITMENTS AND CONTINGENCIES (NOTE 23)
Redeemable Non-Controlling Interest 974,078,949 1,790,617,285
STOCKHOLDERS' EQUITY:    
Additional Paid in Capital 293,570,464 312,945,752
Accumulated Deficit (215,518,760) (39,418,124)
TOTAL STOCKHOLDERS' EQUITY 78,076,015 273,551,441
TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY 1,383,131,449 2,364,108,460
Common Class A    
STOCKHOLDERS' EQUITY:    
Common stock 4,158 4,158
Common Class V    
STOCKHOLDERS' EQUITY:    
Common stock $ 20,153 $ 19,655
[1] The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 25 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the P3 LLC’s VIEs totaling $6.8 million and $8.1 million as of September 30, 2022 and December 31, 2021, respectively, and total liabilities of the P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $9.9 million and $6.1 million as of September 30, 2022 and December 31, 2021, respectively. These VIE assets and liabilities do not include $6.0 million of investment in affiliates as of September 30, 2022 and December 31, 2021, and $27.0 million and $24.1 million of amounts due to affiliates as of September 30, 2022 and December 31, 2021, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 25 “Variable Interest Entities.”
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
VIE    
Preferred Units [Line Items]    
Assets to settle obligations $ 6.8 $ 8.1
Liabilities without recourse to company assets 9.9 6.1
Investment in affiliates 6.0 6.0
Due to affiliates $ 27.0 $ 24.1
Common Class A    
Preferred Units [Line Items]    
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 800,000,000 800,000,000
Common stock shares issued 41,578,890 41,578,890
Common stock shares outstanding 41,578,890 41,578,890
Common Class V    
Preferred Units [Line Items]    
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 205,000,000 205,000,000
Common stock shares issued 201,530,796 196,553,523
Common stock shares outstanding 201,530,796 196,553,523
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 248,260,073 $ 156,185,955 $ 791,258,378 $ 452,070,338
OPERATING EXPENSES:        
Medical Expenses 254,776,548 161,328,123 788,045,718 458,333,145
Premium Deficiency Reserve (7,301,630) 1,600,000 (10,115,714) 4,600,000
Corporate, General and Administrative Expenses 37,862,737 20,433,538 117,560,549 53,883,267
Sales and Marketing Expenses 1,119,552 491,418 3,392,178 1,118,160
Goodwill Impairment 0   851,455,754  
Depreciation and Amortization 21,814,803 456,418 65,286,715 1,218,797
TOTAL OPERATING EXPENSES 308,272,010 184,309,497 1,815,625,200 519,153,369
OPERATING LOSS (60,011,937) (28,123,542) (1,024,366,822) (67,083,031)
OTHER INCOME (EXPENSES):        
Interest Expense, net (2,749,681) (2,529,133) (8,244,806) (7,023,187)
Mark-to-Market of Stock Warrants (2,567,423) (1,401,686) 3,386,394 (12,063,265)
TOTAL OTHER INCOME (EXPENSE) (5,317,104) (3,930,819) (4,858,412) (19,086,452)
LOSS BEFORE INCOME TAXES (65,329,041) (32,054,361) (1,029,225,234) (86,169,483)
PROVISION FOR INCOME TAXES     0 0
NET LOSS (65,329,041) (32,054,361) (1,029,225,234) (86,169,483)
LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS (54,155,858)   (853,124,598)  
NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS $ (11,173,183) $ (32,054,361) $ (176,100,636) $ (86,169,483)
NET LOSS PER SHARE (BASIC) $ (0.27) [1] $ (4.24) [1]
NET LOSS PER SHARE (DILUTED) $ (0.27) [1] $ (4.27) [1]
Capitated Revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 243,988,004 $ 153,072,995 $ 780,775,285 $ 443,598,050
Other Patient Service Revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 4,272,069 $ 3,112,960 $ 10,483,093 $ 8,472,288
[1] The Company analyzed the calculation of net loss per member unit for predecessor periods prior to the Business Combinations and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, net loss per member unit information has not been presented for predecessor periods prior to the Business Combinations on December 3, 2021.
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT) - USD ($)
Accumulated Deficit
Class A Preferred Units
Class B-1 Preferred Units
Class C Preferred Units
Class D Preferred Units
Redemption of Profits Interest
Total
Balance at the beginning at Dec. 31, 2020 $ (130,485,179)   $ 380,000 $ 67,474   $ (180,000) $ (130,217,705)
Balance at the beginning (in shares) at Dec. 31, 2020   43,000,000     16,130,034    
Balance at the beginning at Dec. 31, 2020   $ 43,656,270     $ 47,041,554    
Balance at the beginning (in shares) at Dec. 31, 2020     6,000,000 1,302,083      
Unit Based Compensation       $ 460,515     460,515
Unit Based Compensation (in shares)       333,750      
Net Loss (24,650,712)           (24,650,712)
Balance at the end at Mar. 31, 2021 (155,135,891)   $ 380,000 $ 527,989   (180,000) $ (154,407,902)
Balance at the end (in shares) at Mar. 31, 2021   43,000,000     16,130,034    
Balance at the end at Mar. 31, 2021   $ 43,656,270     $ 47,041,554    
Balance at the end (in shares) at Mar. 31, 2021     6,000,000 1,635,833      
Financial Designation, Predecessor and Successor [Fixed List]             Predecessor
Balance at the beginning at Dec. 31, 2020 (130,485,179)   $ 380,000 $ 67,474   (180,000) $ (130,217,705)
Balance at the beginning (in shares) at Dec. 31, 2020   43,000,000     16,130,034    
Balance at the beginning at Dec. 31, 2020   $ 43,656,270     $ 47,041,554    
Balance at the beginning (in shares) at Dec. 31, 2020     6,000,000 1,302,083      
Net Loss             (86,169,483)
Balance at the end at Sep. 30, 2021 (216,654,662)   $ 760,000 $ 1,066,869   (180,000) (215,007,793)
Balance at the end (in shares) at Sep. 30, 2021   43,000,000 8,000,000   16,130,034    
Balance at the end at Sep. 30, 2021   $ 43,656,270     $ 47,041,554    
Balance at the end (in shares) at Sep. 30, 2021       1,925,833      
Balance at the beginning at Mar. 31, 2021 (155,135,891)   $ 380,000 $ 527,989   (180,000) (154,407,902)
Balance at the beginning (in shares) at Mar. 31, 2021   43,000,000     16,130,034    
Balance at the beginning at Mar. 31, 2021   $ 43,656,270     $ 47,041,554    
Balance at the beginning (in shares) at Mar. 31, 2021     6,000,000 1,635,833      
Unit Based Compensation     $ 380,000 $ 183,792     563,792
Unit Based Compensation (in shares)     2,000,000 140,000      
Net Loss (29,464,410)           (29,464,410)
Balance at the end at Jun. 30, 2021 (184,600,301)   $ 760,000 $ 711,781   (180,000) $ (183,308,520)
Balance at the end (in shares) at Jun. 30, 2021   43,000,000     16,130,034    
Balance at the end at Jun. 30, 2021   $ 43,656,270     $ 47,041,554    
Balance at the end (in shares) at Jun. 30, 2021     8,000,000 1,775,833      
Financial Designation, Predecessor and Successor [Fixed List]             Predecessor
Unit Based Compensation       $ 355,088     $ 355,088
Unit Based Compensation (in shares)       150,000      
Net Loss (32,054,361)           (32,054,361)
Balance at the end at Sep. 30, 2021 $ (216,654,662)   $ 760,000 $ 1,066,869   $ (180,000) $ (215,007,793)
Balance at the end (in shares) at Sep. 30, 2021   43,000,000 8,000,000   16,130,034    
Balance at the end at Sep. 30, 2021   $ 43,656,270     $ 47,041,554    
Balance at the end (in shares) at Sep. 30, 2021       1,925,833      
Financial Designation, Predecessor and Successor [Fixed List]             Successor
Balance at the beginning at Dec. 31, 2021             $ 273,551,441
Net Loss             (1,029,225,234)
Balance at the end at Sep. 30, 2022             $ 78,076,015
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY - USD ($)
Common Stock
Common Class A
Common Stock
Common Class V
Additional Paid-in Capital
Accumulated Deficit
Redeemable Non-Controlling Interests
Total
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 31, 2021 $ 4,158 $ 19,655 $ 312,945,752 $ (39,418,124)   $ 273,551,441
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 31, 2021 41,578,890 196,553,523        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Vesting of stock compensation awards   $ 55       55
Vesting of stock compensation awards (in shares)   549,822        
Net Loss       (10,577,504)   (10,577,504)
STOCKHOLDERS' EQUITY (DEFICIT) at Mar. 31, 2022 $ 4,158 $ 19,710 312,945,752 (49,995,628)   262,973,992
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Mar. 31, 2022 41,578,890 197,103,345        
Beginning Balance at Dec. 31, 2021         $ 1,790,617,285 1,790,617,285
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         11,711,427  
Net Loss         (50,212,750)  
Ending Balance at Mar. 31, 2022         1,752,115,962  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Vesting of stock compensation awards   $ 432       432
Vesting of stock compensation awards (in shares)   4,319,964        
Net Loss       (154,349,949)   (154,349,949)
STOCKHOLDERS' EQUITY (DEFICIT) at Jun. 30, 2022 $ 4,158 $ 20,142 312,945,752 (204,345,577)   108,624,475
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Jun. 30, 2022 41,578,890 201,423,309        
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         3,715,553  
Net Loss         (748,755,990)  
Ending Balance at Jun. 30, 2022         1,007,075,525  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Vesting of stock compensation awards   $ 11       11
Vesting of stock compensation awards (in shares)   107,487        
Net Loss       (11,173,183)   (11,173,183)
Adjustments to Redeemable Non-Controlling Interest     (19,375,288)     (19,375,288)
STOCKHOLDERS' EQUITY (DEFICIT) at Sep. 30, 2022 $ 4,158 $ 20,153 $ 293,570,464 $ (215,518,760)   78,076,015
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Sep. 30, 2022 41,578,890 201,530,796        
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock compensation         1,783,994  
Adjustments to Redeemable Non-Controlling Interest         19,375,288  
Net Loss         (54,155,858)  
Ending Balance at Sep. 30, 2022         $ 974,078,949 $ 974,078,949
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS    
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor
Net Loss $ (1,029,225,234) $ (86,169,483)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:    
Depreciation and Amortization 65,286,715 1,218,797
Stock-Based Compensation 17,210,974 1,379,400
Goodwill Impairment 851,455,754  
Amortization of Debt Origination Fees   525,783
Amortization of Discount from Issuance of Debt   931,958
Mark-to-Market Adjustment of Stock Warrants (3,386,394) 12,063,265
Premium Deficiency Reserve (10,115,714) 4,600,000
Non-cash Interest Expense 290,910  
Changes in Assets and Liabilities:    
Accounts Receivable (1,623,188) 54,602
Health Plan Receivables / Premiums (31,246,699) (884,523)
Other Current Assets 3,462,453 2,667,427
Net Change in ROU Assets and Liabilities 3,500,981 379,235
Accounts Payable 4,560,474 3,606,729
Accrued Payroll 1,053,740 (1,842,877)
Accrued Interest 3,884,853 3,952,044
Health Plan Payables / Premiums (1,921,858) (483,657)
Claims Payable 32,747,102 18,173,851
Net Cash used in Operating Activities (94,065,131) (39,827,450)
Cash Flows from Investing activities    
Purchase of Property, Plant and Equipment (2,283,404) (2,990,130)
Acquisitions (5,500,131) (5,014,500)
Increase in Notes Receivable, Net   120,463
Net Cash used in Investing Activities (7,783,535) (7,884,167)
Cash Flows from Financing activities    
Issuance of Long-Term Debt   12,750,000
Repayment of Short-Term and Long-Term Debt (3,624,662) (67,216)
Loan Origination and Closing Fees   (191,250)
Net Cash (used in) provided by Financing Activities (3,624,662) 12,491,534
Net Change in Cash and Restricted Cash (105,473,328) (35,220,083)
Cash and Restricted Cash, Beginning of Period 140,833,872 39,902,947
Cash and Restricted Cash, End of Period $ 35,360,544 $ 4,682,864
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Basis of Presentation
9 Months Ended
Sep. 30, 2022
Organization and Basis of Presentation  
Organization and Basis of Presentation

Note 1: Organization and Basis of Presentation

Description of Business and Business Combination

P3 Health Partners Inc. (the “Company” or “P3”) is a patient-centered and physician-led population health management company and the successor to P3 Health Group Holdings, LLC

P3 Health Group Holdings, LLC and Subsidiaries was founded on April 12, 2017 and began commercial operations on April 20, 2017 to provide population health management services on an at-risk basis to insurance plans offering medical coverage to Medicare beneficiaries under Medicare Advantage programs. Medicare Advantage programs are insurance products created solely for Medicare beneficiaries. Insurance plans contract directly with the Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare beneficiaries benefits that replace traditional Medicare Fee for Service (“FFS”) coverage.

On December 3, 2021, (the “Closing Date”), the Company consummated the transactions pursuant to which, among other things, P3 Health Group Holdings, LLC merged with and into FAC Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Foresight Acquisition Corp. (“Foresight” or “Merger Sub”) (the “P3 Merger”), with Merger Sub as the surviving company, which was renamed P3 Health Group, LLC (“P3 LLC”), and FAC-A Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight, FAC-B Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight (together with FAC-A Merger Sub Corp., the “Merger Corps”) merged with and into CPF P3 Blocker-A, LLC, a Delaware limited liability company, CPF P3 Blocker-B, LLC a Delaware limited liability company (together with CPF P3 Blocker-A, LLC, the “Blockers”), with the Blockers as the surviving entities and wholly-owned subsidiaries of Foresight (collectively, the “Business Combinations”). Upon completion of the Business Combinations (the “Closing”), the Company and P3 LLC were organized in an “Up-C” structure in which all of the P3 LLC operating subsidiaries are held directly or indirectly by P3 LLC, and the Company directly owned approximately 17.1% of P3 LLC and became the sole manager of P3 LLC. Following Closing, substantially all of the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interest in P3 LLC (“P3 LLC Units”). In connection with the closing of the transactions, the Company changed its name from Foresight Acquisition Corp. to P3 Health Partners Inc.

The Company’s contracts with health plans are based on an at-risk shared savings model. Under this model, the Company is financially responsible for the cost of all contractually covered services provided to members assigned to the Company by health plans in exchange for a fixed monthly “capitation” payment, which is generally a percentage of the payment health plans receive from CMS. Under this arrangement, Medicare beneficiaries generally receive all their healthcare coverage through the Company’s network of employed and affiliated physicians and specialists (except for emergency situations).

The services provided to health plans’ members vary by contract. These may include utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of Company providers, processing and payment of claims and the establishment of a provider network for certain health plans. At September 30, 2022 and December 31, 2021, the Company had agreements with twenty and seventeen health plans, respectively.

The Company has Management Services Agreements (“MSAs”) and deficit funding agreements with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, P3 Health Partners Professional Services P.C., P3 Medical Group, P.C. and P3 Health Partners California, P.C. (collectively, the “Network”). As more fully described in Note 25 “Variable Interest Entities,” the entities in the Network are variable interest entities and the Company is the primary beneficiary of the Network. The MSAs provide that the Company or its subsidiaries will furnish administrative personnel, office supplies and equipment, general business services, contract negotiation and billing and collection services to the Network. Fees for these services are the excess of the Network’s revenue over expenses. Per the deficit funding agreements, the Company or its subsidiaries are obligated to lend amounts to the Network to the extent expenses exceed revenues. The loan will bear interest at prime plus 2%.

In addition to the Company’s contracts with health plans, through its relationship with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, the Company provides primary healthcare services through its employed physician clinic locations. These primary care clinics are reimbursed for services provided under FFS contracts with various payers and through capitated – per member, per month (“PMPM”) arrangements.

Basis of Presentation

These unaudited interim condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of the U.S. Securities and Exchange Commission (“SEC”) Regulation S-X. The condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). Certain information and footnote disclosures, normally included in financial statements prepared in accordance with U.S. GAAP, have been condensed or omitted pursuant to SEC rules and regulations dealing with interim financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. For further information, refer to the consolidated financial statements and notes thereto included in our 2021 Form 10-K. There have been no significant changes to our accounting policies and estimates during the nine months ended September 30, 2022 from those previously disclosed in the 2021 Form 10-K.

As a result of the Business Combinations, for accounting purposes, Foresight is the acquirer and P3 Health Group Holdings, LLC is the accounting acquiree and predecessor. The financial statement presentation includes the financial statements of P3 Health Group Holdings, LLC as “Predecessor” for the periods prior to the Closing Date (the “Predecessor Period(s)”) and of the Company as “Successor” for the periods after the Closing Date (the “Successor Period(s)”), including the consolidation of P3 Health Group Holdings, LLC.

As a result of the application of the acquisition method of accounting as of the Closing Date of the Business Combinations, the accompanying unaudited condensed consolidated financial statements include a black line division that indicates that the Predecessor and Successor reporting entities shown are presented on a different basis and are, therefore, not comparable.

The Company qualifies as an Emerging Growth Company (“EGC”) and as such, has elected the extended transition period for complying with certain new or revised accounting pronouncements. During the extended transition period, the Company is not subject to certain new or revised accounting standards applicable to public companies. The accounting pronouncements pending adoption as described in Note 6 “Recent Accounting Pronouncements Not Yet Adopted” reflect effective dates for the Company as an EGC with the extended transition period.

Restatement of Prior Year Amounts

As discussed in the Company's 2021 consolidated financial statements included in the 2021 Form 10-K, the Company restated the previously issued unaudited condensed consolidated financial statements for each interim period within the fiscal years ended December 31, 2021 and December 31, 2020.

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restatement of Previously Issued Financial Statements
9 Months Ended
Sep. 30, 2022
Restatement of Previously Issued Financial Statements  
Restatement of Previously Issued Financial Statements

Note 2: Restatement of Previously Issued Financial Statements

The Company has restated the condensed consolidated financial statements for the three and nine months ended September 30, 2021.

Network

Since 2017, P3 Health Group Holdings and P3 Health Partners, LLC (collectively with P3 Health Partners, Inc., “P3”) have entered into a collective of arrangements with the Network whereby P3 consolidates the Network under the Variable Interest Entity model in accordance with ASC Topic 810, Consolidation (“ASC 810”). Historically, all of the net losses incurred by the Network were allocated to loss attributable to non-controlling interests. Based on an analysis of the deficit funding agreement between P3 and the Network, P3 is obligated to fund losses incurred by the Network. Because P3 is contractually obligated to fund the losses, losses incurred by the Network should not be allocated to non-controlling interests.

Based on management’s evaluation, it was concluded that the Company’s accounting for non-controlling interests related to the Network is not attributed in the manner contemplated by ASC 810. As a result, the Company has reclassified the loss attributable to non-controlling interest related to the Network to loss attributable to controlling interests on the Consolidated Balance Sheets, Consolidated Statements of Operations, and the Consolidated Statements of Changes in Stockholders’/Members’ Equity for the periods described above.

The Company's accounting for the loss in controlling interests instead of non-controlling interests has no impact on the Company's current or previously reported cash position, revenue, operating expenses or total operating, investing or financing cash flows.

Preferred Returns

P3's capital structure consists of Class A Units, which represent commitments from the Company’s private equity sponsors, and Class D Units, which represents an additional investment from a private equity sponsor. Both the Class A and Class D Units have voting rights and, accrue a preferred return in the amount of 8.0% per annum.

Historically, all of the accrued returns were recognized as interest expense on P3’s Statements of Operations and as equity on P3’s Balance Sheets. Based on the analysis of the Class A and Class D Units, the preferred returns should not be accrued until they are legally declared. As a result, the Company’s historical recording of preferred returns in equity and interest expense has been removed as no recognition is necessary until legally declared.

Class A Units

Historically, the Class A Preferred Units issued by P3 were accounted for as permanent equity. Since the Class A Preferred Units are redeemable upon the occurrence of a Sale of the Company via the liquidation and distribution preferences that returns invested capital and the preferred return, management evaluated whether the occurrence of such an event is outside of the Company’s control. As the Class A preferred unit holders hold a majority vote, the redemption of Class A Preferred Units upon a Sale of the Company, irrespective of probability, is outside of the Company’s control.

Based on management’s evaluation, the Class A Preferred Units should be reclassified from permanent to mezzanine equity. Additionally, the Company entered into the Second Amended and Restated Limited Liability Company Agreement in 2019, which provided the holders of Class A units an 8% per annum preferred return.  The Company determined that the amendment should be accounted for as a modification. Therefore, the Company recorded the incremental increase in fair value as an adjustment to the carrying value of Class A units with an offset to additional paid in capital equivalent and accumulated deficit.

Capitated Revenues

Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient (via a Risk Adjustment Factor, “RAF”). The Company’s policy is to recognize the variable RAF component of capitation revenues, to the extent that it is probable a significant reversal will not occur. At the December 31, 2020 balance sheet date the Company determined its estimates of the RAF components of certain capitation revenues were constrained and therefore not estimable, as it was not probable a significant reversal would not occur. The Company subsequently collected the RAF components of capitation payments prior to the issuance of the 2020 financial statements, effectively relieving the constraints which previously existed at the December 31, 2020 balance sheet date. As a result, capitation revenues for 2020 were restated based on the results of management’s analysis of the RAF component of cash receipts collected prior to the issuance 2020 financial statements which were previously determined to not be estimable. The revenue now recognized in 2020 was previously recognized in June of 2021. The total amount of the RAF adjustment was $6,532,954.

There were two other errors related to capitated revenue, other patient service revenue, and medical expenses which were corrected in the restatement. Firstly, the Company has reclassified capitated revenue streams attributable to the Network. These capitated revenues were previously classified as “other patient service revenue” and have been reclassified into “capitated revenue”. Secondly, the Company has eliminated intercompany revenue and expense related to transactions between Bacchus and P3-NV that should have been eliminated in consolidation. Prior to the restatement noted above regarding capitated revenue, this adjustment was a decrease to other patient service revenue and a decrease to medical expenses.

Disclosure Correction

The disclosure of the condensed financial statements of the Company’s consolidated VIE have been corrected for accrued interest and interest expense relating to the advances made to the VIE for the three and nine month periods ended September 30, 2021 (see Note 25). There is no impact to the condensed consolidated financial statements of the Company for this correction to the disclosures.

The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:

    

As Previously

    

Network

    

Preferred Returns

    

Class A Units

    

Revenue

    

    

Reported

    

Adjustments

    

Adjustments

    

Adjustments

    

Adjustment

    

As Restated

Condensed Consolidated Statement of Operations for the Nine Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

447,137,121

$

$

$

$

(3,539,071)

$

443,598,050

Other Patient Service Revenue

 

12,366,111

 

 

 

 

(3,893,823)

 

8,472,288

Total Operating Revenue

 

459,503,232

 

 

 

 

(7,432,894)

 

452,070,338

Medical Expenses

 

459,233,085

 

 

 

 

(899,940)

 

458,333,145

Total Operating Expenses

 

520,053,309

 

 

 

 

(899,940)

 

519,153,369

Operating Loss

 

(60,550,077)

 

 

 

 

(6,532,954)

 

(67,083,031)

Interest Expense, net

 

(13,130,628)

 

 

6,107,441

 

 

 

(7,023,187)

Total Other Expenses

 

(25,193,893)

 

 

6,107,441

 

 

 

(19,086,452)

Net Loss Attributable to Non-Controlling Interests

 

(8,043,678)

 

8,043,678

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(77,700,292)

 

(8,043,678)

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

152,276,992

$

$

$

$

796,003

$

153,072,995

Other Patient Service Revenue

 

4,243,263

 

 

 

 

(1,130,303)

 

3,112,960

Total Operating Revenue

 

156,520,255

 

 

 

 

(334,300)

 

156,185,955

Medical Expenses

 

161,662,423

 

 

 

 

(334,300)

 

161,328,123

Total Operating Expenses

 

184,643,797

 

 

 

 

(334,300)

 

184,309,497

Interest Expense, net

 

(4,643,254)

 

 

2,114,121

 

 

 

(2,529,133)

Total Other Expenses

 

(6,044,940)

 

 

2,114,121

 

 

 

(3,930,819)

Net Loss Attributable to Non-Controlling Interests

 

(2,801,965)

 

2,801,965

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(31,366,517)

 

(2,801,965)

 

2,114,121

 

 

 

(32,054,361)

Condensed Consolidated Statement of Changes in Members' Deficit for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

2,779,619

$

$

(2,779,619)

$

$

$

Net Loss

 

(85,743,970)

 

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

962,163

$

$

(962,163)

$

$

$

Net Loss

 

(34,168,482)

 

 

2,114,121

 

 

 

(32,054,361)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Net Loss

$

(85,743,970)

$

$

6,107,441

$

$

(6,532,954)

$

(86,169,483)

Health Plan Settlements Receivable/Premiums Receivable

 

(7,417,477)

 

 

 

 

6,532,954

 

(884,523)

Class A and Class D Preferred Returns

 

6,107,441

 

 

(6,107,441)

 

 

 

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended June 30, 2021

Preferred Return at 8% for Class A Units

$

926,852

$

$

(926,852)

$

$

$

Net Loss

(24,967,931)

2,036,476

(6,532,955)

(29,464,410)

Balance as of June 30, 2021

(146,395,455)

6,743,106

(43,656,170)

(183,308,519)

Condensed Consolidated Statements of Changes in Members' Deficit for the 3 Months Ended March 31, 2021

Preferred Return at 8% for Class A Units

$

890,612

$

$

(890,612)

$

$

$

Net Loss

(26,607,560)

1,956,848

(24,650,712)

Balance as of March 31, 2021

(122,918,168)

5,633,581

(43,656,269)

6,532,954

(154,407,902)

Consolidated Statements of Changes in Members' Deficit for the Year Ended December 31, 2020

 

  

 

  

 

  

 

  

 

  

 

  

Balance as of December 31, 2020

$

(97,661,735)

$

$

4,567,346

$

(43,656,270)

$

6,532,954

$

(130,217,705)

*Rounding may cause variances

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Going Concern and Liquidity
9 Months Ended
Sep. 30, 2022
Going Concern and Liquidity  
Going Concern and Liquidity

Note 3: Going Concern and Liquidity

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced losses since its inception and had losses of $ 65,329,041 for the three-months ended September 30, 2022 and $1,029,225,234 for the nine-months ended September 30, 2022. Such losses were primarily the result of costs

incurred in adding new members, building relationships with physician partners and payors, and developing new services. The Company anticipates operating losses and negative cash flows to continue for the foreseeable future as it continues to grow membership.

As of September 30, 2022, and December 31, 2021, the Company had $34,357,237 and $140,477,586, respectively, in unrestricted cash and cash equivalents available to fund future operations. The Company’s capital requirements will depend on many factors, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital. The Company will need to use available capital resources and/or raise additional capital earlier than currently anticipated. When the Company pursues additional debt and/or equity financing, there can be no assurance that such financing will be available on terms commercially acceptable to the Company. If the Company is unable to obtain additional funding when needed, it will need to curtail planned activities in order to reduce costs, which will likely have an unfavorable effect on the Company’s ability to execute on its business plan, and have an adverse effect on its business, results of operations and future prospects. As a result of these matters, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Significant Accounting Policies  
Significant Accounting Policies

Note 4: Significant Accounting Policies

Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities,” the Company is the primary beneficiary of the following physician practices (“Network”):

Kahan, Wakefield, Abdou, PLLC (“KWA”)
Bacchus, Wakefield, Kahan, PC (“BACC”)
P3 Health Partners Professional Services PC
P3 Medical Group, P.C.
P3 Health Partners California, P.C.

All intercompany accounts and transactions have been eliminated in consolidation.

Variable Interest Entities

Management analyzes whether the Company has any financial interests in Variable Interest Entities (“VIE” or “VIEs”). This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.

Segment Reporting

The Company presents its financial statements by segment in accordance with ASC Topic No. 280, Segment Reporting (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined that the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment, which reflects how the CODM manages the Company.

Management’s Use of Estimates

Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.

The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.

Earnings (Loss) per Share and Member Unit

Basic and diluted net loss per share attributable to common stockholders in the Successor Periods is presented in conformity with the two-class method required for participating securities. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.

The Company analyzed the calculation of net loss per member unit for the Predecessor Periods and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Periods.

Cash and Restricted Cash

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At September 30, 2022 and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.

At September 30, 2022 and December 31, 2021, the Company had unrestricted cash of $34,357,237 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.

Successor

    

September 30, 2022

    

December 31, 2021

Unrestricted

$

34,357,237

$

140,477,586

Restricted

 

1,003,307

 

356,286

Total Cash Balances

$

35,360,544

$

140,833,872

Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.

The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at September 30, 2021, that sum to the total of these items reported in the condensed consolidated statements of cash flows.

Predecessor

    

September 30, 2021

Unrestricted

$

4,336,565

Restricted

 

346,299

Total Cash Balances

$

4,682,864

Revenue Recognition and Revenue Sources

The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:

Successor

Predecessor

 

 

 

Three Months Ended

Three Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Capitated Revenue

$

243,988,004

 

98.3

%  

$

153,072,995

 

98.0

%

Other Patient Service Revenue:

 

  

 

  

 

  

 

  

Clinical Fees & Insurance Revenue

 

1,956,604

 

0.8

%  

 

1,278,339

 

0.8

%

Shared Risk Revenue

 

 

0.0

%  

 

139,331

 

0.1

%

Care Coordination / Management Fees

 

1,729,800

 

0.7

%  

 

1,146,355

 

0.7

%

Incentive Fees

 

585,665

 

0.2

%  

 

548,935

 

0.4

%

Total Other Patient Service Revenue

 

4,272,069

 

1.7

%  

 

3,112,960

 

2.0

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

  

  

Nine Months Ended

Nine Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

(As Restated)

    

% of Total

Capitated Revenue

$

780,775,285

 

98.7

%  

$

443,598,050

 

98.1

%

Other Patient Service Revenue:

 

  

 

  

 

Clinical Fees & Insurance Revenue

 

4,103,481

 

0.5

%  

 

3,386,966

 

0.7

%

Shared Risk Revenue

 

55,154

 

0.0

%  

 

341,342

 

0.1

%

Care Coordination / Management Fees

 

4,412,973

 

0.6

%  

 

2,994,755

 

0.7

%

Incentive Fees

 

1,911,485

 

0.2

%  

 

1,749,225

 

0.4

%

Total Other Patient Service Revenue

 

10,483,093

 

1.3

%  

 

8,472,288

 

1.9

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:

Successor

Predecessor

 

 

  

  

Three Months Ended

Three Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Health Plan C

$

48,538,454

 

19.5

%  

$

29,563,741

 

18.9

%

Health Plan B

 

46,082,052

 

18.5

%  

 

38,227,530

 

24.5

%

Health Plan A

 

35,936,246

 

14.5

%  

 

36,417,184

 

23.3

%

Health Plan D

 

31,563,532

 

12.8

%  

 

18,913,641

 

12.1

%

All Other

 

86,139,789

 

34.7

%  

 

33,063,859

 

21.2

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

 

Nine Months Ended

Nine Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

  

    

(As Restated)

    

% of Total

Health Plan C

$

158,252,527

 

20.0

%  

$

84,489,621

 

18.7

%

Health Plan B

 

139,920,223

 

17.7

%  

 

105,261,569

 

23.3

%

Health Plan A

 

124,681,687

 

15.8

%  

 

114,230,860

 

25.3

%

Health Plan D

 

104,439,689

 

13.2

%  

 

56,606,725

 

12.5

%

All Other

 

263,964,252

 

33.3

%  

 

91,481,563

 

20.2

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.

Capitated Revenue

The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on the health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.

The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.

Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first three quarters in 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).

At September 30, 2022 and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across five states) and 17 health plans (across four states), respectively.

Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within twenty-one months following each year-end.

At September 30, 2022, and December 31,2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:

    

Health Plan Receivables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

524,540

$

4,695,712

Health Plan B

 

24,387,307

 

15,473,828

Health Plan C

 

28,798,095

 

1,380,752

Health Plan D

 

15,136,034

 

6,651,586

Health Plan E

 

184,332

 

2,439,046

Health Plan F

 

1,467,834

 

2,925,751

Health Plan G

 

35,179

 

239,375

Health Plan H

 

3,570,820

 

2,185,619

Health Plan I

 

1,586,752

 

1,134,750

Health Plan J

 

(102,380)

 

149,915

Health Plan K

 

 

2,705,147

Health Plan L

 

 

899,560

Health Plan M

 

1,388,190

 

1,747,116

Health Plan N

 

598,056

 

974,092

Health Plan O

 

2,279,489

 

666,291

Health Plan P

 

511,469

 

106,162

Health Plan Q

 

476,057

 

61,990

Health Plan R

 

 

3,578,682

Health Plan S

 

600,639

 

Health Plan T

 

57,607

 

2,175,324

Health Plan U

 

 

60,306

Health Plan W

 

(2,317)

 

Total Health Plan Receivables

$

81,497,703

$

50,251,004

    

Health Plan Settlement Payables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

2,579,575

$

Health Plan B

 

11,700,274

 

11,700,274

Health Plan D

 

 

3,882,250

Health Plan F

 

5,103,534

 

6,085,425

Health Plan G

 

900,314

 

776,164

Health Plan I

 

(10,915)

 

(215,626)

Health Plan O

 

39,365

 

(39,151)

Health Plan U

 

226,209

 

226,209

Health Plan V

 

88,480

 

133,149

Total Health Plan Settlement Payables

$

20,626,836

$

22,548,694

At September 30, 2022, and December 31, 2021, management has deemed the Company’s settlement receivables to be fully collectible from those health plans where the Company is not delegated for claims processing. Accordingly, a constraint on the variable consideration associated with settlement receivables is not necessary.

Other Patient Service Revenue – Clinical Fees and Insurance Revenue

Clinic fees and insurance revenues relate to net patient fees received from various payers and direct patients (“self-payers”) under contracts in which the Company’s sole performance obligation is to provide healthcare services through the operation of medical clinics. The Company recognizes clinic fees and insurance revenue in the period in which services are provided, on the date of service, under FFS payment arrangements, revenue is recognized on the date of service. The Company’s performance obligations are typically satisfied in the same day services are provided. All the Company’s contracts with its customers under these arrangements include a single performance obligation.

The Company’s contractual relationships with patients, in most cases, also involve third-party payers (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through state-sponsored health insurance exchanges). Transaction prices for services provided are dependent upon specific rules in place with third party payers – specifically, Medicare/Medicaid and pre-negotiated rates with managed care health plans and commercial insurance companies. Contractual arrangements with third parties typically include payments at amounts which are less than standard charges. These charges generally have predetermined rates for diagnostic service codes or discounted FFS rates. Management perpetually reviews the Company’s contractual estimation processes to consider and incorporate updates to laws, regulations and frequent changes in the managed care system. Contractual terms are negotiated and updated accordingly upon renewal.

The Company’s revenue is based upon the estimated amounts management expects to receive from patients and third-party payers. Estimates of explicit price concessions under managed care and commercial insurance plans are tied to payment terms specified in related contractual agreements. Retroactively calculated explicit price concessions tied to reimbursement agreements with third-party payers are recognized on an estimated basis in the period related services are rendered and adjusted in future periods as final payments are received. Revenue related to uninsured patients, uninsured co-payments, and deductibles (for patients with healthcare coverage) may also be discounted. The Company records implicit price concessions (based on historical collection experience) related to uninsured accounts to recognize self-pay revenues at their most likely amounts to be collected.

The Company deems FFS revenue to be variable consideration and that its estimates of associated transaction prices will not result in a significant revenue reversal in the future.

Based on satisfaction of single performance obligations occurring on the dates of service, revenue is recognized as of the date services are provided. The Company, therefore, applies a portfolio approach to recognizing revenue from its FFS contracts.

Management has elected two of the available practical expedients provided for by ASC 606. First, the Company did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

Other Patient Service Revenue – Shared Risk Revenue

P3 LLC (via one of its wholly owned subsidiaries – P3 Health Partners ACO, LLC “AzCC”) receives 30% of the shared risk savings from parties with whom it contracts under four separate arrangements. These arrangements are driven solely by medical cost containment year-over-year (“YoY”) expense reductions. This key performance indicator (“KPI”) is measured by the aggregate change in per member per year (“PMPY”) medical costs. If the sequential YoY PMPY aggregate change yields a reduction, the Company receives 30% of the associated total cost savings for that year. Conversely, if the sequential YoY PMPY aggregate change yields an increase in medical costs, no monies are due the Company that year. This KPI is compiled and reviewed on a calendar year basis. The Company recognizes shared risk revenue only upon the receipt of cash. Therefore, the likelihood of any significant revenue reversal in the future is non-existent.

Other Patient Service Revenue – Care Coordination Fees and Management Fees

The Company’s delegated health plans may also pay a Care Coordination Fee (“CCF”) or Management Fee to the Company. CCFs and Management Fees are intended to fund the costs of delegated services provided to certain health plans. CCFs are specifically identified and separated in each monthly capitation payment the Company receives from these parties. None of the Company’s other health plans bifurcate CCFs nor are any of them contractually required to do so.

The Company uses a portfolio approach to account for CCFs and Management Fees. Based on similarities of the terms of the care coordination and administrative services, management believes that revenue recognized by utilizing the portfolio approach approximates that which it would have realized if an individual contract approach were applied.

Patient Fees Receivable

Substantially, all client fees and insurance receivables are due under FFS contracts with third party payors, such as commercial insurance companies (“Commercial”), government-sponsored healthcare programs (“Medicare/Medicaid”) or directly from patients (“Self-Pay”). Management continuously monitors activities from payors (including patients) and records an estimated price concession based on specific contracts and actual historical collection patterns. Patient fees receivable, where a third-party payor is responsible for the amount due, are carried at amounts determined by the original charges for services provided less implicit and explicit price concessions. Price concessions represent amounts made for contractual adjustments (discounts). Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and are recorded net of contractual allowances.

Patient fees receivable are recorded at the invoiced amount, net of any expected contractual adjustments and implicit price concessions, and do not bear interest. The Company has agreements with third-party payors that provide for payments at amounts different from the established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Contractual adjustments arising under reimbursement arrangements with third- party payors are accrued on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined. Implicit price concessions are taken based on historical collection experience and reflect the estimated amounts the Company expects to collect.

Goodwill

In accordance with ASC 350, Intangibles - Goodwill and Other, management tests goodwill for impairment at the reporting unit level. The Company has one reporting unit for goodwill impairment testing purposes. Goodwill is tested for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate the carrying value of goodwill may not be recoverable (a “triggering event”). On the occurrence of a triggering event, an entity has the option to first assess qualitative factors to determine whether a quantitative impairment test is necessary. If it is more likely than not that goodwill is impaired, the fair value of the reporting unit (the Company) is compared with its carrying value. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value, provided, the loss recognized cannot exceed the total amount of goodwill. No goodwill impairment charges were recorded in the first quarter or third quarter of 2022, respectively. Based on management’s analysis, a goodwill impairment charge of $851.5 million was recorded in the second quarter of 2022. See Note 11 “Goodwill.”

Intangible Assets

Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. In determining the estimated useful lives of definite-lived intangibles, the Company considers the nature, competitive position, life cycle position and historical and expected future operating cash flows of each acquired asset, as well as its commitment to support these assets through continued investment and legal infringement protection.

The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. Such events and circumstances include the occurrence of an adverse change in the market involving the business employing the assets or a situation in which it is more likely than not that the Company will dispose of such assets. If the comparison indicates that there is impairment, the impairment loss to be recognized as a non-cash charge to earnings is measured by the amount by which the carrying amount of the asset exceeds its fair value. The impaired asset is written down to its fair value or, if fair value is not readily determinable, to an estimated fair value based on discounted expected future cash flows.

Fair Value Measurements

The Company accounts for fair value measurements in accordance with ASC 820, Fair Value Measurements (“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 8 “Fair Value Measurements and Hierarchy” for further discussion):

Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recent Accounting Pronouncements Adopted
9 Months Ended
Sep. 30, 2022
Recent Accounting Pronouncements Adopted  
Recent Accounting Pronouncements Adopted

Note 5: Recent Accounting Pronouncements Adopted

ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. It is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted the ASU in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures

Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”)

ASU 2021-04 requires issuers to account for modifications or exchanges of freestanding equity-classified written call options (e.g., warrants) that remain equity classified after the modification or exchange based on the economic substance of the modification or exchange. The Company adopted ASU 2014-04 in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.

ASU 2021-10, Government Assistance (Topic 8352), Disclosures by Business Entities about Government Assistance (“ASU 2021-10”)

In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10. ASU 2021-10 requires annual disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model including (i) information about the nature of the transactions and the related accounting policy used to account for the transaction; (ii) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (iii) significant terms and conditions of the transactions, including commitments and contingencies. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company adopted the ASU prospectively on January 1, 2022. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recent Accounting Pronouncements Not Yet Adopted
9 Months Ended
Sep. 30, 2022
Recent Accounting Pronouncements Not Yet Adopted  
Recent Accounting Pronouncements Not Yet Adopted

Note 6: Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016 13”). ASU 2016 13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for the Company beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 eliminates two of the three models in ASC 470-20 that require issuers to separately account for embedded conversion features and eliminates some of the requirements for equity classification in ASC 815-40-25 for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and generally requires them to include the effect of potential share settlement for instruments that may be settled in cash or shares. It is effective for annual periods beginning after December 15, 2023, and interim periods therein. Early adoption is permitted in fiscal years beginning after December 15, 2020, but the Company must adopt the guidance as of the beginning of a fiscal year. The Company is evaluating the effect ASU 2020-06 will have on its financial statements and related disclosures.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires that an entity (acquirer) recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts as if it had originated the contracts. The amendments in this update are effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. Adoption is not currently expected to have a material impact on the Company’s financial statements and related disclosures.

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations
9 Months Ended
Sep. 30, 2022
Business Combinations  
Business Combinations

Note 7: Business Combinations

Foresight Business Combinations

On December 3, 2021, the Company entered into the Business Combinations described in Note 1 “Organization and Basis of Presentation.” The Business Combinations represent a forward merger and is accounted for using the acquisition method of accounting under which P3 Health Group Holdings, LLC is treated as the acquired company for financial reporting purposes. This determination is based primarily on the following facts:

(i)The Company is the sole managing member of P3 LLC subsequent to the consummation of the Business Combinations, and the managing member conducts, directs and exercises full control over all activities of P3 LLC. The non-managing members of P3 LLC do not have substantive kick-out or participating rights; and
(ii)No one predecessor stakeholder of P3 had a controlling interest in P3 before or has a controlling interest in the combined company after the Business Combination. The Business Combination is not a transaction between entities under common control.

These factors support the conclusion that the Company acquired a controlling interest in P3 LLC and is the accounting acquirer. For accounting purposes, the accounting acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated based on the variable interest or voting interest model pursuant to ASC 810. If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. The Company is the primary beneficiary of P3 LLC, which is a variable interest entity, since it has the power to direct the activities of P3 LLC that most significantly impact P3 LLC’s economic performance through its role as the sole managing member. Therefore, the Company is the accounting acquirer of P3 LLC and the Business Combinations should be accounted for using the acquisition method.

Under the acquisition method of accounting, Foresight’s assets and liabilities are recorded at carrying value and the assets and liabilities associated with P3 LLC are recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The acquisition method of accounting is based on ASC Topic 805, Business Combinations (“ASC 805”) and uses the fair value concepts defined in ASC 820. In general, ASC 805 requires, among other things, that assets acquired, and liabilities assumed be recognized at their fair values as of the acquisition date by the accounting acquirer, which was determined to be Foresight.

ASC 820 defines fair value, establishes a framework for measuring fair value, and sets forth a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to develop the fair value measurements. Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for a non-financial asset assume the highest and best use by these market participants. Many of these fair value measurements can be highly subjective, and it is possible that other professionals applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

As a result of the Business Combinations, P3 LLC, which represents substantially all of the economic activity of the Company, is a subsidiary of the Company. Since the Company is the sole managing member of P3 LLC following the Business Combinations, the P3 LLC Units held by certain of the former owners of P3 Health Group Holdings, LLC (the “P3 Equity Holders”) are classified as Redeemable Noncontrolling Interests in the Company’s financial statements for financial reporting purposes. An allocation of net income or loss representing the percentage of ownership of P3 LLC not controlled by the Company, will be attributed to the Redeemable Noncontrolling Interests in the Company’s statement of operations.

Upon the completion of the Business Combinations, the Company entered into a Tax Receivable Agreement (“TRA”) with certain of the P3 Equity holders and P3 LLC. The TRA provides for the payment to the P3 Equity holders of 85% of the income tax benefits, if any, that are actually realized. At the completion of the Business Combinations, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such tax benefits after concluding it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets. See Note 16 “Income Taxes” for further information.

The following summarizes the purchase price consideration:

    

Successor

December 31,

Foresight

2021

Equity

$

80,300,733

Fair Value of Non-controlling Interest

 

1,807,427,576

Stock Compensation Pre-combination Services

26,313,476

Cash Consideration

 

18,405,083

Payment of P3 Health Group Holdings, LLC’s Transaction Costs

 

19,151,752

Total Purchase Consideration

$

1,951,598,620

The Company recorded the allocation of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the Closing Date. The allocation reflects the fair value of assets and liabilities

associated with the Company’s other acquisitions in 2021 which occurred in the Predecessor period described below with the exception of Medcore Health Plan, Inc. (“Medcore HP”) and Omni IPA Medical Group, Inc. (“Omni”), which occurred in the Successor Period.

The aggregate purchase price consideration for the P3 LLC acquisition has been allocated as follows:

Purchase Price Allocation

    

Amounts

Assets Acquired:

Cash

$

5,300,842

Restricted Cash

 

54,095

Health Plan Settlement Receivables

 

47,733,033

Clinic Fees and Insurance Receivables, Net

 

426,064

Other Receivables

 

1,880,939

Prepaid Expenses and Other Current Assets

 

938,413

Property and Equipment, Net

 

7,875,234

Intangible Assets, Net:

 

  

Customer Relationships

 

684,000,000

Provider Network

 

3,700,000

Trademarks

 

147,700,000

Goodwill

 

1,278,452,778

Notes Receivable, Net

 

3,734,012

Right of Use Assets

 

6,870,279

Total Assets Acquired

$

2,188,665,689

Liabilities Assumed:

 

  

Accounts Payable and Accrued Expenses

$

25,819,091

Accrued Payroll

 

2,868,664

Health Plans Settlements Payable

 

25,007,542

Claims Payable

 

76,031,460

Premium Deficiency Reserve

 

11,559,067

Accrued Interest

 

9,268,846

Current Portion of Long-Term Debt

 

301,443

Lease Liability

 

6,210,956

Long-Term Debt, Net of Current Portion

 

80,000,000

Total Liabilities Assumed

$

237,067,069

Net Assets Acquired

$

1,951,598,620

Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $3.8 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes. See Note 16 “Income Taxes.” The useful life of acquired definite lived intangible assets is 10 years.

Other Acquisitions

On December 27, and December 31, 2021, respectively, the Company acquired 100% of the outstanding equity of Medcore HP and the net assets of Omni (collectively the “Medcore Acquisition”). Medcore HP is a health plan licensed under the California Knox-Keen Health Care Service Plan Act of 1975, and Omni is an independent practice association located in California. Omni serves as Medcore HP’s contracted and fully delegated physician network providing medical services to Medcore HP’s patients and members. Because of the extensive inter-reliance of these two businesses, the Company accounted for the purchases as a single, combined business. The total purchase price of $40,013,321 includes $3,486,593 to be paid to the sellers upon resolution of the assumed claims payable, or the cost of services that have been incurred, but not yet reported (“IBNR”), and risk adjustment factor. Due to the volatility of these items, the outcome cannot be currently estimated. Release of this payment, currently expected in the first quarter of 2023, is not subject to resolution of a substantive future contingent event and has therefore been included in the total consideration to be transferred. The cash payment, net of cash acquired and the $3,486,593 retained, was $15,677,205.

Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $8.1 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes.

The aggregate purchase price consideration of the other acquisitions in 2021 has been allocated as follows:

    

Successor Period

  

  

Predecessor Period

Assets Acquired:

Cash

$

20,547,337

$

3,000

Restricted Cash

 

302,187

 

Health Plan Settlement Receivables

 

5,754,006

 

Clinic Fees and Insurance Receivables, Net

 

141,186

 

Other Receivables

 

726,378

 

Prepaid Expenses and Other Current Assets

 

1,189,575

 

Property and Equipment, Net

 

113,436

 

5,896

Intangible Assets, Net:

 

 

Customer Relationships

 

 

2,045,604

Pay or Contracts

 

4,700,271

 

  

Provider Network

 

1,100,000

 

Trademarks

 

900,000

 

Medical Licenses

 

700,000

 

Goodwill

 

31,297,438

 

2,934,500

Total Assets Acquired

$

67,471,814

$

4,989,000

Liabilities Assumed:

 

  

 

  

Accounts Payable and Accrued Expenses

$

150,196

$

Accrued Payroll

 

277,074

 

Health Plans Settlements Payable

 

133,149

 

Claims Payable

 

26,898,074

 

Total Liabilities Assumed

 

27,458,493

 

Net Assets Acquired

$

40,013,321

$

4,989,000

The Company also purchased three other medical practices during the Predecessor Period of 2021 for a total net cash purchase price of $4,989,000. As referenced above, the assets acquired and liabilities assumed in these acquisitions was included in the purchase consideration and allocation for the Business Combinations.

In the third quarter of 2022, the Company acquired two medical practices in separate transactions. The total cash purchase price was $5,500,131, net of cash acquired, and was allocated primarily to goodwill. The acquisitions were determined to be immaterial for disclosure.

Pro Forma Financial Information (Unaudited)

The following unaudited pro forma financial information presents combined results of operations for the periods presented as if the acquisition of P3 Health Group Holdings, LLC and the Medcore Acquisition had occurred on January 1, 2021. The unaudited pro forma results may not necessarily reflect actual results of operations that would have been achieved, nor are they necessarily indicative of future results of operations. The unaudited pro forma results reflect the step-up amortization adjustments for the fair value of intangible assets acquired, transaction expenses, accelerated vesting of equity compensation and income attributable to non-controlling interest holders.

Nine Months Ended

September 30,

2021

    

(Unaudited)

Total Operating Revenue

$

567,305,732

Net Profit

(179,492,450)

Net Loss Attributable to Non-controlling Interest

(148,260,764)

Net Loss Attributable to Controlling Interest

$

(31,231,686)

The unaudited pro forma financial information has been presented for illustrative purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition taken place on the date indicated, or the future consolidated results of operations of the Company. The pro forma financial information presented above has been derived from the historical condensed consolidated financial statements of the Company, the Company's Predecessor Periods and the Company's Successor Period.

The unaudited pro forma results include certain pro forma adjustments to revenue and net loss that were directly attributable to the P3 Health Group Holdings, LLC acquisition, assuming the acquisition had occurred on January 1, 2021, including the following:

1)Transaction costs of approximately $39.4 million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.
2)The acceleration of certain stock-based awards of $2.4 million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy
9 Months Ended
Sep. 30, 2022
Fair Value Measurements and Hierarchy  
Fair Value Measurements and Hierarchy

Note 8: Fair Value Measurements and Hierarchy

See Note 4 “Significant Accounting Policies” for a summary of the Company’s policies relating to fair value measurements.

The following table presents the carrying amounts of the Company’s financial instruments as of September 30, 2022 and December 31, 2021, respectively:

    

Successor

    

September 30, 2022

    

December 31, 2021

Financial assets:

 

  

 

  

Cash

$

34,357,237

$

140,477,586

Restricted cash

 

1,003,307

 

356,286

Clinics fees and insurance receivables, net

 

1,049,253

 

1,090,104

Other receivables

 

2,736,184

 

726,903

Financial liabilities:

 

  

 

  

Accounts payable and accrued expenses

 

24,072,391

 

17,730,683

Warrants liabilities

 

7,996,432

 

11,382,826

The book value of cash, clinic fees and insurance receivables, net, other receivables, and accounts payable and accrued expenses approximate fair value because of the short maturity and high liquidity of these instruments. Liabilities for private placement warrants are measured at fair value using Level 3 inputs.

The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021:

    

Level 1

    

Level 2

    

Level 3

    

Total

Warrant liability as of September 30, 2022

$

7,774,549

$

$

221,883

$

7,996,432

Warrant liability as of December 31, 2021

 

10,880,550

 

 

502,276

 

11,382,826

The key Level 3 inputs into the option pricing model as of September 30, 2022 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

4.16

%

Exercise Price

$

11.50

Expected Term

 

4.2

Years

The key Level 3 inputs into the option pricing model as of December 31, 2021 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

1.26

%

Exercise Price

$

11.50

Expected Term

 

4.9

Years

Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock, and an increase in the remaining term of the warrants would each result in a directionally similar change in the estimated fair value of the Company’s warrant liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability. The Company has not, and does not plan to, declare dividends on its common stock and, as such, there is no change in the estimated fair value of the warrant liabilities due to the dividend assumption.

The following tables set forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated:

Successor

Predecessor

    

Nine Months Ended September

  

  

Nine Months Ended September

30, 2022

30, 2021

Beginning Balance of Private Warrant Liability

$

502,276

$

6,316,605

Mark-to-Market Adjustment for Stock Warrants

 

(280,393)

 

12,063,265

Ending Balance of Private Warrant Liability

$

221,883

$

18,379,870

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Patient Fees Receivable
9 Months Ended
Sep. 30, 2022
Patient Fees Receivable  
Patient Fees Receivable

Note 9: Patient Fees Receivable

Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and consisted of the following categories for each of the periods ending September 30, 2022 and December 31, 2021 presented below:

Successor

    

September 30, 2022

    

December 31, 2021

Total Receivables: Gross

$

5,383,421

$

2,641,182

Less: Contractual Allowances

 

(4,745,367)

 

(1,968,750)

Receivables Net of Contractual Allowances

$

638,054

$

672,432

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment
9 Months Ended
Sep. 30, 2022
Property and Equipment.  
Property and Equipment

Note 10: Property and Equipment

The Company’s property and equipment balances as of September 30, 2022 and December 31, 2021 consisted of the following:

Successor

    

September 30, 2022

    

December 31, 2021

Leasehold Improvements

$

1,809,927

$

1,537,091

Furniture & Fixtures

 

1,450,626

 

1,108,184

Computer Equipment & Software

 

2,852,746

 

2,700,617

Medical Equipment

 

1,066,959

 

414,100

Software (Development in Process)

 

3,918,615

 

2,433,470

Vehicles

373,995

Other

 

36,788

 

36,788

 

11,509,656

 

8,230,250

Less: Accumulated Depreciation

 

(1,994,380)

 

(182,321)

Property and Equipment, Net

$

9,515,276

$

8,047,929

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill
9 Months Ended
Sep. 30, 2022
Goodwill  
Goodwill

Note 11: Goodwill

A summary of changes in the Company’s goodwill during the nine months ended September 30, 2022 is as follows:

    

September 30, 2022

Balance at December 31, 2021

$

1,309,750,216

Acquisition

5,201,729

Impairment charge

 

(851,455,754)

Balance at September 30, 2022

$

463,496,191

Goodwill, which represents the excess of cost over the fair value of net assets acquired, was $463,496,191 and $1,309,750,216 as of September 30, 2022, and December 31, 2021. The Company acquired two medical practices during the nine months ended September 30, 2022. In the second quarter of 2022, the overall market had significantly deteriorated and there was a sustained decrease in the Company’s share price. As a result, and as required by ASC 350, the Company performed an interim goodwill impairment test as of June 30, 2022.

The Company first assessed qualitative factors to determine if it was more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Management noted that the steady decline in share price from April 1, 2022, through June 30, 2022, covers a period of three months. The stock was 63% lower than its opening price on December 2, 2021, and has not surpassed that price since December 15, 2021. Additionally, the Company’s share price continued to decline in May 2022, which did not follow the overall rebound pattern in the healthcare industry. Thus, management determined that it was not just market factors affecting the price and that the share price performance covered a sustained period of time. In addition, the Company incurred higher than expected medical expenses due to the COVID-19 pandemic, which resulted in a decrease in adjusted EBITDA. Management concluded that, given the macroeconomic and financial market conditions, industry-specific considerations, the Company’s performance, and the sustained decrease in share price, it was more likely than not that the fair value of P3 was less than its carrying amount at June 30, 2022. As a result, management performed an interim test of impairment using quantitative methods.

When performing quantitative testing, the Company first estimated the fair values of its reporting units using a weighted combination of discounted cash flows and a market-based method. Taking into consideration the updated business outlook and current difficult market conditions, management updated the assumption for future cash flow estimation. In particular, management increased expected medical expense in the cash flow projection for the goodwill impairment test, which lowered the forecast for adjusted EBITDA. Under the market approach, management estimated a fair value based on comparable companies' market multiples of revenues and EBITDA. Finally, management compared the weighted estimated fair value to the carrying amount. Based on management’s quantitative analysis, an $851.5 million goodwill impairment charge was recorded for the three-month period ended June 30, 2022. No goodwill impairment was recorded for the three-month period ended September 30, 2022 as there were no indicators of impairment during this period.

Because the Company’s goodwill impairment analysis is sensitive to market capitalization, projected revenues, and adjusted EBITDA, the Company will continue to monitor key assumptions and other factors utilized in the interim goodwill impairment analysis.

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets
9 Months Ended
Sep. 30, 2022
Intangible Assets  
Intangible Assets

Note 12: Intangible Assets

The follow tables provide changes in other intangible assets for the nine months ended September 30, 2022.

    

Customer

    

    

Provider

Medical

    

Relationships

    

Trademarks

    

Payor Contracts

    

Network

    

Licenses

    

Total

Balance at December 31, 2021

$

678,300,000

$

147,369,167

$

4,700,271

$

4,769,167

$

700,000

$

835,838,605

Amortization

 

(51,300,000)

 

(11,415,000)

 

(352,522)

 

(360,000)

 

 

(63,427,522)

Balance at September 30, 2022

$

627,000,000

$

135,954,167

$

4,347,749

$

4,409,167

$

700,000

$

772,411,083

Amortization of intangible assets is anticipated to be approximately $84 million in each of the years 2022 through 2026. The weighted average remaining useful life of definite lived intangible assets is 9.2 years.

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Receivable, Net
9 Months Ended
Sep. 30, 2022
Notes Receivable, Net.  
Notes Receivable, Net

Note 13: Notes Receivable, Net

The Company entered into five Promissory Notes (the “Notes”) with three family medical practices (the “Practices”) to fund their working capital needs. The Company simultaneously entered into separate Provider Agreements with each Practice related to four of these five Notes. Each Provider Agreement establishes a preferred, predetermined reimbursement rate for services rendered to the Company’s members and requires that Practice to furnish healthcare services to the Company’s members. The Provider Agreements mature in concert with each practice’s loan. In accordance with each of these four Notes, so long as the corresponding Provider Agreement is in effect on the maturity date of each Note and has not been terminated by the borrower for any reason, the Company will forgive the entire principal, plus accrued interest due on the date of maturity. Likewise, if the Company terminates the Provider Agreement prior to maturity without cause, all principal plus accrued interest due from the borrower will be forgiven. Upon early termination of the Provider Agreement by borrower, all principal and accrued interest will become immediately payable and due the Company. Related to potential forgiveness, the Company records a valuation allowance on a straight-line basis following the early termination date through the date of maturity, due to the probable likelihood of forgiveness of the Notes at maturity, with a full valuation allowance set at the time of maturity.

At September 30, 2022 and December 31, 2021, the Company has recorded notes receivable of $4,526,522 (including $963,060 current portion) and $3,590,715 including accrued interest receivable of $1,040,729 and $885,243, and net of valuation allowances of $709,547 and $526,808, respectively. The Notes carry maturity dates ranging from December 31, 2021 through December 31, 2028 with interest rates ranging from 5.0% to 10.0%. The short-term components of these Notes as of September 30, 2022 and December 31, 2021, is included in Other Receivables in the Company’s condensed consolidated balance sheets.

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Claims Payable
9 Months Ended
Sep. 30, 2022
Claims Payable.  
Claims Payable

Note 14: Claims Payable

Claims payable includes claims reported as of the balance sheet date, including estimates for IBNR, due to third parties for health care services provided to members. IBNR was $134,705,426 and $101,958,324 at September 30, 2022 and December 31, 2021, respectively. Activity in the liability for claims payable and healthcare expenses for the nine months ended September 30, 2022 was as follows:

    

Successor

Nine Months Ended

    

September 30, 2022

Claims Unpaid, Beginning of Period

$

101,958,324

Incurred, Related to:

 

  

Current Period

 

700,236,928

Prior Period(s)

 

5,024,653

Total Incurred

 

705,261,581

Paid, Related to:

 

  

Current Period

 

570,830,033

Prior Period(s)

 

101,684,446

Total Paid

 

672,514,479

Claims Unpaid, End of Period

$

134,705,426

Estimates for incurred claims are based on historical enrollment and cost trends while also taking into consideration operational changes. Future and actual results typically differ from estimates. Differences could result from an overall change in medical expenses per member, changes in member mix or simply due to the addition of new members.

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt
9 Months Ended
Sep. 30, 2022
Long-Term Debt.  
Long-Term Debt

Note 15: Long-Term Debt

On November 19, 2020, the Company entered a Term Loan and Security Agreement (the “Facility” or “Term Loan”) with a commercial lender (“LTD-D”). The Facility was amended on December 21, 2021. The Facility provided funding up to $100,000,000, of which $65,000,000 has been drawn as of September 30, 2022. Access to additional borrowings above $65,000,000 under the Facility ended upon termination of the commitment period on February 28, 2022. Of the $65,000,000 drawn, $61,058,281 was received (net of $3,941,719 in financing costs). Upon closing of the Business Combinations on December 3, 2021, the unamortized financing costs were written off and the debt was recorded at fair value. The Facility may be used to pay certain indebtedness of the Company and for general working capital needs. Accrued interest was $4,320,493 and $2,259,588 at September 30, 2022 and December 31, 2021, respectively. The Facility includes certain restrictive covenants, including restrictions on the payment of cash dividends. Repayment of principal of all amounts drawn are due at maturity.

The Company was required to meet a borrowing base milestone by demonstrating to the lenders that revenue for any three consecutive month period (ending after the Facility’s closing date, but on or prior to December 31, 2021) was greater than or equal to $125.0 million. Additionally, the Company must remain in compliance with financial covenants including minimum liquidity of $5.0 million and annual minimum revenue levels. Beginning in 2021, and on an annual basis thereafter, the Company must post minimum annual revenue equal to or greater than $395.0 million; increasing to $460.0 million in 2022; $525.0 million in 2023; $585.0 million in 2024 and $650.0 million in 2025 and thereafter. Also, the Company is subject to certain restrictions that include indebtedness and liens. As of December 31, 2021, the Company was not in compliance with its Term Loan covenants related to issuance of the 2021 financial statements with an audit opinion free of a “going concern” qualification or timely filing of the 2021 financial statements. The Term Loan lenders granted (i) a waiver of the covenant under the Facility related to the existence of a “going concern” qualification in the audit opinion for our audited financial statements for the fiscal year ended December 31, 2021 and (ii) a consent to extend the deadline to provide audited financial statements for the year ended December 31, 2021 to October 21, 2022. The Company issued the 2021 financial statements on October 21, 2022. The Company was in compliance with all other covenants under the Facility as of September 30,2022. However, there can be no assurance that the Company will be able to maintain compliance with these covenants in the future or that the lenders under the Facility or the lenders of any future indebtedness the Company may incur will grant us any such waiver or forbearance in the future.

The Facility’s expected maturity date is December 31, 2025. This maturity date may be accelerated as a remedy under the certain default provisions in the agreement or in the event a mandatory prepayment trigger occurs. Interest is payable at 12.0% per annum on a quarterly cycle (in arrears) beginning March 31, 2021. Management may elect to pay the full 12.0% per annum in cash or 8.0% per annum interest in cash with the remaining 4.0% per annum being added to principal as “paid in kind” (“PIK”) for a period of three years (or twelve payments). The PIK is subject to acceleration in the event certain occurrences in the Facility’s agreement are triggered. The Facility’s Lenders also received ten-year warrants to purchase 858,351 shares of Series D Preferred Units at $4.68 per share. These warrants have been recorded as a liability in the Company’s consolidated balance sheets at fair market value and are marked to market on a quarterly basis until exercised. A discount was recorded on the debt issued for the same amount and written off upon closing of the Business Combinations.

The Security Agreement provides the Lenders collateral in 100% of the Company’s pledged stock, its subsidiaries (including tangible and intangible personal property) and bank accounts.

On June 7, 2020, the Company repurchased 200,000 Class C (Time-based) Units, at $0.90 per Unit from a former Executive through issuance of a long-term note (“LTD-E”). This repurchase was recognized in the Company’s consolidated balance sheets as a reduction to Members’ Deficit in the amount of $180,000 and a corresponding increase in long-term debt. LTD-E bore interest of 3.25% and fixed monthly payments of $7,757 through date of maturity. On June 7, 2022, the Company repaid all amounts outstanding under the long-term note.

In 2019, the Company executed a share repurchase agreement with one of its investors (“LTD-C”) which was subsequently amended on November 19, 2020. The agreement, as amended stipulated $15.0 million originally contributed by the investor would be repaid by the earlier of June 30, 2026 or a change in control transaction. As part of this repurchase agreement, the investor exchanged its owned units back for a $15.0 million note receivable from the Company – thus, no longer holding its former equity position. The note carries interest of 11.0% per year. The principal balance, accrued interest and an exit fee of $600,000 is due at maturity. Accrued interest was $8,335,425 and $6,511,477 at September 30, 2022 and December 31, 2021, respectively. The total principal balance is included in Long-Term Debt on the Company’s consolidated balance sheets at September 30, 2022 and December 31, 2021.

The following tables roll forward the long-term debt balances, including current portion, presented in the Company’s condensed consolidated balance sheets:

Successor

    

LTD-A

    

LTD-C

    

LTD-D

    

LTD-E

    

Total

Balance at December 31, 2021

$

$

15,000,000

$

65,000,000

$

46,101

$

80,046,101

Issued in 2022

 

 

 

 

 

Principal Payments in 2022

 

 

 

 

(46,101)

 

(46,101)

Balance at September 30, 2022

$

$

15,000,000

$

65,000,000

$

$

80,000,000

As of September 30, 2022, for the periods presented below, the Company’s minimum payments due under debt obligations were as follows:

    

    

Interest

    

Total Cash

    

Principal

    

PIK

    

Cash Interest

    

Payments*

October 1, 2022 to December 31, 2022

$

$

1,342,321

$

1,401,192

$

1,401,192

2023

 

 

5,624,513

 

5,675,461

 

5,675,461

2024

 

 

6,061,814

 

5,882,309

 

5,882,309

2025

 

65,000,000

 

6,274,526

 

19,518,225

 

84,518,225

2026

 

15,000,000

 

1,851,284

 

20,054,451

 

35,054,451

Total

$

80,000,000

$

21,154,458

$

52,531,638

$

132,531,638

*    Total Payments Cash and Non-Cash (PIK)

Long-term debt was comprised of the following at September 30, 2022 and December 31, 2021:

    

Successor

    

September 30, 2022

    

December 31, 2021

Total Principal

$

80,000,000

$

80,046,101

Less: Current Portion of Long-Term Debt

 

 

(46,101)

Long Term Debt

$

80,000,000

$

80,000,000

Short-Term Debt

In 2021, the Company entered into short term financing agreements totaling $3,683,100 for the funding of certain insurance policies. The terms of the agreements ranged from nine to ten months and the weighted average annual interest rate was 2.6%. There are no remaining scheduled principal payments as of September 30, 2022 as the debt was paid off during the third quarter of 2022.

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Taxes  
Income Taxes

Note 16: Income Taxes

As a result of the Business Combinations, substantially all the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interests in P3 LLC. P3 LLC is treated as a partnership for U.S. federal and most applicable state and local income tax jurisdictions. As a partnership, P3 LLC is generally not subject to U.S. federal, state, and local income taxes. Any taxable income or loss generated by P3 LLC is passed through to and included within the taxable income or loss of its members in accordance with the terms of the P3 LLC A&R LLC Agreement. Prior to the Business Combinations, the income and losses of P3 LLC was passed through to its members and nontaxable to P3 LLC.

The Company is taxed as a corporation and pays corporate federal, state, and local taxes on income allocated to it from P3 LLC based on the Company’s economic interest held in P3 LLC. While the Company consolidates P3 LLC for financial purposes, the Company will not be taxed on the earnings attributed to the non-controlling interests. As a result, the income tax burden on the earnings taxed on the non-controlling interests is not reported by the Company in its financial statements.

To calculate the interim tax provision, at the end of each interim period, the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgements including, but not limited to, the expected operating income for the year, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes.

During the quarter ended June 30, 2022, the Company impaired goodwill related to the intangible asset recorded at P3 LLC in the amount of $851.5 million. The impairment reduced the book basis of the Company's investment in P3 LLC such that the recognition of a deferred tax asset on the outside book and tax basis investment difference resulted. The deferred tax asset related to the investment on P3 LLC has been simultaneously reduced fully by an increase to the recorded valuation allowance due to both cumulative losses in recent years of the Company, and the capital character for income tax purposes of the outside basis difference such that the Company would need sufficient capital character gains for income tax purposes to realize the tax over book outside basis difference. Prior to the impairment, the outside basis difference was an unrecognized deferred tax liability due to the amount of book goodwill more than tax goodwill for which a recognition exception applied. The amount of the deferred tax asset and offsetting valuation allowance related to the outside basis difference for the investment in P3 LLC as of September 30, 2022 is an estimated $7.2 million.

No income tax expenses were incurred for the nine months ended September 30, 2022 and 2021. The Company continues to be in a net operating loss and deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to zero. The Company’s effective tax rate for the nine-months ended September 30, 2022 and 2021 was 0.00%. There was no uncertain tax provision nor contingencies as of September 30, 2022 and December 31, 2021.

Tax Receivable Agreement

Pursuant to our election under Section 754 of the Internal Revenue Code (the “Code”), the Company expects to obtain an increase in our share of the tax basis in the net assets of P3 LLC when its units are redeemed or exchanged. The Company intends to treat any redemptions and exchanges of P3 LLC Units as direct purchases of the units for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent the tax basis is allocated to those capital assets.

The Company entered into a TRA with selling equity holders of P3 LLC that require the Company to pay 85% of the tax savings that are realized as a result of (i) the Company’s direct and indirect allocable share of existing tax basis acquired in the Business Combinations, (ii) increases in the tax basis in P3 LLC’s assets as a result of the sale and exchange of the P3 LLC Units for the Company’s Class A Common Stock and cash, and (iii) the Company’s utilization of certain tax attributes and of certain other tax benefits, including those attributable to payments under the TRA. The Company will retain the benefit of the remaining 15% of these cash savings.

The timing and amount of aggregate payments due under the TRA may vary based on a number of factors, including the timing and amount of taxable income generated by the Company each year, as well as the tax rate then applicable, among other factors. Actual tax benefits realized by the Company may differ from tax benefits calculated under the TRA as a result of the use of certain assumptions in the TRA, including the use of an assumed weighted-average state and local income tax rate to calculate tax benefits.

The payment obligation under the TRA is an obligation of the Company and not of P3 LLC. The payments that the Company will be required to make will generally reduce the amount of the overall cash flow that might have otherwise been available, but the Company expects the cash tax savings it will realize from the utilization of the related tax benefits will exceed the amount of any required payments.

As a result of the Business Combinations, the potential future tax benefits are estimated to be $5.4 million, of which $4.6 million is estimated to be the associated TRA liability.

As of September 30, 2022 and December 31, 2021, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such deferred tax assets because it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets.

As non-controlling interest holders exercise their right to exchange their units in P3 LLC, a TRA liability may be recorded based on 85% of the estimated future tax benefits that the Company may realize as a result of increases in the tax basis of P3 LLC. The amount of the increase in the tax basis, the related estimated tax benefits, and the related TRA liability to be recorded will depend on the price of the Company’s Class A Common Stock at the time of the relevant redemption or exchange.

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capitalization and Management Incentive Units
9 Months Ended
Sep. 30, 2022
Capitalization and Management Incentive Units.  
Capitalization and Management Incentive Units

Note 17: Capitalization and Management Incentive Units

Successor Period

Class A Common Stock

The Company is authorized to issue 800,000,000 shares of Class A Common Stock with a par value of $0.0001 per share, of which 41,578,890 shares were issued and outstanding on September 30, 2022 and December 31, 2021. As discussed in the Note 7 “Business Combinations,” upon closing of the Foresight Business Combinations:

8,732,517 shares of Class A Common Stock  were issued as part of the purchase consideration;
3,737,316 shares of Class A Common Stock  (after redemptions) were no longer subject to redemption;
8,738,750 shares of Class A Common Stock were issued in a private placement to the Founder Holders; and
20,370,307 shares of Class A Common Stock were issued in a private placement pursuant to subscription agreements entered into effective as of March 25, 2021 (the “PIPE Investment”).

Class V Common Stock

The Company is authorized to issue 205,000,000 shares of Class V Common Stock with a par value of $0.0001 per share. These shares have no economic value but entitle the holder to one vote per share. The holders of Common Units of P3 LLC subscribed for shares of Class V Common Stock on a one-for-one basis and may exchange their Common Units and Class V Common Stock together for Class A Common Stock on a one-for-one basis. All Class V Common Stock issued as of the Business Combinations date is subject to a 180 day lockup period. As of September 30, 2022 and December 31, 2021, there were 201,530,796 and 196,553,523 shares of Class V Common Stock issued and outstanding, respectively, and an additional 494,127 and 5,471,400 Class V shares which are restricted and subject to time-based vesting requirements related to the underlying incentive units on September 30, 2022 and December 31, 2021, respectively, as further discussed in Note 18.

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share, of which zero shares were outstanding as of September 30, 2022 and December 31, 2021.

P3 Health Group, LLC Common Units

In connection with the Business Combinations, all outstanding Class A Units, Class B Units, Class C Units and Class D Units of P3 Health Group Holdings, LLC were converted into the right to receive the merger consideration, which consisted of cash and newly-issued Common Units of P3 LLC. The Common Units were issued in amounts determined in accordance with the Merger Agreement and the then-existing limited liability company agreement of P3 Health Group Holdings, LLC. Each holder of Common Units was issued shares of Class V Common Stock on a one-for-one basis. At September 30, 2022 and December 31, 2021, there were 243,603,813 Common Units outstanding at P3 LLC of which the Company held 41,578,890 Common Units and non-controlling interests held the remaining 202,024,923 Common Units outstanding, 494,127 and 5,471,400 of which are restricted as discussed above, respectively.

Predecessor Period

Prior to the Business Combinations, P3 Health Group Holdings, LLC’s capital structure consists of Class A Units, which represented commitments from the Company’s private equity sponsors; Class B Units, which represented founders common equity; Class C Units, which represented Management Incentive Units; and Class D Units, which represented an additional investment from a private equity sponsor. Class A and D Units are presented outside of permanent equity in accordance with ASC 480 due to the existence of a redemption provision that is not solely within the control of the P3 Health Group Holdings, LLC.

At December 31, 2020 and September 30, 2021, there were 43,000,000 Class A Units authorized and outstanding; 6,000,000 and 8,000,000 Class B Units authorized and outstanding, respectively; 1,302,083 and 1,925,833 Class C Units authorized and outstanding, respectively; 16,130,034 Class D Units authorized and outstanding. In connection with the Business Combinations, all outstanding Class A, B, C and D Units were converted into the right to receive the merger consideration described above.

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Compensation  
Share-Based Compensation

Note 18: Share-Based Compensation

Successor Company

Successor Awards

In connection with the Business Combinations, Foresight’s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), in order to facilitate the grant of cash and equity incentives to employees, consultants, and directors of the Company and certain affiliates. The 2021 Plan became effective on December 3, 2021. The following table sets forth a summary of Class V share-based compensation activity of the Successor Company:

Weighted

Weighted

    

Average

Average

Grant-Date

Time Based

Grant-Date

Performance

    

Fair Value

    

Units

    

Fair Value

    

Based Units

Outstanding and non-vested at December 31, 2021

$

9.20

 

5,471,400

$

 

Granted during period

 

 

 

 

Vested

 

9.20

 

4,977,273

 

 

Cancelled/forfeited

 

 

 

 

Outstanding and non-vested at September 30, 2022

$

9.20

 

494,127

$

 

Profit interest awards were issued as part of the Business Combination. Time-based units vest ratably over periods of between one month and two years, so long as the optionee stays employed. The time-based units have a weighted average remaining time to vest of 0.12 years at September 30, 2022.

Stock-Based Compensation Expense

The Company recorded $1,783,994 and $17,210,974 of stock-based compensation cost for the three and nine months ended September 30, 2022, respectively, which is classified in Corporate, General and Administrative Expenses. As of September 30, 2022, there was $7,233,627 of unrecognized equity-based compensation cost. The Company did not recognize any tax benefits related to stock-based compensation for the nine months ended September 30, 2022. The Company accounts for forfeitures of awards as they occur.

Stock Options

The following table summarizes stock option activities for the nine months ended September 30, 2022:

Weighted 

Average 

Number of 

Weighted 

Remaining 

Options 

Average 

Contractual 

    

Outstanding

    

Exercise Price

    

Life (Years)

Outstanding and non-vested at December 31, 2021

$

Granted

2,034,279

6.43

3.10

Vested

91,667

5.02

Cancelled/forfeited

Outstanding and non-vested at September 30, 2022

 

1,942,612

 

$

6.50

 

2.52

The majority of the stock options issued during the period follow a time-based vesting schedule. Most stock options vest ratably over a period between two and five years, so long as the optionee continues to provide services to the Company. Stock options are exercisable into shares of Class V Common Stock. In addition to the time-based units, the Company granted 100,000 performance-based option units to an employee during the period with a strike price of $5.02. The vesting criteria for these units has not yet been achieved, therefore no expense has been recorded in relation to these units.

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) per Share
9 Months Ended
Sep. 30, 2022
Earnings (Loss) per Share  
Earnings (Loss) per Share

Note 19: Earnings (Loss) per Share

Loss per Share – Successor Period

Basic earnings per share is calculated as net income divided by the average number of shares of common stock outstanding. Diluted earnings per share assumes, when dilutive, the issuance of the net incremental shares from restricted shares. The following is a reconciliation of the denominators of the basic and diluted per share computations for net income:

    

Successor

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

2022

    

2022

Numerator - Basic:

Net loss

$

(65,329,041)

 

$

(1,029,225,234)

Less: Net loss attributable to Non-controlling interest

 

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Basic

 

(11,173,183)

(176,100,636)

Numerator - Diluted:

Net loss attributable to Class A Common Stockholders - Basic

$

(11,173,183)

$

(176,100,636)

Add: Net loss and tax effect attributable to Non-controlling interest

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Diluted

(65,329,041)

(1,029,225,234)

Denominator - Basic:

Weighted average Class A common shares outstanding - Basic

 

41,578,890

41,578,890

Loss per share attributable to Class A common shareholders - Basic

 

$

(0.27)

$

(4.24)

Denominator - Diluted:

Weighted average Class A common shares outstanding - Basic

41,578,890

41,578,890

Weighted average effect of dilutive Class V shares

201,457,191

199,684,102

Weighted average Class A common shares outstanding - Diluted

243,036,081

241,262,992

Loss per share attributable to Class A common shareholders - Diluted

$

(0.27)

$

(4.27)

The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive. The liability-classified Public and Private Warrants are out of the money and thus have no impact on diluted EPS:

    

Successor

As of September 30, 2022

Public Warrants

 

10,591,605

Private Warrants

 

227,500

Restricted Shares

 

494,127

Options

 

2,134,279

 

13,447,511

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Premium Deficiency Reserve
9 Months Ended
Sep. 30, 2022
Premium Deficiency Reserve  
Premium Deficiency Reserve

Note 20: Premium Deficiency Reserve

The Company assesses the profitability of our at-risk share savings arrangements to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a PDR is recognized. Management concluded a PDR of $27,719,928 and $37,835,642 existed at September 30, 2022 and December 31, 2021, respectively, which represented its estimate of probable contract losses expected to be generated by the Company’s contracts with its health plan partners.

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
9 Months Ended
Sep. 30, 2022
Leases  
Leases

Note 21: Leases

The Company leases real estate in the form of corporate office space and operating facilities. The Company additionally leases certain machinery in the form of office equipment. Generally, the term for real estate leases ranges from one to eight years at inception of the contract. Generally, the term for equipment leases is one to three years at inception of the contract. Some real estate leases include one to two options to renew that can extend the original term by five to ten years.

The Company entered one new operating lease in the nine months ended September 30, 2022. On June 9, 2022, the company entered into the first amendment to the lease agreement for its lease in Henderson, NV. This lease amendment will expand the premises to include three other suites in the same building and extend the term of the lease 94 months commencing on October 1, 2022, after the original lease matured on September 30, 2022. As a result of the lease modification related to the existing premises, ROU Assets and Liabilities increased $3.1 million.

Additionally, during the three months ended September 30, 2022, the Company acquired four new leases as a part of the medical practice acquisitions, as described in Note 7 “Business Combinations.” The acquisitions and related addition to ROU Assets and Liabilities were determined to be immaterial for disclosure.

Operating lease costs are included within operating expenses in the condensed consolidated statements of operations. The Company does not have any finance leases, short-term lease costs, nor any sublease income.

Successor

    

Predecessor

Three Months Ended

Three Months Ended

    

September 30, 2022

    

September 30, 2021

Lease costs

    

$

901,079

    

$

688,104

Successor

    

Predecessor

Nine Months Ended

Nine Months Ended

September 30, 2022

    

September 30, 2021

Lease costs

$

2,374,789

$

1,740,067

Lease terms and discount rates consisted of the following at each of the periods presented below:

Successor

    

Predecessor

 

Nine Months Ended

Nine Months Ended

 

    

September 30, 2022

    

September 30, 2021

Weighted average remaining lease term (years)

 

6.42

 

5.09

Weighted average discount rate

 

11.7

%  

11.2

%

The table below reconciles the undiscounted future minimum lease payments under noncancelable operating leases with terms of more than one year to the total operating and finance lease liabilities recognized on the condensed consolidated balance sheets as of the dates presented.

    

September 30, 2022

October 1, 2022 to December 31, 2022

$

712,565

2023

 

1,347,234

2024

 

2,958,684

2025

 

2,602,888

2026

 

1,950,448

Thereafter

 

4,619,793

Total Payments

 

14,191,612

Less: Interest

 

(2,821,505)

Present Value of Lease Liabilities

$

11,370,107

The current portions of ROU liabilities of $213,158 and $2,087,235 are included in Accounts Payable and Accrued Expenses in the Company’s condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively.

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Non-Controlling Interests
9 Months Ended
Sep. 30, 2022
Redeemable Non-Controlling Interests.  
Redeemable Non-Controlling Interests

Note 22: Redeemable Non-Controlling Interests

Non-controlling interests represents the portion of P3 LLC that the Company controls and consolidates but does not own (i.e., the P3 LLC Common Units held directly by the shareholders other than the Company). The non-controlling interests represent an approximately 83% ownership in P3 LLC as of September 30, 2022.

Generally, P3 LLC Common Units participate in net income or loss allocations and distributions and entitle their holder to the right, subject to the terms set forth in the limited liability agreement, to require P3 to redeem all or a portion of the Common Units held by such participant, together with a corresponding number of shares of Class V Common Stock, in exchange for Class A Common Stock or at the Company’s option, and subject to certain limitations, in cash. As the noncontrolling interest holders have approximately an 83% voting interest in P3 LLC through their Class V Common Stock and can appoint most of the initial members to the Board of Directors, the ability to elect cash settlement upon redemption is outside of the control of the Company.

The P3 LLC Common Units held by outside shareholders have been classified as redeemable noncontrolling interest in the Company. The cash redemption feature is considered outside of the control of the Company for the reason described above. Therefore, in accordance with ASC Topic 480, Distinguishing Liabilities from Equity, the P3 LLC Units are classified as temporary equity in the Company’s condensed consolidated balance sheets.

The redeemable noncontrolling interest was initially measured at its fair value on December 3, 2021. Net income or loss is attributed to the redeemable noncontrolling interest during each reporting period based on its ownership percentage, as appropriate. Subsequent to that, the redeemable noncontrolling interest is measured at its fair value (i.e., based on the Class A stock price) at the end of each reporting period, with the remeasurement amount being no less than the initial value, as adjusted for the redeemable noncontrolling interest’s share of net income or loss. The offset of any fair value adjustment is recorded to equity, with no impact to net income or loss. As of September 30, 2022, the fair value of redeemable non-controlling interest was higher than the carrying value and thus, a remeasurement adjustment of $19,375,288 was recorded to redeemable non-controlling interests with an offset to additional paid in capital. As of December 31, 2021, the fair value of redeemable non-controlling interest was lower than the initial value and there was no remeasurement adjustment recorded.

In addition, pursuant to the Agreement and Plan of Merger, all non-controlling interest holders are subject to certain lock-up period and as a result, there was no exchange or redemption activity as of September 30, 2022 and December 31, 2021.

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies.  
Commitments and Contingencies

Note 23: Commitments and Contingencies

Commitments

The Company has non-cancelable contractual agreements primarily related to leases. For additional discussion on leases, see Note 21 “Leases.”.

Contingencies

The Company is a party to various claims, legal and regulatory proceedings, lawsuits and administrative actions arising in the ordinary course of business and associated with the Business Combinations. The Company carries general and professional liability insurance coverage to mitigate the Company’s risk of potential loss in such cases. An accrual is established when a specific contingency is probable and estimable. The Company also faces contingencies that are reasonably possible to occur that cannot currently be estimated. The Company believes that disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, net loss or cash flows. It is the Company’s policy to expense costs associated with loss contingencies, including any related legal fees, as they are incurred.

In 2021, a discrepancy was identified in the service agreement with one of the Company’s health plans resulting in a renegotiation of the agreement. As of the date of issuance of this Form 10-Q, the renegotiation was in process. The Company has determined it is reasonably possible that resolution of this discrepancy will result in a payment to the health plan of approximately $10.6 million. This contingent liability was reflected in the Company’s financial statements presented in the 2021 Form 10-K. In the fourth quarter of 2021 during the Predecessor Period, the Company recorded a $3.6 million reduction in operating revenue and a $7.0 million charge to operating expense to account for amounts not previously recorded.

Uncertainties

The healthcare industry is subject to numerous laws and regulations of Federal, state, and local governments. These laws and regulations include, but are not limited to, matters of licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare / Medicaid Fraud, Waste and Abuse Prevention. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of Fraud, Waste and Abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties as well as significant repayment for patient services billed.

Management believes the Company is compliant with Fraud, Waste and Abuse regulations as well as other applicable government laws. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as other regulatory actions which might be unknown at this time.

Healthcare reform legislation at both the Federal and state levels continues to evolve. Changes continue to impact existing and future laws and rules. Such changes may impact the manner in which the Company conducts business, restrict the Company’s revenue growth in certain eligibility categories, slow down revenue growth rates for certain eligibility categories, increase certain medical, administrative and capital costs, and expose the Company to increased risk of loss or further liabilities. As a result, the Company’s consolidated financial position could be impacted by such changes.

COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated COVID 19 a global pandemic. The rapid spread of COVID 19 around the world and throughout the U.S. has altered the behavior of businesses and people, with significant negative effects on Federal, state, and local economies, the duration of which continues to remain unknown. Various mandates were implemented by Federal, state, and local governments in response to the pandemic, which caused many people to remain at home along with forced closure of or limitations on certain businesses. This included suspension of elective procedures by healthcare facilities. While restrictions have been eased across the U.S. and most states have lifted moratoriums on non-emergency procedures, some restrictions remain in place. COVID 19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of the Company’s patients.

The COVID 19 pandemic did not have a material impact on the Company’s revenues for the nine-month period ended September 30, 2022 and the year ended December 31, 2021. Nearly 99% of the Company’s total revenues are recurring, consisting of fixed monthly PMPM capitation payments received from Medicare Advantage health plans. Based on claims paid to date, direct costs associated with COVID-19 claims was approximately $93.3 million for the period March 1, 2020 through September 30, 2022. Management instituted multiple safety measures for the Company’s employees including a work-from-home policy and access to free vaccinations and personal protective equipment.

The full extent to which COVID 19 will directly or indirectly impact the Company, its future results of operations and financial condition will depend on factors which are highly uncertain and cannot be accurately predicted. This includes new and emerging information from the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on the Company’s markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, government imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these and other uncertainties, management cannot estimate the length or severity of the impact of the pandemic on the Company’s business. Furthermore, because of the Company’s business model, the full impact of COVID 19 may not be fully reflected in the Company’s results of operations and overall financial condition until future periods. However, management continues to closely evaluate and monitor the nature and extent of these potential impacts to the Company’s business, results of operations and liquidity.

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties
9 Months Ended
Sep. 30, 2022
Related Parties  
Related Parties

Note 24: Related Parties

Intercompany Transactions

P3 has entered into agreements (“Services Agreements”) with the Network, under which P3 provides the Network with certain management, administrative, and other non-medical support services.

The Company and its subsidiaries have “Deficit Funding Agreements” with the Network, whereby the Company or its subsidiaries provide loans (“Advances”) from time to time principally for the purpose of working capital support.  Net Advances made to the Network and accrued interest expense in the three-month period ended September 30, 2022 were as follows:

    

Successor

September 30, 2022

Balance at December 31, 2021

$

27,907,247

Advanced During Period

 

1,742,914

Interest Accrued During period

 

463,905

Balance at September 30, 2022

$

30,114,066

Advances, in most cases, have been constructively made by P3 Health Group Holdings, LLC on P3 NV’s behalf, and were therefore deemed Advances made by P3 NV. P3 NV’s Advances to BACC include all years prior, for which balances have, historically, not been settled periodically between the Parties and, thus have carried forward one year to the next. However, all transactions related to these Services and Deficit Funding Agreements (including accrued interest) have been eliminated in consolidation.

There were no advances transacted between P3 NV and KWA during the periods ended September 30, 2022 or December 31, 2021.

Atrio Health Plans

Successor

    

Three Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

35,365,746

Management Fees

 

570,500

Claims Paid

 

39,861,830

    

Successor

Nine Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

127,505,484

Management Fees

 

1,716,134

Claims Paid

 

137,367,493

Atrio Health Plans was established in 2004 and has since grown to serve Medicare beneficiaries in numerous counties throughout Oregon. Atrio works closely with local providers to improve healthcare outcomes of the population(s) served. In 2019, Chicago Pacific Founders (“CPF”) made an equity investment in Atrio. CPF is also a principal holder of shares of Class V Common Stock and Common Units of P3 LLC. Beginning in 2020, the Company has a Full-Risk capitation agreement in place with Atrio whereby the Company is delegated to perform services on behalf of Atrio’s members assigned to the Company. These delegated services include but are not limited to provider network credentialing, patient authorizations and medical management (care management, quality management and utilization management).

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entities
9 Months Ended
Sep. 30, 2022
Variable Interest Entities  
Variable Interest Entities

Note 25: Variable Interest Entities

The Company prepares its consolidated financial statements in accordance with ASC 810, Consolidation, which provides for the consolidation of VIEs of which an entity is the primary beneficiary.

In connection with the Business Combinations further described in Note 1 and Note 7, the Company became the sole managing member of P3 LLC. The rights of the non-managing members of P3 LLC are limited and protective in nature and do not give substantive participation rights over the sole managing member. As a result, P3 LLC is considered a VIE. As the sole managing member, the Company has the right to direct the most significant activities of P3 LLC and the obligation to absorb losses and receive benefits and accordingly is considered the primary beneficiary.

Additionally, P3 LLC is the primary beneficiary of the Network.

P3, LLC entered Stock Transfer Restriction Agreements with the Practice Shareholders of the Network. The Stock Transfer Restriction Agreements, by way of a call option, unequivocally permit P3 LLC to appoint Successor Physicians if a Practice Shareholder vacates their ownership position.

Pursuant to ASC 810, Consolidation, both the “power of control” and “economics” criteria were reviewed for VIE consideration. P3 LLC’s ability to appoint Successor Physicians the Network demonstrates “power of control”. Also, there are Deficit Funding Agreements in place between P3 LLC and the Network. The Deficit Funding Agreement between P3 LLC and the members of the Network states that P3 LLC will advance funds, as needed, to support working capital needs to the extent operating expenses exceed gross revenue. These funding arrangements further illustrate and fulfill the economic criteria for VIE consolidation.

Practice Shareholders, who are employees of the Company, retain equity ownership in the Network, which represents nominal noncontrolling interests. The noncontrolling interests do not participate in the profit or loss of the Network, however.

P3 LLC, directly or indirectly via its wholly-owned subsidiaries, may not use or access any net assets of these VIEs to settle its obligations or the obligations of its wholly-owned subsidiaries.

The following tables provide a summary of the VIE’s assets, liabilities and operating performance.

Successor

ASSETS

    

September 30, 2022

    

December 31, 2021

Cash

$

5,413,965

$

7,570,247

Client Fees and Insurance Receivable, net

 

16,653

 

60,815

Prepaid Expenses and Other Current Assets

 

1,353,408

 

406,372

Property, Plant and Equipment, net

 

44,494

 

36,416

Investment in Other P3 Entities

 

6,000,000

 

6,000,000

TOTAL ASSETS

 

12,828,520

 

14,073,850

LIABILITIES AND MEMBERS’ DEFICIT

 

  

 

  

Accounts Payable and Accrued Expenses

 

7,653,560

 

4,804,704

Accrued Payroll

 

2,233,567

 

1,303,615

Due to Consolidated Entities of P3

 

27,001,570

 

24,110,831

TOTAL LIABILITIES

 

36,888,697

 

30,219,150

MEMBERS’ DEFICIT

 

(24,060,177)

 

(16,145,300)

TOTAL LIABILITIES AND MEMBERS’ DEFICIT

$

12,828,520

$

14,073,850

Successor

Predecessor

    

Three Months Ended

    

Three Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

13,594,142

$

1,905,404

Expenses

 

15,731,721

 

4,707,369

Net Loss

$

(2,137,579)

$

(2,801,965)

Successor

Predecessor

    

Nine Months Ended

    

Nine Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

39,462,716

$

5,815,261

Expenses

 

46,708,335

 

13,858,939

Net Loss

$

(7,245,619)

$

(8,043,678)

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants
9 Months Ended
Sep. 30, 2022
Warrants.  
Warrants

Note 26: Warrants

As of December 31, 2020, there were 858,351 Class D warrants outstanding for the predecessor entity. In conjunction with the Term Loan issued November 19, 2020, the predecessor entity issued 858,351 10-year warrants to purchase shares of Series D Preferred Units at $4.68 per share. The warrants were recorded as a liability on the consolidated balance sheet with a balance of $6,316,605 as of December 31, 2020. During the year ended December 31, 2020, no change in the fair value of the warrant liability was recognized in the consolidated statements of operations. During 2021, 858,351 warrants were exercised on a cashless basis, with an exercise price of $4.68 per share as part of the Business Combination. There are no Class D Warrants outstanding as of September 30, 2022 and December 31, 2021.

As of September 30, 2022 and December 31, 2021, there were an aggregate of 10,819,105 warrants outstanding, which include the Public Warrants and Private Placement Warrants. Each warrant entitles the holder to purchase one share of Class A Common Stock at a price of $11.50 per share. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire five years after the completion of a Business Combinations. The Company has the right to redeem the Public Warrants when the price per Class A ordinary share equals or exceeds $18.00 for 20 days within a 30-day trading period. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants are subject to certain transfer restrictions, are not redeemable by the Company if they are held by Sponsors, and are exercisable on a cashless basis.

The Public Warrants and Private Placement Warrants are recorded as a liability on the consolidated balance sheets with a balance of $7,996,432 and $11,382,826 as of September 30, 2022 and December 31, 2021, respectively. A loss of $2,567,423 and a gain of $3,386,394 were recognized in the three months and nine months ended September 30, 2022, respectively, and a loss of $1,401,686 and $12,063,265 was recognized in the three months and nine months ended September 30, 2021, respectively from the change in fair value of the warrant liability in the consolidated statements of operations. During the nine months ended September 30, 2022 and the year ended December 31, 2021, zero Public Warrants and Private Placement Warrants were exercised.

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Significant Accounting Policies  
Principles of Consolidation

Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities,” the Company is the primary beneficiary of the following physician practices (“Network”):

Kahan, Wakefield, Abdou, PLLC (“KWA”)
Bacchus, Wakefield, Kahan, PC (“BACC”)
P3 Health Partners Professional Services PC
P3 Medical Group, P.C.
P3 Health Partners California, P.C.

All intercompany accounts and transactions have been eliminated in consolidation.

Variable Interest Entities ("VIE" or "VIEs")

Variable Interest Entities

Management analyzes whether the Company has any financial interests in Variable Interest Entities (“VIE” or “VIEs”). This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.

Segment Reporting

Segment Reporting

The Company presents its financial statements by segment in accordance with ASC Topic No. 280, Segment Reporting (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined that the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment, which reflects how the CODM manages the Company.

Management's Use of Estimates

Management’s Use of Estimates

Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.

The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.

Earnings (Loss) per Share and Member Unit

Earnings (Loss) per Share and Member Unit

Basic and diluted net loss per share attributable to common stockholders in the Successor Periods is presented in conformity with the two-class method required for participating securities. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.

The Company analyzed the calculation of net loss per member unit for the Predecessor Periods and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Periods.

Cash and Restricted Cash

Cash and Restricted Cash

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At September 30, 2022 and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.

At September 30, 2022 and December 31, 2021, the Company had unrestricted cash of $34,357,237 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.

Successor

    

September 30, 2022

    

December 31, 2021

Unrestricted

$

34,357,237

$

140,477,586

Restricted

 

1,003,307

 

356,286

Total Cash Balances

$

35,360,544

$

140,833,872

Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.

The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at September 30, 2021, that sum to the total of these items reported in the condensed consolidated statements of cash flows.

Predecessor

    

September 30, 2021

Unrestricted

$

4,336,565

Restricted

 

346,299

Total Cash Balances

$

4,682,864

Revenue Recognition and Revenue Sources

Revenue Recognition and Revenue Sources

The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:

Successor

Predecessor

 

 

 

Three Months Ended

Three Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Capitated Revenue

$

243,988,004

 

98.3

%  

$

153,072,995

 

98.0

%

Other Patient Service Revenue:

 

  

 

  

 

  

 

  

Clinical Fees & Insurance Revenue

 

1,956,604

 

0.8

%  

 

1,278,339

 

0.8

%

Shared Risk Revenue

 

 

0.0

%  

 

139,331

 

0.1

%

Care Coordination / Management Fees

 

1,729,800

 

0.7

%  

 

1,146,355

 

0.7

%

Incentive Fees

 

585,665

 

0.2

%  

 

548,935

 

0.4

%

Total Other Patient Service Revenue

 

4,272,069

 

1.7

%  

 

3,112,960

 

2.0

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

  

  

Nine Months Ended

Nine Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

(As Restated)

    

% of Total

Capitated Revenue

$

780,775,285

 

98.7

%  

$

443,598,050

 

98.1

%

Other Patient Service Revenue:

 

  

 

  

 

Clinical Fees & Insurance Revenue

 

4,103,481

 

0.5

%  

 

3,386,966

 

0.7

%

Shared Risk Revenue

 

55,154

 

0.0

%  

 

341,342

 

0.1

%

Care Coordination / Management Fees

 

4,412,973

 

0.6

%  

 

2,994,755

 

0.7

%

Incentive Fees

 

1,911,485

 

0.2

%  

 

1,749,225

 

0.4

%

Total Other Patient Service Revenue

 

10,483,093

 

1.3

%  

 

8,472,288

 

1.9

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:

Successor

Predecessor

 

 

  

  

Three Months Ended

Three Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Health Plan C

$

48,538,454

 

19.5

%  

$

29,563,741

 

18.9

%

Health Plan B

 

46,082,052

 

18.5

%  

 

38,227,530

 

24.5

%

Health Plan A

 

35,936,246

 

14.5

%  

 

36,417,184

 

23.3

%

Health Plan D

 

31,563,532

 

12.8

%  

 

18,913,641

 

12.1

%

All Other

 

86,139,789

 

34.7

%  

 

33,063,859

 

21.2

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

 

Nine Months Ended

Nine Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

  

    

(As Restated)

    

% of Total

Health Plan C

$

158,252,527

 

20.0

%  

$

84,489,621

 

18.7

%

Health Plan B

 

139,920,223

 

17.7

%  

 

105,261,569

 

23.3

%

Health Plan A

 

124,681,687

 

15.8

%  

 

114,230,860

 

25.3

%

Health Plan D

 

104,439,689

 

13.2

%  

 

56,606,725

 

12.5

%

All Other

 

263,964,252

 

33.3

%  

 

91,481,563

 

20.2

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.

Capitated Revenue

The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on the health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.

The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.

Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first three quarters in 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).

At September 30, 2022 and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across five states) and 17 health plans (across four states), respectively.

Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within twenty-one months following each year-end.

At September 30, 2022, and December 31,2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:

    

Health Plan Receivables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

524,540

$

4,695,712

Health Plan B

 

24,387,307

 

15,473,828

Health Plan C

 

28,798,095

 

1,380,752

Health Plan D

 

15,136,034

 

6,651,586

Health Plan E

 

184,332

 

2,439,046

Health Plan F

 

1,467,834

 

2,925,751

Health Plan G

 

35,179

 

239,375

Health Plan H

 

3,570,820

 

2,185,619

Health Plan I

 

1,586,752

 

1,134,750

Health Plan J

 

(102,380)

 

149,915

Health Plan K

 

 

2,705,147

Health Plan L

 

 

899,560

Health Plan M

 

1,388,190

 

1,747,116

Health Plan N

 

598,056

 

974,092

Health Plan O

 

2,279,489

 

666,291

Health Plan P

 

511,469

 

106,162

Health Plan Q

 

476,057

 

61,990

Health Plan R

 

 

3,578,682

Health Plan S

 

600,639

 

Health Plan T

 

57,607

 

2,175,324

Health Plan U

 

 

60,306

Health Plan W

 

(2,317)

 

Total Health Plan Receivables

$

81,497,703

$

50,251,004

    

Health Plan Settlement Payables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

2,579,575

$

Health Plan B

 

11,700,274

 

11,700,274

Health Plan D

 

 

3,882,250

Health Plan F

 

5,103,534

 

6,085,425

Health Plan G

 

900,314

 

776,164

Health Plan I

 

(10,915)

 

(215,626)

Health Plan O

 

39,365

 

(39,151)

Health Plan U

 

226,209

 

226,209

Health Plan V

 

88,480

 

133,149

Total Health Plan Settlement Payables

$

20,626,836

$

22,548,694

At September 30, 2022, and December 31, 2021, management has deemed the Company’s settlement receivables to be fully collectible from those health plans where the Company is not delegated for claims processing. Accordingly, a constraint on the variable consideration associated with settlement receivables is not necessary.

Other Patient Service Revenue – Clinical Fees and Insurance Revenue

Clinic fees and insurance revenues relate to net patient fees received from various payers and direct patients (“self-payers”) under contracts in which the Company’s sole performance obligation is to provide healthcare services through the operation of medical clinics. The Company recognizes clinic fees and insurance revenue in the period in which services are provided, on the date of service, under FFS payment arrangements, revenue is recognized on the date of service. The Company’s performance obligations are typically satisfied in the same day services are provided. All the Company’s contracts with its customers under these arrangements include a single performance obligation.

The Company’s contractual relationships with patients, in most cases, also involve third-party payers (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through state-sponsored health insurance exchanges). Transaction prices for services provided are dependent upon specific rules in place with third party payers – specifically, Medicare/Medicaid and pre-negotiated rates with managed care health plans and commercial insurance companies. Contractual arrangements with third parties typically include payments at amounts which are less than standard charges. These charges generally have predetermined rates for diagnostic service codes or discounted FFS rates. Management perpetually reviews the Company’s contractual estimation processes to consider and incorporate updates to laws, regulations and frequent changes in the managed care system. Contractual terms are negotiated and updated accordingly upon renewal.

The Company’s revenue is based upon the estimated amounts management expects to receive from patients and third-party payers. Estimates of explicit price concessions under managed care and commercial insurance plans are tied to payment terms specified in related contractual agreements. Retroactively calculated explicit price concessions tied to reimbursement agreements with third-party payers are recognized on an estimated basis in the period related services are rendered and adjusted in future periods as final payments are received. Revenue related to uninsured patients, uninsured co-payments, and deductibles (for patients with healthcare coverage) may also be discounted. The Company records implicit price concessions (based on historical collection experience) related to uninsured accounts to recognize self-pay revenues at their most likely amounts to be collected.

The Company deems FFS revenue to be variable consideration and that its estimates of associated transaction prices will not result in a significant revenue reversal in the future.

Based on satisfaction of single performance obligations occurring on the dates of service, revenue is recognized as of the date services are provided. The Company, therefore, applies a portfolio approach to recognizing revenue from its FFS contracts.

Management has elected two of the available practical expedients provided for by ASC 606. First, the Company did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.

Other Patient Service Revenue – Shared Risk Revenue

P3 LLC (via one of its wholly owned subsidiaries – P3 Health Partners ACO, LLC “AzCC”) receives 30% of the shared risk savings from parties with whom it contracts under four separate arrangements. These arrangements are driven solely by medical cost containment year-over-year (“YoY”) expense reductions. This key performance indicator (“KPI”) is measured by the aggregate change in per member per year (“PMPY”) medical costs. If the sequential YoY PMPY aggregate change yields a reduction, the Company receives 30% of the associated total cost savings for that year. Conversely, if the sequential YoY PMPY aggregate change yields an increase in medical costs, no monies are due the Company that year. This KPI is compiled and reviewed on a calendar year basis. The Company recognizes shared risk revenue only upon the receipt of cash. Therefore, the likelihood of any significant revenue reversal in the future is non-existent.

Other Patient Service Revenue – Care Coordination Fees and Management Fees

The Company’s delegated health plans may also pay a Care Coordination Fee (“CCF”) or Management Fee to the Company. CCFs and Management Fees are intended to fund the costs of delegated services provided to certain health plans. CCFs are specifically identified and separated in each monthly capitation payment the Company receives from these parties. None of the Company’s other health plans bifurcate CCFs nor are any of them contractually required to do so.

The Company uses a portfolio approach to account for CCFs and Management Fees. Based on similarities of the terms of the care coordination and administrative services, management believes that revenue recognized by utilizing the portfolio approach approximates that which it would have realized if an individual contract approach were applied.

Patient Fees Receivable

Substantially, all client fees and insurance receivables are due under FFS contracts with third party payors, such as commercial insurance companies (“Commercial”), government-sponsored healthcare programs (“Medicare/Medicaid”) or directly from patients (“Self-Pay”). Management continuously monitors activities from payors (including patients) and records an estimated price concession based on specific contracts and actual historical collection patterns. Patient fees receivable, where a third-party payor is responsible for the amount due, are carried at amounts determined by the original charges for services provided less implicit and explicit price concessions. Price concessions represent amounts made for contractual adjustments (discounts). Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and are recorded net of contractual allowances.

Patient fees receivable are recorded at the invoiced amount, net of any expected contractual adjustments and implicit price concessions, and do not bear interest. The Company has agreements with third-party payors that provide for payments at amounts different from the established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Contractual adjustments arising under reimbursement arrangements with third- party payors are accrued on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined. Implicit price concessions are taken based on historical collection experience and reflect the estimated amounts the Company expects to collect.

Goodwill

Goodwill

In accordance with ASC 350, Intangibles - Goodwill and Other, management tests goodwill for impairment at the reporting unit level. The Company has one reporting unit for goodwill impairment testing purposes. Goodwill is tested for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate the carrying value of goodwill may not be recoverable (a “triggering event”). On the occurrence of a triggering event, an entity has the option to first assess qualitative factors to determine whether a quantitative impairment test is necessary. If it is more likely than not that goodwill is impaired, the fair value of the reporting unit (the Company) is compared with its carrying value. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value, provided, the loss recognized cannot exceed the total amount of goodwill. No goodwill impairment charges were recorded in the first quarter or third quarter of 2022, respectively. Based on management’s analysis, a goodwill impairment charge of $851.5 million was recorded in the second quarter of 2022. See Note 11 “Goodwill.”

Intangible Assets

Intangible Assets

Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. In determining the estimated useful lives of definite-lived intangibles, the Company considers the nature, competitive position, life cycle position and historical and expected future operating cash flows of each acquired asset, as well as its commitment to support these assets through continued investment and legal infringement protection.

The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. Such events and circumstances include the occurrence of an adverse change in the market involving the business employing the assets or a situation in which it is more likely than not that the Company will dispose of such assets. If the comparison indicates that there is impairment, the impairment loss to be recognized as a non-cash charge to earnings is measured by the amount by which the carrying amount of the asset exceeds its fair value. The impaired asset is written down to its fair value or, if fair value is not readily determinable, to an estimated fair value based on discounted expected future cash flows.

Fair Value Measurements

Fair Value Measurements

The Company accounts for fair value measurements in accordance with ASC 820, Fair Value Measurements (“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 8 “Fair Value Measurements and Hierarchy” for further discussion):

Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restatement of Previously Issued Financial Statements (Tables)
9 Months Ended
Sep. 30, 2022
Restatement of Previously Issued Financial Statements  
Summary of the effects of the restatement on each financial statement line item affected by the restatement as of the dates, and for the periods

The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:

    

As Previously

    

Network

    

Preferred Returns

    

Class A Units

    

Revenue

    

    

Reported

    

Adjustments

    

Adjustments

    

Adjustments

    

Adjustment

    

As Restated

Condensed Consolidated Statement of Operations for the Nine Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

447,137,121

$

$

$

$

(3,539,071)

$

443,598,050

Other Patient Service Revenue

 

12,366,111

 

 

 

 

(3,893,823)

 

8,472,288

Total Operating Revenue

 

459,503,232

 

 

 

 

(7,432,894)

 

452,070,338

Medical Expenses

 

459,233,085

 

 

 

 

(899,940)

 

458,333,145

Total Operating Expenses

 

520,053,309

 

 

 

 

(899,940)

 

519,153,369

Operating Loss

 

(60,550,077)

 

 

 

 

(6,532,954)

 

(67,083,031)

Interest Expense, net

 

(13,130,628)

 

 

6,107,441

 

 

 

(7,023,187)

Total Other Expenses

 

(25,193,893)

 

 

6,107,441

 

 

 

(19,086,452)

Net Loss Attributable to Non-Controlling Interests

 

(8,043,678)

 

8,043,678

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(77,700,292)

 

(8,043,678)

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2021 (Unaudited)

 

  

 

  

 

  

 

  

 

  

 

  

Capitated Revenue

$

152,276,992

$

$

$

$

796,003

$

153,072,995

Other Patient Service Revenue

 

4,243,263

 

 

 

 

(1,130,303)

 

3,112,960

Total Operating Revenue

 

156,520,255

 

 

 

 

(334,300)

 

156,185,955

Medical Expenses

 

161,662,423

 

 

 

 

(334,300)

 

161,328,123

Total Operating Expenses

 

184,643,797

 

 

 

 

(334,300)

 

184,309,497

Interest Expense, net

 

(4,643,254)

 

 

2,114,121

 

 

 

(2,529,133)

Total Other Expenses

 

(6,044,940)

 

 

2,114,121

 

 

 

(3,930,819)

Net Loss Attributable to Non-Controlling Interests

 

(2,801,965)

 

2,801,965

 

 

 

 

Net Loss (formerly Net Loss Attributable to Controlling Interests)

 

(31,366,517)

 

(2,801,965)

 

2,114,121

 

 

 

(32,054,361)

Condensed Consolidated Statement of Changes in Members' Deficit for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

2,779,619

$

$

(2,779,619)

$

$

$

Net Loss

 

(85,743,970)

 

 

6,107,441

 

 

(6,532,954)

 

(86,169,483)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Preferred Return at 8% for Class A Units

$

962,163

$

$

(962,163)

$

$

$

Net Loss

 

(34,168,482)

 

 

2,114,121

 

 

 

(32,054,361)

Balance as of September 30, 2021

 

(179,246,686)

 

 

7,895,224

 

(43,656,331)

 

 

(215,007,793)

Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

 

  

Net Loss

$

(85,743,970)

$

$

6,107,441

$

$

(6,532,954)

$

(86,169,483)

Health Plan Settlements Receivable/Premiums Receivable

 

(7,417,477)

 

 

 

 

6,532,954

 

(884,523)

Class A and Class D Preferred Returns

 

6,107,441

 

 

(6,107,441)

 

 

 

Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended June 30, 2021

Preferred Return at 8% for Class A Units

$

926,852

$

$

(926,852)

$

$

$

Net Loss

(24,967,931)

2,036,476

(6,532,955)

(29,464,410)

Balance as of June 30, 2021

(146,395,455)

6,743,106

(43,656,170)

(183,308,519)

Condensed Consolidated Statements of Changes in Members' Deficit for the 3 Months Ended March 31, 2021

Preferred Return at 8% for Class A Units

$

890,612

$

$

(890,612)

$

$

$

Net Loss

(26,607,560)

1,956,848

(24,650,712)

Balance as of March 31, 2021

(122,918,168)

5,633,581

(43,656,269)

6,532,954

(154,407,902)

Consolidated Statements of Changes in Members' Deficit for the Year Ended December 31, 2020

 

  

 

  

 

  

 

  

 

  

 

  

Balance as of December 31, 2020

$

(97,661,735)

$

$

4,567,346

$

(43,656,270)

$

6,532,954

$

(130,217,705)

*Rounding may cause variances

XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Significant Accounting Policies  
Summary of total cash balances

Successor

    

September 30, 2022

    

December 31, 2021

Unrestricted

$

34,357,237

$

140,477,586

Restricted

 

1,003,307

 

356,286

Total Cash Balances

$

35,360,544

$

140,833,872

Predecessor

    

September 30, 2021

Unrestricted

$

4,336,565

Restricted

 

346,299

Total Cash Balances

$

4,682,864

Summary of sources (by product type) from which the Company's revenues are derived

Successor

Predecessor

 

 

 

Three Months Ended

Three Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Capitated Revenue

$

243,988,004

 

98.3

%  

$

153,072,995

 

98.0

%

Other Patient Service Revenue:

 

  

 

  

 

  

 

  

Clinical Fees & Insurance Revenue

 

1,956,604

 

0.8

%  

 

1,278,339

 

0.8

%

Shared Risk Revenue

 

 

0.0

%  

 

139,331

 

0.1

%

Care Coordination / Management Fees

 

1,729,800

 

0.7

%  

 

1,146,355

 

0.7

%

Incentive Fees

 

585,665

 

0.2

%  

 

548,935

 

0.4

%

Total Other Patient Service Revenue

 

4,272,069

 

1.7

%  

 

3,112,960

 

2.0

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

  

  

Nine Months Ended

Nine Months Ended

September 30, 2021

Revenue Type

    

September 30, 2022

    

% of Total

    

(As Restated)

    

% of Total

Capitated Revenue

$

780,775,285

 

98.7

%  

$

443,598,050

 

98.1

%

Other Patient Service Revenue:

 

  

 

  

 

Clinical Fees & Insurance Revenue

 

4,103,481

 

0.5

%  

 

3,386,966

 

0.7

%

Shared Risk Revenue

 

55,154

 

0.0

%  

 

341,342

 

0.1

%

Care Coordination / Management Fees

 

4,412,973

 

0.6

%  

 

2,994,755

 

0.7

%

Incentive Fees

 

1,911,485

 

0.2

%  

 

1,749,225

 

0.4

%

Total Other Patient Service Revenue

 

10,483,093

 

1.3

%  

 

8,472,288

 

1.9

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

Summary of health plans from which the Company has a concentration of revenue that is 10.0%, or more

Successor

Predecessor

 

 

  

  

Three Months Ended

Three Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

    

    

(As Restated)

    

% of Total

Health Plan C

$

48,538,454

 

19.5

%  

$

29,563,741

 

18.9

%

Health Plan B

 

46,082,052

 

18.5

%  

 

38,227,530

 

24.5

%

Health Plan A

 

35,936,246

 

14.5

%  

 

36,417,184

 

23.3

%

Health Plan D

 

31,563,532

 

12.8

%  

 

18,913,641

 

12.1

%

All Other

 

86,139,789

 

34.7

%  

 

33,063,859

 

21.2

%

Total Revenue

$

248,260,073

 

100.0

%  

$

156,185,955

 

100.0

%

Successor

Predecessor

 

 

 

Nine Months Ended

Nine Months Ended

September 30, 2021

Plan Name

    

September 30, 2022

    

% of Total

  

    

(As Restated)

    

% of Total

Health Plan C

$

158,252,527

 

20.0

%  

$

84,489,621

 

18.7

%

Health Plan B

 

139,920,223

 

17.7

%  

 

105,261,569

 

23.3

%

Health Plan A

 

124,681,687

 

15.8

%  

 

114,230,860

 

25.3

%

Health Plan D

 

104,439,689

 

13.2

%  

 

56,606,725

 

12.5

%

All Other

 

263,964,252

 

33.3

%  

 

91,481,563

 

20.2

%

Total Revenue

$

791,258,378

 

100.0

%  

$

452,070,338

 

100.0

%

Summary of settlement receivables (health plan surpluses) and settlement payables (health plan deficits), by health plan, by year

    

Health Plan Receivables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

524,540

$

4,695,712

Health Plan B

 

24,387,307

 

15,473,828

Health Plan C

 

28,798,095

 

1,380,752

Health Plan D

 

15,136,034

 

6,651,586

Health Plan E

 

184,332

 

2,439,046

Health Plan F

 

1,467,834

 

2,925,751

Health Plan G

 

35,179

 

239,375

Health Plan H

 

3,570,820

 

2,185,619

Health Plan I

 

1,586,752

 

1,134,750

Health Plan J

 

(102,380)

 

149,915

Health Plan K

 

 

2,705,147

Health Plan L

 

 

899,560

Health Plan M

 

1,388,190

 

1,747,116

Health Plan N

 

598,056

 

974,092

Health Plan O

 

2,279,489

 

666,291

Health Plan P

 

511,469

 

106,162

Health Plan Q

 

476,057

 

61,990

Health Plan R

 

 

3,578,682

Health Plan S

 

600,639

 

Health Plan T

 

57,607

 

2,175,324

Health Plan U

 

 

60,306

Health Plan W

 

(2,317)

 

Total Health Plan Receivables

$

81,497,703

$

50,251,004

    

Health Plan Settlement Payables

Successor

September 30, 2022

December 31, 2021

Health Plan A

$

2,579,575

$

Health Plan B

 

11,700,274

 

11,700,274

Health Plan D

 

 

3,882,250

Health Plan F

 

5,103,534

 

6,085,425

Health Plan G

 

900,314

 

776,164

Health Plan I

 

(10,915)

 

(215,626)

Health Plan O

 

39,365

 

(39,151)

Health Plan U

 

226,209

 

226,209

Health Plan V

 

88,480

 

133,149

Total Health Plan Settlement Payables

$

20,626,836

$

22,548,694

XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations (Tables)
9 Months Ended
Sep. 30, 2022
Business Acquisition [Line Items]  
Summary of future consolidated results of operations

Nine Months Ended

September 30,

2021

    

(Unaudited)

Total Operating Revenue

$

567,305,732

Net Profit

(179,492,450)

Net Loss Attributable to Non-controlling Interest

(148,260,764)

Net Loss Attributable to Controlling Interest

$

(31,231,686)

P3 Llc  
Business Acquisition [Line Items]  
Summary of purchase consideration

    

Successor

December 31,

Foresight

2021

Equity

$

80,300,733

Fair Value of Non-controlling Interest

 

1,807,427,576

Stock Compensation Pre-combination Services

26,313,476

Cash Consideration

 

18,405,083

Payment of P3 Health Group Holdings, LLC’s Transaction Costs

 

19,151,752

Total Purchase Consideration

$

1,951,598,620

Summary of purchase price allocation to assets and liabilities

Purchase Price Allocation

    

Amounts

Assets Acquired:

Cash

$

5,300,842

Restricted Cash

 

54,095

Health Plan Settlement Receivables

 

47,733,033

Clinic Fees and Insurance Receivables, Net

 

426,064

Other Receivables

 

1,880,939

Prepaid Expenses and Other Current Assets

 

938,413

Property and Equipment, Net

 

7,875,234

Intangible Assets, Net:

 

  

Customer Relationships

 

684,000,000

Provider Network

 

3,700,000

Trademarks

 

147,700,000

Goodwill

 

1,278,452,778

Notes Receivable, Net

 

3,734,012

Right of Use Assets

 

6,870,279

Total Assets Acquired

$

2,188,665,689

Liabilities Assumed:

 

  

Accounts Payable and Accrued Expenses

$

25,819,091

Accrued Payroll

 

2,868,664

Health Plans Settlements Payable

 

25,007,542

Claims Payable

 

76,031,460

Premium Deficiency Reserve

 

11,559,067

Accrued Interest

 

9,268,846

Current Portion of Long-Term Debt

 

301,443

Lease Liability

 

6,210,956

Long-Term Debt, Net of Current Portion

 

80,000,000

Total Liabilities Assumed

$

237,067,069

Net Assets Acquired

$

1,951,598,620

Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition")  
Business Acquisition [Line Items]  
Summary of purchase price allocation to assets and liabilities

    

Successor Period

  

  

Predecessor Period

Assets Acquired:

Cash

$

20,547,337

$

3,000

Restricted Cash

 

302,187

 

Health Plan Settlement Receivables

 

5,754,006

 

Clinic Fees and Insurance Receivables, Net

 

141,186

 

Other Receivables

 

726,378

 

Prepaid Expenses and Other Current Assets

 

1,189,575

 

Property and Equipment, Net

 

113,436

 

5,896

Intangible Assets, Net:

 

 

Customer Relationships

 

 

2,045,604

Pay or Contracts

 

4,700,271

 

  

Provider Network

 

1,100,000

 

Trademarks

 

900,000

 

Medical Licenses

 

700,000

 

Goodwill

 

31,297,438

 

2,934,500

Total Assets Acquired

$

67,471,814

$

4,989,000

Liabilities Assumed:

 

  

 

  

Accounts Payable and Accrued Expenses

$

150,196

$

Accrued Payroll

 

277,074

 

Health Plans Settlements Payable

 

133,149

 

Claims Payable

 

26,898,074

 

Total Liabilities Assumed

 

27,458,493

 

Net Assets Acquired

$

40,013,321

$

4,989,000

XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy (Tables)
9 Months Ended
Sep. 30, 2022
Fair Value Measurements and Hierarchy  
Schedule of carrying amounts of financial instruments

    

Successor

    

September 30, 2022

    

December 31, 2021

Financial assets:

 

  

 

  

Cash

$

34,357,237

$

140,477,586

Restricted cash

 

1,003,307

 

356,286

Clinics fees and insurance receivables, net

 

1,049,253

 

1,090,104

Other receivables

 

2,736,184

 

726,903

Financial liabilities:

 

  

 

  

Accounts payable and accrued expenses

 

24,072,391

 

17,730,683

Warrants liabilities

 

7,996,432

 

11,382,826

Schedule of fair value hierarchy for financial liabilities

    

Level 1

    

Level 2

    

Level 3

    

Total

Warrant liability as of September 30, 2022

$

7,774,549

$

$

221,883

$

7,996,432

Warrant liability as of December 31, 2021

 

10,880,550

 

 

502,276

 

11,382,826

Summary of Level 3 inputs into option pricing model

The key Level 3 inputs into the option pricing model as of September 30, 2022 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

4.16

%

Exercise Price

$

11.50

Expected Term

 

4.2

Years

The key Level 3 inputs into the option pricing model as of December 31, 2021 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:

Volatility

    

60.00

%

Risk-Free Interest rate

 

1.26

%

Exercise Price

$

11.50

Expected Term

 

4.9

Years

Schedule of changes in the fair value

Successor

Predecessor

    

Nine Months Ended September

  

  

Nine Months Ended September

30, 2022

30, 2021

Beginning Balance of Private Warrant Liability

$

502,276

$

6,316,605

Mark-to-Market Adjustment for Stock Warrants

 

(280,393)

 

12,063,265

Ending Balance of Private Warrant Liability

$

221,883

$

18,379,870

XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Patient Fees Receivable (Tables)
9 Months Ended
Sep. 30, 2022
Patient Fees Receivable  
Schedule of patient fees receivable

Successor

    

September 30, 2022

    

December 31, 2021

Total Receivables: Gross

$

5,383,421

$

2,641,182

Less: Contractual Allowances

 

(4,745,367)

 

(1,968,750)

Receivables Net of Contractual Allowances

$

638,054

$

672,432

XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2022
Property and Equipment.  
Summary of property and equipment balances

Successor

    

September 30, 2022

    

December 31, 2021

Leasehold Improvements

$

1,809,927

$

1,537,091

Furniture & Fixtures

 

1,450,626

 

1,108,184

Computer Equipment & Software

 

2,852,746

 

2,700,617

Medical Equipment

 

1,066,959

 

414,100

Software (Development in Process)

 

3,918,615

 

2,433,470

Vehicles

373,995

Other

 

36,788

 

36,788

 

11,509,656

 

8,230,250

Less: Accumulated Depreciation

 

(1,994,380)

 

(182,321)

Property and Equipment, Net

$

9,515,276

$

8,047,929

XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill (Tables)
9 Months Ended
Sep. 30, 2022
Goodwill  
Summary of changes in goodwill

    

September 30, 2022

Balance at December 31, 2021

$

1,309,750,216

Acquisition

5,201,729

Impairment charge

 

(851,455,754)

Balance at September 30, 2022

$

463,496,191

XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2022
Intangible Assets  
Schedule of changes in other intangible assets

    

Customer

    

    

Provider

Medical

    

Relationships

    

Trademarks

    

Payor Contracts

    

Network

    

Licenses

    

Total

Balance at December 31, 2021

$

678,300,000

$

147,369,167

$

4,700,271

$

4,769,167

$

700,000

$

835,838,605

Amortization

 

(51,300,000)

 

(11,415,000)

 

(352,522)

 

(360,000)

 

 

(63,427,522)

Balance at September 30, 2022

$

627,000,000

$

135,954,167

$

4,347,749

$

4,409,167

$

700,000

$

772,411,083

XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Claims Payable (Tables)
9 Months Ended
Sep. 30, 2022
Claims Payable.  
Summary of activity in the liability for claims payable and healthcare expenses

    

Successor

Nine Months Ended

    

September 30, 2022

Claims Unpaid, Beginning of Period

$

101,958,324

Incurred, Related to:

 

  

Current Period

 

700,236,928

Prior Period(s)

 

5,024,653

Total Incurred

 

705,261,581

Paid, Related to:

 

  

Current Period

 

570,830,033

Prior Period(s)

 

101,684,446

Total Paid

 

672,514,479

Claims Unpaid, End of Period

$

134,705,426

XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt (Tables)
9 Months Ended
Sep. 30, 2022
Long-Term Debt.  
Schedule of rollforward the long-term debt balances

Successor

    

LTD-A

    

LTD-C

    

LTD-D

    

LTD-E

    

Total

Balance at December 31, 2021

$

$

15,000,000

$

65,000,000

$

46,101

$

80,046,101

Issued in 2022

 

 

 

 

 

Principal Payments in 2022

 

 

 

 

(46,101)

 

(46,101)

Balance at September 30, 2022

$

$

15,000,000

$

65,000,000

$

$

80,000,000

Schedule of long tern debt fiscal maturity disclosures

    

    

Interest

    

Total Cash

    

Principal

    

PIK

    

Cash Interest

    

Payments*

October 1, 2022 to December 31, 2022

$

$

1,342,321

$

1,401,192

$

1,401,192

2023

 

 

5,624,513

 

5,675,461

 

5,675,461

2024

 

 

6,061,814

 

5,882,309

 

5,882,309

2025

 

65,000,000

 

6,274,526

 

19,518,225

 

84,518,225

2026

 

15,000,000

 

1,851,284

 

20,054,451

 

35,054,451

Total

$

80,000,000

$

21,154,458

$

52,531,638

$

132,531,638

*    Total Payments Cash and Non-Cash (PIK)

Schedule of total payments cash and non-Cash of interest

    

Successor

    

September 30, 2022

    

December 31, 2021

Total Principal

$

80,000,000

$

80,046,101

Less: Current Portion of Long-Term Debt

 

 

(46,101)

Long Term Debt

$

80,000,000

$

80,000,000

XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Compensation  
Schedule of number of Class V share-based compensation activity

Weighted

Weighted

    

Average

Average

Grant-Date

Time Based

Grant-Date

Performance

    

Fair Value

    

Units

    

Fair Value

    

Based Units

Outstanding and non-vested at December 31, 2021

$

9.20

 

5,471,400

$

 

Granted during period

 

 

 

 

Vested

 

9.20

 

4,977,273

 

 

Cancelled/forfeited

 

 

 

 

Outstanding and non-vested at September 30, 2022

$

9.20

 

494,127

$

 

Schedule of stock option activity

Weighted 

Average 

Number of 

Weighted 

Remaining 

Options 

Average 

Contractual 

    

Outstanding

    

Exercise Price

    

Life (Years)

Outstanding and non-vested at December 31, 2021

$

Granted

2,034,279

6.43

3.10

Vested

91,667

5.02

Cancelled/forfeited

Outstanding and non-vested at September 30, 2022

 

1,942,612

 

$

6.50

 

2.52

XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) per Share (Tables)
9 Months Ended
Sep. 30, 2022
Earnings (Loss) per Share  
Schedule of computation of net loss per share and weighted average shares

    

Successor

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

2022

    

2022

Numerator - Basic:

Net loss

$

(65,329,041)

 

$

(1,029,225,234)

Less: Net loss attributable to Non-controlling interest

 

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Basic

 

(11,173,183)

(176,100,636)

Numerator - Diluted:

Net loss attributable to Class A Common Stockholders - Basic

$

(11,173,183)

$

(176,100,636)

Add: Net loss and tax effect attributable to Non-controlling interest

(54,155,858)

(853,124,598)

Net loss attributable to Class A common stockholders - Diluted

(65,329,041)

(1,029,225,234)

Denominator - Basic:

Weighted average Class A common shares outstanding - Basic

 

41,578,890

41,578,890

Loss per share attributable to Class A common shareholders - Basic

 

$

(0.27)

$

(4.24)

Denominator - Diluted:

Weighted average Class A common shares outstanding - Basic

41,578,890

41,578,890

Weighted average effect of dilutive Class V shares

201,457,191

199,684,102

Weighted average Class A common shares outstanding - Diluted

243,036,081

241,262,992

Loss per share attributable to Class A common shareholders - Diluted

$

(0.27)

$

(4.27)

Schedule of potentially dilutive securities excluded from the computation of diluted net loss per share

    

Successor

As of September 30, 2022

Public Warrants

 

10,591,605

Private Warrants

 

227,500

Restricted Shares

 

494,127

Options

 

2,134,279

 

13,447,511

XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
9 Months Ended
Sep. 30, 2022
Leases  
Summary of operating lease costs

Successor

    

Predecessor

Three Months Ended

Three Months Ended

    

September 30, 2022

    

September 30, 2021

Lease costs

    

$

901,079

    

$

688,104

Successor

    

Predecessor

Nine Months Ended

Nine Months Ended

September 30, 2022

    

September 30, 2021

Lease costs

$

2,374,789

$

1,740,067

Summary of lease terms and discount rates

Successor

    

Predecessor

 

Nine Months Ended

Nine Months Ended

 

    

September 30, 2022

    

September 30, 2021

Weighted average remaining lease term (years)

 

6.42

 

5.09

Weighted average discount rate

 

11.7

%  

11.2

%

Schedule of reconciliation of undiscounted future minimum lease payments

    

September 30, 2022

October 1, 2022 to December 31, 2022

$

712,565

2023

 

1,347,234

2024

 

2,958,684

2025

 

2,602,888

2026

 

1,950,448

Thereafter

 

4,619,793

Total Payments

 

14,191,612

Less: Interest

 

(2,821,505)

Present Value of Lease Liabilities

$

11,370,107

XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties (Tables)
9 Months Ended
Sep. 30, 2022
Related Party Transaction [Line Items]  
Schedule of related party transactions

    

Successor

September 30, 2022

Balance at December 31, 2021

$

27,907,247

Advanced During Period

 

1,742,914

Interest Accrued During period

 

463,905

Balance at September 30, 2022

$

30,114,066

Atrio  
Related Party Transaction [Line Items]  
Schedule of related party transactions

Successor

    

Three Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

35,365,746

Management Fees

 

570,500

Claims Paid

 

39,861,830

    

Successor

Nine Months Ended

September 30, 2022

(Unaudited)

Revenue Earned from Capitation

$

127,505,484

Management Fees

 

1,716,134

Claims Paid

 

137,367,493

XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entities (Tables)
9 Months Ended
Sep. 30, 2022
Variable Interest Entities  
Summary of balance sheet and income statement of VIEs

Successor

ASSETS

    

September 30, 2022

    

December 31, 2021

Cash

$

5,413,965

$

7,570,247

Client Fees and Insurance Receivable, net

 

16,653

 

60,815

Prepaid Expenses and Other Current Assets

 

1,353,408

 

406,372

Property, Plant and Equipment, net

 

44,494

 

36,416

Investment in Other P3 Entities

 

6,000,000

 

6,000,000

TOTAL ASSETS

 

12,828,520

 

14,073,850

LIABILITIES AND MEMBERS’ DEFICIT

 

  

 

  

Accounts Payable and Accrued Expenses

 

7,653,560

 

4,804,704

Accrued Payroll

 

2,233,567

 

1,303,615

Due to Consolidated Entities of P3

 

27,001,570

 

24,110,831

TOTAL LIABILITIES

 

36,888,697

 

30,219,150

MEMBERS’ DEFICIT

 

(24,060,177)

 

(16,145,300)

TOTAL LIABILITIES AND MEMBERS’ DEFICIT

$

12,828,520

$

14,073,850

Successor

Predecessor

    

Three Months Ended

    

Three Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

13,594,142

$

1,905,404

Expenses

 

15,731,721

 

4,707,369

Net Loss

$

(2,137,579)

$

(2,801,965)

Successor

Predecessor

    

Nine Months Ended

    

Nine Months Ended

September 30, 2022

September 30, 2021

(As Restated)

Revenue

$

39,462,716

$

5,815,261

Expenses

 

46,708,335

 

13,858,939

Net Loss

$

(7,245,619)

$

(8,043,678)

XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Basis of Presentation (Details) - plan
Sep. 30, 2022
Dec. 31, 2021
Dec. 03, 2021
Company Operations [Line Items]      
Number of health plans with agreements entered 20 17  
P3 Health Group, LLC      
Company Operations [Line Items]      
Ownership percentage     17.10%
Network | Prime rate      
Company Operations [Line Items]      
Spread on variable interest rate 2.00%    
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restatement of Previously Issued Financial Statements (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Condensed Consolidated Statement of Operations                  
Total Operating Revenue $ 248,260,073 $ 156,185,955     $ 791,258,378 $ 452,070,338      
Medical Expenses 254,776,548 161,328,123     788,045,718 458,333,145      
Total Operating Expenses 308,272,010 184,309,497     1,815,625,200 519,153,369      
Operating Loss (60,011,937) (28,123,542)     (1,024,366,822) (67,083,031)      
Interest Expense, net (2,749,681) (2,529,133)     (8,244,806) (7,023,187)      
Total Other Expenses (5,317,104) (3,930,819)     (4,858,412) (19,086,452)      
Net Loss Attributable to Non-Controlling Interests (54,155,858)       (853,124,598)        
Net Loss (formerly Net Loss Attributable to Controlling Interests) (11,173,183) (32,054,361)     (176,100,636) (86,169,483)      
Condensed Consolidated Statement of Changes in Members' Deficit                  
Net Loss (65,329,041) (32,054,361) $ (29,464,410) $ (24,650,712) (1,029,225,234) (86,169,483)      
Balance at the end 78,076,015 (215,007,793) (183,308,520) (154,407,902) 78,076,015 (215,007,793)   $ 273,551,441 $ (130,217,705)
Condensed Consolidated Statement of Cash Flows                  
Net Loss (65,329,041) (32,054,361) $ (29,464,410) $ (24,650,712) (1,029,225,234) (86,169,483)      
Health Plan Settlements Receivable/Premiums Receivable           (884,523)      
Capitated Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue 243,988,004 153,072,995     780,775,285 443,598,050      
Condensed Consolidated Statement of Cash Flows                  
Total RAF adjustments         6,532,954        
Other Patient Service Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue $ 4,272,069 $ 3,112,960     $ 10,483,093 $ 8,472,288      
Class A and Class D Units                  
Condensed Consolidated Statement of Changes in Members' Deficit                  
Preferred return         8.00%        
Class A Preferred Units                  
Condensed Consolidated Statement of Changes in Members' Deficit                  
Preferred return   8.00% 8.00% 8.00%   8.00% 8.00%    
As Previously Reported                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   $ 156,520,255       $ 459,503,232      
Medical Expenses   161,662,423       459,233,085      
Total Operating Expenses   184,643,797       520,053,309      
Operating Loss           (60,550,077)      
Interest Expense, net   (4,643,254)       (13,130,628)      
Total Other Expenses   (6,044,940)       (25,193,893)      
Net Loss Attributable to Non-Controlling Interests   (2,801,965)       (8,043,678)      
Net Loss (formerly Net Loss Attributable to Controlling Interests)   (31,366,517)       (77,700,292)      
Condensed Consolidated Statement of Changes in Members' Deficit                  
Net Loss   (34,168,482) $ (24,967,931) $ (26,607,560)   (85,743,970)      
Balance at the end   (179,246,686) (146,395,455) (122,918,168)   (179,246,686)     (97,661,735)
Condensed Consolidated Statement of Cash Flows                  
Net Loss   (34,168,482) (24,967,931) (26,607,560)   (85,743,970)      
Health Plan Settlements Receivable/Premiums Receivable           (7,417,477)      
As Previously Reported | Capitated Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   152,276,992       447,137,121      
As Previously Reported | Other Patient Service Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   4,243,263       12,366,111      
As Previously Reported | Class A and Class D Units                  
Condensed Consolidated Statement of Cash Flows                  
Class A and Class D Preferred Returns           6,107,441      
As Previously Reported | Class A Preferred Units                  
Condensed Consolidated Statement of Changes in Members' Deficit                  
Preferred Return at 8%   962,163 926,852 890,612   2,779,619      
Network Adjustments                  
Condensed Consolidated Statement of Operations                  
Net Loss Attributable to Non-Controlling Interests   2,801,965       8,043,678      
Net Loss (formerly Net Loss Attributable to Controlling Interests)   (2,801,965)       (8,043,678)      
Preferred Returns Adjustments                  
Condensed Consolidated Statement of Operations                  
Interest Expense, net   2,114,121       6,107,441      
Total Other Expenses   2,114,121       6,107,441      
Net Loss (formerly Net Loss Attributable to Controlling Interests)   2,114,121       6,107,441      
Condensed Consolidated Statement of Changes in Members' Deficit                  
Net Loss   2,114,121 2,036,476 1,956,848   6,107,441      
Balance at the end   7,895,224 6,743,106 5,633,581   7,895,224     4,567,346
Condensed Consolidated Statement of Cash Flows                  
Net Loss   2,114,121 2,036,476 1,956,848   6,107,441      
Preferred Returns Adjustments | Class A and Class D Units                  
Condensed Consolidated Statement of Cash Flows                  
Class A and Class D Preferred Returns           (6,107,441)      
Preferred Returns Adjustments | Class A Preferred Units                  
Condensed Consolidated Statement of Changes in Members' Deficit                  
Preferred Return at 8%   (962,163) (926,852) (890,612)   (2,779,619)      
Class A Units Adjustments                  
Condensed Consolidated Statement of Changes in Members' Deficit                  
Balance at the end   (43,656,331) (43,656,170) (43,656,269)   (43,656,331)     (43,656,270)
Revenue Adjustments                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   (334,300)       (7,432,894)      
Medical Expenses   (334,300)       (899,940)      
Total Operating Expenses   (334,300)       (899,940)      
Operating Loss           (6,532,954)      
Net Loss (formerly Net Loss Attributable to Controlling Interests)           (6,532,954)      
Condensed Consolidated Statement of Changes in Members' Deficit                  
Net Loss     (6,532,955)     (6,532,954)      
Balance at the end       $ 6,532,954         $ 6,532,954
Condensed Consolidated Statement of Cash Flows                  
Net Loss     $ (6,532,955)     (6,532,954)      
Health Plan Settlements Receivable/Premiums Receivable           6,532,954      
Revenue Adjustments | Capitated Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   796,003       (3,539,071)      
Revenue Adjustments | Other Patient Service Revenue                  
Condensed Consolidated Statement of Operations                  
Total Operating Revenue   $ (1,130,303)       $ (3,893,823)      
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Going Concern and Liquidity (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Going Concern and Liquidity          
LOSS BEFORE INCOME TAXES $ (65,329,041) $ (32,054,361) $ (1,029,225,234) $ (86,169,483)  
Cash $ 34,357,237 $ 4,336,565 $ 34,357,237 $ 4,336,565 $ 140,477,586
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Significant Accounting Policies            
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor    
Number of reportable segments | segment     1      
Amount insured by Federal Deposit Insurance Corporation $ 250,000   $ 250,000      
Cash 34,357,237 $ 4,336,565 34,357,237 $ 4,336,565 $ 140,477,586  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]            
Unrestricted 34,357,237 4,336,565 34,357,237 4,336,565 140,477,586  
Restricted 1,003,307 346,299 1,003,307 346,299 356,286  
Total Cash Balances $ 35,360,544 $ 4,682,864 $ 35,360,544 $ 4,682,864 $ 140,833,872 $ 39,902,947
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Total Revenue $ 248,260,073 $ 156,185,955 $ 791,258,378 $ 452,070,338
Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 248,260,073 $ 156,185,955 $ 791,258,378 $ 452,070,338
Percentage of total revenue 100.00% 100.00% 100.00% 100.00%
Capitated Revenue        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 243,988,004 $ 153,072,995 $ 780,775,285 $ 443,598,050
Capitated Revenue | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 243,988,004 $ 153,072,995 $ 780,775,285 $ 443,598,050
Percentage of total revenue 98.30% 98.00% 98.70% 98.10%
Clinical Fees & Insurance Revenue | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 1,956,604 $ 1,278,339 $ 4,103,481 $ 3,386,966
Percentage of total revenue 0.80% 0.80% 0.50% 0.70%
Shared Risk Revenue | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue   $ 139,331 $ 55,154 $ 341,342
Percentage of total revenue 0.00% 0.10% 0.00% 0.10%
Care Coordination / Management Fees | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 1,729,800 $ 1,146,355 $ 4,412,973 $ 2,994,755
Percentage of total revenue 0.70% 0.70% 0.60% 0.70%
Incentive Fees | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 585,665 $ 548,935 $ 1,911,485 $ 1,749,225
Percentage of total revenue 0.20% 0.40% 0.20% 0.40%
Other Patient Service Revenue        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 4,272,069 $ 3,112,960 $ 10,483,093 $ 8,472,288
Other Patient Service Revenue | Revenue | Customer Concentration        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 4,272,069 $ 3,112,960 $ 10,483,093 $ 8,472,288
Percentage of total revenue 1.70% 2.00% 1.30% 1.90%
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Concentration of revenue (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Concentration Risk [Line Items]        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Total Revenue $ 248,260,073 $ 156,185,955 $ 791,258,378 $ 452,070,338
Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 248,260,073 $ 156,185,955 $ 791,258,378 $ 452,070,338
Percentage of total revenue 100.00% 100.00% 100.00% 100.00%
Health Plan A | Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 35,936,246 $ 36,417,184 $ 124,681,687 $ 114,230,860
Percentage of total revenue 14.50% 23.30% 15.80% 25.30%
Health Plan B | Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 46,082,052 $ 38,227,530 $ 139,920,223 $ 105,261,569
Percentage of total revenue 18.50% 24.50% 17.70% 23.30%
Health Plan C | Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 48,538,454 $ 29,563,741 $ 158,252,527 $ 84,489,621
Percentage of total revenue 19.50% 18.90% 20.00% 18.70%
Health Plan D | Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 31,563,532 $ 18,913,641 $ 104,439,689 $ 56,606,725
Percentage of total revenue 12.80% 12.10% 13.20% 12.50%
All Other | Revenue | Customer Concentration        
Concentration Risk [Line Items]        
Total Revenue $ 86,139,789 $ 33,063,859 $ 263,964,252 $ 91,481,563
Percentage of total revenue 34.70% 21.20% 33.30% 20.20%
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Capitated Revenue (Details)
9 Months Ended
Sep. 30, 2022
plan
state
Dec. 31, 2021
plan
state
Disaggregation of Revenue [Line Items]    
Term of contract 1 month  
Capitated Revenue    
Disaggregation of Revenue [Line Items]    
Number of health plans percentage of payment contracts entered | plan 20 17
Number of states | state 5 4
Practical expedient for not adjusting effects of a significant financing component true  
Term for reconciliation and distribution of the reserve following end of each quarter 120 days  
Term for reconciliation and distribution of the reserve following each year-end 21 months  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Health Plan Receivables (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Health Plan [Line Items]          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Health Plan Receivables, Net $ 81,497,703   $ 81,497,703   $ 50,251,004
Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 81,497,703   81,497,703   50,251,004
Health Plan A | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 524,540   524,540   4,695,712
Health Plan B | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 24,387,307   24,387,307   15,473,828
Health Plan C | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 28,798,095   28,798,095   1,380,752
Health Plan D | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 15,136,034   15,136,034   6,651,586
Health Plan E | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 184,332   184,332   2,439,046
Health Plan F | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 1,467,834   1,467,834   2,925,751
Health Plan G | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 35,179   35,179   239,375
Health Plan H | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 3,570,820   3,570,820   2,185,619
Health Plan I | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 1,586,752   1,586,752   1,134,750
Health Plan J | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net (102,380)   (102,380)   149,915
Health Plan K | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net         2,705,147
Health Plan L | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net         899,560
Health Plan M | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 1,388,190   1,388,190   1,747,116
Health Plan N | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 598,056   598,056   974,092
Health Plan O | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 2,279,489   2,279,489   666,291
Health Plan P | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 511,469   511,469   106,162
Health Plan Q | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 476,057   476,057   61,990
Health Plan R | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net         3,578,682
Health Plan S | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 600,639   600,639    
Health Plan T | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net 57,607   57,607   2,175,324
Health Plan U | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net         $ 60,306
Health Plan W | Capitated Revenue          
Health Plan [Line Items]          
Health Plan Receivables, Net $ (2,317)   $ (2,317)    
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Health Plan Settlement Payables (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Health Plan [Line Items]          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Health Plans Settlements Payable $ 20,626,836   $ 20,626,836   $ 22,548,694
Health Plan A          
Health Plan [Line Items]          
Health Plans Settlements Payable 2,579,575   2,579,575    
Health Plan B          
Health Plan [Line Items]          
Health Plans Settlements Payable 11,700,274   11,700,274   11,700,274
Health Plan D          
Health Plan [Line Items]          
Health Plans Settlements Payable         3,882,250
Health Plan F          
Health Plan [Line Items]          
Health Plans Settlements Payable 5,103,534   5,103,534   6,085,425
Health Plan G          
Health Plan [Line Items]          
Health Plans Settlements Payable 900,314   900,314   776,164
Health Plan I          
Health Plan [Line Items]          
Health Plans Settlements Payable (10,915)   (10,915)   (215,626)
Health Plan O          
Health Plan [Line Items]          
Health Plans Settlements Payable 39,365   39,365   (39,151)
Health Plan U          
Health Plan [Line Items]          
Health Plans Settlements Payable 226,209   226,209   226,209
Health Plan V          
Health Plan [Line Items]          
Health Plans Settlements Payable $ 88,480   $ 88,480   $ 133,149
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details)
9 Months Ended
Sep. 30, 2022
item
Disaggregation of Revenue [Line Items]  
Number of Revenue, Practical Expedients, Elected 2
Clinical Fees & Insurance Revenue  
Disaggregation of Revenue [Line Items]  
Practical expedients, not adjust the transaction price for any financing components true
Practical expedients, expensed all incremental customer contract acquisition costs as incurred true
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Shared Risk Revenue (Details) - Shared Risk Revenue
9 Months Ended
Sep. 30, 2022
agreement
Disaggregation of Revenue [Line Items]  
Percentage of shared risk savings received 30.00%
Number of separate arrangements 4
Percentage of total cost savings to be received, if the sequential YoY PMPY aggregate change yields a reduction 30.00%
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Goodwill (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2022
Significant Accounting Policies        
Impairment charges $ 0 $ 851,500,000 $ 0 $ 851,455,754
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations - Foresight (Details) - USD ($)
9 Months Ended
Dec. 03, 2021
Sep. 30, 2022
Sep. 30, 2021
Jan. 01, 2021
Business Acquisition [Line Items]        
Cash Consideration   $ 5,500,131 $ 5,014,500  
Useful life of intangible assets (in years)   9 years 2 months 12 days    
P3 LLC        
Business Acquisition [Line Items]        
Income tax benefit paid, percentage 85.00%      
Equity $ 80,300,733      
Fair Value of Noncontrolling Interest 1,807,427,576      
Stock Compensation Pre-combination Services 26,313,476      
Cash Consideration 18,405,083      
Payment of P3 Transaction Costs 19,151,752     $ 39,400,000
Total Purchase Consideration $ 1,951,598,620      
Useful life of intangible assets (in years) 10 years      
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations - Other (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
item
Dec. 02, 2021
USD ($)
item
Sep. 30, 2022
USD ($)
item
Sep. 30, 2022
USD ($)
item
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 27, 2021
Business Acquisition [Line Items]              
Number of other medical practice acquired | item       2      
Goodwill $ 1,309,750,216   $ 463,496,191 $ 463,496,191   $ 1,309,750,216  
Contingent Consideration $ 3,486,593   $ 4,684,503 4,684,503   3,486,593  
Cash Consideration       $ 5,500,131 $ 5,014,500    
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc              
Business Acquisition [Line Items]              
Number of other medical practice acquired | item 2            
Consideration for acquisition of equity interests $ 40,013,321            
Goodwill 31,297,438         31,297,438  
Contingent Consideration $ 3,486,593         3,486,593  
Cash Consideration           $ 15,677,205  
Medcore HP              
Business Acquisition [Line Items]              
Ownership percentage             100.00%
Omni IPA Medical Group, Inc.              
Business Acquisition [Line Items]              
Ownership percentage 100.00%         100.00%  
Other medical practices purchased              
Business Acquisition [Line Items]              
Number of other medical practice acquired | item   3 2        
Consideration for acquisition of equity interests   $ 4,989,000 $ 5,500,131        
Goodwill   $ 2,934,500          
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations - Purchase Price Allocation (Details) - USD ($)
3 Months Ended 9 Months Ended
Dec. 03, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 02, 2021
Business Acquisition [Line Items]                
Financial Designation, Predecessor and Successor [Fixed List]   Successor Predecessor Successor Predecessor      
Assets Acquired:                
Goodwill   $ 463,496,191   $ 463,496,191     $ 1,309,750,216  
Liabilities Assumed:                
Useful life of intangible assets (in years)       9 years 2 months 12 days        
P3 LLC                
Assets Acquired:                
Cash $ 5,300,842              
Restricted Cash 54,095              
Health Plan Settlement Receivables 47,733,033              
Clinic Fees and Insurance Receivables, Net 426,064              
Other Receivables 1,880,939              
Prepaid Expenses and Other Current Assets 938,413              
Property and Equipment, Net 7,875,234              
Goodwill 1,278,452,778              
Notes Receivable, Net 3,734,012              
Right of Use Assets 6,870,279              
Total Assets Acquired 2,188,665,689              
Liabilities Assumed:                
Accounts Payable and Accrued Expenses 25,819,091              
Accrued Payroll 2,868,664              
Health Plans Settlements Payable 25,007,542              
Claims Payable 76,031,460              
Premium Deficiency Reserve 11,559,067              
Accrued Interest 9,268,846              
Current Portion of Long-Term Debt 301,443              
Lease Liability 6,210,956              
Long-Term Debt, Net of Current Portion 80,000,000              
Total Liabilities Assumed 237,067,069              
Net Assets Acquired 1,951,598,620              
Goodwill expected to be deductible for tax purposes $ 3,800,000              
Useful life of intangible assets (in years) 10 years              
P3 LLC | Customer Relationships                
Assets Acquired:                
Intangible Assets, Net: $ 684,000,000              
P3 LLC | Provider Network                
Assets Acquired:                
Intangible Assets, Net: 3,700,000              
P3 LLC | Trademarks                
Assets Acquired:                
Intangible Assets, Net: $ 147,700,000              
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition")                
Assets Acquired:                
Cash             20,547,337  
Restricted Cash             302,187  
Health Plan Settlement Receivables             5,754,006  
Clinic Fees and Insurance Receivables, Net             141,186  
Other Receivables             726,378  
Prepaid Expenses and Other Current Assets             1,189,575  
Property and Equipment, Net             113,436  
Goodwill             31,297,438  
Total Assets Acquired             67,471,814  
Liabilities Assumed:                
Accounts Payable and Accrued Expenses             150,196  
Accrued Payroll             277,074  
Health Plans Settlements Payable             133,149  
Claims Payable             26,898,074  
Total Liabilities Assumed             27,458,493  
Net Assets Acquired             40,013,321  
Goodwill expected to be deductible for tax purposes           $ 8,100,000    
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition") | Payor Contracts.                
Assets Acquired:                
Intangible Assets, Net:             4,700,271  
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition") | Provider Network                
Assets Acquired:                
Intangible Assets, Net:             1,100,000  
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition") | Trademarks                
Assets Acquired:                
Intangible Assets, Net:             900,000  
Medcore Health Plan, Inc and Omni IPA Medical Group, Inc ("Medcore Acquisition") | Other                
Assets Acquired:                
Intangible Assets, Net:             $ 700,000  
Other medical practices purchased                
Assets Acquired:                
Cash               $ 3,000
Property and Equipment, Net               5,896
Goodwill               2,934,500
Total Assets Acquired               4,989,000
Liabilities Assumed:                
Net Assets Acquired               4,989,000
Other medical practices purchased | Customer Relationships                
Assets Acquired:                
Intangible Assets, Net:               $ 2,045,604
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Combinations - Pro Forma Financial Information (Details) - USD ($)
9 Months Ended
Jan. 01, 2021
Sep. 30, 2021
Dec. 03, 2021
Business Acquisition [Line Items]      
Total Operating Revenue   $ 567,305,732  
Net Loss   (179,492,450)  
Net Loss Attributable to Noncontrolling Interest   (148,260,764)  
Net Loss Attributable to Controlling Interest   $ (31,231,686)  
P3 Llc      
Business Acquisition [Line Items]      
Transaction Costs $ 39,400,000   $ 19,151,752
Amortization expense adjustment $ 2,400,000    
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Fair Value Measurements and Hierarchy          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Cash $ 34,357,237 $ 4,336,565 $ 34,357,237 $ 4,336,565 $ 140,477,586
Restricted Cash 1,003,307 $ 346,299 1,003,307 $ 346,299 356,286
Clinic Fees and Insurance Receivables, Net 1,049,253   1,049,253   1,090,104
Other Receivables 2,736,184   2,736,184   726,903
Accounts Payable and Accrued Expenses 24,072,391   24,072,391   17,730,683
Liability for warrants $ 7,996,432   $ 7,996,432   $ 11,382,826
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details) - Recurring - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability $ 7,996,432 $ 11,382,826
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 7,774,549 10,880,550
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability $ 221,883 $ 502,276
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy - Option Pricing (Details) - Private Placement Warrants - Level 3
Sep. 30, 2022
$ / shares
Y
Dec. 31, 2021
Y
$ / shares
Volatility    
Class of Warrant or Right [Line Items]    
Warrants, measurement input 60.00 60.00
Risk-Free Interest rate    
Class of Warrant or Right [Line Items]    
Warrants, measurement input 4.16 1.26
Exercise Price    
Class of Warrant or Right [Line Items]    
Warrants, measurement input | $ / shares 11.50 11.50
Expected Term    
Class of Warrant or Right [Line Items]    
Warrants, measurement input | Y 4.2 4.9
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Fair Value Measurements and Hierarchy        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Beginning balance     $ 502,276 $ 6,316,605
Mark-to-Market Adjustment for Stock Warrants     $ (280,393) 12,063,265
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]     Mark To Market Adjustment Of Foresight Stock Warrants  
Ending balance $ 221,883 $ 18,379,870 $ 221,883 $ 18,379,870
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Patient Fees Receivable (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Patient Fees Receivable          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Total Receivables: Gross $ 5,383,421   $ 5,383,421   $ 2,641,182
Less: Contractual Allowances (4,745,367)   (4,745,367)   (1,968,750)
Receivables Net of Contractual Allowances $ 638,054   $ 638,054   $ 672,432
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment, Net, by Type [Abstract]          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Property and Equipment, Gross $ 11,509,656   $ 11,509,656   $ 8,230,250
Less: Accumulated Depreciation (1,994,380)   (1,994,380)   (182,321)
Property and Equipment, Net 9,515,276   9,515,276   8,047,929
Leasehold Improvements (Cycle: Lease Term)          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 1,809,927   1,809,927   1,537,091
Furniture & Fixtures          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 1,450,626   1,450,626   1,108,184
Computer Equipment & Software          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 2,852,746   2,852,746   2,700,617
Medical Equipment          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 1,066,959   1,066,959   414,100
Software (Development in Process)          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 3,918,615   3,918,615   2,433,470
Vehicles          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross 373,995   373,995    
Other          
Property, Plant and Equipment, Net, by Type [Abstract]          
Property and Equipment, Gross $ 36,788   $ 36,788   $ 36,788
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
item
Goodwill        
Balance at the end $ 463,496,191     $ 463,496,191
Acquisitions       5,201,729
Impairment charges $ 0 $ 851,500,000 $ 0 851,455,754
Balance at the beginning     $ 1,309,750,216 $ 1,309,750,216
Number of medical practice acquired | item       2
Term of steady decline in share price       3 months
Percentage of stock lower than opening price       63.00%
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Changes (Details)
9 Months Ended
Sep. 30, 2022
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning $ 835,838,605
Amortization (63,427,522)
Balance at the end 772,411,083
Customer Relationships  
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning 678,300,000
Amortization (51,300,000)
Balance at the end 627,000,000
Trademarks  
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning 147,369,167
Amortization (11,415,000)
Balance at the end 135,954,167
Payor Contracts  
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning 4,700,271
Amortization (352,522)
Balance at the end 4,347,749
Provider Network  
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning 4,769,167
Amortization (360,000)
Balance at the end 4,409,167
Other  
Finite-Lived Intangible Assets [Line Items]  
Balance at the beginning 700,000
Balance at the end $ 700,000
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Additional Information (Details)
$ in Millions
9 Months Ended
Sep. 30, 2022
USD ($)
Anticipated amortization of intangible assets  
2022 $ 84
2023 84
2024 84
2025 84
2026 $ 84
Useful life of intangible assets (in years) 9 years 2 months 12 days
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Receivable, Net (Details)
Sep. 30, 2022
USD ($)
item
Dec. 31, 2021
USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Number of promissory notes entered | item 5  
Number of family medical practices with whom promissory notes are entered | item 3  
Separate provider agreements with each practice related to number of promissory notes entered | item 4  
Notes receivable including accrued interest net of valuation allowances $ 4,526,522 $ 3,590,715
Notes receivable current portion 963,060  
Notes receivable accrued interest 1,040,729 885,243
Notes receivable valuation allowances $ 709,547 $ 526,808
Minimum    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Interest rates 5.00%  
Maximum    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Interest rates 10.00%  
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Claims Payable - Additional Information (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Claims Payable.    
IBNR $ 134,705,426 $ 101,958,324
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Claims Payable (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Claims Payable.        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Claims Unpaid, Beginning of Period     $ 101,958,324  
Incurred, Related to:        
Current Period     700,236,928  
Prior Period (s)     5,024,653  
Total Incurred     705,261,581  
Paid, Related to:        
Current Period     570,830,033  
Prior Period (s)     101,684,446  
Total Paid     672,514,479  
Claims Unpaid, End of Period $ 134,705,426   $ 134,705,426  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Additional Information (Details)
9 Months Ended 12 Months Ended
Nov. 19, 2020
USD ($)
Jun. 07, 2020
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
payment
$ / shares
shares
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2019
shareholder
Debt Instrument [Line Items]                  
Debt outstanding     $ 80,000,000         $ 80,046,101  
Percentage of pledged stock, Its subsidiaries and bank accounts     100.00%            
Class C Preferred Units                  
Debt Instrument [Line Items]                  
Number of share-purchase agreement | shareholder                 1
Share price | $ / shares   $ 0.90              
Shares repurchased | shares   200,000              
LTD-C                  
Debt Instrument [Line Items]                  
Debt outstanding     $ 15,000,000         15,000,000  
Net proceeds from debt $ 15,000,000.0                
Interest rate 11.00%                
Amount exit fee due at maturity $ 600,000                
Debt instrument accrued interest     8,335,425         6,511,477  
Notes payable related parties 15,000,000.0                
LTD-D                  
Debt Instrument [Line Items]                  
Debt face amount $ 100,000,000                
Debt outstanding     65,000,000         65,000,000  
Net proceeds from debt     61,058,281            
Debt issuance cost     3,941,719            
Accrued interest     $ 4,320,493         2,259,588  
Period when revenue should greater than or equal to $125.0 million 3 months                
Minimum revenue $ 125,000,000.0     $ 650,000,000.0 $ 585,000,000.0 $ 525,000,000.0 $ 460,000,000.0 395,000,000.0  
Minimum liquidity $ 5,000,000.0                
Paid in cash interest, percentage     12.00%            
Partially paid in kind interest, percentage     8.00%            
Gross proceeds from debt     $ 65,000,000            
Paid in kind interest, percentage     4.00%            
Interest payment term     3 years            
Number of payments | payment     12            
Warrant term     10 years            
Warrant issued for securities | shares     858,351            
Share price | $ / shares     $ 4.68            
LTD-E                  
Debt Instrument [Line Items]                  
Debt outstanding               $ 46,101  
Interest rate   3.25%              
LTD-E | Class C Preferred Units                  
Debt Instrument [Line Items]                  
Members deficit decrease   $ 180,000              
Monthly payment   $ 7,757              
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Rollforward (Details) - USD ($)
3 Months Ended 9 Months Ended
Nov. 19, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]          
Financial Designation, Predecessor and Successor [Fixed List]   Successor Predecessor Successor Predecessor
Beginning Balance       $ 80,046,101  
Principal Payments       (46,101)  
Ending Balance   $ 80,000,000   80,000,000  
LTD-C          
Debt Instrument [Line Items]          
Beginning Balance       15,000,000  
Issued $ 15,000,000.0        
Ending Balance   15,000,000   15,000,000  
LTD-D          
Debt Instrument [Line Items]          
Beginning Balance       65,000,000  
Issued       61,058,281  
Ending Balance   $ 65,000,000   65,000,000  
LTD-E          
Debt Instrument [Line Items]          
Beginning Balance       46,101  
Principal Payments       $ (46,101)  
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Maturity (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Principal    
Principal- 2025 $ 65,000,000  
Principal- 2026 15,000,000  
Principal- Total 80,000,000 $ 80,046,101
PIK    
PIK - October 1, 2022 to December 31, 2022 1,342,321  
PIK- 2023 5,624,513  
PIK- 2024 6,061,814  
PIK- 2025 6,274,526  
PIK- 2026 1,851,284  
PIK- Total 21,154,458  
Cash Interest    
Cash Interest - October 1, 2022 to December 31, 2022 1,401,192  
Cash Interest - 2023 5,675,461  
Cash Interest - 2024 5,882,309  
Cash Interest - 2025 19,518,225  
Cash Interest - 2026 20,054,451  
Cash Interest 52,531,638  
Total Payments    
Total Cash Payments - October 1, 2022 to December 31, 2022 1,401,192  
Total Cash Payments - 2023 5,675,461  
Total Cash Payments - 2024 5,882,309  
Total Cash Payments - 2025 84,518,225  
Total Cash Payments - 2026 35,054,451  
Total Cash Payments - Total $ 132,531,638  
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Current and Long Term (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Long-Term Debt.          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Total Principal $ 80,000,000   $ 80,000,000   $ 80,046,101
Less: Current Portion of Long-Term Debt         (46,101)
Long Term Debt $ 80,000,000   $ 80,000,000   $ 80,000,000
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Short-Term (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Sep. 30, 2022
Short-term Debt [Line Items]    
Short-Term Debt $ 3,578,561 $ 0
Short term financing agreements    
Short-term Debt [Line Items]    
Borrowing capacity $ 3,683,100  
Weighted average interest rate 2.60%  
Short term financing agreements | Maximum    
Short-term Debt [Line Items]    
Debt instrument term 10 months  
Short term financing agreements | Minimum    
Short-term Debt [Line Items]    
Debt instrument term 9 months  
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Dec. 03, 2021
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Tax [Line Items]              
Impairment charges   $ 0 $ 851,500,000 $ 0 $ 851,455,754    
Tax benefit         $ 0 $ 0  
Effective tax rate         0.00% 0.00%  
Uncertain tax provision   0     $ 0   $ 0
Deferred tax assets   0     $ 0    
Tax Receivable Agreement with Selling Equity Holders of P3 LLC              
Income Tax [Line Items]              
Percentage of payment of tax savings realized         85.00%    
Retained percentage of cash savings         15.00%    
P3 Llc              
Income Tax [Line Items]              
Investment in P3 LLC   7,200,000     $ 7,200,000    
P3 Llc | Tax Receivable Agreement with Selling Equity Holders of P3 LLC              
Income Tax [Line Items]              
Estimated potential future tax benefits $ 5,400,000            
TRA liability $ 4,600,000 $ 0     $ 0   $ 0
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capitalization and Management Incentive Units (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 03, 2021
shares
Sep. 30, 2022
$ / shares
shares
Sep. 30, 2021
shares
Sep. 30, 2022
Vote
$ / shares
shares
Sep. 30, 2021
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2020
shares
Preferred Units [Line Items]              
Financial Designation, Predecessor and Successor [Fixed List]   Successor Predecessor Successor Predecessor    
Preferred stock, shares authorized   10,000,000   10,000,000   10,000,000  
Preferred stock, par value | $ / shares   $ 0.0001   $ 0.0001   $ 0.0001  
Preferred stock, shares outstanding   0   0   0  
Common Class A [Member]              
Preferred Units [Line Items]              
Common stock shares authorized   800,000,000   800,000,000   800,000,000  
Common stock par or stated value per share | $ / shares   $ 0.0001   $ 0.0001   $ 0.0001  
Common stock shares issued   41,578,890   41,578,890   41,578,890  
Common stock shares outstanding 3,737,316 41,578,890   41,578,890   41,578,890  
Purchase consideration 8,732,517            
Units authorized     43,000,000   43,000,000   43,000,000
Units outstanding     43,000,000   43,000,000   43,000,000
Common Class A [Member] | PIPE Investment              
Preferred Units [Line Items]              
Shares issued (in shares)       20,370,307      
Common Class V              
Preferred Units [Line Items]              
Common stock shares authorized   205,000,000   205,000,000   205,000,000  
Common stock par or stated value per share | $ / shares   $ 0.0001   $ 0.0001   $ 0.0001  
Common stock shares issued   201,530,796   201,530,796   196,553,523  
Common stock shares outstanding   201,530,796   201,530,796   196,553,523  
Number of voting rights per share | Vote       1      
Exchange ratio       1      
Lockup period       180 days      
Common Class V | Restricted Shares              
Preferred Units [Line Items]              
Shares issued       494,127   5,471,400  
Class A Foresight Founder Shares [Member] | Private Placement              
Preferred Units [Line Items]              
Shares issued (in shares)       8,738,750      
Class C Preferred Units              
Preferred Units [Line Items]              
Units authorized     1,925,833   1,925,833   1,302,083
Units outstanding     1,925,833   1,925,833   1,302,083
Class D Preferred Units              
Preferred Units [Line Items]              
Units authorized     16,130,034   16,130,034   16,130,034
Units outstanding     16,130,034   16,130,034   16,130,034
Class B Preferred Units              
Preferred Units [Line Items]              
Units authorized     8,000,000   8,000,000   6,000,000
Units outstanding     8,000,000   8,000,000   6,000,000
P3 Llc              
Preferred Units [Line Items]              
Common unit outstanding   243,603,813   243,603,813   243,603,813  
P3 Llc | Redeemable Non-Controlling Interests              
Preferred Units [Line Items]              
Common unit outstanding   202,024,923   202,024,923   202,024,923  
P3 Llc | Restricted Shares              
Preferred Units [Line Items]              
Common unit outstanding   494,127   494,127   5,471,400  
P3 Llc | Common Class A [Member]              
Preferred Units [Line Items]              
Common unit outstanding   41,578,890   41,578,890   41,578,890  
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Class V Activity (Details) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-Based Compensation        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Time-Based Unit        
Weighted Average Grant-Date Fair Value        
Beginning balance (in dollar per share)     $ 9.20  
Vested (in dollar per share)     9.20  
Ending balance (in dollar per share) $ 9.20   $ 9.20  
Units        
Beginning balance     5,471,400  
Vested     4,977,273  
Ending balance 494,127   494,127  
Other disclosures        
Weighted-average remaining time to vest     1 month 13 days  
Time-Based Unit | Maximum        
Other disclosures        
Vesting period     2 years  
Time-Based Unit | Minimum        
Other disclosures        
Vesting period     1 month  
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Expense (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Share-Based Compensation    
Unrecognized compensation expense $ 7,233,627 $ 7,233,627
Corporate, General and Administrative Expenses    
Share-Based Compensation    
Compensation expense $ 1,783,994 $ 17,210,974
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Stock options activities (Details)
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Number of Options Outstanding  
Granted (in shares) | shares 2,034,279
Vested (in shares) | shares 91,667
Outstanding and non-vested, end (in shares) | shares 1,942,612
Weighted Average Exercise Price  
Granted (in dollar per share) | $ / shares $ 6.43
Vested (in dollar per share) | $ / shares 5.02
Outstanding and non-vested, end (in dollar per share) | $ / shares $ 6.50
Weighted Average Remaining Contractual Life (Years)  
Granted 3 years 1 month 6 days
Outstanding and non-vested, end 2 years 6 months 7 days
Time-based options | Minimum  
Other disclosures  
Vesting period 2 years
Time-based options | Maximum  
Other disclosures  
Vesting period 5 years
Performance-based options  
Number of Options Outstanding  
Granted (in shares) | shares 100,000
Weighted Average Exercise Price  
Granted (in dollar per share) | $ / shares $ 5.02
Other disclosures  
Compensation expense | $ $ 0
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) per Share - Computation (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings (Loss) per Share            
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor     Successor Predecessor
Numerator - Basic:            
Net loss $ (65,329,041) $ (32,054,361) $ (29,464,410) $ (24,650,712) $ (1,029,225,234) $ (86,169,483)
LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS (54,155,858)       (853,124,598)  
Net loss attributable to Class A common stockholders - Basic (11,173,183)       (176,100,636)  
Numerator - Diluted:            
Net loss attributable to Class A Common Stockholders - Basic (11,173,183)       (176,100,636)  
Add: Net loss and tax effect attributable to Non-controlling interest (54,155,858)       (853,124,598)  
Net loss attributable to Class A common stockholders - Diluted $ (65,329,041)       $ (1,029,225,234)  
Denominator - Basic:            
Weighted average Class A common shares outstanding - Basic 41,578,890       41,578,890  
Loss per share attributable to Class A common shareholders - Basic $ (0.27) [1]     $ (4.24) [1]
Denominator - Diluted:            
Weighted average Class A common shares outstanding - Basic 41,578,890       41,578,890  
Weighted average effect of dilutive Class V shares 201,457,191       199,684,102  
Weighted average Class A common shares outstanding - Diluted 243,036,081       241,262,992  
Loss per share attributable to Class A common shareholders - Diluted $ (0.27) [1]     $ (4.27) [1]
[1] The Company analyzed the calculation of net loss per member unit for predecessor periods prior to the Business Combinations and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, net loss per member unit information has not been presented for predecessor periods prior to the Business Combinations on December 3, 2021.
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) per Share - Anti-dilutive securities (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Potentially dilutive securities excluded from the computation of diluted net loss per share     13,447,511  
Public Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from the computation of diluted net loss per share     10,591,605  
Private Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from the computation of diluted net loss per share     227,500  
Restricted Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from the computation of diluted net loss per share     494,127  
Time-based options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from the computation of diluted net loss per share     2,134,279  
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.22.2.2
Premium Deficiency Reserve (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Premium Deficiency Reserve    
Premium Deficiency Reserve $ 27,719,928 $ 37,835,642
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
agreement
Sep. 30, 2022
USD ($)
agreement
Option
Jun. 09, 2022
Lessee, Lease, Description [Line Items]      
Number Of Operating Lease | agreement 4 1  
Real estate on lease | NEVADA      
Lessee, Lease, Description [Line Items]      
Extension term of lease     94 months
Increase in ROU Asset | $   $ 3.1  
Increase in lease liabilities | $   $ 3.1  
Real estate on lease | Minimum      
Lessee, Lease, Description [Line Items]      
Lease term 1 year 1 year  
Number of options to renew | Option   1  
Extension term of lease 5 years 5 years  
Real estate on lease | Maximum      
Lessee, Lease, Description [Line Items]      
Lease term 8 years 8 years  
Number of options to renew | Option   2  
Extension term of lease 10 years 10 years  
Equipment on lease | Minimum      
Lessee, Lease, Description [Line Items]      
Lease term 1 year 1 year  
Equipment on lease | Maximum      
Lessee, Lease, Description [Line Items]      
Lease term 3 years 3 years  
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Operating Lease Costs (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Leases        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Lease costs $ 901,079 $ 688,104 $ 2,374,789 $ 1,740,067
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Lease Terms And Discount Rates (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Leases        
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor
Weighted average remaining lease term (years) 6 years 5 months 1 day 5 years 1 month 2 days 6 years 5 months 1 day 5 years 1 month 2 days
Weighted average discount rate 11.70% 11.20% 11.70% 11.20%
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Future Minimum Lease Payments (Details)
Sep. 30, 2022
USD ($)
Leases  
October 1, 2022 to December 31, 2022 $ 712,565
2023 1,347,234
2024 2,958,684
2025 2,602,888
2026 1,950,448
Thereafter 4,619,793
Total Payments 14,191,612
Less: Interest (2,821,505)
Present Value of Lease Liabilities $ 11,370,107
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Current Portions Of ROU Liabilities (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Leases    
ROU liabilities, current $ 213,158 $ 2,087,235
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accounts Payable and Accrued Liabilities, Current Accounts Payable and Accrued Liabilities, Current
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.22.2.2
Redeemable Non-Controlling Interests (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Noncontrolling Interest [Line Items]    
Re-measurement adjustment recorded against fair value of redeemable noncontrolling interest $ 19,375,288 $ 0
P3 Health Group, LLC    
Noncontrolling Interest [Line Items]    
Non-controlling interests, ownership percentage by noncontrolling owners 83.00%  
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details)
3 Months Ended 9 Months Ended 12 Months Ended 31 Months Ended
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
plan
Sep. 30, 2022
USD ($)
Loss Contingencies [Line Items]              
Financial Designation, Predecessor and Successor [Fixed List] Successor   Predecessor Successor Predecessor    
Number of health plans results in renegotiation | plan           1  
Additional payment to health plan $ 10,600,000     $ 10,600,000     $ 10,600,000
Operating Expenses. $ 308,272,010   $ 184,309,497 $ 1,815,625,200 $ 519,153,369    
Agreed claim settlement amount             $ 93,300,000
Percentage of total revenues recurring       99.00%   99.00%  
Renegotiation of Health Plan Agreement Due to Discrepancy [Member]              
Loss Contingencies [Line Items]              
Reduction in operating revenue   $ 3,600,000          
Operating Expenses.   $ 7,000,000.0          
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Parties (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Related Party Transaction [Line Items]          
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor  
Balance at Beginning of Year     $ 27,907,247    
Advanced During Period     1,742,914    
Interest Accrued During period     463,905    
Balance at End of Year $ 30,114,066   30,114,066   $ 27,907,247
Atrio          
Related Party Transaction [Line Items]          
Revenue Earned from Capitation 35,365,746   127,505,484    
Management Fees 570,500   1,716,134    
Claims Paid $ 39,861,830   137,367,493    
P3 NV | KWA          
Related Party Transaction [Line Items]          
Advanced During Period     $ 0   $ 0
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entities (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Variable Interest Entity [Line Items]                
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor     Successor Predecessor    
ASSETS                
Cash $ 34,357,237 $ 4,336,565     $ 34,357,237 $ 4,336,565 $ 140,477,586  
Client Fees and Insurance Receivable, net 1,049,253       1,049,253   1,090,104  
Prepaid Expenses and Other Current Assets 3,523,867       3,523,867   6,959,067  
Property, Plant and Equipment, net 9,515,276       9,515,276   8,047,929  
TOTAL ASSETS [1] 1,383,131,449       1,383,131,449   2,364,108,460  
LIABILITIES AND MEMBERS' DEFICIT                
Accounts Payable and Accrued Expenses 24,072,391       24,072,391   17,730,683  
Accrued Payroll 7,358,102       7,358,102   6,304,362  
TOTAL LIABILITIES [1] 330,976,485       330,976,485   299,939,734  
MEMBERS' DEFICIT 78,076,015 (215,007,793) $ (183,308,520) $ (154,407,902) 78,076,015 (215,007,793) 273,551,441 $ (130,217,705)
TOTAL LIABILITIES AND MEMBERS' DEFICIT 1,383,131,449       1,383,131,449   2,364,108,460  
Total Operating Revenue 248,260,073 156,185,955     791,258,378 452,070,338    
Expenses 308,272,010 184,309,497     1,815,625,200 519,153,369    
Net Loss (65,329,041) (32,054,361) $ (29,464,410) $ (24,650,712) (1,029,225,234) (86,169,483)    
VIE                
ASSETS                
Cash 5,413,965       5,413,965   7,570,247  
Client Fees and Insurance Receivable, net 16,653       16,653   60,815  
Prepaid Expenses and Other Current Assets 1,353,408       1,353,408   406,372  
Property, Plant and Equipment, net 44,494       44,494   36,416  
Investment in Other P3 Entities 6,000,000       6,000,000   6,000,000  
TOTAL ASSETS 12,828,520       12,828,520   14,073,850  
LIABILITIES AND MEMBERS' DEFICIT                
Accounts Payable and Accrued Expenses 7,653,560       7,653,560   4,804,704  
Accrued Payroll 2,233,567       2,233,567   1,303,615  
Due to Consolidated Entities of P3 27,001,570       27,001,570   24,110,831  
TOTAL LIABILITIES 36,888,697       36,888,697   30,219,150  
MEMBERS' DEFICIT (24,060,177)       (24,060,177)   (16,145,300)  
TOTAL LIABILITIES AND MEMBERS' DEFICIT 12,828,520       12,828,520   $ 14,073,850  
Total Operating Revenue 13,594,142 1,905,404     39,462,716 5,815,261    
Expenses 15,731,721 4,707,369     46,708,335 13,858,939    
Net Loss $ (2,137,579) $ (2,801,965)     $ (7,245,619) $ (8,043,678)    
[1] The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 25 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the P3 LLC’s VIEs totaling $6.8 million and $8.1 million as of September 30, 2022 and December 31, 2021, respectively, and total liabilities of the P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $9.9 million and $6.1 million as of September 30, 2022 and December 31, 2021, respectively. These VIE assets and liabilities do not include $6.0 million of investment in affiliates as of September 30, 2022 and December 31, 2021, and $27.0 million and $24.1 million of amounts due to affiliates as of September 30, 2022 and December 31, 2021, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 25 “Variable Interest Entities.”
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 19, 2020
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
D
$ / shares
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
shares
Warrants              
Financial Designation, Predecessor and Successor [Fixed List]   Successor Predecessor Successor Predecessor    
Common Class A [Member]              
Warrants              
Warrants outstanding (shares)   10,819,105   10,819,105   10,819,105  
Expected term of warrants   5 years   5 years      
Exercise price | $ / shares   $ 11.50   $ 11.50   $ 11.50  
Warrants outstanding | $   $ 7,996,432   $ 7,996,432   $ 11,382,826  
Gain (loss) from change in fair value of warrant liability | $   $ 2,567,423 $ 1,401,686 $ 3,386,394 $ 12,063,265    
Warrants exercised (in shares)       0   0  
Period after completion of business combination warrants become exercisable       30 days      
Threshold share price | $ / shares       $ 18.00      
Threshold trading days | D       20      
Trading period       30 days      
Warrant to purchase   1   1   1  
Class D Warrants              
Warrants              
Warrants outstanding (shares)   0   0   0 858,351
Warrants issued 858,351            
Expected term of warrants 10 years            
Exercise price | $ / shares $ 4.68         $ 4.68  
Warrants outstanding | $             $ 6,316,605
Gain (loss) from change in fair value of warrant liability | $             $ 0
Warrants exercised (in shares)           858,351  
XML 115 piii-20220930x10q_htm.xml IDEA: XBRL DOCUMENT 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2022-09-30 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001832511 piii:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001832511 piii:ClassPreferredUnitsMember 2021-09-30 0001832511 piii:ClassDPreferredUnitsMember 2021-09-30 0001832511 piii:ClassPreferredUnitsMember 2021-06-30 0001832511 piii:ClassDPreferredUnitsMember 2021-06-30 0001832511 piii:ClassPreferredUnitsMember 2021-03-31 0001832511 piii:ClassDPreferredUnitsMember 2021-03-31 0001832511 piii:ClassPreferredUnitsMember 2020-12-31 0001832511 piii:ClassDPreferredUnitsMember 2020-12-31 0001832511 piii:ClassCPreferredUnitsMember 2020-06-07 2020-06-07 0001832511 us-gaap:CommonClassAMember piii:PrivatePlacementPursuantToSubscriptionAgreementsMember 2022-01-01 2022-09-30 0001832511 piii:ClassBForesightFounderSharesMember us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001832511 us-gaap:CommonClassAMember 2021-12-03 2021-12-03 0001832511 us-gaap:RetainedEarningsMember 2022-09-30 0001832511 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001832511 us-gaap:RetainedEarningsMember 2022-06-30 0001832511 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001832511 2022-06-30 0001832511 us-gaap:RetainedEarningsMember 2022-03-31 0001832511 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001832511 2022-03-31 0001832511 us-gaap:RetainedEarningsMember 2021-12-31 0001832511 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001832511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-09-30 0001832511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-06-30 0001832511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-03-31 0001832511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2021-12-31 0001832511 piii:ClassCPreferredUnitsMember 2020-06-07 0001832511 us-gaap:RestrictedStockMember piii:CommonClassVMember 2022-01-01 2022-09-30 0001832511 us-gaap:RestrictedStockMember piii:CommonClassVMember 2021-01-01 2021-12-31 0001832511 piii:TimeBasedProfitsInterestAwardsMember 2022-09-30 0001832511 piii:TimeBasedProfitsInterestAwardsMember 2021-12-31 0001832511 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001832511 srt:MinimumMember piii:TimeBasedProfitsInterestAwardsMember 2022-01-01 2022-09-30 0001832511 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001832511 srt:MaximumMember piii:TimeBasedProfitsInterestAwardsMember 2022-01-01 2022-09-30 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember 2022-01-01 2022-09-30 0001832511 piii:P3LlcMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareClinicalFeesInsuranceRevenueMember 2022-01-01 2022-09-30 0001832511 us-gaap:HealthCarePatientServiceMember 2022-07-01 2022-09-30 0001832511 piii:CapitatedRevenueMember 2022-07-01 2022-09-30 0001832511 us-gaap:HealthCarePatientServiceMember 2022-01-01 2022-09-30 0001832511 us-gaap:HealthCarePatientServiceMember srt:ScenarioPreviouslyReportedMember 2021-07-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember piii:RevenueAdjustmentMember 2021-07-01 2021-09-30 0001832511 piii:CapitatedRevenueMember srt:ScenarioPreviouslyReportedMember 2021-07-01 2021-09-30 0001832511 piii:CapitatedRevenueMember piii:RevenueAdjustmentMember 2021-07-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember 2021-07-01 2021-09-30 0001832511 piii:CapitatedRevenueMember 2021-07-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember piii:RevenueAdjustmentMember 2021-01-01 2021-09-30 0001832511 piii:CapitatedRevenueMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-09-30 0001832511 piii:CapitatedRevenueMember piii:RevenueAdjustmentMember 2021-01-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember 2021-01-01 2021-09-30 0001832511 piii:CapitatedRevenueMember 2021-01-01 2021-09-30 0001832511 piii:LtdELoanMember 2022-01-01 2022-09-30 0001832511 us-gaap:NoncontrollingInterestMember 2022-09-30 0001832511 us-gaap:NoncontrollingInterestMember 2022-06-30 0001832511 us-gaap:NoncontrollingInterestMember 2022-03-31 0001832511 us-gaap:NoncontrollingInterestMember 2021-12-31 0001832511 us-gaap:VehiclesMember 2022-09-30 0001832511 us-gaap:SoftwareDevelopmentMember 2022-09-30 0001832511 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2022-09-30 0001832511 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001832511 us-gaap:FurnitureAndFixturesMember 2022-09-30 0001832511 us-gaap:ComputerEquipmentMember 2022-09-30 0001832511 piii:MedicalEquipmentMember 2022-09-30 0001832511 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001832511 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-12-31 0001832511 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001832511 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001832511 us-gaap:ComputerEquipmentMember 2021-12-31 0001832511 piii:MedicalEquipmentMember 2021-12-31 0001832511 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001832511 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001832511 srt:ScenarioPreviouslyReportedMember 2021-04-01 2021-06-30 0001832511 piii:RevenueAdjustmentMember 2021-04-01 2021-06-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-04-01 2021-06-30 0001832511 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001832511 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-03-31 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-01-01 2021-03-31 0001832511 piii:LtdCLoanMember 2020-11-19 2020-11-19 0001832511 us-gaap:CommonClassAMember 2021-09-30 0001832511 piii:ClassDPreferredUnitsMember 2021-09-30 0001832511 piii:ClassCPreferredUnitsMember 2021-09-30 0001832511 piii:ClassBPreferredUnitsMember 2021-09-30 0001832511 us-gaap:CommonClassAMember 2020-12-31 0001832511 piii:ClassDPreferredUnitsMember 2020-12-31 0001832511 piii:ClassCPreferredUnitsMember 2020-12-31 0001832511 piii:ClassBPreferredUnitsMember 2020-12-31 0001832511 piii:ClassAndClassDPreferredUnitsMember 2022-01-01 2022-09-30 0001832511 piii:ClassPreferredUnitsMember 2021-07-01 2021-09-30 0001832511 piii:ClassPreferredUnitsMember 2021-04-01 2021-06-30 0001832511 piii:ClassPreferredUnitsMember 2021-01-01 2021-09-30 0001832511 piii:ClassPreferredUnitsMember 2021-01-01 2021-03-31 0001832511 piii:ClassPreferredUnitsMember 2019-01-01 2019-12-31 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember 2021-01-01 2021-12-31 0001832511 piii:ClassCPreferredUnitsMember 2021-07-01 2021-09-30 0001832511 piii:ClassCPreferredUnitsMember 2021-04-01 2021-06-30 0001832511 piii:ClassB1PreferredUnitsMember 2021-04-01 2021-06-30 0001832511 2021-04-01 2021-06-30 0001832511 piii:ClassCPreferredUnitsMember 2021-01-01 2021-03-31 0001832511 2021-01-01 2021-03-31 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-07-01 2022-09-30 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-01-01 2022-09-30 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-07-01 2021-09-30 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-01-01 2021-09-30 0001832511 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001832511 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001832511 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001832511 piii:NetworkAdjustmentsMember 2021-07-01 2021-09-30 0001832511 piii:NetworkAdjustmentsMember 2021-01-01 2021-09-30 0001832511 piii:P3HealthGroupLlcMember 2022-09-30 0001832511 piii:NetworkMember us-gaap:PrimeRateMember 2022-09-30 0001832511 piii:KahanWakefieldAbdouPllcMember piii:P3NvMember 2022-01-01 2022-09-30 0001832511 piii:KahanWakefieldAbdouPllcMember piii:P3NvMember 2021-01-01 2021-12-31 0001832511 2020-03-01 2022-09-30 0001832511 us-gaap:RetainedEarningsMember 2021-09-30 0001832511 srt:ScenarioPreviouslyReportedMember 2021-09-30 0001832511 piii:RedemptionOfProfitsInterestMember 2021-09-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-09-30 0001832511 piii:ClassUnitsAdjustmentMember 2021-09-30 0001832511 piii:ClassCPreferredUnitsMember 2021-09-30 0001832511 piii:ClassB1PreferredUnitsMember 2021-09-30 0001832511 us-gaap:RetainedEarningsMember 2021-06-30 0001832511 srt:ScenarioPreviouslyReportedMember 2021-06-30 0001832511 piii:RedemptionOfProfitsInterestMember 2021-06-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-06-30 0001832511 piii:ClassUnitsAdjustmentMember 2021-06-30 0001832511 piii:ClassCPreferredUnitsMember 2021-06-30 0001832511 piii:ClassB1PreferredUnitsMember 2021-06-30 0001832511 2021-06-30 0001832511 us-gaap:RetainedEarningsMember 2021-03-31 0001832511 srt:ScenarioPreviouslyReportedMember 2021-03-31 0001832511 piii:RevenueAdjustmentMember 2021-03-31 0001832511 piii:RedemptionOfProfitsInterestMember 2021-03-31 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-03-31 0001832511 piii:ClassUnitsAdjustmentMember 2021-03-31 0001832511 piii:ClassCPreferredUnitsMember 2021-03-31 0001832511 piii:ClassB1PreferredUnitsMember 2021-03-31 0001832511 2021-03-31 0001832511 us-gaap:RetainedEarningsMember 2020-12-31 0001832511 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001832511 piii:RevenueAdjustmentMember 2020-12-31 0001832511 piii:RedemptionOfProfitsInterestMember 2020-12-31 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2020-12-31 0001832511 piii:ClassUnitsAdjustmentMember 2020-12-31 0001832511 piii:ClassCPreferredUnitsMember 2020-12-31 0001832511 piii:ClassB1PreferredUnitsMember 2020-12-31 0001832511 srt:MinimumMember piii:EquipmentOnLeaseMember 2022-09-30 0001832511 srt:MaximumMember piii:EquipmentOnLeaseMember 2022-09-30 0001832511 srt:MinimumMember us-gaap:RealEstateMember 2022-09-30 0001832511 srt:MaximumMember us-gaap:RealEstateMember 2022-09-30 0001832511 stpr:NV us-gaap:RealEstateMember 2022-06-09 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-07-01 2021-09-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember 2021-01-01 2021-09-30 0001832511 us-gaap:TransmissionServiceAgreementMember 2022-09-30 0001832511 us-gaap:TrademarksMember 2022-09-30 0001832511 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0001832511 us-gaap:CustomerRelationshipsMember 2022-09-30 0001832511 piii:ProviderContractsMember 2022-09-30 0001832511 us-gaap:TransmissionServiceAgreementMember 2021-12-31 0001832511 us-gaap:TrademarksMember 2021-12-31 0001832511 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001832511 us-gaap:CustomerRelationshipsMember 2021-12-31 0001832511 piii:ProviderContractsMember 2021-12-31 0001832511 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001832511 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001832511 us-gaap:CommonClassAMember 2021-01-01 2021-09-30 0001832511 piii:ClassDWarrantsMember 2020-01-01 2020-12-31 0001832511 piii:TimeBasedProfitsInterestAwardsMember 2022-01-01 2022-09-30 0001832511 piii:P3LlcMember 2022-09-30 0001832511 us-gaap:LineOfCreditMember 2021-12-31 0001832511 srt:MinimumMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001832511 srt:MaximumMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001832511 piii:LtdELoanMember 2020-06-07 0001832511 piii:LtdDLoanMember 2020-11-19 0001832511 piii:LtdELoanMember 2021-12-31 0001832511 us-gaap:HealthCarePatientServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanDMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanCMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanBMember 2022-07-01 2022-09-30 0001832511 piii:HealthCareSharedRiskRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 piii:HealthCareIncentiveFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 piii:HealthCareClinicalFeesInsuranceRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 piii:HealthCareCareCoordinationManagementFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 piii:CapitatedRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:AllOtherHealthPlanMember 2022-07-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001832511 us-gaap:HealthCarePatientServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanDMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanCMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanBMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareSharedRiskRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareIncentiveFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareClinicalFeesInsuranceRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareCareCoordinationManagementFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 piii:CapitatedRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:AllOtherHealthPlanMember 2022-01-01 2022-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001832511 us-gaap:HealthCarePatientServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanDMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanCMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanBMember 2021-07-01 2021-09-30 0001832511 piii:HealthCareSharedRiskRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 piii:HealthCareIncentiveFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 piii:HealthCareClinicalFeesInsuranceRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 piii:HealthCareCareCoordinationManagementFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 piii:CapitatedRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:AllOtherHealthPlanMember 2021-07-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001832511 us-gaap:HealthCarePatientServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanDMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanCMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:HealthPlanBMember 2021-01-01 2021-09-30 0001832511 piii:HealthCareSharedRiskRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 piii:HealthCareIncentiveFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 piii:HealthCareClinicalFeesInsuranceRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 piii:HealthCareCareCoordinationManagementFeesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 piii:CapitatedRevenueMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember piii:AllOtherHealthPlanMember 2021-01-01 2021-09-30 0001832511 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001832511 us-gaap:RestrictedStockMember piii:P3LlcMember 2022-09-30 0001832511 us-gaap:NoncontrollingInterestMember piii:P3LlcMember 2022-09-30 0001832511 us-gaap:CommonClassAMember piii:P3LlcMember 2022-09-30 0001832511 piii:P3LlcMember 2022-09-30 0001832511 us-gaap:RestrictedStockMember piii:P3LlcMember 2021-12-31 0001832511 us-gaap:NoncontrollingInterestMember piii:P3LlcMember 2021-12-31 0001832511 us-gaap:CommonClassAMember piii:P3LlcMember 2021-12-31 0001832511 piii:P3LlcMember 2021-12-31 0001832511 us-gaap:CommonClassAMember 2021-12-03 0001832511 piii:CommonClassVMember 2022-09-30 0001832511 piii:CommonClassVMember 2021-12-31 0001832511 piii:ClassDWarrantsMember 2022-09-30 0001832511 piii:ClassDWarrantsMember 2020-12-31 0001832511 us-gaap:CommonClassAMember 2022-09-30 0001832511 us-gaap:CommonClassAMember 2021-12-31 0001832511 piii:ClassDWarrantsMember 2021-12-31 0001832511 piii:ClassDWarrantsMember 2020-11-19 0001832511 2020-12-31 0001832511 2021-09-30 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember us-gaap:TransmissionServiceAgreementMember 2021-12-31 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember us-gaap:TrademarksMember 2021-12-31 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember us-gaap:ContractualRightsMember 2021-12-31 0001832511 piii:P3LlcMember us-gaap:TransmissionServiceAgreementMember 2021-12-03 0001832511 piii:P3LlcMember us-gaap:TrademarksMember 2021-12-03 0001832511 piii:P3LlcMember us-gaap:CustomerRelationshipsMember 2021-12-03 0001832511 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:CustomerRelationshipsMember 2021-12-02 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember 2022-12-31 0001832511 piii:OmniIpaMedicalGroupInc.Member 2021-12-31 0001832511 piii:MedcoreHpMember 2021-12-27 0001832511 piii:P3HealthGroupLlcMember 2021-12-03 0001832511 piii:P3LlcMember 2021-01-01 0001832511 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001832511 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001832511 piii:PublicWarrantsMember 2022-01-01 2022-09-30 0001832511 piii:PrivateWarrantsMember 2022-01-01 2022-09-30 0001832511 us-gaap:TransmissionServiceAgreementMember 2022-01-01 2022-09-30 0001832511 us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001832511 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001832511 piii:ProviderContractsMember 2022-01-01 2022-09-30 0001832511 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001832511 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001832511 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001832511 piii:P3LlcMember 2021-01-01 2021-01-01 0001832511 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001832511 piii:ClassDWarrantsMember 2021-01-01 2021-12-31 0001832511 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001832511 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001832511 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001832511 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001832511 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001832511 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001832511 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001832511 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001832511 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001832511 piii:P3LlcMember piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember 2022-09-30 0001832511 piii:P3LlcMember piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember 2021-12-31 0001832511 piii:P3LlcMember piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember 2021-12-03 0001832511 2022-04-01 2022-06-30 0001832511 2022-01-01 2022-03-31 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001832511 piii:CommonClassVMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001832511 srt:ScenarioPreviouslyReportedMember piii:ClassAndClassDPreferredUnitsMember 2021-01-01 2021-09-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember piii:ClassAndClassDPreferredUnitsMember 2021-01-01 2021-09-30 0001832511 piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember 2022-01-01 2022-09-30 0001832511 piii:LtdDLoanMember 2022-01-01 2022-09-30 0001832511 piii:HealthCareSharedRiskRevenueMember 2022-01-01 2022-09-30 0001832511 piii:ClassCPreferredUnitsMember 2019-12-31 0001832511 srt:MinimumMember us-gaap:RealEstateMember 2022-01-01 2022-09-30 0001832511 srt:MaximumMember us-gaap:RealEstateMember 2022-01-01 2022-09-30 0001832511 2021-01-01 2021-12-31 0001832511 srt:ScenarioPreviouslyReportedMember 2021-07-01 2021-09-30 0001832511 piii:RevenueAdjustmentMember 2021-07-01 2021-09-30 0001832511 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-09-30 0001832511 piii:RevenueAdjustmentMember 2021-01-01 2021-09-30 0001832511 2021-07-01 2021-09-30 0001832511 piii:AtrioMember 2022-07-01 2022-09-30 0001832511 piii:AtrioMember 2022-01-01 2022-09-30 0001832511 srt:ScenarioPreviouslyReportedMember piii:ClassPreferredUnitsMember 2021-07-01 2021-09-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember piii:ClassPreferredUnitsMember 2021-07-01 2021-09-30 0001832511 srt:ScenarioPreviouslyReportedMember piii:ClassPreferredUnitsMember 2021-04-01 2021-06-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember piii:ClassPreferredUnitsMember 2021-04-01 2021-06-30 0001832511 srt:ScenarioPreviouslyReportedMember piii:ClassPreferredUnitsMember 2021-01-01 2021-09-30 0001832511 piii:PreferredReturnsRestatementAdjustmentMember piii:ClassPreferredUnitsMember 2021-01-01 2021-09-30 0001832511 srt:ScenarioPreviouslyReportedMember piii:ClassPreferredUnitsMember 2021-01-01 2021-03-31 0001832511 piii:PreferredReturnsRestatementAdjustmentMember piii:ClassPreferredUnitsMember 2021-01-01 2021-03-31 0001832511 stpr:NV us-gaap:RealEstateMember 2022-01-01 2022-09-30 0001832511 piii:RenegotiationOfAgreementOfHealthPlanDueToDiscrepancyMember 2021-10-01 2021-12-31 0001832511 piii:HealthPlanVMember 2022-09-30 0001832511 piii:HealthPlanUMember 2022-09-30 0001832511 piii:HealthPlanOMember 2022-09-30 0001832511 piii:HealthPlanMember 2022-09-30 0001832511 piii:HealthPlanIMember 2022-09-30 0001832511 piii:HealthPlanGMember 2022-09-30 0001832511 piii:HealthPlanFMember 2022-09-30 0001832511 piii:HealthPlanBMember 2022-09-30 0001832511 piii:HealthPlanVMember 2021-12-31 0001832511 piii:HealthPlanUMember 2021-12-31 0001832511 piii:HealthPlanOMember 2021-12-31 0001832511 piii:HealthPlanIMember 2021-12-31 0001832511 piii:HealthPlanGMember 2021-12-31 0001832511 piii:HealthPlanFMember 2021-12-31 0001832511 piii:HealthPlanDMember 2021-12-31 0001832511 piii:HealthPlanBMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanWMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanTMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanSMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanQMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanPMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanOMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanNMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanMMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanJMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanIMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanHMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanGMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanFMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanEMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanDMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanCMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanBMember 2022-09-30 0001832511 piii:CapitatedRevenueMember 2022-09-30 0001832511 piii:CapitatedRevenueMember piii:HealthPlanUMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanTMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanRMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanQMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanPMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanOMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanNMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanMMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanLMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanKMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanJMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanIMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanHMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanGMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanFMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanEMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanDMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanCMember 2021-12-31 0001832511 piii:CapitatedRevenueMember piii:HealthPlanBMember 2021-12-31 0001832511 piii:CapitatedRevenueMember 2021-12-31 0001832511 srt:MinimumMember 2022-09-30 0001832511 srt:MaximumMember 2022-09-30 0001832511 piii:P3LlcMember piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember 2021-12-03 2021-12-03 0001832511 piii:LtdCLoanMember 2020-11-19 0001832511 piii:LtdDLoanMember 2025-01-01 2025-12-31 0001832511 piii:LtdDLoanMember 2024-01-01 2024-12-31 0001832511 piii:LtdDLoanMember 2023-01-01 2023-12-31 0001832511 piii:LtdDLoanMember 2022-01-01 2022-12-31 0001832511 piii:LtdDLoanMember 2021-01-01 2021-12-31 0001832511 piii:LtdDLoanMember 2022-09-30 0001832511 piii:LtdDLoanMember 2021-12-31 0001832511 piii:LtdCLoanMember 2022-09-30 0001832511 piii:LtdCLoanMember 2021-12-31 0001832511 piii:LtdDLoanMember 2020-11-19 2020-11-19 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-09-30 0001832511 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-12-31 0001832511 piii:ClassDWarrantsMember 2020-11-19 2020-11-19 0001832511 2022-09-30 0001832511 2021-12-31 0001832511 piii:CommonClassVMember 2022-01-01 2022-09-30 0001832511 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-12-02 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember 2021-12-31 0001832511 piii:P3LlcMember 2021-12-03 0001832511 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-07-01 2022-09-30 0001832511 piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember 2021-12-27 2021-12-31 0001832511 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-12-02 2021-12-02 0001832511 2021-01-01 2021-09-30 0001832511 piii:P3LlcMember 2021-12-03 2021-12-03 0001832511 piii:LtdELoanMember piii:ClassCPreferredUnitsMember 2020-06-07 2020-06-07 0001832511 piii:CapitatedRevenueMember 2022-01-01 2022-09-30 0001832511 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001832511 2022-07-01 2022-09-30 0001832511 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001832511 piii:WarrantsExercisableForOneShareOfCommonStockMember 2022-01-01 2022-09-30 0001832511 us-gaap:CommonClassAMember 2022-11-08 0001832511 piii:CommonClassVMember 2022-11-08 0001832511 2022-01-01 2022-09-30 piii:Option piii:shareholder piii:state piii:payment piii:segment piii:Y shares iso4217:USD piii:item iso4217:USD shares piii:D piii:Vote pure piii:plan piii:agreement 41578890 41578890 41578890 41578890 43000000 43000000 16130034 16130034 0001832511 --12-31 2022 Q3 false http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent 201530796 196553523 1218797 -183308520 P21M 1.00 http://www.p3hp.org/20220930#MarkToMarketAdjustmentOfForesightStockWarrants 84000000 84000000 84000000 84000000 P3M P9M 0 196553523 201530796 8000000 6000000 1925833 1302083 P2Y P1Y P1Y P5Y 3100000 P10Y P30D 10-Q true 2022-09-30 false 001-40033 P3 Health Partners Inc. DE 85-2992794 2370 Corporate Circle Suite 300 Henderson NV 89074 702 910–3950 Class A Common Stock, Par Value $0.0001 per share Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 PIII PIIIW NASDAQ NASDAQ Yes Yes Non-accelerated Filer true true false false 41578890 202024923 34357237 140477586 1003307 356286 81497703 50251004 1049253 1090104 2736184 726903 3523867 6959067 124167551 199860950 11509656 8230250 1994380 182321 9515276 8047929 463496191 1309750216 772411083 835838605 3563462 3590715 9977886 7020045 1258963898 2164247510 1383131449 2364108460 24072391 17730683 7358102 6304362 20626836 22548694 134705426 101958324 27719928 37835642 12655918 8771065 46101 3578561 227138601 198773432 11156949 6296883 7996432 11382826 4684503 3486593 80000000 80000000 103837884 101166302 330976485 299939734 974078949 1790617285 0.0001 0.0001 800000000 800000000 41578890 41578890 4158 4158 0.0001 0.0001 205000000 205000000 201530796 196553523 20153 19655 293570464 312945752 -215518760 -39418124 78076015 273551441 1383131449 2364108460 6800000 8100000 9900000 6100000 6000000.0 6000000.0 27000000.0 24100000 Successor Predecessor Successor Predecessor 243988004 153072995 780775285 443598050 4272069 3112960 10483093 8472288 248260073 156185955 791258378 452070338 254776548 161328123 788045718 458333145 -7301630 1600000 -10115714 4600000 37862737 20433538 117560549 53883267 1119552 491418 3392178 1118160 851455754 21814803 456418 65286715 1218797 308272010 184309497 1815625200 519153369 -60011937 -28123542 -1024366822 -67083031 -2749681 -2529133 -8244806 -7023187 2567423 1401686 -3386394 12063265 -5317104 -3930819 -4858412 -19086452 -65329041 -32054361 -1029225234 -86169483 -65329041 -32054361 -1029225234 -86169483 -54155858 -853124598 -11173183 -32054361 -176100636 -86169483 -0.27 -4.24 -0.27 -4.27 43000000 43656270 16130034 47041554 6000000 380000 1302083 67474 -180000 -130485179 -130217705 333750 460515 460515 -24650712 -24650712 43000000 43656270 16130034 47041554 6000000 380000 1635833 527989 -180000 -155135891 -154407902 2000000 380000 140000 183792 563792 -29464410 -29464410 43000000 43656270 16130034 47041554 8000000 760000 1775833 711781 -180000 -184600301 -183308520 150000 355088 355088 -32054361 -32054361 43000000 43656270 16130034 47041554 8000000 760000 1925833 1066869 -180000 -216654662 -215007793 1790617285 41578890 4158 196553523 19655 312945752 -39418124 273551441 549822 55 55 11711427 -50212750 -10577504 -10577504 1752115962 41578890 4158 197103345 19710 312945752 -49995628 262973992 4319964 432 432 3715553 -748755990 -154349949 -154349949 1007075525 41578890 4158 201423309 20142 312945752 -204345577 108624475 107487 11 11 1783994 -19375288 19375288 19375288 -54155858 -11173183 -11173183 974078949 41578890 4158 201530796 20153 293570464 -215518760 78076015 -1029225234 -86169483 65286715 17210974 1379400 851455754 525783 931958 -3386394 12063265 -10115714 4600000 290910 1623188 -54602 31246699 884523 -3462453 -2667427 3500981 379235 4560474 3606729 1053740 -1842877 3884853 3952044 -1921858 -483657 32747102 18173851 -94065131 -39827450 2283404 2990130 5500131 5014500 -120463 -7783535 -7884167 12750000 3624662 67216 -191250 -3624662 12491534 -105473328 -35220083 140833872 39902947 35360544 4682864 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 1: Organization and Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Description of Business and Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 Health Partners Inc. (the “Company” or “P3”) is a patient-centered and physician-led population health management company and the successor to P3 Health Group Holdings, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 Health Group Holdings, LLC and Subsidiaries was founded on April 12, 2017 and began commercial operations on April 20, 2017 to provide population health management services on an at-risk basis to insurance plans offering medical coverage to Medicare beneficiaries under Medicare Advantage programs. Medicare Advantage programs are insurance products created solely for Medicare beneficiaries. Insurance plans contract directly with the Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare beneficiaries benefits that replace traditional Medicare Fee for Service (“FFS”) coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 3, 2021, (the “Closing Date”), the Company consummated the transactions pursuant to which, among other things, P3 Health Group Holdings, LLC merged with and into FAC Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Foresight Acquisition Corp. (“Foresight” or “Merger Sub”) (the “P3 Merger”), with Merger Sub as the surviving company, which was renamed P3 Health Group, LLC (“P3 LLC”), and FAC-A Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight, FAC-B Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight (together with FAC-A Merger Sub Corp., the “Merger Corps”) merged with and into CPF P3 Blocker-A, LLC, a Delaware limited liability company, CPF P3 Blocker-B, LLC a Delaware limited liability company (together with CPF P3 Blocker-A, LLC, the “Blockers”), with the Blockers as the surviving entities and wholly-owned subsidiaries of Foresight (collectively, the “Business Combinations”). Upon completion of the Business Combinations (the “Closing”), the Company and P3 LLC were organized in an “Up-C” structure in which all of the P3 LLC operating subsidiaries are held directly or indirectly by P3 LLC, and the Company directly owned approximately 17.1% of P3 LLC and became the sole manager of P3 LLC. Following Closing, substantially all of the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interest in P3 LLC (“P3 LLC Units”). In connection with the closing of the transactions, the Company changed its name from Foresight Acquisition Corp. to P3 Health Partners Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s contracts with health plans are based on an at-risk shared savings model. Under this model, the Company is financially responsible for the cost of all contractually covered services provided to members assigned to the Company by health plans in exchange for a fixed monthly “capitation” payment, which is generally a percentage of the payment health plans receive from CMS. Under this arrangement, Medicare beneficiaries generally receive all their healthcare coverage through the Company’s network of employed and affiliated physicians and specialists (except for emergency situations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The services provided to health plans’ members vary by contract. These may include utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of Company providers, processing and payment of claims and the establishment of a provider network for certain health plans. At September 30, 2022 and December 31, 2021, the Company had agreements with twenty and seventeen health plans, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has Management Services Agreements (“MSAs”) and deficit funding agreements with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, P3 Health Partners Professional Services P.C., P3 Medical Group, P.C. and P3 Health Partners California, P.C. (collectively, the “Network”). As more fully described in Note 25 “Variable Interest Entities,” the entities in the Network are variable interest entities and the Company is the primary beneficiary of the Network. The MSAs provide that the Company or its subsidiaries will furnish administrative personnel, office supplies and equipment, general business services, contract negotiation and billing and collection services to the Network. Fees for these services are the excess of the Network’s revenue over expenses. Per the deficit funding agreements, the Company or its subsidiaries are obligated to lend amounts to the Network to the extent expenses exceed revenues. The loan will bear interest at prime plus 2%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the Company’s contracts with health plans, through its relationship with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, the Company provides primary healthcare services through its employed physician clinic locations. These primary care clinics are reimbursed for services provided under FFS contracts with various payers and through capitated – per member, per month (“PMPM”) arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Basis of Presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of the U.S. Securities and Exchange Commission (“SEC”) Regulation S-X. The condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). Certain information and footnote disclosures, normally included in financial statements prepared in accordance with U.S. GAAP, have been condensed or omitted pursuant to SEC rules and regulations dealing with interim financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. For further information, refer to the consolidated financial statements and notes thereto included in our 2021 Form 10-K. There have been no significant changes to our accounting policies and estimates during the nine months ended September 30, 2022 from those previously disclosed in the 2021 Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Business Combinations, for accounting purposes, Foresight is the acquirer and P3 Health Group Holdings, LLC is the accounting acquiree and predecessor. The financial statement presentation includes the financial statements of P3 Health Group Holdings, LLC as “Predecessor” for the periods prior to the Closing Date (the “Predecessor Period(s)”) and of the Company as “Successor” for the periods after the Closing Date (the “Successor Period(s)”), including the consolidation of P3 Health Group Holdings, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the application of the acquisition method of accounting as of the Closing Date of the Business Combinations, the accompanying unaudited condensed consolidated financial statements include a black line division that indicates that the Predecessor and Successor reporting entities shown are presented on a different basis and are, therefore, not comparable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an Emerging Growth Company (“EGC”) and as such, has elected the extended transition period for complying with certain new or revised accounting pronouncements. During the extended transition period, the Company is not subject to certain new or revised accounting standards applicable to public companies. The accounting pronouncements pending adoption as described in Note 6 “Recent Accounting Pronouncements Not Yet Adopted” reflect effective dates for the Company as an EGC with the extended transition period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Restatement of Prior Year Amounts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As discussed in the Company's 2021 consolidated financial statements included in the 2021 Form 10-K, the Company restated the previously issued unaudited condensed consolidated financial statements for each interim period within the fiscal years ended December 31, 2021 and December 31, 2020.</p> 0.171 20 17 0.02 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 2: Restatement of Previously Issued Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has restated the condensed consolidated financial statements for the three and nine months ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Network</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since 2017, P3 Health Group Holdings and P3 Health Partners, LLC (collectively with P3 Health Partners, Inc., “P3”) have entered into a collective of arrangements with the Network whereby P3 consolidates the Network under the Variable Interest Entity model in accordance with ASC Topic 810<i style="font-style:italic;">, Consolidation</i> (“ASC 810”). Historically, all of the net losses incurred by the Network were allocated to loss attributable to non-controlling interests. Based on an analysis of the deficit funding agreement between P3 and the Network, P3 is obligated to fund losses incurred by the Network. Because P3 is contractually obligated to fund the losses, losses incurred by the Network should not be allocated to non-controlling interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on management’s evaluation, it was concluded that the Company’s accounting for non-controlling interests related to the Network is not attributed in the manner contemplated by ASC 810. As a result, the Company has reclassified the loss attributable to non-controlling interest related to the Network to loss attributable to controlling interests on the Consolidated Balance Sheets, Consolidated Statements of Operations, and the Consolidated Statements of Changes in Stockholders’/Members’ Equity for the periods described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company's accounting for the loss in controlling interests instead of non-controlling interests has no impact on the Company's current or previously reported cash position, revenue, operating expenses or total operating, investing or financing cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Returns</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3's capital structure consists of Class A Units, which represent commitments from the Company’s private equity sponsors, and Class D Units, which represents an additional investment from a private equity sponsor. Both the Class A and Class D Units have voting rights and, accrue a preferred return in the amount of 8.0% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, all of the accrued returns were recognized as interest expense on P3’s Statements of Operations and as equity on P3’s Balance Sheets. Based on the analysis of the Class A and Class D Units, the preferred returns should not be accrued until they are legally declared. As a result, the Company’s historical recording of preferred returns in equity and interest expense has been removed as no recognition is necessary until legally declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Class A Units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, the Class A Preferred Units issued by P3 were accounted for as permanent equity. Since the Class A Preferred Units are redeemable upon the occurrence of a Sale of the Company via the liquidation and distribution preferences that returns invested capital and the preferred return, management evaluated whether the occurrence of such an event is outside of the Company’s control. As the Class A preferred unit holders hold a majority vote, the redemption of Class A Preferred Units upon a Sale of the Company, irrespective of probability, is outside of the Company’s control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on management’s evaluation, the Class A Preferred Units should be reclassified from permanent to mezzanine equity. <span style="color:#242424;">Additionally, the Company entered into the Second Amended and Restated Limited Liability Company Agreement in 2019, which provided the holders of Class A units an </span><span style="color:#242424;">8%</span><span style="color:#242424;"> per annum preferred return.  The Company determined that the amendment should be accounted for as a modification. Therefore, the Company recorded the incremental increase in fair value as an adjustment to the carrying value of Class A units with an offset to additional paid in capital equivalent and accumulated deficit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="color:#242424;font-weight:bold;">Capitated Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient (via a Risk Adjustment Factor, “RAF”). The Company’s policy is to recognize the variable RAF component of capitation revenues, to the extent that it is probable a significant reversal will not occur. At the December 31, 2020 balance sheet date the Company determined its estimates of the RAF components of certain capitation revenues were constrained and therefore not estimable, as it was not probable a significant reversal would not occur. The Company subsequently collected the RAF components of capitation payments prior to the issuance of the 2020 financial statements, effectively relieving the constraints which previously existed at the December 31, 2020 balance sheet date. As a result, capitation revenues for 2020 were restated based on the results of management’s analysis of the RAF component of cash receipts collected prior to the issuance 2020 financial statements which were previously determined to not be estimable. The revenue now recognized in 2020 was previously recognized in June of 2021. The total amount of the RAF adjustment was $6,532,954.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were two other errors related to capitated revenue, other patient service revenue, and medical expenses which were corrected in the restatement. Firstly, the Company has reclassified capitated revenue streams attributable to the Network. These capitated revenues were previously classified as “other patient service revenue” and have been reclassified into “capitated revenue”. Secondly, the Company has eliminated intercompany revenue and expense related to transactions between Bacchus and P3-NV that should have been eliminated in consolidation. Prior to the restatement noted above regarding capitated revenue, this adjustment was a decrease to other patient service revenue and a decrease to medical expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Disclosure Correction </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The disclosure of the condensed financial statements of the Company’s consolidated VIE have been corrected for accrued interest and interest expense relating to the advances made to the VIE for the three and nine month periods ended September 30, 2021 (see Note 25). There is no impact to the condensed consolidated financial statements of the Company for this correction to the disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Network</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Operations for the Nine Months Ended September 30, 2021 (Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 447,137,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,539,071)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 443,598,050</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 12,366,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,893,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 8,472,288</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 459,503,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,432,894)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 452,070,338</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Medical Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 459,233,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 458,333,145</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 520,053,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 519,153,369</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Operating Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,550,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67,083,031)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Interest Expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,130,628)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,023,187)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,193,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,086,452)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss Attributable to Non-Controlling Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 8,043,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss (formerly Net Loss Attributable to Controlling Interests)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,700,292)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2021 (Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 152,276,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 796,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 153,072,995</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 4,243,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,130,303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 3,112,960</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 156,520,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 156,185,955</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Medical Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 161,662,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 161,328,123</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 184,643,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 184,309,497</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Interest Expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,643,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,529,133)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,044,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,930,819)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss Attributable to Non-Controlling Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,801,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,801,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss (formerly Net Loss Attributable to Controlling Interests)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,366,517)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,801,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,054,361)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Nine Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,779,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,779,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85,743,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,246,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,895,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (215,007,793)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 962,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (962,163)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,168,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,054,361)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,246,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,895,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (215,007,793)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85,743,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Health Plan Settlements Receivable/Premiums Receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,417,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (884,523)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Class A and Class D Preferred Returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,107,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 926,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (926,852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,967,931)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,036,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,955)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,464,410)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146,395,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,743,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,170)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_8hnFjJDhpk2D6ka9QLUTgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> (183,308,519)</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Changes in Members' Deficit for the 3 Months Ended March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 890,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (890,612)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,607,560)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 1,956,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,650,712)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (122,918,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 5,633,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,407,902)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Changes in Members' Deficit for the Year Ended December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (97,661,735)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 4,567,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (130,217,705)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">*Rounding may cause variances</p> 0.080 0.08 6532954 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Network</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Operations for the Nine Months Ended September 30, 2021 (Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 447,137,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,539,071)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 443,598,050</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 12,366,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,893,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 8,472,288</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 459,503,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,432,894)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 452,070,338</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Medical Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 459,233,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 458,333,145</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 520,053,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 519,153,369</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Operating Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,550,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67,083,031)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Interest Expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,130,628)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,023,187)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,193,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,086,452)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss Attributable to Non-Controlling Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 8,043,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss (formerly Net Loss Attributable to Controlling Interests)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,700,292)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2021 (Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 152,276,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 796,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 153,072,995</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 4,243,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,130,303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 3,112,960</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 156,520,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 156,185,955</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Medical Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 161,662,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 161,328,123</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Operating Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 184,643,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (334,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 184,309,497</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Interest Expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,643,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,529,133)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Total Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,044,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,930,819)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss Attributable to Non-Controlling Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,801,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,801,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss (formerly Net Loss Attributable to Controlling Interests)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,366,517)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,801,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,054,361)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Nine Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,779,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,779,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85,743,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,246,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,895,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (215,007,793)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 962,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (962,163)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,168,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,114,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,054,361)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,246,686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,895,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (215,007,793)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85,743,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,169,483)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Health Plan Settlements Receivable/Premiums Receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,417,477)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (884,523)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Class A and Class D Preferred Returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,107,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,107,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statement of Changes in Members' Deficit for the Three Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 926,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (926,852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,967,931)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 2,036,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,532,955)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,464,410)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146,395,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,743,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,170)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_8hnFjJDhpk2D6ka9QLUTgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> (183,308,519)</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Changes in Members' Deficit for the 3 Months Ended March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Preferred Return at 8% for Class A Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 890,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (890,612)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,607,560)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 1,956,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,650,712)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (122,918,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 5,633,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,407,902)</p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Changes in Members' Deficit for the Year Ended December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (97,661,735)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 4,567,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,656,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,532,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (130,217,705)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">*Rounding may cause variances</p> 447137121 -3539071 443598050 12366111 -3893823 8472288 459503232 -7432894 452070338 459233085 -899940 458333145 520053309 -899940 519153369 -60550077 -6532954 -67083031 -13130628 6107441 -7023187 -25193893 6107441 -19086452 -8043678 8043678 -77700292 -8043678 6107441 -6532954 -86169483 152276992 796003 153072995 4243263 -1130303 3112960 156520255 -334300 156185955 161662423 -334300 161328123 184643797 -334300 184309497 -4643254 2114121 -2529133 -6044940 2114121 -3930819 -2801965 2801965 -31366517 -2801965 2114121 -32054361 0.08 2779619 -2779619 -85743970 6107441 -6532954 -86169483 -179246686 7895224 -43656331 -215007793 0.08 962163 -962163 -34168482 2114121 -32054361 -179246686 7895224 -43656331 -215007793 -85743970 6107441 -6532954 -86169483 -7417477 6532954 -884523 6107441 -6107441 0.08 926852 -926852 -24967931 2036476 -6532955 -29464410 -146395455 6743106 -43656170 0.08 890612 -890612 -26607560 1956848 -24650712 -122918168 5633581 -43656269 6532954 -154407902 -97661735 4567346 -43656270 6532954 -130217705 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Note 3: Going Concern and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced losses since its inception and had losses of $ 65,329,041 for the three-months ended September 30, 2022 and $1,029,225,234 for the nine-months ended September 30, 2022. Such losses were primarily the result of costs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">incurred in adding new members, building relationships with physician partners and payors, and developing new services. The Company anticipates operating losses and negative cash flows to continue for the foreseeable future as it continues to grow membership. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, and December 31, 2021, the Company had $34,357,237 and $140,477,586, respectively, in unrestricted cash and cash equivalents available to fund future operations. The Company’s capital requirements will depend on many factors, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital. The Company will need to use available capital resources and/or raise additional capital earlier than currently anticipated. When the Company pursues additional debt and/or equity financing, there can be no assurance that such financing will be available on terms commercially acceptable to the Company. If the Company is unable to obtain additional funding when needed, it will need to curtail planned activities in order to reduce costs, which will likely have an unfavorable effect on the Company’s ability to execute on its business plan, and have an adverse effect on its business, results of operations and future prospects. As a result of these matters, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p> -65329041 -1029225234 34357237 140477586 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 4: Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities,” the Company is the primary beneficiary of the following physician practices (“Network”):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kahan, Wakefield, Abdou, PLLC (“KWA”)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bacchus, Wakefield, Kahan, PC (“BACC”)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Health Partners Professional Services PC</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Medical Group, P.C.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Health Partners California, P.C.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Variable Interest Entities </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management analyzes whether the Company has any financial interests in Variable Interest Entities (“VIE” or “VIEs”). This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, <i style="font-style:italic;">Consolidation</i> (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Segment Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company presents its financial statements by segment in accordance with ASC Topic No. 280, <i style="font-style:italic;">Segment Reporting</i> (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined that the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment, which reflects how the CODM manages the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Management’s Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Earnings (Loss) per Share and Member Unit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders in the Successor Periods is presented in conformity with the two-class method required for participating securities. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company analyzed the calculation of net loss per member unit for the Predecessor Periods and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Cash and Restricted Cash</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At September 30, 2022 and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At September 30, 2022 and December 31, 2021, the Company had unrestricted cash of $34,357,237 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,357,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,477,586</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 356,286</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,360,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,833,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at September 30, 2021, that sum to the total of these items reported in the condensed consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,336,565</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,299</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,682,864</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition and Revenue Sources</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,988,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,072,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,956,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,278,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,729,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 548,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,272,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 780,775,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443,598,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,103,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,386,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 341,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,994,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,483,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,472,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,538,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,563,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,082,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,227,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,936,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,417,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,563,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,913,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,139,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,063,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,252,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,489,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,920,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,261,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,681,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,230,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,439,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,606,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,964,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,481,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Capitated Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on the health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first three quarters in 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022 and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across five states) and 17 health plans (across four states), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within <span style="-sec-ix-hidden:Hidden_ehYgf-kjHkyESFUY0kw90A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-one</span></span> months following each year-end. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At September 30, 2022, and December 31,2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Health Plan Receivables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 524,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,695,712</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,387,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,473,828</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,798,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,380,752</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,136,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,651,586</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,439,046</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,467,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,925,751</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239,375</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan H</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,570,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,185,619</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,134,750</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan J</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,915</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan K</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,705,147</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan L</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 899,560</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,388,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,747,116</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan N</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 598,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 974,092</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,279,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 666,291</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan P</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,162</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan Q</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 476,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,990</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan R</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,578,682</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan S</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan T</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,175,324</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,306</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan W</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,317)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Health Plan Receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,497,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,251,004</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Health Plan Settlement Payables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,579,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,882,250</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,103,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,085,425</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776,164</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215,626)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,151)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan V</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,149</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Health Plan Settlement Payables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,626,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,548,694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022, and December 31, 2021, management has deemed the Company’s settlement receivables to be fully collectible from those health plans where the Company is not delegated for claims processing. Accordingly, a constraint on the variable consideration associated with settlement receivables is not necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Clinical Fees and Insurance Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinic fees and insurance revenues relate to net patient fees received from various payers and direct patients (“self-payers”) under contracts in which the Company’s sole performance obligation is to provide healthcare services through the operation of medical clinics. The Company recognizes clinic fees and insurance revenue in the period in which services are provided, on the date of service, under FFS payment arrangements, revenue is recognized on the date of service. The Company’s performance obligations are typically satisfied in the same day services are provided. All the Company’s contracts with its customers under these arrangements include a single performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s contractual relationships with patients, in most cases, also involve third-party payers (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through state-sponsored health insurance exchanges). Transaction prices for services provided are dependent upon specific rules in place with third party payers – specifically, Medicare/Medicaid and pre-negotiated rates with managed care health plans and commercial insurance companies. Contractual arrangements with third parties typically include payments at amounts which are less than standard charges. These charges generally have predetermined rates for diagnostic service codes or discounted FFS rates. Management perpetually reviews the Company’s contractual estimation processes to consider and incorporate updates to laws, regulations and frequent changes in the managed care system. Contractual terms are negotiated and updated accordingly upon renewal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenue is based upon the estimated amounts management expects to receive from patients and third-party payers. Estimates of explicit price concessions under managed care and commercial insurance plans are tied to payment terms specified in related contractual agreements. Retroactively calculated explicit price concessions tied to reimbursement agreements with third-party payers are recognized on an estimated basis in the period related services are rendered and adjusted in future periods as final payments are received. Revenue related to uninsured patients, uninsured co-payments, and deductibles (for patients with healthcare coverage) may also be discounted. The Company records implicit price concessions (based on historical collection experience) related to uninsured accounts to recognize self-pay revenues at their most likely amounts to be collected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company deems FFS revenue to be variable consideration and that its estimates of associated transaction prices will not result in a significant revenue reversal in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on satisfaction of single performance obligations occurring on the dates of service, revenue is recognized as of the date services are provided. The Company, therefore, applies a portfolio approach to recognizing revenue from its FFS contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has elected two of the available practical expedients provided for by ASC 606. First, the Company did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Shared Risk Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 LLC (via one of its wholly owned subsidiaries – P3 Health Partners ACO, LLC “AzCC”) receives 30% of the shared risk savings from parties with whom it contracts under four separate arrangements. These arrangements are driven solely by medical cost containment year-over-year (“YoY”) expense reductions. This key performance indicator (“KPI”) is measured by the aggregate change in per member per year (“PMPY”) medical costs. If the sequential YoY PMPY aggregate change yields a reduction, the Company receives 30% of the associated total cost savings for that year. Conversely, if the sequential YoY PMPY aggregate change yields an increase in medical costs, no monies are due the Company that year. This KPI is compiled and reviewed on a calendar year basis. The Company recognizes shared risk revenue only upon the receipt of cash. Therefore, the likelihood of any significant revenue reversal in the future is non-existent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Care Coordination Fees and Management Fees</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s delegated health plans may also pay a Care Coordination Fee (“CCF”) or Management Fee to the Company. CCFs and Management Fees are intended to fund the costs of delegated services provided to certain health plans. CCFs are specifically identified and separated in each monthly capitation payment the Company receives from these parties. None of the Company’s other health plans bifurcate CCFs nor are any of them contractually required to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses a portfolio approach to account for CCFs and Management Fees. Based on similarities of the terms of the care coordination and administrative services, management believes that revenue recognized by utilizing the portfolio approach approximates that which it would have realized if an individual contract approach were applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Patient Fees Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially, all client fees and insurance receivables are due under FFS contracts with third party payors, such as commercial insurance companies (“Commercial”), government-sponsored healthcare programs (“Medicare/Medicaid”) or directly from patients (“Self-Pay”). Management continuously monitors activities from payors (including patients) and records an estimated price concession based on specific contracts and actual historical collection patterns. Patient fees receivable, where a third-party payor is responsible for the amount due, are carried at amounts determined by the original charges for services provided less implicit and explicit price concessions. Price concessions represent amounts made for contractual adjustments (discounts). Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and are recorded net of contractual allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient fees receivable are recorded at the invoiced amount, net of any expected contractual adjustments and implicit price concessions, and do not bear interest. The Company has agreements with third-party payors that provide for payments at amounts different from the established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Contractual adjustments arising under reimbursement arrangements with third- party payors are accrued on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined. Implicit price concessions are taken based on historical collection experience and reflect the estimated amounts the Company expects to collect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Goodwill</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 350, <i style="font-style:italic;">Intangibles - Goodwill and Other</i>, management tests goodwill for impairment at the reporting unit level. The Company has one reporting unit for goodwill impairment testing purposes. Goodwill is tested for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate the carrying value of goodwill may not be recoverable (a “triggering event”). On the occurrence of a triggering event, an entity has the option to first assess qualitative factors to determine whether a quantitative impairment test is necessary. If it is more likely than not that goodwill is impaired, the fair value of the reporting unit (the Company) is compared with its carrying value. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value, provided, the loss recognized cannot exceed the total amount of goodwill. No goodwill impairment charges were recorded in the first quarter or third quarter of 2022, respectively. Based on management’s analysis, a goodwill impairment charge of $851.5 million was recorded in the second quarter of 2022. See Note 11 “Goodwill.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Intangible Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. In determining the estimated useful lives of definite-lived intangibles, the Company considers the nature, competitive position, life cycle position and historical and expected future operating cash flows of each acquired asset, as well as its commitment to support these assets through continued investment and legal infringement protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. Such events and circumstances include the occurrence of an adverse change in the market involving the business employing the assets or a situation in which it is more likely than not that the Company will dispose of such assets. If the comparison indicates that there is impairment, the impairment loss to be recognized as a non-cash charge to earnings is measured by the amount by which the carrying amount of the asset exceeds its fair value. The impaired asset is written down to its fair value or, if fair value is not readily determinable, to an estimated fair value based on discounted expected future cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements </i>(“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 8 “Fair Value Measurements and Hierarchy” for further discussion):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities,” the Company is the primary beneficiary of the following physician practices (“Network”):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kahan, Wakefield, Abdou, PLLC (“KWA”)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bacchus, Wakefield, Kahan, PC (“BACC”)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Health Partners Professional Services PC</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Medical Group, P.C.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">P3 Health Partners California, P.C.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Variable Interest Entities </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management analyzes whether the Company has any financial interests in Variable Interest Entities (“VIE” or “VIEs”). This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, <i style="font-style:italic;">Consolidation</i> (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Segment Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company presents its financial statements by segment in accordance with ASC Topic No. 280, <i style="font-style:italic;">Segment Reporting</i> (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined that the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment, which reflects how the CODM manages the Company.</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Management’s Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Earnings (Loss) per Share and Member Unit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders in the Successor Periods is presented in conformity with the two-class method required for participating securities. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company analyzed the calculation of net loss per member unit for the Predecessor Periods and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Cash and Restricted Cash</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At September 30, 2022 and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At September 30, 2022 and December 31, 2021, the Company had unrestricted cash of $34,357,237 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,357,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,477,586</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 356,286</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,360,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,833,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at September 30, 2021, that sum to the total of these items reported in the condensed consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,336,565</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,299</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,682,864</p></td></tr></table> 250000 34357237 140477586 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,357,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,477,586</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 356,286</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,360,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,833,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrestricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,336,565</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,299</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Cash Balances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,682,864</p></td></tr></table> 34357237 140477586 1003307 356286 35360544 140833872 4336565 346299 4682864 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition and Revenue Sources</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,988,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,072,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,956,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,278,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,729,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 548,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,272,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 780,775,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443,598,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,103,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,386,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 341,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,994,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,483,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,472,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,538,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,563,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,082,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,227,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,936,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,417,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,563,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,913,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,139,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,063,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,252,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,489,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,920,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,261,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,681,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,230,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,439,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,606,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,964,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,481,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Capitated Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on the health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g. month) and is recognized net of projected acuity adjustments and performance incentives or penalties as management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first three quarters in 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022 and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across five states) and 17 health plans (across four states), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within <span style="-sec-ix-hidden:Hidden_ehYgf-kjHkyESFUY0kw90A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-one</span></span> months following each year-end. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At September 30, 2022, and December 31,2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Health Plan Receivables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 524,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,695,712</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,387,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,473,828</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,798,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,380,752</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,136,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,651,586</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,439,046</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,467,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,925,751</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239,375</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan H</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,570,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,185,619</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,134,750</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan J</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,915</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan K</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,705,147</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan L</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 899,560</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,388,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,747,116</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan N</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 598,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 974,092</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,279,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 666,291</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan P</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,162</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan Q</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 476,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,990</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan R</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,578,682</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan S</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan T</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,175,324</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,306</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan W</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,317)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Health Plan Receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,497,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,251,004</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Health Plan Settlement Payables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,579,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,882,250</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,103,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,085,425</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776,164</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215,626)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,151)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan V</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,149</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Health Plan Settlement Payables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,626,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,548,694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022, and December 31, 2021, management has deemed the Company’s settlement receivables to be fully collectible from those health plans where the Company is not delegated for claims processing. Accordingly, a constraint on the variable consideration associated with settlement receivables is not necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Clinical Fees and Insurance Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinic fees and insurance revenues relate to net patient fees received from various payers and direct patients (“self-payers”) under contracts in which the Company’s sole performance obligation is to provide healthcare services through the operation of medical clinics. The Company recognizes clinic fees and insurance revenue in the period in which services are provided, on the date of service, under FFS payment arrangements, revenue is recognized on the date of service. The Company’s performance obligations are typically satisfied in the same day services are provided. All the Company’s contracts with its customers under these arrangements include a single performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s contractual relationships with patients, in most cases, also involve third-party payers (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through state-sponsored health insurance exchanges). Transaction prices for services provided are dependent upon specific rules in place with third party payers – specifically, Medicare/Medicaid and pre-negotiated rates with managed care health plans and commercial insurance companies. Contractual arrangements with third parties typically include payments at amounts which are less than standard charges. These charges generally have predetermined rates for diagnostic service codes or discounted FFS rates. Management perpetually reviews the Company’s contractual estimation processes to consider and incorporate updates to laws, regulations and frequent changes in the managed care system. Contractual terms are negotiated and updated accordingly upon renewal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenue is based upon the estimated amounts management expects to receive from patients and third-party payers. Estimates of explicit price concessions under managed care and commercial insurance plans are tied to payment terms specified in related contractual agreements. Retroactively calculated explicit price concessions tied to reimbursement agreements with third-party payers are recognized on an estimated basis in the period related services are rendered and adjusted in future periods as final payments are received. Revenue related to uninsured patients, uninsured co-payments, and deductibles (for patients with healthcare coverage) may also be discounted. The Company records implicit price concessions (based on historical collection experience) related to uninsured accounts to recognize self-pay revenues at their most likely amounts to be collected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company deems FFS revenue to be variable consideration and that its estimates of associated transaction prices will not result in a significant revenue reversal in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on satisfaction of single performance obligations occurring on the dates of service, revenue is recognized as of the date services are provided. The Company, therefore, applies a portfolio approach to recognizing revenue from its FFS contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has elected two of the available practical expedients provided for by ASC 606. First, the Company did not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expensed all incremental customer contract acquisition costs as incurred as such costs are not material and would be amortized over a period less than one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Shared Risk Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 LLC (via one of its wholly owned subsidiaries – P3 Health Partners ACO, LLC “AzCC”) receives 30% of the shared risk savings from parties with whom it contracts under four separate arrangements. These arrangements are driven solely by medical cost containment year-over-year (“YoY”) expense reductions. This key performance indicator (“KPI”) is measured by the aggregate change in per member per year (“PMPY”) medical costs. If the sequential YoY PMPY aggregate change yields a reduction, the Company receives 30% of the associated total cost savings for that year. Conversely, if the sequential YoY PMPY aggregate change yields an increase in medical costs, no monies are due the Company that year. This KPI is compiled and reviewed on a calendar year basis. The Company recognizes shared risk revenue only upon the receipt of cash. Therefore, the likelihood of any significant revenue reversal in the future is non-existent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Patient Service Revenue – Care Coordination Fees and Management Fees</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s delegated health plans may also pay a Care Coordination Fee (“CCF”) or Management Fee to the Company. CCFs and Management Fees are intended to fund the costs of delegated services provided to certain health plans. CCFs are specifically identified and separated in each monthly capitation payment the Company receives from these parties. None of the Company’s other health plans bifurcate CCFs nor are any of them contractually required to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses a portfolio approach to account for CCFs and Management Fees. Based on similarities of the terms of the care coordination and administrative services, management believes that revenue recognized by utilizing the portfolio approach approximates that which it would have realized if an individual contract approach were applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Patient Fees Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially, all client fees and insurance receivables are due under FFS contracts with third party payors, such as commercial insurance companies (“Commercial”), government-sponsored healthcare programs (“Medicare/Medicaid”) or directly from patients (“Self-Pay”). Management continuously monitors activities from payors (including patients) and records an estimated price concession based on specific contracts and actual historical collection patterns. Patient fees receivable, where a third-party payor is responsible for the amount due, are carried at amounts determined by the original charges for services provided less implicit and explicit price concessions. Price concessions represent amounts made for contractual adjustments (discounts). Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and are recorded net of contractual allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient fees receivable are recorded at the invoiced amount, net of any expected contractual adjustments and implicit price concessions, and do not bear interest. The Company has agreements with third-party payors that provide for payments at amounts different from the established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenues are reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Contractual adjustments arising under reimbursement arrangements with third- party payors are accrued on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined. Implicit price concessions are taken based on historical collection experience and reflect the estimated amounts the Company expects to collect.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,988,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,072,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,956,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,278,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,729,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 548,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,272,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,112,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitated Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 780,775,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443,598,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Service Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical Fees &amp; Insurance Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,103,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,386,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shared Risk Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 341,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Care Coordination / Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,412,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,994,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Incentive Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,749,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Other Patient Service Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,483,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,472,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 243988004 0.983 153072995 0.980 1956604 0.008 1278339 0.008 0.000 139331 0.001 1729800 0.007 1146355 0.007 585665 0.002 548935 0.004 4272069 0.017 3112960 0.020 248260073 1.000 156185955 1.000 780775285 0.987 443598050 0.981 4103481 0.005 3386966 0.007 55154 0.000 341342 0.001 4412973 0.006 2994755 0.007 1911485 0.002 1749225 0.004 10483093 0.013 8472288 0.019 791258378 1.000 452070338 1.000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,538,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,563,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,082,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,227,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,936,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,417,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,563,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,913,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,139,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,063,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,260,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 156,185,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,252,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,489,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,920,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,261,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,681,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,230,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,439,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,606,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,964,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,481,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791,258,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,070,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 48538454 0.195 29563741 0.189 46082052 0.185 38227530 0.245 35936246 0.145 36417184 0.233 31563532 0.128 18913641 0.121 86139789 0.347 33063859 0.212 248260073 1.000 156185955 1.000 158252527 0.200 84489621 0.187 139920223 0.177 105261569 0.233 124681687 0.158 114230860 0.253 104439689 0.132 56606725 0.125 263964252 0.333 91481563 0.202 791258378 1.000 452070338 1.000 true P1M 20 5 17 4 P120D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Health Plan Receivables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 524,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,695,712</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,387,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,473,828</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,798,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,380,752</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,136,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,651,586</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,439,046</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,467,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,925,751</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239,375</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan H</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,570,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,185,619</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,134,750</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan J</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,915</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan K</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,705,147</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan L</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 899,560</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,388,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,747,116</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan N</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 598,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 974,092</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,279,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 666,291</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan P</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,162</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan Q</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 476,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,990</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan R</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,578,682</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan S</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan T</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,175,324</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,306</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Health Plan W</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,317)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Health Plan Receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,497,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,251,004</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Health Plan Settlement Payables</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,579,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,700,274</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,882,250</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan F</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,103,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,085,425</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776,164</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan I</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215,626)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan O</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,151)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan U</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,209</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Health Plan V</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,149</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Health Plan Settlement Payables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,626,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,548,694</p></td></tr></table> 524540 4695712 24387307 15473828 28798095 1380752 15136034 6651586 184332 2439046 1467834 2925751 35179 239375 3570820 2185619 1586752 1134750 -102380 149915 2705147 899560 1388190 1747116 598056 974092 2279489 666291 511469 106162 476057 61990 3578682 600639 57607 2175324 60306 -2317 81497703 50251004 2579575 11700274 11700274 3882250 5103534 6085425 900314 776164 -10915 -215626 39365 -39151 226209 226209 88480 133149 20626836 22548694 2 true true 0.30 4 0.30 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Goodwill</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 350, <i style="font-style:italic;">Intangibles - Goodwill and Other</i>, management tests goodwill for impairment at the reporting unit level. The Company has one reporting unit for goodwill impairment testing purposes. Goodwill is tested for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate the carrying value of goodwill may not be recoverable (a “triggering event”). On the occurrence of a triggering event, an entity has the option to first assess qualitative factors to determine whether a quantitative impairment test is necessary. If it is more likely than not that goodwill is impaired, the fair value of the reporting unit (the Company) is compared with its carrying value. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value, provided, the loss recognized cannot exceed the total amount of goodwill. No goodwill impairment charges were recorded in the first quarter or third quarter of 2022, respectively. Based on management’s analysis, a goodwill impairment charge of $851.5 million was recorded in the second quarter of 2022. See Note 11 “Goodwill.”</p> 0 0 851500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Intangible Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. In determining the estimated useful lives of definite-lived intangibles, the Company considers the nature, competitive position, life cycle position and historical and expected future operating cash flows of each acquired asset, as well as its commitment to support these assets through continued investment and legal infringement protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires comparing the carrying amount to the sum of undiscounted cash flows expected to be generated by the asset. Such events and circumstances include the occurrence of an adverse change in the market involving the business employing the assets or a situation in which it is more likely than not that the Company will dispose of such assets. If the comparison indicates that there is impairment, the impairment loss to be recognized as a non-cash charge to earnings is measured by the amount by which the carrying amount of the asset exceeds its fair value. The impaired asset is written down to its fair value or, if fair value is not readily determinable, to an estimated fair value based on discounted expected future cash flows.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements </i>(“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 8 “Fair Value Measurements and Hierarchy” for further discussion):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 5: Recent Accounting Pronouncements Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Simplifying the Accounting for Income Taxes</i> (“ASU 2019-12”). ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. It is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted the ASU in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASU 2021-04 requires issuers to account for modifications or exchanges of freestanding equity-classified written call options (e.g., warrants) that remain equity classified after the modification or exchange based on the economic substance of the modification or exchange. The Company adopted ASU 2014-04 in the first quarter of 2022 on a prospective basis. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASU 2021-10, Government Assistance (Topic 8352), Disclosures by Business Entities about Government Assistance (“ASU 2021-10”)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10. ASU 2021-10 requires annual disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model including (i) information about the nature of the transactions and the related accounting policy used to account for the transaction; (ii) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (iii) significant terms and conditions of the transactions, including commitments and contingencies. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company adopted the ASU prospectively on January 1, 2022. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 6: Recent Accounting Pronouncements Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (“ASU 2016 13”). ASU 2016 13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for the Company beginning January 1, 2023. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </i>(“ASU 2020-06”). ASU 2020-06 eliminates two of the three models in ASC 470-20 that require issuers to separately account for embedded conversion features and eliminates some of the requirements for equity classification in ASC 815-40-25 for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and generally requires them to include the effect of potential share settlement for instruments that may be settled in cash or shares. It is effective for annual periods beginning after December 15, 2023, and interim periods therein. Early adoption is permitted in fiscal years beginning after December 15, 2020, but the Company must adopt the guidance as of the beginning of a fiscal year. The Company is evaluating the effect ASU 2020-06 will have on its financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the FASB issued ASU 2021-08, <i style="font-style:italic;">Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i> (“ASU 2021-08”). ASU 2021-08 requires that an entity (acquirer) recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts as if it had originated the contracts. The amendments in this update are effective for fiscal years beginning after December 15, 2022. Early adoption is permitted. Adoption is not currently expected to have a material impact on the Company’s financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 7: Business Combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Foresight Business Combinations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 3, 2021, the Company entered into the Business Combinations described in Note 1 “Organization and Basis of Presentation.” The Business Combinations represent a forward merger and is accounted for using the acquisition method of accounting under which P3 Health Group Holdings, LLC is treated as the acquired company for financial reporting purposes. This determination is based primarily on the following facts:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is the sole managing member of P3 LLC subsequent to the consummation of the Business Combinations, and the managing member conducts, directs and exercises full control over all activities of P3 LLC. The non-managing members of P3 LLC do not have substantive kick-out or participating rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No one predecessor stakeholder of P3 had a controlling interest in P3 before or has a controlling interest in the combined company after the Business Combination. The Business Combination is not a transaction between entities under common control.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors support the conclusion that the Company acquired a controlling interest in P3 LLC and is the accounting acquirer. For accounting purposes, the accounting acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated based on the variable interest or voting interest model pursuant to ASC 810. If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. The Company is the primary beneficiary of P3 LLC, which is a variable interest entity, since it has the power to direct the activities of P3 LLC that most significantly impact P3 LLC’s economic performance through its role as the sole managing member. Therefore, the Company is the accounting acquirer of P3 LLC and the Business Combinations should be accounted for using the acquisition method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the acquisition method of accounting, Foresight’s assets and liabilities are recorded at carrying value and the assets and liabilities associated with P3 LLC are recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The acquisition method of accounting is based on ASC Topic 805, <i style="font-style:italic;">Business Combinations</i> (“ASC 805”) and uses the fair value concepts defined in ASC 820. In general, ASC 805 requires, among other things, that assets acquired, and liabilities assumed be recognized at their fair values as of the acquisition date by the accounting acquirer, which was determined to be Foresight.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 defines fair value, establishes a framework for measuring fair value, and sets forth a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to develop the fair value measurements. Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for a non-financial asset assume the highest and best use by these market participants. Many of these fair value measurements can be highly subjective, and it is possible that other professionals applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Business Combinations, P3 LLC, which represents substantially all of the economic activity of the Company, is a subsidiary of the Company. Since the Company is the sole managing member of P3 LLC following the Business Combinations, the P3 LLC Units held by certain of the former owners of P3 Health Group Holdings, LLC (the “P3 Equity Holders”) are classified as Redeemable Noncontrolling Interests in the Company’s financial statements for financial reporting purposes. An allocation of net income or loss representing the percentage of ownership of P3 LLC not controlled by the Company, will be attributed to the Redeemable Noncontrolling Interests in the Company’s statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of the Business Combinations, the Company entered into a Tax Receivable Agreement (“TRA”) with certain of the P3 Equity holders and P3 LLC. The TRA provides for the payment to the P3 Equity holders of 85% of the income tax benefits, if any, that are actually realized. At the completion of the Business Combinations, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such tax benefits after concluding it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets. See Note 16 “Income Taxes” for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following summarizes the purchase price consideration:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Foresight</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,300,733</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair Value of Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,807,427,576</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock Compensation Pre-combination Services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,313,476</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash Consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,405,083</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of P3 Health Group Holdings, LLC’s Transaction Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,151,752</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Purchase Consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,951,598,620</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recorded the allocation of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the Closing Date. The allocation reflects the fair value of assets and liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">associated with the Company’s other acquisitions in 2021 which occurred in the Predecessor period described below with the exception of Medcore Health Plan, Inc. (“Medcore HP”) and Omni IPA Medical Group, Inc. (“Omni”), which occurred in the Successor Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The aggregate purchase price consideration for the P3 LLC acquisition has been allocated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Purchase Price Allocation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets Acquired:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,300,842</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,095</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plan Settlement Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,733,033</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinic Fees and Insurance Receivables, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426,064</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,880,939</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 938,413</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,875,234</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible Assets, Net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Customer Relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 684,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Provider Network</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,700,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,700,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,278,452,778</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Notes Receivable, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,734,012</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right of Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,870,279</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,188,665,689</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities Assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,819,091</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,868,664</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plans Settlements Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,007,542</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Claims Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,031,460</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Premium Deficiency Reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,559,067</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,268,846</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Portion of Long-Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301,443</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,210,956</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-Term Debt, Net of Current Portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 237,067,069</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,951,598,620</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $3.8 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes. See Note 16 “Income Taxes.” The useful life of acquired definite lived intangible assets is 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Other Acquisitions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 27, and December 31, 2021, respectively, the Company acquired 100% of the outstanding equity of Medcore HP and the net assets of <span style="-sec-ix-hidden:Hidden_jvtpxhvA1UC0SzvUlstCzQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Omni</span></span> (collectively the “Medcore Acquisition”). Medcore HP is a health plan licensed under the California Knox-Keen Health Care Service Plan Act of 1975, and Omni is an independent practice association located in California. Omni serves as Medcore HP’s contracted and fully delegated physician network providing medical services to Medcore HP’s patients and members. Because of the extensive inter-reliance of these two businesses, the Company accounted for the purchases as a single, combined business. The total purchase price of $40,013,321 includes $3,486,593 to be paid to the sellers upon resolution of the assumed claims payable, or the cost of services that have been incurred, but not yet reported (“IBNR”), and risk adjustment factor. Due to the volatility of these items, the outcome cannot be currently estimated. Release of this payment, currently expected in the first quarter of 2023, is not subject to resolution of a substantive future contingent event and has therefore been included in the total consideration to be transferred. The cash payment, net of cash acquired and the $3,486,593 retained, was $15,677,205.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price over the fair value assigned to tangible and identifiable intangible assets acquired and liabilities assumed and represents the future economic benefits expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and expected future market opportunities. $8.1 million of goodwill recognized in the Business Combinations is expected to be deductible for tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The aggregate purchase price consideration of the other acquisitions in 2021 has been allocated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets Acquired:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,547,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plan Settlement Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,754,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinic Fees and Insurance Receivables, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 726,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,896</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible Assets, Net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Customer Relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,045,604</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Pay or Contracts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,700,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provider Network</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Medical Licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,297,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,934,500</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,471,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989,000</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities Assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plans Settlements Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Claims Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,898,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,458,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,013,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also purchased three other medical practices during the Predecessor Period of 2021 for a total net cash purchase price of $4,989,000. As referenced above, the assets acquired and liabilities assumed in these acquisitions was included in the purchase consideration and allocation for the Business Combinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the third quarter of 2022, the Company acquired two medical practices in separate transactions. The total cash purchase price was $5,500,131, net of cash acquired, and was allocated primarily to goodwill. The acquisitions were determined to be immaterial for disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Pro Forma Financial Information (Unaudited)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following unaudited pro forma financial information presents combined results of operations for the periods presented as if the acquisition of P3 Health Group Holdings, LLC and the Medcore Acquisition had occurred on January 1, 2021. The unaudited pro forma results may not necessarily reflect actual results of operations that would have been achieved, nor are they necessarily indicative of future results of operations. The unaudited pro forma results reflect the step-up amortization adjustments for the fair value of intangible assets acquired, transaction expenses, accelerated vesting of equity compensation and income attributable to non-controlling interest holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,305,732</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,492,450)</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss Attributable to Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (148,260,764)</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss Attributable to Controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,231,686)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma financial information has been presented for illustrative purposes only and is not necessarily indicative of results of operations that would have been achieved had the acquisition taken place on the date indicated, or the future consolidated results of operations of the Company. The pro forma financial information presented above has been derived from the historical condensed consolidated financial statements of the Company, the Company's Predecessor Periods and the Company's Successor Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma results include certain pro forma adjustments to revenue and net loss that were directly attributable to the P3 Health Group Holdings, LLC acquisition, assuming the acquisition had occurred on January 1, 2021, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Transaction costs of approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$39.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The acceleration of certain stock-based awards of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million are assumed to have occurred on January 1, 2021 and are recognized as if incurred on January 1, 2021.</span></td></tr></table><div style="margin-top:12pt;"/> 0.85 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Foresight</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,300,733</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair Value of Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,807,427,576</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock Compensation Pre-combination Services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,313,476</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash Consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,405,083</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of P3 Health Group Holdings, LLC’s Transaction Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,151,752</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Purchase Consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,951,598,620</p></td></tr></table> 80300733 1807427576 26313476 18405083 19151752 1951598620 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Purchase Price Allocation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amounts</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets Acquired:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,300,842</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,095</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plan Settlement Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,733,033</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinic Fees and Insurance Receivables, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426,064</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,880,939</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 938,413</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,875,234</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible Assets, Net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Customer Relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 684,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Provider Network</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,700,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,700,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,278,452,778</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Notes Receivable, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,734,012</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right of Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,870,279</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,188,665,689</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities Assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,819,091</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,868,664</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plans Settlements Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,007,542</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Claims Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,031,460</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Premium Deficiency Reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,559,067</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,268,846</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Portion of Long-Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301,443</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,210,956</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-Term Debt, Net of Current Portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 237,067,069</p></td></tr><tr><td style="vertical-align:bottom;width:83.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,951,598,620</p></td></tr></table> 5300842 54095 47733033 426064 1880939 938413 7875234 684000000 3700000 147700000 1278452778 3734012 6870279 2188665689 25819091 2868664 25007542 76031460 11559067 9268846 301443 6210956 80000000 237067069 1951598620 3800000 P10Y 1 2 40013321 3486593 3486593 15677205 8100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets Acquired:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,547,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plan Settlement Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,754,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinic Fees and Insurance Receivables, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 726,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,189,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,896</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible Assets, Net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Customer Relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,045,604</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Pay or Contracts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,700,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provider Network</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Medical Licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,297,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,934,500</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,471,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989,000</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities Assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Health Plans Settlements Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Claims Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,898,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,458,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,013,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989,000</p></td></tr></table> 20547337 3000 302187 5754006 141186 726378 1189575 113436 5896 2045604 4700271 1100000 900000 700000 31297438 2934500 67471814 4989000 150196 277074 133149 26898074 27458493 40013321 4989000 3 4989000 2 5500131 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Operating Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,305,732</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,492,450)</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss Attributable to Non-controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (148,260,764)</p></td></tr><tr><td style="vertical-align:bottom;width:77.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss Attributable to Controlling Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,231,686)</p></td></tr></table> 567305732 -179492450 -148260764 -31231686 39400000 2400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 8: Fair Value Measurements and Hierarchy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 4 “Significant Accounting Policies” for a summary of the Company’s policies relating to fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents the carrying amounts of the Company’s financial instruments as of September 30, 2022 and December 31, 2021, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Financial assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 34,357,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 140,477,586</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Restricted cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 356,286</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Clinics fees and insurance receivables, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 1,049,253</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 1,090,104</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Other receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,736,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 726,903</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Financial liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Accounts payable and accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,072,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 17,730,683</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Warrants liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 7,996,432</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 11,382,826</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The book value of cash, clinic fees and insurance receivables, net, other receivables, and accounts payable and accrued expenses approximate fair value because of the short maturity and high liquidity of these instruments. Liabilities for private placement warrants are measured at fair value using Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,774,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,996,432</p></td></tr><tr><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,880,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,382,826</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The key Level 3 inputs into the option pricing model as of September 30, 2022 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-Free Interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The key Level 3 inputs into the option pricing model as of December 31, 2021 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-Free Interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock, and an increase in the remaining term of the warrants would each result in a directionally similar change in the estimated fair value of the Company’s warrant liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability. The Company has not, and does not plan to, declare dividends on its common stock and, as such, there is no change in the estimated fair value of the warrant liabilities due to the dividend assumption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning Balance of Private Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 502,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,316,605</p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FJNwWzxE-0G98sFO9RECLQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mark-to-Market Adjustment for Stock Warrants</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (280,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,063,265</p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending Balance of Private Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,379,870</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Financial assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 34,357,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 140,477,586</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Restricted cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 356,286</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Clinics fees and insurance receivables, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 1,049,253</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 1,090,104</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Other receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,736,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 726,903</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Financial liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">  </span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Accounts payable and accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,072,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 17,730,683</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Warrants liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 7,996,432</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="color:#231f20;"> 11,382,826</span></p></td></tr></table> 34357237 140477586 1003307 356286 1049253 1090104 2736184 726903 24072391 17730683 7996432 11382826 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,774,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,996,432</p></td></tr><tr><td style="vertical-align:bottom;width:59.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,880,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,382,826</p></td></tr></table> 7774549 221883 7996432 10880550 502276 11382826 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The key Level 3 inputs into the option pricing model as of September 30, 2022 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-Free Interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The key Level 3 inputs into the option pricing model as of December 31, 2021 relating to the Private Placement Warrants to purchase Class A Common Stock were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-Free Interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Years</p></td></tr></table> 60.00 4.16 11.50 4.2 60.00 1.26 11.50 4.9 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning Balance of Private Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 502,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,316,605</p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FJNwWzxE-0G98sFO9RECLQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mark-to-Market Adjustment for Stock Warrants</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (280,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,063,265</p></td></tr><tr><td style="vertical-align:bottom;width:57.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending Balance of Private Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,379,870</p></td></tr></table> 502276 6316605 -280393 12063265 221883 18379870 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 9: Patient Fees Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Patient fees receivable is included in Clinic Fees and Insurance Receivables in the Company’s condensed consolidated balance sheets and consisted of the following categories for each of the periods ending September 30, 2022 and December 31, 2021 presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Receivables: Gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,383,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,182</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Contractual Allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,745,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,968,750)</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Receivables Net of Contractual Allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672,432</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Receivables: Gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,383,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,182</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Contractual Allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,745,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,968,750)</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Receivables Net of Contractual Allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672,432</p></td></tr></table> 5383421 2641182 4745367 1968750 638054 672432 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 10: Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s property and equipment balances as of September 30, 2022 and December 31, 2021 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold Improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,809,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,537,091</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture &amp; Fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,450,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,108,184</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer Equipment &amp; Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,852,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,700,617</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medical Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,066,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 414,100</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software (Development in Process)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,918,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,433,470</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,788</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,509,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,230,250</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,994,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,321)</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,515,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,047,929</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold Improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,809,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,537,091</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture &amp; Fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,450,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,108,184</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer Equipment &amp; Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,852,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,700,617</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medical Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,066,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 414,100</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software (Development in Process)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,918,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,433,470</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,788</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,509,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,230,250</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,994,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,321)</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,515,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,047,929</p></td></tr></table> 1809927 1537091 1450626 1108184 2852746 2700617 1066959 414100 3918615 2433470 373995 36788 36788 11509656 8230250 1994380 182321 9515276 8047929 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 11: Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of changes in the Company’s goodwill during the nine months ended September 30, 2022 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,309,750,216</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,201,729</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (851,455,754)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,496,191</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill, which represents the excess of cost over the fair value of net assets acquired, was $463,496,191 and $1,309,750,216 as of September 30, 2022, and December 31, 2021. The Company acquired two medical practices during the nine months ended September 30, 2022. In the second quarter of 2022, the overall market had significantly deteriorated and there was a sustained decrease in the Company’s share price. As a result, and as required by ASC 350, the Company performed an interim goodwill impairment test as of June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company first assessed qualitative factors to determine if it was more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Management noted that the steady decline in share price from April 1, 2022, through June 30, 2022, covers a period of three months. The stock was 63% lower than its opening price on December 2, 2021, and has not surpassed that price since December 15, 2021. Additionally, the Company’s share price continued to decline in May 2022, which did not follow the overall rebound pattern in the healthcare industry. Thus, management determined that it was not just market factors affecting the price and that the share price performance covered a sustained period of time. In addition, the Company incurred higher than expected medical expenses due to the COVID-19 pandemic, which resulted in a decrease in adjusted EBITDA. Management concluded that, given the macroeconomic and financial market conditions, industry-specific considerations, the Company’s performance, and the sustained decrease in share price, it was more likely than not that the fair value of P3 was less than its carrying amount at June 30, 2022. As a result, management performed an interim test of impairment using quantitative methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When performing quantitative testing, the Company first estimated the fair values of its reporting units using a weighted combination of discounted cash flows and a market-based method. Taking into consideration the updated business outlook and current difficult market conditions, management updated the assumption for future cash flow estimation. In particular, management increased expected medical expense in the cash flow projection for the goodwill impairment test, which lowered the forecast for adjusted EBITDA. Under the market approach, management estimated a fair value based on comparable companies' market multiples of revenues and EBITDA. Finally, management compared the weighted estimated fair value to the carrying amount. Based on management’s quantitative analysis, an $851.5 million goodwill impairment charge was recorded for the three-month period ended June 30, 2022. No goodwill impairment was recorded for the three-month period ended September 30, 2022 as there were no indicators of impairment during this period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the Company’s goodwill impairment analysis is sensitive to market capitalization, projected revenues, and adjusted EBITDA, the Company will continue to monitor key assumptions and other factors utilized in the interim goodwill impairment analysis.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,309,750,216</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,201,729</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (851,455,754)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,496,191</p></td></tr></table> 1309750216 5201729 851455754 463496191 463496191 1309750216 2 P3M 0.63 851500000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 12: Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The follow tables provide changes in other intangible assets for the nine months ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 60pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Provider </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 60pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Relationships</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trademarks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payor Contracts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Network</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 678,300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,369,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,700,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,769,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835,838,605</p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,415,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (352,522)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (360,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,427,522)</p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 627,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,954,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,347,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,409,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 772,411,083</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization of intangible assets is anticipated to be approximately $84 <span style="-sec-ix-hidden:Hidden_OmRx7LIRx0qMoDYg2kTUfw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> <span style="-sec-ix-hidden:Hidden_NSCwTXwrkk63aUvCiCDkqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span></span> <span style="-sec-ix-hidden:Hidden_V112iwCK0E-1hYAktBUeaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each</span></span> <span style="-sec-ix-hidden:Hidden_MG2FZ5mRcUivmyyXne9fHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span></span> the years 2022 through 2026. The weighted average remaining useful life of definite lived intangible assets is 9.2 years.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 60pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Provider </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 60pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Relationships</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trademarks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payor Contracts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Network</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Licenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 678,300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,369,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,700,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,769,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835,838,605</p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,415,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (352,522)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (360,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,427,522)</p></td></tr><tr><td style="vertical-align:bottom;width:29.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 627,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,954,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,347,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,409,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 772,411,083</p></td></tr></table> 678300000 147369167 4700271 4769167 700000 835838605 51300000 11415000 352522 360000 63427522 627000000 135954167 4347749 4409167 700000 772411083 84000000 P9Y2M12D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 13: Notes Receivable, Net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into five Promissory Notes (the “Notes”) with three family medical practices (the “Practices”) to fund their working capital needs. The Company simultaneously entered into separate Provider Agreements with each Practice related to four of these five Notes. Each Provider Agreement establishes a preferred, predetermined reimbursement rate for services rendered to the Company’s members and requires that Practice to furnish healthcare services to the Company’s members. The Provider Agreements mature in concert with each practice’s loan. In accordance with each of these four Notes, so long as the corresponding Provider Agreement is in effect on the maturity date of each Note and has not been terminated by the borrower for any reason, the Company will forgive the entire principal, plus accrued interest due on the date of maturity. Likewise, if the Company terminates the Provider Agreement prior to maturity without cause, all principal plus accrued interest due from the borrower will be forgiven. Upon early termination of the Provider Agreement by borrower, all principal and accrued interest will become immediately payable and due the Company. Related to potential forgiveness, the Company records a valuation allowance on a straight-line basis following the early termination date through the date of maturity, due to the probable likelihood of forgiveness of the Notes at maturity, with a full valuation allowance set at the time of maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022 and December 31, 2021, the Company has recorded notes receivable of $4,526,522 (including $963,060 current portion) and $3,590,715 including accrued interest receivable of $1,040,729 and $885,243, and net of valuation allowances of $709,547 and $526,808, respectively. The Notes carry maturity dates ranging from December 31, 2021 through December 31, 2028 with interest rates ranging from 5.0% to 10.0%. The short-term components of these Notes as of September 30, 2022 and December 31, 2021, is included in Other Receivables in the Company’s condensed consolidated balance sheets.</p> 5 3 4 5 4 4526522 963060 3590715 1040729 885243 709547 526808 0.050 0.100 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 14: Claims Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Claims payable includes claims reported as of the balance sheet date, including estimates for IBNR, due to third parties for health care services provided to members. IBNR was $134,705,426 and $101,958,324 at September 30, 2022 and December 31, 2021, respectively. Activity in the liability for claims payable and healthcare expenses for the nine months ended September 30, 2022 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, Beginning of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,958,324</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incurred, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,236,928</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,024,653</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705,261,581</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paid, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,830,033</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,684,446</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672,514,479</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, End of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,705,426</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimates for incurred claims are based on historical enrollment and cost trends while also taking into consideration operational changes. Future and actual results typically differ from estimates. Differences could result from an overall change in medical expenses per member, changes in member mix or simply due to the addition of new members.</p> 134705426 101958324 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, Beginning of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,958,324</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incurred, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 700,236,928</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,024,653</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 705,261,581</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paid, Related to:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,830,033</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prior Period(s)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,684,446</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672,514,479</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Unpaid, End of Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,705,426</p></td></tr></table> 101958324 700236928 5024653 705261581 570830033 101684446 672514479 134705426 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 15: Long-Term Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2020, the Company entered a Term Loan and Security Agreement (the “Facility” or “Term Loan”) with a commercial lender (“LTD-D”). The Facility was amended on December 21, 2021. The Facility provided funding up to $100,000,000, of which $65,000,000 has been drawn as of September 30, 2022. Access to additional borrowings above $65,000,000 under the Facility ended upon termination of the commitment period on February 28, 2022. Of the $65,000,000 drawn, $61,058,281 was received (net of $3,941,719 in financing costs). Upon closing of the Business Combinations on December 3, 2021, the unamortized financing costs were written off and the debt was recorded at fair value. The Facility may be used to pay certain indebtedness of the Company and for general working capital needs. Accrued interest was $4,320,493 and $2,259,588 at September 30, 2022 and December 31, 2021, respectively. The Facility includes certain restrictive covenants, including restrictions on the payment of cash dividends. Repayment of principal of all amounts drawn are due at maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was required to meet a borrowing base milestone by demonstrating to the lenders that revenue for any <span style="-sec-ix-hidden:Hidden_C9nZ7xpJ-E2F9JiZEeBX1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> consecutive month period (ending after the Facility’s closing date, but on or prior to December 31, 2021) was greater than or equal to $125.0 million. Additionally, the Company must remain in compliance with financial covenants including minimum liquidity of $5.0 million and annual minimum revenue levels. Beginning in 2021, and on an annual basis thereafter, the Company must post minimum annual revenue equal to or greater than $395.0 million; increasing to $460.0 million in 2022; $525.0 million in 2023; $585.0 million in 2024 and $650.0 million in 2025 and thereafter. Also, the Company is subject to certain restrictions that include indebtedness and liens. As of December 31, 2021, the Company was not in compliance with its Term Loan covenants related to issuance of the 2021 financial statements with an audit opinion free of a “going concern” qualification or timely filing of the 2021 financial statements. The Term Loan lenders granted (i) a waiver of the covenant under the Facility related to the existence of a “going concern” qualification in the audit opinion for our audited financial statements for the fiscal year ended December 31, 2021 and (ii) a consent to extend the deadline to provide audited financial statements for the year ended December 31, 2021 to October 21, 2022. The Company issued the 2021 financial statements on October 21, 2022. The Company was in compliance with all other covenants under the Facility as of September 30,2022. However, there can be no assurance that the Company will be able to maintain compliance with these covenants in the future or that the lenders under the Facility or the lenders of any future indebtedness the Company may incur will grant us any such waiver or forbearance in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Facility’s expected maturity date is December 31, 2025. This maturity date may be accelerated as a remedy under the certain default provisions in the agreement or in the event a mandatory prepayment trigger occurs. Interest is payable at 12.0% per annum on a quarterly cycle (in arrears) beginning March 31, 2021. Management may elect to pay the full 12.0% per annum in cash or 8.0% per annum interest in cash with the remaining 4.0% per annum being added to principal as “paid in kind” (“PIK”) for a period of three years (or twelve payments). The PIK is subject to acceleration in the event certain occurrences in the Facility’s agreement are triggered. The Facility’s Lenders also received ten-year warrants to purchase 858,351 shares of Series D Preferred Units at $4.68 per share. These warrants have been recorded as a liability in the Company’s consolidated balance sheets at fair market value and are marked to market on a quarterly basis until exercised. A discount was recorded on the debt issued for the same amount and written off upon closing of the Business Combinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Security Agreement provides the Lenders collateral in 100% of the Company’s pledged stock, its subsidiaries (including tangible and intangible personal property) and bank accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 7, 2020, the Company repurchased 200,000 Class C (Time-based) Units, at $0.90 per Unit from a former Executive through issuance of a long-term note (“LTD-E”). This repurchase was recognized in the Company’s consolidated balance sheets as a reduction to Members’ Deficit in the amount of $180,000 and a corresponding increase in long-term debt. LTD-E bore interest of 3.25% and fixed monthly payments of $7,757 through date of maturity. On June 7, 2022, the Company repaid all amounts outstanding under the long-term note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, the Company executed a share repurchase agreement with one of its investors (“LTD-C”) which was subsequently amended on November 19, 2020. The agreement, as amended stipulated $15.0 million originally contributed by the investor would be repaid by the earlier of June 30, 2026 or a change in control transaction. As part of this repurchase agreement, the investor exchanged its owned units back for a $15.0 million note receivable from the Company – thus, no longer holding its former equity position. The note carries interest of 11.0% per year. The principal balance, accrued interest and an exit fee of $600,000 is due at maturity. Accrued interest was $8,335,425 and $6,511,477 at September 30, 2022 and December 31, 2021, respectively. The total principal balance is included in Long-Term Debt on the Company’s consolidated balance sheets at September 30, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables roll forward the long-term debt balances, including current portion, presented in the Company’s condensed consolidated balance sheets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-C</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-D</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-E</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,046,101</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issued in 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Payments in 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of September 30, 2022, for the periods presented below, the Company’s minimum payments due under debt obligations were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Cash </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PIK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments*</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October 1, 2022 to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,342,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401,192</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,624,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675,461</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,061,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,882,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,882,309</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,274,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,518,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,518,225</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,851,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,054,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,054,451</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,154,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,531,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132,531,638</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">*    </span><i style="font-style:italic;font-weight:normal;">Total Payments Cash and Non-Cash (PIK)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">Long-term debt was comprised of the following at September 30, 2022 and December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,046,101</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Current Portion of Long-Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Short-Term Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2021, the Company entered into short term financing agreements totaling $3,683,100 for the funding of certain insurance policies. The terms of the agreements ranged from <span style="-sec-ix-hidden:Hidden_dhhZvTEGKk6L90eU9Vcrsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span></span> to ten months and the weighted average annual interest rate was 2.6%. There are no remaining scheduled principal payments as of September 30, 2022 as the debt was paid off during the third quarter of 2022.</p> 100000000 65000000 65000000 65000000 61058281 3941719 4320493 2259588 125000000.0 5000000.0 395000000.0 460000000.0 525000000.0 585000000.0 650000000.0 0.120 0.120 0.080 0.040 P3Y 12 P10Y 858351 4.68 1 200000 0.90 180000 0.0325 7757 1 15000000.0 15000000.0 0.110 600000 8335425 6511477 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-C</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-D</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LTD-E</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,046,101</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issued in 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Payments in 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td></tr><tr><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr></table> 15000000 65000000 46101 80046101 46101 46101 15000000 65000000 80000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Cash </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PIK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments*</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October 1, 2022 to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,342,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401,192</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,624,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675,461</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,061,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,882,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,882,309</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,274,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,518,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,518,225</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,851,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,054,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,054,451</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,154,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,531,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132,531,638</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">*    </span><i style="font-style:italic;font-weight:normal;">Total Payments Cash and Non-Cash (PIK)</i></p> 1342321 1401192 1401192 5624513 5675461 5675461 6061814 5882309 5882309 65000000 6274526 19518225 84518225 15000000 1851284 20054451 35054451 80000000 21154458 52531638 132531638 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,046,101</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Current Portion of Long-Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,101)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long Term Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,000,000</p></td></tr></table> 80000000 80046101 46101 80000000 80000000 3683100 P10M 0.026 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 16: Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Business Combinations, substantially all the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interests in P3 LLC. P3 LLC is treated as a partnership for U.S. federal and most applicable state and local income tax jurisdictions. As a partnership, P3 LLC is generally not subject to U.S. federal, state, and local income taxes. Any taxable income or loss generated by P3 LLC is passed through to and included within the taxable income or loss of its members in accordance with the terms of the P3 LLC A&amp;R LLC Agreement. Prior to the Business Combinations, the income and losses of P3 LLC was passed through to its members and nontaxable to P3 LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is taxed as a corporation and pays corporate federal, state, and local taxes on income allocated to it from P3 LLC based on the Company’s economic interest held in P3 LLC. While the Company consolidates P3 LLC for financial purposes, the Company will not be taxed on the earnings attributed to the non-controlling interests. As a result, the income tax burden on the earnings taxed on the non-controlling interests is not reported by the Company in its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To calculate the interim tax provision, at the end of each interim period, the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgements including, but not limited to, the expected operating income for the year, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the quarter ended June 30, 2022, the Company impaired goodwill related to the intangible asset recorded at P3 LLC in the amount of $851.5 million. The impairment reduced the book basis of the Company's investment in P3 LLC such that the recognition of a deferred tax asset on the outside book and tax basis investment difference resulted. The deferred tax asset related to the investment on P3 LLC has been simultaneously reduced fully by an increase to the recorded valuation allowance due to both cumulative losses in recent years of the Company, and the capital character for income tax purposes of the outside basis difference such that the Company would need sufficient capital character gains for income tax purposes to realize the tax over book outside basis difference. Prior to the impairment, the outside basis difference was an unrecognized deferred tax liability due to the amount of book goodwill more than tax goodwill for which a recognition exception applied. The amount of the deferred tax asset and offsetting valuation allowance related to the outside basis difference for the investment in P3 LLC as of September 30, 2022 is an estimated $7.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No income tax expenses were incurred for the nine months ended September 30, 2022 and 2021. The Company continues to be in a net operating loss and deferred tax asset position. As a result, and in accordance with accounting standards, the Company recorded a valuation allowance to reduce the value of the net deferred tax assets to <span style="-sec-ix-hidden:Hidden_Z3Efw_KyMECRYImf9Uj_0A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero.</span></span> The Company’s effective tax rate for the nine-months ended September 30, 2022 and 2021 was 0.00%. There was no uncertain tax provision nor contingencies as of September 30, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Tax Receivable Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to our election under Section 754 of the Internal Revenue Code (the “Code”), the Company expects to obtain an increase in our share of the tax basis in the net assets of P3 LLC when its units are redeemed or exchanged. The Company intends to treat any redemptions and exchanges of P3 LLC Units as direct purchases of the units for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent the tax basis is allocated to those capital assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a TRA with selling equity holders of P3 LLC that require the Company to pay 85% of the tax savings that are realized as a result of (i) the Company’s direct and indirect allocable share of existing tax basis acquired in the Business Combinations, (ii) increases in the tax basis in P3 LLC’s assets as a result of the sale and exchange of the P3 LLC Units for the Company’s Class A Common Stock and cash, and (iii) the Company’s utilization of certain tax attributes and of certain other tax benefits, including those attributable to payments under the TRA. The Company will retain the benefit of the remaining 15% of these cash savings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing and amount of aggregate payments due under the TRA may vary based on a number of factors, including the timing and amount of taxable income generated by the Company each year, as well as the tax rate then applicable, among other factors. Actual tax benefits realized by the Company may differ from tax benefits calculated under the TRA as a result of the use of certain assumptions in the TRA, including the use of an assumed weighted-average state and local income tax rate to calculate tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment obligation under the TRA is an obligation of the Company and not of P3 LLC. The payments that the Company will be required to make will generally reduce the amount of the overall cash flow that might have otherwise been available, but the Company expects the cash tax savings it will realize from the utilization of the related tax benefits will exceed the amount of any required payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Business Combinations, the potential future tax benefits are estimated to be $5.4 million, of which $4.6 million is estimated to be the associated TRA liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022 and December 31, 2021, the Company did not record a TRA liability related to the tax savings it would realize from the utilization of such deferred tax assets because it is not probable that such a liability would be paid based on its estimates of future taxable income, consistent with the Company’s conclusion that it is not more-likely-than-not to realize its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As non-controlling interest holders exercise their right to exchange their units in P3 LLC, a TRA liability may be recorded based on 85% of the estimated future tax benefits that the Company may realize as a result of increases in the tax basis of P3 LLC. The amount of the increase in the tax basis, the related estimated tax benefits, and the related TRA liability to be recorded will depend on the price of the Company’s Class A Common Stock at the time of the relevant redemption or exchange.</p> 851500000 7200000 0 0 0.0000 0.0000 0 0 0.85 0.15 5400000 4600000 0 0 0.85 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 17: Capitalization and Management Incentive Units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Successor Period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Class A Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 800,000,000 shares of Class A Common Stock with a par value of $0.0001 per share, of which 41,578,890 shares were issued and outstanding on September 30, 2022 and December 31, 2021. As discussed in the Note 7 “Business Combinations,” upon closing of the Foresight Business Combinations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,732,517</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Class A Common Stock  were issued as part of the purchase consideration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,737,316</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Class A Common Stock  (after redemptions) were no longer subject to redemption;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,738,750</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Class A Common Stock were issued in a private placement to the Founder Holders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20,370,307</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Class A Common Stock were issued in a private placement pursuant to subscription agreements entered into effective as of March 25, 2021 (the “PIPE Investment”).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Class V Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 205,000,000 shares of Class V Common Stock with a par value of $0.0001 per share. These shares have no economic value but entitle the holder to one vote per share. The holders of Common Units of P3 LLC subscribed for shares of Class V Common Stock on a one-for-one basis and may exchange their Common Units and Class V Common Stock together for Class A Common Stock on a one-for-one basis. All Class V Common Stock issued as of the Business Combinations date is subject to a 180 day lockup period. As of September 30, 2022 and December 31, 2021, there were 201,530,796 and 196,553,523 shares of Class V Common <span style="-sec-ix-hidden:Hidden_YlFqfRViPEK63V5x1_00aA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock issued</span></span> and <span style="-sec-ix-hidden:Hidden_-_Smmc0UnEe-vTdiSJwSEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively, and an additional 494,127 and 5,471,400 Class V shares which are restricted and subject to time-based vesting requirements related to the underlying incentive units on September 30, 2022 and December 31, 2021, respectively, as further discussed in Note 18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share, of which zero shares were outstanding as of September 30, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">P3 Health Group, LLC Common Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combinations, all outstanding Class A Units, Class B Units, Class C Units and Class D Units of P3 Health Group Holdings, LLC were converted into the right to receive the merger consideration, which consisted of cash and newly-issued Common Units of P3 LLC. The Common Units were issued in amounts determined in accordance with the Merger Agreement and the then-existing limited liability company agreement of P3 Health Group Holdings, LLC. Each holder of Common Units was issued shares of Class V Common Stock on a one-for-one basis. At September 30, 2022 and December 31, 2021, there were 243,603,813 Common Units outstanding at P3 LLC of which the Company held 41,578,890 Common Units and non-controlling interests held the remaining 202,024,923 Common Units outstanding, 494,127 and 5,471,400 of which are restricted as discussed above, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Predecessor Period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combinations, P3 Health Group Holdings, LLC’s capital structure consists of Class A Units, which represented commitments from the Company’s private equity sponsors; Class B Units, which represented founders common equity; Class C Units, which represented Management Incentive Units; and Class D Units, which represented an additional investment from a private equity sponsor. Class A and D Units are presented outside of permanent equity in accordance with ASC 480 due to the existence of a redemption provision that is not solely within the control of the P3 Health Group Holdings, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2020 and September 30, 2021, there were 43,000,000 Class A Units authorized and outstanding; 6,000,000 and 8,000,000 Class B Units <span style="-sec-ix-hidden:Hidden_vnutVw3Ux0-6pWBuE-wj8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorized</span></span> and <span style="-sec-ix-hidden:Hidden_g0isS6C7Nk2R5c5xTCh0OQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively; 1,302,083 and 1,925,833 Class C Units <span style="-sec-ix-hidden:Hidden_Yjnz74TU-EiP6bRA0vowQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorized</span></span> and <span style="-sec-ix-hidden:Hidden_ZahR4Z0wL0SCG6Aq1fYKkg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively; 16,130,034 Class D Units authorized and outstanding. In connection with the Business Combinations, all outstanding Class A, B, C and D Units were converted into the right to receive the merger consideration described above.</p> 800000000 800000000 0.0001 0.0001 41578890 41578890 8732517 3737316 8738750 20370307 205000000 205000000 0.0001 0.0001 1 1 P180D 201530796 196553523 494127 5471400 10000000 10000000 0.0001 0.0001 0 0 243603813 243603813 41578890 41578890 202024923 202024923 494127 5471400 43000000 43000000 6000000 8000000 1302083 1925833 16130034 16130034 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 18: Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Successor Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Successor Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Business Combinations, Foresight’s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”), in order to facilitate the grant of cash and equity incentives to employees, consultants, and directors of the Company and certain affiliates. The 2021 Plan became effective on December 3, 2021. The following table sets forth a summary of Class V share-based compensation activity of the Successor Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Time Based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Based Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding and non-vested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,471,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted during period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> 9.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,977,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding and non-vested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 494,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Profit interest awards were issued as part of the Business Combination. Time-based units vest ratably over periods of between one month and two years, so long as the optionee stays employed. The time-based units have a weighted average remaining time to vest of 0.12 years at September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $1,783,994 and $17,210,974 of stock-based compensation cost for the three and nine months ended September 30, 2022, respectively, which is classified in Corporate, General and Administrative Expenses. As of September 30, 2022, there was $7,233,627 of unrecognized equity-based compensation cost. The Company did not recognize any tax benefits related to stock-based compensation for the nine months ended September 30, 2022. The Company accounts for forfeitures of awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes stock option activities for the nine months ended September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and non-vested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,034,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.10</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and non-vested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,942,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.52</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of the stock options issued during the period follow a time-based vesting schedule. Most stock options vest ratably over a period between <span style="-sec-ix-hidden:Hidden_2yPORN3oU0uPzOv0afp2Cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> and five years, so long as the optionee continues to provide services to the Company. Stock options are exercisable into shares of Class V Common Stock. In addition to the time-based units, the Company granted 100,000 performance-based option units to an employee during the period with a strike price of $5.02. The vesting criteria for these units has not yet been achieved, therefore no expense has been recorded in relation to these units.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Time Based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Based Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding and non-vested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,471,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted during period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> 9.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,977,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:53.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding and non-vested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 494,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 9.20 5471400 9.20 4977273 9.20 494127 P1M P2Y P0Y1M13D 1783994 17210974 7233627 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and non-vested at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,034,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.10</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and non-vested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,942,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.52</p></td></tr></table> 2034279 6.43 P3Y1M6D 91667 5.02 1942612 6.50 P2Y6M7D P5Y 100000 5.02 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 19: Earnings (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Share – Successor Period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Basic earnings per share is calculated as net income divided by the average number of shares of common stock outstanding. Diluted earnings per share assumes, when dilutive, the issuance of the net incremental shares from restricted shares. The following is a reconciliation of the denominators of the basic and diluted per share computations for net income:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.76851654%;padding-left:0pt;padding-right:0pt;width:101.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator - Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,329,041)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,029,225,234)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Net loss attributable to Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,155,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (853,124,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A common stockholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,173,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176,100,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator - Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A Common Stockholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,173,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176,100,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Net loss and tax effect attributable to Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,155,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (853,124,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A common stockholders - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,329,041)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,029,225,234)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator - Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss per share attributable to Class A common shareholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator - Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average effect of dilutive Class V shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201,457,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,684,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,036,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,262,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss per share attributable to Class A common shareholders - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive. The liability-classified Public and Private Warrants are out of the money and thus have no impact on diluted EPS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,591,605</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Private Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,500</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 494,127</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,134,279</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,447,511</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.76851654%;padding-left:0pt;padding-right:0pt;width:101.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator - Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,329,041)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,029,225,234)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Net loss attributable to Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,155,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (853,124,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A common stockholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,173,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176,100,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator - Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A Common Stockholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,173,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (176,100,636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Net loss and tax effect attributable to Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54,155,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (853,124,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to Class A common stockholders - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,329,041)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,029,225,234)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator - Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss per share attributable to Class A common shareholders - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator - Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,578,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average effect of dilutive Class V shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201,457,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,684,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average Class A common shares outstanding - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,036,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,262,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss per share attributable to Class A common shareholders - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> -65329041 -1029225234 -54155858 -853124598 -11173183 -176100636 -11173183 -176100636 -54155858 -853124598 -65329041 -1029225234 41578890 41578890 -0.27 -4.24 41578890 41578890 201457191 199684102 243036081 241262992 -0.27 -4.27 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,591,605</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Private Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,500</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 494,127</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,134,279</p></td></tr><tr><td style="vertical-align:bottom;width:79.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,447,511</p></td></tr></table> 10591605 227500 494127 2134279 13447511 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 20: Premium Deficiency Reserve</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the profitability of our at-risk share savings arrangements to identify contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future revenues, a PDR is recognized. Management concluded a PDR of $27,719,928 and $37,835,642 existed at September 30, 2022 and December 31, 2021, respectively, which represented its estimate of probable contract losses expected to be generated by the Company’s contracts with its health plan partners.</p> 27719928 37835642 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 21: Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases real estate in the form of corporate office space and operating facilities. The Company additionally leases certain machinery in the form of office equipment. Generally, the term for real estate leases ranges from <span style="-sec-ix-hidden:Hidden_FrVogfDU9Eym4KWgmzQw6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to eight years at inception of the contract. Generally, the term for equipment leases is <span style="-sec-ix-hidden:Hidden_X64NpiZPs0CESYirXlDmBQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to three years at inception of the contract. Some real estate leases include one to two options to renew that can extend the original term by <span style="-sec-ix-hidden:Hidden_CNx5STxuxkGUrjHOWiQTDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered one new operating lease in the nine months ended September 30, 2022. On June 9, 2022, the company entered into the first amendment to the lease agreement for its lease in Henderson, NV. This lease amendment will expand the premises to include three other suites in the same building and extend the term of the lease 94 months commencing on October 1, 2022, after the original lease matured on September 30, 2022. As a result of the lease modification related to the existing premises, ROU Assets and <span style="-sec-ix-hidden:Hidden_fbRU7XFFxkCCzQ-nt94E3g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liabilities</span></span> increased $3.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, during the three months ended September 30, 2022, the Company acquired four new leases as a part of the medical practice acquisitions, as described in Note 7 “Business Combinations.” The acquisitions and related addition to ROU Assets and Liabilities were determined to be immaterial for disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Operating lease costs are included within operating expenses in the condensed consolidated statements of operations. The Company does not have any finance leases, short-term lease costs, nor any sublease income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 901,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 688,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,374,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,740,067</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Lease terms and discount rates consisted of the following at each of the periods presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below reconciles the undiscounted future minimum lease payments under noncancelable operating leases with terms of more than one year to the total operating and finance lease liabilities recognized on the condensed consolidated balance sheets as of the dates presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 1, 2022 to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712,565</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,347,234</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,958,684</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,602,888</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,950,448</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,619,793</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,191,612</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,821,505)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present Value of Lease Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,370,107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The current portions of ROU liabilities of $213,158 and $2,087,235 are included in Accounts Payable and Accrued Expenses in the Company’s condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, respectively.</p> P8Y P3Y 1 2 P10Y 1 P94M 3100000 4 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 901,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 688,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,374,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,740,067</p></td></tr></table> 901079 688104 2374789 1740067 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> P6Y5M1D P5Y1M2D 0.117 0.112 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 1, 2022 to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712,565</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,347,234</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,958,684</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,602,888</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,950,448</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,619,793</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,191,612</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,821,505)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present Value of Lease Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,370,107</p></td></tr></table> 712565 1347234 2958684 2602888 1950448 4619793 14191612 2821505 11370107 213158 2087235 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 22: Redeemable Non-Controlling Interests</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-controlling interests represents the portion of P3 LLC that the Company controls and consolidates but does not own (i.e., the P3 LLC Common Units held directly by the shareholders other than the Company). The non-controlling interests represent an approximately 83% ownership in P3 LLC as of September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, P3 LLC Common Units participate in net income or loss allocations and distributions and entitle their holder to the right, subject to the terms set forth in the limited liability agreement, to require P3 to redeem all or a portion of the Common Units held by such participant, together with a corresponding number of shares of Class V Common Stock, in exchange for Class A Common Stock or at the Company’s option, and subject to certain limitations, in cash. As the noncontrolling interest holders have approximately an 83% voting interest in P3 LLC through their Class V Common Stock and can appoint most of the initial members to the Board of Directors, the ability to elect cash settlement upon redemption is outside of the control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The P3 LLC Common Units held by outside shareholders have been classified as redeemable noncontrolling interest in the Company. The cash redemption feature is considered outside of the control of the Company for the reason described above. Therefore, in accordance with ASC Topic 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>, the P3 LLC Units are classified as temporary equity in the Company’s condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The redeemable noncontrolling interest was initially measured at its fair value on December 3, 2021. Net income or loss is attributed to the redeemable noncontrolling interest during each reporting period based on its ownership percentage, as appropriate. Subsequent to that, the redeemable noncontrolling interest is measured at its fair value (i.e., based on the Class A stock price) at the end of each reporting period, with the remeasurement amount being no less than the initial value, as adjusted for the redeemable noncontrolling interest’s share of net income or loss. The offset of any fair value adjustment is recorded to equity, with no impact to net income or loss. As of September 30, 2022, the fair value of redeemable non-controlling interest was higher than the carrying value and thus, a remeasurement adjustment of $19,375,288 was recorded to redeemable non-controlling interests with an offset to additional paid in capital. As of December 31, 2021, the fair value of redeemable non-controlling interest was lower than the initial value and there was no remeasurement adjustment recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, pursuant to the Agreement and Plan of Merger, all non-controlling interest holders are subject to certain lock-up period and as a result, there was no exchange or redemption activity as of September 30, 2022 and December 31, 2021.</p> 0.83 0.83 19375288 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 23: Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Commitments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has non-cancelable contractual agreements primarily related to leases. For additional discussion on leases, see Note 21 “Leases.”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Contingencies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to various claims, legal and regulatory proceedings, lawsuits and administrative actions arising in the ordinary course of business and associated with the Business Combinations. The Company carries general and professional liability insurance coverage to mitigate the Company’s risk of potential loss in such cases. An accrual is established when a specific contingency is probable and estimable. The Company also faces contingencies that are reasonably possible to occur that cannot currently be estimated. The Company believes that disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, net loss or cash flows. It is the Company’s policy to expense costs associated with loss contingencies, including any related legal fees, as they are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2021, a discrepancy was identified in the service agreement with one of the Company’s health plans resulting in a renegotiation of the agreement. As of the date of issuance of this Form 10-Q, the renegotiation was in process. The Company has determined it is reasonably possible that resolution of this discrepancy will result in a payment to the health plan of approximately $10.6 million. This contingent liability was reflected in the Company’s financial statements presented in the 2021 Form 10-K. In the fourth quarter of 2021 during the Predecessor Period, the Company recorded a $3.6 million reduction in operating revenue and a $7.0 million charge to operating expense to account for amounts not previously recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Uncertainties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The healthcare industry is subject to numerous laws and regulations of Federal, state, and local governments. These laws and regulations include, but are not limited to, matters of licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare / Medicaid Fraud, Waste and Abuse Prevention. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of Fraud, Waste and Abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties as well as significant repayment for patient services billed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management believes the Company is compliant with Fraud, Waste and Abuse regulations as well as other applicable government laws. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as other regulatory actions which might be unknown at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare reform legislation at both the Federal and state levels continues to evolve. Changes continue to impact existing and future laws and rules. Such changes may impact the manner in which the Company conducts business, restrict the Company’s revenue growth in certain eligibility categories, slow down revenue growth rates for certain eligibility categories, increase certain medical, administrative and capital costs, and expose the Company to increased risk of loss or further liabilities. As a result, the Company’s consolidated financial position could be impacted by such changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">COVID-19 Pandemic</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2020, the World Health Organization designated COVID 19 a global pandemic. The rapid spread of COVID 19 around the world and throughout the U.S. has altered the behavior of businesses and people, with significant negative effects on Federal, state, and local economies, the duration of which continues to remain unknown. Various mandates were implemented by Federal, state, and local governments in response to the pandemic, which caused many people to remain at home along with forced closure of or limitations on certain businesses. This included suspension of elective procedures by healthcare facilities. While restrictions have been eased across the U.S. and most states have lifted moratoriums on non-emergency procedures, some restrictions remain in place. COVID 19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of the Company’s patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID 19 pandemic did not have a material impact on the Company’s revenues for the nine-month period ended September 30, 2022 and the year ended December 31, 2021. Nearly 99% of the Company’s total revenues are recurring, consisting of fixed monthly PMPM capitation payments received from Medicare Advantage health plans. Based on claims paid to date, direct costs associated with COVID-19 claims was approximately $93.3 million for the period March 1, 2020 through September 30, 2022. Management instituted multiple safety measures for the Company’s employees including a work-from-home policy and access to free vaccinations and personal protective equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The full extent to which COVID 19 will directly or indirectly impact the Company, its future results of operations and financial condition will depend on factors which are highly uncertain and cannot be accurately predicted. This includes new and emerging information from the impact of new variants of the virus, the actions taken to contain it or treat its impact and the economic impact on the Company’s markets. Such factors include, but are not limited to, the scope and duration of stay-at-home practices and business closures and restrictions, government imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Because of these and other uncertainties, management cannot estimate the length or severity of the impact of the pandemic on the Company’s business. Furthermore, because of the Company’s business model, the full impact of COVID 19 may not be fully reflected in the Company’s results of operations and overall financial condition until future periods. However, management continues to closely evaluate and monitor the nature and extent of these potential impacts to the Company’s business, results of operations and liquidity.</p> 1 10600000 -3600000 7000000.0 0.99 0.99 93300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 24: Related Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Intercompany Transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 has entered into agreements (“Services Agreements”) with the Network, under which P3 provides the Network with certain management, administrative, and other non-medical support services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company and its subsidiaries have “Deficit Funding Agreements” with the Network, whereby the Company or its subsidiaries provide loans (“Advances”) from time to time principally for the purpose of working capital support.  Net Advances made to the Network and accrued interest expense in the three-month period ended September 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,907,247</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advanced During Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,742,914</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest Accrued During period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,905</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,114,066</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advances, in most cases, have been constructively made by P3 Health Group Holdings, LLC on P3 NV’s behalf, and were therefore deemed Advances made by P3 NV. P3 NV’s Advances to BACC include all years prior, for which balances have, historically, not been settled periodically between the Parties and, thus have carried forward one year to the next. However, all transactions related to these Services and Deficit Funding Agreements (including accrued interest) have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no advances transacted between P3 NV and KWA during the periods ended September 30, 2022 or December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Atrio Health Plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Earned from Capitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,365,746</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,500</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,861,830</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Earned from Capitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,505,484</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,716,134</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,367,493</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Atrio Health Plans was established in 2004 and has since grown to serve Medicare beneficiaries in numerous counties throughout Oregon. Atrio works closely with local providers to improve healthcare outcomes of the population(s) served. In 2019, Chicago Pacific Founders (“CPF”) made an equity investment in Atrio. CPF is also a principal holder of shares of Class V Common Stock and Common Units of P3 LLC. Beginning in 2020, the Company has a Full-Risk capitation agreement in place with Atrio whereby the Company is delegated to perform services on behalf of Atrio’s members assigned to the Company. These delegated services include but are not limited to provider network credentialing, patient authorizations and medical management (care management, quality management and utilization management).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,907,247</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advanced During Period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,742,914</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest Accrued During period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,905</p></td></tr><tr><td style="vertical-align:bottom;width:78.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,114,066</p></td></tr></table> 27907247 1742914 463905 30114066 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Earned from Capitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,365,746</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,500</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,861,830</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Earned from Capitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,505,484</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,716,134</p></td></tr><tr><td style="vertical-align:bottom;width:76.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,367,493</p></td></tr></table> 35365746 570500 39861830 127505484 1716134 137367493 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 25: Variable Interest Entities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company prepares its consolidated financial statements in accordance with ASC 810, <i style="font-style:italic;">Consolidation</i>, which provides for the consolidation of VIEs of which an entity is the primary beneficiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combinations further described in Note 1 and Note 7, the Company became the sole managing member of P3 LLC. The rights of the non-managing members of P3 LLC are limited and protective in nature and do not give substantive participation rights over the sole managing member. As a result, P3 LLC is considered a VIE. As the sole managing member, the Company has the right to direct the most significant activities of P3 LLC and the obligation to absorb losses and receive benefits and accordingly is considered the primary beneficiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, P3 LLC is the primary beneficiary of the Network.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3, LLC entered Stock Transfer Restriction Agreements with the Practice Shareholders of the Network. The Stock Transfer Restriction Agreements, by way of a call option, unequivocally permit P3 LLC to appoint Successor Physicians if a Practice Shareholder vacates their ownership position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to ASC 810, <i style="font-style:italic;">Consolidation</i>, both the “power of control” and “economics” criteria were reviewed for VIE consideration. P3 LLC’s ability to appoint Successor Physicians the Network demonstrates “power of control”. Also, there are Deficit Funding Agreements in place between P3 LLC and the Network. The Deficit Funding Agreement between P3 LLC and the members of the Network states that P3 LLC will advance funds, as needed, to support working capital needs to the extent operating expenses exceed gross revenue. These funding arrangements further illustrate and fulfill the economic criteria for VIE consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Practice Shareholders, who are employees of the Company, retain equity ownership in the Network, which represents nominal noncontrolling interests. The noncontrolling interests do not participate in the profit or loss of the Network, however.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">P3 LLC, directly or indirectly via its wholly-owned subsidiaries, may not use or access any net assets of these VIEs to settle its obligations or the obligations of its wholly-owned subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables provide a summary of the VIE’s assets, liabilities and operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,413,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,570,247</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Client Fees and Insurance Receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,815</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,353,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 406,372</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, Plant and Equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,416</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment in Other P3 Entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,828,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,073,850</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LIABILITIES AND MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,653,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,804,704</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,303,615</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to Consolidated Entities of P3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,001,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,110,831</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,888,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,219,150</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,060,177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,145,300)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TOTAL LIABILITIES AND MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,828,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,073,850</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,594,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905,404</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,731,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,707,369</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,137,579)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,801,965)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,462,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,815,261</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,708,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,858,939</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,245,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,413,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,570,247</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Client Fees and Insurance Receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,815</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid Expenses and Other Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,353,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 406,372</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, Plant and Equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,416</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment in Other P3 Entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,828,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,073,850</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LIABILITIES AND MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,653,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,804,704</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued Payroll</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,303,615</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to Consolidated Entities of P3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,001,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,110,831</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,888,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,219,150</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,060,177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,145,300)</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TOTAL LIABILITIES AND MEMBERS’ DEFICIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,828,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,073,850</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,594,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905,404</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,731,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,707,369</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,137,579)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,801,965)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Successor</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Predecessor</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As Restated)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,462,716</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,815,261</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,708,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,858,939</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,245,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,043,678)</p></td></tr></table> 5413965 7570247 16653 60815 1353408 406372 44494 36416 6000000 6000000 12828520 14073850 7653560 4804704 2233567 1303615 27001570 24110831 36888697 30219150 -24060177 -16145300 12828520 14073850 13594142 1905404 15731721 4707369 -2137579 -2801965 39462716 5815261 46708335 13858939 -7245619 -8043678 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 26: Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, there were 858,351 Class D warrants outstanding for the predecessor entity. In conjunction with the Term Loan issued November 19, 2020, the predecessor entity issued 858,351 <span style="-sec-ix-hidden:Hidden_Oqrsee_hwU-yyKRyLrzXsQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span> warrants to purchase shares of Series D Preferred Units at $4.68 per share. The warrants were recorded as a liability on the consolidated balance sheet with a balance of $6,316,605 as of December 31, 2020. During the year ended December 31, 2020, no change in the fair value of the warrant liability was recognized in the consolidated statements of operations. During 2021, 858,351 warrants were exercised on a cashless basis, with an exercise price of $4.68 per share as part of the Business Combination. There are no Class D Warrants outstanding as of September 30, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022 and December 31, 2021, there were an aggregate of 10,819,105 warrants outstanding, which include the Public Warrants and Private Placement Warrants. Each warrant entitles the holder to purchase one share of Class A Common Stock at a price of $11.50 per share. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire five years after the completion of a Business Combinations. The Company has the right to redeem the Public Warrants when the price per Class A ordinary share equals or exceeds $18.00 for 20 days within a <span style="-sec-ix-hidden:Hidden_Bd2mKjHTWUapkbIFIuXDsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30</span></span>-day trading period. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants are subject to certain transfer restrictions, are not redeemable by the Company if they are held by Sponsors, and are exercisable on a cashless basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Public Warrants and Private Placement Warrants are recorded as a liability on the consolidated balance sheets with a balance of $7,996,432 and $11,382,826 as of September 30, 2022 and December 31, 2021, respectively. A loss of $2,567,423 and a gain of $3,386,394 were recognized in the three months and nine months ended September 30, 2022, respectively, and a loss of $1,401,686 and $12,063,265 was recognized in the three months and nine months ended September 30, 2021, respectively from the change in fair value of the warrant liability in the consolidated statements of operations. During the nine months ended September 30, 2022 and the year ended December 31, 2021, zero Public Warrants and Private Placement Warrants were exercised.</p> 858351 858351 4.68 6316605 0 858351 4.68 0 0 10819105 10819105 1 1 11.50 11.50 P30D P5Y 18.00 20 7996432 11382826 2567423 3386394 1401686 12063265 0 0 The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 25 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the P3 LLC’s VIEs totaling $6.8 million and $8.1 million as of September 30, 2022 and December 31, 2021, respectively, and total liabilities of the P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $9.9 million and $6.1 million as of September 30, 2022 and December 31, 2021, respectively. These VIE assets and liabilities do not include $6.0 million of investment in affiliates as of September 30, 2022 and December 31, 2021, and $27.0 million and $24.1 million of amounts due to affiliates as of September 30, 2022 and December 31, 2021, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 25 “Variable Interest Entities.” The Company analyzed the calculation of net loss per member unit for predecessor periods prior to the Business Combinations and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, net loss per member unit information has not been presented for predecessor periods prior to the Business Combinations on December 3, 2021. EXCEL 116 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 117 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 118 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 119 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 418 430 1 true 112 0 false 15 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT) Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY Statements 6 false false R7.htm 00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Organization and Basis of Presentation Sheet http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 10201 - Disclosure - Restatement of Previously Issued Financial Statements Sheet http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatements Restatement of Previously Issued Financial Statements Notes 9 false false R10.htm 10301 - Disclosure - Going Concern and Liquidity Sheet http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidity Going Concern and Liquidity Notes 10 false false R11.htm 10401 - Disclosure - Significant Accounting Policies Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 11 false false R12.htm 10501 - Disclosure - Recent Accounting Pronouncements Adopted Sheet http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsAdopted Recent Accounting Pronouncements Adopted Notes 12 false false R13.htm 10601 - Disclosure - Recent Accounting Pronouncements Not Yet Adopted Sheet http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsNotYetAdopted Recent Accounting Pronouncements Not Yet Adopted Notes 13 false false R14.htm 10701 - Disclosure - Business Combinations Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinations Business Combinations Notes 14 false false R15.htm 10801 - Disclosure - Fair Value Measurements and Hierarchy Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchy Fair Value Measurements and Hierarchy Notes 15 false false R16.htm 10901 - Disclosure - Patient Fees Receivable Sheet http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivable Patient Fees Receivable Notes 16 false false R17.htm 11001 - Disclosure - Property and Equipment Sheet http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipment Property and Equipment Notes 17 false false R18.htm 11101 - Disclosure - Goodwill Sheet http://www.p3hp.org/20220630/role/DisclosureGoodwill Goodwill Notes 18 false false R19.htm 11201 - Disclosure - Intangible Assets Sheet http://www.p3hp.org/20220630/role/DisclosureIntangibleAssets Intangible Assets Notes 19 false false R20.htm 11301 - Disclosure - Notes Receivable, Net Notes http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNet Notes Receivable, Net Notes 20 false false R21.htm 11401 - Disclosure - Claims Payable Sheet http://www.p3hp.org/20220630/role/DisclosureClaimsPayable Claims Payable Notes 21 false false R22.htm 11501 - Disclosure - Long-Term Debt Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebt Long-Term Debt Notes 22 false false R23.htm 11601 - Disclosure - Income Taxes Sheet http://www.p3hp.org/20220630/role/DisclosureIncomeTaxes Income Taxes Notes 23 false false R24.htm 11701 - Disclosure - Capitalization and Management Incentive Units Sheet http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnits Capitalization and Management Incentive Units Notes 24 false false R25.htm 11801 - Disclosure - Share-Based Compensation Sheet http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 25 false false R26.htm 11901 - Disclosure - Earnings (Loss) per Share Sheet http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShare Earnings (Loss) per Share Notes 26 false false R27.htm 12001 - Disclosure - Premium Deficiency Reserve Sheet http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserve Premium Deficiency Reserve Notes 27 false false R28.htm 12101 - Disclosure - Leases Sheet http://www.p3hp.org/20220630/role/DisclosureLeases Leases Notes 28 false false R29.htm 12201 - Disclosure - Redeemable Non-Controlling Interests Sheet http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterests Redeemable Non-Controlling Interests Notes 29 false false R30.htm 12301 - Disclosure - Commitments and Contingencies Sheet http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 30 false false R31.htm 12401 - Disclosure - Related Parties Sheet http://www.p3hp.org/20220630/role/DisclosureRelatedParties Related Parties Notes 31 false false R32.htm 12501 - Disclosure - Variable Interest Entities Sheet http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntities Variable Interest Entities Notes 32 false false R33.htm 12601 - Disclosure - Warrants Sheet http://www.p3hp.org/20220630/role/DisclosureWarrants Warrants Notes 33 false false R34.htm 20402 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPolicies 34 false false R35.htm 30203 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsTables Restatement of Previously Issued Financial Statements (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatements 35 false false R36.htm 30403 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPolicies 36 false false R37.htm 30703 - Disclosure - Business Combinations (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables Business Combinations (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureBusinessCombinations 37 false false R38.htm 30803 - Disclosure - Fair Value Measurements and Hierarchy (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables Fair Value Measurements and Hierarchy (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchy 38 false false R39.htm 30903 - Disclosure - Patient Fees Receivable (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableTables Patient Fees Receivable (Tables) Tables http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivable 39 false false R40.htm 31003 - Disclosure - Property and Equipment (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipment 40 false false R41.htm 31103 - Disclosure - Goodwill (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureGoodwillTables Goodwill (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureGoodwill 41 false false R42.htm 31203 - Disclosure - Intangible Assets (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureIntangibleAssets 42 false false R43.htm 31403 - Disclosure - Claims Payable (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureClaimsPayableTables Claims Payable (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureClaimsPayable 43 false false R44.htm 31503 - Disclosure - Long-Term Debt (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureLongTermDebt 44 false false R45.htm 31803 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensation 45 false false R46.htm 31903 - Disclosure - Earnings (Loss) per Share (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables Earnings (Loss) per Share (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShare 46 false false R47.htm 32103 - Disclosure - Leases (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesTables Leases (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureLeases 47 false false R48.htm 32403 - Disclosure - Related Parties (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables Related Parties (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureRelatedParties 48 false false R49.htm 32503 - Disclosure - Variable Interest Entities (Tables) Sheet http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntities 49 false false R50.htm 40101 - Disclosure - Organization and Basis of Presentation (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails Organization and Basis of Presentation (Details) Details http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentation 50 false false R51.htm 40201 - Disclosure - Restatement of Previously Issued Financial Statements (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails Restatement of Previously Issued Financial Statements (Details) Details http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsTables 51 false false R52.htm 40301 - Disclosure - Going Concern and Liquidity (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidityDetails Going Concern and Liquidity (Details) Details http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidity 52 false false R53.htm 40401 - Disclosure - Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details) Details 53 false false R54.htm 40402 - Disclosure - Significant Accounting Policies - Revenue Recognition (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails Significant Accounting Policies - Revenue Recognition (Details) Details 54 false false R55.htm 40403 - Disclosure - Significant Accounting Policies - Concentration of revenue (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails Significant Accounting Policies - Concentration of revenue (Details) Details 55 false false R56.htm 40404 - Disclosure - Significant Accounting Policies - Capitated Revenue (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails Significant Accounting Policies - Capitated Revenue (Details) Details 56 false false R57.htm 40405 - Disclosure - Significant Accounting Policies - Health Plan Receivables (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails Significant Accounting Policies - Health Plan Receivables (Details) Details 57 false false R58.htm 40406 - Disclosure - Significant Accounting Policies - Health Plan Settlement Payables (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails Significant Accounting Policies - Health Plan Settlement Payables (Details) Details 58 false false R59.htm 40407 - Disclosure - Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details) Details 59 false false R60.htm 40408 - Disclosure - Significant Accounting Policies - Shared Risk Revenue (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails Significant Accounting Policies - Shared Risk Revenue (Details) Details 60 false false R61.htm 40409 - Disclosure - Significant Accounting Policies - Goodwill (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesGoodwillDetails Significant Accounting Policies - Goodwill (Details) Details 61 false false R62.htm 40701 - Disclosure - Business Combinations - Foresight (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails Business Combinations - Foresight (Details) Details 62 false false R63.htm 40702 - Disclosure - Business Combinations - Other (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails Business Combinations - Other (Details) Details 63 false false R64.htm 40703 - Disclosure - Business Combinations - Purchase Price Allocation (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails Business Combinations - Purchase Price Allocation (Details) Details 64 false false R65.htm 40704 - Disclosure - Business Combinations - Pro Forma Financial Information (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails Business Combinations - Pro Forma Financial Information (Details) Details 65 false false R66.htm 40801 - Disclosure - Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details) Details 66 false false R67.htm 40802 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details) Details 67 false false R68.htm 40803 - Disclosure - Fair Value Measurements and Hierarchy - Option Pricing (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails Fair Value Measurements and Hierarchy - Option Pricing (Details) Details 68 false false R69.htm 40804 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details) Details 69 false false R70.htm 40901 - Disclosure - Patient Fees Receivable (Details) Sheet http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails Patient Fees Receivable (Details) Details http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableTables 70 false false R71.htm 41001 - Disclosure - Property and Equipment (Details) Sheet http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentTables 71 false false R72.htm 41101 - Disclosure - Goodwill (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails Goodwill (Details) Details http://www.p3hp.org/20220630/role/DisclosureGoodwillTables 72 false false R73.htm 41201 - Disclosure - Intangible Assets - Changes (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails Intangible Assets - Changes (Details) Details 73 false false R74.htm 41202 - Disclosure - Intangible Assets - Additional Information (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails Intangible Assets - Additional Information (Details) Details 74 false false R75.htm 41301 - Disclosure - Notes Receivable, Net (Details) Notes http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails Notes Receivable, Net (Details) Details http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNet 75 false false R76.htm 41401 - Disclosure - Claims Payable - Additional Information (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureClaimsPayableAdditionalInformationDetails Claims Payable - Additional Information (Details) Details 76 false false R77.htm 41402 - Disclosure - Claims Payable (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails Claims Payable (Details) Details http://www.p3hp.org/20220630/role/DisclosureClaimsPayableTables 77 false false R78.htm 41501 - Disclosure - Long-Term Debt - Additional Information (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails Long-Term Debt - Additional Information (Details) Details 78 false false R79.htm 41502 - Disclosure - Long-Term Debt - Rollforward (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails Long-Term Debt - Rollforward (Details) Details 79 false false R80.htm 41503 - Disclosure - Long-Term Debt - Maturity (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails Long-Term Debt - Maturity (Details) Details 80 false false R81.htm 41504 - Disclosure - Long-Term Debt - Current and Long Term (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails Long-Term Debt - Current and Long Term (Details) Details 81 false false R82.htm 41505 - Disclosure - Long-Term Debt - Short-Term (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails Long-Term Debt - Short-Term (Details) Details 82 false false R83.htm 41601 - Disclosure - Income Taxes (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.p3hp.org/20220630/role/DisclosureIncomeTaxes 83 false false R84.htm 41701 - Disclosure - Capitalization and Management Incentive Units (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails Capitalization and Management Incentive Units (Details) Details http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnits 84 false false R85.htm 41801 - Disclosure - Share-Based Compensation - Class V Activity (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails Share-Based Compensation - Class V Activity (Details) Details 85 false false R86.htm 41802 - Disclosure - Share-Based Compensation - Expense (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails Share-Based Compensation - Expense (Details) Details 86 false false R87.htm 41803 - Disclosure - Share-Based Compensation - Stock options activities (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails Share-Based Compensation - Stock options activities (Details) Details 87 false false R88.htm 41901 - Disclosure - Earnings (Loss) per Share - Computation (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails Earnings (Loss) per Share - Computation (Details) Details http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables 88 false false R89.htm 41902 - Disclosure - Earnings (Loss) per Share - Anti-dilutive securities (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails Earnings (Loss) per Share - Anti-dilutive securities (Details) Details http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables 89 false false R90.htm 42001 - Disclosure - Premium Deficiency Reserve (Details) Sheet http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserveDetails Premium Deficiency Reserve (Details) Details http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserve 90 false false R91.htm 42101 - Disclosure - Leases (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesDetails Leases (Details) Details http://www.p3hp.org/20220630/role/DisclosureLeasesTables 91 false false R92.htm 42102 - Disclosure - Leases - Operating Lease Costs (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesOperatingLeaseCostsDetails Leases - Operating Lease Costs (Details) Details 92 false false R93.htm 42103 - Disclosure - Leases - Lease Terms And Discount Rates (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails Leases - Lease Terms And Discount Rates (Details) Details 93 false false R94.htm 42104 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 94 false false R95.htm 42105 - Disclosure - Leases - Current Portions Of ROU Liabilities (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureLeasesCurrentPortionsOfRouLiabilitiesDetails Leases - Current Portions Of ROU Liabilities (Details) Details 95 false false R96.htm 42201 - Disclosure - Redeemable Non-Controlling Interests (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails Redeemable Non-Controlling Interests (Details) Details http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterests 96 false false R97.htm 42301 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingencies 97 false false R98.htm 42401 - Disclosure - Related Parties (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails Related Parties (Details) Details http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables 98 false false R99.htm 42501 - Disclosure - Variable Interest Entities (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails Variable Interest Entities (Details) Details http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesTables 99 false false R100.htm 42601 - Disclosure - Warrants (Details) Sheet http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails Warrants (Details) Details http://www.p3hp.org/20220630/role/DisclosureWarrants 100 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation in us-gaap/2021 used in 1 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. piii-20220930x10q.htm 28 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 34 fact(s) appearing in ix:hidden were eligible for transformation: piii:DebtCovenantAgreementPeriodOfRevenueThreshold, piii:TermForReconciliationAndDistributionOfReserveFollowingEachYearEnd, piii:WarrantRedemptionTradingPeriod, us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentTerm, us-gaap:DeferredTaxAssetsNet, us-gaap:DepreciationAndAmortization, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo, us-gaap:IncreaseDecreaseInOperatingLeaseLiability, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:PreferredUnitsAuthorized, us-gaap:PreferredUnitsOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:WarrantsAndRightsOutstandingTerm - piii-20220930x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 8 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:EarningsPerShareBasic, us-gaap:EarningsPerShareDiluted, us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList - piii-20220930x10q.htm 9 piii-20220930x10q.htm piii-20220930.xsd piii-20220930_cal.xml piii-20220930_def.xml piii-20220930_lab.xml piii-20220930_pre.xml piii-20220930xex10d1.htm piii-20220930xex31d1.htm piii-20220930xex31d2.htm piii-20220930xex32d1.htm piii-20220930xex32d2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 122 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "piii-20220930x10q.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 418, "dts": { "calculationLink": { "local": [ "piii-20220930_cal.xml" ] }, "definitionLink": { "local": [ "piii-20220930_def.xml" ] }, "inline": { "local": [ "piii-20220930x10q.htm" ] }, "labelLink": { "local": [ "piii-20220930_lab.xml" ] }, "presentationLink": { "local": [ "piii-20220930_pre.xml" ] }, "schema": { "local": [ "piii-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 717, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 40, "http://www.p3hp.org/20220930": 3, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 48 }, "keyCustom": 124, "keyStandard": 306, "memberCustom": 66, "memberStandard": 40, "nsprefix": "piii", "nsuri": "http://www.p3hp.org/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Going Concern and Liquidity", "role": "http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidity", "shortName": "Going Concern and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42601 - Disclosure - Warrants (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightOutstanding", "p", "piii:WarrantsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_XJpS5qcusEmlHDdx9k61AA", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_-O0Oa4--vU62wCZdlbjQpA", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Significant Accounting Policies", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:RecentAccountingPronouncementsAdoptedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Recent Accounting Pronouncements Adopted", "role": "http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsAdopted", "shortName": "Recent Accounting Pronouncements Adopted", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:RecentAccountingPronouncementsAdoptedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:RecentAccountingPronouncementsNotYetAdoptedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Recent Accounting Pronouncements Not Yet Adopted", "role": "http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsNotYetAdopted", "shortName": "Recent Accounting Pronouncements Not Yet Adopted", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:RecentAccountingPronouncementsNotYetAdoptedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Business Combinations", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Fair Value Measurements and Hierarchy", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchy", "shortName": "Fair Value Measurements and Hierarchy", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Patient Fees Receivable", "role": "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivable", "shortName": "Patient Fees Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Property and Equipment", "role": "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Goodwill", "role": "http://www.p3hp.org/20220630/role/DisclosureGoodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Intangible Assets", "role": "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Notes Receivable, Net", "role": "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNet", "shortName": "Notes Receivable, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Claims Payable", "role": "http://www.p3hp.org/20220630/role/DisclosureClaimsPayable", "shortName": "Claims Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Long-Term Debt", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Income Taxes", "role": "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PartnersCapitalNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Capitalization and Management Incentive Units", "role": "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnits", "shortName": "Capitalization and Management Incentive Units", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PartnersCapitalNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Share-Based Compensation", "role": "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Earnings (Loss) per Share", "role": "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShare", "shortName": "Earnings (Loss) per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:PremiumDeficiencyReserveTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12001 - Disclosure - Premium Deficiency Reserve", "role": "http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserve", "shortName": "Premium Deficiency Reserve", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:PremiumDeficiencyReserveTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12101 - Disclosure - Leases", "role": "http://www.p3hp.org/20220630/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12201 - Disclosure - Redeemable Non-Controlling Interests", "role": "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterests", "shortName": "Redeemable Non-Controlling Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "b", "link:footnote", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_srt_ConsolidatedEntitiesAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_SO9M1iYe3kKcVuRtUnUEQw", "decimals": "-5", "first": true, "lang": null, "name": "piii:VariableInterestEntityAssetsSettleObligations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "b", "link:footnote", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_srt_ConsolidatedEntitiesAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_SO9M1iYe3kKcVuRtUnUEQw", "decimals": "-5", "first": true, "lang": null, "name": "piii:VariableInterestEntityAssetsSettleObligations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12301 - Disclosure - Commitments and Contingencies", "role": "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12401 - Disclosure - Related Parties", "role": "http://www.p3hp.org/20220630/role/DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12501 - Disclosure - Variable Interest Entities", "role": "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntities", "shortName": "Variable Interest Entities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12601 - Disclosure - Warrants", "role": "http://www.p3hp.org/20220630/role/DisclosureWarrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20402 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsTables", "shortName": "Restatement of Previously Issued Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Business Combinations (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:ScheduleOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Fair Value Measurements and Hierarchy (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables", "shortName": "Fair Value Measurements and Hierarchy (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:ScheduleOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:FinancingReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Patient Fees Receivable (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableTables", "shortName": "Patient Fees Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancingReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "0", "lang": null, "name": "piii:PremiumDeficiencyTestingExpenseLongDurationContractAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Property and Equipment (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Goodwill (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureGoodwillTables", "shortName": "Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Intangible Assets (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Claims Payable (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableTables", "shortName": "Claims Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Long-Term Debt (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31803 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31903 - Disclosure - Earnings (Loss) per Share (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables", "shortName": "Earnings (Loss) per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32103 - Disclosure - Leases (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32403 - Disclosure - Related Parties (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables", "shortName": "Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32503 - Disclosure - Variable Interest Entities (Tables)", "role": "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesTables", "shortName": "Variable Interest Entities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9WSmDq1Gy0CJGx1a2OATkw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT)", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_PreferredUnitsByNameAxis_piii_ClassCPreferredUnitsMember_vOTD_6YZ50qLLOHU8EVL6g", "decimals": "0", "lang": null, "name": "us-gaap:PartnersCapitalAccountUnitBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfHealthPlansAgreementsEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_plan_7cbgNLc-2kqk2qxo-4uwlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and Basis of Presentation (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails", "shortName": "Organization and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfHealthPlansAgreementsEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_plan_7cbgNLc-2kqk2qxo-4uwlw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Restatement of Previously Issued Financial Statements (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "shortName": "Restatement of Previously Issued Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BGFKpM1y-U6tHoL9k_CLSg", "decimals": "0", "lang": null, "name": "piii:ProceedsOrPaymentsFromHealthPlanSettlementsReceivableOrPremiumsReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Going Concern and Liquidity (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidityDetails", "shortName": "Going Concern and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails", "shortName": "Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_sfUxERq9tEO6VuEkDSUHoA", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_piii_CapitatedRevenueMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XqFE160qb0yclJtFzm9pYg", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Significant Accounting Policies - Concentration of revenue (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "shortName": "Significant Accounting Policies - Concentration of revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_piii_HealthPlanNameAxis_piii_HealthPlanMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qpk7i2RlMUWdYY-Z4RU0BQ", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:HealthPlansTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Significant Accounting Policies - Capitated Revenue (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "shortName": "Significant Accounting Policies - Capitated Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "piii:HealthPlansTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Significant Accounting Policies - Health Plan Receivables (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "shortName": "Significant Accounting Policies - Health Plan Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "piii:ScheduleOfSettlementReceivablesHealthPlanSurplusesAndSettlementPayablesHealthPlanDeficitsByHealthPlanByYearTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_srt_ProductOrServiceAxis_piii_CapitatedRevenueMember_kq4ijk3ehE2ETcxgHMrrSw", "decimals": "0", "lang": null, "name": "piii:HealthPlanSettlementReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40406 - Disclosure - Significant Accounting Policies - Health Plan Settlement Payables (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails", "shortName": "Significant Accounting Policies - Health Plan Settlement Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "piii:ScheduleOfSettlementReceivablesHealthPlanSurplusesAndSettlementPayablesHealthPlanDeficitsByHealthPlanByYearTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_piii_HealthPlanNameAxis_piii_HealthPlanBMember_G0eta1lDdUWlvruS-Dk2Kg", "decimals": "0", "lang": null, "name": "piii:HealthPlansSettlementsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfRevenuePracticalExpedientsElected", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40407 - Disclosure - Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "shortName": "Significant Accounting Policies - Clinical Fees and Insurance Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfRevenuePracticalExpedientsElected", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GJcfEYfNTEODuF_bHeL2BA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GJcfEYfNTEODuF_bHeL2BA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_piii_HealthCareSharedRiskRevenueMember_stPjz2uhR0e7dhkGbvs_cg", "decimals": "2", "first": true, "lang": null, "name": "piii:PercentageOfSharedRiskSavingsReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40408 - Disclosure - Significant Accounting Policies - Shared Risk Revenue (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails", "shortName": "Significant Accounting Policies - Shared Risk Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_piii_HealthCareSharedRiskRevenueMember_stPjz2uhR0e7dhkGbvs_cg", "decimals": "2", "first": true, "lang": null, "name": "piii:PercentageOfSharedRiskSavingsReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "p", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40409 - Disclosure - Significant Accounting Policies - Goodwill (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesGoodwillDetails", "shortName": "Significant Accounting Policies - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Business Combinations - Foresight (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "shortName": "Business Combinations - Foresight (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_12_3_2021_To_12_3_2021_us-gaap_BusinessAcquisitionAxis_piii_P3LlcMember_vfYIYAcixE2svnl832EIMA", "decimals": "2", "lang": null, "name": "piii:PercentageOfPaymentOfIncomeTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "first": true, "lang": null, "name": "piii:BusinessCombinationNumberOfBusinessAcquired", "reportCount": 1, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Business Combinations - Other (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "shortName": "Business Combinations - Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_12_27_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_piii_MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember_GKCl1f5IVEKwvSAXjQyXbg", "decimals": "INF", "lang": null, "name": "piii:BusinessCombinationNumberOfBusinessAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Business Combinations - Purchase Price Allocation (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "shortName": "Business Combinations - Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_3_2021_us-gaap_BusinessAcquisitionAxis_piii_P3LlcMember_-kmUrCkR6Ee2VHw7luPjqw", "decimals": "0", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BGFKpM1y-U6tHoL9k_CLSg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - Business Combinations - Pro Forma Financial Information (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "shortName": "Business Combinations - Pro Forma Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BGFKpM1y-U6tHoL9k_CLSg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "shortName": "Fair Value Measurements and Hierarchy - Carrying Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K3plc3aICkmnrGXcLGbOFA", "decimals": "0", "first": true, "lang": null, "name": "piii:WarrantLiabilityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails", "shortName": "Fair Value Measurements and Hierarchy - Summary of Fair value Hierarchy for Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K3plc3aICkmnrGXcLGbOFA", "decimals": "0", "first": true, "lang": null, "name": "piii:WarrantLiabilityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_piii_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DvOBz4j1ckebLB4uA10zFQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Fair Value Measurements and Hierarchy - Option Pricing (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "shortName": "Fair Value Measurements and Hierarchy - Option Pricing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_piii_PrivatePlacementWarrantsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DvOBz4j1ckebLB4uA10zFQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails", "shortName": "Fair Value Measurements and Hierarchy - Summary of Changes in Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_xqktht5TdE2OXWw68-DbEg", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Patient Fees Receivable (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails", "shortName": "Patient Fees Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_xqktht5TdE2OXWw68-DbEg", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Property and Equipment (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_poLGR9KF9EuKKiVOFRF-fA", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Goodwill (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails", "shortName": "Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_xqktht5TdE2OXWw68-DbEg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Intangible Assets - Changes (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails", "shortName": "Intangible Assets - Changes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Intangible Assets - Additional Information (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "shortName": "Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "INF", "first": true, "lang": null, "name": "piii:FinancingReceivableNumberOfPromissoryNotesEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Notes Receivable, Net (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails", "shortName": "Notes Receivable, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "INF", "first": true, "lang": null, "name": "piii:FinancingReceivableNumberOfPromissoryNotesEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wSPcio7hfE2vSQBZORVAcg", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Claims Payable - Additional Information (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableAdditionalInformationDetails", "shortName": "Claims Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Claims Payable (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails", "shortName": "Claims Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Long-Term Debt - Additional Information (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "shortName": "Long-Term Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "lang": null, "name": "piii:SecurityAgreementLendersCollateralPercentageOfPledgedStockItsSubsidiariesAndBankAccounts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Long-Term Debt - Rollforward (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails", "shortName": "Long-Term Debt - Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Basis of Presentation", "role": "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Long-Term Debt - Maturity (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails", "shortName": "Long-Term Debt - Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41504 - Disclosure - Long-Term Debt - Current and Long Term (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails", "shortName": "Long-Term Debt - Current and Long Term (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_xqktht5TdE2OXWw68-DbEg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41505 - Disclosure - Long-Term Debt - Short-Term (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "shortName": "Long-Term Debt - Short-Term (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_Ra7BGPvyLEWQEsFi_6s6AA", "decimals": "0", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "p", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Income Taxes (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "4", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ZMAzvo3gtU6n3cpzyerlaA", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Capitalization and Management Incentive Units (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "shortName": "Capitalization and Management Incentive Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_xqktht5TdE2OXWw68-DbEg", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_-O0Oa4--vU62wCZdlbjQpA", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Share-Based Compensation - Class V Activity (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "shortName": "Share-Based Compensation - Class V Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_piii_TimeBasedProfitsInterestAwardsMember_aSWEFUpxbE-v4VDRyS9Pmg", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_FKMgkOfn3EaC6JT_-7fehw", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41802 - Disclosure - Share-Based Compensation - Expense (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8YMoDlNaVUW5XTHcWg3Whg", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_-O0Oa4--vU62wCZdlbjQpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41803 - Disclosure - Share-Based Compensation - Stock options activities (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails", "shortName": "Share-Based Compensation - Stock options activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_-O0Oa4--vU62wCZdlbjQpA", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Earnings (Loss) per Share - Computation (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "shortName": "Earnings (Loss) per Share - Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41902 - Disclosure - Earnings (Loss) per Share - Anti-dilutive securities (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails", "shortName": "Earnings (Loss) per Share - Anti-dilutive securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_-O0Oa4--vU62wCZdlbjQpA", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Restatement of Previously Issued Financial Statements", "role": "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatements", "shortName": "Restatement of Previously Issued Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "piii:PremiumDeficiencyReserveCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42001 - Disclosure - Premium Deficiency Reserve (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserveDetails", "shortName": "Premium Deficiency Reserve (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R91": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfOperatingLease", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_agreement_W9qX5cvdtECh3BjN6uu4Mg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42101 - Disclosure - Leases (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "INF", "first": true, "lang": null, "name": "piii:NumberOfOperatingLease", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_agreement_W9qX5cvdtECh3BjN6uu4Mg", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42102 - Disclosure - Leases - Operating Lease Costs (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesOperatingLeaseCostsDetails", "shortName": "Leases - Operating Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42103 - Disclosure - Leases - Lease Terms And Discount Rates (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails", "shortName": "Leases - Lease Terms And Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42104 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42105 - Disclosure - Leases - Current Portions Of ROU Liabilities (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureLeasesCurrentPortionsOfRouLiabilitiesDetails", "shortName": "Leases - Current Portions Of ROU Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_p7mfCoT4F02rR_2Exqk2uA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "first": true, "lang": null, "name": "piii:RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42201 - Disclosure - Redeemable Non-Controlling Interests (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails", "shortName": "Redeemable Non-Controlling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "first": true, "lang": null, "name": "piii:RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42301 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_raR-F4FpZEq9OFZdeBEcLg", "decimals": "INF", "lang": null, "name": "piii:NumberOfHealthPlansResultingInRenegotiation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_plan_7cbgNLc-2kqk2qxo-4uwlw", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42401 - Disclosure - Related Parties (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "shortName": "Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Zk-3mJOP_Ean9_Rmp7x8ZQ", "decimals": "0", "lang": null, "name": "us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_WvNYNDeks06PYWijRSFhmA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42501 - Disclosure - Variable Interest Entities (Details)", "role": "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "shortName": "Variable Interest Entities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "piii-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_A6ZnLciwNkqclqCP8VWNQg", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_lnAlYSJDvUapAw43qphfSw", "xsiNil": "false" } } }, "segmentCount": 112, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "piii_AdjustmentToMembersDeficitSharesRepurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of shares repurchased adjusted to members deficit.", "label": "Adjustment to Members Deficit Shares Repurchased", "terseLabel": "Members deficit decrease" } } }, "localname": "AdjustmentToMembersDeficitSharesRepurchased", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemableNonControllingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable non-controlling interest.", "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Non-Controlling Interest", "negatedLabel": "Adjustments to Redeemable Non-Controlling Interest" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemableNonControllingInterest", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "piii_AdjustmentsUnderRiskAdjustmentModel": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of adjustments under risk adjustment model.", "label": "Adjustments Under Risk Adjustment Model", "terseLabel": "Total RAF adjustments" } } }, "localname": "AdjustmentsUnderRiskAdjustmentModel", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "piii_AllOtherHealthPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to all other health plan.", "label": "All Other Health Plan [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherHealthPlanMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "piii_AtrioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Atrio.", "label": "Atrio" } } }, "localname": "AtrioMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "domainItemType" }, "piii_BusinessAcquisitionNonControllingInterestFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of non-controlling interests of the acquirer in consideration for the business combination.", "label": "Business Acquisition, Non-controlling Interest Fair Value", "terseLabel": "Fair Value of Noncontrolling Interest" } } }, "localname": "BusinessAcquisitionNonControllingInterestFairValue", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss attributable to noncontrolling interest for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net Loss Attributable to Noncontrolling Interest" } } }, "localname": "BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationNumberOfBusinessAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of business acquired under business combination.", "label": "Business Combination, Number of Business Acquired", "terseLabel": "Number of other medical practice acquired", "verboseLabel": "Number of medical practice acquired" } } }, "localname": "BusinessCombinationNumberOfBusinessAcquired", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails" ], "xbrltype": "integerItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedInterest": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Accrued Interest", "terseLabel": "Accrued Interest" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedInterest", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedPayroll": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued payroll assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Accrued Payroll", "terseLabel": "Accrued Payroll" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedPayroll", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of total assets acquired assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Assets Including Goodwill", "totalLabel": "Total Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedClaimsPayable": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of claims payable assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Claims Payable", "terseLabel": "Claims Payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedClaimsPayable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedClinicFeesAndInsuranceReceivablesNet": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of clinic fees and insurance receivables, net assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Clinic Fees and Insurance Receivables, Net", "terseLabel": "Clinic Fees and Insurance Receivables, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedClinicFeesAndInsuranceReceivablesNet", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedHealthPlanSettlementReceivables": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of health plan settlement receivables assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Health Plan Settlement Receivables", "terseLabel": "Health Plan Settlement Receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedHealthPlanSettlementReceivables", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedHealthPlansSettlementsPayable": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of health plans settlements payable assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Health Plans Settlements Payable", "terseLabel": "Health Plans Settlements Payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedHealthPlansSettlementsPayable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOtherReceivables": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other receivables assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Other Receivables", "terseLabel": "Other Receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOtherReceivables", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedPremiumDeficiencyReserve": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of premium deficiency reserve assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Premium Deficiency Reserve", "terseLabel": "Premium Deficiency Reserve" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedPremiumDeficiencyReserve", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedRestrictedCash": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted cash assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedRestrictedCash", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 11.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right of use assets assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Right of Use Assets", "terseLabel": "Right of Use Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedRightOfUseAssets", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "piii_BusinessCombinationSharesIssuedLockUpPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period time when shares issued as of business combination are not allowed to be redeemed, sold or transferred.", "label": "Business Combination, Shares Issued Lock Up Period", "terseLabel": "Lockup period" } } }, "localname": "BusinessCombinationSharesIssuedLockUpPeriod", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "durationItemType" }, "piii_CapitatedRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to capitated revenue.", "label": "Capitated Revenue" } } }, "localname": "CapitatedRevenueMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "piii_ClaimsPayableCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of claims payable in twelve months or in the next operating cycle if longer.", "label": "Claims Payable, Current", "terseLabel": "Claims Payable" } } }, "localname": "ClaimsPayableCurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_ClassAndClassDPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class A and Class D Preferred Units.", "label": "Class A and Class D Units" } } }, "localname": "ClassAndClassDPreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "piii_ClassB1PreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class B-1 Preferred Units.", "label": "Class B-1 Preferred Units" } } }, "localname": "ClassB1PreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "piii_ClassBForesightFounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Class B Foresight Founder Shares.", "label": "Class A Foresight Founder Shares [Member]" } } }, "localname": "ClassBForesightFounderSharesMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "domainItemType" }, "piii_ClassBPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class B Preferred Units.", "label": "Class B Preferred Units" } } }, "localname": "ClassBPreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "domainItemType" }, "piii_ClassCPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class C Preferred Units.", "label": "Class C Preferred Units" } } }, "localname": "ClassCPreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "piii_ClassDPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class D Units.", "label": "Class D Preferred Units" } } }, "localname": "ClassDPreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "piii_ClassDWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Class D warrants.", "label": "Class D warrants [Member]", "terseLabel": "Class D Warrants" } } }, "localname": "ClassDWarrantsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "piii_ClassOfWarrantOrRightExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period after specified event in agreement that warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Exercise Period", "terseLabel": "Period after completion of business combination warrants become exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisePeriod", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "piii_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Warrants issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "sharesItemType" }, "piii_ClassOfWarrantOrRightThresholdStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold Price of the entity's common stock which would be required to be attained to redeem warrants", "label": "Class of Warrant or Right, Threshold Stock Price Trigger", "terseLabel": "Threshold share price" } } }, "localname": "ClassOfWarrantOrRightThresholdStockPriceTrigger", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "piii_ClassOfWarrantOrRightThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price must exceed threshold price to trigger redeem feature.", "label": "Class of Warrant or Right, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "ClassOfWarrantOrRightThresholdTradingDays", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "piii_ClassPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class A Preferred Units.", "label": "Class A Preferred Units" } } }, "localname": "ClassPreferredUnitsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "piii_ClassUnitsAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to restatement adjustments relating to Class A Units.", "label": "Class A Units Adjustments" } } }, "localname": "ClassUnitsAdjustmentMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "piii_ClinicFeesAndInsuranceReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of clinic fees and insurance receivables, net due within one year or the normal operating cycle, if longer.", "label": "Clinic Fees and Insurance Receivables, Net, Current", "terseLabel": "Clinic Fees and Insurance Receivables, Net", "verboseLabel": "Client Fees and Insurance Receivable, net" } } }, "localname": "ClinicFeesAndInsuranceReceivablesNetCurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_CommonClassVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Class V member.", "label": "Common Class V" } } }, "localname": "CommonClassVMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "piii_CommonStockNumberOfVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of voting rights per share.", "label": "Common Stock, Number of Voting Rights", "terseLabel": "Number of voting rights per share" } } }, "localname": "CommonStockNumberOfVotingRights", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "integerItemType" }, "piii_CompanyOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Company Operations [Line Items]" } } }, "localname": "CompanyOperationsLineItems", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "piii_CompanyOperationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about company operations.", "label": "Company Operations [Table]" } } }, "localname": "CompanyOperationsTable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "piii_DebtCovenantAgreementPeriodOfRevenueThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over of revenue threshold per debt covenant agreement, , in 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Covenant Agreement, Period Of Revenue Threshold", "terseLabel": "Period when revenue should greater than or equal to $125.0 million" } } }, "localname": "DebtCovenantAgreementPeriodOfRevenueThreshold", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "piii_DebtInstrumentAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Accrued Interest", "terseLabel": "Debt instrument accrued interest" } } }, "localname": "DebtInstrumentAccruedInterest", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_DebtInstrumentAccruedInterestOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest outstanding on debt instrument.", "label": "Debt Instrument Accrued Interest Outstanding", "terseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentAccruedInterestOutstanding", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_DebtInstrumentCovenantComplianceMinimumLiquidity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum liquidity as per debt instrument covenant compliance.", "label": "Debt Instrument Covenant Compliance Minimum Liquidity", "terseLabel": "Minimum liquidity" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumLiquidity", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_DebtInstrumentCovenantComplianceMinimumRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum revenue as per debt instrument covenant compliance.", "label": "Debt Instrument, Covenant Compliance Minimum Revenue", "terseLabel": "Minimum revenue" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumRevenue", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_DebtInstrumentExitFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of exit fee which is due at maturity.", "label": "Debt Instrument Exit Fee", "terseLabel": "Amount exit fee due at maturity" } } }, "localname": "DebtInstrumentExitFee", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_EquipmentOnLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents equipment on lease.", "label": "Equipment on lease" } } }, "localname": "EquipmentOnLeaseMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "piii_EstimatedPotentialFutureTaxBenefits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated potential future tax benefits.", "label": "Estimated Potential Future Tax Benefits", "terseLabel": "Estimated potential future tax benefits" } } }, "localname": "EstimatedPotentialFutureTaxBenefits", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "piii_FinancingReceivableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate on financing receivables.", "label": "Financing Receivable Interest Rate", "terseLabel": "Interest rates" } } }, "localname": "FinancingReceivableInterestRate", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "percentItemType" }, "piii_FinancingReceivableNumberOfFamilyMedicalPracticesWithWhomPromissoryNotesAreEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of family medical practices with whom promissory notes are entered.", "label": "Financing Receivable Number Of Family Medical Practices With Whom Promissory Notes Are Entered", "terseLabel": "Number of family medical practices with whom promissory notes are entered" } } }, "localname": "FinancingReceivableNumberOfFamilyMedicalPracticesWithWhomPromissoryNotesAreEntered", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "integerItemType" }, "piii_FinancingReceivableNumberOfPromissoryNotesEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of promissory notes entered.", "label": "Financing Receivable Number Of Promissory Notes Entered", "terseLabel": "Number of promissory notes entered" } } }, "localname": "FinancingReceivableNumberOfPromissoryNotesEntered", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "integerItemType" }, "piii_FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the separate provider agreements with each practice related to number of promissory notes entered.", "label": "Financing Receivable Separate Provider Agreements With Each Practice Related To Number Of Promissory Notes Entered", "terseLabel": "Separate provider agreements with each practice related to number of promissory notes entered" } } }, "localname": "FinancingReceivableSeparateProviderAgreementsWithEachPracticeRelatedToNumberOfPromissoryNotesEntered", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "integerItemType" }, "piii_GoingConcernAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Going Concern and Liquidity" } } }, "localname": "GoingConcernAndLiquidityAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_HealthCareCareCoordinationManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to care coordination / management fees.", "label": "Care Coordination / Management Fees" } } }, "localname": "HealthCareCareCoordinationManagementFeesMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "piii_HealthCareClinicalFeesInsuranceRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to clinical fees & insurance revenue.", "label": "Clinical Fees & Insurance Revenue" } } }, "localname": "HealthCareClinicalFeesInsuranceRevenueMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "piii_HealthCareIncentiveFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to incentive fees.", "label": "Incentive Fees" } } }, "localname": "HealthCareIncentiveFeesMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "piii_HealthCareSharedRiskRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to shared risk revenue.", "label": "Shared Risk Revenue" } } }, "localname": "HealthCareSharedRiskRevenueMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan B.", "label": "Health Plan B", "terseLabel": "Health Plan B" } } }, "localname": "HealthPlanBMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan C.", "label": "Health Plan C", "terseLabel": "Health Plan C" } } }, "localname": "HealthPlanCMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan D.", "label": "Health Plan D", "terseLabel": "Health Plan D" } } }, "localname": "HealthPlanDMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan E.", "label": "Health Plan E" } } }, "localname": "HealthPlanEMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan F.", "label": "Health Plan F", "terseLabel": "Health Plan F" } } }, "localname": "HealthPlanFMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan G.", "label": "Health Plan G", "terseLabel": "Health Plan G" } } }, "localname": "HealthPlanGMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan H.", "label": "Health Plan H" } } }, "localname": "HealthPlanHMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan I.", "label": "Health Plan I" } } }, "localname": "HealthPlanIMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanJMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan J.", "label": "Health Plan J" } } }, "localname": "HealthPlanJMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan K.", "label": "Health Plan K" } } }, "localname": "HealthPlanKMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan L.", "label": "Health Plan L" } } }, "localname": "HealthPlanLMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Health Plan [Line Items]" } } }, "localname": "HealthPlanLineItems", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "stringItemType" }, "piii_HealthPlanMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan M.", "label": "Health Plan M" } } }, "localname": "HealthPlanMMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan A.", "label": "Health Plan A", "terseLabel": "Health Plan A" } } }, "localname": "HealthPlanMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan N.", "label": "Health Plan N" } } }, "localname": "HealthPlanNMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of health plan.", "label": "Health Plan Name [Axis]" } } }, "localname": "HealthPlanNameAxis", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "stringItemType" }, "piii_HealthPlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of health plan.", "label": "Health Plans" } } }, "localname": "HealthPlanNameDomain", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan O.", "label": "Health Plan O" } } }, "localname": "HealthPlanOMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan O.", "label": "Health Plan P" } } }, "localname": "HealthPlanPMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanQMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan Q.", "label": "Health Plan Q" } } }, "localname": "HealthPlanQMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan R.", "label": "Health Plan R" } } }, "localname": "HealthPlanRMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan S.", "label": "Health Plan S" } } }, "localname": "HealthPlanSMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanSettlementReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of health plan settlement receivables due within one year or the normal operating cycle, if longer.", "label": "Health Plan Settlement Receivables, Current", "terseLabel": "Health Plan Receivables, Net" } } }, "localname": "HealthPlanSettlementReceivablesCurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_HealthPlanTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan T.", "label": "Health Plan T" } } }, "localname": "HealthPlanTMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by health plan.", "label": "Health Plan [Table]" } } }, "localname": "HealthPlanTable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "stringItemType" }, "piii_HealthPlanUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan U.", "label": "Health Plan U" } } }, "localname": "HealthPlanUMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan V.", "label": "Health Plan V" } } }, "localname": "HealthPlanVMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlanWMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Health Plan W.", "label": "Health Plan W" } } }, "localname": "HealthPlanWMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails" ], "xbrltype": "domainItemType" }, "piii_HealthPlansSettlementsPayableCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of health plans settlements payable in twelve months or in the next operating cycle if longer.", "label": "Health Plans Settlements Payable, Current", "terseLabel": "Health Plans Settlements Payable" } } }, "localname": "HealthPlansSettlementsPayableCurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_HealthPlansTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of contract of health plans, in 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Health Plans, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "HealthPlansTermOfContract", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "durationItemType" }, "piii_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "piii_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule providing details of the income tax.", "label": "Income Tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "piii_IncreaseDecreaseInClaimsPayables": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period for claims payables.", "label": "Increase (Decrease) in Claims Payables", "terseLabel": "Claims Payable" } } }, "localname": "IncreaseDecreaseInClaimsPayables", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_IncreaseDecreaseInHealthPlanPayablesPremiums": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period for health plan payables / premiums.", "label": "Increase (Decrease) in Health Plan Payables, Premiums", "terseLabel": "Health Plan Payables / Premiums" } } }, "localname": "IncreaseDecreaseInHealthPlanPayablesPremiums", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_IncreaseDecreaseInHealthPlanReceivablesPremiums": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period for health plan receivables / premiums.", "label": "Increase (Decrease) in Health Plan Receivables, Premiums", "negatedLabel": "Health Plan Receivables / Premiums" } } }, "localname": "IncreaseDecreaseInHealthPlanReceivablesPremiums", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_IncreaseDecreaseInOperatingRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in operating revenue.", "label": "Increase (Decrease) in Operating Revenue", "negatedLabel": "Reduction in operating revenue" } } }, "localname": "IncreaseDecreaseInOperatingRevenue", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "piii_IncreaseInRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right of use assets arising from lease agreements.", "label": "Increase in Right of Use Assets", "terseLabel": "Increase in ROU Asset" } } }, "localname": "IncreaseInRightOfUseAssets", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "piii_IntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_InvestmentInOtherEntities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of investment in other entities.", "label": "Investment in Other Entities", "terseLabel": "Investment in Other P3 Entities" } } }, "localname": "InvestmentInOtherEntities", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "piii_KahanWakefieldAbdouPllcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Kahan, Wakefield, Abdou, PLLC (\"KWA\").", "label": "KWA" } } }, "localname": "KahanWakefieldAbdouPllcMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "piii_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "piii_LimitedPartnersCapitalAccountPreferredReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of preferred returns.", "label": "Limited Partners' Capital Account, Preferred Returns", "terseLabel": "Preferred Return(s) at 8%", "verboseLabel": "Preferred Return at 8%" } } }, "localname": "LimitedPartnersCapitalAccountPreferredReturns", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturity": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest.", "label": "Long Term Debt Cash Interest Maturity", "totalLabel": "Cash Interest" } } }, "localname": "LongTermDebtCashInterestMaturity", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturityRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 1.0, "parentTag": "piii_LongTermDebtCashInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest maturing in remainder of current fiscal year.", "label": "Long Term Debt Cash Interest Maturity Remainder of Fiscal Year", "verboseLabel": "Cash Interest - October 1, 2022 to December 31, 2022" } } }, "localname": "LongTermDebtCashInterestMaturityRemainderOfFiscalYear", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturityYearFour": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 5.0, "parentTag": "piii_LongTermDebtCashInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest maturing in fourth fiscal year following current fiscal year.", "label": "Long Term Debt Cash Interest Maturity Year Four", "terseLabel": "Cash Interest - 2026" } } }, "localname": "LongTermDebtCashInterestMaturityYearFour", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturityYearOne": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 2.0, "parentTag": "piii_LongTermDebtCashInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest maturing in next fiscal year following current fiscal year.", "label": "Long Term Debt Cash Interest Maturity Year One", "terseLabel": "Cash Interest - 2023" } } }, "localname": "LongTermDebtCashInterestMaturityYearOne", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturityYearThree": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 4.0, "parentTag": "piii_LongTermDebtCashInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest maturing in third fiscal year following current fiscal year.", "label": "Long Term Debt Cash Interest Maturity Year Three", "terseLabel": "Cash Interest - 2025" } } }, "localname": "LongTermDebtCashInterestMaturityYearThree", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashInterestMaturityYearTwo": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 3.0, "parentTag": "piii_LongTermDebtCashInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt cash interest maturing in second fiscal year following current fiscal year.", "label": "Long Term Debt Cash Interest Maturity Year Two", "terseLabel": "Cash Interest - 2024" } } }, "localname": "LongTermDebtCashInterestMaturityYearTwo", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtCashKindInterestByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term debt cash interest by maturity abstract.", "label": "Long Term Debt Cash Kind Interest By Maturity [Abstract]", "terseLabel": "Cash Interest" } } }, "localname": "LongTermDebtCashKindInterestByMaturityAbstract", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "stringItemType" }, "piii_LongTermDebtPaidInKindInterestByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term debt paid in kind interest by maturity abstract.", "label": "Long Term Debt Paid In Kind Interest By Maturity [Abstract]", "terseLabel": "PIK" } } }, "localname": "LongTermDebtPaidInKindInterestByMaturityAbstract", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "stringItemType" }, "piii_LongTermDebtPaidInKindInterestMaturity": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest.", "label": "Long-Term Debt, Paid in Kind Interest Maturity", "totalLabel": "PIK- Total" } } }, "localname": "LongTermDebtPaidInKindInterestMaturity", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtPaidInKindInterestMaturityRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 1.0, "parentTag": "piii_LongTermDebtPaidInKindInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Paid in Kind Interest Maturity Remainder of Fiscal Year", "terseLabel": "PIK - October 1, 2022 to December 31, 2022" } } }, "localname": "LongTermDebtPaidInKindInterestMaturityRemainderOfFiscalYear", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtPaidInKindInterestMaturityYearFour": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 5.0, "parentTag": "piii_LongTermDebtPaidInKindInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest maturing in fourth fiscal year following current fiscal year.", "label": "Long-Term Debt, Paid in Kind Interest Maturity Year Four", "terseLabel": "PIK- 2026" } } }, "localname": "LongTermDebtPaidInKindInterestMaturityYearFour", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtPaidInKindInterestMaturityYearOne": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 2.0, "parentTag": "piii_LongTermDebtPaidInKindInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest maturing in next fiscal year following current fiscal year.", "label": "Long-Term Debt, Paid in Kind Interest Maturity Year One", "terseLabel": "PIK- 2023" } } }, "localname": "LongTermDebtPaidInKindInterestMaturityYearOne", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtPaidInKindInterestMaturityYearThree": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 4.0, "parentTag": "piii_LongTermDebtPaidInKindInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest maturing in third fiscal year following current fiscal year.", "label": "Long-Term Debt, Paid in Kind Interest Maturity Year Three", "terseLabel": "PIK- 2025" } } }, "localname": "LongTermDebtPaidInKindInterestMaturityYearThree", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtPaidInKindInterestMaturityYearTwo": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 3.0, "parentTag": "piii_LongTermDebtPaidInKindInterestMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt paid in kind interest maturing in second fiscal year following current fiscal year.", "label": "Long-Term Debt, Paid in Kind Interest Maturity Year Two", "terseLabel": "PIK- 2024" } } }, "localname": "LongTermDebtPaidInKindInterestMaturityYearTwo", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term debt total payments by maturity abstract.", "label": "Long Term Debt Total Payments By Maturity [Abstract]", "terseLabel": "Total Payments" } } }, "localname": "LongTermDebtTotalPaymentsByMaturityAbstract", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "stringItemType" }, "piii_LongTermDebtTotalPaymentsMaturity": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments.", "label": "Long-Term Debt, Total Payments Maturity", "totalLabel": "Total Cash Payments - Total" } } }, "localname": "LongTermDebtTotalPaymentsMaturity", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsMaturityRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 1.0, "parentTag": "piii_LongTermDebtTotalPaymentsMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Total Payments Maturity, Remainder of Fiscal Year", "terseLabel": "Total Cash Payments - October 1, 2022 to December 31, 2022" } } }, "localname": "LongTermDebtTotalPaymentsMaturityRemainderOfFiscalYear", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsMaturityYearFour": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 5.0, "parentTag": "piii_LongTermDebtTotalPaymentsMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments maturing in fourth fiscal year following current fiscal year.", "label": "Long-Term Debt, Total Payments Maturity, Year Four", "terseLabel": "Total Cash Payments - 2026" } } }, "localname": "LongTermDebtTotalPaymentsMaturityYearFour", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsMaturityYearOne": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 2.0, "parentTag": "piii_LongTermDebtTotalPaymentsMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments maturing in next fiscal year following current fiscal year.", "label": "Long-Term Debt, Total Payments Maturity, Year One", "terseLabel": "Total Cash Payments - 2023" } } }, "localname": "LongTermDebtTotalPaymentsMaturityYearOne", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsMaturityYearThree": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 4.0, "parentTag": "piii_LongTermDebtTotalPaymentsMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments maturing in third fiscal year following current fiscal year.", "label": "Long-Term Debt, Total Payments Maturity, Year Three", "terseLabel": "Total Cash Payments - 2025" } } }, "localname": "LongTermDebtTotalPaymentsMaturityYearThree", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LongTermDebtTotalPaymentsMaturityYearTwo": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 3.0, "parentTag": "piii_LongTermDebtTotalPaymentsMaturity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt total payments maturing in second fiscal year following current fiscal year.", "label": "Long-Term Debt, Total Payments Maturity, Year Two", "terseLabel": "Total Cash Payments - 2024" } } }, "localname": "LongTermDebtTotalPaymentsMaturityYearTwo", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "piii_LtdCLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to LTD-C Loan.", "label": "LTD-C" } } }, "localname": "LtdCLoanMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "domainItemType" }, "piii_LtdDLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to LTD-D Loan.", "label": "LTD-D" } } }, "localname": "LtdDLoanMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "domainItemType" }, "piii_LtdELoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to LTD-E Loan.", "label": "LTD-E" } } }, "localname": "LtdELoanMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "domainItemType" }, "piii_ManagementFeesWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of management fees with related party.", "label": "Management Fees with Related Party", "verboseLabel": "Management Fees" } } }, "localname": "ManagementFeesWithRelatedParty", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "piii_MarkToMarketAdjustmentOfForesightStockWarrants": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment mark-to-market adjustment of foresight stock warrants.", "label": "Mark To Market Adjustment Of Foresight Stock Warrants", "negatedLabel": "Mark-to-Market of Stock Warrants" } } }, "localname": "MarkToMarketAdjustmentOfForesightStockWarrants", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "piii_MarkToMarketAdjustmentOfStockWarrants": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment mark-to-market adjustment of stock warrants.", "label": "Mark-to-Market Adjustment of Stock Warrants", "terseLabel": "Mark-to-Market Adjustment of Stock Warrants" } } }, "localname": "MarkToMarketAdjustmentOfStockWarrants", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Medcore Health Plan, Inc and Omni IPA Medical Group, Inc.", "label": "Medcore Health Plan, Inc and Omni IPA Medical Group, Inc (\"Medcore Acquisition\")", "terseLabel": "Medcore Health Plan, Inc and Omni IPA Medical Group, Inc" } } }, "localname": "MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "domainItemType" }, "piii_MedcoreHpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Medcore HP.", "label": "Medcore HP" } } }, "localname": "MedcoreHpMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails" ], "xbrltype": "domainItemType" }, "piii_MedicalEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to medical equipment.\n.", "label": "Medical Equipment" } } }, "localname": "MedicalEquipmentMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "piii_MedicalExpenses": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of medical expenses incurred during the period.", "label": "Medical Expenses", "terseLabel": "Medical Expenses" } } }, "localname": "MedicalExpenses", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "piii_NetChangeInRightsOfUseAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right of use assets and liabilities.", "label": "Net Change in Rights of Use Assets and Liabilities", "terseLabel": "Net Change in ROU Assets and Liabilities" } } }, "localname": "NetChangeInRightsOfUseAssetsAndLiabilities", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_NetworkAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to restatement adjustments relating to network.", "label": "Network Adjustments" } } }, "localname": "NetworkAdjustmentsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "piii_NetworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC (collectively, the \"Network\").", "label": "Network" } } }, "localname": "NetworkMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "piii_NotesReceivableNoncurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of notes receivable, net due after one year or the normal operating cycle, if longer.", "label": "Notes Receivable Noncurrent", "terseLabel": "Notes Receivable, Net" } } }, "localname": "NotesReceivableNoncurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_NumberOfHealthPlansAgreementsEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of health plans with agreements entered.", "label": "Number of Health Plans, Agreements Entered", "terseLabel": "Number of health plans with agreements entered" } } }, "localname": "NumberOfHealthPlansAgreementsEntered", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfHealthPlansPercentageOfPaymentContractsEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of health plans percentage of payment contracts entered.", "label": "Number of Health Plans, Percentage of Payment Contracts Entered", "terseLabel": "Number of health plans percentage of payment contracts entered" } } }, "localname": "NumberOfHealthPlansPercentageOfPaymentContractsEntered", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfHealthPlansResultingInRenegotiation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of health plans results in renegotiation of agreement.", "label": "Number of Health Plans Resulting in Renegotiation", "terseLabel": "Number of health plans results in renegotiation" } } }, "localname": "NumberOfHealthPlansResultingInRenegotiation", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfOperatingLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of operating lease.", "label": "Number Of Operating Lease" } } }, "localname": "NumberOfOperatingLease", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfOptionsToRenew": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of options to renewal of lease.", "label": "Number Of Options To Renew", "terseLabel": "Number of options to renew" } } }, "localname": "NumberOfOptionsToRenew", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfRepurchaseAgreementDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share-repurchase agreement entered during the reporting period.", "label": "Number of Repurchase Agreement During the Period", "verboseLabel": "Number of share-purchase agreement" } } }, "localname": "NumberOfRepurchaseAgreementDuringPeriod", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfRevenuePracticalExpedientsElected": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of practical expedients elected.", "label": "Number of Revenue, Practical Expedients, Elected", "terseLabel": "Number of Revenue, Practical Expedients, Elected" } } }, "localname": "NumberOfRevenuePracticalExpedientsElected", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfSeparateArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of separate arrangements.", "label": "Number Of Separate Arrangements", "terseLabel": "Number of separate arrangements" } } }, "localname": "NumberOfSeparateArrangements", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "integerItemType" }, "piii_NumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states..", "label": "Number of states", "terseLabel": "Number of states" } } }, "localname": "NumberOfStates", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "integerItemType" }, "piii_OmniIpaMedicalGroupInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Omni IPA Medical Group, Inc.", "label": "Omni IPA Medical Group, Inc." } } }, "localname": "OmniIpaMedicalGroupInc.Member", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails" ], "xbrltype": "domainItemType" }, "piii_P3HealthGroupLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to P3 Health Group, LLC.", "label": "P3 Health Group, LLC" } } }, "localname": "P3HealthGroupLlcMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "piii_P3LlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to P3 Llc acquisition.", "label": "P3 Llc", "terseLabel": "P3 LLC" } } }, "localname": "P3LlcMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables", "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "piii_P3NvMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to P3 NV.", "label": "P3 NV" } } }, "localname": "P3NvMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "piii_PaidInCashInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate paid in cash.", "label": "Paid in Cash Interest Rate", "terseLabel": "Paid in cash interest, percentage" } } }, "localname": "PaidInCashInterestRate", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "piii_PaidInKindInterestPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of paid in kind interest payment, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Paid in Kind, Interest Payment Term", "terseLabel": "Interest payment term" } } }, "localname": "PaidInKindInterestPaymentTerm", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "piii_PaidInKindInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate paid in kind.", "label": "Paid in Kind Interest Rate", "terseLabel": "Paid in kind interest, percentage" } } }, "localname": "PaidInKindInterestRate", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "piii_PaidInKindNumberOfPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of payments for paid in kind.", "label": "Paid in Kind, Number of Payments", "terseLabel": "Number of payments" } } }, "localname": "PaidInKindNumberOfPayments", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "piii_PartialPaidInKindInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate partially paid in kind.", "label": "Partial Paid in Kind Interest Rate", "terseLabel": "Partially paid in kind interest, percentage" } } }, "localname": "PartialPaidInKindInterestRate", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "piii_PatientFeesReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Patient Fees Receivable" } } }, "localname": "PatientFeesReceivableAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_PaymentForLoanOriginationAndClosingFees": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash outflow of payment for loan origination and closing fees.", "label": "Payment For Loan Origination And Closing Fees", "terseLabel": "Loan Origination and Closing Fees" } } }, "localname": "PaymentForLoanOriginationAndClosingFees", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_PaymentOfClaimsToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of claims paid to related party.", "label": "Payment Of Claims To Related Party", "verboseLabel": "Claims Paid" } } }, "localname": "PaymentOfClaimsToRelatedParty", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "piii_PaymentOfTaxSavingsRealizedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of payment of tax savings realized.", "label": "Payment of Tax Savings Realized, Percentage", "terseLabel": "Percentage of payment of tax savings realized" } } }, "localname": "PaymentOfTaxSavingsRealizedPercentage", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "piii_PercentageOfPaymentOfIncomeTaxBenefits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of income tax benefits to be paid.", "label": "Percentage of Payment of Income Tax Benefits", "terseLabel": "Income tax benefit paid, percentage" } } }, "localname": "PercentageOfPaymentOfIncomeTaxBenefits", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails" ], "xbrltype": "percentItemType" }, "piii_PercentageOfSharedRiskSavingsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shared risk savings received.", "label": "Percentage Of Shared Risk Savings Received", "terseLabel": "Percentage of shared risk savings received" } } }, "localname": "PercentageOfSharedRiskSavingsReceived", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "percentItemType" }, "piii_PercentageOfStockLowerThanOpeningPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of stock lower than opening price.", "label": "Percentage of Stock Lower than Opening Price", "terseLabel": "Percentage of stock lower than opening price" } } }, "localname": "PercentageOfStockLowerThanOpeningPrice", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails" ], "xbrltype": "percentItemType" }, "piii_PercentageOfTotalCostSavingsToBeReceivedIfSequentialYoyPmpyAggregateChangeYieldsReduction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of total cost savings to be received, if the sequential YoY PMPY aggregate change yields a reduction.", "label": "Percentage Of Total Cost Savings To Be Received, If The Sequential Yoy PMPY Aggregate Change Yields A Reduction", "terseLabel": "Percentage of total cost savings to be received, if the sequential YoY PMPY aggregate change yields a reduction" } } }, "localname": "PercentageOfTotalCostSavingsToBeReceivedIfSequentialYoyPmpyAggregateChangeYieldsReduction", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "percentItemType" }, "piii_PercentageOfTotalRevenuesRecurring": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of total revenues recurring.", "label": "Percentage of Total Revenues Recurring", "terseLabel": "Percentage of total revenues recurring" } } }, "localname": "PercentageOfTotalRevenuesRecurring", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "piii_PreferredReturns": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non cash preferred returns during the period.", "label": "Preferred Returns", "terseLabel": "Class A and Class D Preferred Returns" } } }, "localname": "PreferredReturns", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "piii_PreferredReturnsRestatementAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to restatement adjustments relating to preferred returns.", "label": "Preferred Returns Adjustments" } } }, "localname": "PreferredReturnsRestatementAdjustmentMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "piii_PremiumDeficiencyReserveAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Premium Deficiency Reserve" } } }, "localname": "PremiumDeficiencyReserveAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_PremiumDeficiencyReserveCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of premium deficiency reserve payable in twelve months or in the next operating cycle if longer.", "label": "Premium Deficiency Reserve, Current", "terseLabel": "Premium Deficiency Reserve" } } }, "localname": "PremiumDeficiencyReserveCurrent", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserveDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "piii_PremiumDeficiencyReserveTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of Premium Deficiency Reserve.", "label": "Premium Deficiency Reserve [Text Block]", "terseLabel": "Premium Deficiency Reserve" } } }, "localname": "PremiumDeficiencyReserveTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePremiumDeficiencyReserve" ], "xbrltype": "textBlockItemType" }, "piii_PremiumDeficiencyTestingExpenseLongDurationContractAmount1": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of medical expenses incurred during the period.", "label": "Premium Deficiency Testing Expense Long Duration Contract Amount1", "terseLabel": "Premium Deficiency Reserve" } } }, "localname": "PremiumDeficiencyTestingExpenseLongDurationContractAmount1", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "piii_PrivatePlacementPursuantToSubscriptionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private placement pursuant to subscription agreements (PIPE Investment).", "label": "PIPE Investment" } } }, "localname": "PrivatePlacementPursuantToSubscriptionAgreementsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "domainItemType" }, "piii_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private placement warrants.", "label": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "piii_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to private warrants.", "label": "Private Warrants" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "piii_ProceedsFromIssuanceOfDebtGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes gross proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt Gross", "terseLabel": "Gross proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfDebtGross", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "piii_ProceedsOrPaymentsFromHealthPlanSettlementsReceivableOrPremiumsReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of proceeds or payments from health plan settlements receivable premiums receivable.", "label": "Proceeds Or Payments From Health Plan Settlements Receivable Or Premiums Receivable", "terseLabel": "Health Plan Settlements Receivable/Premiums Receivable" } } }, "localname": "ProceedsOrPaymentsFromHealthPlanSettlementsReceivableOrPremiumsReceivable", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "piii_ProviderContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to payer contracts.", "label": "Payor Contracts" } } }, "localname": "ProviderContractsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "piii_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to public warrants.", "label": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "piii_RecentAccountingPronouncementsAdoptedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Recent Accounting Pronouncements Adopted" } } }, "localname": "RecentAccountingPronouncementsAdoptedAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_RecentAccountingPronouncementsAdoptedTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on recent accounting pronouncements adopted.", "label": "Recent Accounting Pronouncements Adopted [Text Block]", "terseLabel": "Recent Accounting Pronouncements Adopted" } } }, "localname": "RecentAccountingPronouncementsAdoptedTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsAdopted" ], "xbrltype": "textBlockItemType" }, "piii_RecentAccountingPronouncementsNotYetAdoptedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "localname": "RecentAccountingPronouncementsNotYetAdoptedAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_RecentAccountingPronouncementsNotYetAdoptedTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on recent accounting pronouncements not yet adopted.", "label": "Recent Accounting Pronouncements Not Yet Adopted [Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "localname": "RecentAccountingPronouncementsNotYetAdoptedTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRecentAccountingPronouncementsNotYetAdopted" ], "xbrltype": "textBlockItemType" }, "piii_RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of re-measurement adjustment of fair value as of the reporting date of all noncontrolling interests which are redeemable.", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value, Remeasurement Adjustment", "terseLabel": "Re-measurement adjustment recorded against fair value of redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "piii_RedemptionOfProfitsInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to redemption of profits interest.", "label": "Redemption of Profits Interest" } } }, "localname": "RedemptionOfProfitsInterestMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "piii_RenegotiationOfAgreementOfHealthPlanDueToDiscrepancyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to renegotiation of agreement of health plan due to discrepancy.", "label": "Renegotiation of Health Plan Agreement Due to Discrepancy [Member]" } } }, "localname": "RenegotiationOfAgreementOfHealthPlanDueToDiscrepancyMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "piii_RetainedPercentageOfCashSavings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The retained percentage of cash savings.", "label": "Retained Percentage of Cash Savings", "terseLabel": "Retained percentage of cash savings" } } }, "localname": "RetainedPercentageOfCashSavings", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "piii_RevenueAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to restatement adjustments relating to revenue.", "label": "Revenue Adjustments" } } }, "localname": "RevenueAdjustmentMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "piii_ScheduleOfCarryingAmountOfFinancialInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of carrying amounts of financial instruments.", "label": "Schedule of Carrying Amount of Financial Instruments [Table Text Block]", "terseLabel": "Schedule of carrying amounts of financial instruments" } } }, "localname": "ScheduleOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables" ], "xbrltype": "textBlockItemType" }, "piii_ScheduleOfSettlementReceivablesHealthPlanSurplusesAndSettlementPayablesHealthPlanDeficitsByHealthPlanByYearTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of settlement receivables (health plan surpluses) and settlement payables (health plan deficits), by health plan, by year.", "label": "Schedule Of Settlement Receivables (Health Plan Surpluses) And Settlement Payables (Health Plan Deficits), By Health Plan, By Year [Table Text Block]", "terseLabel": "Summary of settlement receivables (health plan surpluses) and settlement payables (health plan deficits), by health plan, by year" } } }, "localname": "ScheduleOfSettlementReceivablesHealthPlanSurplusesAndSettlementPayablesHealthPlanDeficitsByHealthPlanByYearTableTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "piii_ScheduleOfWeightedAverageRemainingLeaseTermsAndWeightedAverageDiscountRatesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of weighted-average remaining lease terms and weighted-average discount rates for operating leases and finance leases of lessee.", "label": "Schedule of Weighted-Average Remaining Lease Terms And Weighted-Average Discount Rates Leases [Table Text Block]", "terseLabel": "Summary of lease terms and discount rates" } } }, "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndWeightedAverageDiscountRatesLeasesTableTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "piii_SecurityAgreementLendersCollateralPercentageOfPledgedStockItsSubsidiariesAndBankAccounts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of pledged stock, its subsidiaries (including tangible and intangible personal property) and bank accounts that is provided as collateral to the lenders under the security agreement.", "label": "Security Agreement, Lenders Collateral, Percentage Of Pledged Stock, Its Subsidiaries And Bank Accounts", "terseLabel": "Percentage of pledged stock, Its subsidiaries and bank accounts" } } }, "localname": "SecurityAgreementLendersCollateralPercentageOfPledgedStockItsSubsidiariesAndBankAccounts", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "piii_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsContractualLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Contractual Life [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsContractualLifeAbstract", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "piii_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "piii_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price of non-vested options at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price,", "periodEndLabel": "Outstanding and non-vested, end (in dollar per share)", "periodStartLabel": "Outstanding and non-vested, beginning (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "piii_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedProfitsInterestAttributableToPreCombinationServiceFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair value of the unvested profits interests attributable to pre-combination services.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Unvested Profits Interest attributable to Pre Combination Service, Fair Value", "verboseLabel": "Stock Compensation Pre-combination Services" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedProfitsInterestAttributableToPreCombinationServiceFairValue", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails" ], "xbrltype": "monetaryItemType" }, "piii_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options that vested during the period.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested in Period, Weighted Average Exercise Price", "terseLabel": "Vested (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "piii_StockIssuedSharesStockCompensationAwardsVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of vesting of stock compensation awards.", "label": "Stock Issued, Shares, Stock Compensation Awards, Vesting", "terseLabel": "Vesting of stock compensation awards (in shares)" } } }, "localname": "StockIssuedSharesStockCompensationAwardsVesting", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "sharesItemType" }, "piii_StockIssuedValueStockCompensationAwardsVesting": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of vesting of stock compensation awards.", "label": "Stock Issued, Value, Stock Compensation Awards, Vesting", "terseLabel": "Vesting of stock compensation awards" } } }, "localname": "StockIssuedValueStockCompensationAwardsVesting", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "piii_TaxReceivableAgreementLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of tax receivable agreement liability.", "label": "Tax Receivable Agreement Liability", "terseLabel": "TRA liability" } } }, "localname": "TaxReceivableAgreementLiability", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "piii_TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tax Receivable Agreement (\"TRA\") with selling equity holders of P3 LLC.", "label": "Tax Receivable Agreement with Selling Equity Holders of P3 LLC" } } }, "localname": "TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "piii_TemporaryEquityStockCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock based compensation classified as temporary equity.", "label": "Temporary Equity, Stock Compensation", "terseLabel": "Stock compensation" } } }, "localname": "TemporaryEquityStockCompensation", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "piii_TermForReconciliationAndDistributionOfReserveFollowingEachYearEnd": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term for reconciliation and distribution of the reserve following each year-end.", "label": "Term For Reconciliation And Distribution Of The Reserve Following Each Year-End", "terseLabel": "Term for reconciliation and distribution of the reserve following each year-end" } } }, "localname": "TermForReconciliationAndDistributionOfReserveFollowingEachYearEnd", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "durationItemType" }, "piii_TermForReconciliationAndDistributionOfReserveFollowingEndOfEachQuarter": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term for reconciliation and distribution of the reserve following end of each quarter.", "label": "Term For Reconciliation And Distribution Of The Reserve Following End Of Each Quarter", "terseLabel": "Term for reconciliation and distribution of the reserve following end of each quarter" } } }, "localname": "TermForReconciliationAndDistributionOfReserveFollowingEndOfEachQuarter", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "durationItemType" }, "piii_TermOfSteadyDeclineInSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of steady decline in share price.", "label": "Term of Steady Decline in Share Price", "terseLabel": "Term of steady decline in share price" } } }, "localname": "TermOfSteadyDeclineInSharePrice", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails" ], "xbrltype": "durationItemType" }, "piii_TimeBasedProfitsInterestAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to class c time-based profits interest awards.", "label": "Time-Based Unit" } } }, "localname": "TimeBasedProfitsInterestAwardsMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "domainItemType" }, "piii_VariableInterestEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Variable Interest Entities" } } }, "localname": "VariableInterestEntitiesAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_VariableInterestEntityAssetsLiabilitiesWithoutRecourseToEntityAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liabilities of variable interest entities that have no recourse to the entity's total assets.", "label": "Variable Interest Entity Assets, Liabilities Without Recourse to Entity Assets", "terseLabel": "Liabilities without recourse to company assets" } } }, "localname": "VariableInterestEntityAssetsLiabilitiesWithoutRecourseToEntityAssets", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "piii_VariableInterestEntityAssetsSettleObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of total assets of variable interest entities that can be used to settle obligations.", "label": "Variable Interest Entity Assets, Settle Obligations", "terseLabel": "Assets to settle obligations" } } }, "localname": "VariableInterestEntityAssetsSettleObligations", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "piii_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrant liabilities.", "label": "Warrant Liability, Fair Value Disclosure", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "piii_WarrantRedemptionTradingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading period that common stock price must exceed threshold price to trigger redemption feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrant Redemption Trading Period", "terseLabel": "Trading period" } } }, "localname": "WarrantRedemptionTradingPeriod", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "piii_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Warrants." } } }, "localname": "WarrantsAbstract", "nsuri": "http://www.p3hp.org/20220930", "xbrltype": "stringItemType" }, "piii_WarrantsExercisableForOneShareOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to warrants exercisable for one share of Class A common stock at an exercise price of $11.50.", "label": "Warrants [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantsExercisableForOneShareOfCommonStockMember", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "piii_WarrantsExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the reported period", "label": "Warrants Exercised During Period", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "WarrantsExercisedDuringPeriod", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "sharesItemType" }, "piii_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of warrants.", "label": "Warrants [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://www.p3hp.org/20220930", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r102", "r240", "r245", "r251", "r405", "r406", "r413", "r414", "r478", "r584" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r102", "r240", "r245", "r251", "r405", "r406", "r413", "r414", "r478", "r584" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r56", "r58", "r100", "r101", "r257", "r288" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r256", "r287", "r337", "r339", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r546", "r549", "r585", "r586" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r256", "r287", "r337", "r339", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r546", "r549", "r585", "r586" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r178", "r315", "r317", "r494", "r545", "r547" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r178", "r315", "r317", "r494", "r545", "r547" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r256", "r287", "r326", "r337", "r339", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r546", "r549", "r585", "r586" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r256", "r287", "r326", "r337", "r339", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r546", "r549", "r585", "r586" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r57", "r58", "r100", "r101", "r257", "r288" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r138", "r189", "r190", "r358", "r372", "r426", "r427", "r428", "r429", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r138", "r189", "r190", "r358", "r372", "r426", "r427", "r428", "r429", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r104", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r115", "r117", "r118", "r138", "r189", "r190", "r358", "r372", "r426", "r427", "r428", "r429", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r179", "r180", "r315", "r318", "r548", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r179", "r180", "r315", "r318", "r548", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "stpr_NV": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEVADA" } } }, "localname": "NV", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement of Previously Issued Financial Statements" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts Payable and Accrued Expenses", "verboseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r10", "r46" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Accrued Payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r220" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r33", "r358", "r483" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r104", "r105", "r106", "r355", "r356", "r357", "r427" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r84", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization expense adjustment" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r341", "r352", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r73", "r84", "r269", "r452" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of Discount from Issuance of Debt" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r68", "r84", "r269", "r454" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of Debt Origination Fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r84", "r207", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "netLabel": "Potentially dilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r96", "r161", "r170", "r176", "r187", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r405", "r413", "r444", "r481", "r483", "r512", "r530" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "TOTAL ASSETS", "totalLabel": "TOTAL ASSETS (1)" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r9", "r55", "r96", "r187", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r405", "r413", "r444", "r481", "r483" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r16", "r17", "r18", "r19", "r20", "r21", "r22", "r23", "r96", "r187", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r405", "r413", "r444", "r481" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "TOTAL LONG-TERM ASSETS" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "LONG-TERM ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r342", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r336", "r338" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables", "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails", "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r336", "r338", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables", "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails", "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Payment of P3 Transaction Costs", "verboseLabel": "Transaction Costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of future consolidated results of operations" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be deductible for tax purposes" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax", "terseLabel": "Net Loss" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net Loss Attributable to Controlling Interest" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r381", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Total Operating Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r392", "r393", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration for acquisition of equity interests", "verboseLabel": "Total Purchase Consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r392", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Equity" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r391", "r394" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent Consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets Acquired:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "terseLabel": "Lease Liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 10.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Notes Receivable, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "terseLabel": "Current Portion of Long-Term Debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 8.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible Assets, Net:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities Assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "verboseLabel": "Long-Term Debt, Net of Current Portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r385", "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 7.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r386" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r38", "r86" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "verboseLabel": "Unrestricted" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidityDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r15", "r89", "r510" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r80", "r86", "r90" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Restricted Cash, End of Period", "periodStartLabel": "Cash and Restricted Cash, Beginning of Period", "totalLabel": "Total Cash Balances" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r80", "r445" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Change in Cash and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Amount insured by Federal Deposit Insurance Corporation" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r94", "r96", "r123", "r124", "r129", "r132", "r134", "r142", "r143", "r144", "r187", "r240", "r245", "r246", "r247", "r251", "r252", "r285", "r286", "r289", "r290", "r444", "r592" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails", "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r300", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrant to purchase" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrant issued for securities" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r300", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r228", "r519", "r536" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 23)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r225", "r226", "r227", "r235", "r571" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails", "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r104", "r105", "r427" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r30", "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30", "r483" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).", "label": "Common Unit, Outstanding", "terseLabel": "Common unit outstanding" } } }, "localname": "CommonUnitOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment & Software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r151", "r152", "r181", "r441", "r442", "r570" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r151", "r152", "r181", "r441", "r442", "r562", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r151", "r152", "r181", "r441", "r442", "r562", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r151", "r152", "r181", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of total revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r149", "r151", "r152", "r153", "r441", "r443", "r570" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r151", "r152", "r181", "r441", "r442", "r570" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r92", "r407" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r412", "r416", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities (\"VIE\" or \"VIEs\")" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of patient fees receivable" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "auth_ref": [ "r302", "r303", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Receivables Net of Contractual Allowances" } } }, "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerReceivableAllowanceForCreditLossCurrent": { "auth_ref": [ "r191", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.", "label": "Contract with Customer, Receivable, Allowance for Credit Loss, Current", "negatedLabel": "Less: Contractual Allowances" } } }, "localname": "ContractWithCustomerReceivableAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent": { "auth_ref": [ "r302", "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.", "label": "Contract with Customer, Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Total Receivables: Gross" } } }, "localname": "ContractWithCustomerReceivableBeforeAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualRightsMember": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Payor Contracts." } } }, "localname": "ContractualRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r150", "r181" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt." } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r25", "r271", "r514", "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Debt outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r253", "r273", "r274", "r453", "r455", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48", "r254" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r49", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r95", "r102", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r273", "r274", "r275", "r276", "r292", "r293", "r294", "r295", "r452", "r453", "r455", "r456", "r528" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "auth_ref": [ "r369", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.", "label": "Deferred Tax Assets, Equity Method Investments", "terseLabel": "Investment in P3 LLC" } } }, "localname": "DeferredTaxAssetsEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r84", "r218" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesSharedRiskRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of sources (by product type) from which the Company's revenues are derived" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToAffiliateCurrentAndNoncurrent": { "auth_ref": [ "r473", "r480", "r518", "r537", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due to Affiliate", "terseLabel": "Due to affiliates" } } }, "localname": "DueToAffiliateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r50", "r99", "r243", "r245", "r246", "r250", "r251", "r252", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Due to Consolidated Entities of P3" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r109", "r110", "r112", "r113", "r114", "r120", "r123", "r132", "r133", "r134", "r138", "r139", "r428", "r429", "r523", "r539" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "netLabel": "Loss per share attributable to Class A common shareholders - Basic", "terseLabel": "NET LOSS PER SHARE (BASIC)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Denominator - Basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r109", "r110", "r112", "r113", "r114", "r123", "r132", "r133", "r134", "r138", "r139", "r428", "r429", "r523", "r539" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "netLabel": "Loss per share attributable to Class A common shareholders - Diluted", "terseLabel": "NET LOSS PER SHARE (DILUTED)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Denominator - Diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (Loss) per Share and Member Unit" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r135", "r136", "r137", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average remaining time to vest" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Time-based options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r61", "r62", "r63", "r104", "r105", "r106", "r108", "r115", "r118", "r141", "r188", "r291", "r296", "r355", "r356", "r357", "r371", "r372", "r427", "r446", "r447", "r448", "r449", "r450", "r451", "r550", "r551", "r552", "r599" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "Error Correction [Text Block]", "terseLabel": "Restatement of Previously Issued Financial Statements" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Restatement of Previously Issued Financial Statements" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r84", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Gain (loss) from change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r430", "r431", "r432", "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r262", "r273", "r274", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r431", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r430", "r431", "r434", "r435", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements and Hierarchy" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Hierarchy" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r262", "r327", "r328", "r333", "r335", "r431", "r484" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r262", "r273", "r274", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r431", "r486" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value hierarchy for financial liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in the fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r437" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Mark-to-Market Adjustment for Stock Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r262", "r273", "r274", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails", "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r438", "r440" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfFairValueHierarchyForFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicates designation of financial information when substantially all business or separately identifiable line of business transfers from one entity to another entity. Acceptable values are \"Predecessor\" and \"Successor\".", "label": "Financial Designation, Predecessor and Successor [Fixed List]" } } }, "localname": "FinancialDesignationPredecessorAndSuccessorFixedList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails", "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails", "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchySummaryOfChangesInFairValueDetails", "http://www.p3hp.org/20220630/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails", "http://www.p3hp.org/20220630/role/DisclosureLeasesOperatingLeaseCostsDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails", "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivableDetails", "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanReceivablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesHealthPlanSettlementPayablesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "financialDesignationType" }, "us-gaap_FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of accrued interest on financing receivable.", "label": "Financing Receivable, Accrued Interest, before Allowance for Credit Loss", "terseLabel": "Notes receivable accrued interest" } } }, "localname": "FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r184", "r191", "r192", "r193", "r516", "r593", "r594", "r595" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "terseLabel": "Notes receivable valuation allowances" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivablesTextBlock": { "auth_ref": [ "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financing receivable.", "label": "Financing Receivables [Text Block]", "terseLabel": "Patient Fees Receivable" } } }, "localname": "FinancingReceivablesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePatientFeesReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life of intangible assets (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r208", "r209", "r213", "r216", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Anticipated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r208", "r212" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture & Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Corporate, General and Administrative Expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "Corporate, General and Administrative Expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r197", "r199", "r483", "r511" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails": { "order": 9.0, "parentTag": "piii_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAssetsIncludingGoodwill", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill.", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r84", "r198", "r201", "r203" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment charges", "verboseLabel": "Goodwill Impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwillDetails", "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesGoodwillDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCarePatientServiceMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.", "label": "Other Patient Service Revenue" } } }, "localname": "HealthCarePatientServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r64", "r161", "r169", "r172", "r175", "r177", "r509", "r521", "r525", "r540" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "LOSS BEFORE INCOME TAXES", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidityDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "verboseLabel": "Condensed Consolidated Statement of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r97", "r364", "r366", "r368", "r373", "r375", "r377", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r117", "r118", "r160", "r362", "r374", "r376", "r541" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "PROVISION FOR INCOME TAXES", "terseLabel": "Tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r83", "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Increase in lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued Payroll" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r206", "r211" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r524" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest Expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r10", "r11", "r46" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalancePrincipalAmount": { "auth_ref": [ "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of principal loans outstanding to affiliates for management investment companies.", "label": "Investments in and Advances to Affiliates, Balance, Principal Amount", "terseLabel": "Investment in affiliates" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesBalancePrincipalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of operating lease costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements (Cycle: Lease Term)" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of reconciliation of undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "October 1, 2022 to December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r467" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Extension term of lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r96", "r171", "r187", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r406", "r413", "r414", "r444", "r481", "r482" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "TOTAL LIABILITIES", "totalLabel": "TOTAL LIABILITIES (1)" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r96", "r187", "r444", "r483", "r515", "r534" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "terseLabel": "TOTAL LIABILITIES AND MEMBERS' DEFICIT", "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS' EQUITY", "verboseLabel": "LIABILITIES AND MEMBERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r47", "r96", "r187", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r406", "r413", "r414", "r444", "r481", "r482", "r483" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r25", "r26", "r96", "r187", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r406", "r413", "r414", "r444", "r481", "r482" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG-TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "terseLabel": "Claims Payable" } } }, "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "terseLabel": "Paid, Related to:" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r543" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Current Period" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r543" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Prior Period (s)" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount", "periodEndLabel": "Claims Unpaid, End of Period", "periodStartLabel": "Claims Unpaid, Beginning of Period", "terseLabel": "IBNR" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r542" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "totalLabel": "Total Incurred" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "terseLabel": "Incurred, Related to:" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r141", "r296" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests.", "label": "Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest", "netLabel": "Balance at the end", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "MEMBERS' DEFICIT", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Short term financing agreements" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Agreed claim settlement amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedParties": { "auth_ref": [ "r473", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.", "label": "Loans and Leases Receivable, Related Parties", "periodEndLabel": "Balance at End of Year", "periodStartLabel": "Balance at Beginning of Year" } } }, "localname": "LoansAndLeasesReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions": { "auth_ref": [ "r473", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount of new advances made to related parties in the form of loan and lease receivables.", "label": "Loans and Leases Receivable, Related Parties, Additions", "terseLabel": "Advanced During Period" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease": { "auth_ref": [ "r473", "r520" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in loans and leases receivable due from related parties.", "label": "Loans and Leases Receivable, Related Parties, Period Increase (Decrease)", "verboseLabel": "Interest Accrued During period" } } }, "localname": "LoansAndLeasesReceivableRelatedPartiesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Notes Receivable, Net" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansReceivableBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable.", "label": "Loans Receivable, Basis Spread on Variable Rate", "terseLabel": "Spread on variable interest rate" } } }, "localname": "LoansReceivableBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r25", "r261", "r272", "r273", "r274", "r514", "r532" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Principal- Total", "verboseLabel": "Total Principal" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Principal" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less: Current Portion of Long-Term Debt", "terseLabel": "Current Portion of Long-Term Debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r102", "r238", "r265" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Principal- 2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r102", "r238", "r265" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Principal- 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt", "verboseLabel": "Long Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtCurrentAndLongTermDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r49", "r239" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Additional payment to health plan" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Exercise Price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Risk-Free Interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MembersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Members' Equity [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "localname": "MembersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r296", "r403", "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Adjustments to Redeemable Non-Controlling Interest" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Redeemable Non-Controlling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Non-controlling interests, ownership percentage by noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r54", "r70", "r401", "r411" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRedeemableNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash (used in) provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r80", "r82", "r85" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r59", "r60", "r63", "r65", "r85", "r96", "r107", "r109", "r110", "r112", "r113", "r117", "r118", "r130", "r161", "r169", "r172", "r175", "r177", "r187", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r429", "r444", "r522", "r538" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Loss (formerly Net Loss Attributable to Controlling Interests)", "totalLabel": "NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r60", "r63", "r117", "r118", "r409", "r423" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "netLabel": "Net Loss Attributable to Non-Controlling Interests", "terseLabel": "LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS", "verboseLabel": "Add: Net loss and tax effect attributable to Non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r109", "r110", "r112", "r113", "r120", "r121", "r131", "r134", "r161", "r169", "r172", "r175", "r177" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to Class A Common Stockholders - Basic", "totalLabel": "Net loss attributable to Class A common stockholders - Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator - Basic:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r122", "r125", "r126", "r127", "r128", "r131", "r134" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss attributable to Class A common stockholders - Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator - Diluted:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r282", "r409", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net Loss" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Non-Controlling Interests." } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r104", "r105", "r106", "r296", "r400" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Redeemable Non-Controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Total Other Expenses", "totalLabel": "TOTAL OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSES):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r6", "r7", "r31", "r182", "r183", "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Notes receivable current portion" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r99", "r473", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes Payable, Related Parties", "terseLabel": "Notes payable related parties" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r32", "r182", "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Notes receivable including accrued interest net of valuation allowances" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses.", "netLabel": "Total Operating Expenses", "terseLabel": "Expenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r169", "r172", "r175", "r177" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Loss", "totalLabel": "OPERATING LOSS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]", "terseLabel": "OPERATING REVENUE:" } } }, "localname": "OperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r462", "r468" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r458" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "netLabel": "Present Value of Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "ROU liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesCurrentPortionsOfRouLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesCurrentPortionsOfRouLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r458" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Right of Use Liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r457" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r464", "r468" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]", "terseLabel": "Other" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r84" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Non-cash Interest Expense", "terseLabel": "Non-cash Interest Expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Controlling Interests" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PartnerCapitalComponentsAxis": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by partner capital components which are allocated for example, but not limited to accumulated other comprehensive income or comprehensive income.", "label": "Partner Capital Components [Axis]" } } }, "localname": "PartnerCapitalComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_PartnerCapitalComponentsDomain": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Partner capital components are the parts of the total Partners' Capital balance including that which is allocated to accumulated other comprehensive income, comprehensive income.", "label": "Partner Capital Components [Domain]" } } }, "localname": "PartnerCapitalComponentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapitalAccountUnitBasedCompensation": { "auth_ref": [ "r296", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in partners' capital account for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.", "label": "Partners' Capital Account, Unit-based Payment Arrangement, Amount", "terseLabel": "Unit Based Compensation" } } }, "localname": "PartnersCapitalAccountUnitBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountUnits": { "auth_ref": [ "r298", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "The number of each class of partnership units outstanding at the balance sheet date. Units represent shares of ownership of the general, limited, and preferred partners.", "label": "Partners' Capital Account, Units", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)" } } }, "localname": "PartnersCapitalAccountUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of units issued for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.", "label": "Partners' Capital Account, Unit-based Payment Arrangement, Number of Units", "terseLabel": "Unit Based Compensation (in shares)" } } }, "localname": "PartnersCapitalAccountUnitsUnitbasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_PartnersCapitalNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalization and Management Incentive Units." } } }, "localname": "PartnersCapitalNotesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PartnersCapitalNotesDisclosureTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the formation, structure, control and ownership of the partnership. Disclosures related to accounts comprising partners' capital. Includes balances of general partners' capital account, limited partners' capital account, preferred partners' capital account and total partners' capital account and units outstanding; accumulated other comprehensive income; amount and nature of changes to amount of partner's capital and units outstanding by class, rights and privileges for each class of units; distribution policies and distributions paid by unit class; impact of and correction of an error in previously issued financial statements; limitations of partners' liability; redemption, conversion and distribution policies; and deferred compensation related to the issuance of units.", "label": "Partners' Capital Notes Disclosure [Text Block]", "terseLabel": "Capitalization and Management Incentive Units" } } }, "localname": "PartnersCapitalNotesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r81", "r543" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total Paid" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromLoansReceivable": { "auth_ref": [ "r87", "r88" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.", "label": "Payments for (Proceeds from) Loans Receivable", "negatedLabel": "Increase in Notes Receivable, Net" } } }, "localname": "PaymentsForProceedsFromLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "verboseLabel": "Debt issuance cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r74", "r396" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedLabel": "Acquisitions", "terseLabel": "Cash Consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of Property, Plant and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance-based options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred return" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r29", "r285" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredUnitsAuthorized": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units authorized to be issued.", "label": "Preferred Units, Authorized", "terseLabel": "Units authorized" } } }, "localname": "PreferredUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredUnitsByNameAxis": { "auth_ref": [ "r298", "r563" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of preferred units or special units.", "label": "Preferred Units by Name [Axis]" } } }, "localname": "PreferredUnitsByNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredUnitsClassDomain": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Type or class of preferred units or special units.", "label": "Preferred Units, Class [Domain]" } } }, "localname": "PreferredUnitsClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredUnitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Preferred Units [Line Items]" } } }, "localname": "PreferredUnitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredUnitsOutstanding": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of preferred units outstanding.", "label": "Preferred Units, Outstanding", "terseLabel": "Units outstanding" } } }, "localname": "PreferredUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r36", "r37" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Net proceeds from debt", "verboseLabel": "Issued" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r76" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "verboseLabel": "Issuance of Long-Term Debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r59", "r60", "r63", "r79", "r96", "r107", "r117", "r118", "r161", "r169", "r172", "r175", "r177", "r187", "r240", "r241", "r242", "r245", "r246", "r247", "r248", "r249", "r251", "r252", "r402", "r408", "r410", "r423", "r424", "r429", "r444", "r525" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Loss", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails", "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment." } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r40", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r223", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r219" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment", "terseLabel": "Property and Equipment", "verboseLabel": "Property and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r221", "r483", "r526", "r535" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "netLabel": "Property, Plant and Equipment, net", "terseLabel": "Property and Equipment, Net", "totalLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net, by Type [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of property and equipment balances" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r219" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails", "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Property consisting of land, land improvement and buildings.", "label": "Real estate on lease" } } }, "localname": "RealEstateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Receivable, Net." } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r280", "r281", "r283", "r284" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Redeemable Non-Controlling Interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r334", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r334", "r472", "r475", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r470", "r471", "r473", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Principal Payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of Short-Term and Long-Term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r5", "r15", "r90" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash", "verboseLabel": "Restricted" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConsolidationCashAndRestrictedCashDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r34", "r296", "r358", "r483", "r533", "r554", "r559" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r104", "r105", "r106", "r108", "r115", "r118", "r188", "r355", "r356", "r357", "r371", "r372", "r427", "r550", "r552" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r158", "r159", "r168", "r173", "r174", "r178", "r179", "r181", "r314", "r315", "r494" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Total Revenue", "terseLabel": "TOTAL OPERATING REVENUE", "verboseLabel": "Total Operating Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r93", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition and Revenue Sources" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r69", "r243", "r245", "r246", "r250", "r251", "r252", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "verboseLabel": "Revenue Earned from Capitation" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePracticalExpedientFinancingComponent": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.", "label": "Revenue, Practical Expedient, Financing Component [true false]", "terseLabel": "Practical expedient for not adjusting effects of a significant financing component" } } }, "localname": "RevenuePracticalExpedientFinancingComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesCapitatedRevenueDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract": { "auth_ref": [ "r196", "r313" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.", "label": "Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]", "terseLabel": "Practical expedients, expensed all incremental customer contract acquisition costs as incurred" } } }, "localname": "RevenuePracticalExpedientIncrementalCostOfObtainingContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to disclose amount of transaction price allocated to remaining performance obligation and explanation of expected timing of revenue recognition for reporting period presented prior to date of initial application under retrospective method.", "label": "Revenue, Practical Expedient, Initial Application and Transition, Nondisclosure of Transaction Price Allocation to Remaining Performance Obligation [true false]", "terseLabel": "Practical expedients, not adjust the transaction price for any financing components" } } }, "localname": "RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesClinicalFeesAndInsuranceRevenueDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Claims Payable." } } }, "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r151", "r181" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesConcentrationOfRevenueDetails", "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureNotesReceivableNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsForesightDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsProFormaFinancialInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of purchase consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of total cash balances" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r49", "r102", "r273", "r275", "r292", "r293", "r294", "r295", "r452", "r453", "r456", "r528" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of total payments cash and non-Cash of interest" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of rollforward the long-term debt balances" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of net loss per share and weighted average shares" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r109", "r110", "r111", "r114", "r115", "r117", "r118", "r138" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Summary of the effects of the restatement on each financial statement line item affected by the restatement as of the dates, and for the periods" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r208", "r212", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r208", "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of changes in other intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of changes in goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Summary of activity in the liability for claims payable and healthcare expenses" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of long tern debt fiscal maturity disclosures" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "terseLabel": "Schedule of number of Class V share-based compensation activity" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPreferredUnitsTable": { "auth_ref": [ "r298", "r563" ], "lang": { "en-us": { "role": { "documentation": "Schedule providing details of the units of a Master Limited Partnership that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. Details include the preferred units authorized, issued and outstanding, the cumulative cash distributions made to preferred partners, the cumulative net income shared by preferred partners, and the aggregate account balances of preferred partners.", "label": "Schedule of Preferred Units [Table]" } } }, "localname": "ScheduleOfPreferredUnitsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r40", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of purchase price allocation to assets and liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesDetails", "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r345", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r342", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r300", "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Level 3 inputs into option pricing model" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r405", "r406", "r413", "r414", "r415", "r417", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r415", "r417", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Summary of balance sheet and income statement of VIEs" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r149", "r151", "r152", "r153", "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Summary of health plans from which the Company has a concentration of revenue that is 10.0%, or more" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r167", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and Marketing Expenses" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Other medical practices purchased" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsOtherDetails", "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Other disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Number of units unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollar per share)", "periodStartLabel": "Beginning balance (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationExpenseDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Other disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r340", "r344" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationClassVActivityDetails", "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Outstanding and non-vested, end (in shares)", "periodStartLabel": "Outstanding and non-vested, beginning (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding and non-vested, end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureShareBasedCompensationStockOptionsActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "STOCKHOLDERS' EQUITY (DEFICIT) (in shares)", "periodStartLabel": "STOCKHOLDERS' EQUITY (DEFICIT) (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": { "auth_ref": [ "r279" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares", "terseLabel": "Warrant Liabilities", "verboseLabel": "Liability for warrants" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyCarryingValueOfFinancialInstrumentsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r24", "r483", "r513", "r531" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-Term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtShortTermDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r91", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software (Development in Process)" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r28", "r29", "r30", "r94", "r96", "r123", "r124", "r129", "r132", "r134", "r142", "r143", "r144", "r187", "r240", "r245", "r246", "r247", "r251", "r252", "r285", "r286", "r289", "r290", "r291", "r444", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails", "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r52", "r61", "r62", "r63", "r104", "r105", "r106", "r108", "r115", "r118", "r141", "r188", "r291", "r296", "r355", "r356", "r357", "r371", "r372", "r427", "r446", "r447", "r448", "r449", "r450", "r451", "r550", "r551", "r552", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "verboseLabel": "Condensed Consolidated Statement of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfPartnersCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS' EQUITY (DEFICIT)", "verboseLabel": "Condensed Consolidated Statement of Changes in Members' Deficit" } } }, "localname": "StatementOfPartnersCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureRestatementOfPreviouslyIssuedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r141", "r494" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DocumentDocumentAndEntityInformation", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r29", "r30", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Purchase consideration" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r29", "r30", "r291", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r29", "r30", "r291", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r62", "r96", "r104", "r105", "r106", "r108", "r115", "r187", "r188", "r296", "r355", "r356", "r357", "r371", "r372", "r400", "r401", "r422", "r427", "r444", "r446", "r447", "r451", "r551", "r552", "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "STOCKHOLDERS' EQUITY (DEFICIT)", "periodStartLabel": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Exchange ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureCapitalizationAndManagementIncentiveUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern and Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureGoingConcernAndLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r542" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current Period" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r542" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "terseLabel": "Prior Period (s)" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureClaimsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r240", "r245", "r246", "r247", "r251", "r252" ], "calculation": { "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Class D Units Subject to Possible Redemption (Predecessor), 16,130,034 Units Net of Issuance Costs $2,958,446, Plus Preferred Returns $4,567,346" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheets", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net Loss" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitAndMezzanineEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Units Subject to Possible Redemption" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedStatementsOfChangesInMembersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransmissionServiceAgreementMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Agreement between a transmission customer and the transmission provider for service.", "label": "Provider Network" } } }, "localname": "TransmissionServiceAgreementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureBusinessCombinationsPurchasePriceAllocationDetails", "http://www.p3hp.org/20220630/role/DisclosureIntangibleAssetsChangesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r361", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Uncertain tax provision" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r145", "r146", "r147", "r148", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Management's Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntities" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r405", "r406", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "VIE" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureVariableInterestEntitiesDetails", "http://www.p3hp.org/20220630/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureFairValueMeasurementsAndHierarchyOptionPricingDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expected term of warrants", "verboseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureLongTermDebtAdditionalInformationDetails", "http://www.p3hp.org/20220630/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r134" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted average effect of dilutive Class V shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r134" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average Class A common shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r134" ], "calculation": { "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted average Class A common shares outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.p3hp.org/20220630/role/DisclosureEarningsLossPerShareComputationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196816" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267963-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL51790836-203054" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130534-203044" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130569-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r425": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=SL2890601-112764" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.7(e))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "40", "Subparagraph": "(SAB TOPIC 5.W)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907" }, "r561": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/subtopic&trid=2560295" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(b))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14.Column B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r587": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r588": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r589": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r590": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r591": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r592": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r593": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r594": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r595": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r596": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r597": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3095-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 123 0001558370-22-017528-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-017528-xbrl.zip M4$L#!!0 ( *8P;E5@VDR7EQ\ +V4 0 1 <&EI:2TR,#(R,#DS,"YX MN"$6>.+>OD^!4(?75F'1[&,BZ0#SS4LX2PTU],5WWOKV B^1%2 V MQ\$]6F)_A6S\[F 1!*NW1T?/S\^O5F>+U2O*YD+(\?D95 (* D8>PP#?4+:\ MPC,4N@%4B/,0>VO4XZ71^:^\K']:DZ?CI)47LJ3A 4@8M3%?LHR0_ZCR"))$>2'QR>' M9RD3P[-"H40V<;%^/(+4M/20X 3%XL1T;XZBQ)34K15Y=O2O6^)]22A]8LL5 MA(2R;L%Z5:.;2)'HYK.@KD;2)!E;L&(UI8*48K$"5JOJ^1&DYLH_1V@E+3Y/ MD!3#A7I2U"-/?H3VDU>VIHK2)$DN^,5>R)7E*05E7RHEBBWXY/S\_$BD)J0> M(K8O%RN2"G)M&GH!J[/T*+' X.$Y[QP4-<^A/8K)$JX&S3BS=**H>>+Y ?)L MG+5KHF_7AV4N $6*E PC+UR>REK>Z3&@%&#/)X\N/N1DF*$ NF__\)1WWQ&[ M$["2911T@N0CGBSD\8RSBG;PBF&[25UGE!E(@1Z@(,N)R/&'!%$C7U\GI"M" MB*;+AO[>LD2/CSR/!J)*Q+?DZVI%O!F-/\%';KMO>9FF4!$6__'Q8:C(Y,>S MXTB%"0@77?\E]1P COPPZ+_Z:(+9S(--4 M?S0;K9)&U@31&DXUM*=-H9U,X9^[Z_OIQ!K=6*/Q]<-@.@2"'N0-0;Y$_N+& MI<^M,)A'V!=/A(O MZKG'(;,7,.T>0Y7B@>M26WROL98.$M26\=/Q6=DRDCRL?";P/ER7)&7H-]II;&VX55B#:NIUY76*Z3#CR@#*\XA^FXE>610 M6SP?Z[1'?#N(=P1;@_/)YCCW ,L!CL]YDG]A77,-"Y!@/?1FE"V%'C&F32C5 M2^/C<[XT3@3D?_+E3"3-RHGK,=MT:W(,@YP7+' ZTNW]3YED5NW:?FFRZ:E M]4,AD[Z9;KR_M4#>'/M#[PXO'S'SK[^&8C(\(S8)6N]Y*86I#>*LXS[8A\'] M^^N)-;RW[J[O+JX?)O]K7?_Z<3C]#?KRZYOAY7#:&\G6C&024/O+@KI.&5SH MW>_P[[\CF#?C**&S[;3)0VU2KS M7\?)O;%I9H8C-@<(?QU W O6>!K_AH!.T158UP#]V !CD6Y!!#_0&)\=- MSH8UT/U4A4YZ^MOCH\'G!A'V";DAOL.(_QWUCY[S@6"&F+VH3&CT#&KD_E9% MCHNTA$PK+U3,<5*Q/9(:),=09NYYC['/>S'RQ(_/R^C)B=2(20X(8S$6EV-E M@GJ,=!@QNL(L6/.S )B[K[B=5R"2T2@1.CF6(!1+B4X*$CD]0-IE'76>B>M6 MEW'Q=S40DGV6A+.O>DW5#T%=;\[]]P>^CZL[)95T-122G9!,@A6)Z#'18 *S MW?Q <8\KO96$0HV+9&=#R,@-(W^U0$R/31N//*4KG@81R9Y%T0>OAZ*%YYW* MU4X#A&3#H>A;UP.A'4-LNL13]%+=U_;6_; M*>^Y-O:YC:6H@#\[/JU>C.[D>6O]$&77&\-&;5R.?!,6-J$[>4'*49"1JB"23_7)TLAZ?]BY2G0V'G(D5-0JG&3S,_K0\3UP+7R)JCI#/-I2G!.)?.\ M.-97CT2G,\ZZ36,)C1H9R?2A=-[90[3IP:<<+ VU&C;)O*+^$+1'<'MA;VI" M(C9G5.'ZNGL0G#XHXLX.Z&H@[RI&;0#;"H[3V\/&87)J<->1J_%M%S2G1W$[ M)ZT/^ E[(0_+0>=1(;L\&%$O18UY!W\+WNI%9E8NM]X:MO:<"+]+$[WN,YK% M-=WQ"1&%))U5M#ZE/[0*&?+1@,5FTIO&=DQ#W,&"U<\F1E$C0V<.E7#8#W;A<3 M' 31.[+Q.#23*3.9G[J,-;$.4?N+GR9DF;>CS[;M1MQ2.$\$/_+!I92*T1G&W]K;QM1 M7A;/K+>%[=I"X@_3Q03*O#KDS]LCG[GK]'!OX$)\0Z$>R'P1M'B:L,*CAK=I M.$KNGYI([E'="-51L,"L!:(%>AV:E3VE.C2%U![)S1X2990_1(_2K?;V6;H/9)448MD5ON@""77V\1V[L_<(D86\/(*(A&LQR\?L!"U2G2 M-D6K+:=K4%NQS125(::ELX)%I>7H+6I[%C4)ETO$U@!X0IDF09M.J_^6H$?B MBE/^K@;6/2>=O55&J*;V%A=)&!IG>1(L&07T83D+S)6LM\#M6>!HQ0O'GZ.& MEM_5N*1"=';3\;X4S'1$;E:<76\,.^B.TA? 4I:-^YUZD3I#J4R%.G0P<>X6 M\?+EL=/FNQB:4M&JPFP=X[[';Z/Y='70*4B5RS0._]\"UOH)7ZZ+48M]/ M%1"^AZ3S+;QX7*E!2$.M!JQ)V'B^:HM'MA[#KA@.'$>4ILEV3RM>';Z5E9,, MWRR'?ENG$]S5=P%JL*TG5 /9]!V!'K-N=VC;M,_FC&I,M2\1]"UST"[F1!6= 0TPJM#LJ*GVL%2B'R ML,>OZTLSM8N6"H4:*\V[,STXVW^!IFX^VY9?#>RF[]'TR&\8R 06$;[_:6!# ME=;?/6S#JL:[Q1LVT0K']ZU/5I)'C_:&:%^_\)^U?KU->'3X5N\"C>(:#6!4O")N MR,?&";9#IK*!]@+4%G!>;?;U49 .+9[5H1/G9?EI9KT);/PX5NTYJII<"6^[ MI[)Z$%N&N:I;VA82U0#5/J'5@]$2C!'T4XC?-A%_7E*_=B6DI==!5MTR.\1/:! T^+T;#I@ZX+.Q3_$?J /@Z!C M)>(M(;]'N"7"\4[KF#(QF1S-'FBH=TUNQ:O#NKJ'F&"=; ,G.5BCF?4P^MC[ M#7<"7/MR86VXK(9\:J [/GS8 [R-)Q#KMB+U'&I0VSZ(V*/9,6QH;=N4$:DQ MTS^4V*.T<>30&KQTY&KD6CV@V(/8^BG%&M#*R6J0% \K?E>0\/\]PD3N <^L M%_$E *)W!SY9KEQ\$'];,#Q[=[ BA!P*=,[/CO\#ZKYZ6;H)"9=?P//ED;DQ MGL=G$9;E&HHS3D0@9E>D/)\)&2?GY^='@@J$".=V:#M'2>$/K*.MJ058M%6K M!)^)6H&AM-6J:%LF*N6BQ[9* 0MV=ZO/AN<> 3/1R^^\Q:M M5L2;4?$M_N)Y-%(A^LB_@:W"ZM?RT!+[*V1GAB1LT,?VJSE]@B9%./ G7U\? M6+Z]@$75+;6%I(C>KV?@/P^CGZ\@P\3L6F3N!RLFA#7,.Z47OT3>S7,N-[_S MR,X]/.'_"@6LT*(5CX7X<)'R_& M&2_&68OZR,M[(_YR@L8%2!AXSF^:YSE#_J,0$?J'\DX>% H??5B$A5R=]XR&JX24 ,F!Y1'7Y>+>'00L MY/,0D0;C/Z'.5 B.>@3(!X$@ANS@W<$,N7Y*^XAU+592O E'/KBBNH-D7-3,+]C,33F[/J Q>16Z*\C;#CL;> M%9(8M2]X;[>I<$*J*:BGW1F?AP'@%^LPP%-T1+JMW>/F(61'76J)(4QA5 M#\4H^M81RXPMZNJ$45#WO+(1;;U2I4#C585J"$Q4Y@X0A$54[(GHY[2HI.S8 MZF2%[SIN@D$U,;H]LCE>W(N3)DK541FKUF43K6J(3%2*'XPNA7LG?Z"(SJ"X MR?Y^1;<&M":JF(+Q@(.0>7YQ\"HE[4V_,?1@0$/\TJTY MC:D3[1"N4BT)7-^R1JILQE1'>Q,IS$K5-5 FW1NMN0<[\M:Q6Q[UHL<2\UUT M#4%>0R@"]SO1Z><$;Q>0SNSP$0]W./*42WQ+/)&?KU(K1]1!M9UVR;"J?Z;L M2V6$*7TW<33A/60ACCJC'ORTX^!U#EW!7'H02RL,GJWX3$.L4?&G^"6X<*G] MI:W>.<8RYD&2],=T-ATKX)X&O^&@*_HUW/ME P4EVEM"';NI]I"L.)/(=)6^ MK([ Q$YM8B^P$[IX-)-N1N?VJD.V1GH%DB=V6'0Z!/'WX MO,-E1[&TD=-,K3))LMF8U%A8/LEL!2X4&ESLAPJ7"A4N]T.%*X4*5_NAPK5" MA>O]4.%&H<+-?JCP7J'">Y-5&+BN>#-*T;76DYBH$+_G>4,9?TK=LXE+DI!) M5X0/RH]A=.P1'V[?4->ESS!47WO.:':-[,6O(6)!0?UM"%&T68CS@TM#^K*JJXCM3QY#[D,.!-\.72'@Q@-^M2_:W\GWPVJR?(=,O #/ M,?N3UY;SL-,6[G#CDT9_K"2'4,44TQLUZ.E1X8K%!^9B%R'GOVJ MHHR&SD35ZNYA2PX)]:2F3:_JG'\ERNE)]T4YV>%5 UI3#YDJ?65\>,+'QY!Q M&%0=JX38S!YR !9%JWL4^:\F=A_%,YW/)%CD G&L\_V\AC#?NLQVXANC-?]K M-(M% ! M4(QSP1SZ>M'PN8+U#+==L6&DI=[]SU4&_*%Q7HYA>^Q/]*KV79%H3H"$Y6Y)4L2 MNS]XF/GQT]QQO 5%$*R6?,9L+^K]*J*W2M=I=W.+/8=K2%W>RS#HUW/N3&,7 M.W/LB!=OAX$_ 46(0Q C(M# !?*^Q%62K[O=96'F]G7%SVT*O1:_CQ,%7N3S MR:M8K'AC"X0.EERC$Y6S7 LAQEA?@S!4R^39]6H_*4DTL4O)7=U3W9S>#Q7N M%2K<[X<*(X4*(Y-5&)_=NG:E\(6O1A8[WWDG[H9#SZ9+/$4O%]C#W*6JQC]6 MQ6!F[WX1^L3#OC^P8=KCBP='Y \QWB#"/B&WX$31A=F8WEP[ETBT@Y[[,0ZW MPJ^LSCWR.W:&#K]",A/.^P/?QX&H Q )HWKR@N@:$L(EGT?Q704;)ESWUTU1XK#O,H-N5_N>TJ=9U!C%[5=F]7W5^F17S1, M:_F$;B=U7WVY+93\ S$ODPI_S\/0)YXVH]FXIPF>5&]<-6Z$;TQFUNZ&6)29(FS M3#7)-/^8I(2RZ\Z2M'*C,^6"9>H/Z"NM&A]9@1 M&T\9F<^KUMF&4W+\(2XR&5T#4X;X#L 56ON-=2_PF#?RB<+#1*7YTY<:8A-[ MI/%9-"\3^4$)BJ3S*MRZ_;,FZ[JC->,W#AG.DFQ)2>KB7-(,[T;"3"N M)F IA;PY2=9>/H_!XE(_9#+7YB;$ILW?IN@EYX:=V";W"YU@<6S,7?""]0?H M3#&#CE;N2;"1%!/;>>H\ )JE\2J1RQ?DF2'+@B&IZD-)1F*IB_9\&+V^F> M;J(JN4?F%7[]X_U0X5>%"K_NAPH/"A4>]D.%B4*%R7ZH,%6H,-T/%3XJ5/BX M'RI4[ZQ)TDQ4(>GXXP,W+A\FFB,O>AUX-,O-K2LJ=N UL0J2-4,]C1,G&+>]GT1$2$\B)/.9&@H3 M+:\8,_;ZA? P*[4Q9=/T_9E%E]9ONEEH+:&)X*77%,M/%I83.FPR_T$O%J8E ME3U8*$LT;;_\&G),=2?HB7^IAJC_MR ME'O3HV0O\'\8WV)41M0MT>84-<5W+ M2IS&C8H#V4G5JA*9-Z=5ODG1].V*/>H(AV([EG\8>N(BZ77\^EUA!*^E,45/ MG:_U%"]7E$'A(H<4L9;,;UP77L;6D>Y/UY/SP^*="%]*>V5?!P6-@5V..)", M'\5(9R"1=V^ZBD[=0$OMM06?@9IG6P7)HP.I'E-H79DIA\WA,%EBH%?61[!JTX#)Q"X$_FC>GL!#E?*-9VLKSCKA7T+]1 M[IG*\ HJ6ROM;38B-:?I-WR^%]21_*F_$R#P> \3="0I#PYR'IZDZ[^HYC*D$ M7?^76>UGQ4'29Y.;;=TMS]1MJ>WUT#K&O0&ULZM-_*CJ>Z'PT(MF/G4OT":S M_A"YI7V)/RE_ R=HV6NU<3,(#I,7*YIJW??ZJ1LI=U)?,:;U-++?CWLGZD M[[ZTJ: V O:FAN+I6=I[I'L3V9W*JN.0FGIO=-]TGI6;0=V2F>RBZLYR,.T\ M?U-%[VGLI5Z:K:;A)'A8A2U6;,/\RNNU'<1OZ+!9JU7>UVC_2:A>LT#H7.7; MS/4/J/A-=GN&GB( JHK(F,FY=F/W[/Y)$D B^VCB5L8O:(&\S^@+GA'L.H-' MAX9C5W*+7D-GHFHEEUWLU!Q!:>B,6P?%Y>4')TO13<219.H4JR4TNY")4%AU)VC#MS=#TGD:[ES9F MGE#B:T@<>5@)/:EI$^G((V028.2LK[#MZ%"]/!_34AK8(^;#F8@MNUOZ MC-D43'0$,TK>FY>4;,H@F2\:$ XE.Q7Q/_(]@@?B?\D=<%,'Y\.+-Z+>FU8* M7<\S93D%JI<'ZDE,G(&)R_PB")S"LT%%9*)2\;&S0J-:"A/5&3-J8^SX(Y;L MT]TPNI0]6I-[$QF(H^C9N6_%BTG;DFE,X]7.-G)M:>WDXR,J?)Z44 ""3@$ %0 '!I:6DM,C R,C Y,S!?8V%L+GAM;.U=6V_C MNA%^+]#_H*8O/4"SL7/9W2QV6SA.R0;T?=#YTC#1'#,3&9 M?3ORW&/=-3 ^^OO?_OB'KW\Z/O[7U>.=9CJ&9R/"-(,BG2%3>\%LKDVY"'8=HOK#3#]W5+_U GD.^:-WN M2??LY+1S>JI=?#D[_=+I:+W[5S#PZ=0?U.]^1?]W=C8XYL_1@3E^G$0$<:E/_B^E_>.8;. M?#M%JK\^42L4<':R:DM8@O]U'!8[YE\==T^/S[H?7EWS*%"1_RS12%C\=:-\ M@*E[>7EYXO^Z*@J"<(KH%6RPGJ9]I8Z%'M%4\V5\86\+].W(Q?;"XFW[W\TI MFGX[6F",CSD#G(X0*F37')]S%*&/*D6[^I7=S@=+A#UW:A,X*(& ME+1 7W?GMY;S4I4!(O)KQ'^-7<-R7(^B,9X1&)X,G;">83@>83":CD!3 R-W MK30PQ#7M$?,1N8QB V#P+ZX1T[&5SSCE-]Z(Y:X\%Q/D@I[V$R9+)QYYU)A# M0R-0$O4L*QB$M[-2D88:L4C?TK'MCO0W_*\%_984WPRX"B>ZM!RR@ M>TRP[=G^5^!Z_@@=:-?7+>.T*-VYFE#9"M4:H !V VSF6;X;W<%O 5[>?/GQ M6<2\Z)4AJ&&NOL6,MPA1.<3SQ]I*+GSN#Q^N;Q[&-]?\TWAX-[CN3>"/J]Y= M[Z%_HXU_N[F9C',@]W$#.[G&G&T3X?PZ^_M%SW8@)+/T)6?YZ*_;C27.:/3C$\"@%@Z?J MN"[VX^/9Y\[99??\K/OI]-/'B\_=3@1 Q*EZ-(Y%IT;8!'S<\+,X9T&)$]>S M;5_:,0:W".M/J6-O6C%HS,FINT--1&%)?*1Y+JCD+'ASNG6DO2 \FS/_ET8( M"N)[,O,[_"-79CC][B(?E8"MU#JJ4I=!T":O^5&63_+FE,"_^?'@,.0^(@/A M9QY^";M7>N&=9ZH O("B4^7ZX:^.8[Y@RQ)TN?#GG>=,"E# TIER+ T(T\D, M@Y\%L!&[>34LC^]P9C H4[4U[!8&&S!_KASS(^K ?,#>1A;?"R'FS7\]O. A MY(-PFDRKTAJF[9#&?Z?_[T0NFA94Y+X5OI1I<;)C/.. M&W,Y?YSM2RR'^TD#L0KD9ZV%TQ17-@ ?4;30L7GSNN ;3>!@0S9'5(8MB9JJ M\;D!< MC_*=7QGF\E;?;1Y+05O^ZEO ZF](M]B<3^ACQ)CE[\A'U$PA5*YF"[C< JBR M2^EXCD#Z@)M8=K=YS0]-V25SD/3!_^'A^+-N\:>%/=;7*7W#9/9/W?*0@%FI MNNU@NCC4@/F/RC%_A_4G;&&&_4EFS!SCY]RQ0%F7(V1O M*SJS6$Q@;&S5"[ M-Y[\H).W.\NX1_;32KL!";8P1WQ9"D['H ,_>8P/Q1.';YTYA($G@8*S 6&( M0@\7&J*R%N..]/GB<^>BX3XCZRS1/E.W@91=HP!PVR&^T5*'TW?%5/2">AE- M&(=E;*2L(_1,$R]U&<$B?$#Z^@(S7?2X25#ZX!8)FU8Y3*7L]M4C3]$BR QS M^6*[JU-L8'&$G57QX#-)P7LAJRG[8/L1F0C980+%IEF6!@T#UI[-4\&%#I5? ME(HNEC]F*0VYLJ/,!-D+A^KT+0E*O'N-])1E?6XY[7"0N(N%,OK>2J;1?9*BYZ2'E MFT)93XH>:,L>$A(+MXO['!B5#<;]N/+$-O7K%:N.Y0_UI MY,JAU'GAN\O">7JC9(N(E$6G;(\,MWV#2S+2.V5RX1;1F0-@;0F((XIL[-G+ M)S:(&!#1N8@^"ZB2J=("P@K#+#^R$68#1^Z>24W[W2S7%H*DL96_2YF9S>NN MET,2+,G4:PMKA;$JFPC8,PSJ(1,@\(>=$_TU:_4@KA 'WMU%D@N"#-C]I"*[ M_-%DZ*'\2-X2F?1B,8>$=O&_%>K (3YG.\37DW=7+%5_[Y+P>L@()<(+F$YE M+V :3^"?^YN'R5@;WFK#TGDB9='>7 [&S V'QHXDCZ@SQ2S%8=<%=I"]#.45WCX(4=T"X.63 M20^<;#WD7J&I0]&RG!]CW+PRJ@,@3'3Z-@"3N;GZ@J^[O"D_8^YWG5*= M;%PT6D!">W@M"[RZ%]8,XV9)"1,32JI'=/-#O*R9E(U,5P""+I+I#V$Y];Q! MEHL4%E/!5;#H$PWAR,1@00$E24449B-5Q?>#KP2JVB;2C>=F$Q@7UH!XYIE0WV/+T1U?J8:.TM)9P6[(!E!U1?T4$K&/Q?6+3Q@2[C(-ZSEA89=3: M?1_8!JBRV95CY <- &89,*[-(4KS$59H#\,Y,2J;1!E>;CRP%SJF?!60$B\G M%VX/J3GP*7N6*GHUZ;L;206LIM2(0S]38,.K*+5Y02J;O_"(GA'Q4+@6Y!'$ M[YC-^["&A_4 7=U:SN]]@O],6! *>"\@26%_R+T>*@N^LC'::D,@Z"I7$)1, MA==J"$JKQWC!YR!RR'+L:C60S]WO@W[?9N^+OJ>0S^ MG83Q"^OB%Q9NO.PQ4G*$*'9,@WNC3C)N]2^[8QGK* M/H$KG-2A@EML28I\$HCJ+/K'1_V7G/,[KF &2UMY)!?> W9S %:81 M_(@H11!_,H^2Q">J[\NTF"9YO,KN]45'CN'T%A.=&&""ON.*7YZ<4J7%9!>& MK^Y)IA@2?CD ?_TY?U0GOG!;(VD#_#5%'R8N&:687A@<_UN)?%SGH15X?>(,D5-$BXDOS1RA Y29Z2YP [>?P(P((] L^FW5)5+^Y:6"!E7;R=NTY_]%V &)_/CK[G-G VX#J'"=7-_/%!M/)>>H:T(4+?4"\;4.#NFY=[Y!LU M-NOOI8/DL47H(^KM,F[B>G?U7=HQV.RJ>^D9DF8(G:+$[<<":XM R<(+B_?U M6\QX.;8(::]^JW%3U=@]?))4Q^OL'[T2^$-*2]QEYME1=/U$@2H MYQG*INO)6D_9]!_H#7XF\JU# 9N!D.F?3[]S=)*]*2E7.6Z0CPJXTY9D)N40 M%#:$PM=S!: F3L^ WD11^.(:Y/Y*4_([,ZKMD3OD,H&Z-W%LP %+P9S,WGBD MQ&#HY8/MPA9?QBDO8!^=(Y\Q,M,+&W,3@:56V1M%(Y0$ >JYB;(1BJSUE$U; M?42+H,<,I]&7; B<2%1&X(Q)!#5S7 VL@*>JS*^Z!$Q0T M0OD+%%%2S=)%(5+FT?&0XEGP#D3^GEK+@3AI=HN2=S0DJ[:8Y*W-(#_*5W(N MEN?O@88>16,\(WB*#1[R+)_/@-HCQ^(90.[ZL"Q/^4F:/*\1T[$E=VCVO'/> MZ6K'VKIQ?H)VW;ZV5D +->#G:J-*_%7CK6HZ,;6U(LOO_A+H\LM1BT_6"D;< M+64V\[;PI5KOE.FQ\*WH_@L44_!FUHUWO$\*'(TR^.6#RN-E^V[(X\"@LJ%Q;>V$ ]R_YK?H+9N<6?FC@0K/B+#@2GT?Q#(F. %,)?Z;QQ9)F+A3Z;@<;^K@ ML]6-TQ*6KFTOK#10Z\2E]>L=(P-Q6WX&6QX M>?#A.FVM[&W4I2X7HF>T1A0M=&P&)[VA_/(L1MH)N$9T.72-RE>16U&A[-T_ M99HH;]I=+6T?>D;5/2.?Z96]":E,DPP(T\D,KPK[P\-DKA/!)GHC.AQZ1M4] MHQ@%Y5\05?)5K +G/?A5FE_)4*[>J:[*(BCQ&K+.I@^N6FO8++F^+/-FK,J? MP7"](O>^5/L4YEUC!_>M\#F,C*VS;^UJP\"=?7]'1:VIX]\UIGTT85-US_95 M,!=%?XA?O5-?)"+6H34^7\@1:PE&^E\]9NXUU."7'7R0&"@;C&E@\>7&TBB*S)=S$-)')[3\7Y'I&6#@Y;34I' MEHEW+W=CXQKS1^0B^ERMKXH:/;AM%6Z;R]JUO3&H[$!(\):H2MLZ^&N%D6VJ MD?&3A6>^N%K.:"4U M?.@"59[0DK:XLLD19=KCP2%&TQ-"I@Z'#E%=ARAF?/DLDHHO-8BMGG-=6] ] M[YR^O[9@*4T+Q.W,G021.U?YNYC]PR'\P_IE^$ MIT,OB?)O>?(_O%@@N.:PJ_"TJ/B#J\F;1=GKQO.C'BQGZN#G\IQL0VXC]AA[B\7R:8UN M#G,I?+15>,]SKS -Q;ON78Q>8MJ<;'P12BY^I69X/E2%":_-"5\G! JEO2<*+M.*8^^LIIY1+:.N>,-I[=@ M9-WB3E=$WT1!ZG3V7#RMGC.5![JV'+XLE;F&0Y+XS%VR:MM)38-96YJ;C)*3 M%Z2^H% *M+1%*1LU;QRLT?89U M]X%*(4YEKW>1>/05+]*XEH&],7*C+SV!904Q\((O240CSW;"U''?-.IBVXSE MX51V:R$WQH11;"M9>^ 668-:O2$CWP0?D']@8N9=BZ;5K%'-0NO2G.+4\0Z-E/ OM&KU,HV0U69]:V$B#C> M4Y7VG:JA6 BZD15ONK(RZ]YL"?M&L1!S;4=CHKI.'*9;8)GK@E[$;"PD2=)2/"M+KM)S8-:",AH%!+B>@OK>Y^4"D"VDBX M)]92)M)+K[TG=*H5V@GUE(GJ4BOO!YTEA'$5)^+1<;KXM.)2O_86W\(NV0%3S&_'?$[QJ9V?.3CP@-B"&8R,_7?D9 M5.9'/R8.8+$=,F:.\7/N6$"N>XTMCZV-]&ZWO("<1IX0Q/5DC.(GH,Q7E1\% M<@CC-_\ PX*C[X7EQ+O-&72;B^;?15Z,^NCC@W+LD!ES-W8KGKR1KG07&UOW M#E_*7OA*,2LH>YY!I8&ENS/>(B:ZFJ&FJ_)8,Z+.%#..3N ;ZP*[/$+DX3P# ML;*CP>]^^\CL/2.JS]"#9S_QK:=@7Z8ME,W9$=AI U]:?)5+QOZX2BX+J'.6AE].XMYZ##[? M8X)MS_:_"CRUL:[V.UWA[ MVJGBR_D[Y+H(#1?@! S8]L&LCGVM#.@)3WI>FWG?P;]>_8QJ9-Z\& M%.W9_*\B4$6RU!LZ\A(>2_TKS03*3BX"< *?$)2.0SX'R)]VF/4\('=M3I"< M#KK;3P>'>8!7_]%8HK>,@C))$]L+W-W1X4?B@>Z2+:'LU"!KI0<81B8OR'I& M]PYA<]'>3%%Q>^D^LG90=G]'%F5RWD=!*?OJ*FGPR\\+:<)#THZGY96SUUXB M-$#YZ28-^$G::;6<8O;92X3XZTM&3M-VXEPAGDW=FS)$4Y.3_ M]3YIC?OU9$E+L-C[V_\!4$L#!!0 ( *8P;E4 @/"X3%L (8D!@ 5 M<&EI:2TR,#(R,#DS,%]D968N>&UL[;U9@^T6^9-/F%+B>9,+2MP5 MGDS.S[YA@W[S8?+V;3;&!0I9G\"?)(.]_^9\_\LL&R_P?YRSL\GTT[[E)P;@DNB;>L3_XT?^GRW@8.B MA$Z%[B]/U,L'^/!N/Y>T!?_K;=[L+?_J[?G[MQ_.OWD)W3<9B/QG@TGRYOQ7 M-]IW*#;^[EWZ8[$I40Q=0#MM7P,E(]?Y#S_\\"[Y]0TC]&3R3QIX^!XO)\EW M/T:[+?[I34@V6X^/E7RWIGCYTYLM(>0M9];9#Q_..-+_XS*3I_S?J>]>^1&) M=C?^,J";A.1O)GS\7^YO2K!L/ZRW&>QLO+]_.'O'6[TS&S!!T(C*[]IB^! Q MN>:0S +?Q3Z3?_8A##SB?+^1;31#*[% '9!" I,%LC?X7#&_\3WCRQ$^GJSYBMV4N\) Z) M>B**9D[8='J( N>/=>"Y5<#9AO<)__47\HF/TQ_Z)I\5* -2]9*$CA>$,<47 M<F*"<]? M"7V9,#'MD3#!6U <,A%,OKW$$2)>4U0MQA^)JV&^X!*PGDD0A][N)@QC[%XS MP?,=@KS#HFQ'C<:SC4*;![+RV3W 04S'OUJPCL$4:R;GF#PGQT*/I%'/!YD^#SB*O&2'7*#=<&123 N/6C,V"+^/76,.OFP@.16APSW6\8-;L@2PF MLXU"FVM$Z&?DQ?@31OSOY$+"]O.?"::(\7+W$&\VB.[FRWW+_4\,I3U"MP0] M$8_PFVX[\O4)$$P*S[=<#/B*80='S\03SS4*7=B:V&(:[;ACX<^8;!-G0ROL ME2..@N.-'R%_19@2.0U#'(69J:\=FKI!1\'T+HCX!3Z_8=SAEKQ4C#<*?K>! MOWK$='.)GZ*IZR;6B0X/#?/A1\?^/O \!M871-WN%9 M'W*D?<,XY=#MKB6AEC)*^>B_$F40_9UA/X$1N4=5TQ!1E3'+9WXYD./\Z)%VPV M),IO>!P^!AOVG=9B;#(P -]\6^8*QQH%K\^($BYFN6 E<7:M,=2..@JNOR)* M46L/>VT4:UP2<'.$JC L4?B4](W#MRN$MNGT&+N;=U<7N=OS\ZS(-;_P2=[(Z2T"0)F M!WB$?)==N/@BC\,HV$Q?2'@9;!!AM\TEBKTJ3DJ]PWPP.3J(.CE&V<Y]^_ M/3]_^S[=^ZIS%5%A^)$T-NB6_9E-R0?I;>]+<<1\WW>QN_^61'S.'W[XX>QL M\G9R&)G]D0\^8:-/TN$G?/Q).L%D/T."5XZ9%SBE&1/?64 ;'RO\F^JIDGW] MVX(-ABG%;F*KN-C=H0WF$.:3>>@)>TGJBK+Y;^<5 <$Z\16<5G:FI5H M%]H;XEWI44;\(,A36B8!6Q7Y\$L:;*S8$!C"$H=LHF";FIGSWMER;+.5I>0X MX/:C'O;)8S Q@CF@;%OXZ4V7(A32J" ^[*^JZ+"O&%"!&SO1G#Y@^LS=VO6% M(FM6$Q15PU&PXE>\# [Q8E"V5>$G;MUX$1B0.#"8?S#!E\/+!5X+9P_";K]? MLLNQCVEF\^96OL!/K **DT+11;YK:CK!HX#ZV%!VLJ9"EP>(&7<"&Z"&/TF4 M2)1.$RWP8QTI]]QC+SE']K\)-]?2KR, _:ET/:R"G?XJ!_SP>ZMS0$2B0#C- MH-M] :Q\CZ^ TYV\A=CY9A4\OW,Q23CWY[?\X]OT8WHGQ.2W6[Q"7IJV*Y V M08L:ZR1MA@$_G5.XV59_%@)>;=!8Z-24"L2S#29[0NBX!(J@&FO+F_'(:$RW M;$^673=ES83[B:SAP'LBWF81K],5Q5F^9QDPJ59MW%>\G]KT;K7;:E@2-(!G MT&U9#/]^A[:!&X)6GOMU[E&DLME4FTGU3E%#&-@IM>QZ0R,,.]2F%10.=),/ MKC77@2UJRF(@(4A['M/+,[.B8F#OQ>Z13:XT6FI[*NQX1GT!DH6#IS%J:GO: MDZ7(/J'XJ#0 M=9-NAR8=(5$CATUY/NBZ65"CWK'UR6#!J\ .M,'/!#TJQ0/!! 6@:U"CIREZ MV*P\&'I9#3"M/J;H88Y^Q_J7&4M4"VQD?4N)@')9=:A?=212A53.&W\;1YKE M)&LN%295!UA8*]>1O(,5YAVN(@-.!*; #+Z"Y, 7EX\:: BKYY;X>+Z<4>R2 MZ!HY/"-?P:5:XA73)21USXJ;2ERT\L;C M8RCUR\H;&V/9F>=52^W !(B!W:TRH'.7JQI8$"<;+ZPR=?Z,29AR2W%B"9K* M3R))8SB8*L\8<6-C;+L\9]14#TR &/X$$0)=/!GDP$)8%0_Q4XC_C-EE[^HY M62?0N0DE4&$4<0-1Y$?/_;C MM%YO.A8&K< ;? U*T"D=6?9H0%B7>95.,R5/TEHJ>HKVL%#F'RE6GVG:?E9D MJ/5LO>;TS DL01I\G4E1**XT(] AK"U>\\BMU3RZ>G&\V,7N-6,>S\6)H^PE M@[QL4EXRZ6(G'D!U">MO1OGQTN^IUKGR2ZVD>L^U58CFCJ%]5R+U_N+W:'- NT2>P"'_X"$ M[QHMASZFDAM8>YJLO4HJD9"@?]B'5SS+N)9,N#WA"&&C2,NC[U]ZS-\^5VP; MBAY2"=?T 8>^KU8PQ@05(@R]")0K%):D%'<+:XL\J1-FS"IJS M6-14'LLH:0P'4W4,I["Q,;9=QFNJJ1Z8 #%\A*80Z%)TIA18"*OB\.PX+YXW M7R;U^%5>>EE[N3ZEZC%BYDT!&G7"3:VA/,]&V+2]4]Z YH$.BN']\7*H2QDU M0F@A+(UKCA&^)<_8K3ZA=;'[A'X/: *[8K%8C""5*)";X H#&P(ZXA'WA&7(+I[0!XV4#1E M[961D=(>(R)^ (;O;O-EP3.CMGIJ.\I)8=2UDVA1'8\"6ZA&"1R58%&R.QI! M#V&I?>2; $[L,;%*/:VUD\J3L"40!)5K2-#2#,D.5XF*S(%V^L&7@P#:*8 "P(^_'>$L*KLD4[H\+XRCYZ6YNLUWA$J$"DW+6%;:5(2UMW9WC3,"$P M &8\^YL8^.*>+@4:PNJY0![R'?RPQMC$(2IK+@\Z5W2 A;4ZZE[:P0KS+N/L M]9P(3($9/L)>"GPIQ%X)-(35LW]P?1I'ZX"JJ]F(&VN[_<>?"::,+.O=+7[& MGLK38]19[JTP[@Z /H4B7F$=6K5WQV8,/;5,1VGOV;%E;] "VN%=.H;8E;PY MMEB!6.)I]1WDW?AA1&-->K6DMG MA.*?E(NZRRGDV>L=3]*%LU^/'RMK!9L/( B_MIF M""BTRF#4!*)+>QA2H]:G@Y#T!@P+C.$;(5K=')]R#+L2C[$.O[V+XR,.5A1M MU\21'H#2ML)]7]EZ8"3QJ@J(],B3MA4CJ6K=ZA@S(79@ ,2@AY8"Z/S@4@(+ MX8@JF'(*AIEKFM2\4YY-!CU-S)>JO@#((@+/VF)9Z6EEIQ3T[=(Z:< ZC6E2 M ."8!DDY0CIKI 1""OT81W0Z-$L#U'85A[\(6L-"%E-FK^PM3G"789^:$@? M&($Q?-"'&.QR_KP4W.KZ^.>["OENV9_I+X(?,N!*N-5$)T$,8W?S[NHEXM@] M>?C*CS2^W93*G5KG)Q_@'__]*8QW(=EOZ4D\:I*8Y$2CV G6_(Q B9'+@CD38Y IG8O1>*G>+HT9\Z7[Y\^6;[8;U-,$_$ M\>\?SM*CYS)PXM1RG_[+WTI.3(TW_C*@F^00,3I_SL[.?CB;O)WD Q4_(M^= MI*-.RL-N/#\L0;GGS_NSLP\)RD\HQ(=C:XPHY4?^THQ,1:LT>C7"M+P6_T-;"%1VYV*%=U;@: &_WH M!'[$M,0K+VGZTYLP]1("$+L_O8EHW$YE"K'SS2IX?N=BDC#HSV_YQ[?I MQX0K[,_?KM[O UHU;"C M; EAQS&G>0U\$.1/8@T3TFGI7V\Z* .^;2WT-?A!<&"!&13L\NQ>,D04Y*^T M&Y3VW[6E?07X40F?6A2NB8?O8H&"(VXR*+G_WI3<=;@!4/H>KP@W<_D1K_^ M6&3-A[7]G+7CAPP)..S(_N%XG.MX46X[+",:W9 U&,#APHQ]G-/'X$O5'*UL M.2P'&M^+I?##H?\B""/D_3?9*L]O<>-AN=#XIJQ"851&<(F84HPDI"__/"RQ M&]^*RT"/2EY>\<-;K -??B&K-QF6S(TOP'7 1R5U]B;@[OS]4Y(\)"!UO D] Y\KOPQ*Y\7VW C4(8;YZ<=;\T2*)>4'< M;%AZ-[[+BH$'H);,8DH9X*DIE4M$4LA2JIC(F@_+AI9W5QD2 -AQXT>81Y*1 M9WR)(I1!JK#SB)L/Z\9J>765(0& '=P$2V<,C55 =TH#5VMP Z MY@\;Y'D7V6/M4II76@U+\Y87U KL &A^M<%TQ7;"CS3X$JUYY4ODR^5=TGI8 M'K2\GDIP@,"+EX.',_6WR1DA:#HL%QK?6^4( &#!PQI[GFX5E!L-2_;&]U@1 MZ (7HB*2^+DPGD=%CZ-[X?RQ$ $=QS@.N:?2/2 M2J4MAV5 XYNQ%'Y ]$\U!#,.E-H.&V'8^#JLP&!4+DP94&X"F(=$QW'E]V&I MW?C^6X%:3^%_ONL\_>Z08!.P,\=/'G'WP\ C+OO>+993-\L"/SL[/^-9>/MQ MV>?9_.[RZN[AZI)_>IC?WEQ.']D?%]/;Z=WL:O+P\]75X\.;4S+>*1GOE(QW M2L;KFQ&G9+RO,,VK>3K=*GNL8.9I+"3,103WJHGA.17+1NL,.J=*3/6A#C7&/.'-6[\ M,*;<2E( Y0Y'"LY8=8>0&FO&'BNTP&UH\VB-J0D+33I R*DUWMI4B(!CTX+B M+2+NU9!0VVF$8[KN$D=1#9A6";E+>G02T0T;03G-N07.3* MFYH:'W!'Z^(! M=I&I0]$8SE5+37X='N 6SGR;O+W@KVXQ"O$]+_4]7_X2IE(C,V:H^\"Y@)DM M%0TZX%A6Q=E4'"/8*6_&4\!&^-YY=L7DINW"! M=ERMX3=JQZ$Q=NM8R,T3YB, XZV),=<&/8CLY; RX!F=O$?T8L!-:0<(YB-K MYDFQ&=!Q'QZ\U;D<&;GM5?T@G&MFS+! :@"_/2(; QZ(VT&P[5C07(Q$[S1> M4+PA\>:2T<@A_+7/>QQB^JPBM[8+!$N-!>6U^( [*)("*#B,E$M#UQB"0WR$#_]CIV(OP[KNWPNIJ&Z>). =KB?\7T^O$:$ M)CD(\V7:5WK M1\8V((VDX(N$ 2)^$EXS"WPNZVFE@)"X^_?A M3;>!EF,"LWB8"4=+G,')15$MUS)9;LR-GCK('L)W-FEE*Y, QCVM8>).' M8S%@N9>' 9Q;]5)\\T3:Z88[\B1<;384L'W2FMW-L 8G!X],SPXHHCL1O-,H MHN0ICCB6C\$"*4[#!N, ,WE;2T #E,&Q/RW*8A8X)&D+S#YNS48)6N!852@R MJZSS4&L&P3ZDE+-ZZ:4B^. 8,75=D@*P0,2]\6=H2R(D"Z>7MH9@L#%FBQ0+ M<-RYQQ'#'[M7B/KDX)[QL_R]U8\!PVQH72<2O6R*0WQAYG!.:E;' #[9$X (5/32F]S4'2#9A? MM(TA0H(A]/J[J0:^QA%Q#D>UMACO=TV*\4[^5IKL?[X!7IS766,W]O!\N6## M8DJQ^POC2*BLU:ON,U9QDP(D%SO^1INB]^;3@7'(6Q$BC@@RSOZKRR[[ZK7@7N>(/5/'; M4WVC5S<=88^79>*:[O%JA"!Q0[BUZQJ/O+V;2):*"Y!V]\^($BX]>Y]I\HS; M@I(-HKL+["=62O91N?/;#C+FJ6 FB,63P18["&PM[P^WFB<6I*W'>V=!@T!) MD57OBD?[]D+%N:U[UM.\&P1%PH*_>H3 6;$++M0%HG.:7 3$X .S8* 13I!YF(K<-([6#,2_$&+KFO&LC@M\7MV$86S.I[PU MA("X-CS*\8#/'_TQ!NAM:DG@6AM.]71\26P.8@TVK:Z59O?,GSRR2A(YJCIB MDP$@Q*,9<*<):J/RJN #_I6P[3CFSX<$,0WQ8U!L9\M"\W$A!%-TP5ESC,'M MI3?^,T,F"7*_26I(N\_ 3+[7\/Y,LO'+AS! MFN"8]Z8O53\\LG\^7=T]/DSFUY/YXNI^^GC#&D /BQGKS6HC:_:"!F[L1.PZ MB^DS<42!+O)F@ )+U?V@.!I,>.?$@UP M;,K.W6N&*$_3YU!R.\PL#B,&/-V_"\.M,.Q_[B-ZD;"OT4@0PM(,)+6<2M8 M3W!\WR.=/?IIO#CK[2$XU"R79AV)WLW)G[#+,V#RF47J?*T)J-4A$Y2]+E\# M?_@2T8\X+(#*2RU=QG1?+8M#G1H1ST7D;S,:!/7"G%-M, 6WDWW$/L/;2XS( M&T9[CG-$GG&&C&0_T_:"H' 8<=08(W"<>\!)$BR#^!.B?^ "HK(KG*(#A%/( MBE\J9,"Q*G\6\&:S180F!ZW\)6%98PA1'79+2H((./84G[6MO&8KD ( MZK!BE!(;<-RJH6:J<\,(Z+#BC 'N/PX7 #-310PMK7&I@F [+@+_* ,:"8[ MFBNJ03\(&YL9JPR0 <>X/+ZG!*_\(7)YI?_L"4R)YU7"N M2D[=W^,TNF:^O XHMR.OHR3H\5=$*?+%@6FV(T"X\UIQJ1&6X%:9%&7;;1'& M';?1.E/@!(Y?A[,V-QD3/V9P'Z*,+O"2"5_:+GE<\.J%8<[(1GQ$=\D1857% MJ]<9(=RS&^[-/5(%J-0Q+#+*I.F1:HD1M(:@V[;@M@ C<)Q:T( !IKAT%!M MN/^9*;!%J,'1G*ED!6=?\WJ)#<:!$+AO> 6Q1PXVHTV8"".2O@&# !(_+[:: MYY9>H) X$B9(VH*(?C?CA@0#\%RY)%X<25,TI:V'Y4RK*#HI#L#S$&9KY*]P M>..7ZLM6*C=K4A,^-$M-F/T\O?MX]3"YN9M\NOIT<77_\/].KO[]R\WC?R9_ MN[RZOIG=/(*OY3E6TD)S2+/'$X+--O"3MU,,2N&)^QQ#6H,A*B#VS#)DRC)X MDK;0*N&I9*VT>8K1@<"5M+2P,AR_W 2"75DI2J4+5 ET"/2N%M%74E[6& (/ M1(*C>BT $A..N;2S+B[^5,L9R"D!O9:S52GG5U/)N8="SBHB7YQ;D5G6'(*; MT)+0,E1Z(_7,BM*2UA"\>9:$EF!RJ@%O5T#LF&O ,UTL\C'-'M$RNONJNP"J M$JS7:Y280&:/6L'1=(*BY1B(G@FW^E1W^-.JFV1(7E65N]3"W-TBW[T,.H%0 M?XQD:[^3&6 %8<6<$M)/">FGA'1X?J_3:XHC)<1_7>\FOHYBX:W2K(^P3OC7 M\O1[J_21U_#(>Z9SAIG2.74<#GQR*U9?9L0]CB>A1(G&$;'I B41$QL>U:E* M<+0:X8C"*FW0.B*VAOP_3ZUY*QL&T'771J8-%[ $Z=YSCC+-3@S9WN1XCZ.8 MBLN96PX /W:V"5;P5BG8B/16X;)V$>DP(O_JSXMGX7^\; 3^ZR_D,XS+#[)K M @*_;1T0^/ XG_WKY_GMI3 J<#*]NYQ\NOKO_Y[>W=Q=93^?0@5/H8*G4,%3 MJ. I5/ K"14LO+-C\%1QJ1T$RNL"! 5@0Z#ZU'5)"L "$??&SS1/)0 M_IB"FQ5H0."*_*7YZEDN: A-E95)5NEP%^ !@A&)TI% -S50JLH-(6A5M1(*PM,TY;HP;.SE^'M\/@IZX&AW!P-5P+Y7VA&W+ $R+# M *>Q(YHD:[T+UH[PD'0"9/K*^&?DQ3CYN^C]G7)HP\]I77^18F,[ @3C0PMF M-<)Y2#:F4M2*CV9#C+FAMI!=$1/-$ :W99;J-FF/ 1YIC3?\S^:ER3J8!$+X M:0>;===DZ7V+.-2HY8]CBRW=.5WX%\68S/GROHC 3"L\@\P((>"U[4G2-XW M[5EU@E6B@9O]LL^L2:8 M]WZR5-,TJFJ4Z&S0]X%YJ3-CF"&*X%;I)^(G .4"E>/-"UT?LF9E9E;CWC"O M@'9KT1A9<$RNX+E79"5'JIA1%JD .$4 @[0UH)C BI;/T,X0+@;','%[<+:+0T_/23D#Q MSQAYT7KA(9^=AU/?G6]\ M.\'*)W]A]\9E DJ6!+O3,,11F.UN+MNR\LHJ!(?LMWB#W43XS<6BHUD@V >: M2TQ'1 G3 **+&C [M8;=.,O^3\F>XCU*!"L#+;"8(WDR,:&>^RA+-&<":2- MF>']MW4S0S;:)!ON^ P,!7+L'BGR0^1D^W[I%R,K@]58([EF3"!46!]L!H!H MD&C [K)7QAQ]"/MX$2JE94+4$(@IPEYF91SKTQPQC=BV+K\CEWZ&8(Z02\8A M7J$(,S1I+DB"[B*K[S;>9=84)9GZ:;&;O8);K0Q?ZZN+V3 0;K/]"(C]!:17 MG71.5XC=HM) 3-_EKR"&O%XS#IDH)M]>\A1ASTQ1_?;L_.R\JJ@6IY@@WYTD MDTR"Y:0XS>1OV42]*;#RQ#)>W_3PKK1(XU2V[&)IAC0J+$OV5W5)LJ\8 #'W M@V^Y3$D>$I(W&U\G-" W7TMR%'HX"8WH?H^W,7763.*F*XJSFE!E (4JGF7? MD;4^G83EO+' J ]U[PY'7P(JKE,B:C"FRM=(>/9:8 41"'K@9T0)7Z_W[&Q3 MW%7KS<;/\#?0H0*._\E8I:@CD5BF3(1GU(27U+RA#E@.EKDU5;07AVBD7 MG7+5Q0KH$*A^O&$Z'UKM0:=(G%,DCB82)XV'2.(>-$$YXI80=J8F\3EB;'HJ M/%)>KC*CE[;U\+8N0P2*-4B$6]/1&K!$+D*V67.CPPK/EY^#J)#8L?<<6SA5 M308;TYAE(0%MT>P] ^8NYIC.EX<8L'!_I0JO$H"JK+/H-V8XA.TZ-<,(7&S# M;< O<<.)L]\7TGL@ ];BI$[]XOJJ63]F7P^(PKI=:P/ BBV1* &%>[0M&='X@:E5;(,/#AO;/=X&-,*N\"IG MUF5\B[=$<'(&Z%'HT7%0J 6A]2$(VHZIS&N)JX&]MX?:DV>-#A-J'FJ7M!Y3 M 3>CK KZ7LP[E<>'BON: ;&MNH^I,IM1WPJ=?A[W?L9^C$U(+VTZ9C4=,S)+ M08=P@]S+0+(*+V11$/KFX_LC^]$@]9C#8V.RK2I]!HKV0'P%.L&4\Z:$36\G M-).E=*+RY)J36M,+@O- *TKETUN#46_TMR([ &I+-BM+:O= Y!:7K04-W-B) MYO0!TV?BR,+GQ,W&=Q[W9W(08SPRFS@V&3SBPT'3%H =0B5P%=J+,.AE,TJ* M'49Z?5]"F, M*')DU3BEK2$HA9T+AA1;O625:SFE0G8 M_]Q']"+A<*.1(%S -()W MBK(P"7\EX8&B'80B)A8K0( !7&X<*N_K^%%L":&22!..%'$ QY,\W"X%,A.> M.RQ7%V3-@53S-^6.'!%P++H+_* L2QFX$AXIV@,IIF_*) 4F\+A4?%"DQ7MI M#<89E*O_:,]5>PQA<]N$DP-SZ?MNN020 WLDYDM>"L''-,S>6]'<>$TZ0E#^ MNK>*&" .CLU[1T_ZPBUY)B[V71ZS?$@=T/EVE5TAW'3-95GH[57BU_LM]Y9L M2%:/I BXX_!<]&IHC>@.;#D A!NR'<.:8 EP(09+$BF.NV(#"/MGTT5UP (< M#S(9RHN/[K)DD'V>8O>O]_8Z(X0+?3,IZ94LX,2N0*,9"M?77O E-%>R!%T@ M,+Y/]4J JD!#&&E.\(?&F\)WH MB.YP<&#ZEE2@"]'!G>$^@!#HU2WP&I4)2_I3E_3/K_[B,T3N25A(A/@4N-@3 M$=NH&P33:6?;H3G:(Z>')0>T1A^ P#Y7'89I]^> MO:]FG!;FFQPFG.0S)CFIR:23PJQ'DW'*4$6K%<6K)"N95ZE,<%'EDJJ[G((W M[?)%31AP"LL\A66>PC)/89FO+RQ3(OV'.6>L,0]6N<8XO/'9D8Q\!VO7A%W_ ML?-,S5>*'5[]EX2_/\!0R5[2O83\M$J M4>RY,!@M"J,1QLY,;;0LC##KES\W/G?BD&=LR@YAAS%#/II27X@(A%-\%B20 MI:67^(*]V%U@WUEO$/U#D2VL[P8G:]CT'F&.&TS&Y3 JTX/UW8!D"9L*IIIS M5>0@<.X!>7MSS!T65T;0M(5@!2EJE2 U2YWVE[@=SYZ@)88I4.)PCL MDNP2-8>(F<7[%D(2IBE*15ZI-\NCS:#E+AV#:Q=;[\ O3@[$DHB7?1)QZGGS:(VIR<8H;SNFM]BB8.RU<9W7),GU^2K=DW6@*L9>75KZA:".U*/ MAGH1G5R0Q^^"M).!D_/QM3@?[?A^Z5[/9G"I]A2D+&E6L]A^(CI9K[,=5"U!['6 M&,)]RX9-.GQZ+\AS%W.4YLL"# =]D1=S2VHUY0"%5TEY-5?$E:8C0;@J6;.L M*;*#\3,I!"4,]JJV@'##:4S_' EP%]$,@P5G?_ZZA\O+-63V%7_%BQT&?KJO M*NP.9B- J'W5(MC9#,G>%P_??:\#R@M'L;D]DB#"U""&65IQ,L,K9&H1O@X\ M+_C"GPKQW?GR"CGK?\>(1F)=KZN1(;P\8+U8NT(>*O\9C/_!B#* .V1]<5 ( M+Q,,Q?4BWI"-58>3_U":,K2U6'UG;[%*YYWPB2>%F?NW6VDU=Y'I2=SDJP]M M5U'N%-!^"F@_!;2? MI/ >VG@/97$=!^F.;*A(A7HQ"Q<0B[ /!^B7AM0L3K M48CX]_9$O!Z&B!]-B/AQ%"+^HST1/PY#Q)]-B/CS*$3\OCT1?QZ&B# MCD/%#BXMM\-0\9/1Y7D<*G9P:_DT#!7O3*AX-PX5.[BVW U#Q;D)%>?C4+&# M>\M\&"HN3*BX&(>*'5Q<%L-0\=\F5/SW.%3LX.;R[V&H>&]"Q?MQJ-C!U>5^ M&"H^F%#Q81PJ=G!W>1B&BH\F5'PEN2)%M!WFSX[ 0= MR"*=X)16?KQIY2;\AI),KK_"[%^=+L32S6)*ZW'95CT!15&8+$@U,L<1AGG M88%VC:(Q_]XN&O, P"2'X!25>8K*[(20IZC,4U3F*2KS-45E @XH[,"_.5! M(>!8N ['&-,?<^W?BL!Q,VW+#TX3\:E#[,()AP$";(=R=[($[%$$\1 :=B MB%(NG"($[(ZJ&:*XN-]5-SN=KFW:_WBB">SP@E#/ZE1.\9C**>;ET:3EM4(& MC1.I"_D9=#[*V6X2)ERY"WQWKQ[.E\D/ M? A^H>%'A9< S?Y\#.XQ)SY753%=!G3#-Z3YDT=2^DK6.0"XCJV.)"#2'9.8 M.S391I$W"\)HOIP_12EJDH*QG8QX;"4R.T$:\NWY8!.6(@-!(3E=?X_I^ELLQ7X0 MJP?TS([T,(UP%E]]#3L>Y;77$+?A*M3C+:(HPE/*;BZKU(.C,D>(VQ_;K<\ MI=XY4)2$QR"[ V2"\!A!Y3[SM>1W07M'V?G MU0M:/OJD.#S[?C_#T5S&'IPUXYG'^)_C-'7^C$EJU0DO=H6_5!#Y>VAG.5:\J^HAXE11."KBL"CG^D6/VJN$&_D6^!AC*IXU0%J5Z.Z ^W MGB._ I9^'O.R9RTSAW.PB )0L===[]1=QKO:F:!2%'+[+0WD52][=6N^O/&= M8,-NI2\7V&>T%]\K3'M"N.R9,M0*,7!>'X$".6/R1QAE4D<6=W$M,657URM& MAVAWDSRK%D;A31C&V.5Q=.R#0F?J= 8(5T_;E=XI 7J_J JPNTL CABE6/=5 M#MTU(O0S\F)AHG.342!<+:T6?1,D>^=?8F:Z8/B\O1)Y/FZ"Y0!:XCE 'E]S.N/; MQ(K.[D'^BK #9\JVINB7$"]C[Y8L91<$LZYCYGLVY:D99@!="/-HC:FM^^"] MJ?L@&?WD.CBY#DZN@Y/KX%6X#CYAUPDH+A3O\)VI[\XW/KG9(O8KCP1F.GJ\ M93_(70R-ACE.5T0C5/MDW5;/ENTH)#VEF"NL]&^ M.]##5^^1,\(.G WM==M)6WI<7XF=]&,0N%\(/].$_#O\?$R>RSKTX.@N%AN^ MB;,MO21 MP0]$8_!?A?XCK"R5T=C'J,+LB7*X,3B=?B7._(X=N%?'MQ5L8BI MLT8AKA1@L'5>?#!U7N3S39())X<93PZ-DT/CY- X.31>A4/CE MQ\@F-YJ 8 MSB=TLJ6/["UY';9T>9P/.X\_H=\#.O,0 U^N=UB-,((N(EGC7>@B5J@#Y_8! M7.D#8HU' :*[-)!U0VZ+T8; \5D<1L$&TWOLI?? -=FJMW!E#P@*4T,A+K)2 MB2,(MF5U]=AIK?AZJJ7R,_514?Y[I>^P$*Y_\Q?8UEU7NM>$:> MH);D4)-"N%#WOXS[DED11<<(8U0@((!_ET%_CQF5"'\ZA.-A&/+8S520#LU^ MQ:Y?.AZ/L!U<4X^4Q?-JN_;[E'Y@X+ MGRD=& (AIYCE%0SZAZ/N";6EZ'VS_ID$&Q8QRB&=4J^[FM.&KV?WS"K2#LJQ;FJJ,G6<:/:^1KLK(&A@%2^;+C$VX# H,3;%@)'-6U MTS+7>*O)(?C0',.*X&OR,LCI>BK/L>+WPP7AB&<%9*5?8Q8 M#"%17K7P90I'\8?T6?5P@79V3[3T"<-K"]=0K/F>54L5E8_HO'<<&B>O6?!W M4_H]YBM3O;80#HTH]DO,XY&X@\L_//C\)9ODH#._MAB.0>510]OC$<^9A\AF M$'&LS 1)93PZ\:O0\GC$;4'QAL2;2\9SAV#?V=WC$-/G?B5//NEK"\L85 CE M9#T>>*#F5W;=O@W\U2.F;/D]#6'VT0'PVJ(D M0%RTRR1^W0*.MB1"WBU&(9X_>625##=(DH]XXM<6&3&&0$M(^ZH%^5"#=KS- MV@"&UQ;=,8)X&U#Y54MZX9MA_4ZO,%ID!/$M$?2U"&KN^A4OV%I&4N^SO;J@ MDGX%54]0L():<#M+ZH3GR/'8?IZ1^HA>+K$;.U$20+KA+C6->'8TQZN+,[$4 MRH[("$X47]?#R.?C^XSLJ /QQ0(:7 =T@_;U:V[\)?^;_VC[;,&WQL\6T&"2 MS#K93SLIS'MZO$ W#)1S[/1X@11-"-N]"#AA]>O3XP6GQPML9::'QPM.90I/ M90K;<'FOS=SC9^S'N@A394](P7BV ,\JDK[O% MQ%_-M]G+;N$%9GHCGJV9SHW#&S^+/&5->"KQ"U/8&8F9DDEW"=7N<#1?LKM: M \GH#Q1(<79=B%I_E!HL;*1H ,BP8E <$)M&$25/<<3WT,> V_EY0?/ \PH/ M\:I"1;H9'U*$G$YP>D#_J':R$GX-MI]*?TAQ:5WL&17TCH&ULR!D^U)N/;IB M^U>T2\KB(R?_V8+19J-!"@AKP78S9,$)P=3]/0XCK@@SF9UN AJ1OU11*(KV MD**A3!FI0&=DR^8U(O0S\F+\"2/^=Q)KSW2)GPG3.*BSWCW$FPU3)^;+?\(G=FA2Q8>^V,G]^?O:\:/_E,DV2J21&J"?+=R7YRUBX#;1(LTR[/29=# M"Z8I%[@J1<4_QGS(.F52^UF?2$8W#M7!!*+A@36D X142;U1Y,]3-M)CV! M6&8MA%K(116*4+D8[B57^9:-65<(QF +4=4QL8X@*"Y>[.J:P2U^QI[9[JOL M#.>)S*$V8"4Y0/&]**%UJ*UW8\48\/9E XG7KFHYOJ#8?.-OXRA,T#LWVYM% M/:!NR5K)%;)1A"%4IGVP9MJ'49BFVW>[9-H'D$QK<;+HG+0=SS&>5[<78@G% MI?TY/[Q_6.*:^151B@Z9%(?3ZV!U$7E(. QA M6P/=AZ8&NG3623;MT5C=D@='Y\N,\7.:%&%4F=%4'48Y4PI<28Z]1S:CXCHF M;P[' J9G2G$;EV,$X<@70:>\,*DZ +D=Z41.QQU(EY\J?$D&P^? 0U%R B@U M:L.^$"Y$>C%4,4V"&$3^W9/PCVN*<1X <8\B;,5$U0 0-*!VG%1A!Y&=5R_L M\"!98I$5'X4](021M6.@$"V8G,MROC#=6#*NWA%"#%=;OM6Q@L VH:ZET!\5 M[>%8\.T42 5*8#FD5"&5/8#HD%JYTW*HUWP42I[9R;CPD),LX6SF4)&BHND! M00DTD*1#OHH&'P@KX[7Z)26*@]VN=G(TGAR-1^!H/!:?U9".1E ^*^&NHW-" MZ3J-YU4R0T>K?!Q[7F!^G$_]]-VA<,Z$+T*^FX0>E:\N$A[;#0'!=&+/>SL< M1_8,Y6^$%I\'M?+_G)^=G5?]/_F@B<-G/^S1^'<.J;[2%U3-BD[HNH^RBJ5 M7>PT;B"CGG \0K9L+*YA(U0AG+1RU'0^(Z.>0#1>"YDUXB(TAU)2IG4=>.[- M9DN#YU0C5"JYRAX0E%P+P2RR3(D7!%9=QY11E)US#*=K\L(_J3FEZ@!!P6G( M*!5:$/@T"S9,O\)TCXZ22=+6$)P_#3DDQ:D/X^6IJ*UM"<-=84EJ) M#X1%\! LHR^(XDMN(0CTRT#1'D):?,.%H, * I,^XS5Q/,TI4FT$(5V](3NJ MJ$#@P3Q:8YK5S.>U+*6H*9ED/0J$7/6&7+3&%0*;I4#J;),F'<>S3YJC):YH MIKL?'ZW%4HK8'64H72?0J]J( MNSH,P?%QZCCQ)O90A-U+O*6822:'AWWV<$)_WRW6R)'B)^%X=\.#-@X8R49W MM G12K"-#CM@1LHVNT$AL][].J)K%3W#[,:EG;.R/=U9^1AW$DZ,/LN&_L( M/9+RYQ"4A9QL!@#V?D9XL?N$?@]HXHA7Q>;9C #12VG*6K/7,01(0]B5%0 ? MP+U#&[7OTGH4('[,!E)NR&TQVA X/HO#*-A@>H^]M$3QFFS5MDYE#PBWK89" M7'+.J'"$P+9'BER\0?0/-:_JS2!)SAZ.K%\>+ M>2QU_E"DA.]F78%K*TH),,,0G&&N:%"<+ZM(R(RVFD[ E2 E'W6XC6R8NPLB MS&O,8O+,=Q,F978VN0]UFUPRY.0PYO\W8:,>H34N>UXG3/"Y#9@*E$1#)MXT M?W7 S\PT9SE:%XLWI%$!;_97%6?VU6_WW%@JL+Q5?H-H4VO$(+XV*[CUL&^: MDUZHGM9^'=G$)124$B5[U">-:/F)4643B^N*"'X?T] D87U.S@JDHQ$4O:@) M6OY]3%5+1] RI""TI.+.Q4M6\LWKL&'I;CWFW<>[^=BB*+[]6&[Q8*JN"D"\ MB[G\)?%XW)02T%V"U%52=\NM<+KI(!!N/$TXWQ3?WE\V5,!TC3;$VV49 @MN MV"0.#G\ET?K7=;"I0#REN!FG&\\"X=+4AR@T)L@8LO* MXCRJCF9"7QO-DT MOD+..L<@\15A]S'H9)_H85X(MNPNY:D'$H&SQM1O]Q*-0M00@OF[C18AP@DF MA^J(,6!G,:7R.$>#?A"RB%KS3XTB.'8*]AE& J97NGE]U?0-YZGG!5]82WP= MT!G;.TBD>-^V[: 0$I':"$);_(]"2H2P8QN1D(XP*/^_'X;_4F3'T/**M9,- M%;1RET$Y]$/_NE49NY%='+>!O^)%=B_Q4S1U79).?>,O^0/::4"\C3.^/8LCR>LMH 06*N6 MBOUQ4@6])P)>:@EX.1H!)895#D# *RT!KT8CH,0<:4[ J\X(V%G"&UYB M=NMU?V&T"R]V/.1/6@'S7F8A$1<,;",J@S1.F./V-JSJ9J%PB:6&-6 M59$!QZX%#1R,W?":X7L3AC$W4LZ7' FI1B#O ,'G:L$J%2KP&(5VB;Q8Y85L .G6)11 M*+I"'R(>1\:V"X?]@%9F3C7U ,,:,LXZUN;5N/6^'!>(L#-VAL*USH,O:SDL M^9M;+Y1(#$!G&A'DI?/_B_BNGMS*#L-2O;FUP027_HDOO92)*F>:=1F6 7%785([S3/I[S'VY@Z:Q0>ZO)#PYC[(+UMYRP(Y@)B K[#Y$@?/'310^Q$\A<0FB)(ELOT#^'WFT MN^AH[&^N85GK^ M'H=1T:]QJ6C^W-*UJ$ &7KWK.;QC*@7Q!U;7-TWVMS= N#GQ)S M3XFYI\3<4V)N:[7OE)A[2LP])>9^58FYI]RW8\U]^[K>EFYO%WXE#TF?\NE. M^72G?+KN&76/MZ6<,@E[ZLV.+'.NC@ @B\G#.J!1^H>=O>0[K;TD&3K]YEC, M)8&84$Q84@XR$2($8<.K@::TIDA; S&G M**5,R1%([Q'SG7N^3"N"*A]^%#6$8(O1"%7)L"5 8=2GC$"^(B6Y]YCN0Z>G MHE[?4U& 7S:R?"JJ]Y>-CO[MK?=V!.W][:UV6H;.O"AK/)YU40V^^-$GT8Y\ MM%;&XBE]C1SBL8MBMFXO DJ#+\1?S="6_5)+]V\V! 2KHCG7[7 #9_2H6,3E M>3JBAA ,A^:<$F$ DA_''N0CL1O:<:IEB,]8A]Q^S6M/N&)+"!9$BX-.A,+( M-L0;WPDV^!&]X-#.(9&Q3]AB%,&_B$,F*F$X M=?Z,29A*KMRZ)VT]OGU/0?2B[$LQ@+ +B8#C'RE6F_8,^@$Q\FG$3<>I"E*] M5!'X<.LY\N"5TL\0['7&,G,H&%!$ 8+8WZQGN M/Q+X(;"A %28QM*CPS>/[%/(7Z,,?''%\\:C -F9E$)8Y* U@GWL4DS$"F^1 MY?FQ_-W0!^RQ[JLKM@5$NY\#CR?,SI>:7:W5S6:+"$T"-N2/9\H:CVDF,^"8#GQP M5_C+['$*AM T#'$4IDOV$X[6@7OC/^,T:5D>&&O:?4RKF07CS!$"Q\H]@E8'://!VL--^?-V(9-_)@=DG.F M+2=1N;)%9C/ F#8U"^[9H 2.H;_X%#O!RB=_)?M$)GDR[DE;CUGGWH)54O@' M*$V8!&S.EVS:!_3,+:[W&'D<$&DQ9IN.8U:P-]7^#%'IG1?WW![L%R>=+WE) MX@PF$1>T7<:L26]*?RT2O5/^*HS()LG;#R(& 4'>=1S%%,MW'O-N8Y:8-^6 M$2*]:"G^'Y1E"HJ:C5H=OY M)OO))LEL1YC\4'XXTBS[0=AGI 2PXWWY5IL$H6#-Z0WP)6T MAN XL'P#5X()A$60/%^39-2F58R3*IJJ3"UY^_&]J8TW*@56$)A4A$JY18D: M MF;M((F**E=P@,$(X+-)O 3Z*9*?[:H(82-2RY))?(+H._E4#C,\UEQ& A: M08@65]-2"GI_I^MU0'F)BW5T'<2\Y'5:65=WRJI[00CV-B&T 2J]$5[RQ+V$ MX)+6$&*U30DM0:$W E]:$5C2&D*TM2F!)2A . *GO/*D)IV_TF8$Q5"6-F*K M&%8P@<" 9%.[X(72^?.B#._4T%0(9;K8'=ID_I,$CP,ROKOPD,^OAYKD_SZF M J*0"@6Y]E!(Y]A#$*%['$:4.%'V[H52DY6TA:#,]KD2RJ5SA"3HCI,A=KY9 M!<_O7$P2)O[Y+?_X-OV8<([]^=LM7B'ORH_XVR;UO5?88H2=5Y8&9KKS"O$8 MFM3IW,*]L?[SR/N90C1R>I;A_9KS'V3,A9OFL'^1:/> DBQSG8%.WGZ$W4"6 M=6AMH)-C!8))!Z#X43)?%H+'U1J604<@^I)6$$O\,L + N,6E#RC"#,=P$DT M!J4J)&L,0AI?G6L24EX:,'@,N60XER73[" O%+;_I2!", MAG9\:H4NA/4U96>M2[R8!R(G&\V,4N+Q#*5?*:-%C X$KO#WW0(_8G1@8Z_RFD)*55_=!<)6IQ2U\@MX*E0@\*>\_F\U MQ0*EK<>K%JA!0%PN4+CK'6UR\^E5$CLY>"6ODJ0!+HGBE 9;3.-HS4#\J_:^ MM5$/"-$F%DQ4X@*95PM$YS0YXMW/R(MQ?DG0\TS>$T( 2S/>R7&"S,-4XOC[ M*N9K+6\-(1:FS3K+\8#/GWDB2:!?XS^XF!>,]M0.>JI64US+!\;6]+L<>P]^66%TEF4O=$4A-= M\?IYRT#[99ON!:*E9]5]6'8U-Y_88P9N29:Q-+_NU9H/R[/V9A0Y)L!Y9'$A MJ+/&%VI=/98W/-/D\ MR>[U1 PCJ/,>E=5I&6H9X"00-> M!#>/;$S@4&0/F?6#$.+9=WZ[!3E&?4!>L$%7?H-8>J[#C;F"[:C,D#Z77OIU MY.U.*#HE2HXMV-ECT?+'Y\N_C[D=Z1Z?+T,Z&D$9690$+?\^9KBPCJ!E2(]" M_9)M9;6+:E=7]5L(!YUP'EHXYG!;>#$D*&14_;)C12GY:,@$* U\F17/K'V=>@ MK;2O:GE]3FB2NV3@K3%K^(Y:NWH-"\V:8U_1:MNS#X1Z-Y[V)JOD>:S:VU>O MG'V=\3JC[?[C:U&O+PK(\F ;61/Z:A0=('K,5R7I4]O(?OI+WJ772-*A.IWC=>HC1_M")) N)"TX\KS9; M+]AA_(#I,W$D<:7[$RT-?WD,(N25XDZ#,+H+HO_@Z!X[PSQE<11*VD X4B4 *@,C];T 1+G;""P!IR"5,3V(_8Q1=[4=Z?N MAE&6'W*\S'6VU2JKV1KVA: /&XEDD76&N$%@X2F*[A1%-VR*DY>,CEVE(BC+ M?3+L?-17#*4(F5+@Z[GJ'D9*.U4O9$/?>O7PO-YXMQ&)"O):FY0*R@T#:;(N MP:'M+?>#Q2TWF7&2HAY.T'[.T[7WE5Q[3RG"IQ3A1OKV*45XV!3AKO6FPU&B MO%=/VQ !@A<76"Z#.@&^9F2),X-U[8^BGM.1QR5$N&4!UX]?4]Y MX")VG/+ 7T':LF4>>.]IRT>?6&^9!]Y[8OW)@GVR8,.V8#>F;&8(*M3H[#&; M0S/946B.PP8_:B@&SJ*>8/&D1_1)@F@E)#];TLK=L(_9CN)6VFI)UZ2S#S+" M%,\6-$TR_L(\C/XC#<+.#VK53$>]0383RZY)"%,D6RR^S\-ME^*ICMIS./A> M*:8A3*GLAJ"5I.FK%TP=$N(%)4Z2U[T<2MH$7*N46?X\Y6]@"+N#WB.FF#Y%K",B8NNT0J[HS$6U(7YC:; O[B?Q8DA'A MO4JK'1J2,;7;H>1]5 +#%/@6!!^T?,VI2$VOA'L]PGDJ1=/SBOZ*"LZI=O3A>S AUS:22RT$<)6(P M7^94R8EOEJO6S23C;#GM0+_8B0=0I;_U.2/$9+HN1;"TI_5)2!#'H1 ^;:Z= MOAN4O+G^UYY>7OI^=',1/WG$^171Q&PC?V13W Z"EFLJAGL+EQB57HA+R3/3 M:@RH*VX(01>T)Z\8%P@[UCV[85#B<#V39S8JTP8E;2%XS&Q8HD$' E>.-4E7 MXC9JPAW@";;?+0Z1')GB7ME3PEV9)$ MTTT0^S+!Z6ALN'I$-Y+4$9E&-OC=8A1:&O/>GY^=5XUYZ3!'8YZ[90L[@44 ZFTL!DU!.(CWX71EJ9Y2N7\V[$W9JU8 M),3,H85P$1$O0YUG0MMK/(>#(4+%BXER*SI:IT"*U9QMS(B'CR;H\1C[^3(/ MNE,I;7#LF"0A^#>^SC+Z(;JJPE!".Y!?65N(!SDHAD M)(%5F'MGW N""[ZC%5/":\#E4H1!O5S*+2&DNS1?+F5<>B?WC>]0/M6-?\]3 MMN;+7T(\9;!'55U VWI0LO^]&[*K\ &W4^7 7N(^QBO.$JYQU_K(@I(X''AEK=,#V3XC"R=+:^KSM;#S-, MV!1O"W-,]I,'6%Z>PNBO;C65RT2!1/9,F>VE!)M,*UFPP+7W:U!)'W/J^AAWMD>[:T3H9^3%O* %TR>9 MHI6D_+J_QV&426IM'^UJ9 A&("-V=XKUR&KZ+-AL2 )*./5=KD,S'+#OV*8V MO_]05] +8T^0SQ_A+(Q^-)HY3\LN0:Z,CY0T'L?P5P6&;3XH8KQ)K#-8E2&2RAY 0B/MQ53.PPJ&_1RD/EX%$X789X\> [X44;QGX):3,:A-!) Y$L')G-<86W_)B@ MZFXWJ@XC.I2U:"CWR&._X)QRRZQE8.QL,8TC[;![A/=-HABC=L2^3&Y69QB/K"\)[W6(CEB(VF#]5 MX(*ZQ\_8KW'&N!<(M[;Y&C-!"=S2VH.8E5J3J2Z"=B#E2;%)H3WL/@;S:(WI E&IW]MR#!"^;[N]SP[!WO? @SUWOGP, M(N1E"YX=LDY,*4-*Z' RZ#4H;[YOO0>:H#1Z((+'"TYRT; V:GXKBCI(AIMD MXQV-&?-06Z1 D-TC99HACBHM68W401N]BDJ#\Y[?\X]OT8X(G M^_.W6[Q"WA43W$ADU12V@&.V;,4@OB"%^'6?R:!F03JWT"99_WED Z1"9')Z MEN'M)U[A[ED5HW#X=4QSGXRUA:"$ Z 0U"JS-:3P?=@, "?CM_4FT@1]:/Q6 M>D1$#8$X0NQE5L:Q/C>L:<3T.?F.5?H9@H="+AG[S:L$C M O;7;TW<;S[YBB)*X\:'5NG)Q MQ^P$:B(H8[N".O,P,'09L&G!MGL&/7GF(ETV%DA=#&:=(?B,FO#8%+\CY6K^ M:$D[]A9&@>!+ZH_/!42/E.'I0T-5=TTK[LN&A.#"ZD\49%B#DXO,"LVKCQKM MZ(KV$+Q>33BJ0*EW]\@GY*/T_:AKC,-?2;0N8B"Z[^AZ0'!9V7#!"*G^W53I MBUWSYJQ@ 2<'4RIN("I'K"0I':+2C9(+J[P#XCL$/81V6U8=M!QL[\ MU0MB4<.SQ0XN6W765FVO\8RMA@B);:V:??-D73UFZVH#R7@EQM6TOI#F1?AJ M(PC&T@8LJZ(!CADS%*YY9B_[AZ(>C64RI)-O>JCN$?5#.&7M\P*VN!4]3)&X6 M7\XP2,*04Y3%3+3J"6%3U*\L(U0 LD[R(@43."G/5%T@N(%,F*7"88#LH6>< MEKZX\1,QR75>T5ZG: S!T:+9V130@UL,PH*8U1\AN$+T @ZVNF5>FY$D1UWR M NPZ\!BR85HK1J,PFW>'L!$U4*7-$03'VJGC\&2D<(%V'&D&?I*>R6]H>YS4 MZH#5"! 4;EMI+BU1&V0A,IO#RH#G)9\>T8L!;Z4=(&CH+5DIQ0TI62>I@\$#;T-_S3H@6-A 5?].0GC*&S#GA(R )FQ(=%AU][QEWZ1O]O7 M),T0O/'Y8\#$7RT"FG @BBAYBB.^]S\&XO)Y4N;V.".$.T4[8>F1. "%3TVI MAFHTC&M.1WN&!$-PO"P$J^7OUO!PJ5D<1L&&79Q?,HGE=SOV/Y?I&?I(/O.1 M("S\!A>F1KB"X_V15R1IP+=C*$NRH,&21+P2A-P6NF\ (3JS 1^**(P]I%\F<$]I\DS-:JX/E6'<3RL(H 4F>6*]G"" M^_1L*?E6Y2A!V,R$X"FSQ)4]@*2+:^5.RZ$^T\23"2_S[4B>Z2QN!\'":2 U M!2^V" L(LK]_#C=#)[D/*'8G17LX92[L=B<%2A X5(3*9%,J-02R%VFE3+ 7 ME? P8A@LPG\!+JI,JY8U!#0CB60I!+Y!="#(+]H4=<4>).#^A9"9+ 9.MHS M^A0+_ IB@>UEX96$ @L1G\=1&"'?K9?)-.\&P>_6T0HOX35 ^*D A)LPC _V MA9IZ+FL.P;MFS@0]/L>Q?/+:[@^\Q&H:*\&.(^Q>[/+[1];0ZLRT&16"O;RC MQ6>#-CCQR$%DIT$*8V$K43SMKN\&P;!NSV ]7N X*$3RZH7=ATF(%Y0X>/_C M7A#/;9:U?BP(QON.%K,>67 "H)+9!LL71HV&;I,N@W+C]:6''/$QN'*(^L2\F"@Q$28')./E*Q6"M>,S1##HITP9/M(>PW*D&X.*#B=P MNINE&> *.>MRVVZL*J)QA^7_6(85$>:-PJ_^^2[E TG#E_[7_P]02P,$% M @ IC!N58+-V>V>L0 '*,+ !4 !P:6EI+3(P,C(P.3,P7VQA8BYX;6SL MO7MSXSB6)_K_C;C? 5O[J*P(N:JRLGON=NW,;LBRG.5IIZ6VE5E3DW&C@Q8A MBUT4J0(II]6?_@+@"Y0 $B1!XM!Y(V:ZG!)P7CKGA]?!P;_^GY>=CYXQB;PP M^+=OWG[_XS<(!^O0]8*G?_OF$%TXT=KSOOD___O__K_^];]<7/S'Y?TM#&*T)=F+LHB]>O$6K<+]W O0!$^+Y/KHDGON$$7K[X_>4Z/?OT,5%2N/2 MB6B?,$"/5-?2_X_6?V/X^4*:*J!M'/+Y'W;]]LXWC_\P\_?/GRY?LO[[X/R1/M M_^/;'_[CP^W#>HMWSH471+$3K/$WB+;_.>(?WH9K)^9V$KJ_/!(_(_#NAYR7 ML@7[UT76[()]=/'VIXMW;[]_B=QO4A'9UQI,LN8O9^U3G=[^Y2]_^8%_FS>E MA-PX;RO2_?,/R9??4,,A]*\D]/$]WB#>_>?XN,?_]DWD[?8^8\L_VQ*\D4OI M$_(#Z_]#@)_8+\K4_ M3\^V_,#7_:_KQK?.(_6\0:_GQ_D:I\%]*M-).7!TM M&_U@5)_X7)>XJ1YQ6QT2=V:=;^E?)57P2XP#%[N9,HQ5!6DN"7<,3IG1#MR[QO:A$G.B$U)67R'K#-F],\::Z0M?EB'-.+W\86?_CZ\^X:$ M.[FH";M0\N7?_<<6OV^F2TD1@J/P0-:XT0\KRJ^R=2XC;<' '@<7'Q\:"/V_ MK[)QP E<- ]B+SZBFV 3DAU'2?0YX_3__FLB47M7VSC1(Q>!CDA/CK/G_O8# M]N,H^X2[W<6/;U,D_:_IQW]_B"EH,"E7SF,1ZJE-E(V .F&U4LP3Y2T NF.- MH&U],B>'/G."(%QOYCM1M-@\Q.'Z]^F+%]690M)^+ ZI4E7JFZ>-Q^"F2IG; M>BPGB,(-XB0I:%*B9UYK1+^8SO+Q+5PE!PQ-4<&K<.=X@<(DTH; @U&MG!B% MYZT AU^%L*9<,B%K*?+LZ3=DT(6[71APN:8?\.X1$Y4U9 VA!YU2N5+0G;6" M''1J85L[)2>)$M^<6HJUOM5"GQ.RK6)M[WE\"?W3CW]Y]R,/'_;)WW]U"'&" M.)J_8++V(C:UO0[)(L /6X?@Q2:1@(>Z-+1:$P$:=MV,PD*R'07+X9IMO?(% MMI&?N+/OW^,]U83*%*%XBY$G; #L,8GIF.,%3R@.T9=4-(0+V1!MC,( HXB) MQT:K+(;624A%?/!RV!Y#U@^C/?'6O/%_>_OV^S__^'TO.")#1DLFSC@J@:5? MX+2LM4$4%:#_DQHFI:T@XZ!:K1SHSIM 1[(*B7N'J@2$/J$=YSLPOO2@>&E^ M\@G"EMBM%^ ;^F?M7IC8$&@,UBLGW?W*6P%> E0(:V"'EA%%G&KW9:G>851V M9+&B5"7G(R=? _4WE2+9293X'4#?4HK8^1R*41O8D?YV< B=./E'.K:$1':^ MJ6XY O=2J'?J:2?-@#N=2MK._I<31@GEH4&-3IEN-T!,:=LQR.7F'BA.P_<*SKF5UC@M-T(?%&JVJDCEAH!]T*YK)U= M,"&+*%W$" _D@$DVRK7GX[N#9)FO: +8[50*91YW^CU09U.*V=;/TK0C1A$E M) ?UL'O\Y+$A8<@)L=9Z*H=L:X7>+_44KOLII5=0'NMGN0=G;C$9((X&Q02 ME+)"C->@GKUR7FY<.G7P-EZ2;E\SA*O;@_?F&E7+?JQH#-J#ZV3NZ+N4/"K3 MMS$)F+HNM5S$(V=!EB1\]H*U&H.5S<&[:[6B96^5MP7MK#4B=_35E'H*L N" M,@8V?#7]#]N ?UMGCY.V8_%2F8I2%Q4;CL$_I?*:<SX_^GM*U=6 MBL9C<4JIDE*_++4<@VO*!3;EG0EU1,D/N5)B,3$EV%&XY,G7@)U0IDA^HU+X M#JBC245LG:7#'8M2&]*3V)UV?[D- _5.N:0)8(]2*91YU>GW0#U+*69;[^($ M$:5UY\=@=7T02PAZD4RCSL]'N@'J84LZV'<2HL+?OM M3V\>OT,9_8'<;$4<5K3DX;A[#&7JGGX/V,&DJF3>5?H2J&O)96SM5PDUE) ; M&+7F+^LM%1LKSO<4S0 [5Y5BIP@FM@'J:I6BMLY138FBC.KPYWNS R$XB).T M'19+L1,?3K.E-9H#]D0=17D44)_X*/H&+,R+]XS MOG)B)Y6IXE13T1R\JU8K>GKJ+&L+VE5K1.Y\SIQ39YE@3N:[@V>$D9D3XZ>0 M')6&.&T%WC&E:IVGAN5-0+NA7%(#"6($950'];F'G>/[EX?("W"D'L!/6X'W M.:E:99\K-0'MR=0XYVJ-7@? MK%2S[(O2IJ!]LEKBCKZ9$4<)=922']9)7XK["4F:N-H6LJ;PW5.IX(EOGK6# M[9AJ<;MZY8MX926A/>Q8O<6^7P>7)XW NZ%,J9.!6F@!VO6D@G8=IAE-*P H MU,S@532BQ2%F5:?9;J=Z0Z&Z$WAOU%'Z9->GH@=H;]42O.L.4%+:@3.9H(0- M$O@,Z]!T/4\<_R9P\>6FX$VSD5LG;UQX0LXG01)3Q4 M1DRRFW3M16O'_PT[1'WKM*(I8#>L4S#/FE&T ^J,M>*VSJ9)M\83RHB1'OH6 M:G8)ME#NFGXBVP-2MP3LD37JG5Z&/FD&U!_KI.U\(5KT1T[:BC,F:RL]=RRW M'8U#2E24NZ30]R[7Q'MNPY_1ZP TI5R9RN]"50 M1Y/+V-:YEC'\_OUNA) !_MOE\B!-MIX'+ M_C/_X^ ].S[5,YK&,X>0HQ<\?7+\P^EV7].^P".TD0E*[X[H= 0QS[E MH1:M+UEN,5IG,QQGQXK_L:N\6\X=[2E5%.7\$2D$0.X!HR]>O/4"_I+3D1UL MA82_L!*P]U5\%.XQ*R](":^/:Q]/D+=!?A@\#?ZTRD"V3-@@Q@<5C)# R1*N MVS)"2?,[W.K.C^I))]K$6U]C'-%9XTT0'8A#P41@2-E5X&.S[I!!LH4ABM>A M]/M"A\LVJAC&S#47 6VH#'PUZ652B+ Y00&.QX2=0QHVX86N,POF[,Z0Q":0 MPK3(T--I&Z;@1\I5IN#197%AOZ 13'0&(:T.0(<=?67%=;ZZ->#%OH;0;=V9 MDX:":S;TM1BF2X+WCN?.7_8XB#"%+BY&=J+;@@DBP0;9@6G"$,J9OLZI*OR0K@W>L82I66\< M).S"V/&U#^B[+SX7J^DM*A_/6X^E.^JA#5)DI,U'$6%J1<^#[;PM^+BK$+EK M"!:D@63,]*#K[>+N_<5J?O\!0-K,DK MI/C(-F)C.M:S4_4]VT)[3\*S>C3: MG8 'J9[2Y4EM50_ :LI>/MY7$*>S]]RVK;FK:]%58WC:2O*3A"G;G,>L5X? M=@??B;%[A?<$KSV^U4__]C%/VP_Q];RI$ 2)DDQ0+@N/85&:"4T5$D,V^ M PRH9R*V=;.,4#_I-'M>3V$>5$Z+C.ERZ?@\$<*)>0H1#LZ2D TJ]1 [I'( MZ$NM1_SD!8&DMMDP$&_<\RRBV4T04]F]1Q^G>Z$XGK^L_0.K'%>#=)I=@:-@ M$P.("*G3#S!Z-A*_K7\73/)C;\H'ODKF6>O*EM!SU.L%-YR1'C"&0O9YD7SN;&CL M@,\][\]@G+*0C2@<3UO(*!].3]O+Z$7F6K>8RG?O/6WCQ>9CE,"S L3K^@!% MM48JES*EJSH GESJR=TZ?S@')4Y^@CB#BW!S05DD Z^EG.E>U>;T&)8KM;28 M[*4Z[CEO!CQ&58I5)74!CD2EJ.:2N&RF4IJ<./%LRM.\+>LA5JG^6,))'43@ M0\=0P-A,;S04&O* &#+:C2J"WKP]VW0:,+IO/>?1\[W8XQ,=V]!WZ2_* M#KKB8TWV=(/NP!&BJ2%$#-'M"QAE&JO0.N&E8)2?I\9'ZQG8P^E_,[V\N;U9 MWQF!0,B]:JN5G88#PQJU%]5MQX'U)FN42J0AE..M4=] MLTM?0O3:O&$R7:_91G.T=(YL:Y$E<:[7Y(#=ZFF&A45$#,TTJJE M6MD/:! V5EU21U7="7K*12,=^JNA&@E%5".T3\!H#RJ3T:4:@;&@G54_,1'$;I5(L&,%H\U?%V&LBG: <9Z:I4 M$^J>GC>"CF25,ANO9,IXC0ZG>C%10A0""@V@GD&,61*\\PZ[*[SQUAX.UL=[ M'&'R7 4W]5T@(X^FPCD(U;2'CD>ZXAN&IGW"%KDY7T02QJ.#J[XMF-)'!0.4 M7;1LY;9 MCDY&WN;A,L7Y%284?1YK"G/+6P*/P KU2N?(Y\T QUZ5M*U/CBG-"^J-;)AX M+(INHP].?"#\(,)6J9Q>M.55;S(=EZS03ABPR10WPRHS@Z7S\AX4;JSJD&_2 M;ZE03)#+D)#P"YV&JK)]Y2V!0U"%>J4'YL^; 8:@*FG;^BBG66"0G>#K3S$( MH::=AS+&=!.]K))1)8_TD R-JJJV]K2SH! M#FA]V8W=VLZ9]'^9M-G%[3ZT+UW>SAE877PZU)0/A\=_X'6\"C\X@^Q MBW=[ME8N$@_8##ZZ=CSRR?$/>+%)^BH7$@8( X<'<\8KKX2[4@4,, :5:QN# MUU[@!&O/\=F#D3$Y)#DUJ4@H#E$N%"JDF@@).(@+-D%,-,1E8Q&=2&=KU6[= MJK\ZA+#ZN\+DR%9:.0!KY-".-B%!7Q+;V$POOSQ$7H"C:!;N'JG_,R/,PH"- M==0(]*_(<_G8%P;Z$[RN-(&CNQ&3B<#>B2!@3#>C5^OZ@BEW)+"?H$( 5)( MU'S3KN%4)@)R&EL+/\K&P'&E6DG5L>PHD*!&8%.'LT7=V+Z/:=N<69I6O-_C M6)TB!/TIAX"="M6#CJ(M=,RI4K%V)QHRXE3*:WCGV?HY48]USL =%M5;8U1A M5Q-LXP@QDX%E_>S&5 BI V=P?#"ODN7R:'1EM/-BOD,W#=Q\Q;)6XT-U#^!X MH:&NB!\5S0'CB8[4[=>T.6U>X*%$W0[B]*KNXL.'F]6'^=TJJ=HU6]RM;N[> MS^]F/'3O%JLY^NF=S0!F>ZYXE]4PI\JS*_S4 %GJ=U+&;)9>ZYGR6ST*0[8D M!3SDNQA(Q((V= "#1"=U6I_.YDQ1F6M^4V&2UDN[?&BJ6H3$SW M]&T7FV_86%'_,GO$IE<+U XM (+D8B:)$HOCS0KO]B%QR%&F^S2.B?=XB)GP MJW#I5.SSM*$#?*1I;1IQF&E,!/ 8TUZ7ULNKC*-J&)D@D2]+1D@XVQM>AC<2 MK#?2K.MO^<&TX?6?^4X4H2OT,?#*>3G+,(KXHVI%(@=ZLR3T'VL<12'Y;H+> M_LOD[;L?)S^^^U/:G;TS&&[0310=N%%G840__6\_3?[RY_\Y^=.?_H4]&WV( M$*6RP822HK3C PEHDS]-_OPO_\_DW9_^Q>)H]@'O'G5+P:O: A^5*E441QYI M0\"C2[6\;8,CI?HME+KM_6@I*\%N,P6>[>&$ 2^_SO/$*K9Z3IH!CSZ58J>[ MC&(;P#&G%+7+?B(=93C%29+K.>&#">YG4J*UF]B'AA&C:+/\K>MZ;$!W_*7C MN3?!S-E[L:.R@KHU\'BK4;-4]5;>%'#TU4GK(=LJ;H7!8=*EH1KH23Y4N?Y24 /U"KM7-L-_#1-3_$F#]&"GC!IBFX@ M]5MX>-9Z%G@_RI[G4>L\JCH4! ZMO.2AW?_A[/;_"QK6/:RWV#WX>+')SX/Y M*?**P;["FG5]@*.*#3>*Y/9D/M.4))"]CDAW\I_U>^D4:G+ MFB0+QQ.EZUL#=4=--<67TQ1-H;]7I"%Y^Q.N/7N#B-U"8[M"7K )R8X+@O:8 ML.,EMDL;AZB4ZSC\XVA]Z9^I=1*8Y@:2B,3"($+_=3J T(_^SJK:A+[GLF.V M>1 G*Y[S:4]-4Z!QJJ,@"]*J=@ '"RUQ.U0\R@FCC++Q24YKWY3.;&H;C\P_ MS^/DT\TELJ8FO@[EVCIGI- MFC<%[+!U$IO:3OG,2"-.VR9^GUSE2DK=+@YQ%#O\.K?"2AK=@#NQKN(5%UW/ M^@!V:VW1S5UC37@@@0F8&ZOFU3_/CD%OO !%G%$_::OM+JOVKGJ>[M*[ 9K> M4S6ONLYU5!A7U)8.61#J*W3]P.\(+3'AYE!83J\G<(AOH+[B;INJ&V"@;R*] MF1MPE U[/#UAE+Y]0%DE^&_]1ES?1N"7Y- ^L4&4V."9VX#B6\26U:R,UJ3IF"+U1&*340KF"GH?FI;"TY/J:3,TZ_=+ M:KJ,+4AK]DFJVH\I7$TN%>4QV_?F2// [4'G4O2&:HT[Y.#(CQFF483C*'G8 M:_'H>T\\W>)T/[X5 : 1V]X8>?).H][0\WG:*=-Z#W2+D<.+H+&<7YYTCQS. MB_W[.94%>:DP"&<'N?'6B=':"= C1H>(KB#C$$5;#=7 B7&4'A4NB1>LO;WC5[[MT(D@T$'#G+'$ M]79[:H!7XP:4:AMS FM6<(W=3,ZXLY K^$^R6O\3E,O0Y^,/M@"&C@?!MO9RR*$& G3 ?3E$0 M<7P3T%D.YH?X#%]JBIZK6P./V!HURR.^M"G@V*R3N/4>\^+N:G[W,.QB MG[[B/O1ENR4)W<,Z7I '3)Z]M:R^0$4SH-%:IUAV?4G6!F!\UHK:/N&=$^6S MYY2NG6MUJ2"\L$TBA_I6755;^/ZH5O'$*<\;PO;,"GF-NFVH9[S329I&6?TF?-&C+G-J[/ILIH5^V5K^]LP MBFIVIJI[ \9#77%R*AH#C@ =*1N/5ADM%%"'+UAY+^S_EQ?KSHG&V]W[]'] M_-/\[N/_-3N[I_[DKYT5ALG:4 M@ =X!_.47SIJ3 8P('31IOT"D?-$[.=!&5>>_($ROA.4D,\+0Q8+BOE[G[["\C#6?B9U[9'*'F_[%DI[,/K>9]BCWU#]CUUHZ?22W; MNCQO C2RJA3*M\]/OH>^;ZX2U]"&>9&QO4L8(9Q%E)>DO[C(/1"^B;[E91B\ MT!UXZ]RT"5)Z.798R(8>6J4. +$D>.<==LDKFCA8'UK@Y)2D0V M;TF2(-_*%.]$#3+L=#=3CE#M24$',P.:?46X9]%:*6M4\$8I\PQB$&./,O[% MRCJ5P *FPC+7/74V\FQS*?4>!W1*ZO/$]9T7>&PZ&GO/.+6'8AY;WPLH"C=4 M6UQQ825NPPQA-4;P*;V=P/F#^1 M20WQP2&_8P'O%):K[ \M.N5+3VDIFP-.* UA&[KTREI[L@Y<;MAW*>VCI^^ M@WFFJ\UX?1^&[A?/]V]V>\NN0IYZV7C0.6WK^&85?T>:-3;;D77M\Q<-F2COV MU/8_98MSO1[ 44=#W=+E3'5SP/BC(W7K6XH"[0E=R^Y]S-?V?.8K,)J@NS#8 M)RG_DIKO/G6OT??P>YTDSF3'TA"0L4B[K#-'J>58T/%WBP2:2T*EM6-8OQN_6/TROTSG6*EDO@R-L"#MY:D=O77DLK;)[&ZP11\K9*T?6M;$IS@H)S M';NDESKD]U68',%,W7\>#=92F]8%P/.4KS35B[VIR,+I.T2PSVLHL!IMN2!H1R6[B,.+'9=0 M_(;2V&1"IB\R?$G%'#HW=E@;,D9H%:9GJJC@B!8;E/-,'N9 &=>>=JF>V$^F MS :S8!CF*ZEAJ(-4VP#"BJ;IK! NMFJKJK5R 3SIJ9>YEY4*L.6)J1UG7G#$ M[NYLCSHFN[2R!=C9[SEX^5&V9Y3==/2" U6^J*MXB=G8FK1;.2\XFK_0Q6A( M7"]PR)$_\LY*L[(4WI"G#V5S6.7W,\SM%U-_^/\ M3&R84>4U6&KP,8F:(1U[+W& -U[U>")K/8JQ0*GF.8Z?-06/P6J).^(G)9S? M?'J3TC8\+:Y?V/:MZ_)^\>GFX69QAVAT#@!C>H!O7D_V8SXFM"RBSI*$5("* M5(52 ^#8LH))1>8K:7:"$44TDM8-_R:^Y#<92:\<\C)G,*A M9B,%FJY6]S>7'U?3RULZDUZ@^_G5?/Z!_^MN<7WMRSO[>9N-;^? M/ZRL#2_#VVKJNC^C;"CB%RUB.C/'FPUF;TE(/$L,.$\1<+:&,!VKCFSHJ1U6 MQC)D## <+!TBN>UG >7,8?L;]I8&)OX1*>%>"O4]'1?6'J69M8(*PK4P>T 0 MFCN$O7$2+3%YV%(GO'0B;ZTPD:HM<%"J5%$$)VE#P"!5+6_K^T8I543)(DZ7 M/:U+*=N8F_:C(@>C/54O8C3/Y@HSWV%@Q=[SWH5!TF@;^BX%4G31ARUTD;H? M:^18M9S?HX=?IO=S].9R^G SLWG0?ZKJE>_3._>SQ_H.@)]F'^X MG-\_?(OF?_MXL_J-AL7\^F9VL^IG,:6Q'32$C33>6YYM*6U>E14E[\Q%WZ9E M-FWN_.0BSO\X>/%Q%N[V8<"*RTI>9=;M,Q:8J%)9BA"R#F, ATJY6T]].%%4 M4#7^CG/SF7I93^E[SG5M@3MOI8JE.;JL(6!GK9;7E)-V>LS95+H,WV"M?$OV MI EPGY0I5$J:$;X'[(%2,3O,".J/#@=]Y8X](8W=;#U4Z7[*QL =L5K)\G-T MLI: G;-&X-8'E^OU87=([HQVF(RJGKEG^P)+V@*S9P@^!EXL][O:QD#]3D_) MXKU[54OH]YOK!6_K?]JOWF=;3+D4B(LQ\"7E_@RAT,]T,%Z^;12.RN;@ [): MT7)(RMN.(BAK1!\H+"\OWD((S)Z,H=31='#.&L6FJC7XT*Q4LQR9TJ:C",QJ MR0>*RQF$J.S'$@H%[2[KV=YRNK6LM9%:TP5H)#=1^&0;0-D>\,I+2^S6%]42 MXBBE#FHW5:5XY;9J;:>1.K5ZH[6ZQP@=V]#6:Y5K=]B$54R@[K&+=WLV$BXV MR?6B*-MV4\^C=#H!]==F2N>SJMH>T"=7^@KT/L'>?")-G\P\\U1K" M+J*Z*0_E;:'AQZG\4'^]9N7Q^'2P&OD4/8!&? -U)<.3K#G\L:E2ZHX#4_1M M/C2EY"?R-80199-W=^=!93F$/K6^=&C'-CLO MQJY6:O_SOP]]5P2 [G+%[=P=XR7_TQM\ M20JU_O6QRKY AX16)E!<(E-W!#Q7;";_4%?)'E:+V5]_6=Q>:=TG&S!49ORB M*[=492*UK!WP$%"J)KK[62/ KJV6M7UN/[_FS$E:=,*IZWIL3N?X2\=S;X)T MO*ITR+H^P)U32V7142L[ '9:/;D[E"M+J2-&_H(N-U,&=E_WD91FJ_3FFB[ MG5E'X9-G?I3M ;NREMA=#J7QCM>AT"[8.&P]?H*IH%]-<#Z[NJ?R7H?D MBT-4)66:4P'N^2W--H(,GDI9 M6[LEISA! DV+6&9>OO,3N<<9L<>9[^, ^?TX8 M%4W68MJ(PX49^!1]8!,ECY$G_":(IW18@^1%)^]?H3# !"M[]&E7YX%!G#H#7^STIVGIH:/F& M*2F=+<)YT12@>66OHG:87$[=?QRBF,TOHE6H2(7(CK'8!X0)-$#.3E] 5X#Q8N( \_&H?\TA7ALA#I)XD)%$AG='J?A*]M!M+!CV+O> M#V?[@A;']P]>$!*>%I1,-3* O:9(4)3J4E7 TN\-%.I:FD$HM'OOTU01E#Q'X4)+!$= VXI*INV9<4.97)^'VO*X8VU:C6"">(F6\L*FQ8 MT1PX2M0I*L*"JBU@'*@5V=Q(7VRFV]G\[DW5+MO8YB_@SYQH>^V'7R+]>_>R M+L##4D=AQ2W[L_: PU-+['[OU$\??D'7MXM?'P \PMJ##72>7Z5<$6=K]#XN'>BM0B;IDH3/GHO=R^-'JM9-L-ACXK#\A.DZ]IZ]V,-UR- 3 M*^"(TJ>!R_?*S?,!C&"]JFMLJIV*AR9 M4B=PTS?FKNK+5@ZYP-JQ-,A_.LE#*-=>X-#Y2? T"R/E8R U78#"3Q.%2PN7 MBO: AWPML3ODO.7$&4I=X<>87Y+@3T=P'I;6 (-KO2#>$V7#/[O&&$XH,^FN MO"@KQ;KS#CLMH\G[C2JH*U171[:DTVC"NTIVH]Z>,4%O4C;]W*=O&.>#J)]I MS@]N_HNL+GAP!QB)R%E8KH"WP:"O_+"D][]Z@5MS45/:$"@JUBM7 M?HOGM!7@*4R%L!W2KB[X;DE&T>[.HTT-K5Z&Q$ 'JC-C5%] M94+5&W!@MU#"\'6)XOPL>S+&]N'D@#:9;=D!#'M7&4VC",<1WWN\]9Q'S[=^ MDGANA_2UF.@>K['WS!(_M4TH[3HZ?% ;H!H9SON-"A,JQ#>,!ADG5+"RE50] MB!DT].VP/W&NPB_8\>/MDDI;,(S2?1CI3D5S$D"#NHM!\MV+AOVA[V.T5:?+ M>6E^^<#Q*\)YMYM%_)0>E_,+]EDN%]I0M;9#+A7Y@1ZU81MWA.%FHW03W MWM,VCA:;CQ%.V$P#5UBNR>"P46^@P=S2#/F\2;\K]"E3"TVZG__(YDPTS@D3 M@'U_H%\YQ?Z!7P@Q\+QH0.OP1&S.BYDBX<:?6*>VD.^E6#CSL6>/Q4=-*X#8 M4%HZ1U[3CSAN\RVED\Y (;2=$?2VE<2>HYH352K0U]92RFR".#LH>\R]F.)4 M9U#!SV=M5$)RP!5SJ#;]1P==QX5$-3IT,L**>5G;XXPO#TRE2D> ML%(=H/ @.R9/L8I.:+3-)>TZ.A10&Z : ,[[C2KV*\0W'/9Y(D8^!:#,H(1\ M#V;(HKU+-9X61TNI!JW/E23]@<9R:U-HG2B==H:^-])*%YMG2?M4*)@'2<9- MIG&*E/'LZPA):]=D4*/(M.]X=*0-F3/?\7;9BD\3)L_ZC L:Y2I7P&&YP_@@ M4"'_T+"WYF+DB&<=Y@R;10%M"9<\KD%@F6'-RRK:?;A)LV*+8DKY71P(0)-6NV*/[JS_ M.'@$4]M0*(R/;,D73P.7%=O=LR8*DS8B !Q8FANC?&=1MS=@(&FA1.LJ22DK M_J)5P@QEW"9\RR&>\/R,G*6M-+TAC2)4SC\Q1K4M;&+&Y2'R AQ%.'I/PDBU M@M'H-C9\4"A>B0HG?<:$!2K132) P6.".!TXVX@_=63I9[UU%/OEA MA;GI;(O8?C8GT_8Z)!19UQB[$7L"Y#9T@OH[F]J=1P)A>D:0 5EUSQ' F:8" MG4&-;2R_R3CQR?]WB#,#<'US(%N(CY'>A3$659>F%X#<8NF\F(0/"\V-T6XK M!3 \M%!BP*T34#NRO=HDVY'5L8)]N,@K5ICL6(U.U9Q.IR-P(-%7 MOK0TJ>T%&"@:"-^^'KVP""F5?&5L+FB0[J3%7XWHKO%"V F.%-ZI5)ZP%"_ MQ_MT':85X!7-@8=UG:)B,*O: @[A6I';>FU!N.]@U=\ZZ%]97HQU&Y(X"5)^ M1;=SR*I>IDE87H>$[7T(-?"G@3OSPXA."U@Q_!-;-.P*-#K;&*!XWD:O'_24 MU*9J=,E,Y>5.PT.\H7-/YN.9N[.-0I]R1Z'P! /S^G4B -K@P7-2A[)+]MH6 M9<0W1TO/4$SY4S.)#61/4@R0H3J4''#([[ 7KZ-AD0/!@DK+_9XDKSXZ/>870*";>FLXSV1<4 M2,L?""V7_(K&^2V!M7]PJ8;SES6OZ7)/YZSSS08K]UP'%P(XB-GY440@'%8" MP&!JR1!=-D\G"?P(%/GZC5X[:QD'XM6(J%(CL!>:2.Z_SH'*'S[[Y9+:9("HV M3XOF.O1HGH?8(?$8#72)G[P@8.-FOV;J=[#LOM?&Q$OBZ=+QV:F/S070@CPY M0?K^(DN%#7W/S7:0EM3ZV>YD_LJKXU,'C/G#\W6Y)*9H Q_XC)I0' "-$ 8\ M$)K5KW4!:D$*#ER73N1%R0V70@:#ASJS<+=W@F-ZIY?JO9)D=E>W!!H1&NKE M)S3R9M /9&JD;NN#[-5;/XP.!"8K1.V*(PYSOP@4M/>J=D M44$7?>:4S_*]3,;;K1?@&PHCTG/3RM:CBKLS-=6QES<=7?R=2][ZC(M20AXC MQ:KP)-"/-MG @U+SL_?>V+Y(D@7LH)AYZ_=HM:7MBS8.#62^_1V'R$UB.ZOM MP]J7(SR*0LJ!S9._>/$6N>'.H:1W>/>(281<3&5(N(54P)"@'8L8YP7SBVFL M:% B@V5 ,/=#R$"!_SBH)!*?UEOL'GR\V)R9A.&,%Y)D(W7J_N,0Q4Q: M04/9OH)1PL #S)SQQ+#K3A5P,!I4KFV(9B*P^.1"($&*=+9 YBIW$E1MQP,8YI:=IU@ 8&G>FZZ#!:_B(.-]R!9) MS)=)P%^@_./@N5Y\5*R:=?L C'B,I^QT5[1%W0#;B #0P&YO MC-(R7+LWX&&YA1*ME]4%*\1YI:D%Y4"Q/WH/:!*8&%'LARY#WUO7EVRJ[ < M ^J5E>]XG[8&'.,:0K>.:>\I\#;>FI5?+MB@C(_-@:Z0[%S_VD%.MS-PYVYF MA-+@IM43L-,W5*"G ( PG($PA,%%*"N16M*%A ']&/E:M5%OZ O7=LJ,>Q4[K,X)MU)XE_BAE.'0P:X:SMM1&'VX2P?V%MU? M1<";&^%8B2)*F#W"X K9\@$B25@X15CLRV'A)*) Q :3>]-ZX&!Q2@39+(-A MYET8_X;CSM,D%9GQHF>E830A5$ICW#A:K=)KGC[UHWDM(%"VB/*U"PP=IE1* M.J\$&MI.K^1$7A$X0)AJ!31XCC1X($ZY>C)64T"!/0$#8B2+.]?9(V.S8 M5KNL.X"IZ0(4>)LH+.Y-5[4'O".M)79;_\Z((Y$ZB&L#F63BI<$ MM,D =_:VAI%? -"C 3@H6JMB(KD_#QJ1YX05"14^ )#(+S'-;4V>?DT7X$&B MH[!L1)"U!^S\6F)W'A%*OGP+XAJ[9"C4OYRNW7DD3JYGA)H)T+BNAS=4P.2D M"-8E;HN&L#D[O'8\\LGQ#[A0MFZ)4],%>*SK*"Q&>%5[P'&M)79;)V;$$:>. M/F"'T4Y/UP(7_>)A0G^.K#>A0')_LFK)52MA4S2'TNXF#*E-+:Z$A]#(!K3L7O4L@J_*7T>LR)# (LL M$R:K6Y69YO$5A''ENL\H@U<>SN96EF)()P*E5Q=RD;(!VF5G-A51GU0( K(H ME4U>ZM:B=7W&$J!5*M?-2\>PX-23V\#,5* /8'DYF-IF)^3*MR@IM@0Q>^V- M'>=YSVS*4)7!5-M6?!K=QNG8E>NRNC[CR#LH>R"P&DOIU4$T?X#ZNI7)I M'535 ;!WZ\G=>D&0/ZTJD(>P#.I5:WB3KR5ASW3$QZ7/+OT&+GL\:L^FX#5G M;#K]@$>RMNIB--=V AS1^K*W]N^4 U_7Y^3/UD]6D@N5VNLE%=9V!^[M30TA M3R*L[@O8]QNKT#4$)H@S*$<"@,6)4OVZY8E61^!!H*^\%N:/89'20/B>7![& M4D5I!_ULPH8DQAH+FIF%3?J/,3[Z2*ZKCA10Z896[%(VB$6T>!^&[A?/]ZGB M-T%,E?+8'CP_P"[TKUDB-:4!'"]:F40$C$8$ "-&.SW:UWU,N(%80V7"Z"V9 M3EL#=_ :->4+HE)3P$Y;)[&).U(990"KG$R4ND6-K!UP-U6J)L/:,:Q0U+)V MQ4PH:X],'OVE1G6/D7BHYD*BHOD(O+:/Z7#NOZ!6!$-H;# %K/&\7;\7T/AK MJ':>$09^-EZ;%C; /!Q&;M@ BA8LTHQM$"N/:V9Y?.L]X[-%E]YB1(, T+!N M;PSYDJ6N-^!!MX42)A8V";,+S@V=Q0> Y4Z%->I60)I=@<=&$P.<).?4]@,< M#XW$[Y"J4^G],-98ZI&Q;JVEUQ-X #107_1_C6Z W;^)],:F0[ 6959,8#', MA;2\FN,7>4O@85RAGABVDF: P[1*VO;+L;B40CE!=QA(HEE:.#+B(MZ&#G^V M5Y)7JK=N:4H-N(-W-)-\1=.(%.! Z:J1B;5.QGF"..\)XMSYP;PL9QO XJ=D M*W;?G0E<2%BW &K0'7AL-36$Y+6ZVKZ HZ>Q"FW#I7&(P%@A<2FYQ"OBN)A: M:!%O,1%&9_TU4UM:P".HDXG$<&I%"'!L==.G;:!QKGF4<'N#=!5O#E2#_Y&.P=SYWYCK=C,)W^X?[C$,7LD&?^ MLL=!5)=<9XXZ<$@R;,;2*M(,:<"P95K#MK&9T$=+YR@],QQR$B 8H4[]J@5J M&SK (ZVU:4H#?U,B@*.GO2ZM!_R,(]J$!*51PT;\],^"+4KY EA_-C%3W6*T M+:U7%%J5R]16A%Y)B)E;P+8),R!K6,%>UX>83J#YJ]''2QS@CX,% MK0G"(XK";L93A60[JB.)SX[*F0G61(CDK?0CRL3@P9L(DL4PK!6Q?3.6I^ V MJT/AQ[@V%[6V,7"HJ5:R5/])VA(P)-0(W'ZO*WBZ6&&R0XR!S24BXW\34+4. M==4QY"U'X)H*]4[]\J09<*=426OB5)![9YQY)RI80[PRGG1GHM7]P >C1KJEO."E;:\!5!/JU!'N&DH?@W_5J%4VL[SZ3T)GSV7)0FY.'8\/V(S M['B+D9?X6.R\#'ZMT*BF1:QT61W418QJHJ]N-8K(D4[L%4U&$T$FSR[H_-UC MI!#!>RHUF]5ODK0[QT>IF2,62_[!Q2[] SDTI-BY.UIM:?NBC4,P.D2T31PB M-QDR,*,:$MZ>=MV$9)<4WW:B**0<8MKZBQ=OD1ON'$IZAW>/=":5W U.N(54 MP)"@G1,<$1LM&'46W;&5^\+&?P QN&$LIB3#?OV=K\HN0(&BB<(UL[DQ++2T MQ#;@QJ".2@92NMTDUE# +AT2!]00,V?OQ8Z?)&S7U!NO[@(\8'44+M76K&@/ M.&"UQ&Y]@)<0]?Z9CL>!BSXX@?/$7Q)#U+/I?[QGC#X&7AS9/#^16:%!D5GM MWB/T>=W2LGI=1Q8)O11.3?E\BU).2;(\K"%M*&,T0@B[[T.ENB\VLW#'$JRX MQ/?89^N+61C%T<.6+DZ86N[2.?*#MKI,@:Y$@<.)&:.=O#S5@2)@\#&D6.M] M+D;ZXI+11B)[$)>SN7!<-E&T*2%4U^1-TLMCT2:US91=(-"[KMV=/O X-&Y* M^97NCL0!1Z=Y'4TD>"1!^W@6M$@4!ST>2PU3D1"7"4 B2*U!5?94;24;)0P] ML(T9KQ31G:E"#F5SRG4;;*OCMB9L*S9QAUD?@#$CJ#F+]BQ.-$OMZYO=J0*' M,4-F:[50D),$#&"F-#.!7CDJ"OZ!;04^X/6! M>+&'H_E+DBYP33V Q=DA3A_U/K629M4V,TR !T@_1E74>#/ 7 P]J2HD8IP M@D"HD AE(B'F%$@0BG7*,6"9!3^ _8&.IJW;)3!('GC@FS9DJ1*=(=J @]VX MBJTKV9D*[8H]!(LST[K%<%5[X!%8JVK5Y'0,2]-ZF3M/3\6AR?8ZVL/!^GB/(TR>*U]:TN@#- 8;J9QG;]=U@)[+K2W_N%]8 MZEW-E $J.*"4Q0 !J1H1M3N-,22E8Z->C[$&I;GA8[7%B.5-T5'2+9+*Z#10 M[<= (M;D\^0J52W.'*SK;O/Z/(XBC+5O[E8T!XIGNHJ6[M$KV@*>Y->*W/J6 M&*;_L9GCF6C&Q;C"T9IX>P;AE155*WN,PD\KU3UW56ES\-Y:+75[AV6T)XA3 MGR"!/H!]4[GB==NA];U&Z=25FY+J$8#-Q=XUMSS9NJ-^'@8Q-0:E M_7034(/@**Y9%-1V AZY>DJ+D5O= W#D:@K>UG_OL8OQCE=\H)PN9@4KE/&R M>J'T@Q>$Q(N/F3!5JPA56^#.7*FBZ,/2AH!=MUK>]EOE8D#D7@I@J7"J;]TB MH:K]R'RVT*+@E#_2(_*R^(Q=&44F8RJ,-56/@3E^M9+F&M:PE8#>N$;A] M>>#. MWLXHC:.EI[)H^@(% 6_3VBW?. #$.=EVZN#2I4OKR6/I&Z^YN,UK G;^3B>0W M<1L0 APFW?0Q<:]6C*,C$CE/6,6>\M?V5U$*,]6MI32Z 0\A7<4UQH\QK*ZT M13<>]J#*N5D;09OK>S'>B M:+%)15F0>^]I6WFOJ+(#T##35[:4$:)L#7CXTQ"Z=3X#(\W6.REQ]K8Q)Z]: MY0R4U0%(8]N!6[>LJ^TTQ@"N7-15]QA;()M;TE6X=L6:SF)$FU,]&W9[F)56 M5M63-0(:;]5*G4U,H:P+M6>F U3%^Z*:W TS236G84;1=H6[_C2SFLP=1*'O MN=QCE_2O];$^=;NR"U!$::)P.2U;W1[RZ*TC=OO$8H'X!"7DT>?TO]9WG'K5 M?4F\8.WM?R;;S[=S+]AZQ[V1_3-=S8S%_ 3F[?>XWU(V!V11'N]^8!N7^"X MT<@$I9P%G8Z \:*9_*WS%1(N*&<##Q4L&<)BV'^,\&(SCV)OY\18M6=WU@AX M(,N5$B.VW )P:"H$;>MZE!Q_-BDC""\$#2O\P0FCQC.LZDK>UK?/'X^"%\Z#V>#T12E^W_D#WCW2#SX&7FQS:>Y$ M6W;;F_YG_L?!>W9\=B'[GBX%B+=F#S=+OZ]>K7K%V]DA MBL,=)GH3EL9$@"-3.Z.4KR VH0 8?5HJTO[2'6>7O0*;,$1?*$>4L82#)99L M,B(\>#H>"%$F83E'T/;S(RO(U@@L/IO]N"A)+. M>,&BVC2:H"$G,D[PJ-&E+Q"1?#0B-.G):&=&L0@OUXY'/CG^ 7_ #DN-8YO! M34XWF_0'#B>-32'"B'9GP/#17(>V$< X($K!R>FZR6D\^WDV],=A'^VY MCC#P4;[YS=U%'Q$UB8P& YL818YZ.A1&@7.-%#&!;,J#)8 @-HQQ!-@*8XI% M:V:81X>2L[OU>^5%SM,3P4\\U9:5N.6;TEK8H=L7.&0T,H&(%%H= 0-$,_G; MNGZ92U+..#GX@((%P]A!@(!$APB]H9../0G=PSI&3+_ODO.S+UN/SEO8)&,6 M[O9.4(@4LH2U=(3EH?6K6%*MH4R=&7H3>_OC]C_]]PB[2[$*"#=ZJ M+R9Q#SB.?9S<#EAC.HFC/V'T"U=A235X.)"]?X@P6Z$639?.\:3=%=YX:R^. M+H_%9Y?'W[!#*B=$UH4!"H?6[9(CJEU)H%<]L&^8+M458N?QX#ODI+Q"E(M' M\2A7!;T1< U%F3K?\<6JT&6?JE1N[Z9J?<<'#>$;_N\C56_@8@[C_>'RW8+% M!A4"H7OQITI$0$P&]%#\5%0%LL#_=A_06$] M8R76+"Y_+@^1%^ HFJ[_.'@13^F;OGBJ"WKJUD#';4TUQ:6*HBG@Y4B=Q&WC M(J.+!,+H,R-MLQJ<3%OV)\'X*MPYWNF\H$F_$7JQ5/4Z?RYU&IEGRV4WZ>,3 ME#%!GQ,VK?Q=L=1;OKOUU\F%,=DP6OX:J$.J%,D7*,)WT)<,,E';)\COJ8S\ M>,@+-B'9)3L)>TQBZD5>\(3B$"W?(#=[AW[KK1W_/0D/>_J%&@O:D8&,&1T,DV-+"QK0 M,:B+2KUB52I8>=E)9> K'R8>NEE.42H@XA+R[P=&-!OV:VL:].:;K*LPYSBO MR30 AH[); "."!<;R7PTNCP*_])/4FI$"BBDFS"0/&%)GP[@U4LG=4PD+\D6 M-\E#RZ45/;!CPF'-5>S][:E&6_HA.P:,/!<3VZ4VQ>>Z^87;?V+WQF4EF#<> M=I/[+NE*U:6P?>LYCYZ?/'X8173"X3;,FS3%931H9=2LJH?C#; 8!<:9U=0$ M_!42H4*D])Y8ML7C\GF'(!9*Y0((BT L+$',/?'6&#D^1T,VIM"E@Y/8F9G7 M+V2"M7&\).$U6_G<% N@.KAL3@4X'+8T2\T6(\D< 4 M#" -;2,!<#:'F"5%K/.BRA2GJ8X'/[DX$^[329O)!T_$_'I"CE[P--V%AR!> M;*ZS^S@W0123PZ[VJHH)>D#1Q)BI)#E.S8E!W^\SHEOK3"-IEM$Z%00Y7!(> M3\6%,Z^0QEIBD 53E6\"I09*^+./<@F0(()UG(9E-FV_@E"Y09@\IU?'W45 MI]T'0J@*ET[DU5[,;DL+**X;,9&TND,30H!GC-WTZ5[C8%):O&:HSJ:2[]\U) 88J+KK9"+T1-[?HH0[8NPG*']] M+WN?$PYD6;1=L?B]Q<]4UW=TSK0_\$/[.*0KWN30GGAK!O2[T,4V*^PU@?:/ M0?@88?*^1&0H('&KTE1>1I;X78"!I M('SK3/R4Q80GAL8<"W(V8*!@ $.(618I-VX,G!L#0,FM8EF<57[6WX"2]0 > M\AKJRC>1SIH##G(=J4T,9WFYX$7T[78,SZK MW=XPC;0)I=%$?&/SR)% F\PH$**Y-B:0(^%ZP=F>OXH $$_LF$D FC#>8L(V MC#-3.;;?2BB,DR^=KD/R,=@[GCOS'6_'BH.D?^3%E^QQ$N-;>K4B.!HG: M&TP.2%"?BP$"Z*_P8-YQ*2;N,!JG4"LN1Z+S] M*)"F0FP32,+( P2%GK6FXO@TOK\XQ$VB/@R>+JAX.^0R>X#:_/C@Q ?"SZ\H M5E(Y5U3,%L&N368T -#,,')0T*,Q"J!HJ(J),"I8\DE)'D1 0<6"A1BP("IB MD #+QHM8W8%=(LA12)*'@37,&F+B=J.IA*+C:/"D3GGUM$+6:Q2842N\D<5* M&1<@76:P9)'D:1.ZJDBLL,Y>@0G"X(*_!$/;> &5&DARU=]%Q2 M95Q6UYRN?)RD8EZR@&HX'6E#<31(TMI<J]8AR)A=L+]=5@V9 M[XM,66KM4_JJY>(01S$-1'X/BRT.6*W&1)0)FK^L_0/_:K$'E>IFU:0"J@4' M5L*)7V;SG2A"GU D&'PM")/ONH -Z.X]EHAS1R:O3H@@X5A&5^ \&0-F2)V MK2*[S0 *>^8.8<40HV6!VQXKDG?E^8>X<8FEIM1&@SZMS*1XHK<)J5'@3SN- M3,15QIF]PHLX[PF_*9"46TSY P0B>Q9CLZ!#G+\ %> 8^2&=*^VI ?ELB5ON M"V;WO%CUJ&=,G">TP">%3J>FUH? MS PR&@W.F3:N' )-<1D%.AI7U@0,B$*A0BJ4B94\)#)67MN9+L8)'E+YTTNO*B-:M2=._$..(-&Q5TZXLET/@?TN"2LG"] M\!M/Y;A^U3=;7"Y;+EUDRR6229O" #M\C$HKJ[RIF\J,"!.:)_V=@$C2,:G= M@[./V-$^CB*,K=6K@_D#B;.NC/E%RAWE,B+.&W$I^3.59TTS21$7-6EO_[AX M'#]!,1R>>G_9V:U.75GL++) XW;(\X#3-!V]DY=VE( .>0;,4YX.-R8#>JK< M7IOVTVC&' M78I162Z,14RZQSZK^+QT"+4.<8*('13QIT'$;RJ>KVU$ #@"-3>&"#SZO0'C M30LEVC^6Q@DB3M'^&[BB?I6/WDH;CLBSU<_:GK<:B:<:>KCVQ"/-OU,[C8D7 MJM^F+'\-U*54BN2["<)WT%?^,E$-O/W(]M+5[S]RI@.OH$TJRFF!.)55#5:- MW^C2) ,T(KL:1O7*E@X-P -$:U7,O),E#B4B4S K)JOV(:E]]MP^L< 4!+)\ M")MCGD4%+;?10HHJ^%B0#)N*&,'MP1S^@$SV>#\SM=S,W""41B048H?\ZA1#ZT=]G M?*^'<$B[U09@6->*VKXZ:T$4,:K&=S2T?)"N0M(' M)*=/!/-H.%57NKG1M"]@;VUL@LR%M3L"]>OF\AMT=O.;)7,_D=;SSLLQN*CVYXF*#E[>V, M3P$NG?5Z>XA*;=)>RQEZLPY]'[,K,-@_3OC^S#>I&M]\-_!6C%GSI=0L+IJR MN1\[VZ\X)Y(T QJO=8J):YS3-@!'AEI1V[I>OD)A%.V?WXCZ59[?2!N.R!?5 MYS?GK4;BCX:F)2<>V6%*8L@GE\3;<06EDQAU*^#>J%"K7)2_U 2P'ZHD;5]N MG]+CN68&Y\++=[_P"HSO27C8W_IK]:18V1*H3VFHET^3Y>?G M$&E;RMW.J8,E2RV^!%2RK;=G")MR,[G9Q(<,)RZ/VP(:QP MEUL@G31P/A-4<$(I*PMW:P:V@(X/V+PE$U*YBK<*6962Z(%.=1UW$8A[!HKA MH4%WH*#8UA"E2S":?0'/B!JKT/JZ"V,DO(Z95/.)4,*,O0AR=+UE*&L4 M6C]G6F=%65MO:G0ZS\ZS.A3I%.N6M<>J.=JB]W^V"$CC#+*Z'-" M>^#TT$'4G49(HK'Y[*/B&:ZH-A%)UA9HY&FI>)J>=-80_ 9+G=R]GKV08K!" M3B%"%'MYM5+$>\?M,:/HIEWKHX]@!C9;S0BFSGH"!O[SP,?#B M2 <'*EM##OMZ-?,H5S>%'M0:DEN/X>2ECRGB8@XT-JKV:QV9TIR^U?ST M5-$']E;0E??LN3APV3EBD5*E.)#4[ H4!]H8H)S>7M\/X$YT*_&[K_XXEPG* M^/!C=#'+T,Z1^L!&2);[1K?#PC7&;K0@Z9-H$7MHHD@B>L!Q["=I/47B &U, M\,X[[(3/Y-L$YH@#Q8!^C"ALM!FB#'UF85[1UH=".U[GF;U]DLJ$0E*\.,S? M.1&RWU!42,;JMZ9BL"TZ+IGPV>";=%!,FDF"%B1[>3%"3!@QD1()\@B)5+Q/ M9LOB8PL9EG#L66^U'S1,UJ4$9;&2_!BXF-Q[D7 0]"%T%04$M;I!1OH&BA>E M+.O[0$?G)BITR3%W=D8I%UEO0@%P[+14I&OH8+ VAN]_.*XBCC+J=[=%!M"6% MMI%"VP$#EL')]=7-["9@C^RYR7:2PCRJML##M%)%,4*E#0$'9[6\K0_M*-4) M8G112A@EE.W$9#]*IMNF7JK@XQ%=8[I&I(NY*QJ>D12>.03/:&-O[?C7&$H,HX;]@49::U/DV\]- M.D/?AVZE2^^92.M4%K2APJ#_X>SV_RL9!_E@9R>7<%!+92S0=6& 8K1/>?4" M#0];A]U"\*+?&^"!NM,X0*!&:4GD*WJ,)]SK%.@]QB,N0'((93NB^S)&0CSES&W&[A]V""GV3HD36VJA5R29'./S20NCYP=$5O/?*(#)(Y:<[ _CLAY^IGLE6^&J+1 M;71N+E>\VLW+?4;EY@K1^W%S^X^//#@^CM+%X!V67[2N:PO;O>)A;4:;-)E- #>!1JJ%LS=$.DS/U*^=%];V@ MN[2>VB6WKNX"V;4U)6_MWBE])/%SNS,I.YI#&IF*._MO=8&OW 5Z(&LH7#DX M">TAA[".V.:&)_M5*'I5N/R05\POZ!%XRZ.J^W?*QF.+5^5M.GG+,<6HF;MQ MLD&U_26XRG-*=OW^SMG)5N3J5D =KD:MDV-(LJZ^OXBWF.AL+E2TA0P2=2H6Y5H5#:%#1JW\MZ.H,2CAM F M3WMONY5MK)TX1RM,=HL-92TK %7;&*@_ZBDIF5"?M(0^2M8+WJ5^.47M'3O* M6J=$3XZUH@D=0=&WR[>__?G#VW=7W[+*A>+559*]N;Y)^X;4E8_8(1.T87<[ M=Y3LEA)A]9CBK4>;X@"YSM'.7=8^C"@>FDW0*C5G1M[J'-ZXOYSXBLEGY].J MFX+P11+78I,^7Y%I$LT#:@/LRM1O30DRS'4S3_&@?2LRT &RHU9=T#/(*[J* MF,D6&D+^8?H03QXV$<*)" -CH"4[%55ORU!93M),N>? &:&4OP4$M6ZH-L[4 M Q@_L%=GI8F"9RW& )YE=[H(4!80;T8!**YT,$?Y M30SM[H!W2]IHT?&2.YT]9-Q0SFZ"+/!;.K 7BU#D?<4>!O:AS7-#;C.1#(XKV#KQ^N0W&,6 M69[O\4%N&KA7'BO4_'A@_^0O$F'RC*]#WP^_4%'F@;O8S)WU]F\'A\3R$QYC ME('B30_FR^<_9LA"GS<9UM)0Y3>^^\;BDY3DXMMEKB 9O\;&M]NX?+1+*B!B M[TK3+S&5$?V1"#GP] V(9?GF%)4#E05!5!(DBH(6&\1FO:E *)>(+CA=]B43 M"J5269@[0C*G:<^T/Y9087[##J'F,FC[$M%7.(*<&ZWKX%%0?*7CAD1!.$,& MBTAV1G-!0W0<@X5!1(:D6 M>+"DZKFU0#*E(KD<61->U070]MB Z%7BP(+JV%D2F5"YI8S6K M:1"-C,#">QU8>#\R6'A?"POOQP8+IP(/!@OOK<&"*95+VEB%A4$T,@(+O^C MPB\C@X5?:F'AE['!PJG @\'"+]9@P93*)6UZ":(;G2"Z&5D0W=0&T1!=%?:X/HKV,+HE.!!PNBOUH+(E,JE[3I)8AN=8+H=F1!=%L; M1+=C"Z)3@0<+HEMK061*Y9(V_917U:JO.K(@^E ;1!_&%D2G @\61!_LU5CM M(8@^]%/:6R>([D861'>U070WMB Z%7BP(+JS5^J[AR"ZZR6(%CI!M!A9$"UJ M@V@QMB Z%7BP(%I8"R)3*I>TZ26(ECI!M!Q9$"UK@V@YMB Z%?@K"")3*HO: M+'L)HK_I!-'?1A9$?ZL-HK^-+8A.!1XLB/YF+8A,J5S2II<@NM<)HON1!=%] M;1#=CRV(3@4>+(CNK061*95+VO021 \Z0?0PLB!ZJ VBA[$%T:G @P71@[4@ M,J5R29M^;G7I!-%J9$&TJ@VBU=B"Z%3@P8)H9>_>5P]!M.HEB#[J!-''D071 MQ]H@^CBV(#H5>+ @^F@MB$RI7-*FER#Z52>(?AU9$/U:&T2_CBV(3@4>+(A^ MM19$IE0N:=-/VH_BG82*9N,(I#/%9,D_0%Y":)+^8^P=!$8)>8Q445(^*S_G M^"BU-(NUM7]PL(MJ$1Z'K1V@^CK#(]:U^* M5R>*0LJ!E:S_XE'G=OG3R6C'(R9"+J8R)-Q8)?N0H)T3')'S@B-&G1=@X3)8 MRT8R]@N(T=W[$Q2?=$;+3R,;+3_5CI:?QC9:G@H\V&CYR5I$F5*YI$T/U;B5 M942CN8_7N[0D]2)LKTKJ\4ZDH^/Z\I&R$<,+*4J7P M_DU0E-RNJC@<35#*T&*1>P?=V&0 MSAP/!"\V_ M&(@R6Q%OCJ<^%IO]T^RR(4D%U!\ MAV2B?.@ (]08Z[X/;IOVL]2J:O*I&DC0@UC4U$#/UG'"[_4GO]2K*(E6^U+JN"#?'/C)E@3 MS.>,_BR,XL5F\9BNKA1//9JA.-YQ1-=V5GVA;BX 8A(P4,UE MR)\'@PV3O9M0#G#L[X#M@[*GK3W!CFN*>>&.3N'S5SZ=]1\'+X%M^F'$-E'Y M7NN!F'U*3'PW[6'K4.+LR=L'YYE:([K':^P]RS%!Q<4&)7R2%Z933BAC M96&W8G 3U'A '\\EXKU#G!A/"9U9/G'LK7X\4=X>,J+IJ'K^L**D,73\TI+= M$&P)[R^FW) CL+/U&F,?FJ<[B0R>,E5%^C:?:NQ17=4OV],\:Q6F,\\475?A M)!MJ3K^-_"XW*W/TZ?G@BF"V\\VS+)?O.P[U)$=@]KG<'=-#/( MZ->[D:5S0*.,0[[,8LO5;*(1A^@1Y].-"?*2IU"B7&ST6_@; M6GY8_H:<3'*TYJ*C(Y<=.;1[*K[%"2NLGZ$\R>6R)=L$V1QW%:)+G,]T)^@F M><;G0;3[,;%[+BI*9$6)L&B*$R?;U]L;H)UN,,KY^42 M!WCCR2?KVCW',G#5JR\=A=3=QC2D:&AA)C@\3A_%S@N-B(1#&AU[Q[.Y_3"8 M!5)&[,^$%:*\4,;,,J[V:(6;LU^>_^038<9@\2SI\A!Y 8ZB6;A[] (>,[,P MB#P7D^1HCAV*;3#;!9[_&&5"D;Z/RDUB"";MRLB[A#$M'82T>,TQ:%Y$\ M\ S2@@ES)!9X\GRKDCDSOH@Q1IRSA:FE!?,4^C)'HMQD5C$(N/S,[I*R=NEX MPM(,DORO8C?[\E@T2:?7TR\.<3\&SU02^AD)V?PZ$VT:)Z\$L^%E%2X)%H:I M!TR>O36NA&[+\D >!"#\5/EP8E,8Z ,3"-MTN23BY,/ M-I.1)5.=),EQFLQCW7D0TZ6>D/S-OC[=6N].#>@ ;,A,LDV@AJ1&L.'35B.S M2PKQQ@;G8W>[9FBC"/OTRW<#&:,"QVV;H]8 ,#?KWW;?!'P['E1M8I"6^^EO M1X"?C=08:$<<_%YW=XO,SG;IQ-L4%$=Q70N/XTB''^,\.;@WWH;U4FF9E?@F-G$ ")6ZO0# MC)&-Q&^]"F-2X4,1@VBUW@W>P=2IO='GU/PL/^)EA_KPZBN@Z00TI+V3S *EM# M#S<]X7L//B8&NEE.42H(XI+P2]T#1V._!FFBYX"3W0=,/!RQK$;7>_;<@^/[ MQYL=_:7HYXXOV5*)I(%O@!Q06#!E*'&BW)86X,ES9Y5:QQ6%%X)V:5"EE>=P MA/;ILM+DM5W)ZCB[#%C2D,@+%#3K#C0>VAKB+%M,HR_T(;2-*MTOAN;)76D> MF(L.@4N_ I3T-81!Y+N,A9G*1S>#[S-:=)!0"HFYNU@Y9[=C"6T;@-A>C"Z/ M'YQ_A&3F.]0:+Y[J"+P9!:#C2 =SZ.TYGG4'/'MJHT4O.Y 12_CA#!'GB#XS MGJT*O/OY:M[ (\/#77%6*AH#MCO=:1N?62=%0 L$;?I MP&DAPH/CWWM/V[C&>96MH3MNM9HEIY4WA>RP-1)WR$AC@)M2/\\"']!->8;$ MSHNB(N%W^D0PSR6N]%BMCL"=5U]YT8_K>P%VZ0;"MR_=&CZSQ!ATA^,O(?G= MKG>[>.>0WZO15](,ON=*%3OQTU(;V%XI%[5#DFM*T*+W\;W^LQE^E2-6]P#N MDQKJBNY9T1RPI^I(W>ELR$X>U>!JV4TRO\?K\"GP_DD7X"ZKV[7QG%SK;%]W M&KBW]&//]V(/1_2[PXY^F#1YC*H>'^B5(7 0Z-_8->GNAK@!AJ !E#9[R%5( MAT3QLBW<3$!>4480$:4R3K*&GS,Y+;V' -CP)Z;\^97 [9P56@K4?:8 MJGJ/Z5#CL<YA!^K M5@8S10V$_5H,,_)1YEB,,86(2(:B=A+@0%B[QC(0QI?BN?D'',<^/U!("KFS MWM+*XP/R_BI&(,V?P/R05,/XJQFC=.W0?=#:5/DS F;W6<:QO M&_#BCO+SU-:9KS<"]":(#84] "T+? MX=/S RL"?!4C8Y,?P_SPJ,/]JQDC&QFC^T"YYNS0!K,1,6"C8HF0B.KK.?+I==A/X)RS(:\^@YR,_3WI00AE*>0##46E+"[*L8 M(E5&-C\+=A[GD#N57L/PS;L,^1J[DDO\K6=X9MWBM=<::K' @ MA)7;YBV7!+-'T>8OK-8UINVYULEW0QQL-I %Z/!FVRS]9CSH"O*U)$(TM@>T M_(A$@?Q.9:H#2I7@'1/@2UJ\@MR)P7ZR$UM&@C'+9G\E \F2A*SHV)'M>,9I M>LJ>35$'^%6K>']% T7M3]#7P*!D_)4,!/7Z P/^3. )/Z"()WF2')<:4&%L M@#])1KELL];[4 "A_/1*#1^U5ELG>!^&[A?/'^+WTY'A*X)V[9^D+XBO%> K M@7I].P"#?$D)E60V&E/A42;]^&?X_?] $DM2['\UMU?$%9+Z_&)@UE\1U-?] M (/L[L YZ;"RF6-YK[[-WHVUC?M1_1AW84R-6% $>WS,2_1["98^P?7"YX4>SY#\?PJQJ$:DYL?CA0,OYI1J4[_[H-3S-]= MS$:E'#E?Y_#4ESG[&*72!58N;,];7\P-^A^K^OH!DM=#3]:DKV2C2_QDN-)8 MRJ56E.;#]+/'#UU0SJX^?0&+ 5W;\('ZQ7K-)5;1T MCHS&<+N/E3)\18BM_9/T?#*A%N K07-].P##]NRL0OB23L13V5$J_/BAOO_? MY]1FW.3T0W+ 1:8IR$VE1$8J-OU9>EX+G;(""M5#&+B'G:,2GZ]GPTBN=O=] M(B<-WGU"^=7N$)FU7R\;0^DOD;I"Q[I335S&V2TCDUGK M]5,.B_\.KV#<,6OK:KM &%66!.^\P^X*;[RUAX/U\1Y'F#SW.\!4,/TJQIHZ MHYL?=E0C?<("N3D/5K^?,7FM U-O1NUCC$J%186T*!5WS.-5 M;S^!OKD@#&/IWN5-0,V.HWZ+%Y_S^BH&+86)>SM[RAA]-4.42F]SIT]>2OJU MCD>F+=CG^5,FY)@''^,>6V.;5Y/L=AL&3RM,Z+#].$0VS_&<#EN M(O>O-L%-:H0Q9+ MNQ&$J=:+1]][DLT>!V7\-2%\I?'[>R=8QO5K0?1JY2'-O[F,J!#R%6!V/\9/ M#)5;\)4@\QW%(MO3<1T9OB*\UOY)^H+N6@&^$A37MP.PJ7DA^."S\X'KW?;_ M$Y7GX[QP%INFG\S<7\EH('PRP(]7YO85(;S$S -< O]*4%NF,3!\%CX.IS[O3CS##LNO;G"[F$=\YKG_&B_YI(7JQND[HK? M,!VHIB<_85DP"+<[0!@V&W[:V@O(JJ1DN!;3@]/^0,>DUJ;0G;27.H]TIBW7 M83#D@3?W-6L0)6+,8,'%U/W'(8K9I(0:8;IC:5'_K,KRKVH/' YJ517#7]D8 M<+C7R]SA#FY.S$[D#J,;/V,(V -].3N+L7GM>.23XQ_PY?$#=J(#X=7=K@G^ MX\ *&4Q?/-4@KM<3>+PV4%^,7(UN@&.XB?1M/5X@C'+*Z#.C??:$B0UWERE^ M%>X<3S4HZ?4C?]!'-:$YV;H_$$IXK&6$*B MB4EJ!P 5@3$$2",]^HD30/.AFV!_B",.$&_UID'2'F.) K6Z4I\_;SX&#Z^0 MNOW5?DH,O07FL>\:>^R[,7OLNV8>^VZ4'GLJ=3>/?6&(_.)>T\ Y M%D/HG/(H"L5,D#!=*AA9R(084OWL1[99)T>8"W,(7E&.%?L$%NHN)8 MJFH+>""M%=G$ABZGC!AI^RM]F<*5R_K*#B-T7O6"7=UZ9 [R?&C7R]DL#('+[>&%5>K^X](M?74*+UR1PE?<%HY_E_B%#J@()A_H+) MVDMO>S>* GG/D;E_A?I5?B_I-B*'KY*^K:=G-!$G"LK!TWH%F.P:^K>DX^C< M6Z5\M7>?]AJ5$.2M.B:\]\)XH6FW0#9T'NO:=M7+%=4M4>N"/7 MJBKZK[(Q8+>ME[G#"YY1Q'9SLXV^D"!.7;%K,DQ2-QQ];0=LY391=8\Q!JUZ MHZBB^=@"U]!6484K*W:++ :O-9T['*'2R>DS77\M?6?-9PPIST@Z,=3K 30F M&ZB;GYE6-X=^7*HI??LDVSU[&Y<21%[ [\GS6T1[3&+JI.R*7QRB?2(#VF=" M9$>J0Y^C]FR,E#S*Z6?1:[,>6R;"-' Y@$2+0QS%3N#R3.OR*D$!= U) (W] M+@81!^@F_0&/V*W4Z'BZ'O%DRX0=$OA-T-EQD)TAW8I1)F@G:._)M+>S::7>-.$L-86>!@[?E>4JE"=K<%H*<_?%"S@"]6KB MNBSQSHP 8UJ_^G;/.B_CW!%WQ1#K$Q9L(SZ%QLKU@95), M:!ZX57@)T^!SCM?HT:']SW?=#5KG(79(/#[[7.9EHQ0F&L%PHS#0>[KJ8%5' M;H*U?W#9D]9SAS!5:R_9#<#_E0Y+K7\*$T-58^:O,'^RQ[-R"NY\#J$#W&X_AW"QD1NT+*%SNQ9 M-N>9 >D8'/,?8[%)JE?-7V(<1*PL_JUW5IAT<.9CP?Q!?@0IX/?*>0QH/XP! M3$"] -)G 'Z.^F>@+P#[!.5RLU..HJ[J+-SM"=XR#9YQ]OGG0BS'1/7^!4'2H9 MH L<N1PH%X3/-A)1>"'( M2?;VK*736NM&3![P*'A&/Z/WI&5)]T%0S#Q^O6KD,HQ9KQ.M[./4T #UE\1D M 7ZB$Y[*W52;EKO%$<6C3((#!:J<'V" VE#8[P&E=,B.&ZJT#=< KVIICA>T M]%7K$[D<)L9()U@#F%"8665O#('#LR4)66[4<4EUC-F+07\:V[Y MZ_4$CDH-U!>!1Z,;8&QI(OW_U][7]D:.(VE^/^#^ S$X7%4#6;-74],+[-SA M )?MZC'&Y4S8[FXT&HOJ.H^@Z*9Z?=IWLKU>^M#J#7@$:W)0YY M@Q4$.H:\^R("MX3*N(M#_V9_2.(74=>P\Z)==P_@@UQ#W>K@[F@.>%#K2#U^ M^25IHRIQ]/[RS0O)WQ#_F5^T.WDW9LX3NV,2!=DQ(=2COP3?V']UC^G.#L"' M=+^RM=,L96O UI#Z-&G1CEI]#_Q_O"_44[>Z5;"_G"DBY!B+NHJVIM!OTW5([6!6U3L64_U3:J]X(](+L"?__M_F_D.E2432+*E SJ< M*7*GOV+%:N/^N:*K/5!7U5:U.E\H&P.>,?IE'CMB<\KH?84VRU.DBU^/M+SP M..,(_HGL KIPZ([.3QH!'ZOM2E4':+T%X%&I$'1T03E)SN&(6].)*[G$AR## M8?!?Q%?N '4.R>%4@(_9D6:I#NJ!) "/^K&:C'4+S@]5&**<(^(L^6W4,N+_ M5;!U5$W"B7$@'@O'&T#HK..D-&!Q&*#&^3H-@ MM6J#@14[.UZAI[>\IK;DZO(TX8\UIBCQWE.?$5RLDC01\)!FZF.:LJ5U^U-[ACQ\Y=UMN'C&#_ M[8IXM .YB1YV=.W'RWJV[9+T=P'J@4,4+C;S>MI#W]73%7]TXC>ES[*14LX! M^8(%VRI(&1-6'\DC,V_CS:6SX("N2ITYD_:"N'8A",ZW-EF[C5#ST+']3)A6 ML??;;?Q*DL<=CM8'PK:-E1"EW1,R4@U3OZSIIM4-.FX-U&)TN%RP$0.;W1\. M&2>4458H%KRE!20O9Y@&O9ZDW94W^ W?E5:4G6X,W&QCY,L^"]N M>G8!/9.9F#P14Y7*WML)J+<.4[JZ/]'= _ .A:;@HQ?L%?*B#D!62^4U7.M% M_RK>C'J[3.BD.)D1GD/=5/'+D2<&5N1D[SU$:=^N_$22P#W?A,%J::,3Z %& M#2-JC4X]YV[; 8^+HCW[+' M5Q*^D*]T";A3EC:=2O2L0$MEM/%XU:1X-E"E5&Q>E.)AV#J:>4<5B,DH4'Q: M#""Q+_7X&ANQ9$GKK."G8:+QJ",)G0W8-/5Q@#&4_1(PQI2EJ,O_=5G00ODK MGQ 93>W\X*5JIHD PTB=%\34-'(!,DR Q<",$6M1 /A^44#SA=K>F TEL;.# MF:J1IJ$,HW16(%-3R '&,/Y+@1@CMJ*>_^_F$"9-L@JZT'\UD87^Z9_W5-*V M.FW-WX#Z?:L*S(UK/P#TRG;Y1E_>9?DJ:<:OG%8N-7Z"/+1,W0Q7#2[C="'XH80T0$QYESA^>W2,&Q4G0<"9YHO44E5\39(LG7P86' M^6USUSL\Y@'-+W@?A&^R6-:&I7@%'DE9R?6?=_&^H?Q%0L:AZG@N"X7=B6;5 MP>61+!8,W%,U-H[L6RY0443OD(LDWEQXI4*=>C>[LPEN G!EV9X90HB%\E)^ MA6"(28:8:*>3")4.YD3BRL9WIH:KW0GI@1QP@C.27W&Z>$Z(*%K-3'2-O5UN MLWL2LO3AQ]A(X&^#[\(F+6NF[YK&C#-=X,1FSP:&IKI4"LAP@4N(<"&B0 U" MA2R0!"5"3'91<@GK'WCV;YT0?68.['G)D?IPP+TTS5 D7GU[P>%1W%+#$-Y\$RN$R+^-<50W3O*;VASNEBE\VTZ.FBWA8.78WKN"GVV M;="Z09QS0(P%C U=HTK?5+^TRYV7VP _!6&0O5$H_C$ZX,"_#'&P9TM1^1_^ M?Q[3C'F)O)ER$_&%H__YF%&XI2.8+A]I+/CY[EYVV,='Y8:-179 87,N0]<> MC[;$"W#895WEL9Y>",:C,2$:$ASXJRKR/TOQREIKN83HZ9BQ(RZ4"XG>,S&_ MDWUYJ;:CI8VK W]VXCKJ+ 4)UOC2N$*F%:)JL,UOBX]["',]9#C)SL%@G\ES M$/%"P7;-UKN( &LP1G"1T[?\N;M4J4'R9SL]MQO2S'12LXO"GKVE,SY<_67>+TB,/L[29*CPG; M]/F1E4-\30)F='F@QF[8]QE4\65F%0 X<,[_,6KO;<_&'3#X.C#"Z/A2GCGS M6APZL.P&>A=HT?;H?#FHO*'B)^XP>0C[\T;DP1_"(!YK\SY?-!YN@M%/Y#!. M9X[$#<#%%+IO+ M_.D6?&0B%L98%'")/V]H2^,[F:VDSPZ^U :E?:8@UZJB6Z K[NLX?)8) MC$G!; ).L4BQ5C>X %51/V.H:S&C*:2KD#Y3H&O3T#7.E?MTCC+XH1@4T!;; M!K_QN@G4(N+J K^ZF6J?5@SI#QRK!INBBD;:G0'CS7 =W"**FVVN^:PDMK/: M-)TS$(JC9PJL^RORE#U2;BW/(?0T!>[V70K6XHV6=H"=N5/.%#=.ZDET#5;1KUDZLE^4F+.E4_N5J4G[1):]U/KASYB4EEN1YF_>2Z MUT^NE^0G+>I4_>1Z47[2)JUU/[EVY"5Z.%PFL"CP)DJSA'_B+]@CG3>\ M.YH#=3==1:N+!55;P,N%7I''#E!&&)645XC1MGDGN7?#VJZJ6Z8>;E7/F5M> MXB1YH\ WP#5/NBS*/=L55KMHO?UBW%0AMJFU_0^)K;)06G4#K.I*>;-(X#,. M65*XR]O^5M4LK^C;U'0@Y!K6D<-N?,S2#/./ZO+@+XD]0OST"\6FFS0],HNO MMTQ U;E'5P?@D-NO;.TL3]D:,-QJ"#W^N%J01LRH*"?.*FDP\F[B3:W<9IYGJB+&[!W04ZE>W+:6@I3ED M'-*0>GPVM*"=0T^)19R^,Q>UJ#)7,\C5].)Q98(5.XWU6*=1#'E=ABEMFT,# M^@)URU$F*/8M=3M"W]$YWMX3^L.1/%(*Z2X. M6U\E'$H .M0--D8-[[1[+P'TABLS.H]O1Y#884&4)W]]+!$\4)8S80T$\'E2 MKO)1LQ5:4>= [S8??_G^Z\=/5^]H]UJYY20OI[G%'D?8."+HC>!DA;;!"T'[ M.,IVZ8JG5F:[@#8E%&7QV]P5F.;Y'DB0JFCG!V/J-( MW5]W= 3D@Y!2/M(12'EC]K)0ML,1BA-$?C_BD!U _H^/?_G^S_\+[8,P'/F\ MCE;\F1OA,MX?PH#%NU^#*-@?]]((_9.4!@7H #W<'(J(M*_[$B!ZA#9C_4*2 M*WP"IR4BEZ%H"(8C3\-2Z74[.1 M +5FBW'B2J?-@=>[1,C\DW@:_'P,_ MR-XF&*-*XPQ@\<0D0X&Q(' FT'BJS]3A'N84%P^/YFS37,5WX6/!%2Y"6APT M8'),J@^@/&2LL@:-BCWF<<^J:XZ#" %T_'&4&>C=/4&?$@Q0@EC 53M1: 5 M$@Q1R1%"VH-5B]2>##(8.K&+DC?1)4YW?4^7*5L"]5P-]8I@I[T9])"F1VHC M0PWQ6\9!A#S*9N:PQ))^&ZD1(^S\J3'+.K*O5IP1K%CXJ0#,21"29 $.A2;_ M""*_'TFZ.\ &% UE*[C2T1H^O.@(;PIE.*_PK<";WRC#V?'&IL*2.LI=DS$ M #\SJ-SXJM;Q2)G\Q1.>6\W0VP4T)NDI7*)2=WOPN*0I_I231SEO;L/X%?G' MA%\J*P\D>7XC]NGZG(I(7?HI3I+XE39B-](0?GY.R#-#-;;3\V=66C<\^B1% MSTR\1I9DNHN33"3ELX/&L$C1YWUGQC_+ANU.B;5X':$' RVK_4/+9V]+CIV\ MBM.+O189=&E&6\L,LV:)KQQ&599B"U!AE%4=9XF:3E20&;J/=#;2T[G>85F MTJ)L!ZY46B\/7MJ$GY@90Z?PU@B?_O5-;.#27S;1+]'7Z.HQ^CO]GX=W2%S= M7_%J=N0;WA]"LCJ#?"W+!J_ 7F5;7+) C <(_#.I\TUC-*&L14LCT'=W9$4; MUMO\$!-IF\KZ72&#ST #%$BD MV0\Z+ U5PPQ&I3N$SZE^=7-+!%CL7V*;:V8@F\M$I9^7G,I$ M=W15&J3]/04C5NBX(.G(&&*LG(X4APE(/^,DP12'+R+_/GC>96GE E7+JG1 M-Z!(.53Q:HI17Q_ B47:HH\=Y3D#OC84+*KW!%<.EDVSZ<[JJGO\'2QVJD = M_55R='7Q>ZZO/7J5: B]+D.OV[BV8&ZX@)>5X9L):<'5(7H]L'!PDP1>\Q2QM0%P3#E5IO9J??$K M8$]O$7+LD..D$*?EZ%5WT[HKNAR/!,_(:R,1^MVLD5>0+UR%A,7 M&TBV&$'?<;*N]X0C0\F6[[4*QBAEG%XIOR5!^P5-(^"HN MB(I_'JA6/ WKD,2L"/C;=[S%$Q6:5 I\RQ"GR"E.P"_ML MQR<4-D)']C_\+W(R?BLW1&;>%@/['7/!JD4BI&RH%&Y5N:3#BD=( =&#^-Y4 M1E05$E$I$1,3Y7(Z.&0 :_).U[EINLZ)$[@,)YF,Y6:F7]W$Y'.X:KVKU1'H M1#=<^5I8VML+9A>C+$ M$>:"L.WL&.V%(,@7DLPOG*)TDVP%/<+H%GI*/A0NX@E" MJ:(M(>AU%W@[MAWDLZIU&=KCC*_XG=9=,J5SL[@2HXLH8>?UDTPI* /$XFLV M/N)K8$5D2M/,DY7\(G2)>"*GS&6#CJFV2(/*" R^U-OXB MIR$'8V\NLUL-3+//;U_E%L7%$UT-8$_E;KV=@#N?GM)55^SN =@Q-04?.Y:; M3W9_"5*/#NQ?"$Y0S@S]FK/[?VYF3\LV*/P9B!M+!0-^IEE 5R'E3<2^#GM\ M2!45CR:V(+[ MM3"6!E"DF&22(H=A* 'H:0VC]9D"2J@H5ZZH ?KT5J3F("PYSYS2X,8P1:PD MWGRX:18K_OSF?@_'C7DV-_^8#1ISX>_)'@?L'M]Z*W;16"0XW!I]Y)8+F%J& MTL3.3EK+AE$]U:9??JD_!:' 5@&L%&L"]C*Y%(CUEOD(:"LVC%F=9%"8:]>* MS:5J>['X GSOJY:K;+&#@V*[5J.HC#Z@M9?%K'+/QQ5;U_Z%73BZ(AZ_<8,^ MR3_.#MY,OW74FL<_E,#R ;IAC(&0+'N?!P@WE7$ NQ'Y5H-9M(W#D+\&M!@0 M-F7%@;#+MPTI7[ P:\HN%%CY)N$G)[CY^!I/,X$@EO$P&TI;!F".1\CP0 M$W5CJ+IEG*86M2FMF534W77)B*N32-31 M;^FH:CUY2(VCBTD:LFDW/1P%DB5DTQ!-G+28*J120R-)J+OKTG&P+S&HH]\Y MX*#59" U#BXH"#7L3?3I[G@4B MVDWN46/B)IZ?OTF&Q-W&GJ^,Y@*+= M9!TU)BXH2<>JZ09@(H"L'*NF:$%$6ZDY;7J,T7WA"#@8^9:.>#,A'3"PF@>D M'&?96%%\CF-EGKZ3%S8>GE_3WWTI"*5IB%:PZNF[)-S25<503@WW,%34#@>6 M5#.+,4IDD]6^8 O4G)-(,H+1(*QZ?3Z)-9+$ Z2JAIH.9" M,FIFM%PS0[N!K#GS%=12/3.:2IB&AYJ%?9RFUK3JKIE;T]-WT0"LDUW3U7'Q M(&L]OZ8#5A>38&/5OHL'QKYTFZZ.9P&, M5A-N.H!Q01DW5FTW#!K=9]U8-882&FTEWZBUTV]?'CLS;_I[GH>$&DW M Z<#))>3@F/9> -1$D :CF6#*)'25C:.4A^==)R^SHO'R=Z$G,Z>9X&2=E-R M.D!R03DY=HTW#"0!Y.78-8<2(FVEY[2J,\H&2X?$X5"X> B<"_J@H==.[NT0-;HR#N-HX!V_!V]'_&-(UMN'79QDA0GP4]A<$FMV 0IF0Q2NOOO7 MU1[P.X!:8H\=RCEQ!F"* MM=';UA#RL.V4=_1XK8]1.N]0RNA71AO40+V*V>&]KFF*UDL;K'4U.X>K:+JD M =N0V/"0%=1=#MK;(**3RF5"_"#[RG,]%)9I;0A\J*J5JST%?-(*\ #M$';2 MV!3YN=L@PI''-E_PS5]3KN4:GL*M6=$"H9: M-U&:)7SCD@&DPD2M#8%[O5JYJF^?M@+LP1W"CAV/?.(J::[XE:!YSW1L:Q<4 M-'EPZ=#?V&)KO;U($JH-#VH[MI!4;8%[7:>*5<=K;0C8][KE'7W--@XIGSC! M6?!"4(4ZPI%?^_*/78FEG:N MZX=3 >X)(\U2]9&!) ![SUA-7/K5A$TQQ4G_(_YV3SP2O+"SC(M\9^/G(-L] MD)!V?[[^_4@CPK_'H4\GR_5V\^DV]%J]Q@ YH.YCRE!%WL $6M S"DRH-M;# M[LF!ZL2/FX-H&R=[+B4ZD"2C7L,6.%F,J("HE! 5(J+W?WJ\O_C3=^B5RHI2 M(2PB7%JT$^*RU>/F$[J]O9PY7\&E594&XX:2_)$0 /V]:2BG2\DM2>@2FBIP MD:8D2X6,7TFVB_V;Z(6D&0=_9>ROW1TH;HTU1'TQJM<7\$0_6(7Q2SO!B&., M8+7*'4-P0Q5VKE:T,QFCI,6R69V#P?5V2SP61-U$7KPG#%!Q1B[C* NB(P6P M-9TE^'2A@H-!!( #PG!C5"%!OS=@4!BAQ%A/*%@AP4N$()0;FU;IQPK"@'-: MH0VA&D8GM:WF008G%LFH*2C5DVLM,R+#CU%"/\-S%/P71\7/)"+;0!D5J%L# M]_D>-:L.KF@*V)O[)!X[4*MTN=OFE-VXJ#TU/;%&XOYX2.*7(*6.;G";0>8! MK[=4[ ?\0N$DO2;!%J]H&\'#%-B]!)U1]@J M7Y)CBT]YKX#])QO2J6"-$LE[YN7[/%;8E#HSJ)*,4,ZI""\H+PVAXYBN^%,0+)$\&E#&BQG+ MH3LS;MG6.J>/ZF[+;PY)'@Z0:C:MU=_9(#)=IUFPIRLL?Q-GE%F PR_'[)@0 M]5)G0#?("#5 \0*E-/I 1ZHA*DQ!*UQ<["0Y1W3(6:(MY\EGW2?)=6;LFL,. M!0]4,$&"B\/%H@/M.[^[].G;IBF\& MM_C>8WFP65SK0&'.$,0IKT'U52>Y!0L'2&5=Z?N+\H-".HV^(\WG)'J: @4J M'04[3Y1I.\!;RYWB&CTIIH09+/V$PZ-(7+E@Y7XP-3R0HV*CFC/TQ9SL9*=, MB??GY_CEWWP2<'_\_:_L/S^(_^1.2/_YSUORC,-K&J9D;RTYSNTM@+I)!(-?XSH0DF=5=O9&NA8TE2S6+JHFT)?M6A(;B"C-:-K M%W56*Y M\%U41^V&JW9U68;+:FE@-1D]']6%)$B*@H0L3OS7JEF$QA=*C=&O@I'3VV.O M./%[RFDUVP!U\4Z5:O>ZJ@T QG;=D=K0\##NUO>\=%A3E7&/2XGGN-3 M&O@!3MX>,"^CRO3LJB3:T1[X*.U5M8;CJL: 1VN_S*,KBV%9!9=1!! ME>JQ M:6.]K=S8[XY]=#I"'\;:RM?&<$1H:>3R0ZHP; ME(V!C^5N):OCM[TEX#';(_#H''=!%A5T3=[3:8B\.2;I$4?98\QF%B\)#CRX M+RJ@JC=&1U,".EX-F*>\VC.*#/1-U8E:6=UH/4B?.>3"H8.4COV:5N2KE/=% M[S>/2)_X4Z M)MMS.(HQN=Y>XX1]\'0C-ZT_O[43Z-K7M^#!6; M@Q?';!(1K"CY^<9CGQW#ZJ_Q8O63A)IEX M-K53H78JU,9*M9VY] 8GZ^0A8Q>G6*HWR2=V+<-U=%Z4B_<90>WJJIZ+ M!8RY/N6$X@0)7OQ> 6$WK04D0("!&4PAX>! 3?'"6("! 0&!ZV.69CCR:80_ M #CKO1;E^$JU^R;W2I?%N+I:X4'!,>VJ7A]@H_5BL]Y&LEDNDG3(_&O M^ ON%,F"V)=ACO?[,4B#KN*20_H#=_?!IJ@=4>IV!@P!PW48?6#)#RH%*R1X M(<$LQX45JC)T@PSSV6-#9=_1_T)TF*:!+\M50H6%._+*?QJ%"=7.2P:$$R-H MHT'1[^-(I*(OM3G%&5[ME]AM9J2OU=@#KQ$(7+^T'=[:&?8^N*/Z4*2<0)LVRC%TX:)9PV M.[46(W;NFS^6=1;T\T7+7:&]8(($%P?51VSK?=?WG5U')_)E$_$*P%V<$;%^ M.X1!=AE'+_0GZB7WS%<^=B'[,#) P6ZJ84YBEP$TH$1L5ZADC#AGAY'-G.:Y_D97.=$S04F;TA,"F\_'-(A(FE)0? HB/C^* M>$K$;;=4HQ\/(FYKP])AW8%BP%A#%,'/@+[0 Z$QJDPLX4U)H2S8$_2Z(WGL MGD?SF#\K]22%HHO\0BI$FZ$HSA!F%9-8<:$8/;&"NCY+C*.KH)2Z)SL*R5C2 MN-A'G#G FM.6.2]485;L%,ME(F.(?CS(=:*#R&M.@S!BQX,<7Q!.@'CM"OVL MCM/F0-%35]'6PYY&6\ 14:_(TT\Y..45G+0-TYIR>L#2,[A, TYD6]HORB]U M3V&;C1?CF78.(*5KPCER-:ZK<$X81ZMBAX9)U.^9JK; O;)3Q:I'MC8$[(W= M\D[<2V1D 7BA51V/E"P0/^PM\Z&J\B'V1&ZB-$OX7TKN8 M7S4BOM@L56VSS,@?.%[,_BD&5;WE"U M7?Z.&)>X>,"X(C3B4J.,BHVDW"M42)X?[UB!8[&$OX[\SAW9Q7R>:X[JZ F' MULI\"XL]9#C)SL-FG\ES$$6VS?9"DJ>X9^-_,28K3R&//+(_2O)+#">JFX0W M4>MIA"T>YQH6=)G4R-3?QN "S\:ZH;\@&A MS6__FM3TS'.&,]E9'V[8_[+U<)U@8*-P?,F(8:R/X88/0K#Q0<1H].%S\ MSOV%I=W_.--9$36 V,S]UUYM[T>9>:GZKYW6#D/ GT=.&_XP M/RTV3;774A>^S\L>XO J2+TP3H^L'*(\'IW]N_5)\X<%>JW/- _N=XKRAYP& M]"P"?U8H]4 51W^O=D?2$3GCO B\B_\/9T[V!X,>QSW^AN;T$CK3>6A?8$/\T$FJ YWK8Z MA_TP^[5782<.O';XSXIH<*6VIV!.\,P M(]2>'=?J"=@=!BI@;>TD&;E9 LUDA-HV'VE7^!RVITI*HE/S)&3NA:B&/, ! MROFGFF7_JD\8P##JWB;S[6I=?_/"([_+)F3HV.>ZV,?'Z&0O9N'[6M8_R8]1 M4C!C3WZ G#386S]"X<[E4E?[I8"N2M564&PV7@)H*66>5(U(8$HLG,+E6P.6AO"GBH]DD\^H6#DBZ8\3KZ,%W./Y6:[!:O M3O4Q ^XM=HUL)+FFDQ-@7[6LL,.$FR)YL2+BLB\KV35Y>;%+\NEZNF)NA'WJ M-]>3PER-6M7KK9B3NCZ.%6Y+P%A[9CX!6?.LH*.L18TAP&S''5''Q8@ &KXZ M)[&SIBB./N36(Y&H',#+!:3NRPPMS'Q/156A#B,N:(7 RU.D^8VU'Y(X[9R[ MC'-:PKQEQ[PF%P8M;*#/5Y:TA3!7"?FJ=7&XC(M[J,6BN3E-TCD3+6@1\--\ M*P %JR7 J"4#FXS]V_A !U);ZD) TI_F#/GUME:@F;M2# P(D)K9?&J44;O^ M1A(O2,DF"3Q>0WP[UUZVOB!+ &$G'\?2'KBF%- !W(TQ(,![1?R6VI&Y"HCK ML-QR .Z^58])#;[W-=4XJKK0-=,T/LRLC(%B^_S&+YXLFX4K]#?/YC7"9!S( M+TH>.*+2<+KN'*HNJ:9T.VCP=$-VXD0!HF./P_'K5@NF M,+=ZS1$"87ZIK&?)*I>K=+7KQ?L]Q7ZQ,*6@3W*TIK_ER]]L1ZG));%_3'@Q MH1V1%>2@K6 !?26C,ZW&RT(N9]K%?1S3+P99V@6^C".^PW_$X6VP)8IRX)99 M+7KVG&9@8WN["CZ+GQ4GJCWZ\D2,?+(-1-T\.@WB@$H=$FBSD2/KF-Q!K&/#]+P0GXY)2+,TRG<9 M:M+',39_C9+BW&>W:48QMOHKB[QZ%:RA0+KG!Y%RZ7:($[&>JRSMXL81A'=, M$JIC6"P$V:2** V/G8C0_O2?*[8(>;>)?HF^1E>/T=_I_SR\0_RB>+;B#,DW MO#^PAN\V'W_Y_NO'3U?OJ(P'=CK*5CQL\4C_2<5A)Z546BY11- ;Q45*@15_ MHXO2;$=G'R94M@MH4T(#=?R6+FR&=S-"+*3NWW0L/-OG.J;) B,$-U],[OJZ M/M>;D,JK3N92&>TOEI**QTD"-(0 \'E,7B<8(0;T%J<8A=8/866"V2JQLD&M5L'5DF MSSYM1@7R;F$E<<']]D@31?4V0?I[ 00T MP$ E=S?XXMQ4>;!!MELB+HSXC#N[*B+BCY]DX $-D]9;E9F&17,=5):(0?UF MT5C#J$@L#7,T-)EI'>-TI].9;8:L9";L)F:ELCZ!='.V4>.Q[OZU2U8DF2R;L468P.G#MZE>QGOA)I M17=!%.543;I7$KS@C&CXEZ(A: ?K4J[TL+96X%VL4VC[/B;8.W,R*]I+JI/< MS%"P?!%E01["/Q#OF 190-+K;UYX](G_A0YQEOE_%.-CO6UN<%SP,F>*0,(4 M;:">;\6$U7#;"&' 0;A9_<8Z8U4*5(J!Q[=:/Z#'A/W2&T@*"8YAV+HS1SX6E+Q^D0O<]"> M)ED%UNF_FI!.__3/!^;/3( ?2/R3=W39GPI!]"LC>7* ;'MF9E.MI#'99^*Q;A4-80Z+GOE M-3,N!='I(Y/&Y']^CE_^+JJJK\7P $[0OBQ8UJP8-51)!/$N:QXS2JV49!S#/J*LT?JL>/L<4=05&0B% ^- MQ"AAY&G,0?_J8O5I25V9=+'>YH67T&.,.&D'!5+MZMCR.8$%"?=BB+64,-?O M!12/!JK=%QM4NBPL,&B3W'A4()DXK&AI6_7K;QF)4G9*DLD(R/1N= E&51VZ M8:O1$J@O:JC7$AM4FRTG-FB5VE1LD'N=VWC J(K5>* &*@8]ZR;R$D;R)KIG M:8[K[8\IN:!PD35WG/M;0_:P?C4++U,WA>YI&I*/SD(0[P523PLD$_:\0\+8 ML#\>Z;\QYX1P$J1LH/)3=.Z,"#\G1#SL-K-?6C3(3<4,][D9*'DDZ#L(V.=2 M=OVCT-%AO)[+O(>QO@IR ,LC=%0#2D/U!4&VV*:C2OW1EP7#] M\#[G]1USB,;8BG%%U57C!@GX":3Q*"HZCJ1Z[* X@/FK91XO,HIQ4WS!J M%^ZGL1@''Z"*,??O>'1&N)*US;G!^#"#>3I>!@R+DSWT_FWT^Z-SX M[L8&M M2>]Q1C:$?A7E/8\19):,+QV&T<:7%AI+Q9SA2\X5,;8K)!F#1!@;!CI! M&#^W!Y7#Y76)MJ.08D4D7XA)!>;Z;$?W"Y4;A^PEY@%G*]H$@7^.)UBNIG FH-,PR!DLD MB3. D*8FLR('90P;.4Q9ASKR7Y<"&)1S,SUK"IUS HVJ:4;#!B-R+L!1TV5> MZ&"L%P >1BQ$W?K[A<#'%VIO W:39,X(/*J&&8L=C,:90$=-E5F1@W&&#QQ& M[$/]^=\-)IQVRO\8?R;,RA=;:@<%$HRG A0()IJE2%P=3@)Z0NL$C:8GNH:< M^;L4':/\](+X*'X*@V=1$FH;)_*\]"#54X_S8M4,!6W080C+V#4XC3@2OGTYYFS=!U\Y:&8+SZ@ M(^1W9:3''4D(UWP!8>/$V1+N[##6$&/"PS,("V>&!CQM)8,$'TFTD8+%:&E0D>O/C9QI,H<">YVR[32R)7XHY'% MJJW^AFY8$$M.\[2=91SV72-:[*6A 5>$EG;O9T M+>O-KNQ6KN:M\LT@L)Y<5%)E>7]RBVHC=ZADL9&GD/;2O-DWB?RBT6&X(?5Q M1)_V8A%GA(H6L6F%'JJ;MX5$*!<)_5H*A:ZCXYZ3C V49!U6+'C]&E'$VP4' M1>'JYN] 74RI2EX(N/8CP$&NEG'T*,VIN:E"7;!7UIX^;;&$P=5>9[KQ,_0! M9JBF=&6(F2HH/3Y,^1I$<4(Q.-^:*(23%Z7P,_G\=D>_,JNL&H=4@&?11#'= M3*$'=" ;,U4U\AA-#*"3F--I=!VQ&M%BGVV%2E\K94!/;ZC1031SLS1R:K4/ M52L$4@*Z?HH+NQUJ=HOJ=HM;[38A=^:>^(3L,0WOZAKGQF'/EV1O7W"0\.V; M>QHKXO28\)!1^;J]6?B&-9R2ME'7.3H).1#A0W"!1^> MW4)E02]\'Q.G[ _L33>1%<.\T^3Z32Y_C.GQP Q M?"E&FTC#.JI'AW0/SYK65'8!0!H-/,>&/4 M#N"U>P,.=TQ03?4+JW[IWH==C4:.^55WU,*\U7\RX M;I?:U$!>%2-YPE:(]2.@DZ@!'=:&S%19)XPE!7]M,%FS\<%4\2AI$&WC9"]R\^FZ/),ES>3[ M(H5\/.;/)63_V'$9T8%*P+/U:0>_E'/V:-^A*1M6$AP18XD*0="5,%&%/_I5 M2& 2GO*2^J76Z3U)CV'&X_6:J&UF'-8=,@"-,,3)@Q$:?:%#S!A5S#PM48&' ME"()XYGRXO=*4''T^L0KYK6'UC"!LQ:Y\+SD MB,.+[!(GR1O](]_RT(MYE7V!XN@H$W2L5-H[+F?-TB._L66XY./HGO0L.E_X M/D^]85"K:,7?"S:H?=9#\EH[BLY<^E_3_RCQV/8MN_M,F*A MR"JNVC^0+ O%,0P?L!>OF!V3/,;K;$>2#4Z45W2&T@ *A)-,4HMDAA" '-&, MTF-T9%-P0R6[E;RJAR1'-O%SGH@S=13US&H7OBGD(R_$P1ZE!4,YK1@,?J780^_5V@ASX#-)@2^E0RMUAJ"+_H M+N<\MGZ7K&8.=V;0?5/36USPS[F@@HV#;9O9=5=]GN17UH5OL5- Z= MJ%'B3?$3>%PYE=3JH=/F$[K[:6[\,*TE>O^G?_Q\ M\:?O9O9$NV:A&CD]2L!1>A'Y_*8BFYY)\,*R$N])R#8SV-HB(.HT/\W.0/U[ MG!'JIPDZ/2$OOH'@?GQT#0PK%(Y"U0\ M,"Q(+!XG3S69 S!IC)3S=74^.Z]Q+OP7AB,^NCJR13Z[\4A1#CR""#&; MQT"3;*HD>1;8TFVPX4#33F_QJ-.CUCP0)(1 +2>PKEY*=6J\_!Z:2)PIH>K@ M&JKD3NP7ZHY::[RN]L!!IE?5*H(H&P.&AWZ9Q^_5<,JBWOPM74=9T++JZ&T, M&6MZE:PDM2M:0L>8?L&GY'%Y\CY'+9<]9\A3FGE.)I$\9\]?MZ7[34U)D7B: M$W>0O36OHIM/2EUGW!;A][#KRTI66*BS&GU?'Z!8-4CEZA9)9P? VR1ZHT M,T4[H'[8JUH1+K0U@AXI=,IL-86,:9,6C1REG;HQ56&/ ^/@$&5RU2XB7^C6OT;IZ0(<,W04KD)#5WO M"* E]N1)DN5U"O+N%R/S:!RKU9S1:XLG"JXG1T M>ZZ>W&,'I\[,9Y[2K] PXB]#Z,T_0[D9?I[2@APHX/ZP]JR!5= M\3CN26[&A#V&7)M\ZO=%,K=('6];YO1U .JP^LH6.PV=K:'O->@);W"W@>2, MD"^N Y3/&+$,JM:[ 78W(.R:H)A["_+=5[9FV(&82>'R2[^G4#73MF>Q]E$" MDUXWR/ T0/'N[=!Z'^A0-42%B:6TV#4NO*5>A-(#\8)M0 ;Z)?H:W3U&/V=_L_#.R0.;5?L?VECO#^PAN\V M'W_Y_NO'3U?O&!CF)[PU;-QBC\'[NR%L91&)Q"-UOD&ZT5O=?)')KJ#,>Q27I M3E;:63)& KPSC*\>% [?A=\%)P^)ICMWUW1&7ZX,>J= MEPNA+4;0!,]*SV7#9ILBTT=T^5!0&?EF@A,/*D7,6P-0/OS1_IAF-+SP6 7E MK" G?J/8F0G?RS%T2_A+@!!"5"L&U4)/R1 QCN!@T\[PJ@XE\[N3[$7D_8&Y MDY2^=WM2W0,R-NJIV]R@5#2'CH*:TH\>FW)$RE6_ 7@34N80]X?: [#\K7(P M+>D7&.IZ,W6>X0DMH2M_F^Z!%1OG%U\N<1@2__/;-?9V];:*LS,3=(%BM7'3 M]29]#2$*^!#9G&X6XK?R3*N4! E1T-,;8L*<] *4'#:K&7,[T!GR0-7;T3]6 M3?%__JT4^Y;^%_UC_B=)XO_^?U!+ P04 " "F,&Y5\RKX:G!_ #EW D M%0 '!I:6DM,C R,C Y,S!?<')E+GAM;.R]:W/C.+8E^OU&W/^@6_/A]HDX MV>5'.A\=I^^$+-M9GG9:.K8S:WJ^9- D)*&+(M5\.*WZ]1?@0R)%XD6"XB;D MF#/53IL N?9:>&UL;/S7_WQ=N:,7%(38]_[^R^E?3WX9(<_V'>PM_OY+'+ZS M0AOC7_[G__=__U__]?^\>_>_+Q_N1HYOQROD12,[0%:$G-%/'"U'3_YZ;7FC MKR@(L.N.+@/L+-!H='KR5U+I7\]'[]YE=5Q:(2GC>Z.DLK._GF[_,LGJ\[V_ MC4Y/?ST]__7LY.QL=/&W\[._G9R,QE^W3WXE'SC'XD==[/WQ-_J?9_+2$8'J MA7][#?'??UE&T?IOO_[Z\^?/O_X\_ZL?+$CYD]-?__?7NT=[B5;6.^R%D>79 MZ)<1>?YO8?++.]^VHL1.A>*OSX&;5W#^Z_9=S"?HO][EC[VCOWIW>O;N_/2O MKZ'S2_:)],\2+\D??ZT\GV$Z_?SY\Z_)7[>/DHHPI^HM;&*]T>B_ M]%#V@^ M2NKX6[19H[__$N+5VJ7O3GZW#-#\[[^L,<;O* ,GG\]/*)+_<96))/_?L>=< M>Q&.-K?>W ]6B1U_&='ZOSWI7N0H3E%*F^[4M MPL>(B)5^R<3W'.0149,?0M_%#A7QI>52.SXN$8I"):!*]<+$.[,"\MP21=BV MW*[ [[T$C"6V?PVG\^D:!8DR=4J ]0*0%I@L+6^!PEOO*UH]DV'F^M\Q:;-7 M:(YM''5D%,$[8=OI,?+M/Y:^Z^Q_..GPOJ(__[0\[*'T#UV;3^E38%K5"I.&1:;YMD=F>;?LQF>YYBQEIAS9&38D5U-F3IFU4^IS M]\B/=BJML>.O2;?36,A2=0/$?>]'_T11E^CWWM"+#2[CD RB83CQ5\^D6U&? M*XJJZ@75C86#[Y8;HZ_(HO].Q>8YOV$R70WL9=,.2J+>7O#.B+7)I]P@%%+) MX1?KF19OA)%15S^X I\L,*(-76R3L6!-[=T45FU5/8V:OO,3NVHKT[KBO7S] M+9F >0M,1#$.0U7G J^:7M"0/KBH\WO45%]U%?6":.):>!7.K$V+/F"OCEYP MW/G>X@D%JROTW)23 M2CB(":>P^X M-?;$J4N=DC,KB)K#VJ^D%R3?K0!3#>6J27;WFF-B5]<+NM^M(+":^R-WQ>%Y MXKKTR/7NF5-S S]1Q1W*YYR_#)XB6IE!JF8POKI64'D5PO3;M8(K73L<'UXK MO-P:P?CSVD'D5-BK;Z\5JOU*0/CY6B%B5=:_AZP5K-J:>O>6M8)45Q$@KTN[ MH9U;)1@/3"N,O I[]%>TTV2I"@#KW);S[+JJ0*UY6^$350HT4ND*119VFX)6 MJ'\0*\EVUFC\-E!13.UL(*P5WKIY%V9(]$IC"\EW4RH#;),.B_ZBG4ETO1R> MY1[0"_)B&N_CDZ?:=R=-7P;/,DD+\*(T2GPZS[Z]6QWQ7@C00LGV)]'X 6S# M>A4\J_R&+#=:SES+V_DN6HY*+=X'V3Z/*(K<9!S-%J*',1/GM?"L-2&5T',Z MU!=&QI5;CY2@1WD.T.0DWPS/9LG2T7G X1_=6XG]+GAVR;US'9JC\@HP^PTW M/EG2X,4R:H=>KFHPJ*?1$@7Z$9>K!8-V%@?VDKQH1J;>:.RZV;%C_?A%+X)C MD<"_H8=\MTO7PJ'?#LPB\S:8^W,3*P@VI"-+'IK."PC(0B[6X%G0^@4P;?@8 MKU96L"'?GC^Y_1.1Q1;0';:>L9MXUCHV:8L/@FGAZ9HV)=KK$*%T;+SZ=\&T MRY;H[1'<;9%#28SS9CB[\NV,P:\2S+Y\2Y"\&GO=F6_KU84P,]_?3L]:33MH MHDI!(!T[3N+QU#@%4WL%D%-*[2!SZNL_(J,#BA7J[Q^_1JC]HBJ&DG1 JGSU MO:-_\%V7?-9/*W#T8:ZKM'>D7ZTH#EKOG7)K[!WC) Z"- /8[K>ZT'+J[AWW MX](/(KUPJU7V?4JS[5RB6A'L,YLM1QOEUP"*)21#91A^']OD(UOW6$IO &2# MZU?Z8]NM':FJ :%.,HNEGIDP8Z>U&ZW1F\#$G-)OCG4$PLE6#@;YF'125]B- M:5?UB&PZUVBMA0;O 752NJWO1U!KCW'(+:X_8;V*R_D%?L8=7\2KY%5G<:]A)DZZ] M1^S9:FA&%@G)?OG\P8^U[7NIO0)FQH2V8=JRU4/+G]!RU2)1,8!3)FW)K:T+ MU#F3=@B%M?::::$=MDHMREC6A;,G=^2/&0#Z'JE/DHV0YR29+-/? MXHB^ZN3DY//)Z-THKZCXH^4YH[364;,T^@E4 M;U[=*W)*%$?E!FC587DOJ2 MND)D_W7AO_SJ($R1G_[[/?WQ7?IC0BGYYX^)_X*"\7,8!98=Y;6YUC-R__[+ MWM]^;?XM'\T\GYY]/WYZ_T?[OQ@ZF7>H&G\Q198I%:=IM5,GSF->+.5''64A5D MZ1"B.XW2*(CZ.YO[ZE.&D"L)+&/O?,!=^':P(ZLK=$M^%,[8M@^"X[K=5(V/ M2U-#;4^UW)(O7YP^D5KW"-W_,UP:^8SLJ)1"I'?\70?8I_$\284'8_._8RL@ M7;V[>4!K/]A?RG.>-(MC&7!ZVVL_=#^1"4:81 0*^=Y_M&R3#\0FIP,F7 J= MWL&X'\9GB+S6N?:<*V(M#MVEY\SB6@PM(_K]$(E._<0WV$7W<S%<9A_0 E-?L!?=6ZNZ%ESWF$D,2R#+6/XP7)9I@&Q !J(L.(X8:T*C M+8+-Q'?8I'-+F:0!=:"9)#X.5Q)/UNNM0T.%:38,^O6"_IWQO$DR4(&8">#3 M< 4P=AS"3IC8:QK, O\%TRO@6?S7/VX2_0H(,_8_#Y[]['^HL4Y%U!>?-9!W M(;S<(7,R>-8GY,=I\.3_W-_TY#QI(.,"<#G?@_3 E8#._#"RW/^#U]SI7MW# M!K(NQI<3/TA?'!7U.$ 6@^KBG\T@5X@HIW.0CK8[4H\[6_H>V_^R_TC9"!\O M/IV]'R"M4JAR:@?I6LN.(VU.SYZ?:-!F#;7[CYA!K12JG-I!^M:> LO!WN)Q MLWKVW1I>2W\W@U0QI)S10?K1O]I)@AZ&M[3N,3/XE4:6TSQ@WUAV.BG= MNZ.B)@:+]^-,1(^;0;LRPIS^ 7O&DI,M%CTVCJZLR,K <]SD=8^;1+\"PIS^ M ;O&Z)Y?,"'&6OC!AKO?N7W*)++%P/)0E0$[PAY7ENOF68"9')>>,HEC,;"< MXP$[OZY7*%B0P>I+X/^,EC0;AN6QVW/MTV73?"*F.1\LY_( <^X'Z?_*P+[N M0K#2 !TV\95'C6)=#EU.^2!]9%F?MD2N*VKEQ8=,HEF(*R=XD)ZR;!&R.Z"2 M'%D)IW$41I9'W0[LM1FGD$D"4,:9"V*0_K4,,Z(7CKFWGH->_X'8C7[O.:-H MEX"6,SU(OUNVUKS!H6VY_T16P(XU9CUJ!M]*Z'+*M?O@S@X86[Z#>D-^4[=* M8SQI!N$JX'*^!^ET*P--)ZERC!>>-9%S$;R<]4'ZVL8$IY-@=:VZZ5OI[V7X MGP?*KAA2?B2H.\_:?_VZGZ%(2]ZB70H*GTQ%O"0=:WZQ,'(N+9=>OD@6*2C: MMFI!^J+3$YJ^:%LO^7DRO;^ZOG^\OJ(_/4[O;J_&3^0?E^.[\?WD>O3XV_7U MT^,OA\ABI.'T ;PKRU=$B3&I$+$>MB.46*0^I)7[K%'BD$?80;[+ M%F)@3/1_0Y8;+6>NY3VB*'*3L75WSVQ8S[9"22.X;XM74[JN;I4P(8]@FUYR M3OJ^6R^, ^IX+R"\1Q%'#@K%S=%$6]":TGO!&B^FT1(%,KH1%S!"*0UA:DH0 M!DL;LP"M+>QD-TV21I,8I615AD@D2AJEEJ9X-64<@R4;&8&8*P5ITMO&;$5^ M9+G 2+_W/5O!>U%]'*@4&CDP)-'!6GEH&SK\-0JB#9V!)Y=;D:7YFD["OP1^ MY2"67"&@TI!DN6[,4$9KI,=B;-OQ*DYNT[M"!(B-LZN,URY*V/2<\8H>1TYO M06>:C=73:*K>-/EU:I>V?=KG5*@>6M#O R-5IA'(ZD"U3R-%3).4,E98KA9- M(OGB^\Y/[.ZG@]G_<]D@I_T?,VY)/A>7D:Z36\*/M\#/+LI,AZ+K5]N-Z5$L M@0ADBIHFD,:88?E6& [9>S]"X^2X"&='44;01^4MGBX,31./:O M%6(C?:D%B\B%!K(+@)-)*[:YXI%!;JH_E5YJ$\ZL#9UV4S^>;0)J3B#-GES%% .\BPO-_,0$,+KR2(KWO.,**E(<+R=C.(G05HA>/5%9IC M&R//WCP0.H(7'L>"(H;1W00M+%>UOGT.1,B+N)T _V%SI-$ IY&>[3O?6SRA M@#2/9T' <,V3YLE!%J21WNO'I1]$%/VE'P3^3^PMF.>2JT^:IP59D+HZ- M"LM!UH\DX:+]M$H0[]PP=G<,; M"P?)Z?#I/"W+G+2TK=A(Z75D%B,[M?P*EHF_>L9>PO3$]VB[14DJS1 [23NF M.3EE.[Q6=1JI2/T6@>6B[6#I+E19_<-&RD=!&;I 6 M+NWC)N_<>PR<*N1IK)\9"<$9Z9@>.PY.<C0\H)>.@\6;L^;"H8-F(%\2(%\,52D.XFM;A+RAX]FM4 MT^YRQ#:^&+*VW!U$V&3W -^Y=LG&MUYVJGY&T[<0GDMSL_HU ].WT]D;P>E4 MNZ_HL*8S\EBLB!.Q2[*VF/G::X#_,%%(_=]+F"Y.ERC"]FX2)KRD\*+))86C MOY1>]A^_'/6EA3]ZBPRQE\B)732=SW(I?_-P%')O,>25 ==_R)J_)HI#&:#:T!-^OINN(6 MA "4R*MQRLM!-* 3T'7%+036)5EC[<$(L4$N=PR JM%'R MK_WV27[UH^BJN?:BU&]5'9]YCX+CN(C/W(';+5*P(M%:4#7@-T &95[V#O! MW>B,I\$(HSMG'A^KIE#D/H6P%Z*8GC*$5, MEX<(*JSC2PS'9?T*+;T%(RQR:F4/(T\LW7HOQ$;).>;;Y"I0YX5&4(9/ M_G@^)Z8B<_\PBZJUH&CRBX 7;=9'7K,? $2K!4GF35QK5L,E-SAVE"-E;^LQGRP;Y M1 SRL;]-6FG&:HF6! H1 OTCRZ9)7J(-)20C^@[2:VTY]O\"L]XL[,']"D*KARX3-?E8PV M]'I'E?[].]NL]>EZZ,X/0\%2E%/"'+VH@C0RM"*;8]T0D]+TF10\];)>&9II4!,X+:E*HBHJ758P,@!L:][KUS7U)$IW0_O/ M@Q-.^TY("B*LX!W&2O8KO#:SY*'9#IW.2OI*O?8%><3";K)?N\(>IM:- M\ O*;,08+@2EC)%1&[RP1A!=WA*4)&PCAOAJ!7^@@DE97A-F >-$H@C5R$C0 M+[[O_,2N>[M:6SA(IFED9L_J16H?-DX7"C U17ZR\GOV%O:"R/?;."6-]*$K MFA+RS^2?K'@7=HFRX3X/7Q^J6&%%?W:U8)5=J!HG!SF$NH(S065%K7$*R;M- MP0E!I[N4IX'6,PA0&KCW/;^,/VL' @^6L)PY^F@&%=:I$FUQ?VG0>\D,]X@= M^%?_.#AM-*.X*A4EP(-PE=&U%;V4EZZPQLZ_XC3D?#J_\0.Z&;F,DH-6OUM! M8'GU!TC4:C!.&KILT-8=]CE5BX<6- ()3(_"-*_JN&.<<)HA-O+JR-W$+-]^ MQ%Y,S+&+R[]$<]*4TN>>K%<47K\2&Q-C8,\*-LEHKW1A18=O-%:HA[:9D?/Q MK7$R#M+D2WR95IXV7&)R>-M.P($.F+/ )X@Y:_7= ^!DT'@))L"DRT4'JB<@ MRX9"L$[SNY>4ZRF9^.($T.$8Y96[%NA&'LPNF49&.8:J@L>X67=@Y7??Y5FV M+JT0VPSF:Y\U1P'R\ YSP+EG)5QA-XZ82:483YNK!A[ W&=W8OB)]\G2\A8H MO/5*EPSNW2DJ. 1_WNP0_.2W\?V7Z\?1[?WHZ_77R^N'Q_]W=/W?WVZ?_CGZ MR]7US>WD]FE %Z#-K"#RB &SJVGEKS]C%ASDH7E0'820%[0KD+G?IJX,7/;9/'+(EX9H@!;2NR:YQW2+C\!E6IJT&H>#"* ! M/.]?BLUEO/[ALFE. 7F86G"O -6 4[I[AN+>9%7[K)$:D$<*[\Z4!BYE_=>8 M@A*"RI"OA*[/]L^[K;(,0G!99=W#X+A4HF4O^D(-)<04.A3 Y:D2J_6/F\>K M DZHK76B1&SMT^;Q*@^SSQ'XD%<&&T&K/$P#[A$J8]5U)_B == ,J*90ZIY] M*M3AF/D;I=QKO"+@]-!LJJV*$&!/_X 9 MJKV^OQEB YQL+,/QQP%N(9/$T0*Q ;XW76M[ES[5(,QZV7)6J;T7/OA._FD:4=OK', MV-F ]7IH(VD:%M>(")J&! 41F+BU0US+.VBM-4*J:5$U ,%,K"#8T)1!2=:Q M<@M+-_SE%"2NQUA)-82N:0('46/[H62V32V3^+7XJ[NZ$N;H1A6D)A_?L!1R M:24AN"MZEHV7GDFAAF-0D!QH(_,V<9H5_<]S:T'55P-.56W%H=1AR9MD$"D] MLA5)/>#MSLP#BN*@_BIAI0K 24>Y0]*$VD/H7&6YDCWSO=2D#CDCI^,@W) &P>>20+PW1 "VT.O(-B6EI MTFIG%7R !O!,#+/RTZD!E^S*/@]*MG%G9NO6SBS)4 MXR1 M,H5 %GPFMMF =[JA=?= 8RA4A&K"8TW:>%!+K MC49G/BX#J+[U[ !9(;I"Z?_6;?@]D*7*C1_\M )6;F_%6N"*A,]W52@Z@)MV M@+1J 8W1?'HJ!R= '3JJZ\8Z,Y8FT4(\9R,;L2<(7#-755*X(9X?9BQJ$J/< MAF&,G.^6&Z/DW\4S&F-JG? [:0M5-32HP7"=Z+*(KBLH.ST$4\"9MHM6XI&I M HQZ=/',5DYC<\ Z/Z5KI3-"*_K/Y+6^M7U(FY^*B]YS^W8R( M!S":KDM*.^T,=U=2AT\^8QL\9X#^HABF/9T_%.TR$2KV &\T7+Y]6=#0&U4' MM^XU3M ',):FG5AX9T0TK7K-U904;DV'L^')HVK4O4-739S$["J.1%2M3:+I MC#@8W_&Y<=\"/&62H7M4 9*@"9BQ,]H\<[WL4ZI86HC(F M:Z6Y 32Y?6%Y7KYB+_F"O(GD%KXA]M]E)&=MDDN6-EE/.DS1UAT,=-6X9].M M*XDA)M;CQZ >)>RP'&8F3H\^&"DR;7;1FHFR;BEX!B=9@!4N;US_YW8$%&0 MN&B8 6#\^-OHYF[Z^^,O@SG-OS6-_"'^FB)O5PT Z&QD6-5[P\ 'K0NM7@^& M-\WO-T#>!5 Z6"'U=!BXL''T@,A0:6,R:!:W0I]\:C!BCQ=,AH'+S3-7B9'>0Z9N083_ MY*4WYI0 )Y^#R:&J1%4S&1F=D^P/R29BKW_X35.-+&2DR_&+[SL_L>O>KM86 M#I*C">S)4_W#;W)J9"%-P]T+"I[]#F.M9!*L\_.)'ZQ.#A/Y]D2 MU5M,_)"9"Y17Y$U1+>RDR4,(66!7Z#FZPF%^N\$*QRLIE=64*YOP(S'AYS>I M*1D+UDTVC''MJQ7\\>33_Z)H9^'LV/7O5A!87J6GDB_X)J+6UH)U_PA[=D2; M09JJ&'GVYBD]+7+]2M<2Q*S>XBH.$J*3J&5BM70KYY0QCVI8VYO>NC&AD7>C MI#'W_\">(P@&KS[XIC-EZVBZ@ 26A*H;XEM[YEGN^:YV^0K>)*?-:KHN-X&N MQ>R&A9"0@_ +)R.\3%%P^FLI AE525JAK8-==Z@<8Y)6Q?<;LMQH.7,M;X

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end

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